RESULT_COUNT: 2688,PAGE_SIZE: 10000,CURRENT_PAGE: 1,TOTAL_PAGES: 1,API_CALL_CREDITS: 1
TICKER,FIGI_TICKER,FIGI,TITLE,PUBLICATION_DATE,URL,SUMMARY
NVS,NVS:US,BBG000LYF3S8,Cancer Treatment Update: Second Gene Therapy Receives Approval,2017-10-21 00:01:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DzHrcKxwe3M/cancer-treatment-update-second-gene-therapy-receives-approval-cm863009,With the approval of Gilead Sciences Inc s GILD Yescarta this week saw the approval of the second CAR T therapy for treating cancer It is regarded as one of the most advanced immune oncology treatment options Moreover the FDA has granted priority review to label expansion applications
,,,Cancer Treatment Update: Second Gene Therapy Receives Approval,2017-10-21 00:01:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DzHrcKxwe3M/cancer-treatment-update-second-gene-therapy-receives-approval-cm863009,With the approval of Gilead Sciences Inc s GILD Yescarta this week saw the approval of the second CAR T therapy for treating cancer It is regarded as one of the most advanced immune oncology treatment options Moreover the FDA has granted priority review to label expansion applications
,,,Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval,2017-10-20 23:59:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jwCW8zJfQ9Y/gilead-gild-car-t-therapy-yescarta-clinches-fda-approval-cm863004,Gilead Sciences Inc GILD announced that the FDA has approved its chimeric antigen receptor T cell CAR T therapy Yescarta axicabtagene ciloleucel for treatment of refractory aggressive non Hodgkin lymphoma which includes DLBCL transformed follicular lymphoma TFL and primary
NVS,NVS:US,BBG000LYF3S8,Gilead (GILD) CAR-T Therapy Yescarta Clinches FDA Approval,2017-10-20 23:59:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jwCW8zJfQ9Y/gilead-gild-car-t-therapy-yescarta-clinches-fda-approval-cm863004,Gilead Sciences Inc GILD announced that the FDA has approved its chimeric antigen receptor T cell CAR T therapy Yescarta axicabtagene ciloleucel for treatment of refractory aggressive non Hodgkin lymphoma which includes DLBCL transformed follicular lymphoma TFL and primary
NVS,NVS:US,BBG000LYF3S8,Roche (RHHBY) Reports Sales Numbers for First 9 Months,2017-10-20 23:59:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8nW7N42diis/roche-rhhby-reports-sales-numbers-for-first-9-months-cm863000,Roche Holding AG s RHHBY reported sales of CHF39 4 billion in the first nine months of 2017 up 5 from the year ago period Roche s stock has gained 7 2 year to date compared with industry s gain of 23 8 The company reports results under two divisions Pharmaceuticals
,,,Roche (RHHBY) Reports Sales Numbers for First 9 Months,2017-10-20 23:59:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8nW7N42diis/roche-rhhby-reports-sales-numbers-for-first-9-months-cm863000,Roche Holding AG s RHHBY reported sales of CHF39 4 billion in the first nine months of 2017 up 5 from the year ago period Roche s stock has gained 7 2 year to date compared with industry s gain of 23 8 The company reports results under two divisions Pharmaceuticals
NVS,NVS:US,BBG000LYF3S8,Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU,2017-10-20 17:06:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uQUwJloB5xE/conatus-liver-disease-drug-gets-orphan-drug-tag-in-the-eu-cm862715,Conatus Pharmaceuticals Inc CNAT announced that the European Medicines Agency EMA has granted orphan drug designation ODD to its pipeline candidate IDN 7314 currently undergoing a phase II study for treatment of primary sclerosing cholangitis PSC PSC is a liver disease that affects
,,,Conatus' Liver Disease Drug Gets Orphan Drug Tag in the EU,2017-10-20 17:06:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uQUwJloB5xE/conatus-liver-disease-drug-gets-orphan-drug-tag-in-the-eu-cm862715,Conatus Pharmaceuticals Inc CNAT announced that the European Medicines Agency EMA has granted orphan drug designation ODD to its pipeline candidate IDN 7314 currently undergoing a phase II study for treatment of primary sclerosing cholangitis PSC PSC is a liver disease that affects
NVS,NVS:US,BBG000LYF3S8,What's in the Cards for Amgen (AMGN) this Earnings Season?,2017-10-20 17:05:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RKiVsbKWKYU/whats-in-the-cards-for-amgen-amgn-this-earnings-season-cm862668,Biotech major Amgen Inc AMGN will report third quarter 2017 results on Oct 25 after the market closes Amgen delivered a positive earnings surprise of 5 83 in the last quarter Amgen shares are up 25 9 so far this year This compares favorably with the 12 1 increase registered by
,,,What's in the Cards for Amgen (AMGN) this Earnings Season?,2017-10-20 17:05:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RKiVsbKWKYU/whats-in-the-cards-for-amgen-amgn-this-earnings-season-cm862668,Biotech major Amgen Inc AMGN will report third quarter 2017 results on Oct 25 after the market closes Amgen delivered a positive earnings surprise of 5 83 in the last quarter Amgen shares are up 25 9 so far this year This compares favorably with the 12 1 increase registered by
NVS,NVS:US,BBG000LYF3S8,Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?,2017-10-20 17:05:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g2f7Jhzk9O0/glaxo-gsk-q3-earnings-will-it-deliver-a-beat-yet-again-cm862664,We expect GlaxoSmithKline plc GSK to beat expectations when it reports third quarter 2017 results on Oct 25 before the market opens Last quarter the company delivered a positive earnings surprise of 2 94 Glaxo s shares are up 6 7 this year so far underperforming the 20 5
,,,Glaxo (GSK) Q3 Earnings: Will it Deliver a Beat Yet Again?,2017-10-20 17:05:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g2f7Jhzk9O0/glaxo-gsk-q3-earnings-will-it-deliver-a-beat-yet-again-cm862664,We expect GlaxoSmithKline plc GSK to beat expectations when it reports third quarter 2017 results on Oct 25 before the market opens Last quarter the company delivered a positive earnings surprise of 2 94 Glaxo s shares are up 6 7 this year so far underperforming the 20 5
,,,"Noteworthy ETF Inflows: VEU, NVS, TM, BTI",2017-10-20 16:02:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vnDUN4HoqcI/noteworthy-etf-inflows-veu-nvs-tm-bti-cm862596,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 64 4 million dollar inflow that s a 0 3 increase week over week
NVS,NVS:US,BBG000LYF3S8,"Noteworthy ETF Inflows: VEU, NVS, TM, BTI",2017-10-20 16:02:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vnDUN4HoqcI/noteworthy-etf-inflows-veu-nvs-tm-bti-cm862596,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 64 4 million dollar inflow that s a 0 3 increase week over week
,,,What&apos;s in the Cards for Amgen (AMGN) this Earnings Season?,2017-10-20 14:50:02 +0000,https://finance.yahoo.com/news/apos-cards-amgen-amgn-earnings-145002859.html?.tsrc=rss,"While Amgen&apos;s (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth."
NVS,NVS:US,BBG000LYF3S8,What&apos;s in the Cards for Amgen (AMGN) this Earnings Season?,2017-10-20 14:50:02 +0000,https://finance.yahoo.com/news/apos-cards-amgen-amgn-earnings-145002859.html?.tsrc=rss,"While Amgen&apos;s (AMGN) growth drugs like Prolia & Xgeva might continue to do well, biosimilar competition and slowdown in sales of mature products can put pressure on sales growth."
,,,The Swiss Stock Market Clung To A Small Increase,2017-10-20 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H5O7bztgQ3k/the-swiss-stock-market-clung-to-a-small-increase-20171020-00746,The Swiss Stock Market Clung To A Small Increase
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Clung To A Small Increase,2017-10-20 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H5O7bztgQ3k/the-swiss-stock-market-clung-to-a-small-increase-20171020-00746,The Swiss Stock Market Clung To A Small Increase
NVS,NVS:US,BBG000LYF3S8,Gilead Slaps Mega-Price on Its Newly Approved CAR-T,2017-10-19 23:31:00 +0000,https://finance.yahoo.com/news/gilead-slaps-mega-price-newly-233100308.html?.tsrc=rss,Gilead Sciences&apos; premium price for Yescarta could help offset hep C headwinds.
,,,Gilead Slaps Mega-Price on Its Newly Approved CAR-T,2017-10-19 23:31:00 +0000,https://finance.yahoo.com/news/gilead-slaps-mega-price-newly-233100308.html?.tsrc=rss,Gilead Sciences&apos; premium price for Yescarta could help offset hep C headwinds.
,,,Does Gilead Now Have A New Multi-Billion-Dollar Franchise?,2017-10-19 20:48:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p7Athhyn3y0/does-gilead-now-have-a-new-multi-billion-dollar-franchise-cm861865,Gilead Sciences GILD jumped early Thursday after the Food and Drug Administration approved what is known as a CAR T drug dubbed Yescarta to treat an aggressive form of non Hodgkin lymphoma ibd display video id 2381354 width 50 float left autostart true The late
NVS,NVS:US,BBG000LYF3S8,Does Gilead Now Have A New Multi-Billion-Dollar Franchise?,2017-10-19 20:48:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p7Athhyn3y0/does-gilead-now-have-a-new-multi-billion-dollar-franchise-cm861865,Gilead Sciences GILD jumped early Thursday after the Food and Drug Administration approved what is known as a CAR T drug dubbed Yescarta to treat an aggressive form of non Hodgkin lymphoma ibd display video id 2381354 width 50 float left autostart true The late
,,,FDA Approves Gene Therapy to Treat Large B-Cell Lymphoma,2017-10-19 20:32:00 +0000,http://finance.yahoo.com/r/65e744b9-2c5d-3ebe-812a-c1e4eec76d04/gilead-sciences-gets-new-gene-therapy-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Gilead Sciences' Kite will make a futuristic one-time dose that claims to cure a rare blood cancer in a few weeks. It costs about a third of a million dollars.
NVS,NVS:US,BBG000LYF3S8,FDA Approves Gene Therapy to Treat Large B-Cell Lymphoma,2017-10-19 20:32:00 +0000,http://finance.yahoo.com/r/65e744b9-2c5d-3ebe-812a-c1e4eec76d04/gilead-sciences-gets-new-gene-therapy-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Gilead Sciences' Kite will make a futuristic one-time dose that claims to cure a rare blood cancer in a few weeks. It costs about a third of a million dollars.
NVS,NVS:US,BBG000LYF3S8,Drugmaker Novartis to close 450-employee Sandoz plant in Broomfield,2017-10-19 17:00:10 +0000,http://finance.yahoo.com/r/39cbd576-1b96-3f8a-8d61-03205454feec/drugmakernovartis-to-close-450-employee-sandoz.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Swiss drugmaker Novartis AG plans to reduce or drop production of some generic drugs and will close its 450-employee Sandoz plant in Broomfield over the next two years as a result.  The Sandoz facility has been in Broomfield for 42 years.  Novartis (NVS) plans to consolidate production of drug ingredients at a sister plant in Wilson, North Carolina, and shut down the Broomfield manufacturing plant by the end of 2019, the company said."
,,,Drugmaker Novartis to close 450-employee Sandoz plant in Broomfield,2017-10-19 17:00:10 +0000,http://finance.yahoo.com/r/39cbd576-1b96-3f8a-8d61-03205454feec/drugmakernovartis-to-close-450-employee-sandoz.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Swiss drugmaker Novartis AG plans to reduce or drop production of some generic drugs and will close its 450-employee Sandoz plant in Broomfield over the next two years as a result.  The Sandoz facility has been in Broomfield for 42 years.  Novartis (NVS) plans to consolidate production of drug ingredients at a sister plant in Wilson, North Carolina, and shut down the Broomfield manufacturing plant by the end of 2019, the company said."
NVS,NVS:US,BBG000LYF3S8,Teva Submits BLA to FDA for Migraine Candidate Fremanezumab,2017-10-19 15:51:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2TSq-mlfqWs/teva-submits-bla-to-fda-for-migraine-candidate-fremanezumab-cm861987,Teva Pharmaceutical Industries Ltd TEVA announced the submission of a biologics license application BLA to the FDA seeking approval for its monoclonal antibody candidate fremanezumab as a preventive treatment for migraine The BLA submission was supported by positive data from two
,,,Teva Submits BLA to FDA for Migraine Candidate Fremanezumab,2017-10-19 15:51:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2TSq-mlfqWs/teva-submits-bla-to-fda-for-migraine-candidate-fremanezumab-cm861987,Teva Pharmaceutical Industries Ltd TEVA announced the submission of a biologics license application BLA to the FDA seeking approval for its monoclonal antibody candidate fremanezumab as a preventive treatment for migraine The BLA submission was supported by positive data from two
NVS,NVS:US,BBG000LYF3S8,Conatus Entrusts Keith W. Marshall With Key Management Roles,2017-10-19 15:49:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d6qvSR09xsM/conatus-entrusts-keith-w-marshall-with-key-management-roles-cm861967,Conatus Pharmaceuticals Inc CNAT announced the appointment of Keith W Marshall as executive vice president chief operating officer and chief financial officer Notably Marshall has over fifteen years of experience in finance operations and business advisory roles Also he was an agent
,,,Conatus Entrusts Keith W. Marshall With Key Management Roles,2017-10-19 15:49:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d6qvSR09xsM/conatus-entrusts-keith-w-marshall-with-key-management-roles-cm861967,Conatus Pharmaceuticals Inc CNAT announced the appointment of Keith W Marshall as executive vice president chief operating officer and chief financial officer Notably Marshall has over fifteen years of experience in finance operations and business advisory roles Also he was an agent
NVS,NVS:US,BBG000LYF3S8,Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?,2017-10-19 15:48:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xaIZlcm4bl8/can-immunogens-key-pipeline-cancer-candidate-drive-growth-cm861945,On Oct 18 2017 we issued an updated report on ImmunoGen Inc IMGN ImmunoGen is a development stage biotechnology company focused on developing targeted cancer therapeutics using its proprietary antibody drug conjugate ADC technology ImmunoGen has made significant progress with
,,,Can ImmunoGen's Key Pipeline Cancer Candidate Drive Growth?,2017-10-19 15:48:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xaIZlcm4bl8/can-immunogens-key-pipeline-cancer-candidate-drive-growth-cm861945,On Oct 18 2017 we issued an updated report on ImmunoGen Inc IMGN ImmunoGen is a development stage biotechnology company focused on developing targeted cancer therapeutics using its proprietary antibody drug conjugate ADC technology ImmunoGen has made significant progress with
,,,"Nike hit with downgrade, Blue Apron cutting jobs, Gilead new cancer drug gets FDA approval",2017-10-19 14:55:25 +0000,https://finance.yahoo.com/news/nike-hit-downgrade-blue-apron-cutting-jobs-gilead-new-cancer-drug-gets-fda-approval-145525248.html?.tsrc=rss,"Verizon, American Express, Nike, Blue Apron and Gilead Sciences are among the stocks to watch."
NVS,NVS:US,BBG000LYF3S8,"Nike hit with downgrade, Blue Apron cutting jobs, Gilead new cancer drug gets FDA approval",2017-10-19 14:55:25 +0000,https://finance.yahoo.com/news/nike-hit-downgrade-blue-apron-cutting-jobs-gilead-new-cancer-drug-gets-fda-approval-145525248.html?.tsrc=rss,"Verizon, American Express, Nike, Blue Apron and Gilead Sciences are among the stocks to watch."
NVS,NVS:US,BBG000LYF3S8,Gilead: Congratulations…But You Still Overpaid for Kite,2017-10-19 14:22:00 +0000,http://finance.yahoo.com/r/720343d4-3921-399a-acd9-752da01535a7/gilead-a-new-cancer-drug-greatbut-you-still-overpaid-for-kite-1508422953?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Less than two months ago, Gilead Sciences (GILD) announced an almost $12 billion deal to buy Kite Pharma.  Late yesterday, the FDA approved Kite’s CAR-T cancer therapy for adults with advanced lymphoma.  It uses genetically-engineered T-cells to attack cancer cells, and it is only the second such therapy to make it through the FDA."
,,,Gilead: Congratulations…But You Still Overpaid for Kite,2017-10-19 14:22:00 +0000,http://finance.yahoo.com/r/720343d4-3921-399a-acd9-752da01535a7/gilead-a-new-cancer-drug-greatbut-you-still-overpaid-for-kite-1508422953?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Less than two months ago, Gilead Sciences (GILD) announced an almost $12 billion deal to buy Kite Pharma.  Late yesterday, the FDA approved Kite’s CAR-T cancer therapy for adults with advanced lymphoma.  It uses genetically-engineered T-cells to attack cancer cells, and it is only the second such therapy to make it through the FDA."
,,,Novartis Reports Positive Results on Thrombocytopenia Drug,2017-10-19 13:00:01 +0000,https://finance.yahoo.com/news/novartis-reports-positive-results-thrombocytopenia-130001643.html?.tsrc=rss,Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.
NVS,NVS:US,BBG000LYF3S8,Novartis Reports Positive Results on Thrombocytopenia Drug,2017-10-19 13:00:01 +0000,https://finance.yahoo.com/news/novartis-reports-positive-results-thrombocytopenia-130001643.html?.tsrc=rss,Novartis AG (NVS) announced encouraging results on Revolade from the EXTEND study.
,,,The Swiss Stock Market Pulled Back As Roche Drops,2017-10-19 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DC5IECjFtfA/the-swiss-stock-market-pulled-back-as-roche-drops-20171019-01110,The Swiss Stock Market Pulled Back As Roche Drops
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back As Roche Drops,2017-10-19 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DC5IECjFtfA/the-swiss-stock-market-pulled-back-as-roche-drops-20171019-01110,The Swiss Stock Market Pulled Back As Roche Drops
,,,FDA approves Gilead's cancer drug,2017-10-19 11:53:00 +0000,https://finance.yahoo.com/video/fda-approves-gileads-cancer-drug-115300791.html?.tsrc=rss,CNBC's Meg Tirrell shares details of the FDA'a approval of Gilead's new immunotherapy drug to treat patients with non-Hodgkin lymphoma.
NVS,NVS:US,BBG000LYF3S8,FDA approves Gilead's cancer drug,2017-10-19 11:53:00 +0000,https://finance.yahoo.com/video/fda-approves-gileads-cancer-drug-115300791.html?.tsrc=rss,CNBC's Meg Tirrell shares details of the FDA'a approval of Gilead's new immunotherapy drug to treat patients with non-Hodgkin lymphoma.
,,,"Novartis to shut U.S. generics plant, cut 450 jobs",2017-10-19 09:47:22 +0000,https://finance.yahoo.com/news/novartis-shut-u-generics-plant-094722807.html?.tsrc=rss,"Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in Colorado and discontinues some products in the face of intense price pressures.  ""To remain competitive in the U.S., Novartis will discontinue or divest limited growth products in saturated markets,"" a company spokesman said on Thursday.  The shutdown of Novartis's Sandoz division plant in the Denver suburb of Broomfield was originally reported by the Denver Post."
NVS,NVS:US,BBG000LYF3S8,"Novartis to shut U.S. generics plant, cut 450 jobs",2017-10-19 09:47:22 +0000,https://finance.yahoo.com/news/novartis-shut-u-generics-plant-094722807.html?.tsrc=rss,"Swiss drugmaker Novartis is to cut 450 jobs in the United States over the next two years as it gradually shuts a generics manufacturing plant in Colorado and discontinues some products in the face of intense price pressures.  ""To remain competitive in the U.S., Novartis will discontinue or divest limited growth products in saturated markets,"" a company spokesman said on Thursday.  The shutdown of Novartis's Sandoz division plant in the Denver suburb of Broomfield was originally reported by the Denver Post."
NVS,NVS:US,BBG000LYF3S8,Gilead Gets FDA Approval for New Cancer Therapy,2017-10-19 04:02:04 +0000,http://finance.yahoo.com/r/cbfa6aad-6783-3964-b232-5e59a9b1e8ca/gilead-cell-therapy-drug-yescarta-gets-fda-approval-1508364454?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients."
,,,Gilead Gets FDA Approval for New Cancer Therapy,2017-10-19 04:02:04 +0000,http://finance.yahoo.com/r/cbfa6aad-6783-3964-b232-5e59a9b1e8ca/gilead-cell-therapy-drug-yescarta-gets-fda-approval-1508364454?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients."
NVS,NVS:US,BBG000LYF3S8,"U.S. FDA approves Gilead cancer gene therapy; price set at $373,000",2017-10-19 00:11:42 +0000,https://finance.yahoo.com/news/u-fda-approves-gilead-cancer-001142734.html?.tsrc=rss,"U.S. regulators approved on Wednesday a  new therapy for a type of lymphoma, which was developed by  Gilead Science Inc's Kite Pharma, marking the second  approval for this potentially revolutionary approach to fighting  cancer.  The Food and Drug Administration approved the gene therapy,  to be sold under the name Yescarta, to treat adults with large  B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed  to respond to other treatments."
,,,"U.S. FDA approves Gilead cancer gene therapy; price set at $373,000",2017-10-19 00:11:42 +0000,https://finance.yahoo.com/news/u-fda-approves-gilead-cancer-001142734.html?.tsrc=rss,"U.S. regulators approved on Wednesday a  new therapy for a type of lymphoma, which was developed by  Gilead Science Inc's Kite Pharma, marking the second  approval for this potentially revolutionary approach to fighting  cancer.  The Food and Drug Administration approved the gene therapy,  to be sold under the name Yescarta, to treat adults with large  B-cell lymphoma, a type of non-Hodgkin lymphoma, who have failed  to respond to other treatments."
,,,FDA Approves Another Amazing And Costly Cancer-Killing Gene Therapy,2017-10-18 23:19:00 +0000,http://finance.yahoo.com/r/933b48e1-7a2c-3bd9-ab0f-4ef4f9a866a7/fda-approves-another-amazing-and-costly-cancer-killing-gene-therapy?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"The Food and Drug Administration just approved Yescarta, a treatment that genetically modifies a patient's own white cells to battle lymphoma. The price? $373,000."
NVS,NVS:US,BBG000LYF3S8,FDA Approves Another Amazing And Costly Cancer-Killing Gene Therapy,2017-10-18 23:19:00 +0000,http://finance.yahoo.com/r/933b48e1-7a2c-3bd9-ab0f-4ef4f9a866a7/fda-approves-another-amazing-and-costly-cancer-killing-gene-therapy?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"The Food and Drug Administration just approved Yescarta, a treatment that genetically modifies a patient's own white cells to battle lymphoma. The price? $373,000."
,,,What to Expect from Big Pharmas After J&J's Solid Q3 Results?,2017-10-18 22:52:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e4YHAAqtt4s/what-to-expect-from-big-pharmas-after-jjs-solid-q3-results-cm861641,Johnson amp Johnson JNJ was the first large cap pharma stock to report its earnings results for this season on Oct 17 J amp J beat the Zacks Consensus Estimate for both earnings and revenues in the third quarter and also raised its 2017 sales and profit outlook Shares of J amp J were up
NVS,NVS:US,BBG000LYF3S8,What to Expect from Big Pharmas After J&J's Solid Q3 Results?,2017-10-18 22:52:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e4YHAAqtt4s/what-to-expect-from-big-pharmas-after-jjs-solid-q3-results-cm861641,Johnson amp Johnson JNJ was the first large cap pharma stock to report its earnings results for this season on Oct 17 J amp J beat the Zacks Consensus Estimate for both earnings and revenues in the third quarter and also raised its 2017 sales and profit outlook Shares of J amp J were up
NVS,NVS:US,BBG000LYF3S8,Gilead Gets FDA Approval for New Cancer Therapy,2017-10-18 22:49:16 +0000,http://finance.yahoo.com/r/cbfa6aad-6783-3964-b232-5e59a9b1e8ca/gilead-cell-therapy-drug-yescarta-gets-fda-approval-1508364454?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients."
,,,Gilead Gets FDA Approval for New Cancer Therapy,2017-10-18 22:49:16 +0000,http://finance.yahoo.com/r/cbfa6aad-6783-3964-b232-5e59a9b1e8ca/gilead-cell-therapy-drug-yescarta-gets-fda-approval-1508364454?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Gilead Sciences’ $11 billion bet on Kite Pharma is poised to pay off, with the approval of Kite’s flagship cell-therapy treatment for advanced lymphoma patients."
,,,What to Expect from Big Pharmas After J&J&apos;s Solid Q3 Results?,2017-10-18 20:21:08 +0000,https://finance.yahoo.com/news/expect-big-pharmas-j-j-202108992.html?.tsrc=rss,"Large-cap pharmas are expected to report encouraging third-quarter results, following J&J&apos;s earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter."
NVS,NVS:US,BBG000LYF3S8,What to Expect from Big Pharmas After J&J&apos;s Solid Q3 Results?,2017-10-18 20:21:08 +0000,https://finance.yahoo.com/news/expect-big-pharmas-j-j-202108992.html?.tsrc=rss,"Large-cap pharmas are expected to report encouraging third-quarter results, following J&J&apos;s earnings beat. Five out of the six companies are expected to deliver earnings beat this quarter."
,,,What's in the Cards for Novartis (NVS) This Earnings Season?,2017-10-18 12:52:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6_mqVaaECPQ/whats-in-the-cards-for-novartis-nvs-this-earnings-season-cm861145,Swiss pharmaceutical company Novartis AG NVS is scheduled to report third quarter 2017 results on Oct 24 Novartis stock has rallied 22 1 year to date compared with the industry s 21 4 gain In the last quarter Novartis delivered a positive earnings surprise of 4 3
NVS,NVS:US,BBG000LYF3S8,What's in the Cards for Novartis (NVS) This Earnings Season?,2017-10-18 12:52:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6_mqVaaECPQ/whats-in-the-cards-for-novartis-nvs-this-earnings-season-cm861145,Swiss pharmaceutical company Novartis AG NVS is scheduled to report third quarter 2017 results on Oct 24 Novartis stock has rallied 22 1 year to date compared with the industry s 21 4 gain In the last quarter Novartis delivered a positive earnings surprise of 4 3
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed As Heavyweights Provide Support,2017-10-18 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hFaJGWNvXfU/the-swiss-stock-market-climbed-as-heavyweights-provide-support-20171018-01025,The Swiss Stock Market Climbed As Heavyweights Provide Support
,,,The Swiss Stock Market Climbed As Heavyweights Provide Support,2017-10-18 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hFaJGWNvXfU/the-swiss-stock-market-climbed-as-heavyweights-provide-support-20171018-01025,The Swiss Stock Market Climbed As Heavyweights Provide Support
NVS,NVS:US,BBG000LYF3S8,What&apos;s in the Cards for Novartis (NVS) This Earnings Season?,2017-10-18 10:36:10 +0000,https://finance.yahoo.com/news/apos-cards-novartis-nvs-earnings-103610575.html?.tsrc=rss,Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.
,,,What&apos;s in the Cards for Novartis (NVS) This Earnings Season?,2017-10-18 10:36:10 +0000,https://finance.yahoo.com/news/apos-cards-novartis-nvs-earnings-103610575.html?.tsrc=rss,Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report third-quarter 2017 results on Oct 24.
NVS,NVS:US,BBG000LYF3S8,"Novartis: Study Results Supports Positive Safety, Efficacy Of Revolade In ITP",2017-10-18 01:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gC2hbBZldYw/novartis-study-results-supports-positive-safety-efficacy-of-revolade-in-itp-20171018-00039,"Novartis: Study Results Supports Positive Safety, Efficacy Of Revolade In ITP"
,,,"Novartis: Study Results Supports Positive Safety, Efficacy Of Revolade In ITP",2017-10-18 01:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gC2hbBZldYw/novartis-study-results-supports-positive-safety-efficacy-of-revolade-in-itp-20171018-00039,"Novartis: Study Results Supports Positive Safety, Efficacy Of Revolade In ITP"
NVS,NVS:US,BBG000LYF3S8,"Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics",2017-10-17 23:50:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/slFIafb6Vig/better-buy-ziopharm-oncology-inc-vs-celldex-therapeutics-cm861040,Ziopharm Oncology Inc NASDAQ ZIOP and Celldex Therapeutics Inc NASDAQ CLDX are both clinical stage biotechs that could make you rich but they ll need to carry at least one of their new cancer drug candidates across the finish line first Let s look at some of
,,,"Better Buy: Ziopharm Oncology, Inc. vs. Celldex Therapeutics",2017-10-17 23:50:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/slFIafb6Vig/better-buy-ziopharm-oncology-inc-vs-celldex-therapeutics-cm861040,Ziopharm Oncology Inc NASDAQ ZIOP and Celldex Therapeutics Inc NASDAQ CLDX are both clinical stage biotechs that could make you rich but they ll need to carry at least one of their new cancer drug candidates across the finish line first Let s look at some of
,,,Aerie (AERI) Up on FDA Review Committee Result for Rhopressa,2017-10-17 23:49:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fp2mfwN6_Eg/aerie-aeri-up-on-fda-review-committee-result-for-rhopressa-cm861041,Shares of Aerie Pharmaceuticals Inc AERI have moved up 15 8 in the last one week on positive news for its lead drug Rhopressa In fact Aerie s stock has surged 71 4 year to date compared with the industry s gain of 3 4 On Oct 13 the Dermatologic and Ophthalmic
NVS,NVS:US,BBG000LYF3S8,Aerie (AERI) Up on FDA Review Committee Result for Rhopressa,2017-10-17 23:49:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fp2mfwN6_Eg/aerie-aeri-up-on-fda-review-committee-result-for-rhopressa-cm861041,Shares of Aerie Pharmaceuticals Inc AERI have moved up 15 8 in the last one week on positive news for its lead drug Rhopressa In fact Aerie s stock has surged 71 4 year to date compared with the industry s gain of 3 4 On Oct 13 the Dermatologic and Ophthalmic
NVS,NVS:US,BBG000LYF3S8,Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks,2017-10-17 22:52:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G3L8_TQwCK8/innovative-pipelines-regulatory-catalysts-to-drive-pharma-stocks-cm861063,Although pharma and biotech stocks had gone through a rough patch due to the drug pricing controversy the sector is showing signs of recovery with investors being more comfortable with the drug pricing scenario and focusing on the fundamentals of the sector instead Innovation mergers
,,,Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks,2017-10-17 22:52:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G3L8_TQwCK8/innovative-pipelines-regulatory-catalysts-to-drive-pharma-stocks-cm861063,Although pharma and biotech stocks had gone through a rough patch due to the drug pricing controversy the sector is showing signs of recovery with investors being more comfortable with the drug pricing scenario and focusing on the fundamentals of the sector instead Innovation mergers
,,,Inside Novartis’s Performance in 3Q17,2017-10-17 21:36:23 +0000,http://finance.yahoo.com/r/24ed24dc-574b-379b-a159-1c0c4be200f8/inside-novartiss-performance-in-3q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,NVS stock rose ~2.8% in 3Q17 and has risen 18.7% YTD (year-to-date) as of October 16.
NVS,NVS:US,BBG000LYF3S8,Inside Novartis’s Performance in 3Q17,2017-10-17 21:36:23 +0000,http://finance.yahoo.com/r/24ed24dc-574b-379b-a159-1c0c4be200f8/inside-novartiss-performance-in-3q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,NVS stock rose ~2.8% in 3Q17 and has risen 18.7% YTD (year-to-date) as of October 16.
NVS,NVS:US,BBG000LYF3S8,Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks,2017-10-17 19:55:07 +0000,https://finance.yahoo.com/news/innovative-pipelines-regulatory-catalysts-drive-195507406.html?.tsrc=rss,Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
,,,Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks,2017-10-17 19:55:07 +0000,https://finance.yahoo.com/news/innovative-pipelines-regulatory-catalysts-drive-195507406.html?.tsrc=rss,Innovative Pipelines & Regulatory Catalysts to Drive Pharma Stocks
,,,The Swiss Stock Market Dipped Slightly - Credit Suisse In Focus,2017-10-17 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wQmzb98AOA4/the-swiss-stock-market-dipped-slightly--credit-suisse-in-focus-20171017-01077,The Swiss Stock Market Dipped Slightly - Credit Suisse In Focus
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped Slightly - Credit Suisse In Focus,2017-10-17 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wQmzb98AOA4/the-swiss-stock-market-dipped-slightly--credit-suisse-in-focus-20171017-01077,The Swiss Stock Market Dipped Slightly - Credit Suisse In Focus
,,,Let's Talk About CAR-T,2017-10-16 15:40:15 +0000,https://finance.yahoo.com/news/lets-talk-car-t-154015824.html?.tsrc=rss,A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market
NVS,NVS:US,BBG000LYF3S8,Let's Talk About CAR-T,2017-10-16 15:40:15 +0000,https://finance.yahoo.com/news/lets-talk-car-t-154015824.html?.tsrc=rss,A quick overview of treatment and the major players in bringing promising cancer-fighting technologies to market
,,,"Regeneron Advances Science To Attack Arthritis, Eye Disease, More",2017-10-16 13:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M9vdvDO8YwA/regeneron-advances-science-to-attack-arthritis-eye-disease-more-cm859977,Its treatment for a common eye disease made Regeneron 160 Pharmaceuticals 160 a star Now a new dermatitis medication could bring superstardom to the fast growing biotechnology company ibd display video id 2326965 width 50 float left autostart true Other breakthrough
NVS,NVS:US,BBG000LYF3S8,"Regeneron Advances Science To Attack Arthritis, Eye Disease, More",2017-10-16 13:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M9vdvDO8YwA/regeneron-advances-science-to-attack-arthritis-eye-disease-more-cm859977,Its treatment for a common eye disease made Regeneron 160 Pharmaceuticals 160 a star Now a new dermatitis medication could bring superstardom to the fast growing biotechnology company ibd display video id 2326965 width 50 float left autostart true Other breakthrough
,,,Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease,2017-10-16 13:17:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sONgkph384Q/incyte-cancer-treatment-uses-patients-immune-system-to-fight-disease-cm859976,Among the biotech companies chasing next generation cancer treatments that work with patients own immune systems Incyte INCY stands out with a treatment analysts say could prove to be a blockbuster ibd display video id 2326965 width 50 float left autostart true
NVS,NVS:US,BBG000LYF3S8,Incyte Cancer Treatment Uses Patients' Immune System To Fight Disease,2017-10-16 13:17:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sONgkph384Q/incyte-cancer-treatment-uses-patients-immune-system-to-fight-disease-cm859976,Among the biotech companies chasing next generation cancer treatments that work with patients own immune systems Incyte INCY stands out with a treatment analysts say could prove to be a blockbuster ibd display video id 2326965 width 50 float left autostart true
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back As Investors Take Profits,2017-10-16 12:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LZiWSXagdME/the-swiss-stock-market-pulled-back-as-investors-take-profits-20171016-00980,The Swiss Stock Market Pulled Back As Investors Take Profits
,,,The Swiss Stock Market Pulled Back As Investors Take Profits,2017-10-16 12:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LZiWSXagdME/the-swiss-stock-market-pulled-back-as-investors-take-profits-20171016-00980,The Swiss Stock Market Pulled Back As Investors Take Profits
,,,Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field,2017-10-16 11:45:07 +0000,http://finance.yahoo.com/r/f86d886c-4a04-300b-b2ee-d3ade70dfd63/kite-pharma-cancer-treatment-stands-out-car-t-field?src=A00220&yptr=yahoo&.tsrc=rss,Gilead&apos;s new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient&apos;s cells. Here&apos;s how its treatment stands out and who it helps.
NVS,NVS:US,BBG000LYF3S8,Kite Pharma Cancer Treatment Stands Out In Hot CAR-T Field,2017-10-16 11:45:07 +0000,http://finance.yahoo.com/r/f86d886c-4a04-300b-b2ee-d3ade70dfd63/kite-pharma-cancer-treatment-stands-out-car-t-field?src=A00220&yptr=yahoo&.tsrc=rss,Gilead&apos;s new Kite Pharma unit is a leader in cutting-edge CAR-T therapy that fights cancer by rebuilding a patient&apos;s cells. Here&apos;s how its treatment stands out and who it helps.
,,,The 1 Stock You've Been Overlooking for Your Roth IRA,2017-10-15 12:16:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cr8uFZ4IVNw/the-1-stock-youve-been-overlooking-for-your-roth-ira-cm859880,Opening a Roth IRA account was one of your best moves in preparing for retirement I m assuming this applies to you If you don t have a Roth IRA get one This article will wait on you until you ve got one set up Seriously Roth IRAs are great retirement tools that many
NVS,NVS:US,BBG000LYF3S8,The 1 Stock You've Been Overlooking for Your Roth IRA,2017-10-15 12:16:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cr8uFZ4IVNw/the-1-stock-youve-been-overlooking-for-your-roth-ira-cm859880,Opening a Roth IRA account was one of your best moves in preparing for retirement I m assuming this applies to you If you don t have a Roth IRA get one This article will wait on you until you ve got one set up Seriously Roth IRAs are great retirement tools that many
,,,"Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study",2017-10-13 16:15:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/09Xo4ts9JoM/bristol-myers-bmy-target-extend-partnership-for-nash-study-cm859417,Bristol Myers Squibb Company BMY extended its strategic partnership with TARGET PharmaSolutions Inc The partnership has been extended for TARGET NASH for a multi year deal We note that both companies announced two new collaborations in Nov 2016 for the treatment of non
NVS,NVS:US,BBG000LYF3S8,"Bristol-Myers (BMY), TARGET Extend Partnership for NASH Study",2017-10-13 16:15:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/09Xo4ts9JoM/bristol-myers-bmy-target-extend-partnership-for-nash-study-cm859417,Bristol Myers Squibb Company BMY extended its strategic partnership with TARGET PharmaSolutions Inc The partnership has been extended for TARGET NASH for a multi year deal We note that both companies announced two new collaborations in Nov 2016 for the treatment of non
NVS,NVS:US,BBG000LYF3S8,Lilly's Verzenio Gets Priority Review in First-Line Setting,2017-10-13 15:18:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tVSPlx-Kjjw/lillys-verzenio-gets-priority-review-in-first-line-setting-cm859350,Eli Lilly and Company LLY announced that the FDA has granted priority review to its new drug application NDA for Verzenio abemaciclib This drug is looking forward to get approved for the first line treatment of advanced breast cancer Markedly the NDA was based upon the positive
,,,Lilly's Verzenio Gets Priority Review in First-Line Setting,2017-10-13 15:18:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tVSPlx-Kjjw/lillys-verzenio-gets-priority-review-in-first-line-setting-cm859350,Eli Lilly and Company LLY announced that the FDA has granted priority review to its new drug application NDA for Verzenio abemaciclib This drug is looking forward to get approved for the first line treatment of advanced breast cancer Markedly the NDA was based upon the positive
NVS,NVS:US,BBG000LYF3S8,"Cascade Investment Advisors, Inc. Buys FedEx Corp, Ubiquiti Networks Inc, McKesson Corp, Sells ...",2017-10-13 15:10:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L-TONgTpT64/cascade-investment-advisors-inc-buys-fedex-corp-ubiquiti-networks-inc-mckesson-corp-sells-cm859395,Cascade Investment Advisors Inc New Purchases UBNT APOG SBH GTN KIM PRTY HDSN DWDP AMZN SO Added Positions FDX MCK DIS VMW CHRW INFY NCLH QCOM DNOW MUR Reduced Positions WGO MAT ILG CSCO MGA WY BWA ORCL R AMGN Sold Out
,,,"Cascade Investment Advisors, Inc. Buys FedEx Corp, Ubiquiti Networks Inc, McKesson Corp, Sells ...",2017-10-13 15:10:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L-TONgTpT64/cascade-investment-advisors-inc-buys-fedex-corp-ubiquiti-networks-inc-mckesson-corp-sells-cm859395,Cascade Investment Advisors Inc New Purchases UBNT APOG SBH GTN KIM PRTY HDSN DWDP AMZN SO Added Positions FDX MCK DIS VMW CHRW INFY NCLH QCOM DNOW MUR Reduced Positions WGO MAT ILG CSCO MGA WY BWA ORCL R AMGN Sold Out
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Continues To Inch Higher,2017-10-13 12:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CV0UPrlsmeI/the-swiss-stock-market-continues-to-inch-higher-20171013-00637,The Swiss Stock Market Continues To Inch Higher
,,,The Swiss Stock Market Continues To Inch Higher,2017-10-13 12:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CV0UPrlsmeI/the-swiss-stock-market-continues-to-inch-higher-20171013-00637,The Swiss Stock Market Continues To Inch Higher
NVS,NVS:US,BBG000LYF3S8,"Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy",2017-10-13 11:02:23 +0000,https://finance.yahoo.com/news/gilead-sciences-inc-gild-stock-110223682.html?.tsrc=rss,"Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion.  The slowdown in Gilead’s HCV business is starting to come to an end.  The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition."
,,,"Gilead Sciences, Inc. (GILD) Stock Is Primed After Kite Pharma Buy",2017-10-13 11:02:23 +0000,https://finance.yahoo.com/news/gilead-sciences-inc-gild-stock-110223682.html?.tsrc=rss,"Markets barely reacted when Gilead Sciences Inc. (NASDAQ:GILD) announced on Sept. 14 that it would buy Kite Pharma, Inc. for $11.9 billion.  The slowdown in Gilead’s HCV business is starting to come to an end.  The HCV segment will continue adding meaningfully to Gilead’s cash flow, which is money it needs to fund the Kite acquisition."
,,,Non-Alcoholic Steatohepatitis 2017 Progress Update,2017-10-13 01:12:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ib7V2EqL_pM/non-alcoholic-steatohepatitis-2017-progress-update-cm859149,Big time investors of late have been investing a substantial portion of their R amp D sources for the treatment of Non Alcoholic Steatohepatitis NASH The market for NASH is poised to witness rapid growth unlike other lucrative but saturated markets like cancer A chronic liver disease NASH
NVS,NVS:US,BBG000LYF3S8,Non-Alcoholic Steatohepatitis 2017 Progress Update,2017-10-13 01:12:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ib7V2EqL_pM/non-alcoholic-steatohepatitis-2017-progress-update-cm859149,Big time investors of late have been investing a substantial portion of their R amp D sources for the treatment of Non Alcoholic Steatohepatitis NASH The market for NASH is poised to witness rapid growth unlike other lucrative but saturated markets like cancer A chronic liver disease NASH
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Rose Above 9,300 Points",2017-10-12 12:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z5l7PNc_Cpw/the-swiss-stock-market-rose-above-9300-points-20171012-01010,"The Swiss Stock Market Rose Above 9,300 Points"
,,,"The Swiss Stock Market Rose Above 9,300 Points",2017-10-12 12:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z5l7PNc_Cpw/the-swiss-stock-market-rose-above-9300-points-20171012-01010,"The Swiss Stock Market Rose Above 9,300 Points"
NVS,NVS:US,BBG000LYF3S8,Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study,2017-10-11 17:13:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nWsQzJD0NC0/lillys-lly-verzenio-fails-in-phase-iii-lung-cancer-study-cm858308,The series of setbacks continues for Eli Lilly and Company LLY as the company announced that its phase III JUNIPER study failed to meet the primary endpoint The study was evaluating Verzenio in advanced non small lung cancer NSCLC with KRAS mutation Shares fell 1 on Tuesday after
,,,Lilly's (LLY) Verzenio Fails in Phase III Lung Cancer Study,2017-10-11 17:13:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nWsQzJD0NC0/lillys-lly-verzenio-fails-in-phase-iii-lung-cancer-study-cm858308,The series of setbacks continues for Eli Lilly and Company LLY as the company announced that its phase III JUNIPER study failed to meet the primary endpoint The study was evaluating Verzenio in advanced non small lung cancer NSCLC with KRAS mutation Shares fell 1 on Tuesday after
NVS,NVS:US,BBG000LYF3S8,Novartis decides not to sell Roche stake chairman tells newspaper,2017-10-11 16:50:54 +0000,https://finance.yahoo.com/news/novartis-decides-not-sell-roche-165054210.html?.tsrc=rss,"Novartis (NOVN.S) has decided not to sell its roughly $14 billion (10.61 billion pounds), 33 percent voting stake in Roche (ROG.S) following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss newspaper HandelsZeitung.  ""We said we would review whether it makes sense to sell the stake,"" Reinhardt told the newspaper.  In May 2016, Chief Executive Officer Joe Jimenez said he was ready to sell the Roche stake without demanding a premium and that Novartis has been discussing options with banks."
,,,Novartis decides not to sell Roche stake chairman tells newspaper,2017-10-11 16:50:54 +0000,https://finance.yahoo.com/news/novartis-decides-not-sell-roche-165054210.html?.tsrc=rss,"Novartis (NOVN.S) has decided not to sell its roughly $14 billion (10.61 billion pounds), 33 percent voting stake in Roche (ROG.S) following a review, Chairman Joerg Reinhardt said in an interview published on Wednesday in Swiss newspaper HandelsZeitung.  ""We said we would review whether it makes sense to sell the stake,"" Reinhardt told the newspaper.  In May 2016, Chief Executive Officer Joe Jimenez said he was ready to sell the Roche stake without demanding a premium and that Novartis has been discussing options with banks."
,,,Mylan Deals a Blow to Teva Pharmaceutical,2017-10-11 13:15:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YdBrYm_IM_U/mylan-deals-a-blow-to-teva-pharmaceutical-cm857951,Generic drugmakers Mylan NASDAQ MYL and Teva Pharmaceutical NYSE TEVA 160 usually deal blows to brand name drug manufacturers not each other but that changed last week when the Food and Drug Administration approved Mylan s generic version of Teva Pharmaceutical
NVS,NVS:US,BBG000LYF3S8,Mylan Deals a Blow to Teva Pharmaceutical,2017-10-11 13:15:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YdBrYm_IM_U/mylan-deals-a-blow-to-teva-pharmaceutical-cm857951,Generic drugmakers Mylan NASDAQ MYL and Teva Pharmaceutical NYSE TEVA 160 usually deal blows to brand name drug manufacturers not each other but that changed last week when the Food and Drug Administration approved Mylan s generic version of Teva Pharmaceutical
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed Ahead Of Fed Minutes,2017-10-11 12:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vzp3dU4IvX4/the-swiss-stock-market-finished-little-changed-ahead-of-fed-minutes-20171011-00897,The Swiss Stock Market Finished Little Changed Ahead Of Fed Minutes
,,,The Swiss Stock Market Finished Little Changed Ahead Of Fed Minutes,2017-10-11 12:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vzp3dU4IvX4/the-swiss-stock-market-finished-little-changed-ahead-of-fed-minutes-20171011-00897,The Swiss Stock Market Finished Little Changed Ahead Of Fed Minutes
,,,Here Come More Gene Therapies -- And More Pricing Debates,2017-10-11 12:35:00 +0000,http://finance.yahoo.com/r/bf13ad14-efdb-3683-80fd-3c333a2089f9/here-come-more-gene-therapies-and-more-pricing-debates?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Gene therapies like Spark Therapeutics' upcoming Luxturna and Novartis' FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer."
NVS,NVS:US,BBG000LYF3S8,Here Come More Gene Therapies -- And More Pricing Debates,2017-10-11 12:35:00 +0000,http://finance.yahoo.com/r/bf13ad14-efdb-3683-80fd-3c333a2089f9/here-come-more-gene-therapies-and-more-pricing-debates?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Gene therapies like Spark Therapeutics' upcoming Luxturna and Novartis' FDA-approved Kymriah are raising concerns about the rising cost of health care, leading some experts to suggest new ways to price treatments based on the benefits they offer."
,,,Amgen Wins Reprieve on Its 2nd-Best-Selling Drug,2017-10-11 00:12:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0tZT0vj6LpE/amgen-wins-reprieve-on-its-2nd-best-selling-drug-cm857860,The composition of matter patent protecting Amgen Inc s NASDAQ AMGN 160 white blood cell boosting drug Neulasta from competition has already expired That may mean it s only a matter of time before generic drug companies including Mylan NASDAQ MYL win FDA approval
NVS,NVS:US,BBG000LYF3S8,Amgen Wins Reprieve on Its 2nd-Best-Selling Drug,2017-10-11 00:12:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0tZT0vj6LpE/amgen-wins-reprieve-on-its-2nd-best-selling-drug-cm857860,The composition of matter patent protecting Amgen Inc s NASDAQ AMGN 160 white blood cell boosting drug Neulasta from competition has already expired That may mean it s only a matter of time before generic drug companies including Mylan NASDAQ MYL win FDA approval
NVS,NVS:US,BBG000LYF3S8,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 16:17:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wP2vD6cg5FA/5-pharma-biotech-stocks-that-could-be-big-winners-in-q3-earnings-cm857590,Pharma and biotech stocks started 2017 on a strong note with this part of the market remaining in favor as the year progresses So far this year the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index are up 25 6 and 14 6 respectively With investors being more
,,,5 Pharma & Biotech Stocks That Could Be Big Winners in Q3 Earnings,2017-10-10 16:17:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wP2vD6cg5FA/5-pharma-biotech-stocks-that-could-be-big-winners-in-q3-earnings-cm857590,Pharma and biotech stocks started 2017 on a strong note with this part of the market remaining in favor as the year progresses So far this year the Nasdaq Biotechnology Index and the NYSE ARCA Pharmaceutical Index are up 25 6 and 14 6 respectively With investors being more
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Again Finished Little Changed,2017-10-10 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CwsIfjft_uk/the-swiss-stock-market-again-finished-little-changed-20171010-01023,The Swiss Stock Market Again Finished Little Changed
,,,The Swiss Stock Market Again Finished Little Changed,2017-10-10 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CwsIfjft_uk/the-swiss-stock-market-again-finished-little-changed-20171010-01023,The Swiss Stock Market Again Finished Little Changed
,,,"VEA, GBF: Big ETF Inflows",2017-10-09 15:51:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-xFjmZchGVQ/vea-gbf-big-etf-inflows-cm856987,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 21 000 000 units or a 1 4 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,"VEA, GBF: Big ETF Inflows",2017-10-09 15:51:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-xFjmZchGVQ/vea-gbf-big-etf-inflows-cm856987,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 21 000 000 units or a 1 4 increase week over week Among the largest underlying components of VEA
,,,Roche (RHHBY) Receives FDA Approval For Cobas Zika Test,2017-10-09 14:56:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HQeuXulvTrY/roche-rhhby-receives-fda-approval-for-cobas-zika-test-cm856932,Roche Holdings AG RHHBY announced that it has obtained the FDA s approval for the cobas Zika test for use on the cobas 6800 8800 Systems The approval makes it the first commercially available test for the detection of the Zika virus RNA in human plasma intended for use in screening
NVS,NVS:US,BBG000LYF3S8,Roche (RHHBY) Receives FDA Approval For Cobas Zika Test,2017-10-09 14:56:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HQeuXulvTrY/roche-rhhby-receives-fda-approval-for-cobas-zika-test-cm856932,Roche Holdings AG RHHBY announced that it has obtained the FDA s approval for the cobas Zika test for use on the cobas 6800 8800 Systems The approval makes it the first commercially available test for the detection of the Zika virus RNA in human plasma intended for use in screening
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Clung To A Small Gain After Early Gains Erode,2017-10-09 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6ZHRoEu65YU/the-swiss-stock-market-clung-to-a-small-gain-after-early-gains-erode-20171009-00728,The Swiss Stock Market Clung To A Small Gain After Early Gains Erode
,,,The Swiss Stock Market Clung To A Small Gain After Early Gains Erode,2017-10-09 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6ZHRoEu65YU/the-swiss-stock-market-clung-to-a-small-gain-after-early-gains-erode-20171009-00728,The Swiss Stock Market Clung To A Small Gain After Early Gains Erode
NVS,NVS:US,BBG000LYF3S8,Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute,2017-10-06 14:45:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/anQgQDkKhIA/lilly-wins-favorable-ruling-from-us-pto-in-alimta-dispute-cm856174,Eli Lilly amp Company LLY announced that it has received a favorable ruling from the U S Patent and Trademark Office PTO in a dispute related to the vitamin regimen patent on its key cancer drug Alimta pemetrexed disodium In an inter partes review IPR ruling the U S PTO
,,,Lilly Wins Favorable Ruling From U.S. PTO in Alimta Dispute,2017-10-06 14:45:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/anQgQDkKhIA/lilly-wins-favorable-ruling-from-us-pto-in-alimta-dispute-cm856174,Eli Lilly amp Company LLY announced that it has received a favorable ruling from the U S Patent and Trademark Office PTO in a dispute related to the vitamin regimen patent on its key cancer drug Alimta pemetrexed disodium In an inter partes review IPR ruling the U S PTO
,,,European Stocks Close Mostly Lower Following U.S. Jobs Report,2017-10-06 12:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/748rZDPHLQg/european-stocks-close-mostly-lower-following-us-jobs-report-20171006-00587,European Stocks Close Mostly Lower Following U.S. Jobs Report
NVS,NVS:US,BBG000LYF3S8,European Stocks Close Mostly Lower Following U.S. Jobs Report,2017-10-06 12:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/748rZDPHLQg/european-stocks-close-mostly-lower-following-us-jobs-report-20171006-00587,European Stocks Close Mostly Lower Following U.S. Jobs Report
NVS,NVS:US,BBG000LYF3S8,European Shares Mostly Lower On Political Worries,2017-10-06 05:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PBQIKpmBZSs/european-shares-mostly-lower-on-political-worries-20171006-00145,European Shares Mostly Lower On Political Worries
,,,European Shares Mostly Lower On Political Worries,2017-10-06 05:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PBQIKpmBZSs/european-shares-mostly-lower-on-political-worries-20171006-00145,European Shares Mostly Lower On Political Worries
NVS,NVS:US,BBG000LYF3S8,Novartis: Alcon Gets European CE Mark For Clareon IOL With AutonoMe,2017-10-06 01:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1quYP0vROq4/novartis-alcon-gets-european-ce-mark-for-clareon-iol-with-autonome-20171006-00027,Novartis: Alcon Gets European CE Mark For Clareon IOL With AutonoMe
,,,Novartis: Alcon Gets European CE Mark For Clareon IOL With AutonoMe,2017-10-06 01:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1quYP0vROq4/novartis-alcon-gets-european-ce-mark-for-clareon-iol-with-autonome-20171006-00027,Novartis: Alcon Gets European CE Mark For Clareon IOL With AutonoMe
,,,Why Glaukos Corp. Stock Sank 12.8% in September,2017-10-05 20:48:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VqikbJXh6cE/why-glaukos-corp-stock-sank-128-in-september-cm855954,What happened After management decided to dial back revenue expectations for 2017 shares of Glaukos NYSE GKOS a medical device maker focused on diseases of the eye tumbled 160 13 in September according to data from S amp P Global Market Intelligence So
NVS,NVS:US,BBG000LYF3S8,Why Glaukos Corp. Stock Sank 12.8% in September,2017-10-05 20:48:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VqikbJXh6cE/why-glaukos-corp-stock-sank-128-in-september-cm855954,What happened After management decided to dial back revenue expectations for 2017 shares of Glaukos NYSE GKOS a medical device maker focused on diseases of the eye tumbled 160 13 in September according to data from S amp P Global Market Intelligence So
NVS,NVS:US,BBG000LYF3S8,4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3,2017-10-05 20:37:08 +0000,https://finance.yahoo.com/news/4-large-cap-drug-stocks-203708072.html?.tsrc=rss,"The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500."
,,,4 Large-Cap Drug Stocks to Buy on Solid Momentum Ahead of Q3,2017-10-05 20:37:08 +0000,https://finance.yahoo.com/news/4-large-cap-drug-stocks-203708072.html?.tsrc=rss,"The Large Cap Pharmaceuticals industry has gained 20.7% year to date, outpacing 14.7% gain for the S&P 500."
,,,Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early,2017-10-05 17:50:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xwWDsqxMNvA/teva-down-as-mylans-copaxone-40-mg-generic-arrives-early-cm855904,Shares of Teva Pharmaceutical Industries Limited TEVA declined almost 15 on Wednesday after Mylan N V MYL after hours on Tuesday announced the FDA approval of its generic version of a 40 mg thrice weekly formulation of the former s blockbuster multiple sclerosis drug Copaxone The FDA
NVS,NVS:US,BBG000LYF3S8,Teva Down as Mylan's Copaxone 40 mg Generic Arrives Early,2017-10-05 17:50:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xwWDsqxMNvA/teva-down-as-mylans-copaxone-40-mg-generic-arrives-early-cm855904,Shares of Teva Pharmaceutical Industries Limited TEVA declined almost 15 on Wednesday after Mylan N V MYL after hours on Tuesday announced the FDA approval of its generic version of a 40 mg thrice weekly formulation of the former s blockbuster multiple sclerosis drug Copaxone The FDA
,,,Changes in GlaxoSmithKline’s Valuation,2017-10-05 14:38:09 +0000,http://finance.yahoo.com/r/30acc338-c42a-3243-bd25-150cdfddf12a/changes-in-glaxosmithklines-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x."
NVS,NVS:US,BBG000LYF3S8,Changes in GlaxoSmithKline’s Valuation,2017-10-05 14:38:09 +0000,http://finance.yahoo.com/r/30acc338-c42a-3243-bd25-150cdfddf12a/changes-in-glaxosmithklines-valuation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of September 29, 2017, GlaxoSmithKline is trading at a forward PE (price-to-earnings) multiple of 14.2x, which is lower than the industry average of 15.7x."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Retreated From The Highs Of The Year,2017-10-05 12:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LkIdWRYj2Jw/the-swiss-stock-market-retreated-from-the-highs-of-the-year-20171005-00954,The Swiss Stock Market Retreated From The Highs Of The Year
,,,The Swiss Stock Market Retreated From The Highs Of The Year,2017-10-05 12:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LkIdWRYj2Jw/the-swiss-stock-market-retreated-from-the-highs-of-the-year-20171005-00954,The Swiss Stock Market Retreated From The Highs Of The Year
,,,"How Mylan's MS-Generic Approval Caused Teva, Momenta To Plunge",2017-10-04 20:32:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RJnO4osjttc/how-mylans-ms-generic-approval-caused-teva-momenta-to-plunge-cm855303,Never count out Mylan MYL an analyst said Wednesday after the Food and Drug Administration approved its generic versions of Teva Pharmaceutical s TEVA Copaxone a multiple sclerosis drug 160 setting shares of the two companies on vastly divergent
NVS,NVS:US,BBG000LYF3S8,"How Mylan's MS-Generic Approval Caused Teva, Momenta To Plunge",2017-10-04 20:32:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RJnO4osjttc/how-mylans-ms-generic-approval-caused-teva-momenta-to-plunge-cm855303,Never count out Mylan MYL an analyst said Wednesday after the Food and Drug Administration approved its generic versions of Teva Pharmaceutical s TEVA Copaxone a multiple sclerosis drug 160 setting shares of the two companies on vastly divergent
NVS,NVS:US,BBG000LYF3S8,A Generic Drug Face-Off Sends Mylan Soaring 19%,2017-10-04 18:33:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nCUCKUKHHkQ/a-generic-drug-face-off-sends-mylan-soaring-19-cm855361,What happened After the Food and Drug Administration surprisingly gave a green light to the company s Copaxone knockoff shares in Mylan Inc NASDAQ MYL 160 are surging 19 5 higher today at 11 30 a m EDT So what Teva Pharmaceutical NYSE TEVA received
,,,A Generic Drug Face-Off Sends Mylan Soaring 19%,2017-10-04 18:33:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nCUCKUKHHkQ/a-generic-drug-face-off-sends-mylan-soaring-19-cm855361,What happened After the Food and Drug Administration surprisingly gave a green light to the company s Copaxone knockoff shares in Mylan Inc NASDAQ MYL 160 are surging 19 5 higher today at 11 30 a m EDT So what Teva Pharmaceutical NYSE TEVA received
,,,Vanguard FTSE All-World ex-US ETF Experiences Big Inflow,2017-10-04 16:30:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dfE6X7P3-DE/vanguard-ftse-all-world-ex-us-etf-experiences-big-inflow-cm855225,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 317 4 million dollar inflow that s a 1 5 increase week over week
NVS,NVS:US,BBG000LYF3S8,Vanguard FTSE All-World ex-US ETF Experiences Big Inflow,2017-10-04 16:30:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dfE6X7P3-DE/vanguard-ftse-all-world-ex-us-etf-experiences-big-inflow-cm855225,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 317 4 million dollar inflow that s a 1 5 increase week over week
,,,"Pre-Market Most Active for Oct 4, 2017 :  TEVA, MYL, CATB, AEG, ECYT, FOLD, SAN, QQQ, F, MNKD, BBVA, NVS",2017-10-04 12:59:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mzO5iVVGQjA/pre-market-most-active-for-oct-4-2017-teva-myl-catb-aeg-ecyt-fold-san-qqq-f-mnkd-bbva-nvs-cm855030,The NASDAQ 100 Pre Market Indicator is down 4 47 to 5 990 59 The total Pre Market volume is currently 8 154 709 shares traded The following are the most active stocks for the pre market session Teva Pharmaceutical Industries Limited TEVA is 2 56 at 16 26
NVS,NVS:US,BBG000LYF3S8,"Pre-Market Most Active for Oct 4, 2017 :  TEVA, MYL, CATB, AEG, ECYT, FOLD, SAN, QQQ, F, MNKD, BBVA, NVS",2017-10-04 12:59:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mzO5iVVGQjA/pre-market-most-active-for-oct-4-2017-teva-myl-catb-aeg-ecyt-fold-san-qqq-f-mnkd-bbva-nvs-cm855030,The NASDAQ 100 Pre Market Indicator is down 4 47 to 5 990 59 The total Pre Market volume is currently 8 154 709 shares traded The following are the most active stocks for the pre market session Teva Pharmaceutical Industries Limited TEVA is 2 56 at 16 26
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Flat After Recent Climb To The Highs,2017-10-04 12:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mWD607hGGV4/the-swiss-stock-market-finished-flat-after-recent-climb-to-the-highs-20171004-00917,The Swiss Stock Market Finished Flat After Recent Climb To The Highs
,,,The Swiss Stock Market Finished Flat After Recent Climb To The Highs,2017-10-04 12:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mWD607hGGV4/the-swiss-stock-market-finished-flat-after-recent-climb-to-the-highs-20171004-00917,The Swiss Stock Market Finished Flat After Recent Climb To The Highs
NVS,NVS:US,BBG000LYF3S8,"Why bluebird bio, Inc. Stock Gained 10% in September",2017-10-03 15:55:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4zb2E1LusVQ/why-bluebird-bio-inc-stock-gained-10-in-september-cm854580,What happened Shares of bluebird bio Inc NASDAQ BLUE a clinical stage biotech developing cell based therapies rose 10 in September according to data from S amp P Global Market Intelligence Although there were a few positive developments last month investors
,,,"Why bluebird bio, Inc. Stock Gained 10% in September",2017-10-03 15:55:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4zb2E1LusVQ/why-bluebird-bio-inc-stock-gained-10-in-september-cm854580,What happened Shares of bluebird bio Inc NASDAQ BLUE a clinical stage biotech developing cell based therapies rose 10 in September according to data from S amp P Global Market Intelligence Although there were a few positive developments last month investors
NVS,NVS:US,BBG000LYF3S8,FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta,2017-10-03 14:58:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TU8B64ry1mY/fda-accepts-roches-rhhby-application-for-adjuvant-perjeta-cm854559,Roche Holdings AG RHHBY announced that the FDA has accepted the company s supplemental Biologics License Application sBLA and granted Priority Review for breast cancer drug Perjeta in combination with Herceptin trastuzumab and chemotherapy the Perjeta based regimen for adjuvant
,,,FDA Accepts Roche's (RHHBY) Application for Adjuvant Perjeta,2017-10-03 14:58:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TU8B64ry1mY/fda-accepts-roches-rhhby-application-for-adjuvant-perjeta-cm854559,Roche Holdings AG RHHBY announced that the FDA has accepted the company s supplemental Biologics License Application sBLA and granted Priority Review for breast cancer drug Perjeta in combination with Herceptin trastuzumab and chemotherapy the Perjeta based regimen for adjuvant
,,,FDA Accepts Roche&apos;s (RHHBY) Application for Adjuvant Perjeta,2017-10-03 13:24:01 +0000,https://finance.yahoo.com/news/fda-accepts-roche-apos-rhhby-132401822.html?.tsrc=rss,Roche Holdings AG (RHHBY) announced that the FDA has accepted the company&apos;s sBLA and granted Priority Review for breast cancer drug regimen Perjeta
NVS,NVS:US,BBG000LYF3S8,FDA Accepts Roche&apos;s (RHHBY) Application for Adjuvant Perjeta,2017-10-03 13:24:01 +0000,https://finance.yahoo.com/news/fda-accepts-roche-apos-rhhby-132401822.html?.tsrc=rss,Roche Holdings AG (RHHBY) announced that the FDA has accepted the company&apos;s sBLA and granted Priority Review for breast cancer drug regimen Perjeta
NVS,NVS:US,BBG000LYF3S8,IIROC Trade Resumption - NVS,2017-10-03 13:14:00 +0000,https://finance.yahoo.com/news/iiroc-trade-resumption-nvs-131400609.html?.tsrc=rss,IIROC Trade Resumption - NVS
,,,IIROC Trade Resumption - NVS,2017-10-03 13:14:00 +0000,https://finance.yahoo.com/news/iiroc-trade-resumption-nvs-131400609.html?.tsrc=rss,IIROC Trade Resumption - NVS
,,,The Swiss Stock Market Climbed To Over A 2-Year High,2017-10-03 12:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5ArR51iu6R0/the-swiss-stock-market-climbed-to-over-a-2year-high-20171003-00989,The Swiss Stock Market Climbed To Over A 2-Year High
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed To Over A 2-Year High,2017-10-03 12:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5ArR51iu6R0/the-swiss-stock-market-climbed-to-over-a-2year-high-20171003-00989,The Swiss Stock Market Climbed To Over A 2-Year High
,,,Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing,2017-10-02 20:48:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qCaFqfJamf0/why-bluebirds-downgrade-sent-these-two-rivals-skyrocketing-cm854190,Bluebird Bio BLUE toppled to a four week low Monday 160 as an analyst downgraded the stock on doubts regarding its sickle cell disease drug 160 sending shares of rivals Crispr Therapeutics CRSP and Editas Medicine EDIT
NVS,NVS:US,BBG000LYF3S8,Why Bluebird's Downgrade Sent These Two Rivals Skyrocketing,2017-10-02 20:48:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qCaFqfJamf0/why-bluebirds-downgrade-sent-these-two-rivals-skyrocketing-cm854190,Bluebird Bio BLUE toppled to a four week low Monday 160 as an analyst downgraded the stock on doubts regarding its sickle cell disease drug 160 sending shares of rivals Crispr Therapeutics CRSP and Editas Medicine EDIT
NVS,NVS:US,BBG000LYF3S8,Here's Why Bluebird Bio (BLUE) Stock Is Falling Today,2017-10-02 17:46:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yT5eEkQXjNs/heres-why-bluebird-bio-blue-stock-is-falling-today-cm854044,Shares of Bluebird Bio BLUE a major player in the emerging gene therapy and CAR T research markets slumped more than 6 in morning trading Monday after receiving a key analyst downgrade In a note to clients Morgan Stanley downgraded the biotech firm from Equal weight to Underweight
,,,Here's Why Bluebird Bio (BLUE) Stock Is Falling Today,2017-10-02 17:46:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yT5eEkQXjNs/heres-why-bluebird-bio-blue-stock-is-falling-today-cm854044,Shares of Bluebird Bio BLUE a major player in the emerging gene therapy and CAR T research markets slumped more than 6 in morning trading Monday after receiving a key analyst downgrade In a note to clients Morgan Stanley downgraded the biotech firm from Equal weight to Underweight
,,,"[$$] Lilly Faces Off With Pfizer, Novartis",2017-10-02 15:14:00 +0000,http://finance.yahoo.com/r/46b527a7-d65b-3b7e-af65-f74cade81a5b/lilly-faces-off-with-pfizer-novartis-1506957267?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse  Lilly’s Verzenio (abemaciclib) has obtained Food and Drug Administration approval for use in patients with HR+, HER2- metastatic breast cancer who progressed on prior therapy.  Given the data that we have seen for Lilly’s (LLY) product from the MONARCH-1 and MONARCH-2 studies, we had expected the approval, although it does comes three to four months earlier than we had expected, representing another example of the agency working to get innovative products to the market quickly.  Along with approval for use in combination with fulvestrant, Verzenio has the unique indication (relative to key competitors Pfizer’s (PFE) Ibrance and Novartis’s (NVS) Kisqali) for use as monotherapy after endocrine therapy and chemotherapy in patients with metastatic disease."
NVS,NVS:US,BBG000LYF3S8,"[$$] Lilly Faces Off With Pfizer, Novartis",2017-10-02 15:14:00 +0000,http://finance.yahoo.com/r/46b527a7-d65b-3b7e-af65-f74cade81a5b/lilly-faces-off-with-pfizer-novartis-1506957267?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Credit Suisse  Lilly’s Verzenio (abemaciclib) has obtained Food and Drug Administration approval for use in patients with HR+, HER2- metastatic breast cancer who progressed on prior therapy.  Given the data that we have seen for Lilly’s (LLY) product from the MONARCH-1 and MONARCH-2 studies, we had expected the approval, although it does comes three to four months earlier than we had expected, representing another example of the agency working to get innovative products to the market quickly.  Along with approval for use in combination with fulvestrant, Verzenio has the unique indication (relative to key competitors Pfizer’s (PFE) Ibrance and Novartis’s (NVS) Kisqali) for use as monotherapy after endocrine therapy and chemotherapy in patients with metastatic disease."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Significant Gain,2017-10-02 12:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vt-plU5uvVY/the-swiss-stock-market-finished-with-a-significant-gain-20171002-01098,The Swiss Stock Market Finished With A Significant Gain
,,,The Swiss Stock Market Finished With A Significant Gain,2017-10-02 12:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vt-plU5uvVY/the-swiss-stock-market-finished-with-a-significant-gain-20171002-01098,The Swiss Stock Market Finished With A Significant Gain
,,,Big Dose Of Healthy News Sends Biotech Stocks To New Heights,2017-09-29 20:35:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3FWQwxHomzs/big-dose-of-healthy-news-sends-biotech-stocks-to-new-heights-cm853272,Biotech news aplenty has breathed renewed life into the sector driving 160 those stocks to new highs ibd display video id 2324623 width 50 float left autostart true Zogenix ZGNX on Friday spiked more than 140 nearing a four year high after reporting positive Phase
NVS,NVS:US,BBG000LYF3S8,Big Dose Of Healthy News Sends Biotech Stocks To New Heights,2017-09-29 20:35:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3FWQwxHomzs/big-dose-of-healthy-news-sends-biotech-stocks-to-new-heights-cm853272,Biotech news aplenty has breathed renewed life into the sector driving 160 those stocks to new highs ibd display video id 2324623 width 50 float left autostart true Zogenix ZGNX on Friday spiked more than 140 nearing a four year high after reporting positive Phase
,,,Training cells to fight cancer,2017-09-29 18:37:00 +0000,https://finance.yahoo.com/video/training-cells-fight-cancer-183700493.html?.tsrc=rss,"In today’s Modern Medicine series, CNBC’s Meg Tirrell brings us the story of a little girl whose life was saved by a different kind of cancer treatment."
NVS,NVS:US,BBG000LYF3S8,Training cells to fight cancer,2017-09-29 18:37:00 +0000,https://finance.yahoo.com/video/training-cells-fight-cancer-183700493.html?.tsrc=rss,"In today’s Modern Medicine series, CNBC’s Meg Tirrell brings us the story of a little girl whose life was saved by a different kind of cancer treatment."
,,,"VEA, JPNL: Big ETF Inflows",2017-09-29 16:36:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_wY_UqnFT6o/vea-jpnl-big-etf-inflows-cm853165,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 12 003 113 units or a 0 8 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,"VEA, JPNL: Big ETF Inflows",2017-09-29 16:36:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_wY_UqnFT6o/vea-jpnl-big-etf-inflows-cm853165,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 12 003 113 units or a 0 8 increase week over week Among the largest underlying components of VEA
,,,"Two patients show the promise of a historic treatment, with an equally historic price tag",2017-09-29 14:52:07 +0000,http://finance.yahoo.com/r/f0e802f0-481a-363e-832e-81cd3b645db3/104740574?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104740574&yptr=yahoo&.tsrc=rss,Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.
NVS,NVS:US,BBG000LYF3S8,"Two patients show the promise of a historic treatment, with an equally historic price tag",2017-09-29 14:52:07 +0000,http://finance.yahoo.com/r/f0e802f0-481a-363e-832e-81cd3b645db3/104740574?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104740574&yptr=yahoo&.tsrc=rss,Kymriah is among a new wave of therapies that use a patient's own cells as medicine. But this historic treatment comes with a historic price.
NVS,NVS:US,BBG000LYF3S8,Ligand&apos;s Captisol Deals Set to Drive Growth in the Long Run,2017-09-29 13:25:01 +0000,https://finance.yahoo.com/news/ligand-apos-captisol-deals-set-132501020.html?.tsrc=rss,"Ligand&apos;s (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn."
,,,Ligand&apos;s Captisol Deals Set to Drive Growth in the Long Run,2017-09-29 13:25:01 +0000,https://finance.yahoo.com/news/ligand-apos-captisol-deals-set-132501020.html?.tsrc=rss,"Ligand&apos;s (LGND) Captisol formulation technology platform allows it to partner with several leading drug companies, thus helping it earn milestones and royalty payments in turn."
,,,Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet,2017-09-29 12:35:00 +0000,http://finance.yahoo.com/r/7dd9fb01-3d84-3fee-9c16-5fa58ba85831/big-pharma-doesnt-want-health-outcomes-to-sway-pricing-at-least-not-yet?utm_source=yahoo&utm_medium=partner&utm_campaign=yahoofeed&partner=yahoofeed&yptr=yahoo&.tsrc=rss,"Health insurers and pharmacy benefits managers argue that drug prices should be tied to the benefits the products bring to patients, but the pharma industry has been slow to buy into that model."
NVS,NVS:US,BBG000LYF3S8,Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet,2017-09-29 12:35:00 +0000,http://finance.yahoo.com/r/7dd9fb01-3d84-3fee-9c16-5fa58ba85831/big-pharma-doesnt-want-health-outcomes-to-sway-pricing-at-least-not-yet?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Health insurers and pharmacy benefits managers argue that drug prices should be tied to the benefits the products bring to patients, but the pharma industry has been slow to buy into that model."
NVS,NVS:US,BBG000LYF3S8,Big Pharma Doesn't Want Health Outcomes To Sway Pricing -- At Least Not Yet,2017-09-29 12:35:00 +0000,http://finance.yahoo.com/r/7dd9fb01-3d84-3fee-9c16-5fa58ba85831/big-pharma-doesnt-want-health-outcomes-to-sway-pricing-at-least-not-yet?utm_source=yahoo&utm_medium=partner&utm_campaign=yahoofeed&partner=yahoofeed&yptr=yahoo&.tsrc=rss,"Health insurers and pharmacy benefits managers argue that drug prices should be tied to the benefits the products bring to patients, but the pharma industry has been slow to buy into that model."
,,,The Swiss Stock Market Climbed After Recovering From Weak Start,2017-09-29 12:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YE9la6A49qk/the-swiss-stock-market-climbed-after-recovering-from-weak-start-20170929-00702,The Swiss Stock Market Climbed After Recovering From Weak Start
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed After Recovering From Weak Start,2017-09-29 12:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YE9la6A49qk/the-swiss-stock-market-climbed-after-recovering-from-weak-start-20170929-00702,The Swiss Stock Market Climbed After Recovering From Weak Start
,,,"Historic treatment, historic price",2017-09-29 12:13:00 +0000,https://finance.yahoo.com/video/historic-treatment-historic-price-121300756.html?.tsrc=rss,"Novartis raised eyebrows with the price of its newly approved CAR-T therapy: $475,000. But some argue the price makes sense, given that CAR-T is a one-time treatment, not a chronic therapy, and there are only about 600 patients each year who may take i..."
NVS,NVS:US,BBG000LYF3S8,"Historic treatment, historic price",2017-09-29 12:13:00 +0000,https://finance.yahoo.com/video/historic-treatment-historic-price-121300756.html?.tsrc=rss,"Novartis raised eyebrows with the price of its newly approved CAR-T therapy: $475,000. But some argue the price makes sense, given that CAR-T is a one-time treatment, not a chronic therapy, and there are only about 600 patients each year who may take i..."
NVS,NVS:US,BBG000LYF3S8,Novartis Could Acquire This Biotech — Why A Deal Is 'Very Logical',2017-09-28 21:34:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WfxMfWXn6qM/novartis-could-acquire-this-biotech-why-a-deal-is-very-logical-cm852694,Advanced Accelerator Applications AAAP launched to a record high Thursday on rumors Swiss drug giant Novartis NVS could attempt to take it over a potential deal one analyst called very logical ibd display video id 2322998 width 50 float
,,,Novartis Could Acquire This Biotech — Why A Deal Is 'Very Logical',2017-09-28 21:34:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WfxMfWXn6qM/novartis-could-acquire-this-biotech-why-a-deal-is-very-logical-cm852694,Advanced Accelerator Applications AAAP launched to a record high Thursday on rumors Swiss drug giant Novartis NVS could attempt to take it over a potential deal one analyst called very logical ibd display video id 2322998 width 50 float
,,,Why Amgen's Drug Win Sent AbbVie Stock Into The Stratosphere,2017-09-28 21:34:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6RgH0tGmS00/why-amgens-drug-win-sent-abbvie-stock-into-the-stratosphere-cm852720,AbbVie ABBV launched to a record high Thursday after it settled a patent dispute with Amgen AMGN that will require the No 1 biotech to pay AbbVie royalties on sales of its Humira copycat ibd display video id 2322998 width 50 float left autostart true By
NVS,NVS:US,BBG000LYF3S8,Why Amgen's Drug Win Sent AbbVie Stock Into The Stratosphere,2017-09-28 21:34:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6RgH0tGmS00/why-amgens-drug-win-sent-abbvie-stock-into-the-stratosphere-cm852720,AbbVie ABBV launched to a record high Thursday after it settled a patent dispute with Amgen AMGN that will require the No 1 biotech to pay AbbVie royalties on sales of its Humira copycat ibd display video id 2322998 width 50 float left autostart true By
NVS,NVS:US,BBG000LYF3S8,Bluebird Hits High On Bullish Report Highlighting Blood Drugs,2017-09-28 21:33:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5o9fy8Hv5g8/bluebird-hits-high-on-bullish-report-highlighting-blood-drugs-cm852795,Bluebird Bio BLUE rocketed to a two year high Thursday on an analyst s bullish report outlining the biotech s blood disease pipeline that includes a tie up with No 2 biotech Celgene CELG ibd display video id 2323827 width 50 float left autostart true By
,,,Bluebird Hits High On Bullish Report Highlighting Blood Drugs,2017-09-28 21:33:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5o9fy8Hv5g8/bluebird-hits-high-on-bullish-report-highlighting-blood-drugs-cm852795,Bluebird Bio BLUE rocketed to a two year high Thursday on an analyst s bullish report outlining the biotech s blood disease pipeline that includes a tie up with No 2 biotech Celgene CELG ibd display video id 2323827 width 50 float left autostart true By
NVS,NVS:US,BBG000LYF3S8,Novartis Could Acquire This Biotech — Why A Deal Is &apos;Very Logical&apos;,2017-09-28 20:50:30 +0000,http://finance.yahoo.com/r/dc15b68f-8765-3c6f-88ef-b6de75620a5d/novartis-could-acquire-this-biotech-why-a-deal-is-very-logical?src=A00220&yptr=yahoo&.tsrc=rss,Advanced Accelerator Applications launched to a record high Thursday on rumors Novartis could attempt to take it over.
,,,Novartis Could Acquire This Biotech — Why A Deal Is &apos;Very Logical&apos;,2017-09-28 20:50:30 +0000,http://finance.yahoo.com/r/dc15b68f-8765-3c6f-88ef-b6de75620a5d/novartis-could-acquire-this-biotech-why-a-deal-is-very-logical?src=A00220&yptr=yahoo&.tsrc=rss,Advanced Accelerator Applications launched to a record high Thursday on rumors Novartis could attempt to take it over.
NVS,NVS:US,BBG000LYF3S8,IIROC Trading Halt - NVS,2017-09-28 20:28:00 +0000,https://finance.yahoo.com/news/iiroc-trading-halt-nvs-202800037.html?.tsrc=rss,IIROC Trading Halt - NVS
,,,IIROC Trading Halt - NVS,2017-09-28 20:28:00 +0000,https://finance.yahoo.com/news/iiroc-trading-halt-nvs-202800037.html?.tsrc=rss,IIROC Trading Halt - NVS
NVS,NVS:US,BBG000LYF3S8,IIROC Trading Halt - NVS,2017-09-28 20:28:00 +0000,https://finance.yahoo.com/news/iiroc-trading-halt-nvs-202800939.html?.tsrc=rss,"VANCOUVER , Sept. 28, 2017 /CNW/ - The following issues have been halted by IIROC: Company: Novicius Corp. CSE Symbol: NVS Reason: At the request of the Company Pending News Halt Time (ET): 4:01 PM IIROC ..."
,,,IIROC Trading Halt - NVS,2017-09-28 20:28:00 +0000,https://finance.yahoo.com/news/iiroc-trading-halt-nvs-202800939.html?.tsrc=rss,"VANCOUVER , Sept. 28, 2017 /CNW/ - The following issues have been halted by IIROC: Company: Novicius Corp. CSE Symbol: NVS Reason: At the request of the Company Pending News Halt Time (ET): 4:01 PM IIROC ..."
NVS,NVS:US,BBG000LYF3S8,Why Advanced Accelerator Application SA Stock Jumped Higher Today,2017-09-28 17:42:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wEov3XtehL4/why-advanced-accelerator-application-sa-stock-jumped-higher-today-cm852701,What happened Shares of Advanced Accelerator Application NASDAQ AAAP 160 are up 12 as of 11 23 a m EDT after Bloomberg reported that Novartis NYSE NVS is considering acquiring the radiopharmaceutical company If it goes through the buyout would be a welcome
,,,Why Advanced Accelerator Application SA Stock Jumped Higher Today,2017-09-28 17:42:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wEov3XtehL4/why-advanced-accelerator-application-sa-stock-jumped-higher-today-cm852701,What happened Shares of Advanced Accelerator Application NASDAQ AAAP 160 are up 12 as of 11 23 a m EDT after Bloomberg reported that Novartis NYSE NVS is considering acquiring the radiopharmaceutical company If it goes through the buyout would be a welcome
,,,Why Advanced Accelerator Application SA Stock Jumped Higher Today,2017-09-28 15:56:30 +0000,http://finance.yahoo.com/r/df8fef75-50d1-31e7-ad54-3957c714642d/why-advanced-accelerator-application-sa-stock-jump.aspx?yptr=yahoo&.tsrc=rss,An acquisition rumor has the radiopharmaceutical company&apos;s shares on the rise.
NVS,NVS:US,BBG000LYF3S8,Why Advanced Accelerator Application SA Stock Jumped Higher Today,2017-09-28 15:56:30 +0000,http://finance.yahoo.com/r/df8fef75-50d1-31e7-ad54-3957c714642d/why-advanced-accelerator-application-sa-stock-jump.aspx?yptr=yahoo&.tsrc=rss,An acquisition rumor has the radiopharmaceutical company&apos;s shares on the rise.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Inched Higher In Light Trade,2017-09-28 12:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dXORSAxZWQE/the-swiss-stock-market-inched-higher-in-light-trade-20170928-01019,The Swiss Stock Market Inched Higher In Light Trade
,,,The Swiss Stock Market Inched Higher In Light Trade,2017-09-28 12:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dXORSAxZWQE/the-swiss-stock-market-inched-higher-in-light-trade-20170928-01019,The Swiss Stock Market Inched Higher In Light Trade
,,,"Novartis forges UC Berkeley pact, sees drug hopefuls in 3 years",2017-09-28 05:39:09 +0000,https://finance.yahoo.com/news/novartis-forges-uc-berkeley-pact-053909234.html?.tsrc=rss,"Novartis's research  head expects an alliance with a University of California  chemistry lab to produce drug candidates within three years as  the Swiss company accelerates its hunt for new medicines.  Novartis announced the Novartis-Berkeley Center for  Proteomics and Chemistry Technologies on Thursday.  Basel-based Novartis hopes Berkeley scientists including  Daniel Nomura, the professor who runs the lab, will speed its  search for the Achilles' heels of hard-to-treat diseases."
NVS,NVS:US,BBG000LYF3S8,"Novartis forges UC Berkeley pact, sees drug hopefuls in 3 years",2017-09-28 05:39:09 +0000,https://finance.yahoo.com/news/novartis-forges-uc-berkeley-pact-053909234.html?.tsrc=rss,"Novartis's research  head expects an alliance with a University of California  chemistry lab to produce drug candidates within three years as  the Swiss company accelerates its hunt for new medicines.  Novartis announced the Novartis-Berkeley Center for  Proteomics and Chemistry Technologies on Thursday.  Basel-based Novartis hopes Berkeley scientists including  Daniel Nomura, the professor who runs the lab, will speed its  search for the Achilles' heels of hard-to-treat diseases."
NVS,NVS:US,BBG000LYF3S8,"STADA Arzneimittel Appoints Claudio Albrecht As CEO, With Immediate Effect",2017-09-28 02:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4OlB3Wx4D0s/stada-arzneimittel-appoints-claudio-albrecht-as-ceo-with-immediate-effect-20170928-00079,"STADA Arzneimittel Appoints Claudio Albrecht As CEO, With Immediate Effect"
,,,"STADA Arzneimittel Appoints Claudio Albrecht As CEO, With Immediate Effect",2017-09-28 02:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4OlB3Wx4D0s/stada-arzneimittel-appoints-claudio-albrecht-as-ceo-with-immediate-effect-20170928-00079,"STADA Arzneimittel Appoints Claudio Albrecht As CEO, With Immediate Effect"
NVS,NVS:US,BBG000LYF3S8,Novartis Reportedly Considers Deal For Advanced Accelerator Applications,2017-09-27 22:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_7GcDAX6CxI/novartis-reportedly-considers-deal-for-advanced-accelerator-applications-20170927-01374,Novartis Reportedly Considers Deal For Advanced Accelerator Applications
,,,Novartis Reportedly Considers Deal For Advanced Accelerator Applications,2017-09-27 22:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_7GcDAX6CxI/novartis-reportedly-considers-deal-for-advanced-accelerator-applications-20170927-01374,Novartis Reportedly Considers Deal For Advanced Accelerator Applications
,,,Novartis Is Said to Eye Deal for Radioactive-Drug Maker AAA,2017-09-27 21:01:05 +0000,http://finance.yahoo.com/r/697df3a4-614d-385e-bcaa-10eb4b98f1df/novartis-is-said-to-consider-acquisition-of-advanced-accelerator?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Novartis AG is considering a deal for radiopharmaceutical company Advanced Accelerator Applications SA as the giant Swiss drugmaker seeks acquisitions to boost growth, according to people familiar with ..."
NVS,NVS:US,BBG000LYF3S8,Novartis Is Said to Eye Deal for Radioactive-Drug Maker AAA,2017-09-27 21:01:05 +0000,http://finance.yahoo.com/r/697df3a4-614d-385e-bcaa-10eb4b98f1df/novartis-is-said-to-consider-acquisition-of-advanced-accelerator?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Novartis AG is considering a deal for radiopharmaceutical company Advanced Accelerator Applications SA as the giant Swiss drugmaker seeks acquisitions to boost growth, according to people familiar with ..."
,,,Galapagos Pops After Eczema Drug Shows Promise Vs. Regeneron,2017-09-27 20:43:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s91TmB0uU6c/galapagos-pops-after-eczema-drug-shows-promise-vs-regeneron-cm852063,Galapagos GLPG popped Wednesday after its eczema drug compared favorably with potential blockbuster Dupixent from Regeneron Pharmaceuticals REGN and Sanofi SNY in a Phase 1 trial ibd display video id 2322091 width 50 float left autostart true
NVS,NVS:US,BBG000LYF3S8,Galapagos Pops After Eczema Drug Shows Promise Vs. Regeneron,2017-09-27 20:43:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s91TmB0uU6c/galapagos-pops-after-eczema-drug-shows-promise-vs-regeneron-cm852063,Galapagos GLPG popped Wednesday after its eczema drug compared favorably with potential blockbuster Dupixent from Regeneron Pharmaceuticals REGN and Sanofi SNY in a Phase 1 trial ibd display video id 2322091 width 50 float left autostart true
,,,3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day,2017-09-27 18:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/otMXU2jUsXw/3-heart-disease-focused-stocks-to-buy-ahead-of-world-heart-day-cm852093,InvestorPlace Stock Market News Stock Advice amp Trading Tips World Heart Day is observed every year on September 29 to raise awareness across the world about cardiovascular CV diseases CV diseases more commonly known as heart disease or stroke are basically diseases of the heart
NVS,NVS:US,BBG000LYF3S8,3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day,2017-09-27 18:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/otMXU2jUsXw/3-heart-disease-focused-stocks-to-buy-ahead-of-world-heart-day-cm852093,InvestorPlace Stock Market News Stock Advice amp Trading Tips World Heart Day is observed every year on September 29 to raise awareness across the world about cardiovascular CV diseases CV diseases more commonly known as heart disease or stroke are basically diseases of the heart
,,,Intercept (ICPT) Provides Safety Guidelines For Ocaliva,2017-09-27 16:00:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/93712jrIyZE/intercept-icpt-provides-safety-guidelines-for-ocaliva-cm851900,Intercept Pharmaceuticals Inc ICPT provided a statement on the recent safety and dosing issues for lead drug Ocaliva Ocaliva was approved in the United States in May 2016 and subsequently in the European Union and Canada for the treatment of patients with primary biliary cholangitis
NVS,NVS:US,BBG000LYF3S8,Intercept (ICPT) Provides Safety Guidelines For Ocaliva,2017-09-27 16:00:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/93712jrIyZE/intercept-icpt-provides-safety-guidelines-for-ocaliva-cm851900,Intercept Pharmaceuticals Inc ICPT provided a statement on the recent safety and dosing issues for lead drug Ocaliva Ocaliva was approved in the United States in May 2016 and subsequently in the European Union and Canada for the treatment of patients with primary biliary cholangitis
NVS,NVS:US,BBG000LYF3S8,Teva Reintroduces Generic Depo-Provera Injection in U.S.,2017-09-27 15:59:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XJ7OhFCSw-A/teva-reintroduces-generic-depo-provera-injection-in-us-cm851858,Teva Pharmaceutical Industries Ltd TEVA announced the reintroduction of the generic equivalent to Depo Prover Contraceptive Injection medroxyprogesterone acetate injectable suspension USP 150 mg mL in the United States indicated for the prevention of pregnancy With the reintroduction
,,,Teva Reintroduces Generic Depo-Provera Injection in U.S.,2017-09-27 15:59:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XJ7OhFCSw-A/teva-reintroduces-generic-depo-provera-injection-in-us-cm851858,Teva Pharmaceutical Industries Ltd TEVA announced the reintroduction of the generic equivalent to Depo Prover Contraceptive Injection medroxyprogesterone acetate injectable suspension USP 150 mg mL in the United States indicated for the prevention of pregnancy With the reintroduction
,,,AstraZeneca's Bevespi Improves Lung Function in Phase III Study,2017-09-27 14:58:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c9HEZap6WeI/astrazenecas-bevespi-improves-lung-function-in-phase-iii-study-cm851768,AstraZeneca plc AZN announced top line data from a late stage study which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with moderate to very severe chronic obstructive pulmonary disease COPD The phase III PINNACLE 4
NVS,NVS:US,BBG000LYF3S8,AstraZeneca's Bevespi Improves Lung Function in Phase III Study,2017-09-27 14:58:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c9HEZap6WeI/astrazenecas-bevespi-improves-lung-function-in-phase-iii-study-cm851768,AstraZeneca plc AZN announced top line data from a late stage study which showed that its Bevespi Aerosphere led to a statistically significant improvement in lung function in patients with moderate to very severe chronic obstructive pulmonary disease COPD The phase III PINNACLE 4
NVS,NVS:US,BBG000LYF3S8,Edison Issues Free Strategic Overview On Future of T-Cell Therapies for Cancer,2017-09-27 14:00:00 +0000,https://finance.yahoo.com/news/edison-issues-free-strategic-overview-140000943.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / September 27, 2017 / The US approval of Novartis AG's (NYSE: NVS) Kymriah for childhood leukaemia opens a dramatic new era of cancer therapy deploying powerful modified white ..."
,,,Edison Issues Free Strategic Overview On Future of T-Cell Therapies for Cancer,2017-09-27 14:00:00 +0000,https://finance.yahoo.com/news/edison-issues-free-strategic-overview-140000943.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / September 27, 2017 / The US approval of Novartis AG's (NYSE: NVS) Kymriah for childhood leukaemia opens a dramatic new era of cancer therapy deploying powerful modified white ..."
NVS,NVS:US,BBG000LYF3S8,Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors,2017-09-27 13:53:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TfZ79p6XiyA/why-aurinia-pharmaceuticals-could-be-a-gold-mine-for-growth-investors-cm851559,Aurinia Pharmaceuticals Inc NASDAQ AUPH stock has already tripled this year on renewed hopes of success for an experimental lupus treatment Despite this year s big run up this clinical stage biotech stock could still be a gold mine for growth investors Aurinia shares
,,,Why Aurinia Pharmaceuticals Could Be a Gold Mine for Growth Investors,2017-09-27 13:53:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TfZ79p6XiyA/why-aurinia-pharmaceuticals-could-be-a-gold-mine-for-growth-investors-cm851559,Aurinia Pharmaceuticals Inc NASDAQ AUPH stock has already tripled this year on renewed hopes of success for an experimental lupus treatment Despite this year s big run up this clinical stage biotech stock could still be a gold mine for growth investors Aurinia shares
NVS,NVS:US,BBG000LYF3S8,"FDA Chief Gottlieb Addresses Opioids, Cancer, New Therapies",2017-09-26 19:53:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zC8vLEUgwK0/fda-chief-gottlieb-addresses-opioids-cancer-new-therapies-cm851328,In his first run with the Food and Drug Administration gene and cell therapy were early stage theoretical concepts FDA Commissioner Scott Gottlieb said Tuesday ibd display video id 2322032 width 50 float left autostart true But last month the FDA approved its first
,,,"FDA Chief Gottlieb Addresses Opioids, Cancer, New Therapies",2017-09-26 19:53:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zC8vLEUgwK0/fda-chief-gottlieb-addresses-opioids-cancer-new-therapies-cm851328,In his first run with the Food and Drug Administration gene and cell therapy were early stage theoretical concepts FDA Commissioner Scott Gottlieb said Tuesday ibd display video id 2322032 width 50 float left autostart true But last month the FDA approved its first
,,,Kite Pharma Triples So Far in 2017: What's Driving the Rally?,2017-09-26 15:57:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v1gBINx_1RA/kite-pharma-triples-so-far-in-2017-whats-driving-the-rally-cm851068,Shares of Kite Pharma Inc KITE have had an impressive run so far this year riding on the progress of its revolutionary CAR T therapy so far this year The biopharmaceutical company s shares have surged 300 significantly outperforming the industry s gain of 15 9 in that period
NVS,NVS:US,BBG000LYF3S8,Kite Pharma Triples So Far in 2017: What's Driving the Rally?,2017-09-26 15:57:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v1gBINx_1RA/kite-pharma-triples-so-far-in-2017-whats-driving-the-rally-cm851068,Shares of Kite Pharma Inc KITE have had an impressive run so far this year riding on the progress of its revolutionary CAR T therapy so far this year The biopharmaceutical company s shares have surged 300 significantly outperforming the industry s gain of 15 9 in that period
,,,3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day,2017-09-26 15:56:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J3oN8-iprTw/3-heart-disease-focused-stocks-to-buy-ahead-of-world-heart-day-cm851047,World Heart Day is observed every year on September 29 to raise awareness across the world about cardiovascular CV diseases CV diseases more commonly known as heart disease or stroke are basically diseases of the heart or blood vessels According to the World Heart Federation CV
NVS,NVS:US,BBG000LYF3S8,Aduro Biotech Says First Patient Dosed in ADU-S100 Clinical Trial,2017-09-26 13:49:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i9PuOe0_LzY/aduro-biotech-says-first-patient-dosed-in-adu-s100-clinical-trial-cm850917,Aduro Biotech ADRO an immunotherapy technologies bio company said Tuesday the first patient has been dosed in the phase 1b dose escalation and dose expansion clinical trial designed to evaluate the safety and efficacy of ADU S100 a novel Sting pathway activator in combination with
,,,Aduro Biotech Says First Patient Dosed in ADU-S100 Clinical Trial,2017-09-26 13:49:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i9PuOe0_LzY/aduro-biotech-says-first-patient-dosed-in-adu-s100-clinical-trial-cm850917,Aduro Biotech ADRO an immunotherapy technologies bio company said Tuesday the first patient has been dosed in the phase 1b dose escalation and dose expansion clinical trial designed to evaluate the safety and efficacy of ADU S100 a novel Sting pathway activator in combination with
,,,3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day,2017-09-26 13:45:01 +0000,https://finance.yahoo.com/news/3-heart-disease-focused-stocks-134501140.html?.tsrc=rss,"With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market."
NVS,NVS:US,BBG000LYF3S8,3 Heart Disease Focused Stocks to Buy Ahead of World Heart Day,2017-09-26 13:45:01 +0000,https://finance.yahoo.com/news/3-heart-disease-focused-stocks-134501140.html?.tsrc=rss,"With World Heart Day coming up, here is a look at some well-positioned stocks including BioTelemetry (BEAT) in this segment of the market."
,,,The Swiss Stock Market Pulled Back Despite Strong Performance By NestlÃ©,2017-09-26 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VeDbY0GhBjM/the-swiss-stock-market-pulled-back-despite-strong-performance-by-nestl%C3%A3-20170926-01000,The Swiss Stock Market Pulled Back Despite Strong Performance By NestlÃ©
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back Despite Strong Performance By NestlÃ©,2017-09-26 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VeDbY0GhBjM/the-swiss-stock-market-pulled-back-despite-strong-performance-by-nestl%C3%A3-20170926-01000,The Swiss Stock Market Pulled Back Despite Strong Performance By NestlÃ©
NVS,NVS:US,BBG000LYF3S8,Roche (RHHBY) Gets Approval for Label Expansion of Tecentriq,2017-09-25 16:48:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-yo4a4Ps4HE/roche-rhhby-gets-approval-for-label-expansion-of-tecentriq-cm850405,Roche Holding AG RHHBY announced that the European Commission EC has approved immunotherapy drug Tecentriq as a monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer after they have been previously treated with chemotherapy regardless of PD
,,,Roche (RHHBY) Gets Approval for Label Expansion of Tecentriq,2017-09-25 16:48:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-yo4a4Ps4HE/roche-rhhby-gets-approval-for-label-expansion-of-tecentriq-cm850405,Roche Holding AG RHHBY announced that the European Commission EC has approved immunotherapy drug Tecentriq as a monotherapy for the treatment of patients with locally advanced or metastatic non small cell lung cancer after they have been previously treated with chemotherapy regardless of PD
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis's new chief sets sights on 'productivity revolution',2017-09-25 16:33:28 +0000,"http://finance.yahoo.com/r/f66009bd-2343-31c2-a102-e55179dda83e/5ab8ba6e-9c7a-11e7-9a86-4d5a475ba4c5,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The incoming chief executive of Novartis, Vas Narasimhan, has vowed to slash drug development costs, eyeing savings of up to 25 per cent on multibillion-dollar clinical trials as part of a ""productivity ..."
,,,[$$] Novartis's new chief sets sights on 'productivity revolution',2017-09-25 16:33:28 +0000,"http://finance.yahoo.com/r/f66009bd-2343-31c2-a102-e55179dda83e/5ab8ba6e-9c7a-11e7-9a86-4d5a475ba4c5,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The incoming chief executive of Novartis, Vas Narasimhan, has vowed to slash drug development costs, eyeing savings of up to 25 per cent on multibillion-dollar clinical trials as part of a ""productivity ..."
,,,The Swiss Stock Market Inched Higher After Weak Start,2017-09-25 12:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8MqTfWK31N4/the-swiss-stock-market-inched-higher-after-weak-start-20170925-00936,The Swiss Stock Market Inched Higher After Weak Start
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Inched Higher After Weak Start,2017-09-25 12:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8MqTfWK31N4/the-swiss-stock-market-inched-higher-after-weak-start-20170925-00936,The Swiss Stock Market Inched Higher After Weak Start
,,,"Oddly, Juno Therapeutics Is Jumping 11.3% Today",2017-09-22 21:48:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D6AIkN0MWtQ/oddly-juno-therapeutics-is-jumping-113-today-cm849862,What happened Despite a 6 1 million share follow on public stock offering shares of Juno Therapeutics NASDAQ JUNO are rallying 11 3 higher at 3 p m EDT So what Juno Therapeutics shares have been rallying since competitor Gilead Sciences NASDAQ GILD acquired
NVS,NVS:US,BBG000LYF3S8,"Oddly, Juno Therapeutics Is Jumping 11.3% Today",2017-09-22 21:48:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D6AIkN0MWtQ/oddly-juno-therapeutics-is-jumping-113-today-cm849862,What happened Despite a 6 1 million share follow on public stock offering shares of Juno Therapeutics NASDAQ JUNO are rallying 11 3 higher at 3 p m EDT So what Juno Therapeutics shares have been rallying since competitor Gilead Sciences NASDAQ GILD acquired
,,,"Oddly, Juno Therapeutics Is Jumping 11.3% Today",2017-09-22 20:00:00 +0000,http://finance.yahoo.com/r/03bfbe08-3495-39a0-b0df-4566490b66cf/oddly-juno-therapeutics-is-jumping-113-today.aspx?yptr=yahoo&.tsrc=rss,Optimism that it can develop CAR-T cancer drugs that are better than its competitors&apos; is trumping news that the company is diluting investors by selling more shares.
NVS,NVS:US,BBG000LYF3S8,"Oddly, Juno Therapeutics Is Jumping 11.3% Today",2017-09-22 20:00:00 +0000,http://finance.yahoo.com/r/03bfbe08-3495-39a0-b0df-4566490b66cf/oddly-juno-therapeutics-is-jumping-113-today.aspx?yptr=yahoo&.tsrc=rss,Optimism that it can develop CAR-T cancer drugs that are better than its competitors&apos; is trumping news that the company is diluting investors by selling more shares.
,,,Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?,2017-09-22 15:41:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NrIOSO31NmU/juno-therapeutics-inc-juno-stock-to-buy-or-not-to-buy-cm849713,InvestorPlace Stock Market News Stock Advice amp Trading Tips It s been a great summer for 160 Juno Therapeutics Inc NASDAQ JUNO JUNO stock is up 50 over the past month and has more than doubled year to date It s been quite the reversal of
NVS,NVS:US,BBG000LYF3S8,Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?,2017-09-22 15:41:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NrIOSO31NmU/juno-therapeutics-inc-juno-stock-to-buy-or-not-to-buy-cm849713,InvestorPlace Stock Market News Stock Advice amp Trading Tips It s been a great summer for 160 Juno Therapeutics Inc NASDAQ JUNO JUNO stock is up 50 over the past month and has more than doubled year to date It s been quite the reversal of
NVS,NVS:US,BBG000LYF3S8,How Is Novartis’s Subsidiary Sandoz Positioned after 1H17?,2017-09-22 14:37:10 +0000,http://finance.yahoo.com/r/349c0611-9f35-372f-80ac-2d952b2576b7/how-is-novartiss-subsidiary-sandoz-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) subsidiary Sandoz reported revenues of around $4.9 billion, which is a 3% decline on a year-over-year (or YoY) basis."
,,,How Is Novartis’s Subsidiary Sandoz Positioned after 1H17?,2017-09-22 14:37:10 +0000,http://finance.yahoo.com/r/349c0611-9f35-372f-80ac-2d952b2576b7/how-is-novartiss-subsidiary-sandoz-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) subsidiary Sandoz reported revenues of around $4.9 billion, which is a 3% decline on a year-over-year (or YoY) basis."
NVS,NVS:US,BBG000LYF3S8,How Is Novartis’s Subsidiary Alcon Positioned after 1H17?,2017-09-22 13:06:05 +0000,http://finance.yahoo.com/r/87f5a046-ccd1-3c9d-a05a-23a1df2ed5f8/how-is-novartiss-subsidiary-alcon-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Alcon reported revenues of around $2.9 billion, which is similar to revenues in 1H16."
,,,How Is Novartis’s Subsidiary Alcon Positioned after 1H17?,2017-09-22 13:06:05 +0000,http://finance.yahoo.com/r/87f5a046-ccd1-3c9d-a05a-23a1df2ed5f8/how-is-novartiss-subsidiary-alcon-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Alcon reported revenues of around $2.9 billion, which is similar to revenues in 1H16."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed In Cautious Trade,2017-09-22 12:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eozWBrNeYq0/the-swiss-stock-market-finished-little-changed-in-cautious-trade-20170922-00585,The Swiss Stock Market Finished Little Changed In Cautious Trade
,,,The Swiss Stock Market Finished Little Changed In Cautious Trade,2017-09-22 12:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eozWBrNeYq0/the-swiss-stock-market-finished-little-changed-in-cautious-trade-20170922-00585,The Swiss Stock Market Finished Little Changed In Cautious Trade
NVS,NVS:US,BBG000LYF3S8,Gilenya and Entresto Could Keep Boosting Novartis’s Revenue Growth,2017-09-22 11:36:16 +0000,http://finance.yahoo.com/r/890bf254-36e5-3b7a-8b8f-1c3c05b9b8cb/gilenya-and-entresto-could-keep-boosting-novartiss-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Gilenya reported revenues of around $1.6 billion, which reflected ~3% growth on a year-over-year (or YoY) basis."
,,,Gilenya and Entresto Could Keep Boosting Novartis’s Revenue Growth,2017-09-22 11:36:16 +0000,http://finance.yahoo.com/r/890bf254-36e5-3b7a-8b8f-1c3c05b9b8cb/gilenya-and-entresto-could-keep-boosting-novartiss-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Gilenya reported revenues of around $1.6 billion, which reflected ~3% growth on a year-over-year (or YoY) basis."
,,,[$$] Alnylam's New Medicine To Enter Pricing Debate,2017-09-22 11:30:05 +0000,http://finance.yahoo.com/r/14b8b343-c3ad-3d1a-916d-6ddfb1d6678d/alnylams-new-medicine-to-enter-pricing-debate-1506079800?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.
NVS,NVS:US,BBG000LYF3S8,[$$] Alnylam's New Medicine To Enter Pricing Debate,2017-09-22 11:30:05 +0000,http://finance.yahoo.com/r/14b8b343-c3ad-3d1a-916d-6ddfb1d6678d/alnylams-new-medicine-to-enter-pricing-debate-1506079800?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Alnylam Pharmaceuticals Inc. will seek approval for a drug treating a rare disease. Its challenge: launching a pricey product amid growing debate about how to fairly value breakthrough medications.
,,,Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?,2017-09-22 11:03:58 +0000,https://finance.yahoo.com/news/juno-therapeutics-inc-juno-stock-110358957.html?.tsrc=rss,"It’s been a great summer for Juno Therapeutics Inc (NASDAQ:JUNO).  JUNO stock is up 50% over the past month and has more than doubled year-to-date.  It’s been quite the reversal of fortunes after a rough period that saw JUNO stock reach $70 in 2015, then plummet to $20, as investors lost faith in its CAR-T platform."
NVS,NVS:US,BBG000LYF3S8,Juno Therapeutics Inc (JUNO) Stock: To Buy or Not to Buy?,2017-09-22 11:03:58 +0000,https://finance.yahoo.com/news/juno-therapeutics-inc-juno-stock-110358957.html?.tsrc=rss,"It’s been a great summer for Juno Therapeutics Inc (NASDAQ:JUNO).  JUNO stock is up 50% over the past month and has more than doubled year-to-date.  It’s been quite the reversal of fortunes after a rough period that saw JUNO stock reach $70 in 2015, then plummet to $20, as investors lost faith in its CAR-T platform."
NVS,NVS:US,BBG000LYF3S8,Corporate News Blog - Novartis Receives EC’s Approval for Rydapt; Set to Treat FLT3-Mutated Active Myeloid Leukemia,2017-09-22 11:00:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-novartis-receives-110000777.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / September 22, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novartis AG (NYSE: NVS ), following which we have published ..."
,,,Corporate News Blog - Novartis Receives EC’s Approval for Rydapt; Set to Treat FLT3-Mutated Active Myeloid Leukemia,2017-09-22 11:00:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-novartis-receives-110000777.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / September 22, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novartis AG (NYSE: NVS ), following which we have published ..."
,,,"Novartis's $475,000 Price on Cancer Therapy Meets Resistance",2017-09-22 08:22:31 +0000,http://finance.yahoo.com/r/8d7d0b16-65af-32de-95a9-01beee64cff7/novartis-s-475-000-price-tag-on-cancer-drug-meets-resistance?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"The $475,000 price tag on Novartis AG’s latest breakthrough cancer therapy came under fire from one of the biggest managers of drug costs in the U.S., underscoring the challenges the Swiss drugmaker will ..."
NVS,NVS:US,BBG000LYF3S8,"Novartis's $475,000 Price on Cancer Therapy Meets Resistance",2017-09-22 08:22:31 +0000,http://finance.yahoo.com/r/8d7d0b16-65af-32de-95a9-01beee64cff7/novartis-s-475-000-price-tag-on-cancer-drug-meets-resistance?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"The $475,000 price tag on Novartis AG’s latest breakthrough cancer therapy came under fire from one of the biggest managers of drug costs in the U.S., underscoring the challenges the Swiss drugmaker will ..."
,,,Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade,2017-09-21 20:39:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ehlFKBmeH0/immunize-juno-therapeutics-inc-juno-stock-with-this-trade-cm849309,InvestorPlace Stock Market News Stock Advice amp Trading Tips Juno Therapeutics Inc NASDAQ JUNO has a lot going for it off and on the price chart That doesn t mean you shouldn t immunize JUNO stock against the always real bearish threats To do that we
NVS,NVS:US,BBG000LYF3S8,Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade,2017-09-21 20:39:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ehlFKBmeH0/immunize-juno-therapeutics-inc-juno-stock-with-this-trade-cm849309,InvestorPlace Stock Market News Stock Advice amp Trading Tips Juno Therapeutics Inc NASDAQ JUNO has a lot going for it off and on the price chart That doesn t mean you shouldn t immunize JUNO stock against the always real bearish threats To do that we
,,,4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid,2017-09-21 20:37:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qdhoMjH8wH0/4-sell-ranked-biotech-stocks-with-falling-estimates-to-avoid-cm849243,The biotech industry witnessed a rebound in 2017 despite facing some odds in the previous year The industry faced some challenges like rising competition pipeline setbacks slowdown in growth of mature products and generic competition for certain key drugs in 2016 However we have seen
NVS,NVS:US,BBG000LYF3S8,4 Sell-Ranked Biotech Stocks with Falling Estimates to Avoid,2017-09-21 20:37:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qdhoMjH8wH0/4-sell-ranked-biotech-stocks-with-falling-estimates-to-avoid-cm849243,The biotech industry witnessed a rebound in 2017 despite facing some odds in the previous year The industry faced some challenges like rising competition pipeline setbacks slowdown in growth of mature products and generic competition for certain key drugs in 2016 However we have seen
NVS,NVS:US,BBG000LYF3S8,Vanguard FTSE Developed Markets ETF Experiences Big Inflow,2017-09-21 19:37:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wGG2n_yx92g/vanguard-ftse-developed-markets-etf-experiences-big-inflow-cm849211,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 216 9 million dollar inflow that s a 0 4 increase week over week
,,,Vanguard FTSE Developed Markets ETF Experiences Big Inflow,2017-09-21 19:37:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wGG2n_yx92g/vanguard-ftse-developed-markets-etf-experiences-big-inflow-cm849211,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 216 9 million dollar inflow that s a 0 4 increase week over week
NVS,NVS:US,BBG000LYF3S8,Why Gilead Sciences Is Flying High With Kite,2017-09-21 19:30:00 +0000,http://finance.yahoo.com/r/ca4cd37b-d554-359f-aa73-4363587e8cb6/why-gilead-sciences-is-flying-high-with-kite?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Gilead Sciences has expanded beyond its leading antiviral drug franchises for the treatment of HIV and hepatitis C with the announced acquisition of Kite Pharmaceuticals, giving Gilead a leading edge in cell therapy technology in oncology."
,,,Why Gilead Sciences Is Flying High With Kite,2017-09-21 19:30:00 +0000,http://finance.yahoo.com/r/ca4cd37b-d554-359f-aa73-4363587e8cb6/why-gilead-sciences-is-flying-high-with-kite?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Gilead Sciences has expanded beyond its leading antiviral drug franchises for the treatment of HIV and hepatitis C with the announced acquisition of Kite Pharmaceuticals, giving Gilead a leading edge in cell therapy technology in oncology."
,,,How is the Age-Related Macular Degeneration Space Faring Now?,2017-09-21 16:40:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zTtLy-KfdzM/how-is-the-age-related-macular-degeneration-space-faring-now-cm849094,The Age Related Macular Degeneration AMD space has been in the spotlight of late due to a number of developments Earlier in the month Swiss pharma company Roche Holdings AG RHHBY suffered a setback when its ophthalmology candidate lampalizumab failed to achieve the primary endpoint
NVS,NVS:US,BBG000LYF3S8,How is the Age-Related Macular Degeneration Space Faring Now?,2017-09-21 16:40:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zTtLy-KfdzM/how-is-the-age-related-macular-degeneration-space-faring-now-cm849094,The Age Related Macular Degeneration AMD space has been in the spotlight of late due to a number of developments Earlier in the month Swiss pharma company Roche Holdings AG RHHBY suffered a setback when its ophthalmology candidate lampalizumab failed to achieve the primary endpoint
NVS,NVS:US,BBG000LYF3S8,Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade,2017-09-21 16:01:35 +0000,https://finance.yahoo.com/news/immunize-juno-therapeutics-inc-juno-160135366.html?.tsrc=rss,"Juno Therapeutics Inc (NASDAQ:JUNO) has a lot going for it off and on the price chart. That doesn&#8217;t mean you shouldn&#8217;t immunize JUNO stock against the always-real bearish threats. To do that, we&#8217;ll explore a fully-hedged, collar-based therapy program. Let me explain."
,,,Immunize Juno Therapeutics Inc (JUNO) Stock With This Trade,2017-09-21 16:01:35 +0000,https://finance.yahoo.com/news/immunize-juno-therapeutics-inc-juno-160135366.html?.tsrc=rss,"Juno Therapeutics Inc (NASDAQ:JUNO) has a lot going for it off and on the price chart. That doesn&#8217;t mean you shouldn&#8217;t immunize JUNO stock against the always-real bearish threats. To do that, we&#8217;ll explore a fully-hedged, collar-based therapy program. Let me explain."
NVS,NVS:US,BBG000LYF3S8,How Did Novartis’s Established Medicines Perform in 1H17?,2017-09-21 14:36:21 +0000,http://finance.yahoo.com/r/8ff47b34-6177-3cf7-92cb-b09c03097ff1/how-did-novartiss-established-medicines-perform-in-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Galvus generated revenues of around $596 million compared to $589 million in 1H16."
,,,How Did Novartis’s Established Medicines Perform in 1H17?,2017-09-21 14:36:21 +0000,http://finance.yahoo.com/r/8ff47b34-6177-3cf7-92cb-b09c03097ff1/how-did-novartiss-established-medicines-perform-in-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Galvus generated revenues of around $596 million compared to $589 million in 1H16."
,,,How is the Age-Related Macular Degeneration Space Faring Now?,2017-09-21 14:15:02 +0000,https://finance.yahoo.com/news/age-related-macular-degeneration-space-141502834.html?.tsrc=rss,The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.
NVS,NVS:US,BBG000LYF3S8,How is the Age-Related Macular Degeneration Space Faring Now?,2017-09-21 14:15:02 +0000,https://finance.yahoo.com/news/age-related-macular-degeneration-space-141502834.html?.tsrc=rss,The Age-Related Macular Degeneration (AMD) space has been in the spotlight of late due to a number of developments.
,,,How Are Novartis’s Respiratory Drugs Positioned after 1H17?,2017-09-21 13:06:30 +0000,http://finance.yahoo.com/r/686a0f77-9346-3b0c-bd61-a5074d3eaeaa/how-are-novartiss-respiratory-drugs-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) COPD (chronic obstructive pulmonary disorder) portfolio reported revenues of around $318 million."
NVS,NVS:US,BBG000LYF3S8,How Are Novartis’s Respiratory Drugs Positioned after 1H17?,2017-09-21 13:06:30 +0000,http://finance.yahoo.com/r/686a0f77-9346-3b0c-bd61-a5074d3eaeaa/how-are-novartiss-respiratory-drugs-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) COPD (chronic obstructive pulmonary disorder) portfolio reported revenues of around $318 million."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On Strength Of Bank Stocks,2017-09-21 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N78U6FkHgC8/the-swiss-stock-market-climbed-on-strength-of-bank-stocks-20170921-00868,The Swiss Stock Market Climbed On Strength Of Bank Stocks
,,,The Swiss Stock Market Climbed On Strength Of Bank Stocks,2017-09-21 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N78U6FkHgC8/the-swiss-stock-market-climbed-on-strength-of-bank-stocks-20170921-00868,The Swiss Stock Market Climbed On Strength Of Bank Stocks
NVS,NVS:US,BBG000LYF3S8,Investor Updates on Novartis’s Immunology and Dermatology Portfolio,2017-09-21 11:36:26 +0000,http://finance.yahoo.com/r/815be4f7-b1c2-3e7d-a22d-6d95cdf8762c/investor-updates-on-novartiss-immunology-and-dermatology-portfolio?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Neoral/Sandimmune reported revenues of around $238 million, which reflected an ~8% decline on a year-over-year (or YoY) basis."
,,,Investor Updates on Novartis’s Immunology and Dermatology Portfolio,2017-09-21 11:36:26 +0000,http://finance.yahoo.com/r/815be4f7-b1c2-3e7d-a22d-6d95cdf8762c/investor-updates-on-novartiss-immunology-and-dermatology-portfolio?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Neoral/Sandimmune reported revenues of around $238 million, which reflected an ~8% decline on a year-over-year (or YoY) basis."
NVS,NVS:US,BBG000LYF3S8,Mylan Down 24% Year to Date: What's Troubling the Stock?,2017-09-21 01:34:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uSeKXC7Yeag/mylan-down-24-year-to-date-whats-troubling-the-stock-cm848771,Shares of Mylan N V MYL have declined 24 7 in the last six months compared to the industry s loss of 20 0 Here we analyze the factors that led to the underperformance Mylan is a global pharmaceutical company with a well established generics business as well as a presence
,,,Mylan Down 24% Year to Date: What's Troubling the Stock?,2017-09-21 01:34:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uSeKXC7Yeag/mylan-down-24-year-to-date-whats-troubling-the-stock-cm848771,Shares of Mylan N V MYL have declined 24 7 in the last six months compared to the industry s loss of 20 0 Here we analyze the factors that led to the underperformance Mylan is a global pharmaceutical company with a well established generics business as well as a presence
,,,Novartis Poised to Grow on Oncology Portfolio & Biosimilars,2017-09-20 20:36:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e7rgUjmdywM/novartis-poised-to-grow-on-oncology-portfolio-biosimilars-cm848634,We issued an updated report on Novartis AG NVS on Sep 19 Novartis has a strong portfolio of oncology drugs like Afinitor Exjade Jakavi Zykadia Tasigna Jadenu and an improved formulation of Exjade In February 2016 the company received a boost with the FDA approving Afinitor for
NVS,NVS:US,BBG000LYF3S8,Novartis Poised to Grow on Oncology Portfolio & Biosimilars,2017-09-20 20:36:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e7rgUjmdywM/novartis-poised-to-grow-on-oncology-portfolio-biosimilars-cm848634,We issued an updated report on Novartis AG NVS on Sep 19 Novartis has a strong portfolio of oncology drugs like Afinitor Exjade Jakavi Zykadia Tasigna Jadenu and an improved formulation of Exjade In February 2016 the company received a boost with the FDA approving Afinitor for
NVS,NVS:US,BBG000LYF3S8,Novartis Poised to Grow on Oncology Portfolio & Biosimilars,2017-09-20 18:32:06 +0000,https://finance.yahoo.com/news/novartis-poised-grow-oncology-portfolio-183206549.html?.tsrc=rss,"Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah."
,,,Novartis Poised to Grow on Oncology Portfolio & Biosimilars,2017-09-20 18:32:06 +0000,https://finance.yahoo.com/news/novartis-poised-grow-oncology-portfolio-183206549.html?.tsrc=rss,"Novartis expects the next growth phase to begin in 2018 driven by Cosentyx Entresto, Kisqali and Kymriah."
NVS,NVS:US,BBG000LYF3S8,Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View,2017-09-20 16:42:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IdUuv4NHi_I/pfizers-sutent-label-expansion-gets-mixed-fda-committee-view-cm848481,Pfizer Inc PFE announced that an FDA advisory committee gave a mixed opinion regarding a regulatory application that was filed to expand the label of its cancer drug Sutent Sutent is presently marketed for the first line treatment of advanced renal cell carcinoma RCC With the
,,,Pfizer's Sutent Label Expansion Gets Mixed FDA Committee View,2017-09-20 16:42:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IdUuv4NHi_I/pfizers-sutent-label-expansion-gets-mixed-fda-committee-view-cm848481,Pfizer Inc PFE announced that an FDA advisory committee gave a mixed opinion regarding a regulatory application that was filed to expand the label of its cancer drug Sutent Sutent is presently marketed for the first line treatment of advanced renal cell carcinoma RCC With the
NVS,NVS:US,BBG000LYF3S8,Why Are Cancer Drugs So Expensive?,2017-09-20 16:37:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ic0f7oSHG7I/why-are-cancer-drugs-so-expensive-cm848397,All drugs are costly to produce but cancer drugs are notoriously expensive to push through to market and every year treatments get more and more expensive In this clip from Industry Focus Healthcare host Kristine Harjes and Motley Fool contributor Todd Campbell explain
,,,Why Are Cancer Drugs So Expensive?,2017-09-20 16:37:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ic0f7oSHG7I/why-are-cancer-drugs-so-expensive-cm848397,All drugs are costly to produce but cancer drugs are notoriously expensive to push through to market and every year treatments get more and more expensive In this clip from Industry Focus Healthcare host Kristine Harjes and Motley Fool contributor Todd Campbell explain
NVS,NVS:US,BBG000LYF3S8,Why Are Cancer Drugs So Expensive?,2017-09-20 15:19:00 +0000,http://finance.yahoo.com/r/0bde97b7-bf30-397b-9743-547e164bbfff/why-are-cancer-drugs-so-expensive.aspx?yptr=yahoo&.tsrc=rss,"If it seems like oncology drug prices are rapidly outpacing inflation, it’s because they are."
,,,Why Are Cancer Drugs So Expensive?,2017-09-20 15:19:00 +0000,http://finance.yahoo.com/r/0bde97b7-bf30-397b-9743-547e164bbfff/why-are-cancer-drugs-so-expensive.aspx?yptr=yahoo&.tsrc=rss,"If it seems like oncology drug prices are rapidly outpacing inflation, it’s because they are."
NVS,NVS:US,BBG000LYF3S8,Why Cosentyx Could Significantly Drive Novartis’s Revenue Growth,2017-09-20 14:36:40 +0000,http://finance.yahoo.com/r/f4e98045-5598-3d17-b414-b6c4c83d3797/why-cosentyx-could-significantly-drive-novartiss-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Cosentyx generated revenues of around $900 million compared to $436 million in 1H16."
,,,Why Cosentyx Could Significantly Drive Novartis’s Revenue Growth,2017-09-20 14:36:40 +0000,http://finance.yahoo.com/r/f4e98045-5598-3d17-b414-b6c4c83d3797/why-cosentyx-could-significantly-drive-novartiss-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Cosentyx generated revenues of around $900 million compared to $436 million in 1H16."
,,,The Swiss Stock Market Closed Nearly Flat Ahead Of Fed Decision,2017-09-20 14:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oFLfJZcDjfw/the-swiss-stock-market-closed-nearly-flat-ahead-of-fed-decision-20170920-00964,The Swiss Stock Market Closed Nearly Flat Ahead Of Fed Decision
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Closed Nearly Flat Ahead Of Fed Decision,2017-09-20 14:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oFLfJZcDjfw/the-swiss-stock-market-closed-nearly-flat-ahead-of-fed-decision-20170920-00964,The Swiss Stock Market Closed Nearly Flat Ahead Of Fed Decision
NVS,NVS:US,BBG000LYF3S8,How Does Novartis’s Ophthalmology Portfolio Look?,2017-09-20 13:06:40 +0000,http://finance.yahoo.com/r/07264212-d520-3264-a8aa-062386a749d6/how-does-novartiss-ophthalmology-portfolio-look?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis's (NVS) Travoprost drugs reported revenues of around $290 million, which is a ~6% decline on a YoY basis."
,,,How Does Novartis’s Ophthalmology Portfolio Look?,2017-09-20 13:06:40 +0000,http://finance.yahoo.com/r/07264212-d520-3264-a8aa-062386a749d6/how-does-novartiss-ophthalmology-portfolio-look?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis's (NVS) Travoprost drugs reported revenues of around $290 million, which is a ~6% decline on a YoY basis."
NVS,NVS:US,BBG000LYF3S8,"How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17",2017-09-20 11:38:08 +0000,http://finance.yahoo.com/r/5671f6c7-9f34-3114-9449-7f52c8142269/how-novartiss-promacta-votrient-and-jakavi-performed-in-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis."
,,,"How Novartis’s Promacta, Votrient, and Jakavi Performed in 1H17",2017-09-20 11:38:08 +0000,http://finance.yahoo.com/r/5671f6c7-9f34-3114-9449-7f52c8142269/how-novartiss-promacta-votrient-and-jakavi-performed-in-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Promacta/Revolade reported revenues of around $385 million, which reflected ~33% growth on a year-over-year (or YoY) basis."
NVS,NVS:US,BBG000LYF3S8,Wall Street Might Open Mixed Ahead Of FOMC Announcement,2017-09-20 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0ik9uMEbDTk/wall-street-might-open-mixed-ahead-of-fomc-announcement-20170920-00311,Wall Street Might Open Mixed Ahead Of FOMC Announcement
,,,Wall Street Might Open Mixed Ahead Of FOMC Announcement,2017-09-20 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0ik9uMEbDTk/wall-street-might-open-mixed-ahead-of-fomc-announcement-20170920-00311,Wall Street Might Open Mixed Ahead Of FOMC Announcement
NVS,NVS:US,BBG000LYF3S8,"An Update on Novartis’s Sandostatin, Afinitor, and Exjade",2017-09-19 14:38:11 +0000,http://finance.yahoo.com/r/f3318f66-5864-332a-a8e7-0ca92d60d8b7/an-update-on-novartiss-sandostatin-afinitor-and-exjade?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis's (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis."
,,,"An Update on Novartis’s Sandostatin, Afinitor, and Exjade",2017-09-19 14:38:11 +0000,http://finance.yahoo.com/r/f3318f66-5864-332a-a8e7-0ca92d60d8b7/an-update-on-novartiss-sandostatin-afinitor-and-exjade?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis's (NVS) Sandostatin generated revenues of around $789 million, which reflected a ~4% decline on a year-over-year (or YoY) basis."
,,,How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?,2017-09-19 13:10:20 +0000,http://finance.yahoo.com/r/508378dd-a948-3094-9331-21a212755bab/how-are-novartiss-blockbuster-drugs-gleevec-and-tasigna-positioned?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis's (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis."
NVS,NVS:US,BBG000LYF3S8,How Are Novartis’s Blockbuster Drugs Gleevec and Tasigna Positioned?,2017-09-19 13:10:20 +0000,http://finance.yahoo.com/r/508378dd-a948-3094-9331-21a212755bab/how-are-novartiss-blockbuster-drugs-gleevec-and-tasigna-positioned?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis's (NVS) Gleevec reported revenues of around $1.1 billion, which reflected a ~39% decline on a year-over-year (or YoY) basis."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed In Cautious Trade,2017-09-19 12:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v3rZfU4DKRs/the-swiss-stock-market-climbed-in-cautious-trade-20170919-01009,The Swiss Stock Market Climbed In Cautious Trade
,,,The Swiss Stock Market Climbed In Cautious Trade,2017-09-19 12:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v3rZfU4DKRs/the-swiss-stock-market-climbed-in-cautious-trade-20170919-01009,The Swiss Stock Market Climbed In Cautious Trade
NVS,NVS:US,BBG000LYF3S8,An Update on Novartis’s Tafinlar and Mekinist post 1H17,2017-09-19 12:08:11 +0000,http://finance.yahoo.com/r/db495b05-6d21-32ff-9543-b0f6d2be2a97/an-update-on-novartiss-tafinlar-mekinist-post-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis's (NVS) Tafinlar & Mekinist reported revenues of around $403 million, which reflected ~25% growth on a year-over-year (or YoY) basis."
,,,An Update on Novartis’s Tafinlar and Mekinist post 1H17,2017-09-19 12:08:11 +0000,http://finance.yahoo.com/r/db495b05-6d21-32ff-9543-b0f6d2be2a97/an-update-on-novartiss-tafinlar-mekinist-post-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis's (NVS) Tafinlar & Mekinist reported revenues of around $403 million, which reflected ~25% growth on a year-over-year (or YoY) basis."
,,,Novartis Announces Positive Data on Urticaria Drug Xolair,2017-09-19 00:34:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jqg09u3TR6o/novartis-announces-positive-data-on-urticaria-drug-xolair-cm847462,Novartis AG NVS announced new data on chronic spontaneous urticaria CSU drug Xolair at the 26th European Academy of Dermatology and Venereology Congress in Geneva Switzerland from a phase IIIb study OPTIMA OPTIMA is a phase IIIb international multicenter randomized open
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Positive Data on Urticaria Drug Xolair,2017-09-19 00:34:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jqg09u3TR6o/novartis-announces-positive-data-on-urticaria-drug-xolair-cm847462,Novartis AG NVS announced new data on chronic spontaneous urticaria CSU drug Xolair at the 26th European Academy of Dermatology and Venereology Congress in Geneva Switzerland from a phase IIIb study OPTIMA OPTIMA is a phase IIIb international multicenter randomized open
,,,Novartis Announces Positive Data on Urticaria Drug Xolair,2017-09-18 22:03:10 +0000,https://finance.yahoo.com/news/novartis-announces-positive-data-urticaria-220310633.html?.tsrc=rss,"Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA."
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Positive Data on Urticaria Drug Xolair,2017-09-18 22:03:10 +0000,https://finance.yahoo.com/news/novartis-announces-positive-data-urticaria-220310633.html?.tsrc=rss,"Novartis AG (NVS) announced new positive data on chronic spontaneous urticaria (CSU) drug Xolair from a phase IIIb study, OPTIMA."
,,,Kisqali Could Significantly Boost Novartis’s Revenue Growth,2017-09-18 21:36:24 +0000,http://finance.yahoo.com/r/d4181742-41fe-3636-8842-f97acf3ec7ec/kisqali-could-significantly-boost-novartiss-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17 and 2Q17, Novartis’s (NVS) Kisqali reported revenues of around $15 million and $8 million, respectively."
NVS,NVS:US,BBG000LYF3S8,Kisqali Could Significantly Boost Novartis’s Revenue Growth,2017-09-18 21:36:24 +0000,http://finance.yahoo.com/r/d4181742-41fe-3636-8842-f97acf3ec7ec/kisqali-could-significantly-boost-novartiss-revenue-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17 and 2Q17, Novartis’s (NVS) Kisqali reported revenues of around $15 million and $8 million, respectively."
NVS,NVS:US,BBG000LYF3S8,How Did Novartis Perform in 1H17?,2017-09-18 20:07:08 +0000,http://finance.yahoo.com/r/5ba3e9a6-47df-31fa-8dc5-d5101825ef60/how-did-novartis-perform-in-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis (NVS) reported revenues of around $23.8 billion, a ~1% decline on a year-over-year (or YoY) basis."
,,,How Did Novartis Perform in 1H17?,2017-09-18 20:07:08 +0000,http://finance.yahoo.com/r/5ba3e9a6-47df-31fa-8dc5-d5101825ef60/how-did-novartis-perform-in-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis (NVS) reported revenues of around $23.8 billion, a ~1% decline on a year-over-year (or YoY) basis."
,,,How Is Novartis’s Lucentis Positioned after 1H17?,2017-09-18 18:19:43 +0000,http://finance.yahoo.com/r/47dd8d9f-1936-3b81-afaa-3abcb70fd447/how-is-novartiss-lucentis-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis."
NVS,NVS:US,BBG000LYF3S8,How Is Novartis’s Lucentis Positioned after 1H17?,2017-09-18 18:19:43 +0000,http://finance.yahoo.com/r/47dd8d9f-1936-3b81-afaa-3abcb70fd447/how-is-novartiss-lucentis-positioned-after-1h17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Novartis’s (NVS) Lucentis reported revenues of around $922 million, which is a ~1% decline on a year-over-year (or YoY) basis."
,,,What Analysts Recommend for Novartis in September 2017,2017-09-18 18:19:40 +0000,http://finance.yahoo.com/r/b2abd793-25e1-39d4-b8dc-faf8e4a167ef/what-analysts-recommend-for-novartis-in-september-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”"
NVS,NVS:US,BBG000LYF3S8,What Analysts Recommend for Novartis in September 2017,2017-09-18 18:19:40 +0000,http://finance.yahoo.com/r/b2abd793-25e1-39d4-b8dc-faf8e4a167ef/what-analysts-recommend-for-novartis-in-september-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Three analysts were analyzing Novartis in September 2017. One analyst recommended a “strong buy,” while the other two recommended a “hold.”"
,,,J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU,2017-09-18 16:41:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LWfnBaT_V3Q/jjs-jnj-psoriasis-drug-guselkumab-gets-chmp-nod-in-eu-cm847197,Johnson amp Johnson JNJ announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has granted a positive opinion recommending approval of its pipeline candidate guselkumab for the treatment of moderate to severe plaque psoriasis in the EU
NVS,NVS:US,BBG000LYF3S8,J&J's (JNJ) Psoriasis Drug Guselkumab Gets CHMP Nod in EU,2017-09-18 16:41:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LWfnBaT_V3Q/jjs-jnj-psoriasis-drug-guselkumab-gets-chmp-nod-in-eu-cm847197,Johnson amp Johnson JNJ announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has granted a positive opinion recommending approval of its pipeline candidate guselkumab for the treatment of moderate to severe plaque psoriasis in the EU
NVS,NVS:US,BBG000LYF3S8,Catalyst (CPRX) Focused on Two Lead Pipeline Candidates,2017-09-18 16:40:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-v4XWh9Yvjw/catalyst-cprx-focused-on-two-lead-pipeline-candidates-cm847180,We issued an updated report on Catalyst Pharmaceuticals Inc CPRX on Sep 15 Catalyst Pharma is a development stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders such as Lambert Eaton
,,,Catalyst (CPRX) Focused on Two Lead Pipeline Candidates,2017-09-18 16:40:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-v4XWh9Yvjw/catalyst-cprx-focused-on-two-lead-pipeline-candidates-cm847180,We issued an updated report on Catalyst Pharmaceuticals Inc CPRX on Sep 15 Catalyst Pharma is a development stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders such as Lambert Eaton
,,,The Swiss Stock Market Climbed As NestlÃ© Provided Support,2017-09-18 12:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DjPvWTH-XQ8/the-swiss-stock-market-climbed-as-nestl%C3%A3-provided-support-20170918-00951,The Swiss Stock Market Climbed As NestlÃ© Provided Support
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed As NestlÃ© Provided Support,2017-09-18 12:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DjPvWTH-XQ8/the-swiss-stock-market-climbed-as-nestl%C3%A3-provided-support-20170918-00951,The Swiss Stock Market Climbed As NestlÃ© Provided Support
NVS,NVS:US,BBG000LYF3S8,Novartis: Xolair Confirms Re-treatment Efficacy In CSU Patients,2017-09-18 02:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eJf0lOMExGQ/novartis-xolair-confirms-retreatment-efficacy-in-csu-patients-20170918-00080,Novartis: Xolair Confirms Re-treatment Efficacy In CSU Patients
,,,Novartis: Xolair Confirms Re-treatment Efficacy In CSU Patients,2017-09-18 02:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eJf0lOMExGQ/novartis-xolair-confirms-retreatment-efficacy-in-csu-patients-20170918-00080,Novartis: Xolair Confirms Re-treatment Efficacy In CSU Patients
,,,AbbVie&apos;s New Hepatitis C Drug Chipping Away At Gilead&apos;s Share,2017-09-15 18:21:22 +0000,http://finance.yahoo.com/r/0cbacd84-870b-3f90-b469-84e91217a657/abbvies-new-hepatitis-c-drug-chipping-away-at-gileads-share?src=A00220&yptr=yahoo&.tsrc=rss,"AbbVie&apos;s newly launched hepatitis C drug Mavyret has grabbed 7% of total new prescriptions, chipping away at Gilead&apos;s share."
NVS,NVS:US,BBG000LYF3S8,AbbVie&apos;s New Hepatitis C Drug Chipping Away At Gilead&apos;s Share,2017-09-15 18:21:22 +0000,http://finance.yahoo.com/r/0cbacd84-870b-3f90-b469-84e91217a657/abbvies-new-hepatitis-c-drug-chipping-away-at-gileads-share?src=A00220&yptr=yahoo&.tsrc=rss,"AbbVie&apos;s newly launched hepatitis C drug Mavyret has grabbed 7% of total new prescriptions, chipping away at Gilead&apos;s share."
,,,How Much Does It Really Cost to Develop a Cancer Drug?,2017-09-15 11:37:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mvLm7t_wR8g/how-much-does-it-really-cost-to-develop-a-cancer-drug-cm846125,Cancer drugs can cost hundreds of thousands of dollars and increasing complexity suggests that prices for these drugs are going higher For instance Novartis NYSE NVS won approval for a new cancer drug last month that will cost 475 000 Cancer drug companies say prices
NVS,NVS:US,BBG000LYF3S8,How Much Does It Really Cost to Develop a Cancer Drug?,2017-09-15 11:37:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mvLm7t_wR8g/how-much-does-it-really-cost-to-develop-a-cancer-drug-cm846125,Cancer drugs can cost hundreds of thousands of dollars and increasing complexity suggests that prices for these drugs are going higher For instance Novartis NYSE NVS won approval for a new cancer drug last month that will cost 475 000 Cancer drug companies say prices
,,,Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?,2017-09-15 11:37:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rdOxPWtmZx8/who-will-win-the-kidney-cancer-battle-between-bristol-myers-squibb-and-exelixis-cm846124,A head to head competition for market share in the renal cell carcinoma RCC market appears to be about to intensify In one corner is Bristol Myers Squibb NYSE BMY With a market cap of over 100 billion and a history dating back to 1887 the big pharma has a lot of muscle to
NVS,NVS:US,BBG000LYF3S8,Who Will Win the Kidney Cancer Battle Between Bristol-Myers Squibb and Exelixis?,2017-09-15 11:37:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rdOxPWtmZx8/who-will-win-the-kidney-cancer-battle-between-bristol-myers-squibb-and-exelixis-cm846124,A head to head competition for market share in the renal cell carcinoma RCC market appears to be about to intensify In one corner is Bristol Myers Squibb NYSE BMY With a market cap of over 100 billion and a history dating back to 1887 the big pharma has a lot of muscle to
NVS,NVS:US,BBG000LYF3S8,How Much Does It Really Cost to Develop a Cancer Drug?,2017-09-15 10:03:00 +0000,http://finance.yahoo.com/r/aec2e777-ef28-3ec1-8975-95f3041e427d/how-much-does-it-really-cost-to-develop-a-cancer-d.aspx?yptr=yahoo&.tsrc=rss,"A new study concludes it costs $757 million to develop a new cancer drug, but is that the only reason why drugmakers charge sky-high drug prices or are other reasons to blame, too?"
,,,How Much Does It Really Cost to Develop a Cancer Drug?,2017-09-15 10:03:00 +0000,http://finance.yahoo.com/r/aec2e777-ef28-3ec1-8975-95f3041e427d/how-much-does-it-really-cost-to-develop-a-cancer-d.aspx?yptr=yahoo&.tsrc=rss,"A new study concludes it costs $757 million to develop a new cancer drug, but is that the only reason why drugmakers charge sky-high drug prices or are other reasons to blame, too?"
,,,Novartis Sees IBD RS Rating Rise To 72,2017-09-15 07:00:00 +0000,http://finance.yahoo.com/r/5c1a23b0-804c-38d6-a0cf-0774833e5228/novartis-sees-ibd-rs-rating-rise-to-72?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Novartis shows improving technical performance. Will it continue?
NVS,NVS:US,BBG000LYF3S8,Novartis Sees IBD RS Rating Rise To 72,2017-09-15 07:00:00 +0000,http://finance.yahoo.com/r/5c1a23b0-804c-38d6-a0cf-0774833e5228/novartis-sees-ibd-rs-rating-rise-to-72?src=A00220&yptr=yahoo&.tsrc=rss,A Relative Strength Rating upgrade for Novartis shows improving technical performance. Will it continue?
,,,Biosimilar 2017 Progress Report: Stocks in Focus,2017-09-14 23:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5aiqYdLEkio/biosimilar-2017-progress-report-stocks-in-focus-cm846042,The biosimilar space remains in the spotlight as a number of regulatory decisions are pending While generic drugs are follow on versions of chemically synthesized molecules biosimilars contain a version of the active substance of an already approved original biological drug Development
NVS,NVS:US,BBG000LYF3S8,Biosimilar 2017 Progress Report: Stocks in Focus,2017-09-14 23:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5aiqYdLEkio/biosimilar-2017-progress-report-stocks-in-focus-cm846042,The biosimilar space remains in the spotlight as a number of regulatory decisions are pending While generic drugs are follow on versions of chemically synthesized molecules biosimilars contain a version of the active substance of an already approved original biological drug Development
,,,"Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale",2017-09-14 20:35:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qfs_wrIDo2M/exelixis-inc-and-bristol-myers-squibb-co-gear-up-for-round-2-of-the-kidney-cancer-drug-battle-royale-cm845933,Take your seats investors The battle in first line advanced renal cell carcinoma the most common type of kidney cancer is about to begin In one corner weighing in at a market cap of 8 billion there s Exelixis NASDAQ EXEL and its tyrosine 160 kinase inhibitor
NVS,NVS:US,BBG000LYF3S8,"Exelixis, Inc. and Bristol-Myers Squibb Co. Gear Up for Round 2 of the Kidney Cancer Drug Battle Royale",2017-09-14 20:35:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qfs_wrIDo2M/exelixis-inc-and-bristol-myers-squibb-co-gear-up-for-round-2-of-the-kidney-cancer-drug-battle-royale-cm845933,Take your seats investors The battle in first line advanced renal cell carcinoma the most common type of kidney cancer is about to begin In one corner weighing in at a market cap of 8 billion there s Exelixis NASDAQ EXEL and its tyrosine 160 kinase inhibitor
,,,Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx,2017-09-14 17:40:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HVCZCiL13UQ/novartis-announces-long-term-data-on-psoriasis-drug-cosentyx-cm845862,Novartis AG NVS announced long lasting skin clearance rates of Cosentyx in plaque psoriasis patients from a phase III study which evaluated the drug for five years Cosentyx is the first and only fully human IL 17A inhibitor to achieve sustained skin clearance rates over five years
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx,2017-09-14 17:40:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HVCZCiL13UQ/novartis-announces-long-term-data-on-psoriasis-drug-cosentyx-cm845862,Novartis AG NVS announced long lasting skin clearance rates of Cosentyx in plaque psoriasis patients from a phase III study which evaluated the drug for five years Cosentyx is the first and only fully human IL 17A inhibitor to achieve sustained skin clearance rates over five years
NVS,NVS:US,BBG000LYF3S8,Here's Why Glaukos Corp. Stock Is Stumbling Today,2017-09-14 17:37:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8SbIa11YDss/heres-why-glaukos-corp-stock-is-stumbling-today-cm845846,What happened Shares of Glaukos Corp NYSE GKOS a medical device manufacturer with an eye on glaucoma are slipping today Just ahead of the company s investors day meeting management made some adjustments to this year s total revenue expectations that aren t sitting well
,,,Here's Why Glaukos Corp. Stock Is Stumbling Today,2017-09-14 17:37:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8SbIa11YDss/heres-why-glaukos-corp-stock-is-stumbling-today-cm845846,What happened Shares of Glaukos Corp NYSE GKOS a medical device manufacturer with an eye on glaucoma are slipping today Just ahead of the company s investors day meeting management made some adjustments to this year s total revenue expectations that aren t sitting well
,,,CAR-T Therapy FDA Approved - Slingshot Insights' Idea Of The Month,2017-09-14 16:39:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iLH-SeqqDws/car-t-therapy-fda-approved-slingshot-insights-idea-of-the-month-cm845854,By Slingshot Insights BySlingshot Insights See also Time To Give Few BDCs Another Go on seekingalpha comSee alsoTime To Give Few BDCs Another Go on seekingalpha
NVS,NVS:US,BBG000LYF3S8,CAR-T Therapy FDA Approved - Slingshot Insights' Idea Of The Month,2017-09-14 16:39:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iLH-SeqqDws/car-t-therapy-fda-approved-slingshot-insights-idea-of-the-month-cm845854,By Slingshot Insights BySlingshot Insights See also Time To Give Few BDCs Another Go on seekingalpha comSee alsoTime To Give Few BDCs Another Go on seekingalpha
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx,2017-09-14 15:00:03 +0000,https://finance.yahoo.com/news/novartis-announces-long-term-data-150003719.html?.tsrc=rss,Novartis&apos; (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.
,,,Novartis Announces Long-Term Data on Psoriasis Drug Cosentyx,2017-09-14 15:00:03 +0000,https://finance.yahoo.com/news/novartis-announces-long-term-data-150003719.html?.tsrc=rss,Novartis&apos; (NVS) Cosentyx showed robust skin clearance data over a period of five years in patients with moderate-to-severe plaque psoriasis.
NVS,NVS:US,BBG000LYF3S8,TransCelerate BioPharma Adds Novartis; Elects Amgen's Elliott Levy As Chair,2017-09-14 07:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3FWBXWVs0cg/transcelerate-biopharma-adds-novartis-elects-amgens-elliott-levy-as-chair-20170914-00379,TransCelerate BioPharma Adds Novartis; Elects Amgen's Elliott Levy As Chair
,,,TransCelerate BioPharma Adds Novartis; Elects Amgen's Elliott Levy As Chair,2017-09-14 07:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3FWBXWVs0cg/transcelerate-biopharma-adds-novartis-elects-amgens-elliott-levy-as-chair-20170914-00379,TransCelerate BioPharma Adds Novartis; Elects Amgen's Elliott Levy As Chair
,,,Novartis: Sandoz Proposed Biosimilar Adalimumab Matches Reference Biologic,2017-09-14 01:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aW_YKcWi8rU/novartis-sandoz-proposed-biosimilar-adalimumab-matches-reference-biologic-20170914-00041,Novartis: Sandoz Proposed Biosimilar Adalimumab Matches Reference Biologic
NVS,NVS:US,BBG000LYF3S8,Novartis: Sandoz Proposed Biosimilar Adalimumab Matches Reference Biologic,2017-09-14 01:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aW_YKcWi8rU/novartis-sandoz-proposed-biosimilar-adalimumab-matches-reference-biologic-20170914-00041,Novartis: Sandoz Proposed Biosimilar Adalimumab Matches Reference Biologic
NVS,NVS:US,BBG000LYF3S8,Roche (RHHBY) Announces Data on Respiratory Drug Esbriet,2017-09-14 00:36:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eiyBe5arWqo/roche-rhhby-announces-data-on-respiratory-drug-esbriet-cm845423,Roche Holdings AG RHHBY announced results from a six month study combining idiopathic pulmonary fibrosis IPF drug Esbriet pirfenidone and Ofev The data was presented at the European Respiratory Society ERS congress in Italy The results revealed a similar safety profile for
,,,Roche (RHHBY) Announces Data on Respiratory Drug Esbriet,2017-09-14 00:36:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eiyBe5arWqo/roche-rhhby-announces-data-on-respiratory-drug-esbriet-cm845423,Roche Holdings AG RHHBY announced results from a six month study combining idiopathic pulmonary fibrosis IPF drug Esbriet pirfenidone and Ofev The data was presented at the European Respiratory Society ERS congress in Italy The results revealed a similar safety profile for
NVS,NVS:US,BBG000LYF3S8,Array's NDAs for Melanoma Combo Accepted for Review by FDA,2017-09-13 16:39:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-x6R-Qh33tw/arrays-ndas-for-melanoma-combo-accepted-for-review-by-fda-cm845165,Array BioPharma ARRY announced that the FDA has accepted for review its two New Drug Applications NDAs seeking approval for the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily COMBO450 to treat patients with BRAF mutant advanced unresectable or
,,,Array's NDAs for Melanoma Combo Accepted for Review by FDA,2017-09-13 16:39:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-x6R-Qh33tw/arrays-ndas-for-melanoma-combo-accepted-for-review-by-fda-cm845165,Array BioPharma ARRY announced that the FDA has accepted for review its two New Drug Applications NDAs seeking approval for the combination of binimetinib 45 mg twice daily and encorafenib 450 mg once daily COMBO450 to treat patients with BRAF mutant advanced unresectable or
,,,"Notable ETF Inflow Detected - VEA, NSRGY, NVS, TM",2017-09-13 16:35:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0r5WLoOmK54/notable-etf-inflow-detected-vea-nsrgy-nvs-tm-cm845149,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 259 9 million dollar inflow that s a 0 4 increase week over week
NVS,NVS:US,BBG000LYF3S8,"Notable ETF Inflow Detected - VEA, NSRGY, NVS, TM",2017-09-13 16:35:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0r5WLoOmK54/notable-etf-inflow-detected-vea-nsrgy-nvs-tm-cm845149,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 259 9 million dollar inflow that s a 0 4 increase week over week
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Ended The Day Unchanged,2017-09-13 12:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pXHbOkO2v2E/the-swiss-stock-market-ended-the-day-unchanged-20170913-00911,The Swiss Stock Market Ended The Day Unchanged
,,,The Swiss Stock Market Ended The Day Unchanged,2017-09-13 12:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pXHbOkO2v2E/the-swiss-stock-market-ended-the-day-unchanged-20170913-00911,The Swiss Stock Market Ended The Day Unchanged
NVS,NVS:US,BBG000LYF3S8,3 Things Amgen Inc.'s Management Just Said That You'll Want to Know,2017-09-12 21:37:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SJQEErZeCAs/3-things-amgen-incs-management-just-said-that-youll-want-to-know-cm844610,It s been a great 2017 for Amgen NASDAQ AMGN shareholders so far Amgen stock is up close to 30 The company announced several positive developments from its pipeline Still though some questions remain about what s next for the big biotech Amgen CEO Robert Bradway and
,,,3 Things Amgen Inc.'s Management Just Said That You'll Want to Know,2017-09-12 21:37:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SJQEErZeCAs/3-things-amgen-incs-management-just-said-that-youll-want-to-know-cm844610,It s been a great 2017 for Amgen NASDAQ AMGN shareholders so far Amgen stock is up close to 30 The company announced several positive developments from its pipeline Still though some questions remain about what s next for the big biotech Amgen CEO Robert Bradway and
,,,3 Things Amgen Inc.&apos;s Management Just Said That You&apos;ll Want to Know,2017-09-12 19:33:00 +0000,http://finance.yahoo.com/r/98f2bd7b-e003-377f-9aa6-c21a164dc272/3-things-amgen-incs-management-just-said-that-youl.aspx?yptr=yahoo&.tsrc=rss,Amgen&apos;s CEO and CFO discussed the big biotech&apos;s future at the Morgan Stanley healthcare conference.
NVS,NVS:US,BBG000LYF3S8,3 Things Amgen Inc.&apos;s Management Just Said That You&apos;ll Want to Know,2017-09-12 19:33:00 +0000,http://finance.yahoo.com/r/98f2bd7b-e003-377f-9aa6-c21a164dc272/3-things-amgen-incs-management-just-said-that-youl.aspx?yptr=yahoo&.tsrc=rss,Amgen&apos;s CEO and CFO discussed the big biotech&apos;s future at the Morgan Stanley healthcare conference.
NVS,NVS:US,BBG000LYF3S8,Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA,2017-09-12 17:37:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MKFHs9aqe_s/novartis-bla-for-biosimilar-of-rituxan-accepted-by-the-fda-cm844473,Novartis AG NVS announced that the FDA accepted its generics arm Sandoz s Biologics License Application BLA for a proposed biosimilar version of Roche Holding AG s RHHBY Rituxan rituximab The application was accepted under the 351 k pathway We note that Rituxan is approved for
,,,Novartis' BLA for Biosimilar of Rituxan Accepted by the FDA,2017-09-12 17:37:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MKFHs9aqe_s/novartis-bla-for-biosimilar-of-rituxan-accepted-by-the-fda-cm844473,Novartis AG NVS announced that the FDA accepted its generics arm Sandoz s Biologics License Application BLA for a proposed biosimilar version of Roche Holding AG s RHHBY Rituxan rituximab The application was accepted under the 351 k pathway We note that Rituxan is approved for
NVS,NVS:US,BBG000LYF3S8,Novartis&apos; BLA for Biosimilar of Rituxan Accepted by the FDA,2017-09-12 15:27:03 +0000,https://finance.yahoo.com/news/novartis-apos-bla-biosimilar-rituxan-152703246.html?.tsrc=rss,Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG&apos;s (RHHBY) Rituxan.
,,,Novartis&apos; BLA for Biosimilar of Rituxan Accepted by the FDA,2017-09-12 15:27:03 +0000,https://finance.yahoo.com/news/novartis-apos-bla-biosimilar-rituxan-152703246.html?.tsrc=rss,Novartis AG (NVS) announced that the FDA accepted its Biologics License Application for a proposed biosimilar version of Roche Holding AG&apos;s (RHHBY) Rituxan.
,,,"The Swiss Stock Market Climbed Back Above The 9,000 Point Level",2017-09-12 12:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LizGrdwd1q0/the-swiss-stock-market-climbed-back-above-the-9000-point-level-20170912-01107,"The Swiss Stock Market Climbed Back Above The 9,000 Point Level"
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Climbed Back Above The 9,000 Point Level",2017-09-12 12:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LizGrdwd1q0/the-swiss-stock-market-climbed-back-above-the-9000-point-level-20170912-01107,"The Swiss Stock Market Climbed Back Above The 9,000 Point Level"
NVS,NVS:US,BBG000LYF3S8,European Markets Finished Mostly Higher As Investors Snap Up Equities,2017-09-12 11:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FV_YRI2onZo/european-markets-finished-mostly-higher-as-investors-snap-up-equities-20170912-01052,European Markets Finished Mostly Higher As Investors Snap Up Equities
,,,European Markets Finished Mostly Higher As Investors Snap Up Equities,2017-09-12 11:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FV_YRI2onZo/european-markets-finished-mostly-higher-as-investors-snap-up-equities-20170912-01052,European Markets Finished Mostly Higher As Investors Snap Up Equities
,,,European Shares Mixed As UK Inflation Unexpectedly Jumps,2017-09-12 06:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ciKnkcefzSs/european-shares-mixed-as-uk-inflation-unexpectedly-jumps-20170912-00240,European Shares Mixed As UK Inflation Unexpectedly Jumps
NVS,NVS:US,BBG000LYF3S8,European Shares Mixed As UK Inflation Unexpectedly Jumps,2017-09-12 06:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ciKnkcefzSs/european-shares-mixed-as-uk-inflation-unexpectedly-jumps-20170912-00240,European Shares Mixed As UK Inflation Unexpectedly Jumps
NVS,NVS:US,BBG000LYF3S8,Novartis: FDA To Review BLA For Proposed Biosimilar Rituximab - Quick Facts,2017-09-12 01:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HcbY_tfFuv4/novartis-fda-to-review-bla-for-proposed-biosimilar-rituximab--quick-facts-20170912-00041,Novartis: FDA To Review BLA For Proposed Biosimilar Rituximab - Quick Facts
,,,Novartis: FDA To Review BLA For Proposed Biosimilar Rituximab - Quick Facts,2017-09-12 01:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HcbY_tfFuv4/novartis-fda-to-review-bla-for-proposed-biosimilar-rituximab--quick-facts-20170912-00041,Novartis: FDA To Review BLA For Proposed Biosimilar Rituximab - Quick Facts
NVS,NVS:US,BBG000LYF3S8,5 Ways To Play The Biotech Bull Market,2017-09-11 23:30:00 +0000,https://finance.yahoo.com/news/5-ways-play-biotech-bull-233000371.html?.tsrc=rss,"After a tough couple of years biotech is making a spectacular comeback, with important breakthroughs in cancer and stroke treatment jolting the market"
,,,5 Ways To Play The Biotech Bull Market,2017-09-11 23:30:00 +0000,https://finance.yahoo.com/news/5-ways-play-biotech-bull-233000371.html?.tsrc=rss,"After a tough couple of years biotech is making a spectacular comeback, with important breakthroughs in cancer and stroke treatment jolting the market"
,,,5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition,2017-09-11 20:02:00 +0000,http://finance.yahoo.com/r/3e70331b-ac11-3881-8b2c-d61bf240ba19/5-tough-questions-for-gilead-sciences-about-the-ki.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences CEO and oncology chief take on direct questions about why buying Kite was the right move.
NVS,NVS:US,BBG000LYF3S8,5 Tough Questions for Gilead Sciences About the Kite Pharma Acquisition,2017-09-11 20:02:00 +0000,http://finance.yahoo.com/r/3e70331b-ac11-3881-8b2c-d61bf240ba19/5-tough-questions-for-gilead-sciences-about-the-ki.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences CEO and oncology chief take on direct questions about why buying Kite was the right move.
,,,Roche's Ophthalmology Drug Fails to Meet Primary Endpoint,2017-09-11 15:40:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DIJMpDb90T0/roches-ophthalmology-drug-fails-to-meet-primary-endpoint-cm843687,Roche Holding AG RHHBY announced that its ophthalmology candidate lampalizumab did not meet the primary endpoint in Spectri the first of two phase III studies Roche is evaluating lampalizumab for the treatment of GA due to age related macular degeneration AMD 160 Following the
NVS,NVS:US,BBG000LYF3S8,Roche's Ophthalmology Drug Fails to Meet Primary Endpoint,2017-09-11 15:40:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DIJMpDb90T0/roches-ophthalmology-drug-fails-to-meet-primary-endpoint-cm843687,Roche Holding AG RHHBY announced that its ophthalmology candidate lampalizumab did not meet the primary endpoint in Spectri the first of two phase III studies Roche is evaluating lampalizumab for the treatment of GA due to age related macular degeneration AMD 160 Following the
,,,"Foreign Stock Roundup: HMC Agrees on $605M Takata Air Bag Settlement, Narasimhan to Head Novartis",2017-09-11 13:22:01 +0000,https://finance.yahoo.com/news/foreign-stock-roundup-hmc-agrees-132201250.html?.tsrc=rss,North Korea-related tensions weighed on stocks across the world last week.
NVS,NVS:US,BBG000LYF3S8,"Foreign Stock Roundup: HMC Agrees on $605M Takata Air Bag Settlement, Narasimhan to Head Novartis",2017-09-11 13:22:01 +0000,https://finance.yahoo.com/news/foreign-stock-roundup-hmc-agrees-132201250.html?.tsrc=rss,North Korea-related tensions weighed on stocks across the world last week.
,,,The Swiss Stock Market Climbed On Strength Of Insurers,2017-09-11 12:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XEqwyhq4qzQ/the-swiss-stock-market-climbed-on-strength-of-insurers-20170911-00941,The Swiss Stock Market Climbed On Strength Of Insurers
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On Strength Of Insurers,2017-09-11 12:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XEqwyhq4qzQ/the-swiss-stock-market-climbed-on-strength-of-insurers-20170911-00941,The Swiss Stock Market Climbed On Strength Of Insurers
,,,Roche: Zelboraf Phase III Study Fails To Meet Primary Endpoint,2017-09-11 03:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_3HWGzqUfsA/roche-zelboraf-phase-iii-study-fails-to-meet-primary-endpoint-20170911-00119,Roche: Zelboraf Phase III Study Fails To Meet Primary Endpoint
NVS,NVS:US,BBG000LYF3S8,Roche: Zelboraf Phase III Study Fails To Meet Primary Endpoint,2017-09-11 03:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_3HWGzqUfsA/roche-zelboraf-phase-iii-study-fails-to-meet-primary-endpoint-20170911-00119,Roche: Zelboraf Phase III Study Fails To Meet Primary Endpoint
,,,Novartis: Phase III COMBI-AD Study Of Tafinlar + Mekinist Meets Primary Goal,2017-09-11 00:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IwwW-iQC4hQ/novartis-phase-iii-combiad-study-of-tafinlar--mekinist-meets-primary-goal-20170911-00008,Novartis: Phase III COMBI-AD Study Of Tafinlar + Mekinist Meets Primary Goal
NVS,NVS:US,BBG000LYF3S8,Novartis: Phase III COMBI-AD Study Of Tafinlar + Mekinist Meets Primary Goal,2017-09-11 00:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IwwW-iQC4hQ/novartis-phase-iii-combiad-study-of-tafinlar--mekinist-meets-primary-goal-20170911-00008,Novartis: Phase III COMBI-AD Study Of Tafinlar + Mekinist Meets Primary Goal
NVS,NVS:US,BBG000LYF3S8,"Novartis posts a win, Roche a flop in skin cancer trials",2017-09-10 22:05:00 +0000,https://finance.yahoo.com/news/novartis-posts-win-roche-flop-220500593.html?.tsrc=rss,"ZURICH/MADRID, Sept 11 (Reuters) - Swiss drugmaker Novartis  notched a trial win for its drug cocktail against skin  cancer on Monday, while a rival treatment from Roche  with slipping sales failed in a separate study with a similar  patient group.  All the medicines were tested in melanoma patients who had  undergone surgery to cut out tumours and had a genetic mutation  called BRAF, making them likely to respond to the targeted  cancer pills."
,,,"Novartis posts a win, Roche a flop in skin cancer trials",2017-09-10 22:05:00 +0000,https://finance.yahoo.com/news/novartis-posts-win-roche-flop-220500593.html?.tsrc=rss,"ZURICH/MADRID, Sept 11 (Reuters) - Swiss drugmaker Novartis  notched a trial win for its drug cocktail against skin  cancer on Monday, while a rival treatment from Roche  with slipping sales failed in a separate study with a similar  patient group.  All the medicines were tested in melanoma patients who had  undergone surgery to cut out tumours and had a genetic mutation  called BRAF, making them likely to respond to the targeted  cancer pills."
,,,"Lilly takes on Pfizer, Novartis with new breast cancer drug data",2017-09-10 08:19:36 +0000,https://finance.yahoo.com/news/lilly-takes-pfizer-novartis-breast-081936133.html?.tsrc=rss,"NEW YORK/MADRID, Sept 10 (Reuters) - Eli Lilly  staked its claim for a slice of sales in a new class of breast  cancer drugs on Sunday as clinical data showed adding its  medicine abemaciclib to standard therapy reduced the risk of  disease progression by 46 percent.  Experts at the European Society for Medical Oncology (ESMO)  congress in Madrid said the experimental drug's efficacy was  comparable to that of rival drugs from Pfizer and  Novartis already on the market."
NVS,NVS:US,BBG000LYF3S8,"Lilly takes on Pfizer, Novartis with new breast cancer drug data",2017-09-10 08:19:36 +0000,https://finance.yahoo.com/news/lilly-takes-pfizer-novartis-breast-081936133.html?.tsrc=rss,"NEW YORK/MADRID, Sept 10 (Reuters) - Eli Lilly  staked its claim for a slice of sales in a new class of breast  cancer drugs on Sunday as clinical data showed adding its  medicine abemaciclib to standard therapy reduced the risk of  disease progression by 46 percent.  Experts at the European Society for Medical Oncology (ESMO)  congress in Madrid said the experimental drug's efficacy was  comparable to that of rival drugs from Pfizer and  Novartis already on the market."
NVS,NVS:US,BBG000LYF3S8,Novartis: New Data Confirm Lucentis Efficacy And Durability Vs Aflibercept,2017-09-09 21:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n9qR_uQOJ68/novartis-new-data-confirm-lucentis-efficacy-and-durability-vs-aflibercept-20170909-00031,Novartis: New Data Confirm Lucentis Efficacy And Durability Vs Aflibercept
,,,Novartis: New Data Confirm Lucentis Efficacy And Durability Vs Aflibercept,2017-09-09 21:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n9qR_uQOJ68/novartis-new-data-confirm-lucentis-efficacy-and-durability-vs-aflibercept-20170909-00031,Novartis: New Data Confirm Lucentis Efficacy And Durability Vs Aflibercept
,,,"[$$] Investors Chronicle: Redrow, Oxford BioMedica, Halfords",2017-09-08 15:07:35 +0000,"http://finance.yahoo.com/r/bb3ea8d2-b6a6-3281-b6ae-c9f2933c2e0a/e078e324-92f5-11e7-bdfa-eda243196c2c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Shares in Redrow have risen sharply this year and are well ahead of our buy tip in March 2016, yet trade on a price/net asset value discount to the peer group. Given the growth profile, we think there's ..."
NVS,NVS:US,BBG000LYF3S8,"[$$] Investors Chronicle: Redrow, Oxford BioMedica, Halfords",2017-09-08 15:07:35 +0000,"http://finance.yahoo.com/r/bb3ea8d2-b6a6-3281-b6ae-c9f2933c2e0a/e078e324-92f5-11e7-bdfa-eda243196c2c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Shares in Redrow have risen sharply this year and are well ahead of our buy tip in March 2016, yet trade on a price/net asset value discount to the peer group. Given the growth profile, we think there's ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed As Traders Turn Cautious,2017-09-08 12:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/khz0As6RNIg/the-swiss-stock-market-finished-little-changed-as-traders-turn-cautious-20170908-00644,The Swiss Stock Market Finished Little Changed As Traders Turn Cautious
,,,The Swiss Stock Market Finished Little Changed As Traders Turn Cautious,2017-09-08 12:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/khz0As6RNIg/the-swiss-stock-market-finished-little-changed-as-traders-turn-cautious-20170908-00644,The Swiss Stock Market Finished Little Changed As Traders Turn Cautious
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018",2017-09-08 12:25:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-lilly-cut-122512134.html?.tsrc=rss,Key highlights this week include Eli Lilly and Company&apos;s (LLY) decision to cut the work force and streamline operations and Merck&apos;s efforts to strengthen its immune-oncology franchise.
,,,"Pharma Stock Roundup: Lilly to Cut Jobs, Streamline Operations, NVS CEO to Step Down in 2018",2017-09-08 12:25:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-lilly-cut-122512134.html?.tsrc=rss,Key highlights this week include Eli Lilly and Company&apos;s (LLY) decision to cut the work force and streamline operations and Merck&apos;s efforts to strengthen its immune-oncology franchise.
NVS,NVS:US,BBG000LYF3S8,Understanding Merck’s Valuation after 2Q17,2017-09-08 11:38:13 +0000,http://finance.yahoo.com/r/63146f08-0644-3585-80c9-23825ddc23cc/understanding-mercks-valuation-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Merck reported EPS of $1.01 on revenues of ~$9.93 billion for 2Q17, compared with its EPS of $0.93 on revenues of $9.84 billion in 2Q16."
,,,Understanding Merck’s Valuation after 2Q17,2017-09-08 11:38:13 +0000,http://finance.yahoo.com/r/63146f08-0644-3585-80c9-23825ddc23cc/understanding-mercks-valuation-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Merck reported EPS of $1.01 on revenues of ~$9.93 billion for 2Q17, compared with its EPS of $0.93 on revenues of $9.84 billion in 2Q16."
NVS,NVS:US,BBG000LYF3S8,Novartis Sees Relative Strength Rating Improve To 75,2017-09-08 07:00:00 +0000,http://finance.yahoo.com/r/ded2040e-d5f1-3779-bd4d-a3a392252a98/novartis-sees-relative-strength-rating-improve-to-75?src=A00220&yptr=yahoo&.tsrc=rss,"Novartis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating"
,,,Novartis Sees Relative Strength Rating Improve To 75,2017-09-08 07:00:00 +0000,http://finance.yahoo.com/r/ded2040e-d5f1-3779-bd4d-a3a392252a98/novartis-sees-relative-strength-rating-improve-to-75?src=A00220&yptr=yahoo&.tsrc=rss,"Novartis shows rising price performance, earning an upgrade to its IBD Relative Strength Rating"
NVS,NVS:US,BBG000LYF3S8,"Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High",2017-09-08 02:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f0NOOpQeAZw/christmas-comes-early-for-kura-anth-on-track-abbv-hits-alltime-high-20170908-00063,"Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High"
,,,"Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High",2017-09-08 02:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f0NOOpQeAZw/christmas-comes-early-for-kura-anth-on-track-abbv-hits-alltime-high-20170908-00063,"Christmas Comes Early For KURA, ANTH On Track, ABBV Hits All-time High"
NVS,NVS:US,BBG000LYF3S8,"Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus",2017-09-07 23:51:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CQa0ae-zpw0/kymriah-first-car-t-therapy-approved-4-pharma-stocks-in-focus-cm842662,Of late biotechnology and pharmaceutical companies are investing in immuno oncology research therapies as it remains a key area of focus thanks to its vast growth potential Last week the immuno oncology space grabbed investors attention with the FDA approving Novartis AG s NVS
,,,"Kymriah, First CAR-T Therapy Approved: 4 Pharma Stocks in Focus",2017-09-07 23:51:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CQa0ae-zpw0/kymriah-first-car-t-therapy-approved-4-pharma-stocks-in-focus-cm842662,Of late biotechnology and pharmaceutical companies are investing in immuno oncology research therapies as it remains a key area of focus thanks to its vast growth potential Last week the immuno oncology space grabbed investors attention with the FDA approving Novartis AG s NVS
,,,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted",2017-09-07 22:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5UtajTIgaUI/nlnk-rallies-on-indoximod-data-vrna-breathes-easy-alny-jolted-20170907-01658,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted"
NVS,NVS:US,BBG000LYF3S8,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted",2017-09-07 22:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5UtajTIgaUI/nlnk-rallies-on-indoximod-data-vrna-breathes-easy-alny-jolted-20170907-01658,"NLNK Rallies On Indoximod Data, VRNA Breathes Easy, ALNY Jolted"
,,,"Are You Buying Gilead Sciences, Inc. for the Wrong Reason?",2017-09-07 18:54:00 +0000,http://finance.yahoo.com/r/e90105bf-b898-394d-9ce6-920db9f1f93f/are-you-buying-gilead-sciences-inc-for-the-wrong-r.aspx?yptr=yahoo&.tsrc=rss,"The acquisition of Kite Pharma is a good move, but don&apos;t get caught up in the hype of Novartis&apos; approval for Kymriah, which uses the same technology as Kite."
NVS,NVS:US,BBG000LYF3S8,"Are You Buying Gilead Sciences, Inc. for the Wrong Reason?",2017-09-07 18:54:00 +0000,http://finance.yahoo.com/r/e90105bf-b898-394d-9ce6-920db9f1f93f/are-you-buying-gilead-sciences-inc-for-the-wrong-r.aspx?yptr=yahoo&.tsrc=rss,"The acquisition of Kite Pharma is a good move, but don&apos;t get caught up in the hype of Novartis&apos; approval for Kymriah, which uses the same technology as Kite."
NVS,NVS:US,BBG000LYF3S8,Departing Novartis CEO Sets His Eyes On Silicon Valley,2017-09-07 13:00:00 +0000,http://finance.yahoo.com/r/74101211-d994-31b0-8856-9afe5f65177f/departing-novartis-ceo-sets-his-eyes-on-silicon-valley?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,“The thing that needs to be fixed is the inefficiency in the U.S. healthcare system. How are we going to pay for the innovation that’s coming?” Jimenez says. “The only way is to get rid of the inefficiency in the system. That’s where I see digital technology starting to have a significant impact.”
,,,Departing Novartis CEO Sets His Eyes On Silicon Valley,2017-09-07 13:00:00 +0000,http://finance.yahoo.com/r/74101211-d994-31b0-8856-9afe5f65177f/departing-novartis-ceo-sets-his-eyes-on-silicon-valley?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,“The thing that needs to be fixed is the inefficiency in the U.S. healthcare system. How are we going to pay for the innovation that’s coming?” Jimenez says. “The only way is to get rid of the inefficiency in the system. That’s where I see digital technology starting to have a significant impact.”
,,,The Swiss Stock Market Climbed On Strength Of Defensive Heavyweights,2017-09-07 12:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rWY8AACy-Vg/the-swiss-stock-market-climbed-on-strength-of-defensive-heavyweights-20170907-01190,The Swiss Stock Market Climbed On Strength Of Defensive Heavyweights
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On Strength Of Defensive Heavyweights,2017-09-07 12:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rWY8AACy-Vg/the-swiss-stock-market-climbed-on-strength-of-defensive-heavyweights-20170907-01190,The Swiss Stock Market Climbed On Strength Of Defensive Heavyweights
,,,The Swiss Stock Market Climbed,2017-09-07 12:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2fkpau7JmNg/the-swiss-stock-market-climbed-20170907-01187,The Swiss Stock Market Climbed
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed,2017-09-07 12:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2fkpau7JmNg/the-swiss-stock-market-climbed-20170907-01187,The Swiss Stock Market Climbed
NVS,NVS:US,BBG000LYF3S8,5 Things Gilead Sciences' Management Just Said That You'll Want to Know,2017-09-07 11:59:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NVtGDnyiJQw/5-things-gilead-sciences-management-just-said-that-youll-want-to-know-cm842060,Last week Gilead Sciences NASDAQ GILD generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma NASDAQ KITE On Wednesday several of the company s top executives sat down at the Citi biotech conference to field questions
,,,5 Things Gilead Sciences' Management Just Said That You'll Want to Know,2017-09-07 11:59:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NVtGDnyiJQw/5-things-gilead-sciences-management-just-said-that-youll-want-to-know-cm842060,Last week Gilead Sciences NASDAQ GILD generated plenty of buzz with the announcement of its planned acquisition of Kite Pharma NASDAQ KITE On Wednesday several of the company s top executives sat down at the Citi biotech conference to field questions
NVS,NVS:US,BBG000LYF3S8,5 Things Gilead Sciences&apos; Management Just Said That You&apos;ll Want to Know,2017-09-07 10:04:00 +0000,http://finance.yahoo.com/r/ea53f393-01e3-3bd5-9678-398d10317f91/5-things-gilead-sciences-management-just-said-that.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences executives answer the big questions on investors&apos; minds -- from the Kite Pharma deal to competition for its HIV and HCV products.
,,,5 Things Gilead Sciences&apos; Management Just Said That You&apos;ll Want to Know,2017-09-07 10:04:00 +0000,http://finance.yahoo.com/r/ea53f393-01e3-3bd5-9678-398d10317f91/5-things-gilead-sciences-management-just-said-that.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences executives answer the big questions on investors&apos; minds -- from the Kite Pharma deal to competition for its HIV and HCV products.
NVS,NVS:US,BBG000LYF3S8,New Drugs Approved In August,2017-09-07 05:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZoP1iaTzo4w/new-drugs-approved-in-august-20170907-00189,New Drugs Approved In August
,,,New Drugs Approved In August,2017-09-07 05:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZoP1iaTzo4w/new-drugs-approved-in-august-20170907-00189,New Drugs Approved In August
NVS,NVS:US,BBG000LYF3S8,Here's What Lifted bluebird bio Inc. Stock 40% Higher in August,2017-09-06 20:51:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dpdO6-VWPd4/heres-what-lifted-bluebird-bio-inc-stock-40-higher-in-august-cm841904,What happened Shares of bluebird bio Inc NASDAQ BLUE a clinical stage biotech developing cell based therapies soared 40 in August according to data from S amp P Global Market Intelligence A generous takeover offer for an industry peer and an FDA approval for
,,,Here's What Lifted bluebird bio Inc. Stock 40% Higher in August,2017-09-06 20:51:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dpdO6-VWPd4/heres-what-lifted-bluebird-bio-inc-stock-40-higher-in-august-cm841904,What happened Shares of bluebird bio Inc NASDAQ BLUE a clinical stage biotech developing cell based therapies soared 40 in August according to data from S amp P Global Market Intelligence A generous takeover offer for an industry peer and an FDA approval for
,,,"Health Care Sector Update for 09/06/2017: XOMA,VSTM,PULM",2017-09-06 18:49:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4IQessK0zV0/health-care-sector-update-for-09062017-xomavstmpulm-cm841851,Top Health Care StocksTop Health Care Stocks JNJ 0 77 JNJ 0 77 PFE 0 77 PFE 0 77 ABT 0 29 ABT 0 29 MRK 0 44 MRK 0 44 AMGN 0 81 AMGN 0 81 Health care stocks were trying to extend their earlier gains this afternoon with the NYSE Health Care Index climbing almost 0 4 in recent
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 09/06/2017: XOMA,VSTM,PULM",2017-09-06 18:49:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4IQessK0zV0/health-care-sector-update-for-09062017-xomavstmpulm-cm841851,Top Health Care StocksTop Health Care Stocks JNJ 0 77 JNJ 0 77 PFE 0 77 PFE 0 77 ABT 0 29 ABT 0 29 MRK 0 44 MRK 0 44 AMGN 0 81 AMGN 0 81 Health care stocks were trying to extend their earlier gains this afternoon with the NYSE Health Care Index climbing almost 0 4 in recent
NVS,NVS:US,BBG000LYF3S8,Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study,2017-09-06 16:54:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WfIumkgNKjU/novartis-nvs-ms-drug-gilenya-positive-in-long-term-study-cm841759,Novartis AG NVS announced positive top line results from the phase III study PARADIGMS The study evaluated the safety and efficacy of oral once daily Gilenya in children and adolescents aged 10 17 with multiple sclerosis MS The flexible duration up to two years double
,,,Novartis' (NVS) MS Drug Gilenya Positive in Long-Term Study,2017-09-06 16:54:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WfIumkgNKjU/novartis-nvs-ms-drug-gilenya-positive-in-long-term-study-cm841759,Novartis AG NVS announced positive top line results from the phase III study PARADIGMS The study evaluated the safety and efficacy of oral once daily Gilenya in children and adolescents aged 10 17 with multiple sclerosis MS The flexible duration up to two years double
NVS,NVS:US,BBG000LYF3S8,MEI Pharma-Presage Biosciences on License Deal for Voruciclib,2017-09-06 16:53:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/18_ZlShHWBQ/mei-pharma-presage-biosciences-on-license-deal-for-voruciclib-cm841743,MEI Pharma Inc MEIP announced that it has inked an exclusive license agreement with Presage Biosciences an oncology company for developing its oral and selective cyclin dependent kinase CDK inhibitor voruciclib formerly P1446A for treatment of B cell lymphoma 2 BCL2 Pursuant to
,,,MEI Pharma-Presage Biosciences on License Deal for Voruciclib,2017-09-06 16:53:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/18_ZlShHWBQ/mei-pharma-presage-biosciences-on-license-deal-for-voruciclib-cm841743,MEI Pharma Inc MEIP announced that it has inked an exclusive license agreement with Presage Biosciences an oncology company for developing its oral and selective cyclin dependent kinase CDK inhibitor voruciclib formerly P1446A for treatment of B cell lymphoma 2 BCL2 Pursuant to
,,,Ligand (LGND) Diabetes Candidate Positive in Phase II Study,2017-09-06 15:56:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uHP3XhvvZQU/ligand-lgnd-diabetes-candidate-positive-in-phase-ii-study-cm841603,Ligand Pharmaceuticals Incorporated LGND announced positive top line results from a phase II study evaluating its diabetes candidate LGD 6972 The study achieved a statistically significant change in hemoglobin A1c HbA1c a measure of blood glucose from baseline after 12 weeks of
NVS,NVS:US,BBG000LYF3S8,Ligand (LGND) Diabetes Candidate Positive in Phase II Study,2017-09-06 15:56:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uHP3XhvvZQU/ligand-lgnd-diabetes-candidate-positive-in-phase-ii-study-cm841603,Ligand Pharmaceuticals Incorporated LGND announced positive top line results from a phase II study evaluating its diabetes candidate LGD 6972 The study achieved a statistically significant change in hemoglobin A1c HbA1c a measure of blood glucose from baseline after 12 weeks of
,,,Novartis&apos; (NVS) MS Drug Gilenya Positive in Long-Term Study,2017-09-06 14:30:02 +0000,https://finance.yahoo.com/news/novartis-apos-nvs-ms-drug-143002906.html?.tsrc=rss,"Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents."
NVS,NVS:US,BBG000LYF3S8,Novartis&apos; (NVS) MS Drug Gilenya Positive in Long-Term Study,2017-09-06 14:30:02 +0000,https://finance.yahoo.com/news/novartis-apos-nvs-ms-drug-143002906.html?.tsrc=rss,"Novartis AG (NVS) announced positive top-line results from the phase III study, PARADIGMS on MS Drug Gilenya for children and adolescents."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Slid On North Korea Concerns,2017-09-06 12:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aN71bvdrgNw/the-swiss-stock-market-slid-on-north-korea-concerns-20170906-01130,The Swiss Stock Market Slid On North Korea Concerns
,,,The Swiss Stock Market Slid On North Korea Concerns,2017-09-06 12:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aN71bvdrgNw/the-swiss-stock-market-slid-on-north-korea-concerns-20170906-01130,The Swiss Stock Market Slid On North Korea Concerns
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis Deal Could Send Xoma Stock to $19,2017-09-06 11:20:00 +0000,http://finance.yahoo.com/r/6026ce0e-7fc6-320a-9614-518aac9bd76e/novartis-deal-could-send-xoma-stock-to-19-1504696834?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Xoma (XOMA:Nasdaq)  By Wedbush ($11.18, Sept. 5, 2017) We are upgrading our rating on Xoma to Outperform from Neutral and increasing our 12-month price target to $19 from $9.  Due to clinical failures, we thought gevokizumab was shelved but recent cardiovascular clinical success with Novartis’ (NVS) canakinumab apparently created strategic value to have more than one anti-IL-1β treatment--prompting Novartis to license gevokizumab and anti-IL-1β.  For gevokizumab, Xoma receives $16 million upfront cash and is eligible for up to $438 million in milestones and high single digit to mid-double-digit percentage tiered royalties on sales."
,,,[$$] Novartis Deal Could Send Xoma Stock to $19,2017-09-06 11:20:00 +0000,http://finance.yahoo.com/r/6026ce0e-7fc6-320a-9614-518aac9bd76e/novartis-deal-could-send-xoma-stock-to-19-1504696834?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Xoma (XOMA:Nasdaq)  By Wedbush ($11.18, Sept. 5, 2017) We are upgrading our rating on Xoma to Outperform from Neutral and increasing our 12-month price target to $19 from $9.  Due to clinical failures, we thought gevokizumab was shelved but recent cardiovascular clinical success with Novartis’ (NVS) canakinumab apparently created strategic value to have more than one anti-IL-1β treatment--prompting Novartis to license gevokizumab and anti-IL-1β.  For gevokizumab, Xoma receives $16 million upfront cash and is eligible for up to $438 million in milestones and high single digit to mid-double-digit percentage tiered royalties on sales."
NVS,NVS:US,BBG000LYF3S8,Corporate News Blog - Leadership Change in Novartis as CEO Jimenez to Retire in 2018; Vasant Narasimhan Named His Successor,2017-09-06 11:10:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-leadership-change-111000332.html?.tsrc=rss,"Research Desk Line-up: GW Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 6, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novartis ..."
,,,Corporate News Blog - Leadership Change in Novartis as CEO Jimenez to Retire in 2018; Vasant Narasimhan Named His Successor,2017-09-06 11:10:00 +0000,https://finance.yahoo.com/news/corporate-news-blog-leadership-change-111000332.html?.tsrc=rss,"Research Desk Line-up: GW Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / September 6, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Novartis ..."
NVS,NVS:US,BBG000LYF3S8,"INSM Breathes Easy, XOMA Rises On Analyst Upgrade, CLLS Down On Clinical Hold",2017-09-05 21:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HZy-GVjhxxo/insm-breathes-easy-xoma-rises-on-analyst-upgrade-clls-down-on-clinical-hold-20170905-01610,"INSM Breathes Easy, XOMA Rises On Analyst Upgrade, CLLS Down On Clinical Hold"
,,,"INSM Breathes Easy, XOMA Rises On Analyst Upgrade, CLLS Down On Clinical Hold",2017-09-05 21:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HZy-GVjhxxo/insm-breathes-easy-xoma-rises-on-analyst-upgrade-clls-down-on-clinical-hold-20170905-01610,"INSM Breathes Easy, XOMA Rises On Analyst Upgrade, CLLS Down On Clinical Hold"
,,,Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018,2017-09-05 20:37:08 +0000,https://finance.yahoo.com/news/narasimhan-replace-jimenez-novartis-nvs-203708630.html?.tsrc=rss,"Novartis AG (NVS) announced that its Chief Executive Officer (CEO), Joseph Jimenez will step down from his position in 2018."
NVS,NVS:US,BBG000LYF3S8,Narasimhan to Replace Jimenez as Novartis (NVS) CEO in 2018,2017-09-05 20:37:08 +0000,https://finance.yahoo.com/news/narasimhan-replace-jimenez-novartis-nvs-203708630.html?.tsrc=rss,"Novartis AG (NVS) announced that its Chief Executive Officer (CEO), Joseph Jimenez will step down from his position in 2018."
,,,Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better,2017-09-05 14:49:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wQZGi4WCQhQ/gilead-sciences-couldnt-have-timed-its-splash-into-car-t-better-cm840926,Investors have been wondering for a few years now when Gilead Sciences NASDAQ GILD would spend some of its massive cash hoard and acquire a new company and this week Gilead put those wonders to rest for now with its 11 9 billion acquisition of Kite Pharmaceuticals
NVS,NVS:US,BBG000LYF3S8,Gilead Sciences Couldn't Have Timed its Splash Into CAR-T Better,2017-09-05 14:49:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wQZGi4WCQhQ/gilead-sciences-couldnt-have-timed-its-splash-into-car-t-better-cm840926,Investors have been wondering for a few years now when Gilead Sciences NASDAQ GILD would spend some of its massive cash hoard and acquire a new company and this week Gilead put those wonders to rest for now with its 11 9 billion acquisition of Kite Pharmaceuticals
NVS,NVS:US,BBG000LYF3S8,Biotech Stocks Back in Favor: Will the Rally Continue?,2017-09-05 13:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I7MKDiXq3RQ/biotech-stocks-back-in-favor-will-the-rally-continue-cm840879,The biotech sector got a shot in the arm last week thanks to two major developments that led to a rally in the sector The first catalyst was Gilead Sciences GILD decision to acquire immunotherapy focused company Kite Pharma KITE and the second was the FDA approval of the first gene therapy
,,,Biotech Stocks Back in Favor: Will the Rally Continue?,2017-09-05 13:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I7MKDiXq3RQ/biotech-stocks-back-in-favor-will-the-rally-continue-cm840879,The biotech sector got a shot in the arm last week thanks to two major developments that led to a rally in the sector The first catalyst was Gilead Sciences GILD decision to acquire immunotherapy focused company Kite Pharma KITE and the second was the FDA approval of the first gene therapy
,,,Gilead Sciences Couldn&apos;t Have Timed its Splash Into CAR-T Better,2017-09-05 12:53:00 +0000,http://finance.yahoo.com/r/1945bf8c-089b-32c7-b80e-2721be215bb8/gilead-sciences-couldnt-have-timed-its-splash-into.aspx?yptr=yahoo&.tsrc=rss,"The FDA approved the world&apos;s first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion."
NVS,NVS:US,BBG000LYF3S8,Gilead Sciences Couldn&apos;t Have Timed its Splash Into CAR-T Better,2017-09-05 12:53:00 +0000,http://finance.yahoo.com/r/1945bf8c-089b-32c7-b80e-2721be215bb8/gilead-sciences-couldnt-have-timed-its-splash-into.aspx?yptr=yahoo&.tsrc=rss,"The FDA approved the world&apos;s first CAR-T therapy on Wednesday, one month ahead of schedule, and only days after Gilead Sciences announced it’s buying CAR-T powerhouse Kite Pharma in a deal valued at $11.9 billion."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed In Cautious Trade,2017-09-05 12:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xa-XNErcuOI/the-swiss-stock-market-finished-little-changed-in-cautious-trade-20170905-01154,The Swiss Stock Market Finished Little Changed In Cautious Trade
,,,The Swiss Stock Market Finished Little Changed In Cautious Trade,2017-09-05 12:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xa-XNErcuOI/the-swiss-stock-market-finished-little-changed-in-cautious-trade-20170905-01154,The Swiss Stock Market Finished Little Changed In Cautious Trade
,,,Why Juno Therapeutics Shares Vaulted 46% Higher in August,2017-09-05 11:15:00 +0000,http://finance.yahoo.com/r/d7f4d5bf-dc64-3b11-9b80-533e47e03fc5/why-juno-therapeutics-shares-vaulted-46-higher-in.aspx?yptr=yahoo&.tsrc=rss,Optimism is soaring following the FDA approval of Novartis&apos; CAR-T and the $11.9 billion acquisition of CAR-T developer Kite Pharma.
NVS,NVS:US,BBG000LYF3S8,Why Juno Therapeutics Shares Vaulted 46% Higher in August,2017-09-05 11:15:00 +0000,http://finance.yahoo.com/r/d7f4d5bf-dc64-3b11-9b80-533e47e03fc5/why-juno-therapeutics-shares-vaulted-46-higher-in.aspx?yptr=yahoo&.tsrc=rss,Optimism is soaring following the FDA approval of Novartis&apos; CAR-T and the $11.9 billion acquisition of CAR-T developer Kite Pharma.
NVS,NVS:US,BBG000LYF3S8,"3 Stocks to Watch on Tuesday: Boeing Co (BA), McDonald’s Corporation (MCD) and Novartis AG (ADR) (NVS)",2017-09-05 11:00:58 +0000,https://finance.yahoo.com/news/3-stocks-watch-tuesday-boeing-111058895.html?.tsrc=rss,"No investing took place yesterday due to Labor Day, which saw gasoline prices decline in the country.  U.S. crude prices were mixed as several refineries were back in action as Hurricane Harvey exited most of the affected regions in Texas.  Labor Day weekend was busy for certain companies and their employees, as Boeing Co (NYSE:BA), McDonald’s Corporation (NYSE:MCD) and Novartis AG (ADR) (NYSE:NVS) all made Monday’s headlines."
,,,"3 Stocks to Watch on Tuesday: Boeing Co (BA), McDonald’s Corporation (MCD) and Novartis AG (ADR) (NVS)",2017-09-05 11:00:58 +0000,https://finance.yahoo.com/news/3-stocks-watch-tuesday-boeing-111058895.html?.tsrc=rss,"No investing took place yesterday due to Labor Day, which saw gasoline prices decline in the country.  U.S. crude prices were mixed as several refineries were back in action as Hurricane Harvey exited most of the affected regions in Texas.  Labor Day weekend was busy for certain companies and their employees, as Boeing Co (NYSE:BA), McDonald’s Corporation (NYSE:MCD) and Novartis AG (ADR) (NYSE:NVS) all made Monday’s headlines."
NVS,NVS:US,BBG000LYF3S8,Novartis’ CAR-T therapy was the first approved in U.S. — here’s how to invest in the space,2017-09-05 10:58:50 +0000,http://finance.yahoo.com/r/1e4ebc0b-7052-3326-95e4-6f91dd2e40c6/Story.aspx?guid=63C6994E-8E49-11E7-9800-D762A918DF1A&siteid=yhoof2&yptr=yahoo&.tsrc=rss,How to get in on “the very early innings” of a growth cycle that could last a decade.
,,,Novartis’ CAR-T therapy was the first approved in U.S. — here’s how to invest in the space,2017-09-05 10:58:50 +0000,http://finance.yahoo.com/r/1e4ebc0b-7052-3326-95e4-6f91dd2e40c6/Story.aspx?guid=63C6994E-8E49-11E7-9800-D762A918DF1A&siteid=yhoof2&yptr=yahoo&.tsrc=rss,How to get in on “the very early innings” of a growth cycle that could last a decade.
NVS,NVS:US,BBG000LYF3S8,Novartis CEO to step down next year,2017-09-05 10:44:00 +0000,https://finance.yahoo.com/video/novartis-ceo-step-down-next-104400264.html?.tsrc=rss,The &quot;Squawk Box&quot; news team discusses some of the morning's most provocative headlines.
,,,Novartis CEO to step down next year,2017-09-05 10:44:00 +0000,https://finance.yahoo.com/video/novartis-ceo-step-down-next-104400264.html?.tsrc=rss,The &quot;Squawk Box&quot; news team discusses some of the morning's most provocative headlines.
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis CEO to Step Down in January,2017-09-05 04:03:43 +0000,http://finance.yahoo.com/r/d9087da7-0a83-3415-8052-642c75d882ee/novartis-ceo-to-step-down-in-january-1504510846?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,Novartis said its Chief Executive Joe Jimenez is to step down in January after leading the company through a tumultuous eight years marked by big patent expiries and intensifying scrutiny on drug pricing ...
,,,[$$] Novartis CEO to Step Down in January,2017-09-05 04:03:43 +0000,http://finance.yahoo.com/r/d9087da7-0a83-3415-8052-642c75d882ee/novartis-ceo-to-step-down-in-january-1504510846?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,Novartis said its Chief Executive Joe Jimenez is to step down in January after leading the company through a tumultuous eight years marked by big patent expiries and intensifying scrutiny on drug pricing ...
NVS,NVS:US,BBG000LYF3S8,Novartis Calls the Doctor to Push Breakthrough Drugs Forward,2017-09-05 04:00:00 +0000,http://finance.yahoo.com/r/2efe741d-eece-3da8-bca8-d5ec6c6a28b6/harvard-doctor-replaces-heinz-man-as-novartis-focuses-on-cancer?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"The last time Novartis AG hired a new chief, the drugmaker went with a guy who spent years at companies that make bleach and ketchup. This time around, the Swiss company chose someone with a deep understanding ..."
,,,Novartis Calls the Doctor to Push Breakthrough Drugs Forward,2017-09-05 04:00:00 +0000,http://finance.yahoo.com/r/2efe741d-eece-3da8-bca8-d5ec6c6a28b6/harvard-doctor-replaces-heinz-man-as-novartis-focuses-on-cancer?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"The last time Novartis AG hired a new chief, the drugmaker went with a guy who spent years at companies that make bleach and ketchup. This time around, the Swiss company chose someone with a deep understanding ..."
,,,Novartis Announces Positive Results From Phase III PARADIGMS Study,2017-09-05 02:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ez-2y0wYs3s/novartis-announces-positive-results-from-phase-iii-paradigms-study-20170905-00050,Novartis Announces Positive Results From Phase III PARADIGMS Study
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Positive Results From Phase III PARADIGMS Study,2017-09-05 02:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ez-2y0wYs3s/novartis-announces-positive-results-from-phase-iii-paradigms-study-20170905-00050,Novartis Announces Positive Results From Phase III PARADIGMS Study
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis names chief to replace Jimenez who is to step down,2017-09-04 16:14:18 +0000,"http://finance.yahoo.com/r/7bc79bd1-40d6-3680-819f-066403b04190/bf5f9abc-9141-11e7-bdfa-eda243196c2c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Swiss pharmaceuticals group Novartis has appointed 41-year-old Vas Narasimhan, its head of drug development, as chief executive to succeed Joe Jimenez early next year. Mr Jimenez, 57, who is stepping down ..."
,,,[$$] Novartis names chief to replace Jimenez who is to step down,2017-09-04 16:14:18 +0000,"http://finance.yahoo.com/r/7bc79bd1-40d6-3680-819f-066403b04190/bf5f9abc-9141-11e7-bdfa-eda243196c2c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Swiss pharmaceuticals group Novartis has appointed 41-year-old Vas Narasimhan, its head of drug development, as chief executive to succeed Joe Jimenez early next year. Mr Jimenez, 57, who is stepping down ..."
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis: doctor in the house,2017-09-04 14:52:14 +0000,"http://finance.yahoo.com/r/043f26dc-40d8-385d-b9a0-210ce326457e/125a4c90-9164-11e7-bdfa-eda243196c2c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Surprisingly few doctors run pharmaceutical companies. Finance or marketing types are more common leaders of European pharma groups; only two physicians hold the top job, a number set to swell to three. ..."
,,,[$$] Novartis: doctor in the house,2017-09-04 14:52:14 +0000,"http://finance.yahoo.com/r/043f26dc-40d8-385d-b9a0-210ce326457e/125a4c90-9164-11e7-bdfa-eda243196c2c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Surprisingly few doctors run pharmaceutical companies. Finance or marketing types are more common leaders of European pharma groups; only two physicians hold the top job, a number set to swell to three. ..."
NVS,NVS:US,BBG000LYF3S8,Weekend roundup: Campbell in the soup | New cancer treatment | Exposing bad investment advice,2017-09-04 14:31:25 +0000,https://finance.yahoo.com/news/weekend-roundup-campbell-soup-cancer-143125624.html?.tsrc=rss,Here are MarketWatch articles to read this weekend.
,,,Weekend roundup: Campbell in the soup | New cancer treatment | Exposing bad investment advice,2017-09-04 14:31:25 +0000,https://finance.yahoo.com/news/weekend-roundup-campbell-soup-cancer-143125624.html?.tsrc=rss,Here are MarketWatch articles to read this weekend.
NVS,NVS:US,BBG000LYF3S8,Weekend roundup: Campbell in the soup | New cancer treatment | Exposing bad investment advice,2017-09-04 14:31:25 +0000,http://finance.yahoo.com/r/aeb307bf-0480-3bce-957e-bfceae3c81e8/Story.aspx?guid=01F9F022-8F1A-11E7-870C-6A0275252EA1&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Here are MarketWatch articles to read this weekend.
,,,Novartis names drugs chief as CEO to deliver return to growth,2017-09-04 13:48:48 +0000,https://finance.yahoo.com/news/novartiss-jimenez-stepping-down-narasimhan-052537794.html?.tsrc=rss,"Novartis (NOVN.S) CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth.  Jimenez, who will have been at the helm for eight years when he retires, has hived off animal health, vaccines and over-the-counter drugs businesses at Novartis to focus on generally more profitable prescription medicines, particularly in cancer."
NVS,NVS:US,BBG000LYF3S8,Novartis names drugs chief as CEO to deliver return to growth,2017-09-04 13:48:48 +0000,https://finance.yahoo.com/news/novartiss-jimenez-stepping-down-narasimhan-052537794.html?.tsrc=rss,"Novartis (NOVN.S) CEO Joe Jimenez will step down on Feb. 1 and hand over to drug development chief Vas Narasimhan to decide the fate of $50 billion in assets and make good on a pledge to return the Swiss company to sales growth.  Jimenez, who will have been at the helm for eight years when he retires, has hived off animal health, vaccines and over-the-counter drugs businesses at Novartis to focus on generally more profitable prescription medicines, particularly in cancer."
NVS,NVS:US,BBG000LYF3S8,Novartis CEO Jimenez to step down early next year,2017-09-04 13:19:33 +0000,https://finance.yahoo.com/news/novartis-ceo-jimenez-step-down-070341964.html?.tsrc=rss,"Novartis CEO Joseph Jimenez will step down early next year and be replaced by fellow American Dr. Vasant Narasimhan, the Swiss pharmaceutical company said Monday. Narasimhan, currently its chief medical ..."
,,,Novartis CEO Jimenez to step down early next year,2017-09-04 13:19:33 +0000,http://finance.yahoo.com/r/5a94a26f-e80c-3870-97ef-c861a244c7c2/novartis-ceo-jimenez-step-down-070341964.html?.tsrc=rss,"GENEVA (AP) — Novartis CEO Joseph Jimenez will step down early next year and be replaced by fellow American Dr. Vasant Narasimhan, the Swiss pharmaceutical company said Monday."
NVS,NVS:US,BBG000LYF3S8,Novartis CEO Jimenez to step down early next year,2017-09-04 13:19:33 +0000,http://finance.yahoo.com/r/5a94a26f-e80c-3870-97ef-c861a244c7c2/novartis-ceo-jimenez-step-down-070341964.html?.tsrc=rss,"GENEVA (AP) — Novartis CEO Joseph Jimenez will step down early next year and be replaced by fellow American Dr. Vasant Narasimhan, the Swiss pharmaceutical company said Monday."
NVS,NVS:US,BBG000LYF3S8,Novartis Calls for the Doctor,2017-09-04 12:35:24 +0000,http://finance.yahoo.com/r/b4942085-5806-34a5-ad2e-1ef767a357a7/novartis-calls-for-a-new-doctor?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Swiss giant is looking a little too comfortable and needs a fresh pair of eyes.
,,,Novartis Calls for the Doctor,2017-09-04 12:35:24 +0000,http://finance.yahoo.com/r/b4942085-5806-34a5-ad2e-1ef767a357a7/novartis-calls-for-a-new-doctor?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Swiss giant is looking a little too comfortable and needs a fresh pair of eyes.
,,,New CEO as Novartis bids for growth,2017-09-04 10:55:42 +0000,https://www.yahoo.com/news/ceo-novartis-bids-growth-105542670.html?.tsrc=rss,"Novartis changes leadership as CEO Joseph Jimenez announces his 2018 retirement in favour of chief drug developer Vasant Narasimhan.  As Ciara Lee reports, Novartis has been criticised for missing the first wave of promising cancer immunotherapy drugs and billions in sales."
NVS,NVS:US,BBG000LYF3S8,New CEO as Novartis bids for growth,2017-09-04 10:55:42 +0000,https://www.yahoo.com/news/ceo-novartis-bids-growth-105542670.html?.tsrc=rss,"Novartis changes leadership as CEO Joseph Jimenez announces his 2018 retirement in favour of chief drug developer Vasant Narasimhan.  As Ciara Lee reports, Novartis has been criticised for missing the first wave of promising cancer immunotherapy drugs and billions in sales."
,,,Novartis Names Narasimhan CEO as Jimenez Retires,2017-09-04 09:59:52 +0000,https://finance.yahoo.com/video/novartis-names-narasimhan-ceo-jimenez-095952730.html?.tsrc=rss,Sep.04 -- Novartis announced the surprise departure of Chief Executive Officer Joseph Jimenez after eight years at the helm of Europe’s largest drugmaker. Bloomberg’s James Paton reports on “Bloomberg Surveillance.”
NVS,NVS:US,BBG000LYF3S8,Novartis Names Narasimhan CEO as Jimenez Retires,2017-09-04 09:59:52 +0000,https://finance.yahoo.com/video/novartis-names-narasimhan-ceo-jimenez-095952730.html?.tsrc=rss,Sep.04 -- Novartis announced the surprise departure of Chief Executive Officer Joseph Jimenez after eight years at the helm of Europe’s largest drugmaker. Bloomberg’s James Paton reports on “Bloomberg Surveillance.”
NVS,NVS:US,BBG000LYF3S8,Novartis CEO Joseph Jimenez Is Stepping Down,2017-09-04 08:30:45 +0000,https://finance.yahoo.com/news/novartis-ceo-joseph-jimenez-stepping-083045470.html?.tsrc=rss,A trained physician will take his place.
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis CEO to Step Down In January,2017-09-04 07:40:48 +0000,http://finance.yahoo.com/r/d9087da7-0a83-3415-8052-642c75d882ee/novartis-ceo-to-step-down-in-january-1504510846?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Novartis said its Chief Executive Joe Jimenez is to step down in January after leading the company through a tumultuous eight years marked by big patent expiries and intensifying scrutiny on drug pricing ...
NVS,NVS:US,BBG000LYF3S8,Novartis CEO Joe Jimenez to Step Down in 2018,2017-09-04 07:32:00 +0000,http://finance.yahoo.com/r/e9aa0de7-964a-3eab-86ec-2889179f260a/novartis-ceo-joe-jimenez-to-step-down-in-2018.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Novartis CEO Joe Jimenez will step down next year to make room for chief medical officer Vas Narasimhan.
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis CEO Joe Jimenez to Step Down in January,2017-09-04 05:48:28 +0000,http://finance.yahoo.com/r/49102a0b-6550-3ae9-bb93-96e986590087/novartis-ceo-joe-jimenez-to-step-down-in-january-1504504106?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Novartis said Chief Executive Joe Jimenez will step down in January after eight years at the helm. He will be replaced by Vas Narasimhan, who is currently global head of drug development at the company...."
NVS,NVS:US,BBG000LYF3S8,Novartis CEO Joseph Jimenez to retire in 2018,2017-09-04 05:23:00 +0000,https://finance.yahoo.com/video/novartis-ceo-joseph-jimenez-retire-052300874.html?.tsrc=rss,There are a lot of questions surrounding Novartis CEO Joseph Jiminez’s surprise retirement announcement. CNBC’s Carolin Roth discusses his departure.
NVS,NVS:US,BBG000LYF3S8,"Novartis CEO's decision to step down ‘very sensible,’ ana...",2017-09-04 05:23:00 +0000,https://finance.yahoo.com/video/novartis-ceos-decision-step-down-052300638.html?.tsrc=rss,"David Marsh, managing director and co-founder of OMFIF, wished outgoing Novartis CEO Joseph Jimenez luck and said that bosses should do their best to stay out of the headlines."
NVS,NVS:US,BBG000LYF3S8,European Shares Drift Lower On North Korea Tensions,2017-09-04 05:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rm8QmkvgrMY/european-shares-drift-lower-on-north-korea-tensions-20170904-00123,European Shares Drift Lower On North Korea Tensions
,,,European Shares Drift Lower On North Korea Tensions,2017-09-04 05:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rm8QmkvgrMY/european-shares-drift-lower-on-north-korea-tensions-20170904-00123,European Shares Drift Lower On North Korea Tensions
NVS,NVS:US,BBG000LYF3S8,"Novartis CEO Jimenez to Quit, Giving Reins to Harvard Doctor",2017-09-04 05:10:32 +0000,https://finance.yahoo.com/news/novartis-ceo-jimenez-quit-giving-051032512.html?.tsrc=rss,"Novartis AG announced the surprise departure of Chief Executive Officer Joseph Jimenez after eight years at the helm of Europe’s largest drugmaker, handing off the challenge of selling underperforming ..."
NVS,NVS:US,BBG000LYF3S8,"Novartis CEO Jimenez to Depart, Handing Reins to Harvard Doctor",2017-09-04 05:10:32 +0000,http://finance.yahoo.com/r/78508e89-2d60-3a78-bc5b-80a50b7649a4/novartis-names-narasimhan-ceo-after-jimenez-retires-next-year?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Novartis AG announced the surprise departure of Chief Executive Officer Joseph Jimenez after eight years at the helm of Europe’s largest drugmaker, handing off the challenge of selling underperforming ..."
NVS,NVS:US,BBG000LYF3S8,Novartis Appoints Vasant Narasimhan To Succeed Joseph Jimenez As CEO In 2018,2017-09-04 02:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XL91JEFJhgw/novartis-appoints-vasant-narasimhan-to-succeed-joseph-jimenez-as-ceo-in-2018-20170904-00061,Novartis Appoints Vasant Narasimhan To Succeed Joseph Jimenez As CEO In 2018
,,,Novartis Appoints Vasant Narasimhan To Succeed Joseph Jimenez As CEO In 2018,2017-09-04 02:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XL91JEFJhgw/novartis-appoints-vasant-narasimhan-to-succeed-joseph-jimenez-as-ceo-in-2018-20170904-00061,Novartis Appoints Vasant Narasimhan To Succeed Joseph Jimenez As CEO In 2018
NVS,NVS:US,BBG000LYF3S8,Novartis Names Vasant Narasimhan CEO; Joseph Jimenez To Retire - Quick Facts,2017-09-04 01:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3v14nNx7i4E/novartis-names-vasant-narasimhan-ceo-joseph-jimenez-to-retire--quick-facts-20170904-00012,Novartis Names Vasant Narasimhan CEO; Joseph Jimenez To Retire - Quick Facts
,,,Novartis Names Vasant Narasimhan CEO; Joseph Jimenez To Retire - Quick Facts,2017-09-04 01:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3v14nNx7i4E/novartis-names-vasant-narasimhan-ceo-joseph-jimenez-to-retire--quick-facts-20170904-00012,Novartis Names Vasant Narasimhan CEO; Joseph Jimenez To Retire - Quick Facts
,,,3 Reasons Gilead Sciences Jumped to Buy Kite Pharma,2017-09-02 01:48:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v01wPWbI11k/3-reasons-gilead-sciences-jumped-to-buy-kite-pharma-cm840554,Gilead Sciences Inc NASDAQ GILD might be the most disciplined capital allocator in biotech For years its management has resisted calls from the peanut gallery to make a big acquisition while it built a fortress balance sheet that boasted 36 6 billion cash and equivalents at
NVS,NVS:US,BBG000LYF3S8,3 Reasons Gilead Sciences Jumped to Buy Kite Pharma,2017-09-02 01:48:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v01wPWbI11k/3-reasons-gilead-sciences-jumped-to-buy-kite-pharma-cm840554,Gilead Sciences Inc NASDAQ GILD might be the most disciplined capital allocator in biotech For years its management has resisted calls from the peanut gallery to make a big acquisition while it built a fortress balance sheet that boasted 36 6 billion cash and equivalents at
NVS,NVS:US,BBG000LYF3S8,3 Reasons Gilead Sciences Jumped to Buy Kite Pharma,2017-09-02 00:27:00 +0000,http://finance.yahoo.com/r/5d424d59-7689-3aa6-8eec-da5b6f487784/3-reasons-gilead-sciences-bought-kite-pharma.aspx?yptr=yahoo&.tsrc=rss,"If you&apos;re scratching your head over Gilead&apos;s $11.9 billion acquisition of the cancer-focused biotech, what management had to say about the deal should remove your confusion."
,,,Parkinson's Now a Hot Therapeutic Area: What's Up Lately?,2017-09-01 21:49:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UlPon7i0Jjs/parkinsons-now-a-hot-therapeutic-area-whats-up-lately-cm840483,Parkinson s disease PD is a progressive degenerative neurological movement disorder resulting from the loss of dopamine producing brain cells The disease mainly progresses with age It is the second most common neurodegenerative disease after Alzheimer s An estimated seven to 10
NVS,NVS:US,BBG000LYF3S8,Parkinson's Now a Hot Therapeutic Area: What's Up Lately?,2017-09-01 21:49:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UlPon7i0Jjs/parkinsons-now-a-hot-therapeutic-area-whats-up-lately-cm840483,Parkinson s disease PD is a progressive degenerative neurological movement disorder resulting from the loss of dopamine producing brain cells The disease mainly progresses with age It is the second most common neurodegenerative disease after Alzheimer s An estimated seven to 10
NVS,NVS:US,BBG000LYF3S8,"[$$] Week in Review, September 2",2017-09-01 21:24:21 +0000,"http://finance.yahoo.com/r/84643974-f4a4-3cef-999d-7e9ee1f620e0/cf4da9c2-8f17-11e7-a352-e46f43c5825d,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","A round up of some of the week's most significant corporate events and news stories. New Uber chief reveals plan for IPO within three years After a difficult search, Uber appointed a new chief executive ..."
,,,"Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods",2017-09-01 18:50:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75OeYDw6U0I/gilead-buys-kite-the-future-of-car-t-and-a-visit-to-the-new-whole-foods-cm840411,0 35 Hurricane 160 Harvey 160 and 160 North Korea 160 Tensions 2 30 160 Gilead s Acquisition of Kite Pharma What Is CAR T Therapy 4 45 Novartis CAR T Cell Therapy Receives Approval By FDA 6 50 CAR T Biotech Stocks On The Rise 10 40 Is This
NVS,NVS:US,BBG000LYF3S8,"Gilead Buys Kite, the Future of CAR-T, and A Visit to the New Whole Foods",2017-09-01 18:50:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/75OeYDw6U0I/gilead-buys-kite-the-future-of-car-t-and-a-visit-to-the-new-whole-foods-cm840411,0 35 Hurricane 160 Harvey 160 and 160 North Korea 160 Tensions 2 30 160 Gilead s Acquisition of Kite Pharma What Is CAR T Therapy 4 45 Novartis CAR T Cell Therapy Receives Approval By FDA 6 50 CAR T Biotech Stocks On The Rise 10 40 Is This
NVS,NVS:US,BBG000LYF3S8,Cancer Breakthroughs Can Quickly Become Tomorrow's Also-Ran,2017-09-01 17:04:27 +0000,http://finance.yahoo.com/r/19e6b7c3-af60-3e1c-9753-2c48822b715e/today-s-miracle-is-tomorrow-s-also-ran-in-hottest-cancer-field?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Last week was historic in the fight against cancer. Novartis AG got approval for the first treatment in a revolutionary new class of drugs, shortly after Gilead Sciences Inc. spent $11.9 billion on a biotech ..."
NVS,NVS:US,BBG000LYF3S8,Novartis CEO: Here's How We Handled A Milestone In Pediatric Cancer,2017-09-01 15:31:00 +0000,http://finance.yahoo.com/r/0cc08e47-15fb-37d4-a45c-147f45f4f09f/novartis-ceo-heres-how-i-handled-a-milestone-in-pediatric-cancer?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Immunotherapies are opening new ways to treat cancer, enabling us to target disease like never before and in cancers where progress has been elusive for years. Here, Novartis's chief executive explains why he decided to charge $475,000 for one such breakthrough."
NVS,NVS:US,BBG000LYF3S8,Ligand Pharmaceuticals Projects Higher Average Royalty Rate for Promacta,2017-09-01 14:36:19 +0000,http://finance.yahoo.com/r/70f4dfde-a72a-3d41-a30a-aab47cfc003d/ligand-pharmaceuticals-projected-higher-average-royalty-rate-promacta-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Ligand Pharmaceuticals (LGND) receives royalties from Novartis on Promacta’s sales according to a tiered annual payment structure.
,,,"Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update",2017-09-01 13:54:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O-ksqXE2hTc/pharma-stock-roundup-novartis-car-t-drug-gets-fda-nod-lilly-gives-baricitinib-update-cm840130,It was a historic week not just for Novartis NVS but also for the medical community and patients with the FDA giving its nod to the first gene therapy in the United States Novartis Kymriah This marks the beginning of a new era for the treatment of cancer and other serious and life
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update",2017-09-01 13:54:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O-ksqXE2hTc/pharma-stock-roundup-novartis-car-t-drug-gets-fda-nod-lilly-gives-baricitinib-update-cm840130,It was a historic week not just for Novartis NVS but also for the medical community and patients with the FDA giving its nod to the first gene therapy in the United States Novartis Kymriah This marks the beginning of a new era for the treatment of cancer and other serious and life
NVS,NVS:US,BBG000LYF3S8,Label Expansion Could Boost Promacta’s Revenues Going Forward,2017-09-01 13:09:01 +0000,http://finance.yahoo.com/r/2589af3e-e863-38e4-8285-787819ff750a/label-expansion-may-boost-promactas-revenues-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"To boost Promacta’s revenues, Novartis (NVS) is evaluating the potential of the drug in 35 ongoing clinical trials, mainly for oncology-related thrombocytopenia."
NVS,NVS:US,BBG000LYF3S8,Promacta: A Major Growth Driver for Ligand Pharmaceuticals in 2017,2017-09-01 13:06:33 +0000,http://finance.yahoo.com/r/2d1c81c2-feae-3ecf-8367-1cfe99d160ea/promacta-continues-major-growth-driver-ligand-pharmaceuticals-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Promacta was discovered by Ligand Pharmaceuticals (LGND) and GlaxoSmithKline (GSK) as a part of their thrombopoietin (or TPO) receptor agonist research collaboration.
,,,The Swiss Stock Market Clung To A Small Increase,2017-09-01 12:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TpryQhCKXew/the-swiss-stock-market-clung-to-a-small-increase-20170901-00612,The Swiss Stock Market Clung To A Small Increase
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Clung To A Small Increase,2017-09-01 12:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TpryQhCKXew/the-swiss-stock-market-clung-to-a-small-increase-20170901-00612,The Swiss Stock Market Clung To A Small Increase
NVS,NVS:US,BBG000LYF3S8,Today's Research Reports on Stocks to Watch: Seattle Genetics and Novartis,2017-09-01 12:10:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-121000053.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / September 1, 2017 / Shares of Seattle Genetics closed higher on Thursday as more traders digested the big news from the company earlier in the week when it announced that it ..."
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Novartis CAR-T Drug Gets FDA Nod, Lilly Gives Baricitinib Update",2017-09-01 11:57:11 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-novartis-car-115711976.html?.tsrc=rss,"It was a landmark week for the pharmaceutical sector and the medical community with the FDA approving Novartis&apos; (NVS) Kymriah, the first CAR-T cell treatment to be approved in the United States."
NVS,NVS:US,BBG000LYF3S8,Novartis on the Street: Analysts’ Recommendations after 2Q17,2017-09-01 11:37:06 +0000,http://finance.yahoo.com/r/478f5d51-71c7-3d80-bbda-8e4f52911c03/novartis-on-the-street-analysts-recommendations-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Novartis (NVS) has undergone various changes through acquisitions and divestments over the past two years.
NVS,NVS:US,BBG000LYF3S8,"Profit on $475,000 Novartis cancer drug could be a while coming",2017-09-01 07:00:00 +0000,https://finance.yahoo.com/news/profit-475-000-novartis-cancer-070000464.html?.tsrc=rss,"Novartis's new  gene-modifying cancer therapy's $475,000-per-patient sticker  price has drawn fire from advocate groups calling for cheaper  drugs, but analysts said the Swiss drugmaker could initially  struggle to break even.  In a first for gene therapy in the United States, regulators  approved Kymriah on Wednesday for patients up to 25 years of age  who have relapsed or not been helped by previous treatment for  B-cell acute lymphoblastic leukemia (ALL).  While patient groups hailed the potent immunotherapy as a  potential cancer game-changer, the Swiss drugmaker was also  criticised for setting a price that places Kymriah among the  most-expensive drugs ever."
,,,"Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences",2017-09-01 02:49:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gftwlDrCNzI/novartis-475000-price-tag-sets-the-stage-for-a-price-war-with-gilead-sciences-cm840051,On Monday Gilead Sciences NASDAQ GILD wowed investors with an 11 9 billion deal to buy clinical stage CAR T drugmaker Kite Pharma NASDAQ KITE and on Wednesday the FDA approved Novartis NYSE NVS 160 CAR T 160 Kymriah making it the first CAR T to secure
NVS,NVS:US,BBG000LYF3S8,"Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences",2017-09-01 02:49:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gftwlDrCNzI/novartis-475000-price-tag-sets-the-stage-for-a-price-war-with-gilead-sciences-cm840051,On Monday Gilead Sciences NASDAQ GILD wowed investors with an 11 9 billion deal to buy clinical stage CAR T drugmaker Kite Pharma NASDAQ KITE and on Wednesday the FDA approved Novartis NYSE NVS 160 CAR T 160 Kymriah making it the first CAR T to secure
NVS,NVS:US,BBG000LYF3S8,"Novartis $475,000 Price Tag Sets the Stage for a Price War With Gilead Sciences",2017-09-01 01:00:00 +0000,http://finance.yahoo.com/r/774aac2a-6061-37c3-8768-867b70343c22/novartis-475000-price-tag-sets-the-stage-for-a-pri.aspx?yptr=yahoo&.tsrc=rss,"Ahead of Gilead Sciences completing its acquisition of CAR-T powerhouse Kite Pharma later this year, Novartis has secured FDA approval for its own CAR-T cancer therapy, and priced it at $475,000."
,,,"IPXL Reveals Oriental Stakeholder, LENS Has A Vision, STDY Is Very Shaky",2017-08-31 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ROot-VXEmZc/ipxl-reveals-oriental-stakeholder-lens-has-a-vision-stdy-is-very-shaky-20170831-01377,"IPXL Reveals Oriental Stakeholder, LENS Has A Vision, STDY Is Very Shaky"
NVS,NVS:US,BBG000LYF3S8,"IPXL Reveals Oriental Stakeholder, LENS Has A Vision, STDY Is Very Shaky",2017-08-31 21:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ROot-VXEmZc/ipxl-reveals-oriental-stakeholder-lens-has-a-vision-stdy-is-very-shaky-20170831-01377,"IPXL Reveals Oriental Stakeholder, LENS Has A Vision, STDY Is Very Shaky"
,,,Why bluebird bio Inc Continued Its March Higher Again Today,2017-08-31 21:51:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-XGHSEdvCE8/why-bluebird-bio-inc-continued-its-march-higher-again-today-cm839982,What happened Shares of bluebird bio NASDAQ BLUE continued their seemingly unstoppable march higher this week jumping another 10 8 today as of 2 58 p m EDT after two analysts increased their price targets on the biotech All told Bluebird is up a whopping 27 for the
NVS,NVS:US,BBG000LYF3S8,Why bluebird bio Inc Continued Its March Higher Again Today,2017-08-31 21:51:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-XGHSEdvCE8/why-bluebird-bio-inc-continued-its-march-higher-again-today-cm839982,What happened Shares of bluebird bio NASDAQ BLUE continued their seemingly unstoppable march higher this week jumping another 10 8 today as of 2 58 p m EDT after two analysts increased their price targets on the biotech All told Bluebird is up a whopping 27 for the
NVS,NVS:US,BBG000LYF3S8,"Novartis’ CAR-T gene therapy, the first approved by FDA, to cost $475,000",2017-08-31 18:14:35 +0000,http://finance.yahoo.com/r/6fc4bdc5-108f-3e0d-953e-798c84ab2447/Story.aspx?guid=6695960A-8D97-11E7-8370-1FB643782890&siteid=yhoof2&yptr=yahoo&.tsrc=rss,The therapy is an innovative new cancer treatment that uses a patient’s immune system to better fight the disease.
NVS,NVS:US,BBG000LYF3S8,"Read the Fine Print on the $475,000 Price of a Cancer Breakthrough",2017-08-31 18:00:10 +0000,http://finance.yahoo.com/r/901cf2a4-34d7-3265-9f75-90b6a5bcf1a3/novartis-kymriah-cancer-drug-475-000-but-read-the-fine-print?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Novartis could have priced Kymriah much higher, and it's being unusually flexible."
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval,2017-08-31 17:49:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1nHqwL6Johw/novartis-nvs-car-t-therapy-kymriah-receives-fda-approval-cm839843,Novartis AG NVS announced that the FDA has approved its breakthrough gene transfer treatment Kymriah tisagenlecleucel suspension for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia ALL that is refractory or in second or later
,,,Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval,2017-08-31 17:49:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1nHqwL6Johw/novartis-nvs-car-t-therapy-kymriah-receives-fda-approval-cm839843,Novartis AG NVS announced that the FDA has approved its breakthrough gene transfer treatment Kymriah tisagenlecleucel suspension for the treatment of patients up to 25 years of age with B cell precursor acute lymphoblastic leukemia ALL that is refractory or in second or later
NVS,NVS:US,BBG000LYF3S8,"Novartis Cancer Drug Is Approved With $475,000 Price Tag",2017-08-31 16:54:39 +0000,https://finance.yahoo.com/video/novartis-cancer-breakthrough-may-herald-165439471.html?.tsrc=rss,"Aug.31 -- The approval of Novartis AG’s breakthrough therapy for a deadly form of leukemia opened the door to a new class of treatments even as its $475,000 price tag reignited the debate on how to value potentially life-saving drugs. Bloomberg's Anna Edney reports on &quot;Bloomberg Markets.&quot;"
NVS,NVS:US,BBG000LYF3S8,Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion,2017-08-31 16:53:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DWTvY0Adp6c/roches-rhhby-actemra-gets-fda-nod-for-label-expansion-cm839821,Roche Holding AG s RHHBY member Genentech announced that the FDA has approved a label expansion for Actemra tocilizumab 160 Actemra is now approved for the treatment of chimeric antigen receptor CAR T cell induced severe or life threatening cytokine release syndrome CRS in
,,,Roche's (RHHBY) Actemra Gets FDA Nod for Label Expansion,2017-08-31 16:53:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DWTvY0Adp6c/roches-rhhby-actemra-gets-fda-nod-for-label-expansion-cm839821,Roche Holding AG s RHHBY member Genentech announced that the FDA has approved a label expansion for Actemra tocilizumab 160 Actemra is now approved for the treatment of chimeric antigen receptor CAR T cell induced severe or life threatening cytokine release syndrome CRS in
,,,Vanguard FTSE Europe ETF Experiences Big Inflow,2017-08-31 16:49:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vipjcyEitgA/vanguard-ftse-europe-etf-experiences-big-inflow-cm839787,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Europe ETF Symbol VGK where we have detected an approximate 56 2 million dollar inflow that s a 0 3 increase week over week in outstanding
NVS,NVS:US,BBG000LYF3S8,Vanguard FTSE Europe ETF Experiences Big Inflow,2017-08-31 16:49:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vipjcyEitgA/vanguard-ftse-europe-etf-experiences-big-inflow-cm839787,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Europe ETF Symbol VGK where we have detected an approximate 56 2 million dollar inflow that s a 0 3 increase week over week in outstanding
NVS,NVS:US,BBG000LYF3S8,Changes in GlaxoSmithKline’s Valuation after 2Q17,2017-08-31 16:34:10 +0000,http://finance.yahoo.com/r/1f7978bc-3038-361b-94f4-d8fc6d93e4f0/changes-glaxosmithklines-valuation-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of August 30, 2017, GlaxoSmithKline is trading at a forward PE multiple of 13.3x, which is slightly lower than the industry average of 15.5x."
NVS,NVS:US,BBG000LYF3S8,"Profit on $475,000 Novartis cancer drug could be a while coming",2017-08-31 16:25:48 +0000,https://finance.yahoo.com/news/profit-475-000-novartis-cancer-162548219.html?.tsrc=rss,"Novartis's new  gene-modifying cancer therapy's $475,000-per-patient sticker  price has drawn fire from advocate groups calling for cheaper  drugs, but analysts said the Swiss drugmaker could initially  struggle to break even.  In a first for gene therapy in the United States, regulators  approved Kymriah on Wednesday for patients up to 25 years of age  who have relapsed or not been helped by previous treatment for  B-cell acute lymphoblastic leukemia (ALL).  While patient groups hailed the potent immunotherapy as a  potential cancer game-changer, the Swiss drugmaker was also  criticised for setting a price that places Kymriah among the  most-expensive drugs ever."
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) CAR-T Therapy Kymriah Receives FDA Approval,2017-08-31 15:51:03 +0000,https://finance.yahoo.com/news/novartis-nvs-car-t-therapy-155103797.html?.tsrc=rss,"Novartis AG (NVS) gets a major boost as the FDA approved its breakthrough gene transfer treatment, Kymriah for the treatment of B-cell precursor acute lymphoblastic leukemia (ALL)."
NVS,NVS:US,BBG000LYF3S8,"A medical breakthrough that hacks genes to fight cancer just got approved, and it's the beginning of 'a big new field of medicine'",2017-08-31 15:45:17 +0000,https://finance.yahoo.com/news/medical-breakthrough-hacks-genes-fight-154517308.html?.tsrc=rss,The Food and Drug Administration on Wednesday approved the first-ever gene therapy in the US. The...
NVS,NVS:US,BBG000LYF3S8,"Gilead Sciences: No, the Novartis Approval Wasn't Good News",2017-08-31 14:55:00 +0000,http://finance.yahoo.com/r/d24c8d2f-97e4-3758-ae55-2a6b4afb6803/gilead-sciences-no-the-novartis-approval-wasnt-good-news-1504191311?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The CAR-T party continues today following Gilead Sciences (GILD) acquisition of Kite Pharma (KITE) on Monday, and approval of a CAR-T treatment from Novartis (NVS) yesterday. And Morgan Stanley's Matthew ..."
NVS,NVS:US,BBG000LYF3S8,Understanding Novartis’s Recent Developments after 2Q17,2017-08-31 14:37:25 +0000,http://finance.yahoo.com/r/27a8dbaf-e83c-3fe2-98e9-782cb5b09af3/understanding-novartiss-recent-developments-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis is focused on integrated drug development as well as centralized operations, and its new organizational structure has proven to be beneficial."
NVS,NVS:US,BBG000LYF3S8,How Novartis’s Alcon Eye Care Business Performed in 2Q17,2017-08-31 13:07:41 +0000,http://finance.yahoo.com/r/04cb66f8-ff15-3af6-ac41-00f4ea1ab914/how-novartiss-alcon-eye-care-business-performed-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Alcon reported revenues of $1.52 billion for 2Q17, which was 1% higher YoY (year-over-year) than the $1.51 billion we saw in 2Q16."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed After Strong Performance From Novartis,2017-08-31 13:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gDORI_0-eXw/the-swiss-stock-market-climbed-after-strong-performance-from-novartis-20170831-00939,The Swiss Stock Market Climbed After Strong Performance From Novartis
,,,The Swiss Stock Market Climbed After Strong Performance From Novartis,2017-08-31 13:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gDORI_0-eXw/the-swiss-stock-market-climbed-after-strong-performance-from-novartis-20170831-00939,The Swiss Stock Market Climbed After Strong Performance From Novartis
NVS,NVS:US,BBG000LYF3S8,"A Cancer Doctor Weighs In On CAR-T, Precision Medicine And Pricing Debates",2017-08-31 13:01:00 +0000,http://finance.yahoo.com/r/2b36e96d-6f28-32e7-a10b-fca795905e8d/a-cancer-doc-weighs-in-on-car-t-precision-medicine-and-pricing-debates?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"The approval of Novartis' CAR-T leukemia treatment is ushering in a new class of lifesaving products, but at a high cost. Here's how one oncologist is working to make cancer care more effective for patients, doctors and payers alike."
NVS,NVS:US,BBG000LYF3S8,Today's Research Reports on Stocks to Watch: Mazor Robotics and Novartis,2017-08-31 12:20:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-122000491.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / August 31, 2017 / Shares of Mazor Robots moved higher on Wednesday and even hit a new high after it was revealed that the company has entered the next phase of a partnership ..."
NVS,NVS:US,BBG000LYF3S8,How Novartis’s Sandoz Performed in 2Q17,2017-08-31 11:38:22 +0000,http://finance.yahoo.com/r/eed85fda-1fa3-32cb-bf94-a0e2660c31fe/how-novartiss-sandoz-performed-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis's Sandoz reported revenues of nearly $2.5 billion in 2Q17, representing ~20% of NVS's total revenues."
NVS,NVS:US,BBG000LYF3S8,FDA approves new treatment for childhood leukemia,2017-08-31 10:41:00 +0000,https://finance.yahoo.com/video/fda-approves-treatment-childhood-leukemia-104100425.html?.tsrc=rss,"The &quot;Squawk Box&quot; news team discusses some of the morning's most provocative headlines, including gene therapy for cancer and a recall on certain pacemakers."
NVS,NVS:US,BBG000LYF3S8,"AMGN's Endeavor Awaits Verdict, NVS Scripts History, OTIC Is Not Music To Ears",2017-08-31 02:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bBxkaP_xFs8/amgns-endeavor-awaits-verdict-nvs-scripts-history-otic-is-not-music-to-ears-20170831-00080,"AMGN's Endeavor Awaits Verdict, NVS Scripts History, OTIC Is Not Music To Ears"
,,,"AMGN's Endeavor Awaits Verdict, NVS Scripts History, OTIC Is Not Music To Ears",2017-08-31 02:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bBxkaP_xFs8/amgns-endeavor-awaits-verdict-nvs-scripts-history-otic-is-not-music-to-ears-20170831-00080,"AMGN's Endeavor Awaits Verdict, NVS Scripts History, OTIC Is Not Music To Ears"
NVS,NVS:US,BBG000LYF3S8,"Novartis's $475,000 Cancer Breakthrough Heralds New Era of Cures",2017-08-30 23:40:46 +0000,http://finance.yahoo.com/r/5842d93c-0e22-3aec-8521-52215ec7dfc6/cancer-breakthrough-heralds-new-era-of-cures-costs-and-choices?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"The approval of Novartis AG’s breakthrough therapy for a deadly form of leukemia opened the door to a new class of treatments even as its $475,000 price tag reignited the debate on how to value potentially ..."
NVS,NVS:US,BBG000LYF3S8,"Novartis's $475,000 cancer breakthrough heralds new era of cures",2017-08-30 23:40:46 +0000,https://finance.yahoo.com/news/novartiss-475-000-cancer-breakthrough-234046265.html?.tsrc=rss,"The approval of Novartis AG’s breakthrough therapy for a deadly form of leukemia opened the door to a new class of treatments even as its $475,000 price tag reignited the debate on how to value potentially ..."
NVS,NVS:US,BBG000LYF3S8,[$$] Torque Therapeutics Gathers $21 Million for Novel Cancer Cellular Therapies,2017-08-30 22:55:08 +0000,http://finance.yahoo.com/r/1ba20233-2634-36c8-8cf6-22b14a7e9009/torque-therapeutics-gathers-21-million-for-novel-cancer-cellular-therapies-1504133706?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Torque Therapeutics Inc., whose technology could enable more effective cellular cancer therapies, has secured $21 million toward a $35 million financing, according to a regulatory filing."
,,,"Why Analog Devices, Gilead Sciences, and Universal Display Jumped Today",2017-08-30 22:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Urx0q9D528E/why-analog-devices-gilead-sciences-and-universal-display-jumped-today-cm839437,The major benchmarks posted gains on Wednesday as geopolitical fears and hurricane concerns gave way to positive economic news A report released by the U S Department of Commerce showed that GDP rose at a rate of 3 in the second quarter higher than previously estimated The tech
NVS,NVS:US,BBG000LYF3S8,"Why Analog Devices, Gilead Sciences, and Universal Display Jumped Today",2017-08-30 22:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Urx0q9D528E/why-analog-devices-gilead-sciences-and-universal-display-jumped-today-cm839437,The major benchmarks posted gains on Wednesday as geopolitical fears and hurricane concerns gave way to positive economic news A report released by the U S Department of Commerce showed that GDP rose at a rate of 3 in the second quarter higher than previously estimated The tech
NVS,NVS:US,BBG000LYF3S8,What Happened to Novartis’s Innovative Medicines Business in 2Q17?,2017-08-30 22:06:31 +0000,http://finance.yahoo.com/r/b21e7a08-2848-3ca5-a52f-76593d96e88d/what-happened-to-novartiss-innovative-medicines-business-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Novartis's Innovative Medicines segment contributed over 67% of NVS's total revenues at nearly $8.3 billion for the quarter.
NVS,NVS:US,BBG000LYF3S8,Why bluebird bio Inc Jumped Higher Today,2017-08-30 21:50:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wJ4WvnQYe38/why-bluebird-bio-inc-jumped-higher-today-cm839403,What happened bluebird bio NASDAQ BLUE is up 10 1 at 3 40 p m EDT after Novartis NYSE NVS got its chimeric antigen receptor T cell CAR T therapy Kymriah 160 approved by the Food and Drug Administration FDA today Bluebird is developing CAR T therapies of its
NVS,NVS:US,BBG000LYF3S8,US clears breakthrough gene therapy for childhood leukemia,2017-08-30 21:27:04 +0000,http://finance.yahoo.com/r/214d3852-62e2-3af9-96dd-f46c4bb511c7/us-clears-first-living-drug-tough-childhood-leukemia-145702479--finance.html?.tsrc=rss,"WASHINGTON (AP) — Opening a new era in cancer care, U.S. health officials on Wednesday approved a breakthrough treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy childhood leukemia."
NVS,NVS:US,BBG000LYF3S8,US clears breakthrough gene therapy for childhood leukemia,2017-08-30 21:27:04 +0000,https://finance.yahoo.com/news/us-clears-first-living-drug-tough-childhood-leukemia-145702479--finance.html?.tsrc=rss,"Opening a new era in cancer care, U.S. health officials on Wednesday approved a breakthrough treatment that genetically engineers patients' own blood cells into an army of assassins to seek and destroy ..."
NVS,NVS:US,BBG000LYF3S8,"John Rogers Continues to Buy Accenture, Novartis, Apache",2017-08-30 21:24:18 +0000,https://finance.yahoo.com/news/john-rogers-continues-buy-accenture-212418644.html?.tsrc=rss,The guru purchased these stocks in the last 2 quarters
NVS,NVS:US,BBG000LYF3S8,Close Update: Stocks Close Higher as Risk Aversion Dissolves; Nasdaq Rallies on Biotechs,2017-08-30 21:09:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wPCn4rf4GY0/close-update-stocks-close-higher-as-risk-aversion-dissolves-nasdaq-rallies-on-biotechs-cm839420,Stocks closed higher again on Wednesday as investors rotated out of safe havens and into equity assets as tensions with North Korea waned and hopes for substantial tax reform was rekindled The Nasdaq raced to a two week high on outsized gains in the biotech sector while the S amp P 500
NVS,NVS:US,BBG000LYF3S8,"Novartis CEO's Dilemma: Is $475,000 Too Much For A Leukemia Breakthrough? Or Is It Not Enough?",2017-08-30 21:01:00 +0000,http://finance.yahoo.com/r/fa87981d-1682-3412-8b8f-648edd506e89/novartis-ceos-dilemma-is-475000-too-much-for-a-leukemia-breakthrough-or-is-it-not-enough?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Joseph Jimenez, the CEO of Novartis, is taking heat from all sides over his decision to charge $475,000 for a new leukemia treatment. In an exclusive interview with Forbes, he argues that the price is fair, and how he intends to charge it could shake up health care."
NVS,NVS:US,BBG000LYF3S8,"Why Analog Devices, Gilead Sciences, and Universal Display Jumped Today",2017-08-30 20:57:13 +0000,http://finance.yahoo.com/r/d8abf867-f750-3b86-acfb-74eb086687a4/why-analog-devices-gilead-sciences-and-universal-d.aspx?yptr=yahoo&.tsrc=rss,These stocks helped lead the market higher. Find out why.
NVS,NVS:US,BBG000LYF3S8,Why Novatis' $475K CAR-T Cancer Treatment Is Actually Cheap,2017-08-30 20:49:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pcMabnKGw6w/why-novatis-475k-car-t-cancer-treatment-is-actually-cheap-cm839366,The cancer treatment industry is celebrating a massive victory on Wednesday as Novartis NVS received approval for its innovative new lymphoblastic leukemia treatment making it the first approved CAR T therapy in the world After achieving unprecedented results in patients with this deadly
NVS,NVS:US,BBG000LYF3S8,Why bluebird bio Inc Jumped Higher Today,2017-08-30 20:37:00 +0000,http://finance.yahoo.com/r/5b1497ab-af91-3a50-8743-0edc5ca97146/why-bluebird-bio-inc-jumped-higher-today.aspx?yptr=yahoo&.tsrc=rss,"FDA approval of Novartis&apos; CAR-T therapy bodes well for the biotech, even if it was widely expected."
NVS,NVS:US,BBG000LYF3S8,Inside Novartis’s 2Q17 Revenues,2017-08-30 20:36:05 +0000,http://finance.yahoo.com/r/f4a6da4f-2f4a-373b-94a6-fd5a8da312c0/inside-novartiss-2q17-revenues?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Novartis (NVS) reported flat revenues of $12.24 billion on a constant-currency basis for 2Q17. This included a 2% decline due to foreign exchange.
NVS,NVS:US,BBG000LYF3S8,FDA Greenlights Novartis' Gene Therapy for Leukemia,2017-08-30 20:05:00 +0000,http://finance.yahoo.com/r/7190f014-8a14-35f6-bea1-13bdaddc67e2/fda-greenlights-novartis-gene-therapy-for-leukemia.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Novartis' Kymriah is the first gene therapy approved by the FDA.
NVS,NVS:US,BBG000LYF3S8,FDA OKs first-of-its-kind T-cell cancer therapy developed by Penn & CHOP,2017-08-30 19:35:08 +0000,http://finance.yahoo.com/r/61e41e33-3902-33ab-8aa1-2f94138251a9/fda-oks-first-of-its-kindt-cell-cancer-therapy.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"The Food and Drug Administration approved a personalized cellular therapy treatment for leukemia developed by researchers at the University of Pennsylvania and Children’s Hospital of Philadelphia.  The T-Cell therapy, which will be marketed by Novartis as Kymriah, was OK'd as treatment for patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia that is refractory, or in second or later relapse.  In 2012, Penn and Novartis — a Swiss drug company that has its U.S headquarters in New York — entered into a global collaboration to further research, develop and commercialize Kymriah and other CAR-T cell therapies for the treatment of cancers."
NVS,NVS:US,BBG000LYF3S8,"[$$] Novartis's new $475,000 cancer drug among most expensive ever",2017-08-30 19:27:05 +0000,"http://finance.yahoo.com/r/bf916363-4e58-37bb-8992-91f2e067d560/b97f063a-8da1-11e7-a352-e46f43c5825d,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Swiss pharmaceuticals group Novartis has said it will charge $475,000 a patient for its new cancer therapy, putting it among the most expensive drugs of all time. Bruno Strigini, chief executive of oncology ..."
NVS,NVS:US,BBG000LYF3S8,Why Novatis&apos; $475K CAR-T Cancer Treatment Is Actually Cheap,2017-08-30 19:10:07 +0000,https://finance.yahoo.com/news/why-novatis-apos-475k-car-191007313.html?.tsrc=rss,"The cancer treatment industry is celebrating a massive victory on Wednesday, as Novartis (NVS) received approval for its innovative new lymphoblastic leukemia treatment, making it the first approved CAR-T therapy in the world."
NVS,NVS:US,BBG000LYF3S8,Behind Novartis’s Valuation after 2Q17,2017-08-30 18:54:23 +0000,http://finance.yahoo.com/r/630f9090-ad8c-3473-80f0-ab573d9c6f41/behind-novartiss-valuation-after-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis missed the analysts’ estimate for 2Q17 revenues, reporting $12.24 billion and falling short of $12.27 billion, but surpassed the estimate for EPS."
NVS,NVS:US,BBG000LYF3S8,"Novartis: A New $475,000 Drug",2017-08-30 17:59:00 +0000,http://finance.yahoo.com/r/1aa47894-7cc2-3f90-9f70-36bdfc0cd64c/novartis-a-new-475-000-drug-1504115985?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"The FDA issued a landmark decision today when it granted approval for Novartis’s (NVS) new leukemia Kymriah.  As Bernstein’s Tim Anderson notes: Today's approval marks a paradigm shift in how cancer patients are treated as this represents the first CAR-T approval by any company.  It shows how Novartis' R&D efforts are often focused on high science, and the company’s overall ability in R&D is (only) one of the reasons it has been one of our top picks since the start of the year.  As part of the deal, Novartis can only recognize revenue from the drug if the patient demonstrates a clinical response by the end of the first month."
NVS,NVS:US,BBG000LYF3S8,Novartis Wins FDA Approval for Groundbreaking Cancer Gene Therapy,2017-08-30 17:37:32 +0000,https://finance.yahoo.com/news/novartis-wins-fda-approval-groundbreaking-173732951.html?.tsrc=rss,"The Food and Drug Administration (FDA) has approved the latest Novartis AG (ADR) (NYSE:NVS) cancer treatment.  The drug is considered a groundbreaking approach to treating the deadly illness and it is called CAR-T, consisting of advanced gene therapy.  It harvests patients’ white blood cells and rewires them to target tumors."
NVS,NVS:US,BBG000LYF3S8,The Way We Treat Cancer Will Be Revolutionized As Gene Therapy Comes to the U.S.,2017-08-30 17:35:02 +0000,https://finance.yahoo.com/news/way-treat-cancer-revolutionized-gene-173502781.html?.tsrc=rss,FDA approves Novartis treatment that reengineers human cells to kill cancer
NVS,NVS:US,BBG000LYF3S8,Novartis' CAR-T Gene Therapy Receives FDA Approval,2017-08-30 17:08:00 +0000,http://finance.yahoo.com/r/cc13f922-d287-31fe-8914-5fd4558626ba/novartis-car-t-gene-therapy-receives-fda-approval.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The treatment is the first of its kind to be authorized in the U.S.
NVS,NVS:US,BBG000LYF3S8,Novartis Wins FDA Approval for CAR-T; So Why Is Gilead Getting a Boost?,2017-08-30 16:38:00 +0000,http://finance.yahoo.com/r/aa6d4dc3-fd9d-3ac1-a8f9-3fac57d0ebfb/novartis-wins-fda-approval-for-car-t-so-why-is-gilead-getting-a-boost-1504111101?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Swiss drug maker Novartis (NVS) won a landmark FDA approval today for the first-ever CAR-T cancer drug.  As MarketWatch reports: CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Novartis' Kymriah was approved for young people up to age 25 with a form of acute lymphoblastic leukemia.  CAR-T, or chimeric antigen receptor T-cell therapy, uses a patient's immune T-cells and re-engineers them to better fight cancer."
NVS,NVS:US,BBG000LYF3S8,FDA Approves Novartis Treatment That Alters Patients Cells To Fight Cancer,2017-08-30 16:00:00 +0000,http://finance.yahoo.com/r/be28f854-3352-3fa0-80d9-4834a8addfc1/fda-approves-novartis-treatment-that-alters-patients-cells-to-fight-cancer?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"In a move the Food and Drug Administration itself called ""a historic action,"" the agency has approved a treatment made by Novartis that uses a virus to genetically alter patients own white blood cells to battle a form of leukemia. The big question now: How much will it cost?"
NVS,NVS:US,BBG000LYF3S8,Pfizer's sNDA for Bosulif Accepted in the U.S. and Europe,2017-08-30 15:54:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uq0Y531Kt1M/pfizers-snda-for-bosulif-accepted-in-the-us-and-europe-cm839183,Pfizer Inc PFE and partner Avillion announced that a supplemental New Drug Application sNDA for Bosulif has been accepted and granted priority review by the FDA We remind investors that Bosulif is currently approved for the treatment of chronic accelerated or blast phase
NVS,NVS:US,BBG000LYF3S8,Novartis AG's CAR-T cell therapy for leukemia approved by FDA in 'historic action'; price to be based on outcomes,2017-08-30 15:21:48 +0000,http://finance.yahoo.com/r/2e836255-1d3c-3b3d-8590-1a9cf3cb9538/Story.aspx?guid=C144607C-858D-41D5-A849-D1D177BD5E88&siteid=yhoof2&yptr=yahoo&.tsrc=rss,"Novartis AG's CAR-T cell therapy was approved by the Food and Drug Administration on Wednesday, making it the first gene therapy to be available in the U.S. Novartis' Kymriah was approved for young people ..."
NVS,NVS:US,BBG000LYF3S8,A cancer treatment that one expert called the 'most exciting thing I've seen in my lifetime' just got approved,2017-08-30 15:07:13 +0000,https://finance.yahoo.com/news/cancer-treatment-one-expert-called-150713405.html?.tsrc=rss,The US Food and Drug Administration just approved a cutting-edge cancer therapy. On Wednesday...
NVS,NVS:US,BBG000LYF3S8,Novartis gene therapy for leukemia wins U.S. approval,2017-08-30 15:06:10 +0000,https://finance.yahoo.com/news/novartis-gene-therapy-leukemia-wins-150610017.html?.tsrc=rss,"The U.S. Food and Drug Administration on Wednesday approved Novartis AG's keenly anticipated leukemia treatment, marking the first gene therapy approval in the United States. The drug, Kymriah, was approved ..."
NVS,NVS:US,BBG000LYF3S8,"The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie's and Novartis AG",2017-08-30 14:53:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0-p6XgsSHeg/the-zacks-analyst-blog-highlights-gilead-sciences-kite-pharma-abbvies-and-novartis-ag-cm839095,For Immediate Release Chicago IL August 30 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
NVS,NVS:US,BBG000LYF3S8,Breakthrough Cancer Therapy for Dire Cases Gets FDA Approval,2017-08-30 14:51:59 +0000,http://finance.yahoo.com/r/653d7392-54cd-3c93-98f5-4dd8563edebe/breakthrough-genetic-treatment-for-dire-cancers-approved-by-fda?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"U.S. regulators approved a revolutionary new cancer treatment from Novartis AG on Wednesday, the first in a group of coming therapies that offer breakthrough cures for dire cases as well as stratospheric ..."
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline Recent Pullback Delivers A Healthy Opportunity To Buy,2017-08-30 13:55:38 +0000,https://finance.yahoo.com/news/glaxosmithkline-recent-pullback-delivers-healthy-135538171.html?.tsrc=rss,Argus said in a note on Wednesday that the recent weakness in GlaxoSmithKline plc (ADR) (NYSE: GSK ) shares offers a buying opportunity. The firm noted that as against the 1 percent gain by the broader ...
NVS,NVS:US,BBG000LYF3S8,"The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie&apos;s and Novartis AG",2017-08-30 12:48:12 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-gilead-124812331.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Gilead Sciences, Kite Pharma, AbbVie&apos;s and Novartis AG"
,,,The Swiss Stock Market Rebounded As Geopolitical Concerns Eased,2017-08-30 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B6fj4YYuvmM/the-swiss-stock-market-rebounded-as-geopolitical-concerns-eased-20170830-00816,The Swiss Stock Market Rebounded As Geopolitical Concerns Eased
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Rebounded As Geopolitical Concerns Eased,2017-08-30 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B6fj4YYuvmM/the-swiss-stock-market-rebounded-as-geopolitical-concerns-eased-20170830-00816,The Swiss Stock Market Rebounded As Geopolitical Concerns Eased
,,,Novartis Gets FDA Nod For Leukemia Gene Cell Therapy,2017-08-30 11:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a-5-Ju6s45Y/novartis-gets-fda-nod-for-leukemia-gene-cell-therapy-20170830-00764,Novartis Gets FDA Nod For Leukemia Gene Cell Therapy
NVS,NVS:US,BBG000LYF3S8,Novartis Gets FDA Nod For Leukemia Gene Cell Therapy,2017-08-30 11:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a-5-Ju6s45Y/novartis-gets-fda-nod-for-leukemia-gene-cell-therapy-20170830-00764,Novartis Gets FDA Nod For Leukemia Gene Cell Therapy
NVS,NVS:US,BBG000LYF3S8,East Africa Seeks Streamlined Drug Oversight to Ease Access,2017-08-30 04:01:00 +0000,http://finance.yahoo.com/r/4732d51e-0e96-3151-933c-6f7c767a5651/east-africa-seeks-streamlined-drug-oversight-to-ease-access?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"One of the world’s poorest regions is making itself more friendly to new products from Novartis AG, Roche Holding AG and other drugmakers by combining the pharmacy regulators of six countries."
NVS,NVS:US,BBG000LYF3S8,Gilead to Fly High with Kite Pharma Acquisition for $11.9B,2017-08-29 22:50:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H1ePGDpSKkg/gilead-to-fly-high-with-kite-pharma-acquisition-for-119b-cm838870,Biotech giant Gilead Sciences Inc GILD announced that it will buy Kite Pharma Inc KITE to foray into the emerging field of cell therapy Terms of the Agreement As per the agreement Gilead will pay 180 00 per share in cash at a transaction valued at approximately 11 9 billion
NVS,NVS:US,BBG000LYF3S8,How Did Pfizer Perform in 2Q17?,2017-08-29 22:06:51 +0000,http://finance.yahoo.com/r/53988d07-b494-3973-a11b-af559e026fff/how-did-pfizer-perform-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1H17, Pfizer generated revenues of ~$25.3 billion, which reflected ~3% growth on a YoY basis."
NVS,NVS:US,BBG000LYF3S8,"Analysts Mixed On Gilead-Kite, But One Key Rival Stands To Benefit",2017-08-29 20:12:48 +0000,http://finance.yahoo.com/r/a7fce0af-7831-3ae5-b27b-5ba740285a70/analysts-mixed-on-gilead-kite-but-one-key-rival-stands-to-benefit?src=A00220&yptr=yahoo&.tsrc=rss,"Analysts were mixed Tuesday on Gilead&apos;s takeout of Kite, but rivals Juno and Bluebird stand to benefit from the headlines."
NVS,NVS:US,BBG000LYF3S8,Can Gilead Sciences Squeeze $12 Billion From Kite Pharma?,2017-08-29 15:48:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I1nRuVHau1Q/can-gilead-sciences-squeeze-12-billion-from-kite-pharma-cm838567,Gilead Sciences Inc NASDAQ GILD just took a bold leap into the unknown with an agreement to acquire Kite Pharma Inc NASDAQ KITE for 180 per share or about 11 9 billion Gilead s last 11 figure bet turned out to be one of the best investments in biopharma history and it
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Positive Data on Cardiovascular Drug,2017-08-28 22:49:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MoaLDpvbS7I/novartis-announces-positive-data-on-cardiovascular-drug-cm838208,Novartis AG NVS announced positive primary data from the phase III study CANTOS on pipeline candidate canakinumab ACZ885 The study evaluated quarterly injections of canakinumab in patients with a prior heart attack and inflammatory atherosclerosis as measured by high sensitivity C
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Positive Data on Cardiovascular Drug,2017-08-28 20:40:08 +0000,https://finance.yahoo.com/news/novartis-announces-positive-data-cardiovascular-204008359.html?.tsrc=rss,Novartis AG (NVS) announced positive primary data on pipeline candidate canakinumab (ACZ885).
NVS,NVS:US,BBG000LYF3S8,Dow Member J&J And Bayer Face A Battle In Augmenting Aspirin,2017-08-28 20:25:55 +0000,http://finance.yahoo.com/r/64d7e4d4-55be-3a68-89b7-dea7df16db36/dow-member-jj-and-bayer-face-a-battle-in-augmenting-aspirin?src=A00220&yptr=yahoo&.tsrc=rss,"Dow&apos;s J&J and Bayer face an uphill battle in getting Xarelto added to aspirin therapy for heart patients, analysts say."
NVS,NVS:US,BBG000LYF3S8,This Drug Is A Dual Threat Against Heart Disease and Cancer,2017-08-28 19:50:02 +0000,https://finance.yahoo.com/news/drug-dual-threat-against-heart-195002033.html?.tsrc=rss,But it’s not the one getting all the buzz.
NVS,NVS:US,BBG000LYF3S8,3 Reasons to Applaud Gilead Sciences' Acquisition of Kite Pharma,2017-08-28 16:53:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HJReWA2pEBk/3-reasons-to-applaud-gilead-sciences-acquisition-of-kite-pharma-cm838043,Finally Gilead Sciences NASDAQ GILD announced on Monday that it was acquiring Kite Pharma NASDAQ KITE for 11 9 billion Investors had long waited for the big biotech to make a deal One analyst even wrote a letter to the company earlier this year urging it to
NVS,NVS:US,BBG000LYF3S8,"VEA, DYB: Big ETF Inflows",2017-08-28 16:52:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U6MiBfEq21w/vea-dyb-big-etf-inflows-cm838004,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF which added 20 501 912 units or a 1 5 increase week over week Among the largest underlying components of VEA in
NVS,NVS:US,BBG000LYF3S8,The Promising New Cancer Treatment Behind Gilead's $11 Billion Deal,2017-08-28 15:56:24 +0000,http://finance.yahoo.com/r/d92deb23-2eee-341c-81a6-b7341630407a/the-promising-new-cancer-treatment-behind-gileads-11-billion-deal-1503935780?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Gilead Sciences’ planned acquisition of Kite Pharma underscores the promise of a new type of treatment, called CAR-T, that uses the body’s own immune system to attack cancer."
NVS,NVS:US,BBG000LYF3S8,Gilead-Kite: A Breakthrough. A $12 Billion Deal. Another Expensive Drug,2017-08-28 15:45:00 +0000,http://finance.yahoo.com/r/7af19119-44a7-3944-b9a3-cb7ef58f4135/gilead-kite-a-breakthrough-a-12-billion-deal-another-expensive-drug?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Gilead Sciences, the leading maker of drugs for HIV and hepatitis C, is making a gutsy move into the cutting edge of cancer treatment, spending $11.9 billion in cash to buy Kite Pharma, developer of a treatment that attacks tumors by genetically modifying patients’ own white blood cells."
NVS,NVS:US,BBG000LYF3S8,"Foreign Stock Roundup: WPP 1H17, BHP Billiton Fiscal 2017 Results Impress",2017-08-28 14:52:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pQGOyTqSfh0/foreign-stock-roundup-wpp-1h17-bhp-billiton-fiscal-2017-results-impress-cm837865,Foreign markets remained focused on the outcome of the annual economic symposium at Jackson Hole last week Meanwhile events at the White House weighed on investors Military drills held jointly by the U S and South Korea weighed on Asia s investors for a while until they chose to ignore
NVS,NVS:US,BBG000LYF3S8,Gilead’s Deal to Buy Kite Pharma Is a Game-Changer,2017-08-28 14:41:45 +0000,https://finance.yahoo.com/news/gilead-deal-buy-kite-pharma-144145057.html?.tsrc=rss,Kite Pharma stock rose 29% on the news.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Starts The Week With A Loss,2017-08-28 13:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gjx_ofkRjUM/the-swiss-stock-market-starts-the-week-with-a-loss-20170828-00707,The Swiss Stock Market Starts The Week With A Loss
,,,The Swiss Stock Market Starts The Week With A Loss,2017-08-28 13:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gjx_ofkRjUM/the-swiss-stock-market-starts-the-week-with-a-loss-20170828-00707,The Swiss Stock Market Starts The Week With A Loss
NVS,NVS:US,BBG000LYF3S8,Novartis shares slip after mixed heart drug data,2017-08-28 08:43:06 +0000,https://finance.yahoo.com/news/novartis-shares-slip-mixed-heart-084306205.html?.tsrc=rss,"Investors shrugged off Novartis's  optimism that its new anti-inflammatory drug will make  inroads into treating heart-attack survivors and sent its shares  lower on Monday as some experts called new data unconvincing.  On Sunday, trial data showed heart-attack survivors on the  Swiss drugmaker's canakinumab were 15 percent less likely to  suffer another major cardiac event than those on a placebo.  Novartis plans to seek regulatory approval this year."
NVS,NVS:US,BBG000LYF3S8,"Novartis hopeful for novel heart drug, despite 'modest' benefit",2017-08-27 17:18:33 +0000,https://finance.yahoo.com/news/novartis-hopeful-novel-heart-drug-171833247.html?.tsrc=rss,"Novartis will seek  regulatory approval this year for a new kind of  anti-inflammatory heart drug, though some experts fear fatal  infection risks and a high price may overshadow the medicine's  limited benefits.  Keenly awaited clinical trial results released on Sunday  showed heart-attack survivors on one of three doses of  canakinumab were 15 percent less likely to suffer another major  cardiac event than those on a placebo.  Novartis had said in June that the drug met its goal in the  study but details were only unveiled at European Society of  Cardiology meeting in Barcelona."
NVS,NVS:US,BBG000LYF3S8,Here Are the Big Pharma Stocks to Own Based on R&D Spending,2017-08-27 11:47:00 +0000,http://finance.yahoo.com/r/8e381b2f-d9bb-3e0c-a662-f302b29483ec/here-are-the-big-pharma-stocks-to-own-based-on-r-2.aspx?yptr=yahoo&.tsrc=rss,"Roche, Novartis, Pfizer, Johnson & Johnson, and Merck are investing the heaviest in R&D. That could bode well for these big pharma stocks."
NVS,NVS:US,BBG000LYF3S8,"Novartis Drug May Be A New Way To Prevent Heart Attacks -- And Maybe Cancer, Too",2017-08-27 09:00:00 +0000,http://finance.yahoo.com/r/1e7ef58a-fb16-3481-962b-727e8f6db3af/a-new-way-to-prevent-heart-attacks-and-maybe-cancer-too?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,A study of a Novartis drug proves that reducing inflammation can prevent heart attacks. But is this medicine ready for prime time?
NVS,NVS:US,BBG000LYF3S8,"Novartis hopeful for novel heart drug, despite 'modest' benefit",2017-08-27 09:00:00 +0000,https://finance.yahoo.com/news/novartis-hopeful-novel-heart-drug-090000013.html?.tsrc=rss,"Novartis will seek  regulatory approval this year for a new kind of  anti-inflammatory heart drug, though some experts fear fatal  infection risks and a high price may overshadow the medicine's  limited benefits.  Keenly awaited clinical trial results released on Sunday  showed heart-attack survivors on one of three doses of  canakinumab were 15 percent less likely to suffer another major  cardiac event than those on a placebo.  Novartis had said in June that the drug met its goal in the  study but details were only unveiled at European Society of  Cardiology meeting in Barcelona."
,,,Novartis Announces ACZ885 Reduces Lung Cancer Mortality By 77% In CANTOS Study,2017-08-27 08:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1ZbibgcpGlM/novartis-announces-acz885-reduces-lung-cancer-mortality-by-77-in-cantos-study-20170827-00003,Novartis Announces ACZ885 Reduces Lung Cancer Mortality By 77% In CANTOS Study
NVS,NVS:US,BBG000LYF3S8,Novartis Announces ACZ885 Reduces Lung Cancer Mortality By 77% In CANTOS Study,2017-08-27 08:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1ZbibgcpGlM/novartis-announces-acz885-reduces-lung-cancer-mortality-by-77-in-cantos-study-20170827-00003,Novartis Announces ACZ885 Reduces Lung Cancer Mortality By 77% In CANTOS Study
NVS,NVS:US,BBG000LYF3S8,Novartis CANTOS Study Meets Primary Endpoint In Cardiovascular Risk Reduction,2017-08-27 08:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wzDp6sYpydI/novartis-cantos-study-meets-primary-endpoint-in-cardiovascular-risk-reduction-20170827-00002,Novartis CANTOS Study Meets Primary Endpoint In Cardiovascular Risk Reduction
NVS,NVS:US,BBG000LYF3S8,Is the System Rigged Against Biosimilars?,2017-08-26 17:37:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/atpUwvwykm8/is-the-system-rigged-against-biosimilars-cm837567,If you think prescription drug costs are high now imagine what costs would be without generic drugs Roughly 25 of total prescription drug sales in 2016 were generics But it s a different story altogether for biologics drugs made from living organisms or components of
NVS,NVS:US,BBG000LYF3S8,Wall Street Ends Mostly Stronger Amid Tax Reform Talk With Yellen Mum on Monetary Policy,2017-08-25 20:58:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pHCwdxfboD0/wall-street-ends-mostly-stronger-amid-tax-reform-talk-with-yellen-mum-on-monetary-policy-cm837426,Stocks in the US ended mainly on a stronger note with hopes for a renewed focus on tax reform in Washington D C bolstering investors after Federal Reserve Chair Janet Yellen refrained from touching on monetary policy in her Jackson Hole Wyo speech Stocks in the US ended mainly on a
NVS,NVS:US,BBG000LYF3S8,Midday Update: Stocks Back Off Highs as Wall Street Shifts Focus to ECB's Draghi,2017-08-25 17:40:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A4RCPyUe71s/midday-update-stocks-back-off-highs-as-wall-street-shifts-focus-to-ecbs-draghi-cm837315,Wall Street s major averages are mixed at midday on Friday after returning most of their earlier gains that resulted from Federal Reserve Chair Janet Yellen s speech at a central bank symposium and economic advisor Gary Cohn s assurances that tax reform is a top priority of the
NVS,NVS:US,BBG000LYF3S8,Mylan and Otsuka Ink Agreement to Commercialize Deltyba,2017-08-25 17:40:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DsK3Ay1t5rc/mylan-and-otsuka-ink-agreement-to-commercialize-deltyba-cm837283,Mylan N V MYL and Japan based Otsuka Pharmaceutical signed a license agreementto commercialize Deltyba delamanid in low and middle income countries including South Africa and India The drug is approved for treatment of pulmonary multidrug resistant tuberculosis MDR TB in adults
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Receives EC Approval for Breast Cancer Drug,2017-08-25 15:45:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ap4qE9FMRQg/novartis-nvs-receives-ec-approval-for-breast-cancer-drug-cm837134,Novartis AG NVS announced that the European Commission EC has approved breast cancer drug Kisqali ribociclib The EC approved the drug in combination with an aromatase inhibitor for treatment of postmenopausal women with hormone receptor positive human epidermal growth factor receptor
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Receives EC Approval for Breast Cancer Drug,2017-08-25 13:51:01 +0000,https://finance.yahoo.com/news/novartis-nvs-receives-ec-approval-135101080.html?.tsrc=rss,Novartis AG (NVS) obtained approval for its breast cancer drug Kisqali in Europe.
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug",2017-08-25 13:47:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-8O4vBBSNiU/pharma-stock-roundup-roche-drug-gets-priority-review-eu-nod-for-novartis-drug-cm836996,Key news this week include priority review for Roche s RHHBY experimental hemophilia A drug and EU approval for Novartis NVS advanced breast cancer drug Meanwhile deals involving companies like AstraZeneca plc AZN and Eli Lilly and Company LLY were also announced this week Recap of
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 08/25/2017: JNJ, PFE, ABT, MRK, AMGN, XOMA, VEEV, ADMS, NVS",2017-08-25 13:41:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iqKfuF5RzBk/health-care-sector-update-for-08252017-jnj-pfe-abt-mrk-amgn-xoma-veev-adms-nvs-cm837016,Top Health Care Stocks Top Health Care Stocks JNJ 0 5 JNJ 0 5 PFE flatPFE flat ABT flatABT flat MRK 0 5 MRK 0 5 AMGN 0 4 AMGN 0 4 Health care shares were mixed in pre market trade Friday Health care shares were mixed in pre market trade Friday In sector news
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Lower In Choppy Trade,2017-08-25 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NNuqPxPZXIk/the-swiss-stock-market-finished-lower-in-choppy-trade-20170825-00578,The Swiss Stock Market Finished Lower In Choppy Trade
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Roche Drug Gets Priority Review, EU Nod for Novartis Drug",2017-08-25 11:22:11 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-roche-drug-112211459.html?.tsrc=rss,It was a pretty slow week with key highlights including regulatory updates from companies like Roche (RHHBY) and Novartis.
NVS,NVS:US,BBG000LYF3S8,"Chris Davis Keeps Buying Intel, Ctrip.com, Novartis",2017-08-24 20:46:10 +0000,https://finance.yahoo.com/news/chris-davis-keeps-buying-intel-204610773.html?.tsrc=rss,The guru bought these stocks in the last 2 quarters
NVS,NVS:US,BBG000LYF3S8,Kite Pharma at New 52-Week High: What's Driving the Stock?,2017-08-24 20:38:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5E3sgvPjfng/kite-pharma-at-new-52-week-high-whats-driving-the-stock-cm836783,Kite Pharma Inc s KITE shares hit a new 52 week high of 143 00 on Thursday before eventually closing at 138 17 Shares of the company have risen sharply so far this year as its CAR T therapy axicabtagene ciloleucel previously KTE C19 is nearing an FDA approval In fact Kite Pharma
NVS,NVS:US,BBG000LYF3S8,Kite Pharma at New 52-Week High: What&apos;s Driving the Stock?,2017-08-24 18:34:06 +0000,https://finance.yahoo.com/news/kite-pharma-52-week-high-183406866.html?.tsrc=rss,Kite Pharma (KITE) shares hit a new 52-week high as the company&apos;s CAR-T therapy with axicabtagene ciloleucel nears an FDA nod. It has also filed regulatory application for the candidate in the EU.
NVS,NVS:US,BBG000LYF3S8,"Lannett (LCI) Q4 Earnings In Line, Stock Up on Solid View",2017-08-24 17:39:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_i49UMeyNcI/lannett-lci-q4-earnings-in-line-stock-up-on-solid-view-cm836702,Lannett Company Inc LCI reported earnings of 40 cents per share in fiscal fourth quarter of 2017 which were in line with the Zacks Consensus Estimate The company had reported earnings of 73 cents per share in the year ago quarter Lannett s shares rose 1 8 in after hours trading on
NVS,NVS:US,BBG000LYF3S8,"Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for August 25, 2017",2017-08-24 13:17:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LggFy1Gf3FE/johnson-johnson-jnj-ex-dividend-date-scheduled-for-august-25-2017-cm836394,Johnson amp Johnson JNJ will begin trading ex dividend on August 25 2017 A cash dividend payment of 0 84 per share is scheduled to be paid on September 12 2017 Shareholders who purchased JNJ prior to the ex dividend date are eligible for the cash dividend payment This represents an
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Slipped Ahead Of Jackson Hole Meeting,2017-08-24 12:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hdJ4XmxdJeY/the-swiss-stock-market-slipped-ahead-of-jackson-hole-meeting-20170824-00871,The Swiss Stock Market Slipped Ahead Of Jackson Hole Meeting
NVS,NVS:US,BBG000LYF3S8,AmerisourceBergen-owned specialty pharmacy to pay $13.4M to settle kickback allegations,2017-08-24 11:55:07 +0000,http://finance.yahoo.com/r/12ced9dc-7e41-3db0-a7e1-df0e1a7632a0/amerisourcebergen-pharmacy-bioservices-exjade.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"U.S. Bioservices Corp., a specialty pharmacy owned by Valley Forge-based AmerisourceBergen, has agreed to pay $13.4 million to settle claims the company violated anti-kickbacks laws and the False Claims Act.  The U.S. Attorney’s Office alleged Texas-based U.S. Bioservices conspired with Novartis Pharmaceuticals Corp. in a deal whereby U.S. Bioservices was promised additional patient referrals and related benefits in true form of service fees and rebates from Novartis in return for refilling a higher percentage of Exjade than the two other pharmacies that also dispensed Exjade."
NVS,NVS:US,BBG000LYF3S8,Novartis picks retail expert for new role of digital chief,2017-08-24 06:56:15 +0000,https://finance.yahoo.com/news/novartis-picks-retail-expert-role-065615970.html?.tsrc=rss,"Novartis has appointed a  senior retail expert to the new post of chief digital officer,  following a similar move by GlaxoSmithKline last month,  underscoring how drugmakers are grappling with the impact of new  technology.  Pharmaceutical companies face a range of challenges from the  digital world as mobile apps offer patients new ways to monitor  their health and online communications with prescribers and  consumers become routine.  Bertrand Bodson, currently chief digital and marketing  officer for Sainsbury's Argos chain, will start in his  new role on Jan. 1, 2018, and report directly to CEO Joe  Jimenez, the Swiss drugmaker said on Thursday."
NVS,NVS:US,BBG000LYF3S8,Why Have Mylan's (MYL) Shares Lost 19.4% So Far This Year?,2017-08-23 23:37:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N6YXe7oyKZw/why-have-mylans-myl-shares-lost-194-so-far-this-year-cm836257,Shares of Mylan N V MYL have lost almost 19 4 in the year so far thereby underperforming the 4 5 increase registered by the industry during this period Here we analyze the factors that led to the underperformance Mylan a global pharmaceutical company has a well
NVS,NVS:US,BBG000LYF3S8,"Noteworthy ETF Inflows: VGK, NSRGY, NVS, BTI",2017-08-23 19:38:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ICX4VsVk2as/noteworthy-etf-inflows-vgk-nsrgy-nvs-bti-cm836148,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Europe ETF Symbol VGK where we have detected an approximate 56 4 million dollar inflow that s a 0 3 increase week over week in outstanding
NVS,NVS:US,BBG000LYF3S8,Are Glaxo's Successful New Drugs Enough to Drive Growth?,2017-08-23 15:41:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aJUWCw-mbFc/are-glaxos-successful-new-drugs-enough-to-drive-growth-cm835959,GlaxoSmithKline plc GSK enjoys a diversified base and presence in different geographical areas GlaxoSmithKline reshaped its business following the Mar 2015 completion of the three part inter conditional transaction with Novartis AG NVS Under the deal Glaxo sold its oncology assets
NVS,NVS:US,BBG000LYF3S8,Are Glaxo&apos;s Successful New Drugs Enough to Drive Growth?,2017-08-23 13:47:01 +0000,https://finance.yahoo.com/news/glaxo-apos-successful-drugs-enough-134701634.html?.tsrc=rss,"Despite the success of new products, GlaxoSmithKline plc (GSK) believes that its overall performance has been weaker than it would have liked."
NVS,NVS:US,BBG000LYF3S8,Profit finally in sight for gene therapy specialist Oxford Bio,2017-08-23 13:35:36 +0000,https://finance.yahoo.com/news/profit-finally-sight-gene-therapy-133536592.html?.tsrc=rss,"After 20 years of losses, gene  therapy specialist Oxford BioMedica is at last close to  achieving its first profit thanks to the success of Novartis  with a pioneering cancer treatment.  As manufacturer of the virus-based gene delivery system  central to the Novartis therapy, which re-engineers a patient's  immune cells to attack cancer, the small British company will  receive a modest slice of the revenue once the new drug is  approved.  The payout will hardly make a dent in returns for Swiss  drugs giant Novartis, but the 65-75 million pounds ($83-96  million) a year that Jefferies analysts predict Oxford Bio will  earn should put it on a path to sustainable profitability."
NVS,NVS:US,BBG000LYF3S8,Inside Incyte’s Jakafi Performance in 2Q17,2017-08-23 13:07:28 +0000,http://finance.yahoo.com/r/c0265097-65a9-3a6f-8737-63ba618a4e60/inside-incytes-jakafi-performance-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte's Jakafi is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed After Early Drop,2017-08-23 12:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-8HVDi6nnyc/the-swiss-stock-market-finished-little-changed-after-early-drop-20170823-00802,The Swiss Stock Market Finished Little Changed After Early Drop
NVS,NVS:US,BBG000LYF3S8,Understanding Incyte’s 2Q17 Revenue Stream,2017-08-22 18:05:53 +0000,http://finance.yahoo.com/r/c5b7b710-8803-38ec-972c-961e8e32b384/understanding-incytes-2q17-revenue-stream?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte's 2Q17 revenue growth was driven by the increased demand for Jakafi.
NVS,NVS:US,BBG000LYF3S8,US Bioservices to resolve kickback claims for $13.4 mln -filing,2017-08-22 16:49:42 +0000,https://finance.yahoo.com/news/us-bioservices-resolve-kickback-claims-164942787.html?.tsrc=rss,"Specialty pharmacy firm US Bioservices  Corp has agreed to pay $13.4 million to settle U.S. government  claims that it pushed patients to refill prescriptions of  Novartis AG's iron overload drug Exjade in exchange for  referrals from the Swiss drugmaker.  US Bioservices, a unit of drug wholesaler AmerisourceBergen  , agreed to pay $10.6 million to the federal government  and $2.8 million to states, according to a filing on Tuesday in  Manhattan federal court by Acting U.S. Attorney Joon Kim."
NVS,NVS:US,BBG000LYF3S8,4 Biotech Stocks to Add to your Portfolio Post Q2 Earnings,2017-08-22 16:42:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JuE8UGVzVjw/4-biotech-stocks-to-add-to-your-portfolio-post-q2-earnings-cm835473,The second quarter earnings season is drawing to a close with 94 8 of S amp P 500 stocks having reported results as of Aug 18 2017 Thirteen of the 16 Zacks sectors recorded earnings growth with total earnings increasing 10 6 from the year ago period on revenue growth of 5 6 While 74 9
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Rose In Cautious Trade,2017-08-22 12:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/viUx8pvXg9c/the-swiss-stock-market-rose-in-cautious-trade-20170822-00825,The Swiss Stock Market Rose In Cautious Trade
NVS,NVS:US,BBG000LYF3S8,Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here's Why,2017-08-21 15:45:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zk1JPQZtteU/biogen-6-other-multiple-sclerosis-drug-stocks-in-focus-heres-why-cm834684,Drug pricing is back in the news with an investigation being launched by Rep Elijah E Cummings and Rep Peter Welch into the skyrocketing prices of multiple sclerosis MS drugs MS an unpredictable and often disabling disease of the central nervous system CNS interrupts the flow
NVS,NVS:US,BBG000LYF3S8,Biogen & 6 Other Multiple Sclerosis Drug Stocks in Focus: Here&apos;s Why,2017-08-21 13:31:01 +0000,https://finance.yahoo.com/news/biogen-6-other-multiple-sclerosis-133101020.html?.tsrc=rss,"Late last week, Biogen (BIIB) and six other pharma and biotech stocks were in the news due to the pricing of their multiple sclerosis (""MS"") drugs."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Inched Higher In Quiet Trade,2017-08-21 12:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KRZjkLAFNRs/the-swiss-stock-market-inched-higher-in-quiet-trade-20170821-00732,The Swiss Stock Market Inched Higher In Quiet Trade
NVS,NVS:US,BBG000LYF3S8,"Early movers: SRE, ADP, FCAU, TCS, NVS, GS, EA & more",2017-08-21 11:48:00 +0000,http://finance.yahoo.com/r/04fb9de8-92a8-3267-b00a-d6ee5a86e0d7/104664033?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104664033&yptr=yahoo&.tsrc=rss,These are the stocks posting the largest moves before the bell.
NVS,NVS:US,BBG000LYF3S8,"Early movers: SRE, ADP, FCAU, TCS, NVS, GS, EA & more",2017-08-21 11:48:00 +0000,https://finance.yahoo.com/news/early-movers-sre-adp-fcau-114800331.html?.tsrc=rss,These are the stocks posting the largest moves before the bell.
NVS,NVS:US,BBG000LYF3S8,[$$] New malaria drug could be 'game changer',2017-08-21 05:15:29 +0000,"http://finance.yahoo.com/r/c5d6fb4f-770f-30d1-a76b-1f7baf112660/d17bfbd8-842a-11e7-a4ce-15b2513cb3ff,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The first new malaria drug to emerge for 20 years is beginning clinical trials in nine countries across Africa and Asia. KAF156 could be ""a game changer"", its developers say, at a time when the ..."
NVS,NVS:US,BBG000LYF3S8,Novartis Speeds New Anti-Malarial as Older Drug Loses Potency,2017-08-21 05:15:02 +0000,http://finance.yahoo.com/r/062b06ec-334e-3a6c-9fa3-51c2b109faa1/novartis-speeds-new-anti-malarial-as-older-drug-loses-potency?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Novartis AG began testing a new anti-malaria pill in Africa, advancing development of an alternative to its most effective treatment that billionaire philanthropist Bill Gates said risked losing potency...."
NVS,NVS:US,BBG000LYF3S8,"The FDA Just Approved a New Pfizer Cancer Drug for a Rare, Vicious Leukemia",2017-08-18 15:35:20 +0000,https://finance.yahoo.com/news/fda-just-approved-pfizer-cancer-153520775.html?.tsrc=rss,"The therapy, Besponsa, treats a rapidly progressing version of the disease."
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Multiple Sclerosis Drug Prices in Focus, Mixed Data on BMY's Opdivo",2017-08-18 13:42:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QJF6KhgQNco/pharma-stock-roundup-multiple-sclerosis-drug-prices-in-focus-mixed-data-on-bmys-opdivo-cm833799,Pharmaceutical stocks were in the limelight this week with Merck s MRK CEO Ken Frazier resigning from President Donald Trump s manufacturing council The sector was also in the news with an investigation being launched into the rising prices of multiple sclerosis MS drugs Recap of
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Recent Losses,2017-08-18 13:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xiw3YJdPVHI/the-swiss-stock-market-extended-recent-losses-20170818-00533,The Swiss Stock Market Extended Recent Losses
NVS,NVS:US,BBG000LYF3S8,European Pharma Companies Slip on MS Pricing Probe,2017-08-18 08:18:00 +0000,http://finance.yahoo.com/r/c85da406-5289-3cb7-aa88-ee8d96be950a/european-pharma-companies-slip-on-ms-pricing-probe.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,House Democrats start probe into MS drug prices
NVS,NVS:US,BBG000LYF3S8,Cramer's lightning round: I don't want to recommend any o...,2017-08-17 22:58:00 +0000,https://finance.yahoo.com/video/cramers-lightning-round-dont-want-225800133.html?.tsrc=rss,"Jim Cramer shares his take on callers' favorite stocks at lightning speed, including one oil name."
NVS,NVS:US,BBG000LYF3S8,Cramer's lightning round: I don't want to recommend any oil stocks right now,2017-08-17 22:48:48 +0000,http://finance.yahoo.com/r/c7b853b2-cf96-305e-b4d4-ea679963791a/104658803?__source=yahoo%7Cfinance%7Cheadline%7Cheadline%7Cstory&par=yahoo&doc=104658803&yptr=yahoo&.tsrc=rss,"Jim Cramer shares his take on callers' favorite stocks at lightning speed, including one oil name."
NVS,NVS:US,BBG000LYF3S8,Cramer&apos;s lightning round: I don&apos;t want to recommend any oil stocks right now,2017-08-17 22:48:48 +0000,https://finance.yahoo.com/news/cramer-apos-lightning-round-don-224848422.html?.tsrc=rss,"Jim Cramer shares his take on callers&apos; favorite stocks at lightning speed, including one oil name."
NVS,NVS:US,BBG000LYF3S8,Can Pfizer Bank on New Immunotherapy Bavencio for Growth?,2017-08-17 16:41:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HYggztvPYLY/can-pfizer-bank-on-new-immunotherapy-bavencio-for-growth-cm833410,As demand for immuno oncology drugs and their combinations rises Pfizer Inc s PFE newly approved immunotherapy Bavencio is being considered a significant top line driver for this New York based pharma giant Pfizer s shares are up 5 8 so far this year comparing unfavorably with
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped On U.S. Political Concerns,2017-08-17 12:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZPUxztcANMA/the-swiss-stock-market-dropped-on-us-political-concerns-20170817-00819,The Swiss Stock Market Dropped On U.S. Political Concerns
NVS,NVS:US,BBG000LYF3S8,Ophthotech's Fovista Combo Regimen Disappoints in Phase III,2017-08-16 16:37:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L5Q0wn2eSIQ/ophthotechs-fovista-combo-regimen-disappoints-in-phase-iii-cm832863,Ophthotech Corporation OPHT announced disappointing results from a phase III study OPH1004 evaluating its pipeline candidate Fovista an anti PDGF therapy in combination with Regeneron Pharmaceuticals Inc s REGN Eylea aflibercept or Roche Holding AG s RHHBY Avastin bevacizumab
NVS,NVS:US,BBG000LYF3S8,Ophthotech&apos;s Fovista Combo Regimen Disappoints in Phase III,2017-08-16 14:23:02 +0000,https://finance.yahoo.com/news/ophthotech-apos-fovista-combo-regimen-142302907.html?.tsrc=rss,Ophthotech (OPHT) disappoints with poor evaluation of Fovista combined with Eylea or Avastin for treatment of AMD in phase III. The study misses the primary endpoint.
NVS,NVS:US,BBG000LYF3S8,CYRX: Raising Price Target on CAR-T Opportunity,2017-08-16 14:00:00 +0000,https://finance.yahoo.com/news/cyrx-raising-price-target-car-140000329.html?.tsrc=rss,"Cryoport (CYRX) reported Q2 2017 financial results.  Results continue to impress as revenue set another new high, extending that streak to 11 straight quarters.  Consistent increases in the number of clinical trials that the company supports remains the major catalyst to the topline growth.  That metric (i.e.  Q2 revenue, at $2.9M, was up 52% yoy and inline with our $2.9M estimate.  It is also a new record and up almost 8% sequentially from Q1 (the prior best).  This is the fifth consecutive quarter in which revenue came in slightly better and operating loss much better than our respective estimates.  The $60k revenue difference in Q2 compared to our estimate relates to $36k beat ($2.22M A vs. $2.19M) in biopharma and $25k ($426k A vs. $401k E) beat in reproductive medicine, partially offset by $20k miss ($263k A vs. $283k E) in animal health."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Inched Higher Ahead Of Fed Minutes,2017-08-16 12:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/imC18US68tE/the-swiss-stock-market-inched-higher-ahead-of-fed-minutes-20170816-00760,The Swiss Stock Market Inched Higher Ahead Of Fed Minutes
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 08/15/2017: TEVA,CGIX,FMS,MYL,NVS",2017-08-15 20:36:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h9uY_SAfW-4/health-care-sector-update-for-08152017-tevacgixfmsmylnvs-cm832442,Top Health Care StocksTop Health Care Stocks JNJ 0 07 JNJ 0 07 PFE 0 26 PFE 0 26 ABT 0 51 ABT 0 51 MRK 0 28 MRK 0 28 AMGN 0 26 AMGN 0 26 Health care stocks were putting up narrow gains Tuesday with the NYSE Health Care Index climbing almost 0 3 while shares of health care
NVS,NVS:US,BBG000LYF3S8,Catalyst (CPRX) Focused on Development of Pipeline Candidates,2017-08-15 16:39:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pRe6tE-TvEA/catalyst-cprx-focused-on-development-of-pipeline-candidates-cm832307,We issued an updated report on Catalyst Pharmaceuticals Inc CPRX on Aug 14 In fact Catalyst Pharma is a development stage biopharmaceutical company focused on the development and commercialization of therapies targeting rare neurological diseases and disorders such as Lambert
NVS,NVS:US,BBG000LYF3S8,Can Ligand's Captisol Deals Boost Growth in the Long Run?,2017-08-15 16:39:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L-mwemjVgzw/can-ligands-captisol-deals-boost-growth-in-the-long-run-cm832301,On Aug 14 2017 we issued an updated report on Ligand Pharmaceuticals Incorporated LGND Ligand s Captisol formulation technology platform has allowed it to enter into partnerships with several leading drug companies like Novartis AG NVS Merck amp Co Inc MRK and Amgen Inc
NVS,NVS:US,BBG000LYF3S8,"VGK, NSRGY, NVS, BTI: ETF Inflow Alert",2017-08-15 16:35:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eOEH72f1ZdA/vgk-nsrgy-nvs-bti-etf-inflow-alert-cm832267,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Europe ETF Symbol VGK where we have detected an approximate 84 5 million dollar inflow that s a 0 5 increase week over week in outstanding
NVS,NVS:US,BBG000LYF3S8,Are Amgen's New Drugs Doing Well Enough to Drive Sales?,2017-08-15 15:43:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J8IoSwR2b5Y/are-amgens-new-drugs-doing-well-enough-to-drive-sales-cm832237,We issued an updated research report on Amgen Inc AMGN on Aug 14 The leading biotech beat estimates on both earnings amp sales in the second quarter the results of which were announced on Jul 25 While Amgen slightly tightened the sales guidance it raised the earnings outlook backed by
NVS,NVS:US,BBG000LYF3S8,Pfizer’s Important Product Developments in 2Q17,2017-08-15 13:06:11 +0000,http://finance.yahoo.com/r/b82d2fba-b671-3a2f-acd7-05b8c1a5636d/pfizers-important-product-developments-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Pfizer’s (PFE) innovative health business and essential health business are focusing on growth. To strengthen the innovative health business, the company is focusing on the development of new drugs…"
NVS,NVS:US,BBG000LYF3S8,3 Stocks to Buy With Dividends Yielding More Than 3%,2017-08-15 01:35:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YrGT8cvpOL8/3-stocks-to-buy-with-dividends-yielding-more-than-3-cm831965,Dividend stocks offer both income and long term growth prospects Smart dividend investors focus on the stocks that have the best chances of giving them both maximizing their returns Among above average yielding stocks Darden Restaurants NYSE DRI Cypress
NVS,NVS:US,BBG000LYF3S8,3 Stocks to Buy With Dividends Yielding More Than 3%,2017-08-14 23:50:00 +0000,http://finance.yahoo.com/r/dff0e56e-b121-3459-80e3-70694a5900c4/3-stocks-to-buy-with-dividends-yielding-more-than.aspx?yptr=yahoo&.tsrc=rss,Look out for stocks with good dividend growth and solid yields.
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Climbed Back Above 9,000 Points",2017-08-14 12:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OlSwyrU8msI/the-swiss-stock-market-climbed-back-above-9000-points-20170814-00879,"The Swiss Stock Market Climbed Back Above 9,000 Points"
NVS,NVS:US,BBG000LYF3S8,Luspatercept: Opportunity for Celgene’s Long-Term Growth?,2017-08-11 13:06:04 +0000,http://finance.yahoo.com/r/1273d6bf-e79c-3769-aaf6-35adf89dc808/luspatercept-opportunity-celgenes-long-term-growth?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Celgene and Acceleron are conducting the Phase 3 MEDALIST trial to evaluate the safety and efficacy of luspatercept in individuals with ring sideroblasts.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell Further On North Korea Concerns,2017-08-11 13:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nH1dnhu_G9E/the-swiss-stock-market-fell-further-on-north-korea-concerns-20170811-00647,The Swiss Stock Market Fell Further On North Korea Concerns
NVS,NVS:US,BBG000LYF3S8,7 Reliable Dividend Stocks to Buy Now,2017-08-11 12:34:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AEe6_sU8sok/7-reliable-dividend-stocks-to-buy-now-cm830750,Plenty of stocks yield more than the market average of 2 for large companies But if you re investing for income you ll want dividends that are both reliable and secure And that s not always easy to find Consider what recently happened with Teva Pharmaceutical Industries
NVS,NVS:US,BBG000LYF3S8,"The Medicines Company (MDCO) Q2 Loss Widens, Revenues Miss",2017-08-10 22:37:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/of36tncPCgA/the-medicines-company-mdco-q2-loss-widens-revenues-miss-cm830606,The Medicines Company 160 MDCO reported second quarter 2017 loss of 5 52 per share massively wider than the Zacks Consensus Estimate of a loss of 1 29 However adjusted loss per share was 1 02 excluding the impact of share based compensation expenses versus a loss of 69 cents in
NVS,NVS:US,BBG000LYF3S8,"VEA, GUSH: Big ETF Inflows",2017-08-10 15:36:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JgA4XRa-LKk/vea-gush-big-etf-inflows-cm830285,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 19 000 423 units or a 1 4 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,CAH Named A Top Socially Responsible Dividend Stock,2017-08-10 14:35:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6_VVl67KWi8/cah-named-a-top-socially-responsible-dividend-stock-cm830168,Cardinal Health Inc Symbol CAH has been named a Top Socially Responsible Dividend Stock by Dividend Channel signifying a stock with above average DividendRank statistics including a strong 2 7 yield as well as being recognized by prominent asset managers as being a
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped Further On North Korea Concerns,2017-08-10 12:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hUXd5USuFgk/the-swiss-stock-market-dropped-further-on-north-korea-concerns-20170810-01000,The Swiss Stock Market Dropped Further On North Korea Concerns
NVS,NVS:US,BBG000LYF3S8,How Celgene Performed in 2Q17,2017-08-09 18:36:00 +0000,http://finance.yahoo.com/r/4590d37d-74d8-37e8-96cf-f78c29b8283f/celgene-performed-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Celgene updated its adjusted diluted EPS from $7.15–$7.30 to $7.25–$7.35 and its adjusted operating margin from about 57.0%–57.5%.
NVS,NVS:US,BBG000LYF3S8,"Kite Pharma (KITE) Q2 Loss Narrower than Expected, Shares Up",2017-08-09 16:38:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MS_GGct0iGw/kite-pharma-kite-q2-loss-narrower-than-expected-shares-up-cm829533,Kite Pharma Inc KITE reported narrower than expected loss in the second quarter of 2017 and beat estimates for sales Shares of the biotech company rose 5 8 on Tuesday In fact this year so far Kite Pharma s stock is up 167 9 which compares favorably with a 9 7 increase registered by
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Sank On Geopolitical Concerns,2017-08-09 12:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fDiLR34eCpA/the-swiss-stock-market-sank-on-geopolitical-concerns-20170809-01151,The Swiss Stock Market Sank On Geopolitical Concerns
NVS,NVS:US,BBG000LYF3S8,Why Vertex Pharmaceuticals Incorporated (VRTX) Will Keep Rolling Higher,2017-08-09 01:00:38 +0000,https://finance.yahoo.com/news/why-vertex-pharmaceuticals-incorporated-vrtx-010038677.html?.tsrc=rss,"InvestorPlace - Stock Market News, Stock Advice &#38; Trading Tips"
NVS,NVS:US,BBG000LYF3S8,"Ligand (LGND) Q2 Earnings & Revenues Top, 2017 View Raised",2017-08-08 17:36:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cbz3i1mBhf0/ligand-lgnd-q2-earnings-revenues-top-2017-view-raised-cm828893,Ligand Pharmaceuticals Incorporated LGND reported second quarter 2017 earnings of 54 cents per share including the after tax impact of stock based compensation expenses significantly up 157 1 from the year ago figure of 21 cents Earnings also beat the Zacks Consensus Estimate of 25 cents
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Inched Higher In Late Trade,2017-08-08 12:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/po_x7L5FqoI/the-swiss-stock-market-inched-higher-in-late-trade-20170808-01257,The Swiss Stock Market Inched Higher In Late Trade
NVS,NVS:US,BBG000LYF3S8,"Notable ETF Inflow Detected - VGK, NSRGY, NVS, BTI",2017-08-07 16:35:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DxvwV9nO2tA/notable-etf-inflow-detected-vgk-nsrgy-nvs-bti-cm828142,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Europe ETF Symbol VGK where we have detected an approximate 57 6 million dollar inflow that s a 0 3 increase week over week in outstanding
NVS,NVS:US,BBG000LYF3S8,Why Cardinal Health is a Top 25 SAFE Dividend Stock (CAH),2017-08-07 13:36:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CkCBL1OgWk0/why-cardinal-health-is-a-top-25-safe-dividend-stock-cah-cm827908,Cardinal Health Inc Symbol CAH has been named to the Dividend Channel S A F E 25 list signifying a stock with above average DividendRank statistics including a strong 2 7 yield as well as a superb track record of at least two decades of dividend growth according to the
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Small Loss In Quiet Trade,2017-08-07 12:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XMqfYNbwe6M/the-swiss-stock-market-finished-with-a-small-loss-in-quiet-trade-20170807-00889,The Swiss Stock Market Finished With A Small Loss In Quiet Trade
NVS,NVS:US,BBG000LYF3S8,"Juno Therapeutics (JUNO) Q2 Loss Widens, Revenues Surpass",2017-08-04 22:59:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vqSM8N6U090/juno-therapeutics-juno-q2-loss-widens-revenues-surpass-cm827597,Juno Therapeutics Inc JUNO reported second quarter 2017 loss of 75 cents per share including stock based compensation expenses wider than both the Zacks Consensus Estimate of a loss of 74 cents and the year ago loss of 65 cents per share Juno s shares have significantly outperformed
NVS,NVS:US,BBG000LYF3S8,Analysts say a United Therapeutics sale is premature,2017-08-04 22:04:40 +0000,http://finance.yahoo.com/r/090b1829-e942-3f19-b2d2-9b8c474545dd/united-therapeutics-stock-up-9-percent-on-gsk.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Silver Spring-based United Therapeutics Corp.'s stock jumped Friday following a report that GlaxoSmithKline PLC or other drug giants may be looking to acquire it.  According to a report from the Evening Standard in London on Friday , GSK may be eyeing United Therapeutics in a deal worth nearly $9 billion, or $200 a share.  United Therapeutics' share price jumped more than 9 percent on the report from a previous close of $126.96 to open at $138.90."
NVS,NVS:US,BBG000LYF3S8,United Therapeutics Corporation (UTHR) Shares Soar on Takeover Talk,2017-08-04 21:08:43 +0000,https://finance.yahoo.com/news/united-therapeutics-corporation-uthr-shares-210843508.html?.tsrc=rss,"United Therapeutics Corporation (NASDAQ:UTHR) stock surged on Friday as rumors of a takeover surged.  The company is reportedly being considered as an acquisition by a major pharmaceutical giant, including Gilead Sciences Inc (NASDAQ:GILD), GlaxoSmithKline PLC (NYSE:GSK) and Novartis AG (NYSE:NVS).  GlaxoSmithKline and United Therapeutics both declined to comment on the matter."
NVS,NVS:US,BBG000LYF3S8,Gilead Could Be Making An Acquisition — But It&apos;s Not What You Think,2017-08-04 16:15:05 +0000,http://finance.yahoo.com/r/85b1f35d-463e-30a6-9503-52af91e9b1de/gilead-could-be-making-an-acquisition-but-its-not-what-you-think?src=A00220&yptr=yahoo&.tsrc=rss,"United Therapeutics surged to an 18-week high Friday on reports Gilead, Glaxo and Novartis could be considering takeover bids on it."
NVS,NVS:US,BBG000LYF3S8,"Teva Q2 Earnings Lag, '17 View & Dividend Cut, Stock Slumps",2017-08-04 16:05:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DlQMZMjR9Ms/teva-q2-earnings-lag-17-view-dividend-cut-stock-slumps-cm827296,Teva Pharmaceutical Industries Limited TEVA reported second quarter 2017 earnings of 99 cents per share including equity compensation expenses which missed the Zacks Consensus Estimate of 1 06 per share by 6 6 The year ago adjusted earnings were 1 22 per share Revenues of 5 69
NVS,NVS:US,BBG000LYF3S8,"ETFs with exposure to Novartis AG : August 4, 2017",2017-08-04 00:56:04 +0000,http://finance.yahoo.com/r/ad0a258d-c34e-3bde-84b7-d1e38eb548e4/etfs-with-exposure-to-novartis-ag-august-4-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Novartis AG Here are 5 ETFs with the largest exposure to NVS-US. Comparing the performance and risk of Novartis AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
NVS,NVS:US,BBG000LYF3S8,Juno Therapeutics' Cash Position and Potential Cash Cow JCAR017 Are Still What's Important,2017-08-04 00:00:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l16rarK2VpU/juno-therapeutics-cash-position-and-potential-cash-cow-jcar017-are-still-whats-important-cm826942,It s been a pretty good year for Juno Therapeutics NASDAQ JUNO so far The clinical stage biotech s share price is up more than 50 year to date Its financial position in the first quarter looked great thanks to its collaboration with Celgene NASDAQ CELG And at
NVS,NVS:US,BBG000LYF3S8,"Conatus (CNAT) Q2 Loss Narrows Y/Y, Revenues Beat Estimates",2017-08-03 20:41:08 +0000,https://finance.yahoo.com/news/conatus-cnat-q2-loss-narrows-204108656.html?.tsrc=rss,"Conatus (CNAT) reports wider-than-expected loss in Q2. However, revenue beat estimates, courtesy higher collaboration benefits."
NVS,NVS:US,BBG000LYF3S8,"Aduro (ADRO) Q2 Loss Narrower than Expected, Revenues Top",2017-08-03 20:08:08 +0000,https://finance.yahoo.com/news/aduro-adro-q2-loss-narrower-200808503.html?.tsrc=rss,"Aduro (ADRO) incurs loss in Q2 but revenues beat estimates. However, the same declines year over year, courtesy a milestone payment from the year-ago quarter."
NVS,NVS:US,BBG000LYF3S8,"Momenta Pharmaceuticals, Inc. Treads Water in the Second Quarter",2017-08-03 19:52:00 +0000,http://finance.yahoo.com/r/090dc948-00bb-3079-8fcd-70779c433031/momenta-pharmaceuticals-inc-treads-water-in-the-se.aspx?yptr=yahoo&.tsrc=rss,Waiting for an FDA approval is hard work.
NVS,NVS:US,BBG000LYF3S8,Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Hits 13-Year Low,2017-08-03 18:00:36 +0000,https://finance.yahoo.com/news/teva-pharmaceutical-industries-ltd-adr-180036878.html?.tsrc=rss,"InvestorPlace - Stock Market News, Stock Advice &#38; Trading Tips"
NVS,NVS:US,BBG000LYF3S8,Novartis a Top Ranked SAFE Dividend Stock With 3.2% Yield (NVS),2017-08-03 14:01:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ed0zx7ux1iU/novartis-a-top-ranked-safe-dividend-stock-with-32-yield-nvs-cm826310,Novartis Symbol NVS has been named to the Dividend Channel International S A F E 10 list signifying an international stock with above average DividendRank statistics including a strong 3 2 yield as well as a superb track record of at least five years of dividend growth
NVS,NVS:US,BBG000LYF3S8,Moderna taps Novartis exec to lead manufacturing blitz,2017-08-03 12:30:13 +0000,http://finance.yahoo.com/r/d394773d-ac39-3c8b-9273-c90530c36ad3/moderna-taps-novartis-exec-to-lead-manufacturing.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Cambridge-based Moderna Therapeutics has hired a former Novartis executive to help it ramp up manufacturing of its experimental drugs and vaccines at a new facility in Norwood.  Moderna, one of the state’s largest and most valuable private biotechs, said Thursday that it has appointed Juan Andres to lead late-stage technical development and manufacturing.  In that role, he will oversee the 500-employee company’s efforts to scale up manufacturing of its medicines for testing in preclinical studies and early and mid-stage human trials."
NVS,NVS:US,BBG000LYF3S8,"Incyte (INCY) Q2 Loss Wider than Expected, Jakafi Strong",2017-08-02 16:58:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/e_mI3CYOJII/incyte-incy-q2-loss-wider-than-expected-jakafi-strong-cm825857,Shares of Incyte Corporation INCY were down 3 4 after the company reported a loss in the second quarter of 2017 Incyte reported a loss of 6 cents a penny wider than the Zacks Consensus Estimate of a loss of 5 cents Incyte had reported earnings of 18 cents per share in the year
NVS,NVS:US,BBG000LYF3S8,Drugmakers Hunt for Patients in India’s Remote Corners,2017-08-02 16:00:01 +0000,http://finance.yahoo.com/r/90dfba7d-eae3-354d-8063-598701d45534/drug-giants-are-hunting-for-patients-in-india-s-remote-corners?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"First, foreign food brands flooded India with chips, cookies and soft drinks that fundamentally changed the nation’s eating habits. Now, Big Pharma wants to cash in on an upsurge in cases of diabetes and ..."
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline’s 2Q17 Earnings: Vaccines Business,2017-08-02 13:07:50 +0000,http://finance.yahoo.com/r/1b936996-5900-3396-8f31-a5a5bd685134/glaxosmithklines-2q17-earnings-vaccines-business?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GSK's Vaccines business reported 16.0% growth to ~1.1 billion pounds in 2Q17, including 5.0% growth at constant exchange rates and 11.0% positive impact of foreign exchange."
NVS,NVS:US,BBG000LYF3S8,MondelÄ“z Appoints Dirk Van De Put To Succeed Irene Rosenfeld As CEO,2017-08-02 10:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cgBGxa_gc8M/mondel%C3%A4z-appoints-dirk-van-de-put-to-succeed-irene-rosenfeld-as-ceo-20170802-01118,MondelÄ“z Appoints Dirk Van De Put To Succeed Irene Rosenfeld As CEO
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis faces vexing decisions over asset sales,2017-08-02 04:00:26 +0000,"http://finance.yahoo.com/r/ca23c836-585a-351a-92fb-775d7dd5da1b/a5202d02-72cd-11e7-93ff-99f383b09ff9,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","With 123,000 employees, almost $50bn in annual sales and a $200bn-plus market capitalisation, the status of Novartis as a leading Big Pharma company is beyond doubt. Yet management, staff and shareholders ..."
NVS,NVS:US,BBG000LYF3S8,Can Ligand (LGND) Pull a Surprise This Earnings Season?,2017-08-01 22:55:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LKKTK5QUcAw/can-ligand-lgnd-pull-a-surprise-this-earnings-season-cm825337,Ligand Pharmaceuticals Incorporated LGND is scheduled to report second quarter 2017 results on Aug 7 after the market closes Ligand s earnings history has been disappointing as it missed expectations in all of the last four quarters The company delivered an average negative surprise
NVS,NVS:US,BBG000LYF3S8,Dow Keeps Win Streak Alive; Which Foreign Plays Breaking Out?,2017-08-01 18:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UeOMOExqC3A/dow-keeps-win-streak-alive-which-foreign-plays-breaking-out-cm824760,A pair of exchange traded funds investing in foreign stocks triggered buy points Tuesday ibd display video id 2066035 width 50 float left autostart true At Monday s close WisdomTree International Equity Fund DWM was at a two year high and just shy of a 53 51 buy point of
NVS,NVS:US,BBG000LYF3S8,Intercept (ICPT) Posts Narrower-than-Expected Loss in Q2,2017-08-01 16:59:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d2BWA3c-znY/intercept-icpt-posts-narrower-than-expected-loss-in-q2-cm825073,Intercept Pharmaceuticals Inc ICPT reported a loss of 3 46 per share in the second quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 3 62 but wider than the year ago loss of 3 14 Quarterly revenues were 30 9 million up significantly from 5 5 million in
NVS,NVS:US,BBG000LYF3S8,"Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for August 02, 2017",2017-08-01 13:15:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_XoWgegzURM/pfizer-inc-pfe-ex-dividend-date-scheduled-for-august-02-2017-cm824832,Pfizer Inc PFE will begin trading ex dividend on August 02 2017 A cash dividend payment of 0 32 per share is scheduled to be paid on September 01 2017 Shareholders who purchased PFE prior to the ex dividend date are eligible for the cash dividend payment This marks the 3rd quarter
NVS,NVS:US,BBG000LYF3S8,"Drug Stocks Q2 Earnings Releases on Aug 1: PFE, AERI & INCY",2017-07-31 16:58:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EpIjHOlJH7M/drug-stocks-q2-earnings-releases-on-aug-1-pfe-aeri-incy-cm824357,We have already crossed the halfway mark of the second quarter reporting cycle The earning season has shown broad based growth with record earnings this quarter As of Jul 28 2017 286 S amp P 500 members accounting for 68 8 of the index s total market capitalization reported
NVS,NVS:US,BBG000LYF3S8,Roche's (RHHBY) Sales Grow Y/Y in 1H17 on New Drug Launches,2017-07-28 17:03:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lUeqF9aPDKs/roches-rhhby-sales-grow-yy-in-1h17-on-new-drug-launches-cm823451,Roche Holding AG s RHHBY reported sales of CHF26 3 billion in the first half of 2017 up 5 from the year ago period Core earnings came in at CHF8 23 per share up 6 from the first half of 2016 Shares of Roche have performed better than the Zacks classified industry in the year
NVS,NVS:US,BBG000LYF3S8,Interesting NVS Put And Call Options For June 2018,2017-07-28 15:00:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0fZ7NAYRBJA/interesting-nvs-put-and-call-options-for-june-2018-cm823267,Investors in Novartis Symbol NVS saw new options begin trading today for the June 2018 expiration One of the key inputs that goes into the price an option buyer is willing to pay is the time value so with 322 days until expiration the newly trading contracts represent a possible
NVS,NVS:US,BBG000LYF3S8,Pfizer on the Street: Inside the Analysts’ Recommendations,2017-07-28 13:06:15 +0000,http://finance.yahoo.com/r/f61ecc0e-052d-339a-8f0b-78e5710d90bf/pfizer-on-the-street-inside-the-analysts-recommendations?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"No analyst has recommended any form of ""sell"" for Pfizer stock."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Nearly Unchanged - Banks In Focus,2017-07-28 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_HRK2MWtLbA/the-swiss-stock-market-finished-nearly-unchanged--banks-in-focus-20170728-00946,The Swiss Stock Market Finished Nearly Unchanged - Banks In Focus
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline Capital Inc. -- Moody's changes outlook on GSK's A2 rating to stable from negative; affirms ratings,2017-07-27 20:27:10 +0000,http://finance.yahoo.com/r/cf54cb1e-880d-3082-820c-cf2bb6a39df4/viewresearchdoc.aspx?docid=PR_370520&WT.mc_id=AM~WWFob29fRmluYW5jZTQyX1NCX0NWX1JhdGluZ19OZXdzX0FsbF9Fbmc=~20170727_PR_370520&yptr=yahoo&.tsrc=rss,"Rating Action: Moody's changes outlook on GSK's A2 rating to stable from negative; affirms ratings. Global Credit Research- 27 Jul 2017. London, 27 July 2017-- Moody's Investors Service has today changed ..."
NVS,NVS:US,BBG000LYF3S8,"VGK, NSRGY, NVS, BTI: Large Inflows Detected at ETF",2017-07-27 15:59:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7ZOT3unBu6Y/vgk-nsrgy-nvs-bti-large-inflows-detected-at-etf-cm822460,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Europe ETF Symbol VGK where we have detected an approximate 141 9 million dollar inflow that s a 0 8 increase week over week in outstanding
NVS,NVS:US,BBG000LYF3S8,"Ophthotech (OPHT) Q2 Loss Narrows, Focus Shifts to Zimura",2017-07-27 14:28:02 +0000,https://finance.yahoo.com/news/ophthotech-opht-q2-loss-narrows-142802340.html?.tsrc=rss,Ophthotech Corporation (OPHT) reported narrower-than-expected loss in the second quarter and also beat sales expectations.
NVS,NVS:US,BBG000LYF3S8,AMGN Named A Top Socially Responsible Dividend Stock,2017-07-27 12:59:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/luvGXy2f7fA/amgn-named-a-top-socially-responsible-dividend-stock-cm822208,Amgen Inc Symbol AMGN has been named a Top Socially Responsible Dividend Stock by Dividend Channel signifying a stock with above average DividendRank statistics including a strong 2 6 yield as well as being recognized by prominent asset managers as being a socially
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Climbed Back Above 9,000 Points",2017-07-27 12:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oPAyHut9wzo/the-swiss-stock-market-climbed-back-above-9000-points-20170727-01712,"The Swiss Stock Market Climbed Back Above 9,000 Points"
NVS,NVS:US,BBG000LYF3S8,Featured Company News – Novartis Ropes in Cryoport for a Three-Year Contract to Provide Cryogenic Logistics Support for Commercialization of CTL019/CD19 CAR-T Cell Therapy,2017-07-27 11:40:00 +0000,https://finance.yahoo.com/news/featured-company-news-novartis-ropes-114000802.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / July 27, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for Cryoport, Inc. (NASDAQ: CYRX ), following which we have published ..."
NVS,NVS:US,BBG000LYF3S8,"Reduced Risk, Upcoming Pipeline Inspire Bull Case For Novartis",2017-07-26 19:52:30 +0000,https://finance.yahoo.com/news/reduced-risk-upcoming-pipeline-inspire-195230369.html?.tsrc=rss,"Novartis AG (ADR) (NYSE: NVS ) has been all over the news lately as its cancer drug moves closer to FDA approval, and Morgan Stanley analyst Vincent Meunier believes the recent news flow suggests a less ..."
NVS,NVS:US,BBG000LYF3S8,What's in Store for Conatus (CNAT) this Earnings Season?,2017-07-26 17:02:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Yd_RQUvS8KQ/whats-in-store-for-conatus-cnat-this-earnings-season-cm821852,Conatus Pharmaceuticals Inc CNAT is expected to report second quarter 2017 results on Aug 2 Last quarter Conatus earnings were in line with expectations Conatus earnings history is a mixed bag The company surpassed expectations on two occasions missed expectations in one and
NVS,NVS:US,BBG000LYF3S8,Amgen (AMGN) Stock Falls Despite Q2 Earnings & Sales Beat,2017-07-26 16:05:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZsrQxOYmcEI/amgen-amgn-stock-falls-despite-q2-earnings-sales-beat-cm821718,Biotech major Amgen Inc AMGN reported second quarter 2017 earnings of 3 27 per share which beat the Zacks Consensus Estimate of 3 09 by 5 8 and increased 15 from the year ago period Better revenues and lower operating costs drove the bottom line A lower tax rate and share count
NVS,NVS:US,BBG000LYF3S8,"Biotech Stocks Jul27 Q2 Earnings Roster: BMY, CELG & ALXN",2017-07-26 15:03:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gcMbigB7vzo/biotech-stocks-jul27-q2-earnings-roster-bmy-celg-alxn-cm821738,The second quarter earnings season is off to a strong start As of July 25 approximately 128 S amp P 500 companies or 36 1 of the index s total membership have reported results 160 A deep look into the results show that earnings for the companies reported so far are up 7 year over year
NVS,NVS:US,BBG000LYF3S8,"Glaxo (GSK) Beats Q2 Earnings, Misses Sales",2017-07-26 13:10:01 +0000,https://finance.yahoo.com/news/glaxo-gsk-beats-q2-earnings-131001708.html?.tsrc=rss,"Glaxo&apos;s (GSK) Q2 earnings beat estimate, with revenue missing the same. Glaxo lowered its core 2017 earnings growth in the quarter, with no Advair generics are launched this year."
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Is Climbing Back Near 9,000 Points",2017-07-26 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8SGJqy09EuU/the-swiss-stock-market-is-climbing-back-near-9000-points-20170726-01276,"The Swiss Stock Market Is Climbing Back Near 9,000 Points"
NVS,NVS:US,BBG000LYF3S8,"Drug Stocks Q2 Earnings Releases on Jul 26: GILD, VRTX, GSK",2017-07-25 18:03:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LVJd7sECmpI/drug-stocks-q2-earnings-releases-on-jul-26-gild-vrtx-gsk-cm820959,We are entering the peak period of the second quarter reporting cycle this week The quarter undoubtedly is off to a strong start As of Jul 21 2017 97 S amp P 500 members accounting for 28 1 of the index s total market capitalization reported results according to 160 Earnings
NVS,NVS:US,BBG000LYF3S8,"VEA, RETL: Big ETF Inflows",2017-07-25 16:01:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j2HUOhA1Pp4/vea-retl-big-etf-inflows-cm820845,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 13 028 992 units or a 1 0 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,Merck a Top Socially Responsible Dividend Stock With 3.0% Yield (MRK),2017-07-25 14:03:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zGlLYECCFSs/merck-a-top-socially-responsible-dividend-stock-with-30-yield-mrk-cm820699,Merck amp Co Inc Symbol MRK has been named a Top Socially Responsible Dividend Stock by Dividend Channel signifying a stock with above average DividendRank statistics including a strong 3 0 yield as well as being recognized by prominent asset managers as being a socially
NVS,NVS:US,BBG000LYF3S8,Novartis in 2Q17: Performance of Alcon,2017-07-25 13:09:27 +0000,http://finance.yahoo.com/r/d9014813-607e-3a02-ada3-f6445ce73840/novartis-in-2q17-performance-of-alcon?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For 2Q17, Alcon reported a 1.0% growth in revenues to $1.52 billion compared to $1.51 billion in 2Q16."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On Strength Of The Financials,2017-07-25 12:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OkUOfj8N-O8/the-swiss-stock-market-climbed-on-strength-of-the-financials-20170725-01162,The Swiss Stock Market Climbed On Strength Of The Financials
NVS,NVS:US,BBG000LYF3S8,Novartis in 2Q17: Performance of Sandoz,2017-07-25 11:39:12 +0000,http://finance.yahoo.com/r/0042dcbe-c661-3236-99ce-05fc691cc973/novartis-in-2q17-performance-of-sandoz?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Sandoz contributed ~20.0% of total revenues at $2.45 billion in 2Q17, a 5.0% fall compared to $2.58 billion in 2Q16."
NVS,NVS:US,BBG000LYF3S8,3 Key Things Every CAR-T Investor Should Watch,2017-07-25 10:02:00 +0000,http://finance.yahoo.com/r/8b5930bc-aba1-3363-b912-d191104f702f/3-key-things-every-car-t-investor-should-know.aspx?yptr=yahoo&.tsrc=rss,The first CAR-T therapy recently won a unanimous thumbs up for approval. But that doesn&apos;t mean CAR-T stocks are out of the woods just yet.
NVS,NVS:US,BBG000LYF3S8,"Foreign Stock Roundup: ABB, Novartis Beat on Earnings",2017-07-24 20:50:08 +0000,https://finance.yahoo.com/news/foreign-stock-roundup-abb-novartis-205008103.html?.tsrc=rss,Global markets were weighed down by comments from the ECB and Bank of Japan even as bullish GDP data emerged from China this week
NVS,NVS:US,BBG000LYF3S8,Biotechs Find Strength In Numbers In Treating Multiple Sclerosis,2017-07-24 20:45:02 +0000,http://finance.yahoo.com/r/06e1cfaf-3d8c-3f7d-9983-b0d05eb22cd0/new-ms-drugs-threaten-biogen-novartis-dominance?src=A00220&yptr=yahoo&.tsrc=rss,"Roche, Celgene and Novartis could change the multiple sclerosis landscape, a sector now dominated by Biogen."
NVS,NVS:US,BBG000LYF3S8,Novartis in 2Q17: Performance of Innovative Medicines,2017-07-24 18:35:43 +0000,http://finance.yahoo.com/r/39086da0-2137-31af-ae6a-94ae7bfecfe0/novartis-in-2q17-performance-of-innovative-medicines?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The overall contribution of the Innovative Medicines segment was ~67.6% at $8.28 billion for 2Q17.
NVS,NVS:US,BBG000LYF3S8,Foreign Exchange Impacts Novartis’s Growth in 2Q17,2017-07-24 17:05:51 +0000,http://finance.yahoo.com/r/98399dd6-17dd-3126-a5e6-75babe9b768a/foreign-exchange-impacts-novartiss-growth-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In its earnings release on July 8, 2017, Novartis (NVS) reported flat revenues at constant currencies for 2Q17."
NVS,NVS:US,BBG000LYF3S8,Novartis: Here’s What Impacted 2Q17 Earnings and Missed Estimates,2017-07-24 15:15:30 +0000,http://finance.yahoo.com/r/fe3c4f7d-b980-3612-98bf-390f513901a6/novartis-heres-what-impacted-2q17-earnings-and-missed-estimates?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis (NVS) released its 2Q17 earnings on July 18, 2017. It reported flat revenues at constant exchange rates compared to 2Q16."
NVS,NVS:US,BBG000LYF3S8,"Big Pharma Q2 Earnings Releases on Jul 25: LLY, BIIB, AMGN",2017-07-24 13:05:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/na8HBi0HD_Y/big-pharma-q2-earnings-releases-on-jul-25-lly-biib-amgn-cm820000,The second quarter reporting cycle seems to have gotten off to a good start with an abundance of positive surprises particularly on the revenue front Meanwhile earnings and revenue growth also bettered expectations As of Jul 21 2017 97 S amp P 500 members accounting for 28 1 of
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back As Defensive Heavyweights Weaken,2017-07-24 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/90kHJgEI484/the-swiss-stock-market-pulled-back-as-defensive-heavyweights-weaken-20170724-00874,The Swiss Stock Market Pulled Back As Defensive Heavyweights Weaken
NVS,NVS:US,BBG000LYF3S8,One Step Closer To EU Approval...,2017-07-23 23:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0Tnuvvu6IN0/one-step-closer-to-eu-approval-20170723-00089,One Step Closer To EU Approval...
NVS,NVS:US,BBG000LYF3S8,2 Reasons Incyte Is a Better Growth Stock Than Exelixis -- and 1 Reason It Isn't,2017-07-21 20:04:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IM7_-ts66fs/2-reasons-incyte-is-a-better-growth-stock-than-exelixis-and-1-reason-it-isnt-cm819529,Exelixis NASDAQ EXEL is without question one of the hottest biotech stocks on the market We re talking about a stock that has more than tripled in value in just the last 12 months and has soared over 70 so far this year Exelixis is simply put a fantastic growth stock But
NVS,NVS:US,BBG000LYF3S8,Amgen (AMGN) to Report Q2 Earnings: What's in the Cards?,2017-07-21 14:11:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Uvnop-IL6zQ/amgen-amgn-to-report-q2-earnings-whats-in-the-cards-cm819288,Biotech major Amgen Inc AMGN will report second quarter 2017 results on Jul 25 after the market closes Amgen delivered a positive earnings surprise of 5 0 in the last quarter Amgen shares are up 22 6 so far this year This compares favorably with the 10 5 increase registered by
NVS,NVS:US,BBG000LYF3S8,"Manning & Napier Advisors, Inc Buys Biogen Inc, FedEx Corp, Ball Corp, Sells Liberty Global ...",2017-07-21 14:03:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VIR_AEm1nqM/manning-napier-advisors-inc-buys-biogen-inc-fedex-corp-ball-corp-sells-liberty-global-cm819200,Manning Napier Advisors Inc Charles Schwab New Purchases BLL QRVO ADBE CDK EZU MCD HON GILD CF SNP Added Positions BIIB FDX SEE DVA SCHW NKE BMRN DKS AZO ORLY Reduced Positions LBTYA AAPL MA FB AMZN MSFT AMX UL CERN
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Sank Below The 9,000 Point Level",2017-07-21 13:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hq_FC8-RAFo/the-swiss-stock-market-sank-below-the-9000-point-level-20170721-00751,"The Swiss Stock Market Sank Below The 9,000 Point Level"
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: J&J, NVS&apos; Q2 Earnings, Merck Drug Gets Tentative FDA Nod",2017-07-21 12:35:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-j-j-123512662.html?.tsrc=rss,Pharma sector second quarter earnings season has started with industry bellwether Johnson & Johnson (JNJ) reporting earlier this week while AstraZeneca and Merck provided regulatory updates.
NVS,NVS:US,BBG000LYF3S8,Novartis: CHMP Adopts Positive Recommendation On Rydapt - Quick Facts,2017-07-21 07:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2daohDm1ecM/novartis-chmp-adopts-positive-recommendation-on-rydapt--quick-facts-20170721-00356,Novartis: CHMP Adopts Positive Recommendation On Rydapt - Quick Facts
NVS,NVS:US,BBG000LYF3S8,3 Hottest Biotech Stocks of 2017 -- Are They Still Buys Now?,2017-07-21 03:02:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PcU5QIOFpvk/3-hottest-biotech-stocks-of-2017-are-they-still-buys-now-cm819044,Biotechnology s top performing stocks this year have already given investors envy inspiring returns but there s reason to believe that Calithera Biosciences NASDAQ CALA Aurinia Pharmaceuticals NASDAQ AUPH and Esperion Therapeutics NASDAQ ESPR could still go
NVS,NVS:US,BBG000LYF3S8,5 New Breast Cancer Treatments That Are Helping to Save Lives,2017-07-20 23:30:00 +0000,http://finance.yahoo.com/r/fa9ce2cc-dc7b-3464-a331-dbc17fc49825/5-new-breast-cancer-treatments-from-lilly-novartis-and-pfizer-that-could-double-sales-by-2021.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"In the U.S., one in eight women will be diagnosed with breast cancer in their lifetime; for men, the risk is one in 1,000."
NVS,NVS:US,BBG000LYF3S8,Amgen Says FDA Accepts BLA For Aimovig,2017-07-20 23:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tLE7Kzj6NcM/amgen-says-fda-accepts-bla-for-aimovig-20170720-01780,Amgen Says FDA Accepts BLA For Aimovig
NVS,NVS:US,BBG000LYF3S8,"Novartis AG :NVS-US: Earnings Analysis: Q2, 2017 By the Numbers : July 20, 2017",2017-07-20 15:31:16 +0000,http://finance.yahoo.com/r/fb9c8177-4749-3fac-8465-bf29171d8332/novartis-ag-nvs-us-earnings-analysis-q2-2017-by-the-numbers-july-20-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Novartis AG reports financial results for the quarter ended June 30, 2017. We analyze the earnings along side the following peers of Novartis AG – Johnson & Johnson (JNJ-US) that have also reported for this period. Highlights Summary numbers: Revenues of USD 12,462.71 million, Net Earnings of USD 2,015.70 million. Gross ... Read more
<b>(Read more...)</b>"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed,2017-07-20 13:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/949gwCsEM1o/the-swiss-stock-market-finished-little-changed-20170720-01190,The Swiss Stock Market Finished Little Changed
NVS,NVS:US,BBG000LYF3S8,Earnings Review and Free Research Report: Novartis' EPS Grew 15% on Constant Currency Basis; Free Cash Flow Soared 28%,2017-07-20 11:00:00 +0000,https://finance.yahoo.com/news/earnings-review-free-research-report-110000122.html?.tsrc=rss,"LONDON, UK / ACCESSWIRE / July 20, 2017 / Pro-Trader Daily has just published a free post-earnings coverage on Novartis AG (NYSE: NVS ), which can be viewed by registering at http://protraderdaily.com/optin/?symbol=NVS ..."
NVS,NVS:US,BBG000LYF3S8,"FDA Panel Votes To Approve CTL019, Positive Implications for CYRX",2017-07-19 17:30:00 +0000,https://finance.yahoo.com/news/fda-panel-votes-approve-ctl019-173000865.html?.tsrc=rss,"Last week an FDA advisory panel voted unanimously (10-0) to approve CTL019 (tisagenlecleucel-T), a novel CAR-T cell immunotherapy developed by Novartis (NVS), for the treatment of children and young adults (ages 3 - 25) with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL).  B-cell ALL is a form of Leukemia (i.e."
NVS,NVS:US,BBG000LYF3S8,European ADRs Move Higher in Wednesday Trading,2017-07-19 15:22:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zNQGngm3Y64/european-adrs-move-higher-in-wednesday-trading-cm818078,American depositary receipts of European stocks were trading 0 12 higher at 135 67 on the Bank of New York Mellon Europe ADR Index on Wednesday American depositary receipts of European stocks were trading 0 12 higher at 135 67 on the Bank of New York Mellon Europe ADR Index on Wednesday
NVS,NVS:US,BBG000LYF3S8,"[$$] Novartis, Glaxo and Lilly Bigly Back New Biotech",2017-07-19 13:21:00 +0000,http://finance.yahoo.com/r/25ac3e8d-d93e-3285-9d3e-8e3027a7f8db/novartis-glaxo-and-lilly-bigly-back-new-biotech-1500458556?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Aileron Therapeutics’ initial public offering was priced at $15 a share on June 28.  You can be forgiven if you hadn’t heard of the cancer biotech’s IPO.  Apart from a low media profile, the low-end IPO pricing was also a disappointment."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Higher In Cautious Trade,2017-07-19 12:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hjZ-L3vSkbc/the-swiss-stock-market-finished-higher-in-cautious-trade-20170719-00912,The Swiss Stock Market Finished Higher In Cautious Trade
NVS,NVS:US,BBG000LYF3S8,"Better Buy: Celldex Therapeutics, Inc. vs. Juno Therapeutics",2017-07-19 12:03:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DAq2yLLqSiI/better-buy-celldex-therapeutics-inc-vs-juno-therapeutics-cm817864,Celldex Therapeutics NASDAQ CLDX and Juno Therapeutics NASDAQ JUNO are both once promising clinical stage biotechs that have fallen on extremely hard times of late Over the past two and half years for example these former stars have each lost a staggering amount of
NVS,NVS:US,BBG000LYF3S8,Poor test results for Roche cloud growth prospects,2017-07-19 11:33:27 +0000,https://finance.yahoo.com/news/poor-test-results-roche-cloud-105119905.html?.tsrc=rss,"A run of disappointing drug  trials at Roche has left analysts suggesting the view  from its new 41-storey office building in Basel has become more  clouded, with little chance of management now upgrading its  growth forecast next week, when it reports first-half earnings.  ""Their impact in the second half might limit Roche's chances  of upgrading 2017 guidance,"" he said."
NVS,NVS:US,BBG000LYF3S8,Puma's (PBYI) Breast Cancer Drug Neratinib Gets FDA Approval,2017-07-19 00:02:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xaMjkjRGb40/pumas-pbyi-breast-cancer-drug-neratinib-gets-fda-approval-cm817798,Puma Biotechnology Inc PBYI shares rose more than 7 in after hours trading on Monday after the company announced that the FDA has approved of its lead breast cancer candidate neratinib Puma Biotech expects to make the drug commercially available in September under the brand name
NVS,NVS:US,BBG000LYF3S8,Novartis AG (ADR) (NVS) Stock Pops on Solid Q2 Earnings,2017-07-18 22:02:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NRu4czkdhlE/novartis-ag-adr-nvs-stock-pops-on-solid-q2-earnings-cm817779,InvestorPlace Stock Market News Stock Advice amp Trading Tips Novartis AG ADR NYSE NVS stock got a boost on Tuesday with the release of its earnings report for the second quarter of 2017 Source Shutterstock In its earnings report for the second quarter of
NVS,NVS:US,BBG000LYF3S8,Novartis beats 2Q profit forecasts,2017-07-18 20:47:05 +0000,https://finance.yahoo.com/news/novartis-beats-2q-profit-forecasts-104309205.html?.tsrc=rss,"The Basel, Switzerland-based company said it had profit of 83 cents per share. Earnings, adjusted for non-recurring costs, came to $1.21 per share. The results topped Wall Street expectations. The average ..."
NVS,NVS:US,BBG000LYF3S8,These 2 Drug Giants In Buy Range Just Beat Earnings Views,2017-07-18 20:16:52 +0000,http://finance.yahoo.com/r/6344fe91-679f-3ff1-a7bd-fccb051748d0/novartis-tops-earnings-views-dows-johnson-johnson-on-tap?src=A00220&yptr=yahoo&.tsrc=rss,Novartis reported smaller earnings and revenue declines for Q2 than expected. Johnson & Johnson topped on earnings but fell just shy on revenue.
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis Looks Attractive; Eye-Care Unit Sees Upside,2017-07-18 20:16:00 +0000,http://finance.yahoo.com/r/423675c2-ef77-3175-9500-d296fbd17909/novartis-looks-attractive-eye-care-unit-sees-upside-1500408973?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"All eyes were on Novartis (NVS) Tuesday morning when the Swiss drug maker announced second-quarter results.  The results were a sight for sore eyes, particularly for Novartis’ eye-care business, Alcon.  Novartis earned $1.22 a share, beating the Street’s $1.18 consensus estimate."
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis sales buoyed by recovery in eyecare unit,2017-07-18 19:30:40 +0000,"http://finance.yahoo.com/r/00e3d867-0a33-3933-aaf0-e7860f6867d7/4451deac-6bad-11e7-b9c7-15af748b60d0,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss",Rebounding sales at Novartis's eyecare division Alcon enabled the Swiss drugmaker to beat analyst expectations for second-quarter earnings. The improvement makes it more likely that Novartis would consider ...
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis Quarterly Net Income Beats Expectations,2017-07-18 17:48:44 +0000,http://finance.yahoo.com/r/83cd9e6e-a0ef-3da2-9be2-7fe6cd83edb2/novartis-second-quarter-core-net-income-2-87-billion-beating-expectations-1500400120?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Novartis reported a slight rise in second-quarter net income, as proceeds from divestments helped offset its heavier investment into the launch of new drugs that it hopes will compensate the decline of ..."
NVS,NVS:US,BBG000LYF3S8,Novartis AG (ADR) (NVS) Stock Pops on Solid Q2 Earnings,2017-07-18 17:30:18 +0000,https://finance.yahoo.com/news/novartis-ag-adr-nvs-stock-173018488.html?.tsrc=rss,"InvestorPlace - Stock Market News, Stock Advice &#38; Trading Tips"
NVS,NVS:US,BBG000LYF3S8,"Ligand Signs Agreement with Amgen, Grants Rights to Captisol",2017-07-18 17:04:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gr4KXZBVDuw/ligand-signs-agreement-with-amgen-grants-rights-to-captisol-cm817609,Ligand Pharmaceuticals Incorporated LGND announced that it has signed a commercial license and supply agreement with Amgen Inc AMGN Per the deal Amgen was granted exclusive worldwide rights to use Ligand s Captisol technology for the development of its pipeline candidate AMG 330 for a
NVS,NVS:US,BBG000LYF3S8,"Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure",2017-07-18 16:08:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lfqMoLGWZdw/novartis-tops-q2-earnings-sandoz-faces-pricing-pressure-cm817560,Novartis AG NVS reported second quarter 2017 core earnings of 1 22 per share beating the Zacks Consensus Estimate of 1 16 but the recorded figure was a penny lower than the year ago figure of 1 23 Revenues declined 2 to 12 2 billion as volume growth was offset by the negative impact
NVS,NVS:US,BBG000LYF3S8,Analyst Ratings and Recommendations for Novartis Post 2Q17,2017-07-18 14:37:48 +0000,http://finance.yahoo.com/r/00de6b56-0f90-3b4f-96db-2f25e3dbc996/analyst-ratings-and-recommendations-for-novartis-post-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"For 2Q17, analysts are estimating EPS of $1.18 for Novartis (NVS) on revenues of $12.3 billion."
NVS,NVS:US,BBG000LYF3S8,5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote,2017-07-18 14:08:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pKNcNeEiq00/5-car-t-stocks-in-focus-as-nvs-drug-wins-fda-advisory-panel-vote-cm817351,The CAR T chimeric antigen receptor T cells space got a significant boost recently with an FDA advisory panel issuing a positive recommendation for an experimental treatment in this corner of the immune oncology market Last week Swiss pharma giant Novartis NVS experimental CAR T
NVS,NVS:US,BBG000LYF3S8,"Novartis Tops Q2 Earnings, Sandoz Faces Pricing Pressure",2017-07-18 13:46:01 +0000,https://finance.yahoo.com/news/novartis-tops-q2-earnings-sandoz-134601418.html?.tsrc=rss,"Novartis AG (NVS) reported second-quarter 2017 core earnings of $1.22 per share, beating the Zacks Consensus Estimate of $1.16 but the recorded figure was a penny lower than the year-ago figure of $1.23."
NVS,NVS:US,BBG000LYF3S8,"Novartis’s 2Q17 Estimates: Alcon, the Eye Care Business",2017-07-18 13:08:13 +0000,http://finance.yahoo.com/r/fdf991b2-ca55-3f3b-b27b-41666ecc5439/novartiss-2q17-estimates-alcon-the-eye-care-business?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Analysts expect Novartis's 2Q17 revenues for Alcon to increase operationally following strong sales of products from the vision care franchise.
NVS,NVS:US,BBG000LYF3S8,JNJ Named Top 25 SAFE Dividend Stock Increasing Payments For Decades,2017-07-18 13:02:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WSHlEDD7eeQ/jnj-named-top-25-safe-dividend-stock-increasing-payments-for-decades-cm817279,Johnson amp Johnson Symbol JNJ has been named to the Dividend Channel S A F E 25 list signifying a stock with above average DividendRank statistics including a strong 2 5 yield as well as a superb track record of at least two decades of dividend growth according to the
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Lower After Afternoon Sell-Off,2017-07-18 12:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W7t_ttaY0a4/the-swiss-stock-market-finished-lower-after-afternoon-selloff-20170718-00995,The Swiss Stock Market Finished Lower After Afternoon Sell-Off
NVS,NVS:US,BBG000LYF3S8,5 CAR-T Stocks in Focus as NVS Drug Wins FDA Advisory Panel Vote,2017-07-18 12:10:12 +0000,https://finance.yahoo.com/news/5-car-t-stocks-focus-121012021.html?.tsrc=rss,It&apos;s time to look at these 5 CAR-T stocks given the interest generated by a positive FDA advisory panel vote for Novartis&apos; (NVS) experimental CAR-T treatment.
NVS,NVS:US,BBG000LYF3S8,European Markets Dropped After Euro Strengthened,2017-07-18 11:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6XyM5OFjN2I/european-markets-dropped-after-euro-strengthened-20170718-00930,European Markets Dropped After Euro Strengthened
NVS,NVS:US,BBG000LYF3S8,Novartis’s 2Q17 Estimates: How Sandoz Might Perform,2017-07-18 11:39:23 +0000,http://finance.yahoo.com/r/8729f4d6-d5db-36c3-b0cb-87bb43266651/novartiss-2q17-estimates-how-sandoz-might-perform?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Revenues for Sandoz are expected to report operational growth in 2Q17 following an increased demand for biopharmaceuticals.
NVS,NVS:US,BBG000LYF3S8,"Earnings Reaction History: Novartis AG, 42.9% Follow-Through Indicator, 1.5% Sensitive",2017-07-18 11:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/07-zqw-cj0A/earnings-reaction-history-novartis-ag-429-follow-through-indicator-15-sensitive-cm817260,Expected Earnings Release 07 18 2017 PremarketExpected Earnings Release 07 18 2017 Premarket Avg Extended Hours Dollar Volume 1 829 728Avg Extended Hours Dollar Volume 1 829 728 Novartis AG NVS is due to issue its quarterly earnings report in the upcoming extended hours
NVS,NVS:US,BBG000LYF3S8,5 Things You Must Know Before the Market Opens Tuesday,2017-07-18 10:51:00 +0000,http://finance.yahoo.com/r/b71de347-12eb-33fd-b8fa-df7b18835aa9/5-things-you-must-know-before-the-market-opens-tuesday.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"U.S. stock futures are slightly higher on Tuesday, following the collapse of healthcare overhaul in the U.S."
NVS,NVS:US,BBG000LYF3S8,European Stocks Drift Lower; Dollar Slumps Further After Healthcare Bill Collapse,2017-07-18 08:20:00 +0000,http://finance.yahoo.com/r/4123847d-0d7e-3f40-be60-9cb0f8accde5/european-stocks-drift-lower-dollar-slumps-further-after-healthcare-bill-collapse.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,European stocks are firmly on the back foot.
NVS,NVS:US,BBG000LYF3S8,"Novartis Tops Q2 Earnings Estimate, Boosts Alcon Full Year Sales Guidance",2017-07-18 07:32:00 +0000,http://finance.yahoo.com/r/8a54ba27-9578-3fa5-a9cd-2b7444725d67/novartis-tops-q2-earnings-estimate-boosts-alcon-full-year-sales-guidance.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Novartis sees stronger full-year Alcon sales
NVS,NVS:US,BBG000LYF3S8,Novartis sees Alcon recovery opening door to spin-off IPO,2017-07-18 07:27:43 +0000,https://finance.yahoo.com/news/novartis-sees-alcon-recovery-opening-072743583.html?.tsrc=rss,"Novartis long-suffering  Alcon eye care unit's sales growth accelerated in the second  quarter, boosting options for the business including a possible  disposal, Chief Executive Joe Jimenez said on Tuesday.  Alcon sales rose 1 percent to $1.5 billion, including  intraocular lenses that grew for the first time in the second  quarter since 2014.  Novartis has been reviewing Alcon for a possible disposal,  with an update slated for this year."
NVS,NVS:US,BBG000LYF3S8,Novartis' CEO Says Getting Momentum Back in Alcon Unit,2017-07-18 07:18:04 +0000,https://finance.yahoo.com/video/novartis-ceo-says-getting-momentum-071804630.html?.tsrc=rss,"Jul.18 -- Joe Jimenez, chief executive officer at Novartis, discusses second-quarter earnings, the revival at its Alcon eye-care division, the possible IPO for the Alcon unit, their joint venture with Glaxo and drug pricing in the U.S. He speaks on &quot;Bloomberg Daybreak: Europe.&quot;"
NVS,NVS:US,BBG000LYF3S8,"Novartis net profit grows 10 percent in Q2, but sales dip",2017-07-18 07:11:06 +0000,http://finance.yahoo.com/r/14ceabb6-82f4-399e-bd80-2c48cf28834d/novartis-net-profit-grows-10-071106591.html?.tsrc=rss,"BERLIN (AP) — Swiss pharmaceutical company Novartis says its net profit rose 10 percent in the second quarter, helped by gains from divestments."
NVS,NVS:US,BBG000LYF3S8,European Shares Slide Amid Mixed Earnings,2017-07-18 06:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TxEmSWlNkDU/european-shares-slide-amid-mixed-earnings-20170718-00205,European Shares Slide Amid Mixed Earnings
NVS,NVS:US,BBG000LYF3S8,Novartis Points to Early Signs of Rebound at Alcon Eye-Care Unit,2017-07-18 05:23:19 +0000,http://finance.yahoo.com/r/d5bf6489-31c1-3ed9-a230-c34b05fda1bf/novartis-second-quarter-profit-drops-less-than-analysts-expected?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Novartis AG Chief Executive Officer Joe Jimenez pointed to early signs of a revival at the Swiss drugmaker’s Alcon eye-care division, which will strengthen his hand as he considers an exit from the ailing ..."
NVS,NVS:US,BBG000LYF3S8,Our M&A strategy focused on bolt-on acquisitions: Novarti...,2017-07-18 05:07:00 +0000,https://finance.yahoo.com/video/m-strategy-focused-bolt-acquisitions-050700511.html?.tsrc=rss,"Novartis CEO Joseph Jimenez talks about M&A strategy and how the business is performing, in light of its recent earnings report."
NVS,NVS:US,BBG000LYF3S8,Novartis CEO: About to enter next growth phase,2017-07-18 05:07:00 +0000,https://finance.yahoo.com/video/novartis-ceo-enter-next-growth-050700775.html?.tsrc=rss,Novartis CEO Joseph Jimenez talks about the company’s latest drug CTL019 and expectations for it and its developments going forward.
NVS,NVS:US,BBG000LYF3S8,Novartis Second Quarter Core EPS Beats Estimates,2017-07-18 05:00:39 +0000,http://finance.yahoo.com/r/64a93eca-aecd-3f6b-90f1-526b971d1dbf/novartis-second-quarter-core-eps-beats-estimates?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Novartis reported core earnings per share for the second quarter that beat the average analyst estimate.
NVS,NVS:US,BBG000LYF3S8,Europe opens lower on US health-care gridlock; Novartis r...,2017-07-18 04:58:00 +0000,https://finance.yahoo.com/video/europe-opens-lower-us-health-045800549.html?.tsrc=rss,Bourses in Europe open lower on Tuesday with global sentiment dampened by a gridlock in U.S. politics over health-care reform.
NVS,NVS:US,BBG000LYF3S8,"Continuing to innovate, launch new drugs in US: Novartis ...",2017-07-18 04:58:00 +0000,https://finance.yahoo.com/video/continuing-innovate-launch-drugs-us-045800037.html?.tsrc=rss,Novartis CEO Joseph Jimenez tells CNBC why developments of the U.S. health bill do not really have an impact on the pharmaceutical company.
NVS,NVS:US,BBG000LYF3S8,"Novartis Q2 Profit Rises, Net Sales Down; Backs FY17 View",2017-07-18 01:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OJnKTDxRyWo/novartis-q2-profit-rises-net-sales-down-backs-fy17-view-20170718-00036,"Novartis Q2 Profit Rises, Net Sales Down; Backs FY17 View"
NVS,NVS:US,BBG000LYF3S8,Novartis Q2 Profit Rises; Confirms Full Year Guidance,2017-07-18 01:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jssajHXYqrM/novartis-q2-profit-rises-confirms-full-year-guidance-20170718-00028,Novartis Q2 Profit Rises; Confirms Full Year Guidance
NVS,NVS:US,BBG000LYF3S8,"Pre-Market Earnings Report for July 18, 2017 :  JNJ, BAC, UNH, GS, LMT, PLD, NVS, PGR, AMTD, ERIC, CMA, HOG",2017-07-17 20:16:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FnGf_VrobdM/pre-market-earnings-report-for-july-18-2017-jnj-bac-unh-gs-lmt-pld-nvs-pgr-amtd-eric-cma-hog-cm817145,The following companies are expected to report earnings prior to market open on 07 18 2017 Visit our Earnings Calendar for a full list of expected earnings releases Johnson amp Johnson JNJ is reporting for the quarter ending June 30 2017 The large
NVS,NVS:US,BBG000LYF3S8,Novartis’s 2Q17 Estimates: Innovative Medicines Segment,2017-07-17 17:35:43 +0000,http://finance.yahoo.com/r/c7d7cdc2-dcb1-30ff-9b50-ae12563624ca/novartiss-2q17-estimates-innovative-medicines-segment?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The overall contribution of Novartis's (NVS) Innovative Medicines segment is ~67.0% of its total revenues.
NVS,NVS:US,BBG000LYF3S8,"Notable ETF Inflow Detected - VEA, NSRGY, NVS, TM",2017-07-17 16:46:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N-e7Zh0GVF0/notable-etf-inflow-detected-vea-nsrgy-nvs-tm-cm816972,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 126 3 million dollar inflow that s a 0 2 increase week over week
NVS,NVS:US,BBG000LYF3S8,Analysts Expect Novartis’s Revenues to Fall in 2Q17,2017-07-17 16:05:52 +0000,http://finance.yahoo.com/r/fc7d7571-c80a-3337-ad93-40acbb18f59d/analysts-expect-novartiss-revenues-to-fall-in-2q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Analysts expect Novartis's (NVS) revenues to fall ~1.6% to $12.3 billion in 2Q17 due to the effects of the acquisition and divestiture of some of its products.
NVS,NVS:US,BBG000LYF3S8,4 Sell-Ranked Drug Stocks to Avoid Ahead of Q2 Earnings,2017-07-17 15:54:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8eXeQBNoh8k/4-sell-ranked-drug-stocks-to-avoid-ahead-of-q2-earnings-cm816931,Earnings season for the biotech and pharma sector kicks off this week with industry bellwether Johnson amp Johnson JNJ reporting second quarter results tomorrow before the market opens Swiss pharma giant Novartis NVS which was in the news recently related to a favorable FDA advisory
NVS,NVS:US,BBG000LYF3S8,How Bayer Is Creating Value through Innovation,2017-07-17 15:26:59 +0000,http://finance.yahoo.com/r/2508cf97-4943-33cb-a49a-ceaac095fa85/bayer-creating-value-innovation?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Bayer owned ~51,000 valid patent applications and patents relating to ~5,000 protected inventions worldwide."
NVS,NVS:US,BBG000LYF3S8,How Bristol-Meyers Squibb Has Benefited from Intangible Assets,2017-07-17 15:26:54 +0000,http://finance.yahoo.com/r/8e730d71-3e24-3f9c-9a0f-9f9008707a54/bristol-meyers-benefited-intangible-assets?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Bristol-Meyers Squibb considers its people to be its competitive advantage, and it plans to build long-term, sustainable growth through innovation."
NVS,NVS:US,BBG000LYF3S8,Novartis’s 2Q17 Earnings: Analyst Estimates,2017-07-17 14:27:26 +0000,http://finance.yahoo.com/r/11f2826d-df52-3aef-bf3c-16cc4e9eb155/novartiss-2q17-earnings-analyst-estimates?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis is set to release its 2Q17 earnings on July 18, 2017. Analysts estimate EPS (earnings per share) of $1.18 and revenues of $12.3 billion."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Inched Higher In Cautious Trade,2017-07-17 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z6GJzDgJ2eI/the-swiss-stock-market-inched-higher-in-cautious-trade-20170717-00841,The Swiss Stock Market Inched Higher In Cautious Trade
NVS,NVS:US,BBG000LYF3S8,Prima BioMed To Get 2nd Milestone Payment From Novartis For IMP701 Program,2017-07-16 23:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mlOyAmW35u8/prima-biomed-to-get-2nd-milestone-payment-from-novartis-for-imp701-program-20170716-00075,Prima BioMed To Get 2nd Milestone Payment From Novartis For IMP701 Program
NVS,NVS:US,BBG000LYF3S8,Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here's Why It Doesn't Matter,2017-07-16 20:45:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pI0eIW1eHvs/pfizer-is-set-to-lose-its-no-1-spot-among-drugmakers-heres-why-it-doesnt-matter-cm816611,Pfizer NYSE PFE stands at the top of the mountain when it comes to prescription drug sales Last year the big pharma company made 45 9 billion from prescription drugs well ahead of runners up Novartis NYSE NVS and Roche NASDAQOTH RHHBY However Pfizer
NVS,NVS:US,BBG000LYF3S8,Pfizer Is Set to Lose Its No. 1 Spot Among Drugmakers: Here&apos;s Why It Doesn&apos;t Matter,2017-07-16 19:03:00 +0000,http://finance.yahoo.com/r/15e4a5a2-7249-3d89-9075-298cd19957e3/pfizer-is-set-to-lose-its-no-1-spot-among-drugmake.aspx?yptr=yahoo&.tsrc=rss,Novartis could take the top spot from Pfizer in prescription-drug sales by 2022. So what?
NVS,NVS:US,BBG000LYF3S8,Novartis Confirms Positive 5 Year Efficacy And Safety Results For Cosentyx,2017-07-16 13:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/or1pguljS4c/novartis-confirms-positive-5-year-efficacy-and-safety-results-for-cosentyx-20170716-00005,Novartis Confirms Positive 5 Year Efficacy And Safety Results For Cosentyx
NVS,NVS:US,BBG000LYF3S8,Is It Too Late to Get In on This Millionaire-Maker Stock?,2017-07-16 12:45:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qk6Tu3lmlOQ/is-it-too-late-to-get-in-on-this-millionaire-maker-stock-cm816577,Corcept Therapeutics NASDAQ CORT is one hot biotech stock no matter how you look at it Shares have nearly quintupled in value in just three years So far in 2017 Corcept stock is up around 70 Those kinds of returns could make millionaires out of some investors if the
NVS,NVS:US,BBG000LYF3S8,"Cascade Investment Advisors, Inc. Buys Qualcomm Inc, Sensata Technologies Holding N.V. ...",2017-07-15 18:45:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JAYULvFWu88/cascade-investment-advisors-inc-buys-qualcomm-inc-sensata-technologies-holding-nv-cm816544,Cascade Investment Advisors Inc New Purchases ST VMW TROW SEDG CCL NCLH CPSI HIMX NOK NOC Added Positions QCOM GILD XOM KR WFC NUE DNOW SNI IBM PK Reduced Positions KSS LXP MAT ECA WY VZ MSFT TUP ZBRA AAPL Sold Out FLS
NVS,NVS:US,BBG000LYF3S8,Why You're Smart to Buy Vertex Pharmaceuticals Stock,2017-07-15 17:44:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DV_ZdeHofnI/why-youre-smart-to-buy-vertex-pharmaceuticals-stock-cm816533,You might look at Vertex Pharmaceuticals NASDAQ VRTX stock and shake your head at its valuation After soaring more than 70 so far in 2017 shares of the biotech now trade at a whopping 180 times trailing 12 month earnings That s the kind of price tag that would cause
NVS,NVS:US,BBG000LYF3S8,Why You&apos;re Smart to Buy Vertex Pharmaceuticals Stock,2017-07-15 16:03:00 +0000,http://finance.yahoo.com/r/5b1a79b6-9e38-35e1-a484-f324b89ab35a/why-youre-smart-to-buy-vertex-pharmaceuticals-stoc.aspx?yptr=yahoo&.tsrc=rss,Forget the sky-high valuation. Vertex Pharmaceuticals stock is a smart pick.
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 07/14/2017: NVS,CTIC,MYND",2017-07-14 20:45:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tOn9t_eEmkk/health-care-sector-update-for-07142017-nvscticmynd-cm816370,Top Health Care StocksTop Health Care Stocks JNJ 0 67 JNJ 0 67 PFE 0 63 PFE 0 63 ABT 1 85 ABT 1 85 MRK 0 37 MRK 0 37 AMGN 1 40 AMGN 1 40 Health care stocks continued to rise with the NYSE Health Care Index climbing more than 0 7 while shares of health care companies in the S amp
NVS,NVS:US,BBG000LYF3S8,J&J (JNJ) Gets FDA Nod for Psoriasis Drug -- Guselkumab,2017-07-14 16:46:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M7f5uAAlLKY/jj-jnj-gets-fda-nod-for-psoriasis-drug-guselkumab-cm816222,Johnson amp Johnson JNJ a healthcare bellwether announced that the FDA has approved its pipeline candidate guselkumab for the treatment of moderate to severe plaque psoriasis The drug will be marketed by the trade name of Tremfya The drug was approved under an accelerated
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.",2017-07-14 13:50:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QAofaLZsNT0/pharma-stock-roundup-fda-panel-votes-for-novartis-car-t-drug-sny-to-buy-vaccines-co-cm816035,It was a busy week for the FDA s Oncologic Drugs Advisory Committee ODAC which reviewed several experimental treatments this week including Novartis NVS CAR T cell drug Meanwhile French pharma giant Sanofi SNY announced it will be acquiring a vaccines company Recap of the Week s
NVS,NVS:US,BBG000LYF3S8,Can Novartis (NVS) Spring a Surprise This Earnings Season?,2017-07-14 13:49:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LFC_W2T1xC4/can-novartis-nvs-spring-a-surprise-this-earnings-season-cm816112,Swiss pharmaceutical company Novartis AG NVS is scheduled to report second quarter 2017 results on Jul 18 A look at Novartis share price movement year to date shows that the stock has outperformed the Zacks classified Large Cap Pharma industry Its shares have rallied 13 3 compared with
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed Despite Weakness Among Financial Stocks,2017-07-14 12:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XIbHwGXAJ-I/the-swiss-stock-market-climbed-despite-weakness-among-financial-stocks-20170714-00626,The Swiss Stock Market Climbed Despite Weakness Among Financial Stocks
NVS,NVS:US,BBG000LYF3S8,"Professional Advisory Services Inc Buys Facebook Inc, TJX Inc, US Bancorp, Sells Verizon ...",2017-07-14 12:45:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4tFfASWHvTg/professional-advisory-services-inc-buys-facebook-inc-tjx-inc-us-bancorp-sells-verizon-cm816013,Professional Advisory Services Inc New Purchases FB ABBV Added Positions TJX USB UPS NKE VTR ESRX COF XLE BBT DG Reduced Positions CERN UTX PYPL PCLN SRCL SYK GOOG RMD NVS STT Sold Out VZ INTC PAYX AAPL New Purchases
NVS,NVS:US,BBG000LYF3S8,Can Novartis (NVS) Spring a Surprise This Earnings Season?,2017-07-14 12:18:12 +0000,https://finance.yahoo.com/news/novartis-nvs-spring-surprise-earnings-121812801.html?.tsrc=rss,Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report second-quarter 2017 results on Jul 18.
NVS,NVS:US,BBG000LYF3S8,"Novartis stocks drug cabinet with ""Big-3"" arthritis blockbusters",2017-07-14 11:44:30 +0000,https://finance.yahoo.com/news/novartis-stocks-drug-cabinet-big-114430840.html?.tsrc=rss,"Switzerland's Novartis  is stocking up cheaper versions of the world's top-selling  arthritis medicines, hoping a broad portfolio gives it an edge  on rivals with narrower offerings.  Novartis's near-copy of Amgen's Enbrel won European  approval last month."
NVS,NVS:US,BBG000LYF3S8,[$$] Gormley's Take: Racing Against Time to Defeat Cancer,2017-07-14 11:30:10 +0000,http://finance.yahoo.com/r/30386088-d5c8-34cc-a95b-e8232b74bddc/gormleys-take-racing-against-time-to-defeat-cancer-1500031802?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"CEOs don’t usually root for a competing company, but that’s precisely what Kite Pharma Inc.’s Arie Belldegrun did this week."
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: FDA Panel Votes for Novartis CAR-T Drug, SNY to Buy Vaccines Co.",2017-07-14 11:28:11 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-fda-panel-112811804.html?.tsrc=rss,Novartis (NVS) was in the limelight this week with its CAR-T cell therapy receiving the support of an FDA advisory panel.
NVS,NVS:US,BBG000LYF3S8,"Abbott, Novartis Show Promise Amid Healthcare Decline, Tiffany Lands Much Needed Boost -ICYMI Thurs.",2017-07-14 03:47:00 +0000,http://finance.yahoo.com/r/7d88895a-bc16-3373-be1e-667d85d18b30/snap-in-danger-of-missing-out-abbott-novartis-show-promise-icymi-thursday.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here's what you need to know now.
NVS,NVS:US,BBG000LYF3S8,A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared,2017-07-14 00:46:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0Kn63CJBHf4/a-new-cancer-treatment-is-on-the-way-and-cancer-better-be-scared-cm815937,A key FDA advisory committee voted unanimously on Wednesday to recommend approval of Novartis NYSE NVS ground breaking drug for pediatric and young adult B cell acute lymphoblastic leukemia or ALL The recommendation clears the way for a formal FDA green light and it begins a
NVS,NVS:US,BBG000LYF3S8,A New Cancer Treatment Is on the Way -- and Cancer Better Be Scared,2017-07-13 23:31:00 +0000,http://finance.yahoo.com/r/db7bcfe5-0d4c-3c65-8dda-182573e5e332/a-new-cancer-treatment-is-on-the-way-and-cancer-be.aspx?yptr=yahoo&.tsrc=rss,Reprogramming a cancer patient&apos;s immune system to find and destroy cancer just got a step closer to FDA approval.
NVS,NVS:US,BBG000LYF3S8,Can ImmunoGen's Lead Pipeline Cancer Candidate Boost Growth?,2017-07-13 22:48:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uZgTgpaHS0k/can-immunogens-lead-pipeline-cancer-candidate-boost-growth-cm815898,On Jul 12 2017 we issued an updated report on ImmunoGen Inc IMGN ImmunoGen is a development stage biotechnology company focused on developing targeted cancer therapeutics using its proprietary antibody drug conjugate ADC technology The company s shares have significantly
NVS,NVS:US,BBG000LYF3S8,Novartis CAR-T Therapy Drug Recommended by FDA Panel,2017-07-13 22:47:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X9FqoH3jG_I/novartis-car-t-therapy-drug-recommended-by-fda-panel-cm815892,Novartis AG NVS announced that the FDA Oncologic Drugs Advisory Committee ODAC has unanimously 10 0 recommended the approval of immunocellular therapy candidate CTL019 tisagenlecleucel CTL019 an investigational chimeric antigen receptor T cell CAR T therapy is being evaluated for
NVS,NVS:US,BBG000LYF3S8,Novartis CAR-T Therapy Drug Recommended by FDA Panel,2017-07-13 20:49:08 +0000,https://finance.yahoo.com/news/novartis-car-t-therapy-drug-204908784.html?.tsrc=rss,Novartis AG (NVS) announced that the FDA Oncologic Drugs Advisory Committee (ODAC) has unanimously (10-0) recommended the approval of immunocellular therapy candidate CTL019 (tisagenlecleucel).
NVS,NVS:US,BBG000LYF3S8,[$$] 3 Drug Stocks That Can Ride Novartis' Coattails,2017-07-13 20:49:00 +0000,http://finance.yahoo.com/r/fe861c52-51bc-30d3-874d-e8f465d76261/3-drug-stocks-that-can-ride-novartis-coattails-1499978962?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,A first-of-its kind cancer therapy by the Swiss drugmaker Novartis is one step closer to hitting the market after a panel of Food and Drug Administration experts unanimously voted Wednesday to recommend regulatory approval.  The drug from Novartis (NVS) could drastically advance the treatment of children with an aggressive form of leukemia.  It could also provide the Swiss drugmaker with a new revenue stream.
NVS,NVS:US,BBG000LYF3S8,Can ImmunoGen&apos;s Lead Pipeline Cancer Candidate Boost Growth?,2017-07-13 20:38:08 +0000,https://finance.yahoo.com/news/immunogen-apos-lead-pipeline-cancer-203808856.html?.tsrc=rss,"On Jul 12, 2017, we issued an updated report on ImmunoGen, Inc. (IMGN)."
NVS,NVS:US,BBG000LYF3S8,How Novartis&apos; FDA Win In Cancer Also Could Be A Boon For Its Rivals,2017-07-13 20:24:58 +0000,http://finance.yahoo.com/r/a6eb8a57-0a30-3afe-9db3-4b2e6e0a6220/how-novartis-fda-win-in-cancer-also-could-be-a-boon-for-its-rivals?src=A00220&yptr=yahoo&.tsrc=rss,"Novartis grabbed a key FDA approval Wednesday, but Kite ultimately could benefit more from regulators&apos; excitement over an emerging class of cancer drugs."
NVS,NVS:US,BBG000LYF3S8,CAR-Ts Clear One Roadblock But Face Many More,2017-07-13 18:00:10 +0000,http://finance.yahoo.com/r/c1e6dbbd-04c5-37b1-8052-8aa05b5fc9cd/novartis-car-t-gets-fda-panel-nod-but-the-class-has-more-hurdles?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&trackingId=yhoo.headline&yptr=yahoo&.tsrc=rss,Novartis wins over an FDA panel but the road to commercial viability is long.
NVS,NVS:US,BBG000LYF3S8,Is Juno Therapeutics Stock Still a Strong Buy?,2017-07-13 15:51:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h8TTYLEIinc/is-juno-therapeutics-stock-still-a-strong-buy-cm815608,What happened Shares of the clinical stage biotech Juno Therapeutics NASDAQ JUNO rose by a healthy 22 last month according to S amp P Global Market Intelligence The drugmaker s shares seemed to get a lift from two different catalysts during the month First off the
NVS,NVS:US,BBG000LYF3S8,"Target jumps on outlook, Snap gets upgraded to buy, Yandex soars on Uber partnership",2017-07-13 14:33:42 +0000,https://finance.yahoo.com/video/target-jumps-outlook-snap-gets-143342900.html?.tsrc=rss,"Target, Delta, Snap, Yandex and Novartis are among the stocks to watch."
NVS,NVS:US,BBG000LYF3S8,"Target jumps on outlook, Snap gets upgraded to buy, Yandex soars on Uber partnership",2017-07-13 14:33:20 +0000,https://finance.yahoo.com/news/target-jumps-outlook-snap-gets-upgraded-buy-yandex-soars-uber-partnership-143320153.html?.tsrc=rss,"Target, Delta, Snap, Yandex and Novartis are among the stocks to watch."
NVS,NVS:US,BBG000LYF3S8,Is Juno Therapeutics Stock Still a Strong Buy?,2017-07-13 14:30:00 +0000,http://finance.yahoo.com/r/93549107-b17b-3826-9285-d0957740d649/is-juno-therapeutics-stock-still-a-strong-buy.aspx?yptr=yahoo&.tsrc=rss,Investors are piling into this speculative biotech stock -- but is it a buy after rallying 22% in June?
NVS,NVS:US,BBG000LYF3S8,"Novartis Passes FDA Blood Cancer Panel 'With Flying Colors,' Gives Positive Read Through For Others",2017-07-13 13:48:00 +0000,http://finance.yahoo.com/r/ea9cdc8e-1355-328a-a984-c7171f454cff/recommendation-for-novartis-may-give-new-hope-for-some-cancer-patients.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The company received a thumbs up from an FDA advisory committee for its CAR-T therapy to treat leukemia in children and young adults.
NVS,NVS:US,BBG000LYF3S8,Novartis FDA Panel Approval: 'Pharma Innovation At Its Best',2017-07-13 13:47:00 +0000,http://finance.yahoo.com/r/3d05cf3f-75a1-3627-88db-8676338af69c/novartis-fda-panel-approval-pharma-innovation-at-its-best-1499953655?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Although the FDA doesn't have to follow its panels' recommendations, it usually does.  The news is important for the sector, as Novartis and others have been racing to get Chimeric Antigen Receptor T-Cell Therapy (CAR-T) gene treatments to market.  Wells Fargo's David Maris writes that with the Novartis win, ""the best of the industry was in full display."" The groundbreaking cancer treatment was praised by panel members, one of whom said it was ""the most exciting thing I've seen in my lifetime.'' The FDA is expected to make a final ruling in October, and in the interim, Maris expects that ""the approval of CAR-T therapy will be judged as a true watershed event in medical innovation."" More from his note:  CAR-T treatment is a new, personalized treatment which requires taking a patient's own cells, removing them from the body, reengineering them for immunotherapy, and placing them back in the body."
NVS,NVS:US,BBG000LYF3S8,"Rally resumes, Target shares rise and Janet Yellen returns to Capitol Hill",2017-07-13 13:19:46 +0000,https://finance.yahoo.com/news/rally-resumes-target-shares-rise-janet-yellen-returns-capitol-hill-131946851.html?.tsrc=rss,"Wall Street is seeing green again as Fed chair Janet Yellen returns to Capitol Hill after helping spark a rally Wednesday with comments investors took as dovish on interest rates.  Stock futures are signaling gains at the open with the Dow Industrials eyeing another record high. Yahoo Finance’s Alexis Christoforous, Myles Udland, Dan Howley and Dan Roberts discuss the top stories of the day, including Target (TGT) boosting its second-quarter forecast, some rare good news for a traditional retailer."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back Following Yesterday's Rally,2017-07-13 12:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U4zYox1rgL4/the-swiss-stock-market-pulled-back-following-yesterdays-rally-20170713-00927,The Swiss Stock Market Pulled Back Following Yesterday's Rally
NVS,NVS:US,BBG000LYF3S8,Alnylam (ALNY) Upgraded to Buy on Solid Pipeline Growth,2017-07-13 12:45:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PQ3oFvEicfY/alnylam-alny-upgraded-to-buy-on-solid-pipeline-growth-cm815393,On Jul 11 Alnylam Pharmaceuticals Inc ALNY was upgraded to a Zacks Rank 2 Buy Why the Upgrade Alnylam s key pipeline candidate Fitusiran aRNA interference RNAi therapeutic being developed for the treatment of hemophilia A and B and rare bleeding disorders RBD has
NVS,NVS:US,BBG000LYF3S8,FDA panel backs Novartis cancer drug,2017-07-13 10:49:00 +0000,https://finance.yahoo.com/video/fda-panel-backs-novartis-cancer-104900549.html?.tsrc=rss,An FDA advisory panel has unanimously recommended approval of Novartis’ leukemia treatment.
NVS,NVS:US,BBG000LYF3S8,"T-cell cancer therapy holds promise, longer-term results await",2017-07-13 10:00:00 +0000,https://finance.yahoo.com/news/t-cell-cancer-therapy-holds-100000858.html?.tsrc=rss,A novel cell treatment that saved the  life of 9-year-old Austin Schuetz was given the green light by  U.S. regulatory advisers on Wednesday and doctors hope it can  save the lives of more children with the most common type of  childhood cancer.  An advisory committee to the U.S. Food and Drug  Administration voted unanimously to recommend approval of  Novartis AG's tisagenlecleucel for treating B-cell  acute lymphoblastic leukemia (ALL) in children and young adults  who relapsed or failed chemotherapy.  The FDA is not required to  follow the recommendations of its advisers but typically does  so.
NVS,NVS:US,BBG000LYF3S8,Novartis gets FDA panel approval for leukemia treatment,2017-07-13 08:05:00 +0000,https://finance.yahoo.com/video/novartis-gets-fda-panel-approval-080500889.html?.tsrc=rss,"John Rountree, managing partner at Novasecta, discusses the news that Novartis has gained FDA panel approval for a gene therapy drug to treat leukemia."
NVS,NVS:US,BBG000LYF3S8,[$$] FDA Panel Votes Unanimously to Support Leukemia Gene-Therapy Treatment,2017-07-13 04:21:39 +0000,http://finance.yahoo.com/r/66e8b68f-e666-3880-bcad-54180bc08eb6/fda-panel-considers-leukemia-gene-therapy-treatment-1499873113?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,A group of cancer experts voted unanimously to support U.S. regulatory approval for a first-of-its kind gene therapy targeting an aggressive form of leukemia in children and young adults.
NVS,NVS:US,BBG000LYF3S8,"[$$] The Price Dilemma Over a $16,000 Drug",2017-07-13 04:20:48 +0000,http://finance.yahoo.com/r/4eda832f-d03c-3404-8d7a-1deb7f625aa1/the-price-dilemma-over-a-16-000-drug-1499832421?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Novartis recently discovered that a drug it sells for a group of very rare diseases could be used to treat a much more common ailment. There is just one problem: its $16,000-per-dose price tag."
NVS,NVS:US,BBG000LYF3S8,"NVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track",2017-07-13 02:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hzBiyLUIVzY/nvs-gets-thumbs-up-two-biosimilar-candidates-to-face-fda-panel-vktx-on-track-20170713-00059,"NVS Gets Thumbs Up, Two Biosimilar Candidates To Face FDA Panel, VKTX On Track"
NVS,NVS:US,BBG000LYF3S8,A Cancer Breakthrough Near FDA Approval Has a Costly Side Effect,2017-07-12 22:01:08 +0000,http://finance.yahoo.com/r/547df2e3-9769-317e-b02b-62a62b8f8eb6/cancer-breakthrough-near-fda-approval-carries-costly-side-effect?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&trackingId=yhoo.headline&yptr=yahoo&.tsrc=rss,"A breakthrough cancer therapy that can wipe out leukemia in some deathly ill children and young adults comes with an expensive, long-lasting side effect."
NVS,NVS:US,BBG000LYF3S8,Novartis gets FDA panel recommendation for leukemia drug approval,2017-07-12 21:46:14 +0000,http://finance.yahoo.com/r/b8979828-707e-3246-b5f1-022654071ac1/Story.aspx?guid=45822426-7ED2-4FBB-983A-E0C18750593B&siteid=yhoof2&yptr=yahoo&.tsrc=rss,U.S. shares of Novartis AG rose in the extended session Wednesday after a Food and Drug Administration advisory panel unanimously recommended that the agency approve one of its cancer drugs. U.S.-traded ...
NVS,NVS:US,BBG000LYF3S8,"[$$] The Price Dilemma Over a $16,000 Drug",2017-07-12 21:44:13 +0000,http://finance.yahoo.com/r/4eda832f-d03c-3404-8d7a-1deb7f625aa1/the-price-dilemma-over-a-16-000-drug-1499832421?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Novartis recently discovered that a drug it sells for a group of very rare diseases could be used to treat a much more common ailment. There is just one problem: its $16,000-per-dose price tag."
NVS,NVS:US,BBG000LYF3S8,A cancer treatment that one expert called the 'most exciting thing I’ve seen in my lifetime' just got closer to approval,2017-07-12 21:28:00 +0000,https://finance.yahoo.com/news/revolutionary-experimental-cancer-treatment-just-192832487.html?.tsrc=rss,A US Food and Drug Administration (FDA) advisory committee just gave a critical...
NVS,NVS:US,BBG000LYF3S8,Novartis Grabs Key FDA Panel Approval Of Experimental Cancer Drug,2017-07-12 21:08:24 +0000,http://finance.yahoo.com/r/8f5f1893-2747-3ba9-8de9-374ebf7633bc/novartis-grabs-key-fda-panel-approval-of-experimental-cancer-drug?src=A00220&yptr=yahoo&.tsrc=rss,An FDA panel voted to recommended an experimental immuno-oncology treatment from Novartis Wednesday.
NVS,NVS:US,BBG000LYF3S8,FDA panel backs Novartis' pioneering new cancer gene therapy,2017-07-12 20:49:53 +0000,https://finance.yahoo.com/news/pioneering-cancer-gene-therapy-novartis-193109248.html?.tsrc=rss,"The panel unanimously recommended that the Food and Drug Administration approve the drug, tisagenlecleucel, for patients ages 3 to 25 with relapsed B-cell acute lymphoblastic leukemia (ALL), the most common form of U.S childhood cancer.  It would also advance a technique scientists have been attempting to perfect for decades and help lift the entire field of cell therapy."
NVS,NVS:US,BBG000LYF3S8,[$$] FDA Panel Votes to Support Leukemia Gene-Therapy Treatment,2017-07-12 20:24:55 +0000,http://finance.yahoo.com/r/66e8b68f-e666-3880-bcad-54180bc08eb6/fda-panel-considers-leukemia-gene-therapy-treatment-1499873113?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,A group of cancer experts voted unanimously on Wednesday to support U.S. regulatory approval for a first-of-its kind gene therapy targeting an aggressive form of leukemia that occurs in children and young ...
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis cancer drug moves step closer to approval,2017-07-12 20:21:51 +0000,"http://finance.yahoo.com/r/f5d331c1-cdee-3885-b808-be7d4267daa5/36540334-6739-11e7-8526-7b38dcaef614,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss",A revolutionary new cancer therapy developed by Novartis moved a step closer to the market on Wednesday when a panel of scientists reporting to US regulators unanimously recommended it be approved. The ...
NVS,NVS:US,BBG000LYF3S8,Novartis Secures FDA Panel's Approval for Cutting Edge Cancer Drug,2017-07-12 19:50:00 +0000,http://finance.yahoo.com/r/c56e7460-6986-32f7-927b-0d78aa2379b1/novartis-secures-fda-panel-s-approval-for-cutting-edge-cancer-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The panel voted 10-0 that the drug, tisagenlecleucel, should be approved to treat patients with relapsed B-cell acute lymphoblastic leukemia (ALL), the most common form of U.S. childhood cancer."
NVS,NVS:US,BBG000LYF3S8,A revolutionary experimental cancer treatment just got one step closer to approval,2017-07-12 19:28:32 +0000,https://finance.yahoo.com/news/revolutionary-experimental-cancer-treatment-just-192832163.html?.tsrc=rss,A US Food and Drug Administration (FDA) advisory committee just gave a critical...
NVS,NVS:US,BBG000LYF3S8,Landmark Novartis Immunotherapy Faces Crucial FDA Hearing Wednesday,2017-07-12 13:50:00 +0000,http://finance.yahoo.com/r/5fb74609-40d4-341e-8af9-a4942988af57/landmark-novartis-immunotherapy-faces-crucial-fda-hearing-wednesday.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,FDA advisory committee poised to make recommendation regarding CAR T therapy from Novartis that represents the first possibility of treatment calling on the body's own engineered cells to attack cancer....
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Jumped On Yellen Comments,2017-07-12 12:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yYPKlp45MwY/the-swiss-stock-market-jumped-on-yellen-comments-20170712-00857,The Swiss Stock Market Jumped On Yellen Comments
NVS,NVS:US,BBG000LYF3S8,FDA Decision on Novartis Gene Therapy Drug Could Benefit Kite Pharma,2017-07-11 18:19:00 +0000,http://finance.yahoo.com/r/1593e9ee-c7c8-374e-bb61-37d9a8fe52dd/fda-decision-on-novartis-gene-therapy-could-benefit-kite-pharma-analyst-says.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Investment firm Canaccord Genuity believes Kite Pharma is poised to take advantage of the positive results from Novartis' experimental gene therapy drug.
NVS,NVS:US,BBG000LYF3S8,FDA Moves On Novartis Gene Therapy May Be Good For Kite Pharma,2017-07-11 17:20:00 +0000,http://finance.yahoo.com/r/af8a0e8c-f76f-3641-84bd-c985870f8719/fda-moves-on-novartis-gene-therapy-may-be-good-for-kite-pharma-1499793628?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"A Food And Drug Administration panel is expected to meet tomorrow to discuss Novartis's (NVS) experimental gene therapy drug, a move that could be good news for Kite Pharma (KITE), according to Canaccord Genuity.  Analyst John Newman reiterated a Buy rating and $115 price target on Kite today, writing that the briefing documents thus far are positive.  Details from his note:  We view the Novartis briefing documents as suggestive of FDA support for approval, and beneficial to all CART players."
NVS,NVS:US,BBG000LYF3S8,Lilly's Breast Cancer Drug Gets Priority Review Status by FDA,2017-07-11 15:49:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9YNBGKO0CvQ/lillys-breast-cancer-drug-gets-priority-review-status-by-fda-cm814438,Eli Lilly and Company LLY announced that its new drug application for its pipeline candidate abemaciclib both as a potential monotherapy and combination therapy has been accepted for priority review by the FDA for patients with advanced breast cancer Lilly is looking to get the CDK 4
NVS,NVS:US,BBG000LYF3S8,Novartis readies for FDA review of $1 bln CAR-T child cancer hope,2017-07-11 13:14:14 +0000,https://finance.yahoo.com/news/novartis-readies-fda-review-1-131414772.html?.tsrc=rss,"Two decades ago in a Memphis,  Tenn., hospital lab, cancer scientist Dario Campana and his team  were hunting for a new way to fight deadly acute lymphoblastic  leukemia (ALL).  ""Our first tests convinced us these T cells were special,""  Campana, now a scientist at the National University Cancer  Institute in Singapore, told Reuters by email this week."
NVS,NVS:US,BBG000LYF3S8,Here’s how much the 10 largest pharmaceutical companies spend on R&D,2017-07-11 13:04:00 +0000,https://finance.yahoo.com/news/much-10-largest-pharmaceutical-companies-130400175.html?.tsrc=rss,"The pharmaceutical industry is among the biggest in the world, containing some of the largest..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped After Good Start To The Week,2017-07-11 12:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kaTJUq3XY5Q/the-swiss-stock-market-dropped-after-good-start-to-the-week-20170711-00944,The Swiss Stock Market Dropped After Good Start To The Week
NVS,NVS:US,BBG000LYF3S8,3 Dividend ETFs to Score Big With European Stocks,2017-07-10 23:43:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AEkek-_SX1M/3-dividend-etfs-to-score-big-with-european-stocks-cm814155,InvestorPlace Stock Market News Stock Advice amp Trading Tips In search of value investors are funneling billions of dollars into exchange traded funds ETFs dedicated to European stocks this year That faith is being rewarded The Euro STOXX 50 Index one of the most widely
NVS,NVS:US,BBG000LYF3S8,The 10 largest pharmaceutical companies in the world,2017-07-10 20:44:56 +0000,https://finance.yahoo.com/news/10-largest-pharmaceutical-companies-world-204456951.html?.tsrc=rss,"The pharmaceutical industry is among the biggest in the world, containing some of the largest..."
NVS,NVS:US,BBG000LYF3S8,Novartis' Cosentyx Superior to Stelara in Psoriasis Study,2017-07-10 17:44:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0ecoAJRcmpo/novartis-cosentyx-superior-to-stelara-in-psoriasis-study-cm813910,Novartis AG NVS announced that the Committee for Medicinal Products for Human Use CHMP has approved a label update for psoriasis drug Cosentyx The label update includes 52 week data from the CLEAR study which demonstrated the long term superiority of Cosentyx over Johnson amp Johnson s
NVS,NVS:US,BBG000LYF3S8,Lilly Gets Favorable Ruling in Alimta Patent Lawsuit in UK,2017-07-10 15:52:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xMu7Cfg6emk/lilly-gets-favorable-ruling-in-alimta-patent-lawsuit-in-uk-cm813829,Eli Lilly and Company LLY announced that it has received favorable ruling from the UK Supreme Court in a patent lawsuit against generic drugmaker Actavis related to its key cancer drug Alimta pemetrexed disodium Per the court s verdict alternative salt forms of Alimta launched by
NVS,NVS:US,BBG000LYF3S8,Novartis&apos; Cosentyx Superior to Stelara in Psoriasis Study,2017-07-10 15:12:03 +0000,https://finance.yahoo.com/news/novartis-apos-cosentyx-superior-stelara-151203960.html?.tsrc=rss,"Novartis&apos; (NVS) psoriasis drug Cosentyx got a label update from the Committee for Medicinal Products for Human Use (CHMP) in the EU,"
NVS,NVS:US,BBG000LYF3S8,FDA panel to focus on safety of Novartis gene therapy drug,2017-07-10 13:25:59 +0000,https://finance.yahoo.com/news/fda-panel-focus-safety-novartis-125657657.html?.tsrc=rss,"The U.S. Food and Drug Administration  will ask a panel of advisors to focus on the safety of Novartis  AG's experimental gene therapy drug when it meets to  review the product on Wednesday.  The keenly anticipated preliminary review of the leukemia  treatment, posted on the FDA's website on Monday, comes two days  ahead of the advisory panel meeting, which will discuss the drug  and vote on whether the benefits exceed the risks.  If approved, the drug, tisagenlecleucel, would be the first  gene therapy to be approved in the United States."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed As NestlÃ© Provides Support,2017-07-10 12:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7aApNgFWgKE/the-swiss-stock-market-climbed-as-nestl%C3%A3-provides-support-20170710-00945,The Swiss Stock Market Climbed As NestlÃ© Provides Support
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 07/07/2017: CNAT,NVO,ARNA,DXTR",2017-07-07 20:24:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BxfFY594W5A/health-care-sector-update-for-07072017-cnatnvoarnadxtr-cm813279,Top Health Care StocksTop Health Care Stocks JNJ 0 13 JNJ 0 13 PFE 0 21 PFE 0 21 ABT 0 94 ABT 0 94 MRK 0 13 MRK 0 13 AMGN 0 10 AMGN 0 10 Health care stocks were rising Friday with the NYSE Health Care Index moving almost 0 5 higher in recent trading while shares of health
NVS,NVS:US,BBG000LYF3S8,Novartis Stock in 2Q17: How Has It Performed?,2017-07-07 19:51:31 +0000,http://finance.yahoo.com/r/584979b7-94d5-3484-9895-46f5f15398e7/novartis-stock-in-2q17-how-has-it-performed?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products, mainly pharmaceuticals. ..."
NVS,NVS:US,BBG000LYF3S8,Vanguard FTSE Developed Markets ETF Experiences Big Inflow,2017-07-07 16:44:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YnG8IcAgdgo/vanguard-ftse-developed-markets-etf-experiences-big-inflow-cm813066,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 984 3 million dollar inflow that s a 1 8 increase week over week
NVS,NVS:US,BBG000LYF3S8,Bristol-Myers Gets FDA Nod for Orencia's Label Expansion,2017-07-07 15:51:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iFDGcYsWCE8/bristol-myers-gets-fda-nod-for-orencias-label-expansion-cm813048,Bristol Myers Squibb Company BMY announced that the FDA has approved Orencia for the treatment of adults with active psoriatic arthritis PsA The approval was based on results from two randomized double blind placebo controlled trials Per the data from the trials Orencia improved
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: MRK's Keytruda MM Combo Studies on Clinical Hold, Bayer to Revise Outlook",2017-07-07 13:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2RgckUoZQQ8/pharma-stock-roundup-mrks-keytruda-mm-combo-studies-on-clinical-hold-bayer-to-revise-outlook-cm812971,Merck s MRK Keytruda has hit a stumbling block with the FDA placing three combination studies on clinical hold Meanwhile Bayer BAYRY said that it will be revising its outlook when it reports second quarter results later this month to reflect inventory issues associated with the Crop
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 07/07/2017: JNJ, PFE, ABT, MRK, AMGN, NVS, DXTR, CNAT, ADXS",2017-07-07 13:24:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L2Csjw39BOE/health-care-sector-update-for-07072017-jnj-pfe-abt-mrk-amgn-nvs-dxtr-cnat-adxs-cm812890,Top Health Care stocks Top Health Care stocks JNJ 1 1 JNJ 1 1 PFE 0 7 PFE 0 7 ABT flatABT flat MRK flatMRK flat AMGN 0 7 AMGN 0 7 Health care shares were mostly higher in pre market trade Friday Health care shares were mostly higher in pre market trade Friday Dextera
NVS,NVS:US,BBG000LYF3S8,Why Conatus Pharma Wins With Newest Licensing Agreement,2017-07-07 12:50:44 +0000,https://finance.yahoo.com/news/why-conatus-pharma-wins-newest-125044524.html?.tsrc=rss,Conatus Pharmaceuticals saw its shares make a handy gain on Friday after the firm announced an exclusive license agreement with Novartis.
NVS,NVS:US,BBG000LYF3S8,Conatus Pharmaceuticals Posting Strong Gain In Afternoon Trading,2017-07-07 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FZv5Lcw_5pM/conatus-pharmaceuticals-posting-strong-gain-in-afternoon-trading-20170707-00600,Conatus Pharmaceuticals Posting Strong Gain In Afternoon Trading
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed Ahead Of The Weekend,2017-07-07 12:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1oUGDZgjEx4/the-swiss-stock-market-finished-little-changed-ahead-of-the-weekend-20170707-00585,The Swiss Stock Market Finished Little Changed Ahead Of The Weekend
NVS,NVS:US,BBG000LYF3S8,Sophie’s Choice for Oncologists: Who Gets New Life-Saving Drug,2017-07-07 07:00:00 +0000,http://finance.yahoo.com/r/3f95ae23-f239-37a4-a0ad-14fa7c4b795e/sophie-s-choice-for-oncologists-who-gets-new-life-saving-drug?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&trackingId=yhoo.headline&yptr=yahoo&.tsrc=rss,"It’s a choice no doctor ever wants to make: which patient will get a chance to live, and which will not."
NVS,NVS:US,BBG000LYF3S8,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track",2017-07-07 01:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/grM11UAzP9M/bmys-orencia-scores-another-fda-nod-janssen-ends-deal-with-capr-pbyi-on-track-20170707-00017,"BMY's Orencia Scores Another FDA Nod, Janssen Ends Deal With CAPR, PBYI On Track"
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of July 6: VSTM, BGNE, ALRN, TXMD, OCUL...",2017-07-06 21:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GwZFFCJZQoc/gainers--losers-of-july-6-vstm-bgne-alrn-txmd-ocul-20170706-01273,"Gainers & Losers Of July 6: VSTM, BGNE, ALRN, TXMD, OCUL..."
NVS,NVS:US,BBG000LYF3S8,Novartis Faces Key FDA Panel On Cancer Drug; Why Kite Could Be The Winner,2017-07-06 20:25:11 +0000,http://finance.yahoo.com/r/bc36bec3-54b4-3ec4-a4c2-2b80e748c861/novartis-is-going-before-the-fda-but-kite-could-benefit-more?src=A00220&yptr=yahoo&.tsrc=rss,"Kite should benefit from an FDA hearing on an experimental cancer treatment from rival Novartis later this month, an analyst said Thursday."
NVS,NVS:US,BBG000LYF3S8,See How Pfizer Ranks Among Analysts' Top Dow 30 Picks,2017-07-06 17:43:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x920mOkEaJQ/see-how-pfizer-ranks-among-analysts-top-dow-30-picks-cm812560,A study of analyst recommendations at the major brokerages shows that Pfizer Inc Symbol PFE is the 20 broker pick on average out of the 30 stocks making up the Dow Jones Industrial Average according to ETF Channel Within the broader S amp P 500 when components were ranked in terms
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Recent Losing Streak,2017-07-06 13:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PqZOXTHdjfI/the-swiss-stock-market-extended-its-recent-losing-streak-20170706-00915,The Swiss Stock Market Extended Its Recent Losing Streak
NVS,NVS:US,BBG000LYF3S8,Oxford BioMedica wins big contract for Novartis cell therapy,2017-07-06 07:29:47 +0000,https://finance.yahoo.com/news/oxford-biomedica-wins-big-contract-072947681.html?.tsrc=rss,"Novartis has signed a  major contract with Oxford BioMedica that could earn the  British company more than $100 million over three years for  supplying the Swiss drugmaker with material for its novel cell  therapy CTL019.  The deal, announced by Oxford BioMedica on Thursday, could  help put the veteran biotech firm on a path to sustainable  profitability.  The contract is for the supply of lentiviral vectors used to  generate CTL019, a new kind of treatment for hard-to-treat  leukaemia that is expected to reach the market this year."
NVS,NVS:US,BBG000LYF3S8,Street Sees Red On Upbeat Crude Prices,2017-07-06 07:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uA_MgBBskNo/street-sees-red-on-upbeat-crude-prices-20170706-00299,Street Sees Red On Upbeat Crude Prices
NVS,NVS:US,BBG000LYF3S8,"Lung, Liver and Stomach Cancers Kill a Million Chinese a Year; Big Pharma Responds",2017-07-06 04:06:34 +0000,http://finance.yahoo.com/r/41327cc4-f8a2-3600-a47f-01c6f931f73f/why-big-pharma-is-targeting-chinas-deadliest-diseases-1499252401?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Big Pharma is investing billions of dollars to tackle deadly diseases prevalent in China, developing new drugs to combat a lineup of top killers that differ from those in the West."
NVS,NVS:US,BBG000LYF3S8,Tesla&apos;s Stock Is Only Worth This Much: Goldman,2017-07-05 20:14:57 +0000,http://finance.yahoo.com/r/e4b5dc5c-db27-3403-839d-5a3932986031/tesla-worth-half-its-current-stock-price-goldman-says-oracle-cloud-cheered-novartis-cut?src=A00220&yptr=yahoo&.tsrc=rss,Tesla&apos;s price target was cut while Oracle was upgraded on cloud offerings. Novartis was downgraded.
NVS,NVS:US,BBG000LYF3S8,"These 6 Biotech, Drug Plays Are In Buy Range: Investing Action Plan",2017-07-05 20:12:28 +0000,http://finance.yahoo.com/r/71be4e45-6819-36e8-8405-b096d99fe3bb/these-6-biotech-drug-plays-are-in-buy-range-investing-action-plan?src=A00220&yptr=yahoo&.tsrc=rss,Here&apos;s your Investing Action Plan for Thursday: what you need to know as an investor for the coming day.
NVS,NVS:US,BBG000LYF3S8,Why Sanofi is a Top 10 SAFE International Dividend Stock,2017-07-05 14:46:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FhmSLPkmKxo/why-sanofi-is-a-top-10-safe-international-dividend-stock-cm811720,Sanofi Symbol SNY has been named to the Dividend Channel International S A F E 10 list signifying an international stock with above average DividendRank statistics including a strong 3 3 yield as well as a superb track record of at least five years of dividend growth according
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell Due To Weak Performance Of Index Heavyweights,2017-07-05 12:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z6Ic9MBUw8o/the-swiss-stock-market-fell-due-to-weak-performance-of-index-heavyweights-20170705-00820,The Swiss Stock Market Fell Due To Weak Performance Of Index Heavyweights
NVS,NVS:US,BBG000LYF3S8,[$$] Biotechs Race to Unleash Cellular Cancer Therapies,2017-07-05 11:30:05 +0000,http://finance.yahoo.com/r/f0e5063e-312d-3b2b-b984-9e7a95c18df6/biotechs-race-to-unleash-cellular-cancer-therapies-1499254200?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Startups are working to introduce new cellular treatments that could vanquish cancers by unleashing an immune system assault on tumors.
NVS,NVS:US,BBG000LYF3S8,Why Big Pharma Is Targeting China's Deadliest Diseases,2017-07-05 11:00:06 +0000,http://finance.yahoo.com/r/41327cc4-f8a2-3600-a47f-01c6f931f73f/why-big-pharma-is-targeting-chinas-deadliest-diseases-1499252401?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Big Pharma is investing billions of dollars to tackle deadly diseases prevalent in China, developing new drugs to combat a lineup of top killers that differ from those in the West."
NVS,NVS:US,BBG000LYF3S8,Johnson & Johnson’s Pharmaceuticals Business in 1Q17,2017-07-04 14:37:45 +0000,http://finance.yahoo.com/r/d46c7119-6e7d-34fc-8ed3-0d1793eed31b/johnson-and-johnsons-pharmaceuticals-business-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"JNJ's Pharmaceutical segment reported revenues of $8.2 billion during 1Q17, representing 1.0% growth compared to its 1Q16 revenues."
NVS,NVS:US,BBG000LYF3S8,Incyte & Lilly's Olumiant Gets Marketing Approval in Japan,2017-07-04 13:45:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y32zXwOVkZM/incyte-lillys-olumiant-gets-marketing-approval-in-japan-cm811536,Incyte Corporation INCY and partner Eli Lilly and Company LLY announced that Japan s Ministry of Health Labor and Welfare MHLW granted marketing approval for Olumiant baricitinib 2 mg and 4 mg tablets The drug will be used for treating rheumatoid arthritis RA including the
NVS,NVS:US,BBG000LYF3S8,Incyte & Lilly&apos;s Olumiant Gets Marketing Approval in Japan,2017-07-04 11:53:11 +0000,https://finance.yahoo.com/news/incyte-lilly-apos-olumiant-gets-115311158.html?.tsrc=rss,Incyte Corporation (INCY) and partner Eli Lilly and Company (LLY) announced that arthritis drug Olumiant got approval in Japan.
NVS,NVS:US,BBG000LYF3S8,Why Big Pharma Is Struggling to Profit From the Obesity Epidemic,2017-07-04 04:00:05 +0000,http://finance.yahoo.com/r/669e5439-4d89-3dce-ad85-f298eac161a4/why-big-pharma-is-struggling-to-profit-from-the-obesity-epidemic?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&trackingId=yhoo.headline&yptr=yahoo&.tsrc=rss,"New medicines offer hope to 600 million, but drugmakers face a problem."
NVS,NVS:US,BBG000LYF3S8,Key FDA Events to Watch Out for in Jul 2017,2017-07-03 13:47:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/so-gVBAE_RE/key-fda-events-to-watch-out-for-in-jul-2017-cm811144,Halfway into the year and the FDA has already crossed its total tally of 22 approvals in 2016 So far in 2017 the FDA has given its nod to 23 novel drugs including 2 in June Key approvals so far in 2017 include Regeneron Sanofi s Kevzara rheumatoid arthritis Roche s multiple
NVS,NVS:US,BBG000LYF3S8,"The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva",2017-07-03 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-merck-133001364.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Merck, Sanofi, Roche, Esperion and Teva"
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Climbed Back Above 9,000 Points",2017-07-03 12:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3ab68LfEtGA/the-swiss-stock-market-climbed-back-above-9000-points-20170703-00504,"The Swiss Stock Market Climbed Back Above 9,000 Points"
NVS,NVS:US,BBG000LYF3S8,Teva's (TEVA) Filing for Biosimilar Rituxan Accepted by FDA,2017-06-30 17:41:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7fYHmfThxNU/tevas-teva-filing-for-biosimilar-rituxan-accepted-by-fda-cm810646,Teva Pharmaceutical Industries Ltd TEVA and Korean partner Celltrion Inc announced that the FDA has accepted for review their Biologics License Application BLA for CT P10 a proposed biosimilar to Roche Holding AG s RHHBY Rituxan rituximab The regulatory action by the FDA is expected
NVS,NVS:US,BBG000LYF3S8,The Cure For Cancer? Look At Your Blood,2017-06-30 17:10:32 +0000,http://finance.yahoo.com/r/dc2e0f7e-738c-30ab-bf2a-12edd93714f9/drugmakers-make-science-fiction-reality-in-cancer?src=A00220&yptr=yahoo&.tsrc=rss,What once seemed sci-fi is becoming real in treating blood cancers: doctoring patients&apos; blood to kill tumors. The FDA is about to consider the first such drug.
NVS,NVS:US,BBG000LYF3S8,Bluebird Bio: Too Much Good News?,2017-06-30 14:40:00 +0000,http://finance.yahoo.com/r/4f7a2953-e80e-3444-b70e-61b5c6bdcb41/bluebird-bio-too-much-good-news-1498833622?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Bluebird Bio (BLUE) has had a great run this year, soaring more than 73% since the start of 2017.  The drug maker emerged as a big winner from the American College of Clinical Oncology’s (ASCO) annual confab, which is part of the reasons why the stock has spiked 40% in the past month, and peaked above $120 a share along the way.  High hopes for bb2121, the experimental cancer drug Bluebird Bio is developing with Celgene (CELG), are a big ingredient in the stock’s performance."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Was Unable To Hold Onto Gains,2017-06-30 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fq4XXPxuf68/the-swiss-stock-market-was-unable-to-hold-onto-gains-20170630-00642,The Swiss Stock Market Was Unable To Hold Onto Gains
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Sanofi RA Drug Gets EU Nod, Merck CETP Inhibitor Surprises",2017-06-30 12:15:12 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-sanofi-ra-121512991.html?.tsrc=rss,Merck&apos;s (MRK) results on its CETP inhibitor took the investment community by surprise while Sanofi gained EU approval for its rheumatoid arthritis (RA) drug.
NVS,NVS:US,BBG000LYF3S8,"Popular Cancer Pill Goes Generic, Yet Patients' Costs Stay High",2017-06-30 09:00:00 +0000,http://finance.yahoo.com/r/e3755681-017d-38e7-8ef6-67a2e8e5b15f/popular-cancer-pill-goes-generic-yet-patients-costs-stay-high?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Donald Jones used to pay at least $500 a month for a brand-name drug, Gleevec, that’s kept his leukemia at bay for five years."
NVS,NVS:US,BBG000LYF3S8,Novartis Gets EC Nod for Lung Cancer Drug's Label Expansion,2017-06-29 16:08:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eyIsO9lupAs/novartis-gets-ec-nod-for-lung-cancer-drugs-label-expansion-cm809991,Novartis AG NVS announced that the European Commission has approved a label expansion of oncology drug Zykadia The drug is now approved for the first line treatment of patients with advanced non small cell lung cancer NSCLC whose tumors are anaplastic lymphoma kinase ALK positive
NVS,NVS:US,BBG000LYF3S8,"Notable ETF Inflow Detected - VEA, NSRGY, NVS, TM",2017-06-29 16:04:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ohQY6Hmw0XA/notable-etf-inflow-detected-vea-nsrgy-nvs-tm-cm809959,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 478 0 million dollar inflow that s a 0 9 increase week over week
NVS,NVS:US,BBG000LYF3S8,"Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca",2017-06-29 15:08:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kh6QkYi0BYs/zacks-industry-outlook-highlights-johnson-johnson-incyte-pfizer-novartis-and-astrazeneca-cm809831,For Immediate Release Chicago IL June 29 2017 Today Zacks Equity Research discusses the Industry Pharmaceuticals including Johnson amp Johnson NYSE JNJ Free Report Incyte NASDAQ INCY Free Report Pfizer NYSE PFE Free Report Novartis NYSE NVS
NVS,NVS:US,BBG000LYF3S8,Novartis Gets EC Nod for Lung Cancer Drug&apos;s Label Expansion,2017-06-29 13:54:01 +0000,https://finance.yahoo.com/news/novartis-gets-ec-nod-lung-135401833.html?.tsrc=rss,Novartis AG (NVS) announced that the European Commission has approved a label expansion of lung cancer drug drug Zykadia.
NVS,NVS:US,BBG000LYF3S8,"Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca",2017-06-29 13:30:01 +0000,https://finance.yahoo.com/news/zacks-industry-outlook-highlights-johnson-133001328.html?.tsrc=rss,"Zacks Industry Outlook Highlights: Johnson & Johnson, Incyte, Pfizer, Novartis and AstraZeneca"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Ended With A Significant Loss,2017-06-29 12:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G91TCebZgXY/the-swiss-stock-market-ended-with-a-significant-loss-20170629-00902,The Swiss Stock Market Ended With A Significant Loss
NVS,NVS:US,BBG000LYF3S8,"Sales hopes for new Novartis, Merck heart drugs under microscope",2017-06-29 11:22:05 +0000,https://finance.yahoo.com/news/sales-hopes-novartis-merck-heart-112205139.html?.tsrc=rss,"Novartis and Merck  have both surprised experts in the past week by finding  new ways to tackle heart disease, although the jury remains out  as to whether this scientific success will translate into  blockbuster sales.  Detailed data on both Novartis's canakinumab and Merck's  anacetrapib will be presented on Aug. 27 and 29 at the annual  meeting of the European Society of Cardiology (ESC), conference  organisers said on Thursday."
NVS,NVS:US,BBG000LYF3S8,Details on surprise Novartis heart drug success due Aug 27,2017-06-29 07:21:11 +0000,https://finance.yahoo.com/news/details-surprise-novartis-heart-drug-072111533.html?.tsrc=rss,"Full details on the surprise  success of a Novartis anti-inflammatory drug in cutting  cardiovascular risk for heart attack survivors will be presented  at a medical meeting on Aug. 27, conference organisers said on  Thursday.  The so-called CANTOS study will be one of the highlights of  the annual meeting of the European Society of Cardiology (ESC),  the region's largest professional gathering of heart  specialists.  Novartis said last week that canakinumab had been found to  reduce further heart attacks or strokes in a large study,  confounding expectations among analysts who had not expected it  to work, given past setbacks with anti-inflammatory approaches."
NVS,NVS:US,BBG000LYF3S8,Novartis : EU Oks First-line Use Of Zykadia In ALK-positive Advanced NSCLC,2017-06-29 01:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FdO32Ug159E/novartis--eu-oks-firstline-use-of-zykadia-in-alkpositive-advanced-nsclc-20170629-00030,Novartis : EU Oks First-line Use Of Zykadia In ALK-positive Advanced NSCLC
NVS,NVS:US,BBG000LYF3S8,Biotech Stocks Facing FDA Decision In July,2017-06-29 00:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pgpziX5aPwc/biotech-stocks-facing-fda-decision-in-july-20170629-00014,Biotech Stocks Facing FDA Decision In July
NVS,NVS:US,BBG000LYF3S8,Better Days Ahead for the Pharma Sector?,2017-06-28 22:03:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3MnO6tocceA/better-days-ahead-for-the-pharma-sector-cm809665,We are halfway through 2017 and the pharma and biotech sector has bounced back nicely with the NYSE ARCA Pharmaceutical Index gaining 12 9 while the NASDAQ Biotechnology Index is up 17 2 This is in sharp contrast to 2016 which was a tough year for pharma and biotech stocks with the
NVS,NVS:US,BBG000LYF3S8,"Novartis' Erelzi, Biosimilar of Enbrel Approved In Europe",2017-06-28 15:08:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_7D9qBHjVOA/novartis-erelzi-biosimilar-of-enbrel-approved-in-europe-cm809364,Novartis AG NVS announced that the European Commission EC has approved Erelzi the biosimilar version of Amgen s AMGN Enbrel Erelzi is approved for use in all indications of the branded drug like rheumatoid arthritis axial spondyloarthritis ankylosing spondylitis and non
NVS,NVS:US,BBG000LYF3S8,Is It The Right Time To Add Foreign Stocks To Your Portfolio?,2017-06-28 15:02:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HHPx38DjGvg/is-it-the-right-time-to-add-foreign-stocks-to-your-portfolio-cm809276,Overseas stocks are taking a breather which could set up an opportunity for investors to add or increase international exposure IShares MSCI EAFE EFA is extended from a 60 26 flat base buy point cleared early this year but is now testing support at its 50 day moving
NVS,NVS:US,BBG000LYF3S8,"Novartis&apos; Erelzi, Biosimilar of Enbrel Approved In Europe",2017-06-28 13:26:01 +0000,https://finance.yahoo.com/news/novartis-apos-erelzi-biosimilar-enbrel-132601577.html?.tsrc=rss,Novartis AG (NVS) announced that the European Commission (EC) has approved Erelzi ??? the biosimilar version of Enbrel.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed As NestlÃ© Gains Ground,2017-06-28 12:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NxNWcQxqZ9I/the-swiss-stock-market-finished-little-changed-as-nestl%C3%A3-gains-ground-20170628-00874,The Swiss Stock Market Finished Little Changed As NestlÃ© Gains Ground
NVS,NVS:US,BBG000LYF3S8,Invest in these European underperformers now before Daniel Loeb does,2017-06-28 07:02:31 +0000,http://finance.yahoo.com/r/d171c91f-0e86-32a8-a164-c7978b93ab40/Story.aspx?guid=C409565C-5B4A-11E7-A66F-1E360CB4ED10&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Matthew Lynn says these four European underperformers could be the next targets for activist investors such as Daniel Loeb.
NVS,NVS:US,BBG000LYF3S8,AstraZeneca's Faslodex Recommended by CHMP for 1st Line Use,2017-06-27 16:52:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fpC77U1mUg8/astrazenecas-faslodex-recommended-by-chmp-for-1st-line-use-cm808905,AstraZeneca PLC AZN announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has adopted a positive opinion recommending the marketing authorisation of Faslodex fulvestrant for 1st line treatment for postmenopausal women with HR
NVS,NVS:US,BBG000LYF3S8,Conatus's PSC Candidate Gets Orphan Designation in the U.S.,2017-06-27 14:56:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ZvXYpdyca8/conatuss-psc-candidate-gets-orphan-designation-in-the-us-cm808734,Conatus Pharmaceuticals Inc s CNAT shares increased almost 10 after the biotech company announced FDA s grant of Orphan Drug Designation ODD to its pipeline candidate IDN 7314 for treatment of primary sclerosing cholangitis PSC IDN 7314 is an oral pan caspase protease
NVS,NVS:US,BBG000LYF3S8,"Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?",2017-06-27 12:52:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HO5ppxqXXKk/will-abbvie-outsmart-biosimilars-and-can-clovis-win-the-parp-race-cm808480,AbbVie Inc NYSE ABBV Regeneron Pharmaceuticals NASDAQ REGN and Clovis Oncology NASDAQ CLVS all have at least one thing in common All three are subjects of this week s Industry Focus Healthcare In this edition host Kristine Harjes is joined by
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Slid As NestlÃ© Endures Profit Taking,2017-06-27 12:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NN7gqgZc9gg/the-swiss-stock-market-slid-as-nestl%C3%A3-endures-profit-taking-20170627-00921,The Swiss Stock Market Slid As NestlÃ© Endures Profit Taking
NVS,NVS:US,BBG000LYF3S8,"Will AbbVie Outsmart Biosimilars, and Can Clovis Win the PARP Race?",2017-06-27 11:02:00 +0000,http://finance.yahoo.com/r/1ebec010-2c7c-3f86-a7f8-8c0c17597b09/will-abbvie-outsmart-biosimilars-and-can-clovis-wi.aspx?yptr=yahoo&.tsrc=rss,"A look under the hood at AbbVie Inc., how Novartis is prepping to fight Regeneron, and can Clovis capture the lead in the PARP race?"
NVS,NVS:US,BBG000LYF3S8,Novartis gets European OK for biosimilar of Amgen's Enbrel,2017-06-27 05:31:18 +0000,https://finance.yahoo.com/news/novartis-gets-european-ok-biosimilar-053118994.html?.tsrc=rss,"Novartis's generics  unit Sandoz said the European Commission approved Erelzi, its  biosimilar to Amgen's Enbrel, to treat inflammatory  diseases such as rheumatoid arthritis, psoriasis, and psoriatic  arthritis.  The approval was based on a development programme that  demonstrated that Erelzi, a biosimilar of the drug also known as  etanercept, matches its reference medicine in terms of safety,  efficacy, and quality, Sandoz said in a statement on Tuesday."
NVS,NVS:US,BBG000LYF3S8,Sandoz Gets EC Approval For Erelzi To Treat Multiple Inflammatory Diseases,2017-06-27 02:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VOvE-DPiy_8/sandoz-gets-ec-approval-for-erelzi-to-treat-multiple-inflammatory-diseases-20170627-00060,Sandoz Gets EC Approval For Erelzi To Treat Multiple Inflammatory Diseases
NVS,NVS:US,BBG000LYF3S8,"The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk",2017-06-26 15:53:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5TmcVKWRQVs/the-zacks-analyst-blog-highlights-novartis-roche-shire-neos-and-novo-nordisk-cm808108,For Immediate Release Chicago IL June 26 2017 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
NVS,NVS:US,BBG000LYF3S8,Roche's (RHHBY) Combination Cancer Remedy Wins FDA Approval,2017-06-26 15:52:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kf59Vfzgzw0/roches-rhhby-combination-cancer-remedy-wins-fda-approval-cm808067,Roche RHHBY announced that the FDA has granted approval to the subcutaneous injection of its marketed lymphoma drug MabThera Rituxan as Rituxan Hycela for the treatment of adults with different types of blood cancers The injection used Halozyme Therapeutics HALO proprietary
NVS,NVS:US,BBG000LYF3S8,Epizyme Progressing Well on Two Lead Pipeline Candidates,2017-06-26 14:55:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sCU3DvRRyTg/epizyme-progressing-well-on-two-lead-pipeline-candidates-cm808031,We issued an updated research report on Epizyme Inc EPZM on Jun 23 2017 Currently Epizyme is a development stage biopharmaceutical company focused on bringing novel epigenetic therapies for the treatment of cancer and other diseases to market Key candidates in Epizyme s pipeline
NVS,NVS:US,BBG000LYF3S8,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",2017-06-26 14:55:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1pXkDJkLVzE/novartis-cardiovascular-drug-positive-nsclc-drug-approved-cm808013,Shares of Novartis AG NVS were up after the company announced positive top line results from the global phase III study CANTOS The study evaluated the efficacy safety and tolerability of ACZ885 canakinumab in combination with standard of care in patients with a prior heart attack
NVS,NVS:US,BBG000LYF3S8,Corcept Therapeutics Incorporated in 3 Charts,2017-06-26 13:52:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KD-1dpbut-Y/corcept-therapeutics-incorporated-in-3-charts-cm807952,Corcept Therapeutics Incorporated NASDAQ CORT is definitely on a roll The drugmaker s stock is up nearly 70 so far in 2017 Corcept s share price has has more than doubled over the past 12 months And over the last three years the company s market cap has nearly quadrupled What
NVS,NVS:US,BBG000LYF3S8,"The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk",2017-06-26 13:30:01 +0000,https://finance.yahoo.com/news/zacks-analyst-blog-highlights-novartis-133001119.html?.tsrc=rss,"The Zacks Analyst Blog Highlights: Novartis, Roche, Shire, Neos and Novo Nordisk"
NVS,NVS:US,BBG000LYF3S8,"Novartis Cardiovascular Drug Positive, NSCLC Drug Approved",2017-06-26 13:00:01 +0000,https://finance.yahoo.com/news/novartis-cardiovascular-drug-positive-nsclc-130001710.html?.tsrc=rss,"Shares of Novartis AG (NVS) were up after the company announced positive top-line results from the global phase III study, CANTOSon cardiovascular drug."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed As NestlÃ© Charges Higher,2017-06-26 12:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5CciPNJbNE8/the-swiss-stock-market-climbed-as-nestl%C3%A3-charges-higher-20170626-00858,The Swiss Stock Market Climbed As NestlÃ© Charges Higher
NVS,NVS:US,BBG000LYF3S8,"Better Buy: Exelixis, Inc. vs. Novartis AG",2017-06-24 10:42:00 +0000,http://finance.yahoo.com/r/39f1a352-5fbb-3dd1-a475-d97531d3d0a9/better-buy-exelixis-inc-vs-novartis.aspx?yptr=yahoo&.tsrc=rss,Is fast-rising Exelixis a better stock pick than huge drugmaker Novartis?
NVS,NVS:US,BBG000LYF3S8,Regeneron (REGN) Stock on Fire: What's Behind the Surge?,2017-06-23 15:55:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D-iVUGQCMNI/regeneron-regn-stock-on-fire-whats-behind-the-surge-cm807450,Shares of Regeneron Pharmaceuticals Inc REGN have moved up 14 9 over the last 30 days In fact so far this year Regeneron s shares have rallied 43 4 compared with the 12 gain of the Zacks classified Medical Biomedical and Genetics industry Let s find out what is driving
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Dipped Friday, But Finished Higher For The Week",2017-06-23 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/98nQKl5NP2A/the-swiss-stock-market-dipped-friday-but-finished-higher-for-the-week-20170623-00558,"The Swiss Stock Market Dipped Friday, But Finished Higher For The Week"
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: NVS Scores with Positive Data, Shire ADHD Drug Gets FDA Nod",2017-06-23 11:42:11 +0000,https://finance.yahoo.com/news/pharma-stock-roundup-nvs-scores-114211183.html?.tsrc=rss,All major pharma stocks were up this week with companies like Novartis (NVS) presenting positive data and others gaining FDA approval.
NVS,NVS:US,BBG000LYF3S8,Novartis breast cancer drug Kisqali wins European panel backing,2017-06-23 09:55:53 +0000,https://finance.yahoo.com/news/novartis-breast-cancer-drug-kisqali-095553501.html?.tsrc=rss,"A European Medicines Agency  (EMA) panel recommended on Friday approving Novartis's  Kisqali drug, bolstering the Swiss drugmaker's bid to challenge  rival Pfizer's Ibrance against tough-to-treat breast  cancer.  The EMA's Committee for Medicinal Products for Human Use  (CHMP) backed Kisqali in combination with hormone therapy as a  first-line treatment for hormone receptor positive, human  epidermal growth factor receptor-2 negative locally advanced or  metastatic breast cancer.  This latest CHMP opinion sets the stage for likely  European Commission approval this year."
NVS,NVS:US,BBG000LYF3S8,Amended: Street To Open Broadly Lower At Opening,2017-06-23 07:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Hjkz_Wfs5_s/amended-street-to-open-broadly-lower-at-opening-20170623-00243,Amended: Street To Open Broadly Lower At Opening
NVS,NVS:US,BBG000LYF3S8,Street To Open Broadly Lower At Opening,2017-06-23 07:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MdTQJTFfA04/street-to-open-broadly-lower-at-opening-20170623-00218,Street To Open Broadly Lower At Opening
NVS,NVS:US,BBG000LYF3S8,Street To Open Mixed At Opening,2017-06-23 07:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B4i7xszn5fc/street-to-open-mixed-at-opening-20170623-00217,Street To Open Mixed At Opening
NVS,NVS:US,BBG000LYF3S8,Novartis' Kisqali Receives Positive CHMP Opinion,2017-06-23 05:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p-M5RDwQDAw/novartis-kisqali-receives-positive-chmp-opinion-20170623-00101,Novartis' Kisqali Receives Positive CHMP Opinion
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Results From Addl Analyses Of ENESTfreedom &ENESTop Trials,2017-06-23 03:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K32Vp9LQ6Ss/novartis-announces-results-from-addl-analyses-of-enestfreedom-enestop-trials-20170623-00059,Novartis Announces Results From Addl Analyses Of ENESTfreedom &ENESTop Trials
NVS,NVS:US,BBG000LYF3S8,Novartis Updates Results From ELIANA Clinical Trial,2017-06-23 02:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iuOwq3AEVYc/novartis-updates-results-from-eliana-clinical-trial-20170623-00054,Novartis Updates Results From ELIANA Clinical Trial
NVS,NVS:US,BBG000LYF3S8,Novartis: FDA Approves Tafinlar Plus Mekinist For BRAF V600E-mutant NSCLC,2017-06-23 00:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UV0rUT7XIuU/novartis-fda-approves-tafinlar-plus-mekinist-for-braf-v600emutant-nsclc-20170623-00004,Novartis: FDA Approves Tafinlar Plus Mekinist For BRAF V600E-mutant NSCLC
NVS,NVS:US,BBG000LYF3S8,Healthcare Stock Rally Can't Save S&P 500 From Another Bad Day,2017-06-23 00:00:00 +0000,http://finance.yahoo.com/r/6649c2ac-3f2c-3439-9ca9-f573b784d6bd/healthcare-rally-can-t-save-s-amp-p-500-from-another-down-day.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Healthcare leads markets after the release of the Senate health plan.
NVS,NVS:US,BBG000LYF3S8,The Long Case For Taro Pharmaceutical,2017-06-22 22:20:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vq8cOU9r0MA/the-long-case-for-taro-pharmaceutical-cm807125,By Alessandro Villadei ByAlessandro Villadei Target Price and Rationale Target Price and RationaleTarget Price and Rationale Taro Pharmaceutical TARO is a recommended buy with a price target of 175 Taro Pharmaceutical TARO is a recommended buy with a price target of 175
NVS,NVS:US,BBG000LYF3S8,Novartis Pops To 5-Month High On Strong Trial In Heart Attack Survivors,2017-06-22 20:11:28 +0000,http://finance.yahoo.com/r/606d4f42-d36e-3912-8b68-6366e98efced/novartis-pops-to-5-month-high-on-strong-trial-in-heart-attack-survivors?src=A00220&yptr=yahoo&.tsrc=rss,Novartis stock rocketed to a five-month high Thursday after the drugmaker&apos;s anti-inflammatory proved successful in a trial.
NVS,NVS:US,BBG000LYF3S8,Drugmakers May Lose $390B In Sales Over 5 Years,2017-06-22 19:00:00 +0000,http://finance.yahoo.com/r/46e9b8ca-fe45-39be-8899-a7de32130e7a/drugmakers-may-lose-390b-sales-over-5-years-0?partner=YahooSA&yptr=yahoo&.tsrc=rss,Drug stocks may be hurt by slashed sales and earnings as prices soften
NVS,NVS:US,BBG000LYF3S8,Novartis' CANTOS Heart Trial Results Could Lead To Drastic Drop In Arthritis Drug Price,2017-06-22 17:14:00 +0000,http://finance.yahoo.com/r/8430b85a-2602-3f4d-a151-7973c71103ac/novartis-cantos-heart-trial-results-could-lead-to-drastic-drop-in-arthritis-drug-price?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,But who would have thought at the results of a heart disease study could potentially provide an unexpected financial benefit to those patients with juvenile arthritis.
NVS,NVS:US,BBG000LYF3S8,Health stocks help European equities cut losses,2017-06-22 16:36:27 +0000,https://finance.yahoo.com/news/health-stocks-help-european-equities-163627235.html?.tsrc=rss,"A rise in European health stocks  helped pull European shares out of negative territory on  Thursday, pegged back by the slide in the energy sector on the  back of weakened oil prices.  The pan-European STOXX 600 index ended the session  flat following two days of straight losses, while the blue chips  were also flat."
NVS,NVS:US,BBG000LYF3S8,European ADRs Move Higher in Thursday Trading,2017-06-22 16:19:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KpprAV8GZqU/european-adrs-move-higher-in-thursday-trading-cm806970,American depository receipts of European stocks were trading 0 41 higher at 133 26 on the Bank of New York Mellon Europe ADR Index on Thursday American depository receipts of European stocks were trading 0 41 higher at 133 26 on the Bank of New York Mellon Europe ADR Index on Thursday
NVS,NVS:US,BBG000LYF3S8,Major Averages Close Mixed For Second Straight Session - U.S. Commentary,2017-06-22 16:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0-HjPw8HhSw/major-averages-close-mixed-for-second-straight-session--us-commentary-20170622-01071,Major Averages Close Mixed For Second Straight Session - U.S. Commentary
NVS,NVS:US,BBG000LYF3S8,Healthcare Leads as Stocks Turn Higher After Release of Senate Bill,2017-06-22 15:31:00 +0000,http://finance.yahoo.com/r/42461956-c4ff-3c9c-b232-9bf0bf68d4c8/stock-tiptoe-higher-as-crude-oil-looks-to-correct-days-long-slide.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Healthcare leads markets after Senate bill's release.
NVS,NVS:US,BBG000LYF3S8,Novartis Moves Notably Higher On Upbeat Heart Drug Trial Results,2017-06-22 14:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n712-4zY3OU/novartis-moves-notably-higher-on-upbeat-heart-drug-trial-results-20170622-00946,Novartis Moves Notably Higher On Upbeat Heart Drug Trial Results
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Positive Results for Cardiovascular Drug,2017-06-22 13:47:01 +0000,https://finance.yahoo.com/news/novartis-announces-positive-results-cardiovascular-134701106.html?.tsrc=rss,"Novartis AG (NVS) announced top-line results from the global phase III study, CANTOS on cardiovascular drug."
NVS,NVS:US,BBG000LYF3S8,Stock Futures Dip as Crude Oil Looks to Correct Days-Long Slide,2017-06-22 12:34:00 +0000,http://finance.yahoo.com/r/7e1c2a31-8970-3455-9114-5279b86439f1/stock-futures-dip-as-crude-oil-looks-to-correct-days-long-slide.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Futures lower even as crude oil rises.
NVS,NVS:US,BBG000LYF3S8,Novartis Drug Becomes First To Prevent Heart Attacks And Strokes By Targeting Inflammation,2017-06-22 12:21:00 +0000,http://finance.yahoo.com/r/e628d5b2-5594-3694-8667-df421ff4c29d/novartis-drug-becomes-first-to-prevent-heart-attacks-and-strokes-by-targeting-inflammation?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"This morning, Novartis, the Swiss drug giant, announced that a drug that targets inflammation prevented heart attacks and strokes. It could be a scientific breakthrough, and a commercial one, too."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed After Rally In Shares Of Novartis,2017-06-22 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tIHU2LQyHDE/the-swiss-stock-market-climbed-after-rally-in-shares-of-novartis-20170622-00860,The Swiss Stock Market Climbed After Rally In Shares Of Novartis
NVS,NVS:US,BBG000LYF3S8,Stocks Seeing Modest Strength In Mid-Day Trading - U.S. Commentary,2017-06-22 12:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JknqgspDong/stocks-seeing-modest-strength-in-midday-trading--us-commentary-20170622-00843,Stocks Seeing Modest Strength In Mid-Day Trading - U.S. Commentary
NVS,NVS:US,BBG000LYF3S8,Major Averages Near The Unchanged Line In Morning Trading - U.S. Commentary,2017-06-22 10:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KyzrnfRCd8c/major-averages-near-the-unchanged-line-in-morning-trading--us-commentary-20170622-00759,Major Averages Near The Unchanged Line In Morning Trading - U.S. Commentary
NVS,NVS:US,BBG000LYF3S8,Novartis Shares Lead Swiss Market Higher After CANTOS Trial Success,2017-06-22 07:50:00 +0000,http://finance.yahoo.com/r/4ba48e7f-f133-3392-85f3-21082aa92b43/novartis-shares-lead-swiss-market-higher-after-cantos-trial-success.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Novartis shares led gainers in Switzerland Thursday after the pharmaceuticals group told investors that its Canakinumab drug met its primary endpoint in phase three clinical trials.
NVS,NVS:US,BBG000LYF3S8,Novartis: ACZ885 Phase III CANTOS Study Meets Primary Endpoint - Quick Facts,2017-06-22 01:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RWzBgnTnb5o/novartis-acz885-phase-iii-cantos-study-meets-primary-endpoint--quick-facts-20170622-00016,Novartis: ACZ885 Phase III CANTOS Study Meets Primary Endpoint - Quick Facts
NVS,NVS:US,BBG000LYF3S8,Ligand Gets Milestone Payment on Partner Drug FDA Approval,2017-06-21 23:22:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ktu6KYR0CSk/ligand-gets-milestone-payment-on-partner-drug-fda-approval-cm806592,Ligand Pharmaceuticals Incorporated LGND announced receipt of a milestone payment of 1 5 million after its partner Melinta Therapeutics pipeline candidate Baxdela delafloxacin was approved by the FDA Baxdela was approved to treat acute bacterial skin and skin structure infections
NVS,NVS:US,BBG000LYF3S8,"Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM",2017-06-21 17:21:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/skERWs-Q2lo/noteworthy-etf-inflows-vea-nsrgy-nvs-tm-cm806350,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 83 9 million dollar inflow that s a 0 2 increase week over week
NVS,NVS:US,BBG000LYF3S8,"Novartis Migraine Drug Accepted, AMD Positive in Phase III",2017-06-21 15:16:03 +0000,https://finance.yahoo.com/news/novartis-migraine-drug-accepted-amd-151603303.html?.tsrc=rss,Novartis (NVS) announced that the EMA accepted its application for migraine candidate AMG 334.
NVS,NVS:US,BBG000LYF3S8,Featured Company News - DURECT-SANDOZ Collaboration Clears HSR Review; Paves Path for POSIMIR Development and Marketing in the U.S.,2017-06-21 12:15:00 +0000,https://finance.yahoo.com/news/featured-company-news-durect-sandoz-121500196.html?.tsrc=rss,"Research Desk Line-up: Taro Pharma Post Earnings Coverage LONDON, UK / ACCESSWIRE / June 21, 2017 / Pro-Trader Daily takes a look at the latest corporate events and news making the headlines for DURECT ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back But Finished Off Its Lows,2017-06-21 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PDsEvSLxZNQ/the-swiss-stock-market-pulled-back-but-finished-off-its-lows-20170621-00849,The Swiss Stock Market Pulled Back But Finished Off Its Lows
NVS,NVS:US,BBG000LYF3S8,Novartis Says EMA Accepts MAA For AMG 334 For Prevention Of Migraine,2017-06-21 01:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pmoFxYCBc_M/novartis-says-ema-accepts-maa-for-amg-334-for-prevention-of-migraine-20170621-00023,Novartis Says EMA Accepts MAA For AMG 334 For Prevention Of Migraine
NVS,NVS:US,BBG000LYF3S8,Regeneron Pharmaceuticals Inc (REGN) Stock Looks Good Despite the Backdrop,2017-06-21 00:19:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cnLUCF3jnq0/regeneron-pharmaceuticals-inc-regn-stock-looks-good-despite-the-backdrop-cm806012,InvestorPlace Stock Market News Stock Advice amp Trading Tips By almost all accounts Regeneron Pharmaceuticals Inc NASDAQ REGN should be tanking today Fellow biopharma name 160 Novartis AG ADR NYSE NVS announced some trial results this morning that
NVS,NVS:US,BBG000LYF3S8,Novartis Takes Aim at Regeneron Pharmaceuticals' Eylea,2017-06-20 22:21:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TEOX4i2grUM/novartis-takes-aim-at-regeneron-pharmaceuticals-eylea-cm805977,Novartis AG s NYSE NVS vision restoring drug Lucentis has been locked in a heated battle for market share with Regeneron Pharmaceuticals NASDAQ REGN 160 Eylea ever since the latter won FDA approval in 2011 Eylea is generating billions of dollars in sales every
NVS,NVS:US,BBG000LYF3S8,Regeneron Soars After Eye Drug Competitor Novartis Releases Positive Data,2017-06-20 21:50:00 +0000,http://finance.yahoo.com/r/797f515e-9ca8-33b3-9171-3656e3220bc6/regeneron-soars-after-eye-drug-competitor-novartis-releases-positive-data.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Novartis released data from its RTH258 clinical trials illustrating that RTH258 does not need to be injected as often as Regeneron's rival drug, Eylea."
NVS,NVS:US,BBG000LYF3S8,Gilead's (GILD) HBV Drug Vemlidy Receives Approval in Canada,2017-06-20 21:20:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o91wj7k3cXk/gileads-gild-hbv-drug-vemlidy-receives-approval-in-canada-cm805929,Gilead Sciences Inc GILD announced that hepatitis B virus HBV drug Vemlidy has been approved in Canada Health Canada granted a Notice of Compliance NOC for Vemlidy 25mg tablets a once daily treatment for adults with chronic HBV infection with compensated liver disease The approval
NVS,NVS:US,BBG000LYF3S8,"Close Update: Wall Street Retreats From Record Highs on Losses in Energy, Retail and Tech",2017-06-20 20:59:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0jZe4Bgp4ao/close-update-wall-street-retreats-from-record-highs-on-losses-in-energy-retail-and-tech-cm805947,Fresh off Monday s record highs Wall Street traded lower on Tuesday with losses concentrated in the energy technology and retail sectors The energy complex was again plagued by oversupply pressures while retailers went on the defensive after Amazon AMZN launched Prime Wardrobe
NVS,NVS:US,BBG000LYF3S8,Could Novartis&apos; Drug Topple Regeneron&apos;s Blockbuster Eylea?,2017-06-20 20:45:16 +0000,http://finance.yahoo.com/r/c4a30f9a-c15e-3756-8851-03c07e8a71f5/could-novartis-drug-topple-regenerons-blockbuster-eylea?src=A00220&yptr=yahoo&.tsrc=rss,Regeneron stock rocketed to a five-month high Tuesday despite the looming launch of a Novartis drug likely to chip away at blockbuster eye-disease drug Eylea.
NVS,NVS:US,BBG000LYF3S8,The (Second) Hottest Stock: Regeneron Pharmaceuticals Jumps 5%,2017-06-20 20:25:00 +0000,http://finance.yahoo.com/r/dc3c3197-b962-386e-ae95-809b2bbc5988/the-hot-stock-regeneron-pharmaceuticals-jumps-5-1497990064?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Regeneron Pharmaceuticals (REGN) soared almost to the top S&P 500 today after a drug trial showed a Novartis (NVS) treatment for age-related macular degeneration was not worse than but not better than ...
NVS,NVS:US,BBG000LYF3S8,Novartis Takes Aim at Regeneron Pharmaceuticals&apos; Eylea,2017-06-20 20:21:00 +0000,http://finance.yahoo.com/r/a4c80de2-a613-36a0-8016-1ffa4cfdc920/novartis-takes-aim-at-regeneron-pharmaceuticals-ey.aspx?yptr=yahoo&.tsrc=rss,New data suggest that Novartis may have a drug that works similarly to Eylea but requires fewer monthly eye injections per year.
NVS,NVS:US,BBG000LYF3S8,Novartis eye drug works with fewer injections than rival,2017-06-20 18:30:28 +0000,https://finance.yahoo.com/news/novartis-eye-drug-works-fewer-163107910.html?.tsrc=rss,"A Novartis drug to  treat a leading cause of vision loss in people over 65 does not  need to be injected as frequently as a rival medicine from  Regeneron Pharmaceuticals to be effective, clinical  trials showed on Tuesday.  Novartis said the trials showed its RTH258 drug would reduce  the injection burden for patients with neovascular age-related  macular degeneration (nAMD).  Novartis shares were up 0.8 percent, with analysts saying  the trial results gave RTH258 a competitive advantage over rival  treatments."
NVS,NVS:US,BBG000LYF3S8,Amgen's Xgeva Myeloma Label Expansion sBLA Accepted by FDA,2017-06-20 17:21:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZkNC73aeY18/amgens-xgeva-myeloma-label-expansion-sbla-accepted-by-fda-cm805779,Amgen Inc 160 AMGN announced that the FDA has accepted its supplemental Biologics License Application sBLA to expand the label of its key drug Xgeva Xgeva is currently approved for the prevention of skeletal related events SREs in solid tumors in patients with bone metastases Amgen
NVS,NVS:US,BBG000LYF3S8,Midday Update: Oil Sell-Off Puts Averages in Negative Turf,2017-06-20 17:20:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BzcCXK6vYsQ/midday-update-oil-sell-off-puts-averages-in-negative-turf-cm805823,The major benchmark averages were all trading defensively on Tuesday with a sell off in oil driving energy shares sharply lower and West Texas intermediate oil futures into bear market territory The major benchmark averages were all trading defensively on Tuesday with a sell off in oil
NVS,NVS:US,BBG000LYF3S8,Regeneron stock surges 7% after Novartis releases positive data for rival drug,2017-06-20 16:09:31 +0000,http://finance.yahoo.com/r/7ffd916e-3e4c-3b01-abc2-3dcc736ec790/Story.aspx?guid=9194D982-A6E3-46E1-BCF6-A81F0127C705&siteid=yhoof2&yptr=yahoo&.tsrc=rss,Regeneron Pharmaceuticals Inc. shares surged 6.6% in midday trade Tuesday after Novartis AG released positive data for two late-stage trials comparing its eye disease drug head-to-head with Regeneron's ...
NVS,NVS:US,BBG000LYF3S8,The Eyes Have It! Why Regeneron Is Hitting A 52-Week High,2017-06-20 14:56:00 +0000,http://finance.yahoo.com/r/4eafa0ef-6edf-36d0-96ad-724c978fd54f/the-eyes-have-it-why-regeneron-is-hitting-a-52-week-high-1497970591?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Earlier today, shares of Regeneron Pharmaceuticals (REGN) were falling on news that that Novartis (NVS) released clinical trial data for an experimental eye drug that is poised to rival Eylea, the blockbuster medication marketed by Regeneron.  Piper Jaffray analyst Ed Tenthoff is telling investors to not only buy stock, but lifted his price target from $446 to $557 a share.  Yes, Novartis’s eye drug is “a competitive threat to Eylea,” Tenthoff says."
NVS,NVS:US,BBG000LYF3S8,Bristol-Myers Squibb a Top Socially Responsible Dividend Stock With 2.8% Yield (BMY),2017-06-20 13:22:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hevXj_Eh9UI/bristol-myers-squibb-a-top-socially-responsible-dividend-stock-with-28-yield-bmy-cm805455,Bristol Myers Squibb Co Symbol BMY has been named a Top Socially Responsible Dividend Stock by Dividend Channel signifying a stock with above average DividendRank statistics including a strong 2 8 yield as well as being recognized by prominent asset managers as being a
NVS,NVS:US,BBG000LYF3S8,5 Most Profitable Big Pharma Stocks on the Market Right Now,2017-06-20 13:21:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MukY_YPYtXs/5-most-profitable-big-pharma-stocks-on-the-market-right-now-cm805467,It s no secret that many big pharma companies are highly profitable In fact the industry s gigantic profits have attracted plenty of negative attention from politicians and the press For investors though stocks for businesses that are very profitable are a great thing Five
NVS,NVS:US,BBG000LYF3S8,UPDATE 1-Novartis eye drug works with fewer injections than rivals,2017-06-20 12:29:46 +0000,https://finance.yahoo.com/news/novartis-eye-drug-works-fewer-111122285.html?.tsrc=rss,"A drug developed by Novartis  to treat vision loss in people over 65 does not need to  be injected as frequently as a rival medicine from Regeneron  to be effective, clinical trials showed on Tuesday.  Novartis said the trials showed its RTH258 drug would reduce  the injection burden for patients with neovascular age-related  macular degeneration (nAMD), the leading cause of vision loss  for over 65s in North America, Europe, Australia and Asia.  Novartis shares climbed 1.4 percent by 1041 GMT,  outperforming the Stoxx European health care sector index  , with analysts saying the trial results gave RTH258 a  competitive advantage over rival treatments."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped As Roche And Banks Struggle,2017-06-20 12:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2uNZ9ep0iRc/the-swiss-stock-market-dipped-as-roche-and-banks-struggle-20170620-00975,The Swiss Stock Market Dipped As Roche And Banks Struggle
NVS,NVS:US,BBG000LYF3S8,European Markets Finished Lower As Early Gains Erode,2017-06-20 12:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YHcrT1x3fTQ/european-markets-finished-lower-as-early-gains-erode-20170620-00963,European Markets Finished Lower As Early Gains Erode
NVS,NVS:US,BBG000LYF3S8,5 Most Profitable Big Pharma Stocks on the Market Right Now,2017-06-20 11:27:00 +0000,http://finance.yahoo.com/r/003646c7-280d-3ef3-b660-d57cff7b2db6/5-most-profitable-big-pharma-stocks-on-the-market.aspx?yptr=yahoo&.tsrc=rss,"Looking for big pharma stocks with big-time profit margins? Check out Gilead Sciences, Amgen, Novartis, Biogen, and Bristol-Myers Squibb."
NVS,NVS:US,BBG000LYF3S8,Stocks May Show A Lack Of Direction In Early Trading - U.S. Commentary,2017-06-20 08:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/36ZPC4A059c/stocks-may-show-a-lack-of-direction-in-early-trading--us-commentary-20170620-00576,Stocks May Show A Lack Of Direction In Early Trading - U.S. Commentary
NVS,NVS:US,BBG000LYF3S8,European Shares Follow Wall Street Higher,2017-06-20 06:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tVXmpSXOXsg/european-shares-follow-wall-street-higher-20170620-00247,European Shares Follow Wall Street Higher
NVS,NVS:US,BBG000LYF3S8,Novartis: RTH258 Meets Endpoints In Two Phase III Studies - Quick Facts,2017-06-20 01:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_UxmFztuuI8/novartis-rth258-meets-endpoints-in-two-phase-iii-studies--quick-facts-20170620-00034,Novartis: RTH258 Meets Endpoints In Two Phase III Studies - Quick Facts
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Biosimilar of MabThera Approved in the EU,2017-06-19 23:20:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/utLNnKRjv5g/novartis-nvs-biosimilar-of-mabthera-approved-in-the-eu-cm805387,Novartis AG NVS announced that its generic arm Sandoz has received European Commission EC approval for Rixathon a biosimilar version of Roche s RHHBY MabThera in Europe The biosimilar version has been approved for all the indications of the branded drug Rixathon is approved
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Biosimilar of MabThera Approved in the EU,2017-06-19 20:56:08 +0000,https://finance.yahoo.com/news/novartis-nvs-biosimilar-mabthera-approved-205608212.html?.tsrc=rss,"Novartis AG (NVS) announced that its generic arm, Sandoz, has received European Commission (EC) approval for Rixathon."
NVS,NVS:US,BBG000LYF3S8,Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock: Time to Go Contrarian?,2017-06-19 20:19:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YxM29o3La_c/teva-pharmaceutical-industries-ltd-adr-teva-stock-time-to-go-contrarian-cm805346,InvestorPlace Stock Market News Stock Advice amp Trading Tips The pharmaceutical business is a love hate affair Right now Wall Street is feeling the latter for Teva Pharmaceutical Industries Ltd ADR NYSE TEVA Although the Israeli pharma is one of the most respected names
NVS,NVS:US,BBG000LYF3S8,Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock: Time to Go Contrarian?,2017-06-19 15:52:13 +0000,https://finance.yahoo.com/news/teva-pharmaceutical-industries-ltd-adr-155213099.html?.tsrc=rss,"The pharmaceutical business is a love-hate affair.  Right now, Wall Street is feeling the latter for Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).  Although the Israeli pharma is one of the most respected names in the industry, TEVA stock plays the opposite role."
NVS,NVS:US,BBG000LYF3S8,3 Biotech Stocks That More than Doubled Year to Date,2017-06-19 15:25:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8kKdR_t4FAE/3-biotech-stocks-that-more-than-doubled-year-to-date-cm805064,We are almost half way through 2017 and the biotech sector which had a rough and challenging 2016 has been showing signs of recovery despite some ups and downs Year to date YTD the NASDAQ Biotechnology Index is up 10 4 providing a glimmer of hope to biotech investors who saw the
NVS,NVS:US,BBG000LYF3S8,Eylea Continues to Be a Key Growth Driver for Regeneron in 2017,2017-06-19 13:08:16 +0000,http://finance.yahoo.com/r/1dc6c2e6-273d-3a09-80fd-9c195b6b69ba/eylea-continues-key-growth-driver-regeneron-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Regeneron's (REGN) Eylea reported revenues of about $854.0 million in the US market, which is a YoY (year-over-year) rise of about 9.0%."
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Climbed Back Above 9,000 Points",2017-06-19 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6C7b4pk1cq0/the-swiss-stock-market-climbed-back-above-9000-points-20170619-00891,"The Swiss Stock Market Climbed Back Above 9,000 Points"
NVS,NVS:US,BBG000LYF3S8,European Markets Jumped On French Election Results,2017-06-19 12:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2s6wcsWqnw0/european-markets-jumped-on-french-election-results-20170619-00877,European Markets Jumped On French Election Results
NVS,NVS:US,BBG000LYF3S8,DURECT's Collaboration with Sandoz Clears HSR Review and is Effective,2017-06-19 11:00:00 +0000,https://finance.yahoo.com/news/durects-collaboration-sandoz-clears-hsr-110000564.html?.tsrc=rss,"CUPERTINO, Calif., June 19, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that the previously disclosed development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery, has cleared review under the Hart-Scott-Rodino (HSR) Antitrust Improvements Act of 1976 and has become effective.  Under the terms of the agreement, Sandoz has made an upfront payment to DURECT of $20 million, with the potential for up to an additional $43 million in development and regulatory milestones, up to an additional $230 million in sales-based milestones, as well as a tiered double-digit royalty on product sales in the United States."
NVS,NVS:US,BBG000LYF3S8,Novartis Secures European Approval For Biosimilar Cancer Treatment Rixathon,2017-06-19 08:42:00 +0000,http://finance.yahoo.com/r/6fb4f336-998a-3cb9-837f-a1e4d8bf7356/novartis-secures-european-approval-for-biosimilar-cancer-treatment-rixathon.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Novartis said Monday that it has received EC approval for a blood cancer treatment known as Rixathon, a biosimilar version of Roche's Rituxan that generated $7.5 billion in 2016 sales."
NVS,NVS:US,BBG000LYF3S8,European Shares Rise As Brexit Talks Begin,2017-06-19 06:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P-ueD-bCp20/european-shares-rise-as-brexit-talks-begin-20170619-00252,European Shares Rise As Brexit Talks Begin
NVS,NVS:US,BBG000LYF3S8,Could Legalized Marijuana Be Making Big Pharma Nervous?,2017-06-18 19:19:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hJp4i0ldJpI/could-legalized-marijuana-be-making-big-pharma-nervous-cm804826,An effort in Arizona to legalize recreational marijuana failed last year Insys Therapeutics NASDAQ INSY helped make it happen The drugmaker donated 500 000 to an organization that opposed a marijuana legalization proposition It makes sense that Insys would be
NVS,NVS:US,BBG000LYF3S8,The Supreme Court Just Made a Big Opportunity for Biosimilars Even Bigger,2017-06-17 20:19:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oI8-ABK_5oQ/the-supreme-court-just-made-a-big-opportunity-for-biosimilars-even-bigger-cm804759,The market opportunity for biosimilars is already 160 big but it got even bigger 160 after the 160 Supreme Court voted unanimously this week 160 to remove a 180 day waiting period that s been delaying 160 biosimilar drug launches The Court s 160 decision clears the way
NVS,NVS:US,BBG000LYF3S8,Google and Novartis Back Medicxi's New $300 Million Fund,2017-06-16 13:45:00 +0000,http://finance.yahoo.com/r/45bc8690-ec8b-3831-a073-83d5cec361b8/google-and-novartis-back-medicxi-s-new-300-million-fund.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Developing a promising drug? This new investment fund is looking to invest in Phase 2 candidates.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed As NestlÃ© Shares Surged,2017-06-16 12:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PlAzz7mcHSk/the-swiss-stock-market-climbed-as-nestl%C3%A3-shares-surged-20170616-00549,The Swiss Stock Market Climbed As NestlÃ© Shares Surged
NVS,NVS:US,BBG000LYF3S8,Investor Update: Incyte’s Key Developments in 1Q17,2017-06-16 11:36:27 +0000,http://finance.yahoo.com/r/94b81c76-9f9f-3b1b-9ac9-41535254b745/investor-update-incytes-key-developments-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte (INCY) distributes its key drug Jakafi through its own network of specialty pharmacy providers and wholesalers in the US.
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Announced Positive Data on Psoriasis Cosentyx,2017-06-16 00:06:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ixrP1mLphN4/novartis-nvs-announced-positive-data-on-psoriasis-cosentyx-cm804157,Novartis AG NVS announced positive data on arthritis drug Cosentyx from two phase III studies at the Annual European Congress of Rheumatology EULAR 2017 in Madrid Cosentyx fully human monoclonal antibody is already approved in the U S and EU for the treatment of moderate to severe
NVS,NVS:US,BBG000LYF3S8,Puma (PBYI) Stock Surges as Neratinib Nears FDA Approval,2017-06-15 23:07:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/c7lrUXK2K9A/puma-pbyi-stock-surges-as-neratinib-nears-fda-approval-cm804131,Puma Biotechnology Inc PBYI is a Los Angeles CA based biopharmaceutical company focused on the development and commercialization of innovative treatments that enhance cancer care Puma s stock has significantly outperformed the Zacks classified Medical Biomed Genetics industry in
NVS,NVS:US,BBG000LYF3S8,Why Is ImmunoGen (IMGN) Stock Up 131% This Year?,2017-06-15 21:07:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hQ23dJRFkMQ/why-is-immunogen-imgn-stock-up-131-this-year-cm804075,Shares of ImmunoGen Inc IMGN are massively up 130 9 this year so far outperforming the the Zacks classified Medical Drugs industry s registered 3 6 increase during this period Let s analyze the factors that led to the rally Waltham MA based ImmunoGen is a development
NVS,NVS:US,BBG000LYF3S8,Why is Alnylam's (ALNY) Stock Close to 100% this Year?,2017-06-15 16:10:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_cMnAtT_nS0/why-is-alnylams-alny-stock-close-to-100-this-year-cm803900,Shares of Alnylam Pharmaceuticals Inc ALNY soared 99 8 this year so far massively outperforming the 3 1 increase registered by the Zacks classified Biomed Genetics industry during this period Here we analyze the factors that led to the rally Alnylam Pharmaceuticals Inc is
NVS,NVS:US,BBG000LYF3S8,How Incyte’s Jakafi Performed in 1Q17,2017-06-15 14:37:25 +0000,http://finance.yahoo.com/r/edce9106-ea1e-337a-b137-984745e05c66/how-incytes-jakafi-performed-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte’s (INCY) Jakafi (ruxolitinib) is the only FDA-approved drug for the treatment of myelofibrosis and polycythemia vera, both of which are rare types of blood cancer."
NVS,NVS:US,BBG000LYF3S8,AbbVie a Top Socially Responsible Dividend Stock With 3.6% Yield (ABBV),2017-06-15 13:08:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GfIhSnSHzu0/abbvie-a-top-socially-responsible-dividend-stock-with-36-yield-abbv-cm803670,AbbVie Inc Symbol ABBV has been named a Top Socially Responsible Dividend Stock by Dividend Channel signifying a stock with above average DividendRank statistics including a strong 3 6 yield as well as being recognized by prominent asset managers as being a socially
NVS,NVS:US,BBG000LYF3S8,How Did Incyte’s Product Portfolio Look in 1Q17?,2017-06-15 13:07:51 +0000,http://finance.yahoo.com/r/ec25bbe5-7330-39da-b1fc-0e0a365a4625/how-did-incytes-product-portfolio-look-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Incyte’s (INCY) product portfolio includes oncology and non-oncology drugs.
NVS,NVS:US,BBG000LYF3S8,Google's Owner Is Getting Into Drugs,2017-06-15 12:15:24 +0000,http://finance.yahoo.com/r/259e438e-bf79-3ea8-913c-73852e148e9a/alphabet-s-drug-adventure?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,New Medicxi fund is a boon to scientists.
NVS,NVS:US,BBG000LYF3S8,Analyzing Incyte’s Revenue Streams in 1Q17,2017-06-15 11:37:06 +0000,http://finance.yahoo.com/r/77097dd8-5021-34c2-8fef-5911b58253d0/analyzing-incytes-revenue-streams-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Incyte (INCY) reported revenues of $384.1 million in its 1Q17 results, which translates to 45.7% revenue growth in 1Q17 as compared to $263.5 million in 1Q16."
NVS,NVS:US,BBG000LYF3S8,Novartis' Cosentyx Shows Improvements In Signs And Symptoms For Both AS And PsA,2017-06-15 01:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sEMdY6TofBU/novartis-cosentyx-shows-improvements-in-signs-and-symptoms-for-both-as-and-psa-20170615-00020,Novartis' Cosentyx Shows Improvements In Signs And Symptoms For Both AS And PsA
NVS,NVS:US,BBG000LYF3S8,[$$] Alphabet life sciences arm to invest in EU drug development,2017-06-14 23:01:33 +0000,"http://finance.yahoo.com/r/d9663ce3-9ce9-3fc2-beaf-415653cb9915/a7d73bc0-5113-11e7-a1f2-db19572361bb,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The life sciences division of Google's parent company has made its biggest push into drug development by investing in a new fund that will buy stakes in European biotech groups, underscoring its growing ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Slipped Into The Red Ahead Of Fed Announcement,2017-06-14 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9qxayuna_Tk/the-swiss-stock-market-slipped-into-the-red-ahead-of-fed-announcement-20170614-00848,The Swiss Stock Market Slipped Into The Red Ahead Of Fed Announcement
NVS,NVS:US,BBG000LYF3S8,Coherus Stock Plummets as FDA Rejects Neulasta Biosimilar,2017-06-13 16:32:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HJqx_ZblBpk/coherus-stock-plummets-as-fda-rejects-neulasta-biosimilar-cm802794,Coherus Biosciences Inc CHRS shares declined nearly 24 in yesterday s trading as it announced that it has received a complete response letter CRL from the FDA for its biosimilar version of Amgen Inc s AMGN blockbuster drug Neulasta The CRL will delay the potential regulatory clearance
NVS,NVS:US,BBG000LYF3S8,"Notable ETF Inflow Detected - VEA, NSRGY, NVS, TM",2017-06-13 16:30:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hYBU7XPRC8o/notable-etf-inflow-detected-vea-nsrgy-nvs-tm-cm802779,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 457 0 million dollar inflow that s a 0 8 increase week over week
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Rebounded Following Monday's Loss,2017-06-13 12:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ac254Uhevew/the-swiss-stock-market-rebounded-following-mondays-loss-20170613-00974,The Swiss Stock Market Rebounded Following Monday's Loss
NVS,NVS:US,BBG000LYF3S8,Novartis Presents Positive Data on CAR-T Cell Therapy Drug,2017-06-12 23:27:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gzatca_SWnI/novartis-presents-positive-data-on-car-t-cell-therapy-drug-cm802378,Novartis AG NVS announced data from an interim analysis from its multi center global phase II study JULTIET NCT02445248 The study examined pipeline candidate CTL019 among adult patients suffering from relapsed or refractory r r diffuse large B cell lymphoma DLBCL The study showed
NVS,NVS:US,BBG000LYF3S8,Novartis Presents Positive Data on CAR-T Cell Therapy Drug,2017-06-12 21:02:09 +0000,https://finance.yahoo.com/news/novartis-presents-positive-data-car-210209873.html?.tsrc=rss,Novartis AG (NVS) announced data from an interim analysis from a phase II study on lymphoma candidate.
NVS,NVS:US,BBG000LYF3S8,[$$] Cancer treatment: scaling up a vein-to-vein solution,2017-06-12 17:16:35 +0000,"http://finance.yahoo.com/r/dfa5d5dd-2b45-3f71-b77a-5b723986374b/e2c8eaa2-415b-11e7-9d56-25f963e998b2,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","The huge tumour protruding from Jami Cameron's pelvis was shrinking before her eyes. Having battled lymphoma since 1994, she thought she had run out of options. The 53-year-old had tried numerous rounds ..."
NVS,NVS:US,BBG000LYF3S8,U.S. Supreme Court speeds copycat biologic drugs to market,2017-06-12 16:51:12 +0000,https://finance.yahoo.com/news/u-supreme-court-speeds-copycat-143605359.html?.tsrc=rss,"The U.S. Supreme Court on  Monday cut the time it will take for copycat versions of  biologic drugs to get to the market in a pivotal ruling about an  expensive class of medicines that can yield billions of dollars  in sales for drug companies.  The justices, in a 9-0 ruling, overturned a lower court's  decision that had prevented Swiss pharmaceutical company  Novartis AG from selling its copycat version of  California-based Amgen Inc's Neupogen until six months  after the U.S. Food and Drug Administration approved it."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market,2017-06-12 12:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H9sKfLBhv6c/the-swiss-stock-market-20170612-00788,The Swiss Stock Market
NVS,NVS:US,BBG000LYF3S8,Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma,2017-06-09 22:28:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mUbsbBzgLjw/get-paid-while-you-wait-3-top-dividend-stocks-in-big-pharma-cm801509,It s a fact Dividend stocks are often the foundation of most retirement portfolios But not all dividend stocks are created equally Income investors are usually on the lookout for stocks with as high a dividend yield as possible but also a yield that ll be sustainable over
NVS,NVS:US,BBG000LYF3S8,Get Paid While You Wait: 3 Top Dividend Stocks in Big Pharma,2017-06-09 20:45:00 +0000,http://finance.yahoo.com/r/2ee72777-339d-3ef7-8524-04abd0a8e13c/get-paid-while-you-wait-3-top-dividend-stocks-in-b.aspx?yptr=yahoo&.tsrc=rss,Good things come to those income investors who wait.
NVS,NVS:US,BBG000LYF3S8,Why is Kite Pharma (KITE) Stock Up Close to 100% this Year?,2017-06-09 16:30:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bXO_lV_7Wx8/why-is-kite-pharma-kite-stock-up-close-to-100-this-year-cm801256,Shares of Kite Pharma Inc KITE were up around 5 6 on Thursday In fact shares of this small biotech are up a massive 93 3 this year so far outperforming the 1 8 increase registered by the Zacks classified Biomed Genetics industry during this period Here we analyze the factors that led
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Finished Higher Friday, But Ended The Week With A Loss",2017-06-09 12:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4qUwUpFbpbI/the-swiss-stock-market-finished-higher-friday-but-ended-the-week-with-a-loss-20170609-00618,"The Swiss Stock Market Finished Higher Friday, But Ended The Week With A Loss"
NVS,NVS:US,BBG000LYF3S8,Small Biotech Pops As Rival Novartis Struggles To Keep Pace,2017-06-08 20:13:28 +0000,http://finance.yahoo.com/r/4af72441-7572-3c72-aef8-9a3b89787adb/small-biotech-pops-as-rival-novartis-struggles-to-keep-pace?src=A00220&yptr=yahoo&.tsrc=rss,Kite stock jumped for the third straight day Thursday after rival Novartis presented data on a cancer drug that would have to be 20% better to hurt Kite.
NVS,NVS:US,BBG000LYF3S8,Biotech Stocks To Watch And Pharma Industry News,2017-06-08 19:53:44 +0000,http://finance.yahoo.com/r/d95a9140-bcb4-38ab-b942-e0c45662051a/biotech-and-pharma-industry-and-stock-news-merk-bristol-myers-amgn-gilead?src=A00220&yptr=yahoo&.tsrc=rss,Track the latest trends and leading stocks in the biotech and pharmaceutical industries.
NVS,NVS:US,BBG000LYF3S8,There's a race to get 2 revolutionary new cancer treatments on the market — here's who's in the lead,2017-06-08 17:31:00 +0000,https://finance.yahoo.com/news/theres-race-2-revolutionary-cancer-173100625.html?.tsrc=rss,Two cutting-edge treatments for blood cancers are poised to get approved by the end of the...
NVS,NVS:US,BBG000LYF3S8,Teva Migraine Candidate Succeeds in Second Phase III Study,2017-06-08 16:31:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qckKAoLJf5o/teva-migraine-candidate-succeeds-in-second-phase-iii-study-cm800670,Teva Pharmaceutical Industries Ltd TEVA announced that its experimental migraine prevention drug fremanezumab met all the primary and secondary endpoints in a second late stage study Pivotal data from the second phase III HALO study in episodic migraine prevention showed that patients
NVS,NVS:US,BBG000LYF3S8,"VGK, MMTM: Big ETF Inflows",2017-06-08 16:30:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HNfx5Kp_MYk/vgk-mmtm-big-etf-inflows-cm800668,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Europe ETF VGK which added 10 200 000 units or a 3 9 increase week over week Among the largest underlying components of VGK in morning
NVS,NVS:US,BBG000LYF3S8,The Reasons Kite Pharma Is Set to Fly Higher,2017-06-08 15:43:00 +0000,http://finance.yahoo.com/r/18226960-e533-3373-9c30-df9da2545e38/three-reasons-kite-pharma-is-set-to-fly-higher.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,BTIG analyst Dane Leone noted three key reasons why he executed today's upgrade of the stock.
NVS,NVS:US,BBG000LYF3S8,3 Stocks to Buy With Dividends Yielding 3% or More,2017-06-08 15:30:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kSfgTSF3nO4/3-stocks-to-buy-with-dividends-yielding-3-or-more-cm800560,Top dividend stocks feature handsome yields and good growth prospects But just because a stock has a high dividend yield doesn t mean that it has withstood the test of time Instead it s essential to look beyond the yield and see whether companies have a blue chip pedigree
NVS,NVS:US,BBG000LYF3S8,Kite Pharma Flies Higher…Why?,2017-06-08 14:55:00 +0000,http://finance.yahoo.com/r/a4cf0d10-85de-3748-9de2-213da604ddab/kite-pharma-flies-higherwhy-1496933723?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"Shares of Kite Pharma (KITE) are up 2.4% today thanks to a bullish note from BTIG analyst Dane Leone.  In a note published today, he upgraded the drug maker from a Neutral to a Buy, citing three key reasons.  Earlier today, Leone downgraded  Juno Therapeutics (JUNO) to a Sell, arguing that the rival drug maker lags Kite in the CAR-T race."
NVS,NVS:US,BBG000LYF3S8,"Juno Therapeutics: To Sell, Or Not To Sell…Good Question",2017-06-08 14:13:00 +0000,http://finance.yahoo.com/r/7e2b76a1-5269-37d2-be3a-a3263c8586b9/juno-therapeutics-to-sell-or-not-to-sellgood-question-1496931199?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,Is it time to shed shares of Juno Therapeutics (JUNO)?  BTIG analyst Dane Leone thinks so.  The drug maker’s stock price is down 4% today to $22.75 a share after Leone cut his rating from a Neutral to a Sell with a $12 price target.
NVS,NVS:US,BBG000LYF3S8,3 Stocks to Buy With Dividends Yielding 3% or More,2017-06-08 14:09:00 +0000,http://finance.yahoo.com/r/f012f875-572b-3f08-8db9-b6b4fe28210a/3-stocks-to-buy-with-dividends-yielding-3-or-more.aspx?yptr=yahoo&.tsrc=rss,Looking for both good yields and solid business prospects is important. These stocks deliver the goods.
NVS,NVS:US,BBG000LYF3S8,Conatus (CNAT) Down 33.1% Since Earnings Report: Can It Rebound?,2017-06-08 13:54:01 +0000,https://finance.yahoo.com/news/conatus-cnat-down-33-1-135401335.html?.tsrc=rss,Conatus (CNAT) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
NVS,NVS:US,BBG000LYF3S8,Key Reasons BTIG Just Upgraded Kite Pharma,2017-06-08 13:20:07 +0000,https://finance.yahoo.com/news/key-reasons-btig-just-upgraded-132007630.html?.tsrc=rss,"A solid strategy and great execution have led BTIG analyst, Dane Leone , to upgrade his recommendation on Kite Pharma Inc. (NASDAQ: KITE ) to Buy, and set a price target of $100. The Core Theses That Sees ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped As NestlÃ© Shares,2017-06-08 12:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LnVf78il_dI/the-swiss-stock-market-dropped-as-nestl%C3%A3-shares-20170608-00915,The Swiss Stock Market Dropped As NestlÃ© Shares
NVS,NVS:US,BBG000LYF3S8,Spring Bank Pharmaceuticals' Hepatitis B Results in Context,2017-06-08 12:26:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qg86FEsoP2E/spring-bank-pharmaceuticals-hepatitis-b-results-in-context-cm800407,Spring Bank Pharmaceuticals Inc SBPH announced positive initial Phase II results for its new antiviral hepatitis B HBV treatment SB 9200 Shares have recorded all time highs up as much as 28 on the news Spring Bank Pharmaceuticals Inc Spring Bank Pharmaceuticals Inc
NVS,NVS:US,BBG000LYF3S8,Jazz Pharma Sleep Disorder Candidate Positive in Phase III,2017-06-07 17:28:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t_h_xfQu2rU/jazz-pharma-sleep-disorder-candidate-positive-in-phase-iii-cm800157,Jazz Pharmaceuticals plc JAZZ announced positive efficacy results from studies evaluating its lead pipeline candidate JZP 110 in adult patients with excessive sleepiness ES associated with narcolepsy and obstructive sleep apnea OSA The data were presented at the 31st
NVS,NVS:US,BBG000LYF3S8,Novartis touts new T-cell therapy data in race for FDA approval,2017-06-07 15:36:42 +0000,https://finance.yahoo.com/news/novartis-touts-t-cell-therapy-153642283.html?.tsrc=rss,"Novartis on Wednesday  touted new data from its T-cell therapy CTL019, saying it is on  a par with results of experimental molecules from Kite Pharma  and Juno Therapeutics that also target  aggressive blood cancers.  Three months after infusion, the overall response rate  (ORR)among 51 adult patients with relapsed or refractory diffuse  large B-cell lymphoma (DLBCL) was 45 percent, Novartis said,  with 37 percent complete responses (CR), or no sign of disease.  Novartis aims for $1 billion in annual sales for CTL019, a  drug made by taking T cells from a patient, reprogramming them  in the lab to fight cancer, and re-infusing them."
NVS,NVS:US,BBG000LYF3S8,Novartis' (NVS) Tasigna Receives Label Update Nod in EU,2017-06-07 15:28:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4L41Nd5hfqc/novartis-nvs-tasigna-receives-label-update-nod-in-eu-cm800064,Novartis AG NVS announced that the European Commission EC has approved the inclusion of Treatment free Remission TFR data in the oncology drug Tasigna s Summary of Product Characteristics SmPC We note that Tasigna is approved for the treatment of chronic phase and accelerated
NVS,NVS:US,BBG000LYF3S8,Novartis&apos; (NVS) Tasigna Receives Label Update Nod in EU,2017-06-07 14:10:02 +0000,https://finance.yahoo.com/news/novartis-apos-nvs-tasigna-receives-141002888.html?.tsrc=rss,Novartis AG (NVS) announced that the EC has approved the inclusion of Treatment-free Remission (TFR) data in the oncology drug Tasigna&apos;s label.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Was Unable To Hold Onto Gains Wednesday,2017-06-07 12:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mmbofrGci00/the-swiss-stock-market-was-unable-to-hold-onto-gains-wednesday-20170607-00984,The Swiss Stock Market Was Unable To Hold Onto Gains Wednesday
NVS,NVS:US,BBG000LYF3S8,"Roche Announces Data on Perjeta, Alecensa and Tecentriq",2017-06-07 00:16:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JEq-IHdiX2Y/roche-announces-data-on-perjeta-alecensa-and-tecentriq-cm799727,Roche Holdings AG RHHBY announced data from the phase III study APHINITY on breast cancer drug Perjeta The data from the study showed that the combination of Perjeta Herceptin and chemotherapy the Perjeta based regimen significantly reduced the risk of breast cancer recurrence or
NVS,NVS:US,BBG000LYF3S8,"Novartis, Bristol-Myers Collaborate for Opdivo Combination",2017-06-07 00:16:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d8OUTMPlgXQ/novartis-bristol-myers-collaborate-for-opdivo-combination-cm799724,Novartis AG NVS announced that it has entered into clinical research collaboration with Bristol Myers Squibb Company BMY Per the terms of the agreement Bristol Myers will investigate the safety tolerability and efficacy of Novartis s Mekinist in combination with its own Opdivo
NVS,NVS:US,BBG000LYF3S8,"Bristol Myers, Novartis to Explore Potential Treatment for Metastatic Colorectal Cancer",2017-06-06 22:17:00 +0000,http://finance.yahoo.com/r/160739d8-7c1f-39ad-b306-700b6b5e1475/bristol-myers-novartis-to-explore-potential-treatment-for-metastatic-colorectal-cancer.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Bristol-Myers will conduct the study and both companies will evaluate the findings.
NVS,NVS:US,BBG000LYF3S8,"Novartis, Bristol-Myers Collaborate for Opdivo Combination",2017-06-06 22:12:10 +0000,https://finance.yahoo.com/news/novartis-bristol-myers-collaborate-opdivo-221210611.html?.tsrc=rss,Novartis AG (NVS) and Bristol-Myers Squibb Company (BMY) collaborate for Opdivo combination therapies.
NVS,NVS:US,BBG000LYF3S8,"Bluebird Bio Is Liked by Analysts, Cognizant Isn't",2017-06-06 12:55:00 +0000,https://finance.yahoo.com/news/bluebird-bio-liked-analysts-cognizant-125500436.html?.tsrc=rss,"Here are Tuesday's top research calls, including upgrades for Bluebird Bio and Tenet Healthcare, a downgrade for Cognizant and new coverage of Hormel."
NVS,NVS:US,BBG000LYF3S8,The Swiss Market Sank As Roche Leads The Way Lower,2017-06-06 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O4LpwwzwMd8/the-swiss-market-sank-as-roche-leads-the-way-lower-20170606-00938,The Swiss Market Sank As Roche Leads The Way Lower
NVS,NVS:US,BBG000LYF3S8,Novartis Presents Data on Tafinlar-Mekinist Combination,2017-06-06 00:00:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sfZTIliA3Ek/novartis-presents-data-on-tafinlar-mekinist-combination-cm799050,Novartis AG NVS announced results from a phase II study BRF113220 on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology ASCO The results from the study showed a durable survival benefit for some patients with BRAF
NVS,NVS:US,BBG000LYF3S8,Teva Pharmaceutical Industries Ltd (ADR) (TEVA): Nibble on Its Dividend and Wait,2017-06-05 22:00:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fxo3gwbQRik/teva-pharmaceutical-industries-ltd-adr-teva-nibble-on-its-dividend-and-wait-cm799037,InvestorPlace Stock Market News Stock Advice amp Trading Tips Investors have yet to warm to embattled generic drug maker Teva Pharmaceutical Industries Ltd ADR NYSE TEVA So far this year Teva stock is down close to 20 which is a far cry from the market s return of
NVS,NVS:US,BBG000LYF3S8,Novartis Presents Data on Tafinlar-Mekinist Combination,2017-06-05 21:26:09 +0000,https://finance.yahoo.com/news/novartis-presents-data-tafinlar-mekinist-212609458.html?.tsrc=rss,"Novartis AG (NVS) announced results from a phase II study, BRF113220, on the combination of Tafinlar and Mekinist at the 53rd Annual Meeting of the American Society of Clinical Oncology (ASCO)."
NVS,NVS:US,BBG000LYF3S8,"Novartis, Bristol-Myers To Evaluate Treatments In Metastatic Colorectal Cancer",2017-06-05 21:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cC8p26fxQhE/novartis-bristolmyers-to-evaluate-treatments-in-metastatic-colorectal-cancer-20170605-01301,"Novartis, Bristol-Myers To Evaluate Treatments In Metastatic Colorectal Cancer"
NVS,NVS:US,BBG000LYF3S8,Why I'm Positive on Novartis,2017-06-05 20:05:00 +0000,http://finance.yahoo.com/r/46f33545-69e0-323b-b888-bddeabfcbbac/why-im-positive-novartis?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Here's where to buy NVS.
NVS,NVS:US,BBG000LYF3S8,Amgen (AMGN) Presents Positive Clinical Data on Cancer Drugs,2017-06-05 19:00:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wTYOISxRRM0/amgen-amgn-presents-positive-clinical-data-on-cancer-drugs-cm798903,Amgen Inc AMGN presented encouraging results from a phase III study evaluating its marketed drug Xgeva denosumab for an expanded indication at the American Society of Clinical Oncology ASCO The company is looking to expand Xgeva s label for treating patients with multiple myeloma
NVS,NVS:US,BBG000LYF3S8,Radius (RDUS) Announces Positive Data on Breast Cancer Drug,2017-06-05 18:03:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CstpWQAfnbs/radius-rdus-announces-positive-data-on-breast-cancer-drug-cm798860,Radius Health Inc RDUS announced encouraging results from an ongoing phase I study on pipeline candidate elacestrant RAD1901 in patients suffering from estrogen receptor positive ER breast cancer RAD1901 an oral selective estrogen receptor degrader SERD is being evaluated
NVS,NVS:US,BBG000LYF3S8,Pfizer Provides Final Update on Phase II Talazoparib Study,2017-06-05 17:03:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vf13TjdWlh8/pfizer-provides-final-update-on-phase-ii-talazoparib-study-cm798793,Pfizer Inc PFE announced data from its phase II study ABRAZO which is evaluating talazoparib in advanced breast cancer patients with germline BRCA 1 2 positive gBRCA mutations showing anti tumor activity The results were presented at the Annual Meeting of the American Society of
NVS,NVS:US,BBG000LYF3S8,Juno Therapeutics Mounts CAR-T Comeback With Strong Lymphoma Study Results,2017-06-05 13:00:00 +0000,http://finance.yahoo.com/r/2622e856-5e14-323f-b2f6-1354854d3032/juno-therapeutics-mounts-car-t-comeback-with-strong-lymphoma-study-results.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Rivals Kite Pharma and Novartis are still out in front, but updated efficacy and safety data from Juno's JCAR017 program in patients with aggressive non-Hodgkin's lymphoma are very competitive."
NVS,NVS:US,BBG000LYF3S8,"Novartis, IBM Watson Health team up for breast cancer project",2017-06-05 11:35:03 +0000,https://finance.yahoo.com/news/novartis-ibm-watson-health-team-113503624.html?.tsrc=rss,"Novartis has agreed to work with IBM Watson Health to explore ways to use patient data and advanced analysis to glean insights on the likely outcomes of breast cancer treatments, the Swiss drugmaker said ..."
NVS,NVS:US,BBG000LYF3S8,Novartis Collaborates With IBM On Outcomes-based Care In Advanced Breast Cancer,2017-06-05 07:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sp6sPiZqjjY/novartis-collaborates-with-ibm-on-outcomesbased-care-in-advanced-breast-cancer-20170605-00316,Novartis Collaborates With IBM On Outcomes-based Care In Advanced Breast Cancer
NVS,NVS:US,BBG000LYF3S8,"AMGN Finds New Use For Old Drug, NLNK Disappointed, ECYT Cuts Workforce",2017-06-05 02:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_X--m_S9v_U/amgn-finds-new-use-for-old-drug-nlnk-disappointed-ecyt-cuts-workforce-20170605-00056,"AMGN Finds New Use For Old Drug, NLNK Disappointed, ECYT Cuts Workforce"
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Results From Phase II Study On Tafinlar + Mekinist,2017-06-04 12:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CnGR6kbVnDw/novartis-announces-results-from-phase-ii-study-on-tafinlar--mekinist-20170604-00024,Novartis Announces Results From Phase II Study On Tafinlar + Mekinist
NVS,NVS:US,BBG000LYF3S8,A New Cancer Drug Helped Almost Everyone Who Took It. Almost. Here's What It Teaches Us,2017-06-03 14:56:00 +0000,http://finance.yahoo.com/r/878537e7-582e-3f14-9d68-f8d473f8400e/a-new-cancer-drug-helped-almost-everyone-who-took-it-almost-heres-what-it-teaches-us?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix&yptr=yahoo&.tsrc=rss,"Of the first 50 people, 38, or 76%, had clear shrinkage of their tumors. Of those, 30, or 79%, hadn’t had their tumors start growing or had new ones appear after 12 months of treatment, and are still on the drug."
NVS,NVS:US,BBG000LYF3S8,Novartis Reports Positive Data on Breast Cancer Drug Kisqali,2017-06-02 17:32:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7O3SKS8XtGk/novartis-reports-positive-data-on-breast-cancer-drug-kisqali-cm798080,Novartis AG NVS announced positive data from the phase III study MONALEESA 2 on breast cancer drug Kisqali The study reinforced the efficacy and safety of Kisqali plus letrozole in postmenopausal women with hormone receptor positive human epidermal growth factor receptor 2
NVS,NVS:US,BBG000LYF3S8,Stocks to watch during ASCO,2017-06-02 16:49:00 +0000,https://finance.yahoo.com/video/stocks-watch-during-asco-164900354.html?.tsrc=rss,"CNBC's Meg Tirrell reports on what stocks to watch during ASCO, the biggest cancer research conference in Chicago. The “Fast Money Halftime Report” traders weigh in."
NVS,NVS:US,BBG000LYF3S8,Aduro's Drug Gets Clearance by the FDA for Solid Tumors,2017-06-02 16:34:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sRWXaNPefDs/aduros-drug-gets-clearance-by-the-fda-for-solid-tumors-cm798009,Aduro Biotech Inc ADRO announced that the FDA has cleared the Investigational New Drug application IND for its pipeline candidate ADU S100 MIW815 This candidate will be evaluated in combination with Novartis NVS investigational anti PD 1 checkpoint inhibitor PDR001 for the treatment
NVS,NVS:US,BBG000LYF3S8,Novartis Reports Positive Data on Breast Cancer Drug Kisqali,2017-06-02 15:36:03 +0000,https://finance.yahoo.com/news/novartis-reports-positive-data-breast-153603246.html?.tsrc=rss,"Novartis AG (NVS) announced positive data from the phase III study, MONALEESA-2 on breast cancer drug Kisqali."
NVS,NVS:US,BBG000LYF3S8,Aduro&apos;s Drug Gets Clearance by the FDA for Solid Tumors,2017-06-02 14:49:02 +0000,https://finance.yahoo.com/news/aduro-apos-drug-gets-clearance-144902233.html?.tsrc=rss,"Aduro Biotech, Inc. (ADRO) announced that the FDA has cleared the Investigational New Drug application (IND) for its pipeline candidate ADU-S100 (MIW815)."
NVS,NVS:US,BBG000LYF3S8,Why Novartis’s Eye Care Business Matters,2017-06-02 13:06:57 +0000,http://finance.yahoo.com/r/a4a2bf9d-3239-3e6f-b1cb-4bc3bfafebb0/why-novartiss-eye-care-business-matters?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,NVS's Alcon reported 1% operational growth in revenues to ~$1.4 billion in 1Q17.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Trimmed Its Gains After Weak US Jobs Report,2017-06-02 12:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QzHtnh6pJNs/the-swiss-stock-market-trimmed-its-gains-after-weak-us-jobs-report-20170602-00671,The Swiss Stock Market Trimmed Its Gains After Weak US Jobs Report
NVS,NVS:US,BBG000LYF3S8,Inside Novartis’s Generics Business Now,2017-06-02 11:36:50 +0000,http://finance.yahoo.com/r/3ddce4e5-8bf5-3a04-97b2-017e42be2ab1/inside-novartiss-generics-business-now?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Sandoz is also a leader in differentiated generics. Its contribution made up ~21% of Novartis's total revenues in 1Q17.
NVS,NVS:US,BBG000LYF3S8,Mylan Launches Generic Version Of Novartis' Reclast Injection - Quick Facts,2017-06-02 07:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dp6mE06z9kY/mylan-launches-generic-version-of-novartis-reclast-injection--quick-facts-20170602-00256,Mylan Launches Generic Version Of Novartis' Reclast Injection - Quick Facts
NVS,NVS:US,BBG000LYF3S8,"Avita Medical Names Michael Perry CEO, Succeeding Adam Kelliher - Quick Facts",2017-06-02 01:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SjXBcAt1kwo/avita-medical-names-michael-perry-ceo-succeeding-adam-kelliher--quick-facts-20170602-00020,"Avita Medical Names Michael Perry CEO, Succeeding Adam Kelliher - Quick Facts"
NVS,NVS:US,BBG000LYF3S8,Inside Novartis’s Innovative Medicines Segment in 1Q17,2017-06-01 14:37:41 +0000,http://finance.yahoo.com/r/c2668383-b4ae-3692-9319-13c5a5bbded6/inside-novartiss-innovative-medicines-segment-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Novartis’s (NVS) Innovative Medicines segment contributed ~67% of NVS's total revenues in 1Q17.
NVS,NVS:US,BBG000LYF3S8,Inside Novartis’s Segment-Wise Performance in 1Q17,2017-06-01 13:09:01 +0000,http://finance.yahoo.com/r/a67aa64a-bed2-3aa4-9f51-fedd4fb072b1/inside-novartiss-segment-wise-performance-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis is largely exposed to currency risk, as ~50% of its total revenues are reported from international markets."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Inched Higher In Lackluster Trade,2017-06-01 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_qYbq4okNUM/the-swiss-stock-market-inched-higher-in-lackluster-trade-20170601-01136,The Swiss Stock Market Inched Higher In Lackluster Trade
NVS,NVS:US,BBG000LYF3S8,What Happened to Novartis’s Valuation after 1Q17?,2017-06-01 11:38:52 +0000,http://finance.yahoo.com/r/4539076a-c0cd-3f2b-b885-aaaa0f1709f7/what-happened-to-novartiss-valuation-after-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis reported EPS of $1.13 on revenues of $11.54 billion for 1Q17, which represents 2% YoY operational growth in revenues."
NVS,NVS:US,BBG000LYF3S8,Merck Expects Solid Growth Trends for Cardio-Metabolic Franchise,2017-06-01 11:36:25 +0000,http://finance.yahoo.com/r/262f4b39-63ac-3403-b852-fac9d41202e3/merck-expects-witness-solid-growth-trends-cardio-metabolic-franchise-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Merck’s (MRK) leading diabetes drug, Januvia, accounts for a 65% share of the global Dipeptidyl peptidase-4 (or DPP-4) inhibitor market."
NVS,NVS:US,BBG000LYF3S8,Roche : FDA Oks Companion Diagnostic To Identify ALK-positive NSCLC Patients,2017-06-01 10:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I2K4f7sW_Lg/roche--fda-oks-companion-diagnostic-to-identify-alkpositive-nsclc-patients-20170601-00968,Roche : FDA Oks Companion Diagnostic To Identify ALK-positive NSCLC Patients
NVS,NVS:US,BBG000LYF3S8,"Novartis Biosimilar Pipeline, 2018 Growth Plans on Track",2017-05-31 23:31:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aOjNH9VSyBs/novartis-biosimilar-pipeline-2018-growth-plans-on-track-cm797151,Novartis AG NVS announced that the European Medicines Agency EMA has accepted the company s Marketing Authorization Applications for biosimilar versions of AbbVie s ABBV Humira adalimumab and Johnson amp Johnson s JNJ Remicade infliximab for review Sandoz is seeking approval for
NVS,NVS:US,BBG000LYF3S8,"Novartis Biosimilar Pipeline, 2018 Growth Plans on Track",2017-05-31 21:30:09 +0000,https://finance.yahoo.com/news/novartis-biosimilar-pipeline-2018-growth-213009842.html?.tsrc=rss,Novartis AG (NVS) announced that the EMA has accepted its applications for biosimilar versions of AbbVie&apos;s (ABBV) Humira (adalimumab) and Johnson & Johnson&apos;s (JNJ) Remicade (infliximab) for review.
NVS,NVS:US,BBG000LYF3S8,Common Share Consolidation and Name Change,2017-05-31 21:03:00 +0000,https://finance.yahoo.com/news/common-share-consolidation-name-change-210300812.html?.tsrc=rss,"TORONTO, ON / ACCESSWIRE / May 31, 2017 / NOVICIUS CORP . (formerly: Intelligent Content Enterprises Inc.) (OTCQB: ICEID, CSE: NVS) (""Novicius"" or the ""Company"") announces that, further ..."
NVS,NVS:US,BBG000LYF3S8,5 Drug Stocks in Focus on World MS Day,2017-05-31 16:36:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WraSAmDK038/5-drug-stocks-in-focus-on-world-ms-day-cm796902,Since 2009 World MS Day is officially marked on the last Wednesday of May with events and campaigns focused on bringing the worldwide multiple sclerosis MS community together and raising awareness about the disease Life with MS This World MS Day the theme is Life with MS
NVS,NVS:US,BBG000LYF3S8,"VGK, NSRGY, NVS, BTI: ETF Inflow Alert",2017-05-31 16:33:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f9WQoO1mMlc/vgk-nsrgy-nvs-bti-etf-inflow-alert-cm796900,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Europe ETF Symbol VGK where we have detected an approximate 643 8 million dollar inflow that s a 4 6 increase week over week in outstanding
NVS,NVS:US,BBG000LYF3S8,Novartis CEO sees no need for big takeover,2017-05-31 15:49:49 +0000,https://finance.yahoo.com/news/novartis-continues-review-options-alcon-053826265.html?.tsrc=rss,"Novartis (NOVN.S) does not need a big acquisition to kick-start growth, Chief Executive Joe Jimenez told investors on Wednesday, playing down suggestions he could use proceeds from a slew of asset sales for a significant takeover.  Amid speculation Novartis might use proceeds to buy AstraZeneca (AZN.L) or Bristol-Myers Squibb (BMY.N) to fill holes in its cancer drug portfolio, Jimenez said he remained focused on smaller purchases of up to $5 billion to bolster his pipeline.  ""Obviously, there's been a lot of speculation because that would be a lot of capital,"" Jimenez said at an event at Novartis's research campus in Boston."
NVS,NVS:US,BBG000LYF3S8,Pharma CEOs expect Trump to do something about drug pricing in the next 3 months,2017-05-31 15:12:15 +0000,https://finance.yahoo.com/news/pharma-ceos-expect-trump-something-151215018.html?.tsrc=rss,Pharma CEOs are bracing for a presidential action on drug pricing.  Novartis CEO Joe Jimenez...
NVS,NVS:US,BBG000LYF3S8,5 Drug Stocks in Focus on World MS Day,2017-05-31 14:08:02 +0000,https://finance.yahoo.com/news/5-drug-stocks-focus-world-140802344.html?.tsrc=rss,"Life with MS -- this world MS day, here&apos;s a look at 5 stocks including Biogen (BIIB) that are key players in the multiple sclerosis (MS) market."
NVS,NVS:US,BBG000LYF3S8,Drugmakers Brace for Trump's Proposals on U.S. Medicine Prices,2017-05-31 13:51:49 +0000,https://finance.yahoo.com/news/drugmakers-brace-trumps-proposals-u-135149557.html?.tsrc=rss,Novartis AG Chief Executive Officer Joe Jimenez said he expects President Donald Trump’s administration to outline proposals to lower the burden of drug prices on patients within three months.
NVS,NVS:US,BBG000LYF3S8,Drugmakers Brace for Trump's Proposals to Tackle U.S. Prices,2017-05-31 13:51:49 +0000,http://finance.yahoo.com/r/ce76f5bf-db5c-357d-a285-22c63040e677/drugmakers-brace-for-trump-s-proposals-on-u-s-medicine-prices?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,"Two top pharmaceutical CEOs say they expect President Donald Trump, a frequent critic of industry pricing practices, to take steps soon to address high U.S. drug costs."
NVS,NVS:US,BBG000LYF3S8,Celgene's Stock May Be Incredibly Overvalued Right Now -- Here's Why,2017-05-31 13:33:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mHlfqeeLba8/celgenes-stock-may-be-incredibly-overvalued-right-now-heres-why-cm796644,Celgene NASDAQ CELG has long garnered one of the richest valuations among large cap biotechs and for good reason The long and short of it is that Celgene has been able to post industry leading levels of revenue growth year after year thanks to its unmatched ability to churn out
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Inched Higher On Novartis Strength,2017-05-31 12:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3zggVxbs43o/the-swiss-stock-market-inched-higher-on-novartis-strength-20170531-00988,The Swiss Stock Market Inched Higher On Novartis Strength
NVS,NVS:US,BBG000LYF3S8,Celgene&apos;s Stock May Be Incredibly Overvalued Right Now -- Here&apos;s Why,2017-05-31 12:06:00 +0000,http://finance.yahoo.com/r/bf6c9f14-c440-3467-851e-c72094a53932/celgenes-stock-may-be-incredibly-overvalued-right.aspx?yptr=yahoo&.tsrc=rss,Celgene&apos;s long thesis might be unraveling.
NVS,NVS:US,BBG000LYF3S8,European Markets Finished Mixed On UK Election Worries,2017-05-31 11:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EczqRDAkVm0/european-markets-finished-mixed-on-uk-election-worries-20170531-00941,European Markets Finished Mixed On UK Election Worries
NVS,NVS:US,BBG000LYF3S8,Novartis Cautions on U.S. Pricing Pressures; Shares Edge Higher on Steady Outlook for Sandoz Sales,2017-05-31 07:13:00 +0000,http://finance.yahoo.com/r/97305e71-23e4-3364-9412-3ed5cbc2a272/novartis-cautions-on-u-s-pricing-pressures-shares-edge-higher-on-steady-outlook-for-sandoz-sales.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Novartis shares edged higher after the Swiss drugmaker cautioned that pricing pressures in the U.S. and the delay of a multiple sclerosis therapy dosage would hit its generic division's sales.
NVS,NVS:US,BBG000LYF3S8,Novartis warns of U.S. price pressure on Sandoz generics,2017-05-31 06:16:56 +0000,https://finance.yahoo.com/news/novartis-warns-u-price-pressure-061656152.html?.tsrc=rss,"Novartis warned on  Wednesday that price pressure on its generics drugs in the  United States has intensified in the second quarter, cutting  into its Sandoz division's sales growth in the world's largest  healthcare market.  An update on the future of loss-making Alcon, which is among  $50 billion in assets Novartis is considering unloading, is  expected by the end of the year.  Novartis's Sandoz business, whose $10.1 billion in revenue  in 2016 made up a fifth of the company's total, joins generics  makers including India's Sun Pharmaceutical Industries  and Lupin that have said revenue growth will be muted  this year amid intensifying U.S. price pressure."
NVS,NVS:US,BBG000LYF3S8,European Shares Lackluster On Political Worries,2017-05-31 05:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IydfgpimvAo/european-shares-lackluster-on-political-worries-20170531-00180,European Shares Lackluster On Political Worries
NVS,NVS:US,BBG000LYF3S8,The 3 Best Marijuana Stocks to Buy,2017-05-31 00:30:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6B2y380kDec/the-3-best-marijuana-stocks-to-buy-cm796537,InvestorPlace Stock Market News Stock Advice amp Trading Tips The cannabis industry is one which has seen significant growth of late due to increasingly loosening regulations worldwide with respect to the green commodity And in turn many marijuana stocks have made investors a
NVS,NVS:US,BBG000LYF3S8,Bristol-Myers Hookup Boosts Array BioPharma,2017-05-30 22:20:00 +0000,http://finance.yahoo.com/r/108e2294-4a2d-3e8e-bbe1-cea652cc1a4e/bristol-myers-hookup-boosts-array-biopharma.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Arrary reacquired MEK inhibitor in 2015 as part of FTC settlement with Novartis.
NVS,NVS:US,BBG000LYF3S8,The 5 Best Dividend Stocks in Cholesterol Drugs,2017-05-30 12:30:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2R9nK9SZcX4/the-5-best-dividend-stocks-in-cholesterol-drugs-cm795970,There s good news bad news and more good news about high cholesterol levels The first good news is that the percentage of Americans with high cholesterol is falling The bad news is that over 73 million Americans still have high bad cholesterol levels What s the other piece of
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Lower Despite Late Recovery,2017-05-30 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dtdfHFrxzuM/the-swiss-stock-market-finished-lower-despite-late-recovery-20170530-00876,The Swiss Stock Market Finished Lower Despite Late Recovery
NVS,NVS:US,BBG000LYF3S8,The 5 Best Dividend Stocks in Cholesterol Drugs,2017-05-30 11:23:00 +0000,http://finance.yahoo.com/r/b8a0819f-c871-3045-9a42-f036d61f1f5f/the-5-best-dividend-stocks-in-cholesterol-drugs.aspx?yptr=yahoo&.tsrc=rss,"Looking for great dividend stocks of companies that make cholesterol drugs? Check out Amgen, AstraZeneca, Novartis, Pfizer, and Sanofi."
NVS,NVS:US,BBG000LYF3S8,"Novartis has assets to sell, investors wary of what it might buy",2017-05-30 08:09:54 +0000,https://finance.yahoo.com/news/novartis-assets-sell-investors-wary-080954895.html?.tsrc=rss,"As Novartis considers  asset sales that could raise $50 billion, investors are worried  any cash raised may give the Swiss drugmaker firepower for  another unsuccessful megadeal.  Novartis's $52 billion takeover of U.S.-based eye care giant  Alcon, completed in 2011, saddled it with a business whose sales  and profit have faltered two years running.  Now, Chief Executive Joe Jimenez is reviewing Alcon's  surgical devices and contact lens businesses, suggesting they  could be valued at $25-$35 billion if he unloads them."
NVS,NVS:US,BBG000LYF3S8,Intercept's (ICPT) Liver Drug Ocaliva Approved in Canada,2017-05-29 17:30:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GNMSaZ4_iLI/intercepts-icpt-liver-drug-ocaliva-approved-in-canada-cm795894,Intercept Pharmaceuticals Inc ICPT announced that Health Canada has granted a conditional approval for Ocaliva obeticholic acid for the treatment of primary biliary cholangitis PBC when used in combination with ursodeoxycholic acid UDCA in adults with an inadequate response to UDCA
NVS,NVS:US,BBG000LYF3S8,Kite Pharma Cancer Drug BLA Gets Priority Review Status,2017-05-29 14:31:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Iu6G3rbQTUw/kite-pharma-cancer-drug-bla-gets-priority-review-status-cm795855,Kite Pharma Inc KITE announced that its biologics license application BLA for its experimental CAR T therapy axicabtagene ciloleucel has been accepted for priority review by the FDA The biotech companyis looking to get axicabtagene ciloleucel approved for the treatment of
NVS,NVS:US,BBG000LYF3S8,3 Top Dividend Stocks in Generic Drugs,2017-05-26 20:31:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qBDKcygCAVo/3-top-dividend-stocks-in-generic-drugs-cm795538,There haven t been too many positive developments in prescription drug price trends However there is at least one 160 Generic drugs now make up nearly eight out of every 10 prescriptions That s good news for payers and patients It s also good news for dividend seeking investors
NVS,NVS:US,BBG000LYF3S8,3 Top Dividend Stocks in Generic Drugs,2017-05-26 19:02:00 +0000,http://finance.yahoo.com/r/c1cdeb46-8ed1-384b-afe0-af26791b8111/3-top-dividend-stocks-in-generic-drugs.aspx?yptr=yahoo&.tsrc=rss,"Why Pfizer, Novartis, and Sanofi rank at the top of all dividend stocks in the generic-drug industry."
NVS,NVS:US,BBG000LYF3S8,"VEA, CRAK: Big ETF Inflows",2017-05-26 16:34:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MqyKLZhqxlA/vea-crak-big-etf-inflows-cm795368,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 9 012 611 units or a 0 7 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline's New CEO Is Off to a Good Start,2017-05-26 16:33:39 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4cnUpEigjhg/glaxosmithklines-new-ceo-is-off-to-a-good-start-cm795322,Sir Andrew Witty s last quarter as CEO of GlaxoSmithKline plc NYSE GSK produced positive results and incoming leader Emma Walmsley gave some clues as to how things will be changing or not Q1 2017 marked the eighth reporting period since the closure of a 20 billion asset
NVS,NVS:US,BBG000LYF3S8,"Merrimack Pharmaceuticals, Inc. (MACK) Ex-Dividend Date Scheduled for May 30, 2017",2017-05-26 13:21:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PfTyK5df2VI/merrimack-pharmaceuticals-inc-mack-ex-dividend-date-scheduled-for-may-30-2017-cm795080,Merrimack Pharmaceuticals Inc MACK will begin trading ex dividend on May 30 2017 A cash dividend payment of 1 06 per share is scheduled to be paid on May 26 2017 Shareholders who purchased MACK prior to the ex dividend date are eligible for the cash dividend payment At the
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Inched Higher On Positive US Data,2017-05-26 12:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vo52B9c-9IQ/the-swiss-stock-market-inched-higher-on-positive-us-data-20170526-00529,The Swiss Stock Market Inched Higher On Positive US Data
NVS,NVS:US,BBG000LYF3S8,Changes in Sanofi’s Valuation after Its 1Q17 Earnings,2017-05-26 11:37:49 +0000,http://finance.yahoo.com/r/6c12b624-3c60-3176-8901-153b1c123416/changes-in-sanofis-valuation-after-its-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Paris-based Sanofi (SNY) reported revenues of ~8.7 billion euros in 1Q17. Sanofi surpassed analyst estimates, posting EPS of 1.42 euros in 1Q17, compared to estimates of 1.31 euros."
NVS,NVS:US,BBG000LYF3S8,I Still Can't Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug,2017-05-25 21:32:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xeXBdnKpBpU/i-still-cant-believe-juno-therapeutics-spent-464-million-on-this-failed-drug-cm794838,In March Juno Therapeutics NASDAQ JUNO announced that it was ending development of JCAR015 after five patients with acute lymphoblastic leukemia ALL died from cerebral edema brain swelling in its phase 2 clinical trial The lethal side effect made it unlikely
NVS,NVS:US,BBG000LYF3S8,I Still Can&apos;t Believe Juno Therapeutics Spent $46.4 Million on This Failed Drug,2017-05-25 20:21:00 +0000,http://finance.yahoo.com/r/a4927e0c-f92e-376f-9cef-7c104e9e2418/i-still-cant-believe-juno-therapeutics-spent-464-m.aspx?yptr=yahoo&.tsrc=rss,A costly learning exercise.
NVS,NVS:US,BBG000LYF3S8,Could There Be a Revenue Fall for Neulasta in 2017?,2017-05-25 14:36:15 +0000,http://finance.yahoo.com/r/f779f743-2dcd-3164-ab39-567b243b24c2/could-there-be-a-revenue-fall-for-neulasta-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, Amgen’s (AMGN) Neulasta generated revenues close to $4.6 billion, which was a slight drop from its 2015 net sales of ~$4.7 billion."
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Positive Data on Ultibro Breezhaler,2017-05-25 13:35:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fbEOu3-CSO8/novartis-nvs-reports-positive-data-on-ultibro-breezhaler-cm794357,Novartis AG NVS recently announced positive data from the FLAME study on Ultibro Breezhaler Data was published in the centenary issue of the American Thoracic Society s American Journal of Respiratory and Critical Care Medicine Novartis has outperformed the Zacks classified industry
NVS,NVS:US,BBG000LYF3S8,Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline,2017-05-25 13:34:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qJrvtDr6u_k/alnylam-pharmaceuticals-alny-progressing-well-on-pipeline-cm794351,We issued an updated research report on Alnylam Pharmaceuticals Inc ALNY on May 23 2017 Alnylam s shares are up 86 5 year to date comparing favorably with an increase of 0 2 witnessed by the Zacks classified Medical Biomedical and Genetics industry Alnylam
NVS,NVS:US,BBG000LYF3S8,"Phibro Animal Health Corporation (PAHC) Ex-Dividend Date Scheduled for May 26, 2017",2017-05-25 13:21:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/870KPE5iCNw/phibro-animal-health-corporation-pahc-ex-dividend-date-scheduled-for-may-26-2017-cm794390,Phibro Animal Health Corporation PAHC will begin trading ex dividend on May 26 2017 A cash dividend payment of 0 1 per share is scheduled to be paid on June 22 2017 Shareholders who purchased PAHC prior to the ex dividend date are eligible for the cash dividend payment This marks
NVS,NVS:US,BBG000LYF3S8,Alnylam Pharmaceuticals (ALNY) Progressing Well on Pipeline,2017-05-25 11:43:11 +0000,https://finance.yahoo.com/news/alnylam-pharmaceuticals-alny-progressing-well-114311598.html?.tsrc=rss,"We issued an updated research report on Alnylam Pharmaceuticals, Inc. (ALNY) on May 23, 2017."
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Positive Data on Ultibro Breezhaler,2017-05-25 11:11:11 +0000,https://finance.yahoo.com/news/novartis-nvs-reports-positive-data-111111083.html?.tsrc=rss,"Novartis AG (NVS) announced positive data from the FLAME study on COPD drug, Ultibro Breezhaler."
NVS,NVS:US,BBG000LYF3S8,Cambridge largely spared as Novartis cuts hundreds of jobs,2017-05-24 20:45:09 +0000,http://finance.yahoo.com/r/6298f90c-dceb-3a1d-9876-0b725d64c754/cambridge-largely-spared-as-novartis-cuts-hundreds.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Novartis has announced plans to lay off around 250 employees in the U.S. and another 500 overseas, but the Swiss drug giant’s Massachusetts operations are being spared — for the most part.  It comes just days after Novartis said it will eliminate 500 positions in Basel, Switzerland, while adding 350 “high-tech” roles there focused on biologics development and production.  The company’s Massachusetts operations are largely avoiding the chopping block, however."
NVS,NVS:US,BBG000LYF3S8,Neupogen and Enbrel Could See Falling Revenues in 2017,2017-05-24 14:37:07 +0000,http://finance.yahoo.com/r/3a4d55e9-aae8-3009-ac17-98341fc7a411/neupogen-and-enbrel-could-see-falling-revenues-in-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 1Q17, Neupogen generated revenues of ~$148 million, a significant drop from the drug’s 1Q16 revenues of ~$213 million."
NVS,NVS:US,BBG000LYF3S8,"Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for May 25, 2017",2017-05-24 13:12:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w0z9pxUSxe0/johnson-johnson-jnj-ex-dividend-date-scheduled-for-may-25-2017-cm793738,Johnson amp Johnson JNJ will begin trading ex dividend on May 25 2017 A cash dividend payment of 0 84 per share is scheduled to be paid on June 13 2017 Shareholders who purchased JNJ prior to the ex dividend date are eligible for the cash dividend payment This represents an 5
NVS,NVS:US,BBG000LYF3S8,Wide-Moat Roche Is Undervalued,2017-05-24 11:00:00 +0000,http://finance.yahoo.com/r/453ecae6-8a16-32cb-be14-4f661f302b0d/article.aspx?id=810174&SR=Yahoo&yptr=yahoo&.tsrc=rss,The biotech giant trades at a wide discount to what we think it's worth.
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 05/23/2017: ALXN, ETRM, CERS, JNJ, NVS",2017-05-23 18:52:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lSTULCjqg3w/health-care-sector-update-for-05232017-alxn-etrm-cers-jnj-nvs-cm793514,Top Health Care StocksTop Health Care Stocks JNJ 0 20 JNJ 0 20 PFE 0 03 PFE 0 03 ABT 0 30 ABT 0 30 MRK 0 59 MRK 0 59 AMGN 0 83 AMGN 0 83 Health care stocks were putting up small gains during Tuesday trading with the NYSE Health Care Index advancing about 0 2 while shares of
NVS,NVS:US,BBG000LYF3S8,House Cleaning To Re-Shape Alexion?,2017-05-23 18:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BPeOceNMufc/house-cleaning-to-reshape-alexion-20170523-01352,House Cleaning To Re-Shape Alexion?
NVS,NVS:US,BBG000LYF3S8,Here's Why Alexion Pharma (ALXN) Stock is Sinking Today,2017-05-23 18:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FucJeURjKUg/heres-why-alexion-pharma-alxn-stock-is-sinking-today-cm793431,On Tuesday shares of Alexion Pharmaceuticals Inc ALXN are sinking down over about 8 5 in mid morning trading after the company announced a series of changes to its management team Alexion s Chief Commercial Officer Carsten Thiel will resign effective June 1 and Brian Goff has been hired
NVS,NVS:US,BBG000LYF3S8,"Perrigo Company (PRGO) Ex-Dividend Date Scheduled for May 24, 2017",2017-05-23 13:15:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7LC5wETe0C4/perrigo-company-prgo-ex-dividend-date-scheduled-for-may-24-2017-cm793095,Perrigo Company PRGO will begin trading ex dividend on May 24 2017 A cash dividend payment of 0 16 per share is scheduled to be paid on June 13 2017 Shareholders who purchased PRGO prior to the ex dividend date are eligible for the cash dividend payment This represents an 10 34
NVS,NVS:US,BBG000LYF3S8,The Current State Of The Breast Cancer Treatment Space,2017-05-23 12:59:04 +0000,https://finance.yahoo.com/news/current-state-breast-cancer-treatment-125904515.html?.tsrc=rss,"Puma Biotechnology Inc (NASDAQ: PBYI ) popped 88 percent Monday on news that its neratinib candidate , an early-stage breast cancer treatment for human epidermal growth factor receptor-2 (HER2) positive ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back After Weak Performance By Index Heavyweights,2017-05-23 12:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gMMn_w74o3E/the-swiss-stock-market-pulled-back-after-weak-performance-by-index-heavyweights-20170523-01006,The Swiss Stock Market Pulled Back After Weak Performance By Index Heavyweights
NVS,NVS:US,BBG000LYF3S8,Novartis: Ultibro Breezhaler Shows Benefits Over Seretide In FLAME Study,2017-05-23 01:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ie0-DNNfUEg/novartis-ultibro-breezhaler-shows-benefits-over-seretide-in-flame-study-20170523-00033,Novartis: Ultibro Breezhaler Shows Benefits Over Seretide In FLAME Study
NVS,NVS:US,BBG000LYF3S8,Novartis' (NVS) Lung Cancer Drug Gets Positive CHMP Opinion,2017-05-23 00:11:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ymxyvSK-Pe0/novartis-nvs-lung-cancer-drug-gets-positive-chmp-opinion-cm792969,Novartis NVS recently announced that the Committee for Medicinal Products for Human Use CHMP of the European Medicines Agency EMA has recommended the approval of a label expansion of Zykadia ceritinib to include the first line treatment of patients with advanced non small cell lung
NVS,NVS:US,BBG000LYF3S8,Novartis&apos; (NVS) Lung Cancer Drug Gets Positive CHMP Opinion,2017-05-22 21:53:09 +0000,https://finance.yahoo.com/news/novartis-apos-nvs-lung-cancer-215309275.html?.tsrc=rss,Novartis (NVS) recently announced that the CHMP of the European Medicines Agency (EMA) has recommended the approval of a label expansion of Zykadia.
NVS,NVS:US,BBG000LYF3S8,Will Novartis&apos; MS Drug Stomp Celgene&apos;s Before It Even Hits The Market?,2017-05-22 20:15:21 +0000,http://finance.yahoo.com/r/5d4d168a-3771-3d37-a518-bdc22c66168a/will-novartis-ms-drug-stomp-celgenes-before-it-even-hits-the-market?src=A00220&yptr=yahoo&.tsrc=rss,Celgene stock dipped to a four-month low Monday after ozanimod failed to show a disability benefit over interferon in multiple sclerosis patients.
NVS,NVS:US,BBG000LYF3S8,"VT, CVX, NVS, DIS: ETF Inflow Alert",2017-05-22 17:13:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8pobMxDWw0U/vt-cvx-nvs-dis-etf-inflow-alert-cm792744,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Total World Stock ETF Symbol VT where we have detected an approximate 80 4 million dollar inflow that s a 1 0 increase week over week in
NVS,NVS:US,BBG000LYF3S8,"Pre-Market Most Active for May 22, 2017 :  F, HUN, TOT, RDS/B, NVS, FCAU, RDUS, TVIX, NVDA, USLV, XIV, GLYC",2017-05-22 12:51:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hvKMJw0OZpg/pre-market-most-active-for-may-22-2017-f-hun-tot-rdsb-nvs-fcau-rdus-tvix-nvda-uslv-xiv-glyc-cm792459,The NASDAQ 100 Pre Market Indicator is up 9 88 to 5 661 44 The total Pre Market volume is currently 6 696 360 shares traded The following are the most active stocks for the pre market session Ford Motor Company F is 0 21 at 11 08 with 1 483 967 shares traded Over
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed As Defensive Heavyweights Provide Support,2017-05-22 12:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/F7CsfG1lNvg/the-swiss-stock-market-climbed-as-defensive-heavyweights-provide-support-20170522-00848,The Swiss Stock Market Climbed As Defensive Heavyweights Provide Support
NVS,NVS:US,BBG000LYF3S8,Amgen (AMGN) Submits BLA to FDA for Migraine Drug Erenumab,2017-05-19 14:20:02 +0000,https://finance.yahoo.com/news/amgen-amgn-submits-bla-fda-142002963.html?.tsrc=rss,Amgen Inc. (AMGN) recently announced the submission of a biologics license application (BLA) to the FDA for its pipeline candidate erenumab (AMG 334) for the prevention of migraine.
NVS,NVS:US,BBG000LYF3S8,CHMP backs Novartis's Zykadia for first-line use in lung cancer,2017-05-19 12:38:44 +0000,https://finance.yahoo.com/news/chmp-backs-novartiss-zykadia-first-123844663.html?.tsrc=rss,Novartis's push to win approval for Zykadia as an initial treatment for a type of lung cancer got a lift on Friday with a positive recommendation from the European Medicines Agency's Committee for Medicinal ...
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Bounced Back Above 9,000 Points",2017-05-19 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-cKLglfFQxk/the-swiss-stock-market-bounced-back-above-9000-points-20170519-00594,"The Swiss Stock Market Bounced Back Above 9,000 Points"
NVS,NVS:US,BBG000LYF3S8,Conference Spotlights Drug Giant Donnybrooks In Cancer Treatments,2017-05-18 19:44:45 +0000,http://finance.yahoo.com/r/fe46b8b5-dce5-35cf-9497-7339351dd0e6/conference-spotlights-lilly-pfizer-merck-bristol-donnybrooks-in-cancer?src=A00220&yptr=yahoo&.tsrc=rss,"Preliminary data highlights breast, ovarian, lung and skin cancer data to presented during the American Society of Clinical Oncology meeting next month."
NVS,NVS:US,BBG000LYF3S8,"VEA, SJB: Big ETF Inflows",2017-05-18 16:14:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xM6egFxuHu8/vea-sjb-big-etf-inflows-cm791314,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF which added 18 005 000 units or a 1 4 increase week over week Among the largest underlying components of VEA in
NVS,NVS:US,BBG000LYF3S8,"Novartis to cut around 500 jobs in Switzerland, add 350",2017-05-18 13:48:33 +0000,https://finance.yahoo.com/news/novartis-cut-around-500-jobs-134833107.html?.tsrc=rss,"Novartis (NOVN.S) plans to cut or transfer around 500 traditional production and development jobs at Swiss sites over the next 18 months and add 350 others, mostly in its biotech business, the drugmaker said on Thursday.  Swiss domestic head Matthias Leuenberger gave the figures in an interview posted on the company's website.  Novartis said in October it was closing some of its research operations in Switzerland and China and cutting 175 jobs as it  centralises control over its drug discovery programs and contains costs."
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Slipped Back Below 9,000 Points",2017-05-18 12:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fm2Zo2NEsw4/the-swiss-stock-market-slipped-back-below-9000-points-20170518-01012,"The Swiss Stock Market Slipped Back Below 9,000 Points"
NVS,NVS:US,BBG000LYF3S8,"Aduro Biotech, Merch Team on Cancer Drug Trial",2017-05-17 18:16:00 +0000,http://finance.yahoo.com/r/8f075429-6b65-3b82-96d4-52f4a0516591/aduro-biotech-merch-team-on-cancer-drug-trial.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Aduro Biotech and Merck will team on two separate trials featuring Aduro's CRS-207 and Merck's Keytruda to explore treatments for mesothelioma and gastric cancer.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Sharply Lower,2017-05-17 12:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PHYp23x2ozY/the-swiss-stock-market-finished-sharply-lower-20170517-00864,The Swiss Stock Market Finished Sharply Lower
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Rebounded After Strong Performance From NestlÃ©,2017-05-16 12:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ryRqQS_gec/the-swiss-stock-market-rebounded-after-strong-performance-from-nestl%C3%A3-20170516-01019,The Swiss Stock Market Rebounded After Strong Performance From NestlÃ©
NVS,NVS:US,BBG000LYF3S8,Today's Research Reports on Stocks to Watch: GlaxoSmithKline and Novartis,2017-05-16 12:00:00 +0000,https://finance.yahoo.com/news/todays-research-reports-stocks-watch-120000494.html?.tsrc=rss,"NEW YORK, NY / ACCESSWIRE / May 16, 2017 / GlaxoSmithKline and Novartis shares traded flat on Monday despite news revealing that Glaxo could be ready to buy out Novartis' stake in their joint venture for ..."
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline Could Buy Out Partner Novartis,2017-05-15 12:27:00 +0000,http://finance.yahoo.com/r/af361fbc-a555-3c03-b885-2213bf61d409/glaxosmithkline-could-buy-out-partner-novartis.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Novartis holds a 36.5% stake in the healthcare company.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back After Reaching A New Annual High,2017-05-15 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9UVaQz035W0/the-swiss-stock-market-pulled-back-after-reaching-a-new-annual-high-20170515-01031,The Swiss Stock Market Pulled Back After Reaching A New Annual High
NVS,NVS:US,BBG000LYF3S8,Can Teva Hold Its Own In Bringing Migraine Drugs To Market?,2017-05-12 20:20:16 +0000,http://finance.yahoo.com/r/0c80360d-ceac-374a-ad04-a77e44d33a28/can-teva-hold-its-own-in-migraine-vs-lilly-amgen-alder?src=A00220&yptr=yahoo&.tsrc=rss,"Teva will square off with Eli Lilly, Amgen, Novartis and Alder next month when it unveils the results of a Phase 3 study in migraines."
NVS,NVS:US,BBG000LYF3S8,European ADRs Edge Higher as Telecommunication Stocks Advance,2017-05-12 15:23:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7iNRnqbKWno/european-adrs-edge-higher-as-telecommunication-stocks-advance-cm788539,American depository receipts of European stocks were 0 6 higher at 133 66 on the Bank of New York Mellon Europe ADR Index on Friday morning American depository receipts of European stocks were 0 6 higher at 133 66 on the Bank of New York Mellon Europe ADR Index on Friday morning Gainers
NVS,NVS:US,BBG000LYF3S8,"Teva (TEVA) Q1 Earnings In Line, Sales Lag as Copaxone Falls",2017-05-12 14:07:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aS3gg3JZRig/teva-teva-q1-earnings-in-line-sales-lag-as-copaxone-falls-cm788375,Teva Pharmaceutical Industries Ltd TEVA reported first quarter 2017 earnings of 1 03 per share including equity compensation expenses which was in line with the Zacks Consensus Estimate The year ago adjusted earnings were 1 18 per share Revenues of 5 63 billion missed the
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On Strength Of Pharmaceutical Heavyweights,2017-05-12 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hsasg0wf-Go/the-swiss-stock-market-climbed-on-strength-of-pharmaceutical-heavyweights-20170512-00711,The Swiss Stock Market Climbed On Strength Of Pharmaceutical Heavyweights
NVS,NVS:US,BBG000LYF3S8,3 Healthcare Stocks to Buy for Retirement Income,2017-05-12 00:02:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uzr7auSKuuk/3-healthcare-stocks-to-buy-for-retirement-income-cm788250,InvestorPlace Stock Market News Stock Advice amp Trading Tips The past few months have been a roller coaster ride for healthcare stocks The continued Republican attempts to end Obamacare have thrown the sector for a loop especially after the recent successful vote in the
NVS,NVS:US,BBG000LYF3S8,Ionis Pharmaceuticals Inc.'s First Royalties Roll In,2017-05-11 21:02:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bqni9gNdiZE/ionis-pharmaceuticals-incs-first-royalties-roll-in-cm788134,Ionis Pharmaceuticals NASDAQ IONS released first quarter earnings on May 9 but the most interesting number sales of Spinraza was already known since Ionis partner Biogen NASDAQ BIIB disclosed sales of 47 million a few weeks ago Ionis Pharmaceuticals
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Losses,2017-05-11 12:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d_eDVHQj3XQ/the-swiss-stock-market-extended-its-losses-20170511-01208,The Swiss Stock Market Extended Its Losses
NVS,NVS:US,BBG000LYF3S8,Better Buy: GlaxoSmithKline vs. Johnson & Johnson,2017-05-10 18:03:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OuDHx88rOyA/better-buy-glaxosmithkline-vs-johnson-johnson-cm787352,The stocks of big pharmaceutical companies are usually not very exciting but that s just fine for savvy investors who value safe dividends and the fact that these stocks often outperform the market in downturns GlaxoSmithKline NYSE GSK and Johnson amp Johnson NYSE JNJ
NVS,NVS:US,BBG000LYF3S8,Ligand Pharmaceuticals (LGND) Q1 Earnings Miss Estimates,2017-05-10 16:04:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Qt8gmm3tfkU/ligand-pharmaceuticals-lgnd-q1-earnings-miss-estimates-cm787223,Ligand Pharmaceuticals Incorporated LGND reported first quarter 2017 earnings of 31 cents per share including the impact of stock based compensation expenses down 32 5 from the year ago figure The bottom line also missed the Zacks Consensus Estimate of 55 cents per share
NVS,NVS:US,BBG000LYF3S8,"VEA, NVS, RDS.A, BP: ETF Inflow Alert",2017-05-10 16:02:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W1I-MsQo2Fw/vea-nvs-rdsa-bp-etf-inflow-alert-cm787194,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 448 7 million dollar inflow that s a 0 9 increase week over week
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back As Roche Weighs,2017-05-10 12:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ox4XaKPGyTo/the-swiss-stock-market-pulled-back-as-roche-weighs-20170510-01230,The Swiss Stock Market Pulled Back As Roche Weighs
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of May 8: DRRX, CXRX, URGN, ARLX, TXMD...",2017-05-09 00:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/g4CTkd7tUrg/gainers--losers-of-may-8-drrx-cxrx-urgn-arlx-txmd-20170509-00006,"Gainers & Losers Of May 8: DRRX, CXRX, URGN, ARLX, TXMD..."
NVS,NVS:US,BBG000LYF3S8,"Incyte (INCY) Q1 Loss Narrower than Expected, Revenues Beat",2017-05-08 21:01:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E9GXrJIoBuI/incyte-incy-q1-loss-narrower-than-expected-revenues-beat-cm786131,Incyte Corporation INCY reported first quarter 2017 loss of 96 cents a penny narrower than the Zacks Consensus Estimate of a loss of 97 cents Incyte had reported earnings of 12 cents per share in the year ago quarter Quarterly revenues were 384 1 million up 45 8 year over year and
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 05/08/2017: KITE,HZNP,NVS,HZNP",2017-05-08 20:40:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tGZgbqcfVSg/health-care-sector-update-for-05082017-kitehznpnvshznp-cm786164,Top Health Care StocksTop Health Care Stocks JNJ 0 30 JNJ 0 30 PFE 0 28 PFE 0 28 ABT 0 03 ABT 0 03 MRK 0 21 MRK 0 21 AMGN 0 54 AMGN 0 54 Health care stocks were ending mostly lower today with the NYSE Health Care Index dropping almost 0 8 while shares of health care companies
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit",2017-05-08 14:48:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8K6xYdrQySI/pharma-stock-roundup-merck-pfizer-report-q1-earnings-jj-talc-powder-lawsuit-cm785710,Last week big names like Merck MRK and Pfizer PFE reported earnings results Johnson amp Johnson JNJ was also in the news related to a jury verdict for its talc powder lawsuit 160 Recap of the Week s Most Important Stories A Look at Earnings Results Two major
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Merck, Pfizer Report Q1 Earnings, J&J Talc Powder Lawsuit",2017-05-08 12:46:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-merck-pfizer-124612890.html?.tsrc=rss,Major pharma companies like Pfizer (PFE) and Merck reported Q1 results last week.
NVS,NVS:US,BBG000LYF3S8,DURECT and Sandoz have Signed a $293 Million Development and Commercialization Agreement for POSIMIR® (SABER®-Bupivacaine) Covering the United States,2017-05-08 11:00:00 +0000,http://finance.yahoo.com/news/durect-sandoz-signed-293-million-110000339.html?.tsrc=rss,"CUPERTINO, Calif., May 8, 2017 /PRNewswire/ -- DURECT Corporation (DRRX) today announced a development and commercialization agreement with Sandoz AG, a division of Novartis (NVS), to develop and market in the United States DURECT's POSIMIR® (SABER®-Bupivacaine), an investigational locally-acting, non-opioid analgesic intended to provide up to three days of continuous pain relief after surgery.  Sandoz is a global leader in driving sustainable access to high-quality healthcare.  Sandoz's differentiated product portfolio includes a range of state-of-the-art technologies, formulations and devices.  In the U.S., Sandoz Inc. has a dedicated hospital sales and marketing organization, with expertise and relationships, which will be employed to deliver POSIMIR to the market."
NVS,NVS:US,BBG000LYF3S8,"Barron's Picks And Pans: Amazon, Novartis, Tesla And More",2017-05-07 18:06:25 +0000,http://finance.yahoo.com/news/barrons-picks-pans-amazon-novartis-180625276.html?.tsrc=rss,This weekend's Barron's takes a look at why the king of e-commerce must avoid becoming too profitable. Other featured articles offer the prospects for retail stocks that benefit from woes in the sector ...
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis Has the Right Prescription for Profits,2017-05-06 04:53:00 +0000,http://finance.yahoo.com/r/b93d8518-3f6b-30fa-99b6-f6ee0156207e/novartis-has-the-right-prescription-for-profits-1494046390?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"After a period of weak financial performance, Novartis could be poised for a multiyear run of earnings gains starting in 2018.  Novartis shares (NVS) are trading for 16 times projected 2017 earnings of $4.74 a share, and 15 times estimated 2018 profit of $5.23 a share.  “Novartis is an out-of-favor company with a long-term growth profile that is better than the peer average,” says Tim Anderson, a Bernstein drug analyst, who calls the company’s new-product pipeline “underappreciated.” Anderson has an Outperform rating on the stock and a price target of $87 a share."
NVS,NVS:US,BBG000LYF3S8,AVEO Pharmaceuticals (AVEO) Q1 Loss Narrower Than Expected,2017-05-05 22:26:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xj53nelCGZA/aveo-pharmaceuticals-aveo-q1-loss-narrower-than-expected-cm785320,AVEO Pharmaceuticals Inc AVEO reported a first quarter 2017 loss of 12 cents per share narrower than the Zacks Consensus Estimate as well as year ago loss of 13 cents Shares of the company fell more than 3 on Thursday However AVEO s share price movement shows that the stock
NVS,NVS:US,BBG000LYF3S8,"Intercept (ICPT) Q1 Loss Narrower than Expected, Sales Beat",2017-05-05 22:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Wue-GlX3d5g/intercept-icpt-q1-loss-narrower-than-expected-sales-beat-cm785316,Intercept Pharmaceuticals Inc ICPT posted a loss of 3 61 per share in the first quarter of 2017 narrower than the Zacks Consensus Estimate of a loss of 4 27 and also the year ago loss of 5 17 Quarterly revenues were 21 1 million up significantly from 0 4 million in the year ago
NVS,NVS:US,BBG000LYF3S8,"Conatus (CNAT) Q1 Loss Narrows Y/Y, Revenues Beat Estimates",2017-05-05 15:06:03 +0000,http://finance.yahoo.com/news/conatus-cnat-q1-loss-narrows-150603122.html?.tsrc=rss,"Conatus Pharmaceuticals Inc. (CNAT) reported first-quarter 2017 loss of 14 cents per share, in line with the Zacks Consensus Estimate but narrower than the year-ago figure of 35 cents."
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Climbed Past The 9,000 Point Mark",2017-05-05 12:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SBSXv-8xOHQ/the-swiss-stock-market-climbed-past-the-9000-point-mark-20170505-00785,"The Swiss Stock Market Climbed Past The 9,000 Point Mark"
NVS,NVS:US,BBG000LYF3S8,Blog Coverage: Novartis Exercises Option for Global Development and Commercialization of Conatus Pharmaceuticals' Drug Emricasan,2017-05-05 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-novartis-exercises-option-121500394.html?.tsrc=rss,"Upcoming AWS Coverage on Bioverativ Post-Earnings Results LONDON, UK / ACCESSWIRE / May 5, 2017 / Active Wall St. blog coverage looks at the headline from Conatus Pharmaceuticals Inc. (NASDAQ: CNAT ) as ..."
NVS,NVS:US,BBG000LYF3S8,Is Endo (ENDP) Poised for a Beat This Earnings Season?,2017-05-04 23:09:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7QVZSNAJgas/is-endo-endp-poised-for-a-beat-this-earnings-season-cm784623,Endo International plc ENDP is scheduled to report first quarter 2017 results on May 9 before the opening bell Endo posted a positive surprise in each of the trailing four quarters with an average positive surprise of 12 7 Last quarter the company delivered a positive earnings surprise
NVS,NVS:US,BBG000LYF3S8,Can Ligand (LGND) Spring a Surprise this Earnings Season?,2017-05-04 16:15:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RhxvkGeYlAc/can-ligand-lgnd-spring-a-surprise-this-earnings-season-cm784212,Ligand Pharmaceuticals Incorporated LGND is scheduled to report first quarter 2017 results on May 9 after the market closes Ligand s earnings history has been disappointing as it missed expectations in three of the last four quarters and beat estimates in one Overall the company had
NVS,NVS:US,BBG000LYF3S8,"Ophthotech (OPHT) Q1 Loss Narrower than Expected, Sales Miss",2017-05-04 14:48:02 +0000,http://finance.yahoo.com/news/ophthotech-opht-q1-loss-narrower-144802762.html?.tsrc=rss,"Ophthotech Corporation (OPHT) reported first-quarter 2017 loss of $1.20 per share, narrower than the Zacks Consensus Estimate of a loss of $1.31 but wider than the year-ago loss of $1.03"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Continues To March Higher,2017-05-04 12:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nO9-aN5VKTo/the-swiss-stock-market-continues-to-march-higher-20170504-01545,The Swiss Stock Market Continues To March Higher
NVS,NVS:US,BBG000LYF3S8,Company Spotlight: Conatus Pharma,2017-05-04 08:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AQsyITXY0Ec/company-spotlight-conatus-pharma-20170504-01027,Company Spotlight: Conatus Pharma
NVS,NVS:US,BBG000LYF3S8,"Novartis, Roche back French gene therapy start-up Vivet",2017-05-04 06:56:22 +0000,http://finance.yahoo.com/news/novartis-roche-back-french-gene-065622822.html?.tsrc=rss,"French gene therapy start-up Vivet  Therapeutics said on Thursday it had raised 37.5 million euros  ($41 million) in an initial financing round, with backing from  the venture arms of Swiss drugmakers Novartis and Roche  .  Other investors include Columbus Venture Partners,  HealthCap, Kurma Partners and Ysios Capital.  Vivet, created last year in Paris with a wholly owned  subsidiary in Spain, is focused on developing novel gene  therapies for rare, inherited metabolic diseases."
NVS,NVS:US,BBG000LYF3S8,Novartis exercises option with Conatus for NASH product,2017-05-04 05:51:09 +0000,http://finance.yahoo.com/news/novartis-exercises-option-conatus-nash-055109883.html?.tsrc=rss,"Novartis is exercising  its option with Conatus  Pharmaceuticals for an exclusive license  for the global development and commercialization of emricasan  for treating liver disease NASH, the Swiss drugmaker said.  In December, Novartis said it signed a licensing deal to  co-develop the fatty liver disease drug with Conatus, under  which the small U.S. company receives $50 million up front."
NVS,NVS:US,BBG000LYF3S8,"Momenta Pharmaceuticals, Inc. Looks for Some Momentum",2017-05-03 20:50:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WgWUKnda0r8/momenta-pharmaceuticals-inc-looks-for-some-momentum-cm783792,Momenta Pharmaceuticals NASDAQ MNTA reported first quarter earnings on Tuesday but given the relatively small sales it was an update on the potential FDA approval of higher strength Glatopa and pipeline plans that should most interest investors Momenta Pharmaceuticals results
NVS,NVS:US,BBG000LYF3S8,Bristol-Myers: Going Stag to the Ball?,2017-05-03 14:33:00 +0000,http://finance.yahoo.com/r/b14b4c1f-eaba-38e4-987f-4883fde11706/bristol-myers-going-stag-to-the-ball-1493822038?mod=yahoobarrons&ru=yahoo&yptr=yahoo&.tsrc=rss,"When Bristol-Myers Squibb (BMY) tumbled last year following disappointing drug trial data, analysts were quick to talk up a potential acquisition, naming companies like Pfizer (PFE), Gilead Sciences (GILD) ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Gains,2017-05-03 12:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_HnH86TDlSw/the-swiss-stock-market-extended-its-gains-20170503-01269,The Swiss Stock Market Extended Its Gains
NVS,NVS:US,BBG000LYF3S8,"Dow&apos;s Pfizer Tops Earnings Views, But Sales Come Up Short",2017-05-02 20:27:58 +0000,http://finance.yahoo.com/r/2eae07a9-fbd1-353c-9555-e00a3f5daddb/pfizer-earnings-top-but-sales-come-up-short?src=A00220&yptr=yahoo&.tsrc=rss,Pfizer on Tuesday reported mixed first-quarter results on declining sales in its what it calls its Essential Health unit.
NVS,NVS:US,BBG000LYF3S8,Can Conatus Pharma (CNAT) Deliver a Beat in Q1 Earnings?,2017-05-02 16:32:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3m-HcLlEakc/can-conatus-pharma-cnat-deliver-a-beat-in-q1-earnings-cm782807,We expect Conatus Pharmaceuticals Inc CNAT to beat expectations when it reports first quarter 2017 results on May 4 after the market closes Conatus earnings history is a mixed bag The company surpassed expectations on two occasions missed expectation in one and posted in
NVS,NVS:US,BBG000LYF3S8,Vanguard FTSE Developed Markets ETF Experiences Big Inflow,2017-05-02 16:27:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMOUdMofdBY/vanguard-ftse-developed-markets-etf-experiences-big-inflow-cm782746,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 403 2 million dollar inflow that s a 0 8 increase week over week
NVS,NVS:US,BBG000LYF3S8,"Cambridge's bluebird bio licenses delivery tech to Novartis, GSK",2017-05-02 15:10:09 +0000,http://finance.yahoo.com/r/dc8397be-ec6b-343a-b367-1cca935128d2/cambridges-bluebird-bio-licenses-delivery-tech-to.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Cambridge-based bluebird bio said Tuesday that Novartis and GlaxoSmithKline will pay undisclosed sums to license its technology for delivering genetic material into cells.  Bluebird bio (BLUE) announced that it's selling the non-exclusive rights to the patents covering the technology, called lentiviral vectors, to Novartis (NVS) for use in developing cancer treatments and to GSK (GSK) for drugs targeting rare genetic diseases."
NVS,NVS:US,BBG000LYF3S8,How GlaxoSmithKline’s Vaccines Business Performed in 1Q17,2017-05-02 13:07:32 +0000,http://finance.yahoo.com/r/13e0908e-c61f-333c-9fab-14ebd28c89d3/how-glaxosmithklines-vaccines-business-performed-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"GlaxoSmithKline (GSK) is focused on strengthening its vaccines business, so it acquired the meningitis and other vaccines business from Novartis (NVS)."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed To A New High For The Year,2017-05-02 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3GpdR6RTrCQ/the-swiss-stock-market-climbed-to-a-new-high-for-the-year-20170502-01262,The Swiss Stock Market Climbed To A New High For The Year
NVS,NVS:US,BBG000LYF3S8,European Markets Climbed On Greek Bailout Deal,2017-05-02 12:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IR9knS3RrMw/european-markets-climbed-on-greek-bailout-deal-20170502-01234,European Markets Climbed On Greek Bailout Deal
NVS,NVS:US,BBG000LYF3S8,"Stem cell biotech Magenta bags $50M, strikes licensing deal with Novartis",2017-05-02 11:35:09 +0000,http://finance.yahoo.com/r/f43d92dc-8c63-3374-82e7-7cc7fc41c2f4/stem-cell-biotech-magenta-bags-50m-strikes.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Less than six months after launching with $48.5 million in financing, Cambridge-based stem cell transplant biotech Magenta Therapeutics has raised another $50 million and unveiled a licensing pact with Novartis.  Tuesday's Series B round was led by GV, formerly called Google Ventures.  Atlas Venture and Third Rock Ventures, which led the initial round in November, also participated."
NVS,NVS:US,BBG000LYF3S8,European Shares Inch Higher As Greece Secures Bailout Deal,2017-05-02 06:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a1sYh-CHoKo/european-shares-inch-higher-as-greece-secures-bailout-deal-20170502-00280,European Shares Inch Higher As Greece Secures Bailout Deal
NVS,NVS:US,BBG000LYF3S8,"ETFs with exposure to Novartis AG : May 1, 2017",2017-05-01 20:13:18 +0000,http://finance.yahoo.com/r/5ba92bef-ecf9-3399-a9d4-a320c2ad2e79/etfs-with-exposure-to-novartis-ag-may-1-2017?yptr=yahoo&.tsrc=rss,"Categories:  ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Novartis AG Here are 5 ETFs with the largest exposure to NVS-US. Comparing the performance and risk of Novartis AG with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more
<b>(Read more...)</b>"
NVS,NVS:US,BBG000LYF3S8,How GlaxoSmithKline’s Business Segments Performed in 1Q17,2017-05-01 11:40:30 +0000,http://finance.yahoo.com/r/d754436c-0e29-3307-ba7d-de45b98e7ea1/how-glaxosmithklines-business-segments-performed-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,The company reported operational growth of 5% in its revenues to 7.4 billion pounds for 1Q17.
NVS,NVS:US,BBG000LYF3S8,Novartis’s Valuation after 1Q17 Earnings,2017-05-01 11:37:08 +0000,http://finance.yahoo.com/r/d9099371-d2e2-3e5b-9eab-4bc4858fd2a1/novartiss-valuation-after-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On April 27, 2017, Novartis was trading at a forward PE multiple of ~15.8x. The industry currently trades at a forward PE multiple of ~15.9x."
NVS,NVS:US,BBG000LYF3S8,How Far Into the Drug Pipeline Should the FTC Reach?,2017-04-30 20:00:00 +0000,http://finance.yahoo.com/r/fd1f0eb2-61ba-3ab5-87f3-94cb28429432/how-far-into-the-drug-pipeline-should-the-ftc-reach.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Novartis exec argues the FTC should keep its hands off when pharmaceutical products are in early stages of development.
NVS,NVS:US,BBG000LYF3S8,5 Big Drugmakers With Important Catalysts in May,2017-04-30 15:41:00 +0000,http://finance.yahoo.com/r/e2a4e917-6b0c-3f71-8d17-ca9e1bb3fe0d/5-big-drugmakers-with-important-catalysts-in-may.aspx?yptr=yahoo&.tsrc=rss,"Merck, Novartis, Novo Nordisk, Regeneron, and Sanofi await big FDA decisions in May."
NVS,NVS:US,BBG000LYF3S8,Novartis: FDA Approves Rydapt To Treat FLT3-mutated Acute Myeloid Leukemia,2017-04-29 11:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UCh3hpJTzKk/novartis-fda-approves-rydapt-to-treat-flt3mutated-acute-myeloid-leukemia-20170429-00007,Novartis: FDA Approves Rydapt To Treat FLT3-mutated Acute Myeloid Leukemia
NVS,NVS:US,BBG000LYF3S8,What's Worrying Me About Biogen,2017-04-28 19:26:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pn2WeLMrHMo/whats-worrying-me-about-biogen-cm781369,Biogen Inc NASDAQ BIIB recently reported its first quarter financial results and while the company remains the market share leader in multiple sclerosis MS treatment there are signs that its dominance could be waning An increasingly competitive market MS is a central
NVS,NVS:US,BBG000LYF3S8,U.S. FDA approves Novartis' leukemia treatment,2017-04-28 17:08:17 +0000,http://finance.yahoo.com/news/u-fda-approves-novartis-leukemia-144045916.html?.tsrc=rss,"The U.S. Food and Drug Administration  approved Novartis AG's Rydapt as an initial treatment  for acute myeloid leukemia (AML) as well as certain other blood  disorders, the agency said on Friday.  AML is a cancer that originates in the bone marrow and  progresses rapidly, resulting in an abnormal increase in white  blood cells.  Rydapt is approved to be used along with chemotherapy to  treat adults newly diagnosed with AML and carrying a specific  genetic mutation called FLT3, the FDA said."
NVS,NVS:US,BBG000LYF3S8,[$$] Biotech and big pharma reap rewards from partnerships,2017-04-28 16:01:56 +0000,"http://finance.yahoo.com/r/8f450c63-0c66-34bd-9c52-b436c562536b/e8fccaf6-2c0c-11e7-bc4b-5528796fe35c,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","Biotech can easily get overshadowed by its larger and more profit-generating cousin, big pharma. However, the symbiosis between the two sectors has never been greater. Previously the small companies, usually ..."
NVS,NVS:US,BBG000LYF3S8,"Novartis AG :NVS-US: Earnings Analysis: Q1, 2017 By the Numbers : April 28, 2017",2017-04-28 15:13:46 +0000,http://finance.yahoo.com/r/44f188b6-ed05-3eb6-98de-a1f7026a8b04/novartis-ag-nvs-us-earnings-analysis-q1-2017-by-the-numbers-april-28-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Novartis AG reports financial results for the quarter ended March 31, 2017. We analyze the earnings along side the following peers of Novartis AG – Johnson & Johnson, GlaxoSmithKline plc Sponsored ADR and Abbott Laboratories (JNJ-US, GSK-US and ABT-US) that have also reported for this period. Highlights Summary numbers: Revenues of ... Read more
<b>(Read more...)</b>"
NVS,NVS:US,BBG000LYF3S8,Novartis’s 1Q17 Earnings: Recent Developments,2017-04-28 14:37:38 +0000,http://finance.yahoo.com/r/4f4172b4-7c67-341d-a2a0-7f4d6076ff06/novartiss-1q17-earnings-recent-developments?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics."
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More",2017-04-28 14:31:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hbwmZ5eBk3Y/pharma-stock-roundup-lilly-bristol-myers-novartis-q1-earnings-more-cm780993,Earnings season for the pharma sector started in full flow this week with companies like Lilly LLY Novartis NVS Bristol Myers BMY Roche AstraZeneca Glaxo GSK and Sanofi SNY reporting results So far it looks like a mixed quarter for the sector Recap of the Week s Most
NVS,NVS:US,BBG000LYF3S8,"1Q17 Earnings for Novartis’s Alcon, Its Eye Care Business",2017-04-28 13:08:00 +0000,http://finance.yahoo.com/r/0cef8094-77e2-30ee-802a-1fe69a326178/1q17-earnings-for-novartiss-alcon-its-eye-care-business?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Alcon's revenues fell ~1.0% to $1.41 billion in 1Q17 compared to $1.43 billion in 1Q16.
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Lilly, Bristol-Myers, Novartis Q1 Earnings & More",2017-04-28 12:41:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-lilly-bristol-124112594.html?.tsrc=rss,Several major pharma companies including Lilly (LLY) and Bristol-Myers reported Q1 results this week.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back On Profit Taking,2017-04-28 12:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CdrZ6TPcTPg/the-swiss-stock-market-pulled-back-on-profit-taking-20170428-00949,The Swiss Stock Market Pulled Back On Profit Taking
NVS,NVS:US,BBG000LYF3S8,"1Q17 Earnings for Novartis’s Sandoz, Its Generics Business",2017-04-28 11:39:26 +0000,http://finance.yahoo.com/r/9ccb62d5-62a5-3687-972d-4bf533413f2a/1q17-earnings-for-novartiss-sandoz-its-generics-business?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Sandoz, the generics arm of Novartis (NVS), is the number-two generic medicines provider in the world."
NVS,NVS:US,BBG000LYF3S8,Novartis’s 1Q17 Earnings: Innovative Medicines Segment,2017-04-27 21:05:50 +0000,http://finance.yahoo.com/r/6697ac17-8039-39a0-89b2-3a2923a3c554/novartiss-1q17-earnings-innovative-medicines-segment?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis’s (NVS) Innovative Medicines segment contributed ~66.6% to overall 1Q17 revenue, or $7.7 billion."
NVS,NVS:US,BBG000LYF3S8,Novartis’s 1Q17 Earnings: Segment Performances,2017-04-27 19:36:08 +0000,http://finance.yahoo.com/r/f632168b-96d7-3ff4-a5a9-6f905e38cf53/novartiss-1q17-earnings-segment-performances?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"On April 25, 2017, Novartis (NVS) reported a 2.0% rise in revenues at constant currencies for 1Q17. Revenues fell due to a 3.0% negative impact of foreign exchange."
NVS,NVS:US,BBG000LYF3S8,"Burns Wealth Management, Inc. Buys General Electric Co, Microsoft, Reynolds American, Sells ...",2017-04-27 18:26:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9b8nVFfe-PE/burns-wealth-management-inc-buys-general-electric-co-microsoft-reynolds-american-sells-cm780592,Burns Wealth Management Inc New Purchases RAI ZLTQ PM XLV MDT XLK FEYE NG CTRV Added Positions GE MSFT NVS IJR PII EFA SLB CVS XLF PXD Reduced Positions AAPL UPRO CSCO IXJ SSO AKRX PNC VOE WFC FB Sold Out LNCE PNRA ED
NVS,NVS:US,BBG000LYF3S8,Why Novartis’s 1Q17 Revenues Missed Analysts’ Estimates,2017-04-27 18:01:51 +0000,http://finance.yahoo.com/r/d52d15de-f5ba-3cbf-a10d-1ddf5a03d2f4/why-novartiss-1q17-revenues-missed-analysts-estimates?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis (NVS) released its 1Q17 earnings on April 25, 2017, reporting a 25.0% rise in revenues at constant exchange rates compared to 1Q16."
NVS,NVS:US,BBG000LYF3S8,"Amgen (AMGN) Q1 Earnings Top, Sales Miss, Shares Decline",2017-04-27 17:31:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QnQb6278TN0/amgen-amgn-q1-earnings-top-sales-miss-shares-decline-cm780471,Biotech major Amgen Inc AMGN reported first quarter 2017 earnings of 3 15 per share beating the Zacks Consensus Estimate of 3 00 by 5 and increasing 9 from the year ago period Higher operating margins offset a weak top line performance to drive the bottom line Total
NVS,NVS:US,BBG000LYF3S8,The Medicines Company (MDCO) Q1 Loss Wider Than Expected,2017-04-27 15:29:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D99dWKkZ4m4/the-medicines-company-mdco-q1-loss-wider-than-expected-cm780246,The Medicines Company MDCO reported a loss of 1 44 per share in first quarter 2017 wider than the Zacks Consensus Estimate of a loss of 1 13 Including share based compensation expenses however adjusted loss was 1 14 per share The reported figure widened from the year ago loss of 1
NVS,NVS:US,BBG000LYF3S8,Jerome Dodson Comments on Novartis,2017-04-27 12:25:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hTCoHn_GKDY/jerome-dodson-comments-on-novartis-cm780086,NYSE NVS Jerome Dodson Trades Portfolio Premium Members This article first appeared on GuruFocus This article first appeared
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Recent Gains,2017-04-27 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CyIkgo-R9S4/the-swiss-stock-market-extended-its-recent-gains-20170427-01579,The Swiss Stock Market Extended Its Recent Gains
NVS,NVS:US,BBG000LYF3S8,U.S. top court grapples over making copycat biologics available sooner,2017-04-26 18:19:27 +0000,http://finance.yahoo.com/news/u-top-court-grapples-over-181927753.html?.tsrc=rss,"U.S. Supreme Court justices  on Wednesday struggled over whether to speed up the time it  takes to bring to the market copycat versions of biologic drugs,  expensive medicines that can generate billions of dollars in  sales for drug makers.  The nine justices heard arguments in an appeal by Novartis  AG of a lower court decision that prevented the Swiss  pharmaceutical company from selling its biosimilar version of  California-based Amgen Inc's $1-billion-a-year Neupogen  until six months after the Food and Drug Administration approved  it.  The ruling in the case, due by the end of June, could  determine how quickly patients have access to near-copies of  biologic drugs called biosimilars at potentially cheaper prices."
NVS,NVS:US,BBG000LYF3S8,Jerome Dodson Comments on Novartis,2017-04-26 16:46:33 +0000,http://finance.yahoo.com/news/jerome-dodson-comments-novartis-164633130.html?.tsrc=rss,Guru stock highlight
NVS,NVS:US,BBG000LYF3S8,U.S. top court debates making copycat biologics available sooner,2017-04-26 16:23:44 +0000,http://finance.yahoo.com/news/u-top-court-debates-making-162344164.html?.tsrc=rss,"U.S. Supreme Court justices  on Wednesday struggled over whether to speed up the time it  takes to bring to the market copycat versions of biologic drugs,  expensive medicines that can generate billions of dollars in  sales for drug makers.  The nine justices heard arguments in an appeal by Novartis  AG of a lower court decision that prevented the Swiss  pharmaceutical company from selling its biosimilar version of  California-based Amgen Inc's $1-billion-a-year Neupogen  until six months after the Food and Drug Administration approved  it."
NVS,NVS:US,BBG000LYF3S8,What Awaits Aerie Pharmaceuticals (AERI) in Q1 Earnings?,2017-04-26 15:10:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7JpijALQScg/what-awaits-aerie-pharmaceuticals-aeri-in-q1-earnings-cm779429,Aerie Pharmaceuticals Inc AERI is scheduled to report first quarter 2017 results on May 2 Last quarter the company missed expectations by 33 85 In fact Aerie s performance over the last four quarters has been disappointing The company reported a wider than expected loss in the
NVS,NVS:US,BBG000LYF3S8,Glaxo (GSK) Beats Earnings and Revenues in Q1,2017-04-26 13:11:01 +0000,http://finance.yahoo.com/news/glaxo-gsk-beats-earnings-revenues-131101302.html?.tsrc=rss,"Glaxo reported core earnings of 63 cents per American depositary share, which marginally beat our consensus estimate of 62 cents."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed To A New High For The Year,2017-04-26 12:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jbpBo4ALy_U/the-swiss-stock-market-climbed-to-a-new-high-for-the-year-20170426-01291,The Swiss Stock Market Climbed To A New High For The Year
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline’s 1Q17 Estimates: Vaccines Business,2017-04-26 11:36:33 +0000,http://finance.yahoo.com/r/012cf927-5928-32a1-89dd-d4788d4f6fd1/glaxosmithklines-1q17-estimates-vaccines-business?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"The Novartis acquisition has improved sales for GSK's Vaccines business, mainly driven by the sales of meningitis vaccines Bexsero in Europe and Menveo in the US and Europe."
NVS,NVS:US,BBG000LYF3S8,"Novartis Earnings Top, But Sales Dip Despite New Blockbuster Drug",2017-04-25 20:45:13 +0000,http://finance.yahoo.com/r/d87c9066-5cd2-327e-8bb3-8ce3723c038f/can-novartis-newest-blockbuster-outperform-again-in-q1?src=A00220&yptr=yahoo&.tsrc=rss,"Sales of plaque psoriasis drug Cosentyx shot up 133% to $410 million in the first quarter, but Novartis reported a mixed first quarter."
NVS,NVS:US,BBG000LYF3S8,"Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales",2017-04-25 20:07:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7OImiOnjrq0/novartis-tops-q1-earnings-cosentyx-entresto-boost-sales-cm779012,Novartis AG NVS reported first quarter 2017 core earnings of 1 13 per share beating the Zacks Consensus Estimate of 1 10 but it was lower than the year ago figure of 1 17 Novartis AG Price and EPS Surprise Novartis AG Price and EPS
NVS,NVS:US,BBG000LYF3S8,"Novartis, Amgen Divvy Global Marketing of New Migraine Drug",2017-04-25 19:46:00 +0000,http://finance.yahoo.com/r/b8230433-005c-3bb6-a794-ea9e5a1de6d5/novartis-amgen-divvy-global-marketing-of-new-migraine-drug.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Estimates for erenumab annual sales run as high as $2.3 billion.
NVS,NVS:US,BBG000LYF3S8,"Novartis Tops Q1 Earnings: Cosentyx, Entresto Boost Sales",2017-04-25 17:53:05 +0000,http://finance.yahoo.com/news/novartis-tops-q1-earnings-cosentyx-175305001.html?.tsrc=rss,"Novartis AG (NVS) reported first-quarter 2017 core earnings of $1.13 per share, beating the Zacks Consensus Estimate of $1.10."
NVS,NVS:US,BBG000LYF3S8,"Novartis to speed up bid for MS drug approval, changes target",2017-04-25 16:01:02 +0000,http://finance.yahoo.com/news/novartis-speed-bid-ms-drug-160102207.html?.tsrc=rss,"Novartis said on  Tuesday it would accelerate its bid to win approval for its  experimental multiple sclerosis (MS) drug BAF312 and said it was  now targeting patients at an earlier stage of the neurological  disease.  With BAF312, Basel-based Novartis aims to join its rival  Roche in developing a lucrative new drug to treat MS.  Novartis plans to file BAF312 for approval with the U.S.  Food and Drug Administration in the first half of 2018 for  patients with relapsing/remitting MS (RRMS), a form of the  disease where patients suffer clearly defined attacks."
NVS,NVS:US,BBG000LYF3S8,Novartis sets sights on return to growth in 2018,2017-04-25 15:39:00 +0000,http://finance.yahoo.com/news/novartis-sets-sights-return-growth-092007771.html?.tsrc=rss,"Novartis reported  better-than-expected first-quarter profits on Tuesday with Chief  Executive Joe Jimenez saying he remained confident the Swiss  drugmaker would return to growth in 2018 as spending to promote  new drugs pays off.  Jimenez is now counting on psoriasis treatment Cosentyx,  chronic heart failure drug Entresto and newly approved breast  cancer drug Kisqali to help counteract generics eating into  sales of its once top-selling blood cancer drug Gleevec.  ""We're investing heavily in the growth drivers,"" Jimenez  said on a call with reporters."
NVS,NVS:US,BBG000LYF3S8,Key Factors to Look Out for in Celgene's (CELG) Q1 Results,2017-04-25 14:08:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UsVLGeMUSN0/key-factors-to-look-out-for-in-celgenes-celg-q1-results-cm778639,Earnings season for the pharma and biotech sector will start in full flow this week with several major companies scheduled to report results Celgene Corporation CELG is one of the companies that will be reporting results later this week A look at the company s earnings track record
NVS,NVS:US,BBG000LYF3S8,Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?,2017-04-25 14:05:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_luUbEaDs2o/will-low-pricing-for-siliq-be-enough-to-help-valeant-turn-things-around-cm778473,Valeant Pharmaceuticals NYSE VRX has been more bullish about the prospects for brodalumab now branded as Siliq than anyone Amgen bailed out on the 160 psoriasis drug after late stage study results raised concerns about Siliq causing patients to have suicidal
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline’s 1Q17 Estimates: Revenues Expected to Grow,2017-04-25 13:09:37 +0000,http://finance.yahoo.com/r/34d38ef7-3d1d-32f3-95c2-fd0c90343f15/glaxosmithklines-1q17-estimates-revenues-expected-to-grow?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Analysts expect ~16.5% growth in GlaxoSmithKline’s (GSK) 1Q17 revenues to ~7.3 billion pounds following strong product launches, acquired products from Novartis (NVS), and improvement in the supply chain...."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On Novartis Strength,2017-04-25 12:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xCF7uI8ngQ4/the-swiss-stock-market-climbed-on-novartis-strength-20170425-01310,The Swiss Stock Market Climbed On Novartis Strength
NVS,NVS:US,BBG000LYF3S8,Stock Futures See More Gains on a Stream of Positive Earnings,2017-04-25 12:28:00 +0000,http://finance.yahoo.com/r/c7058aab-4abb-3252-9110-74bd9ded77c4/stock-futures-see-more-gains-on-a-stream-of-positive-earnings.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"Stock futures move higher on Tuesday, extending gains seen a day earlier, after a series of positive earnings results from the likes of DuPont, Novartis, and Rite Aid."
NVS,NVS:US,BBG000LYF3S8,Will Low Pricing for Siliq Be Enough to Help Valeant Turn Things Around?,2017-04-25 12:22:00 +0000,http://finance.yahoo.com/r/76d5aafd-2c86-3a08-a9b8-17abb615f26a/will-low-pricing-for-siliq-be-enough-to-help-valea.aspx?yptr=yahoo&.tsrc=rss,Valeant is undercutting Novartis and Lilly with its pricing of psoriasis drug Siliq. How much will the strategy help?
NVS,NVS:US,BBG000LYF3S8,European Markets Inched Higher After Yesterday's Strong Rally,2017-04-25 12:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/E1HFeHPDdhk/european-markets-inched-higher-after-yesterdays-strong-rally-20170425-01261,European Markets Inched Higher After Yesterday's Strong Rally
NVS,NVS:US,BBG000LYF3S8,"Earnings Reaction History: Novartis AG, 42.9% Follow-Through Indicator, 1.2% Sensitive",2017-04-25 10:43:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/noRy8mJa8x0/earnings-reaction-history-novartis-ag-429-follow-through-indicator-12-sensitive-cm778376,Expected Earnings Release 04 25 2017 PremarketExpected Earnings Release 04 25 2017 Premarket Avg Extended Hours Dollar Volume 8 834 940Avg Extended Hours Dollar Volume 8 834 940 Novartis AG NVS is due to issue its quarterly earnings report in the upcoming extended hours
NVS,NVS:US,BBG000LYF3S8,Novartis beats 1Q profit forecasts,2017-04-25 10:00:55 +0000,http://finance.yahoo.com/news/novartis-beats-1q-profit-forecasts-100055688.html?.tsrc=rss,"The Basel, Switzerland-based company said it had profit of 70 cents per share. Earnings, adjusted for non-recurring costs, came to $1.13 per share. The results beat Wall Street expectations. The average ..."
NVS,NVS:US,BBG000LYF3S8,Swiss drugs giant Novartis posts 15 percent drop in profit,2017-04-25 09:56:22 +0000,http://finance.yahoo.com/r/0fafd9da-c6b0-3790-8a4d-e0f50afe48df/swiss-drugs-giant-novartis-posts-065351314.html?.tsrc=rss,GENEVA (AP) — Swiss pharmaceuticals group Novartis says net income fell 15 percent in the first quarter as it continued to adjust to generic competition for its Gleevec leukemia drug and stopped work on a hoped-for treatment for heart failure.
NVS,NVS:US,BBG000LYF3S8,Novartis Shares Jump After Group Holds To Full Year Forecasts; Sees Entresto Growth,2017-04-25 09:56:00 +0000,http://finance.yahoo.com/r/876cc752-722e-3b93-8e86-b81ddc8e64a8/novartis-shares-jump-after-group-holds-to-full-year-forecasts-sees-entresto-growth.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,Novartis shares led gainers in Zurich Tuesday after the pharmaceuticals group held on to full year earnings targets and narrowly beast analysts' forecasts for first quarter earnings.
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis Profit Dented by Investment in New Drugs,2017-04-25 06:59:01 +0000,http://finance.yahoo.com/r/55c4d59b-b295-30fc-93bf-8ae3e6398c4e/novartis-profit-dented-by-investment-in-new-drugs-1493103198?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,Novartis said profit fell in the first quarter as it pumped investment into the launch of its new heart-failure drug Entresto that it hopes will help offset revenue lost as best-selling cancer medicine ...
NVS,NVS:US,BBG000LYF3S8,European Shares Mostly Higher On Earnings,2017-04-25 06:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pAj-4TcZkJE/european-shares-mostly-higher-on-earnings-20170425-00295,European Shares Mostly Higher On Earnings
NVS,NVS:US,BBG000LYF3S8,Novartis Moves M&A Search to Early-Stage Drugs on Price Gain,2017-04-25 05:26:33 +0000,http://finance.yahoo.com/r/efe27beb-3efc-3be7-bb49-b6b801994741/novartis-profit-declines-after-boosting-investment-in-new-drugs?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Swiss drugmaker Novartis AG said it will scout for medicines that are in earlier stages of development as acquisition price tags climb across the industry.
NVS,NVS:US,BBG000LYF3S8,Novartis Q1 Core Profit Tops Estimates; Backs; Backs FY17 View; Shares Up,2017-04-25 05:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/R0oa5EqqNOc/novartis-q1-core-profit-tops-estimates-backs-backs-fy17-view-shares-up-20170425-00218,Novartis Q1 Core Profit Tops Estimates; Backs; Backs FY17 View; Shares Up
NVS,NVS:US,BBG000LYF3S8,Novartis Q1 Profit Down On Weak Sales; Backs FY17 View - Quick Facts,2017-04-25 01:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fryvFj2PQJM/novartis-q1-profit-down-on-weak-sales-backs-fy17-view--quick-facts-20170425-00036,Novartis Q1 Profit Down On Weak Sales; Backs FY17 View - Quick Facts
NVS,NVS:US,BBG000LYF3S8,[$$] Malaria experts set sights on single-shot cure by 2030s,2017-04-24 23:03:36 +0000,"http://finance.yahoo.com/r/79f2a6cb-46d0-37ab-b6e1-a2fd25430ff6/cb7b7238-0e53-11e7-a88c-50ba212dce4d,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","To those engaged daily in the war against malaria, talk of a cure-all is fanciful. The mosquito-borne disease is always adapting, mutating its genetic make-up to overcome whatever humans throw at it. Not ..."
NVS,NVS:US,BBG000LYF3S8,CEO Gassner Makes Sure Veeva Has A 'Second Act'  — And More,2017-04-24 21:02:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/km1ZGjpPSgs/ceo-gassner-makes-sure-veeva-has-a-second-act-and-more-cm776897,When Peter Gassner launched Veeva Systems VEEV in 2007 he didn t expect to outstrip 500 million in revenue watch its stock 160 triple in a span of less than three years or expand its arsenal of products to 23 applications Instead Gassner 160 was in survival
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 04/24/2017: JNJ,NVS,BCR,AKTX,BDX",2017-04-24 20:22:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k7xN0KsndGc/health-care-sector-update-for-04242017-jnjnvsbcraktxbdx-cm778234,Top Health Care StocksTop Health Care Stocks JNJ 0 91 JNJ 0 91 PFE 0 34 PFE 0 34 MRK 1 52 MRK 1 52 ABT 0 37 ABT 0 37 AMGN 1 86 AMGN 1 86 Health care stocks put up big gains today with the NYSE Health Care Index climbing almost 1 3 while shares of health care companies in
NVS,NVS:US,BBG000LYF3S8,"How Lilly&apos;s New Drug Could Spark A Deeper Rivalry With Pfizer, Novartis",2017-04-24 20:14:13 +0000,http://finance.yahoo.com/r/d01069bd-417e-34dd-949c-a3b4a467022d/how-lillys-new-drug-could-spark-a-deeper-rivalry-with-pfizer-novartis?src=A00220&yptr=yahoo&.tsrc=rss,Eli Lilly stock popped Monday after the drugmaker said its breast cancer drug &quot;has the potential to be best in class.&quot;
NVS,NVS:US,BBG000LYF3S8,"Noteworthy ETF Outflows: PPH, NVS, SNY, AZN",2017-04-24 18:02:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/i0p90ntjMVM/noteworthy-etf-outflows-pph-nvs-sny-azn-cm778024,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Pharmaceutical ETF Symbol PPH where we have detected an approximate 21 4 million dollar outflow that s a 6 5 decrease week over week from 6 138 138
NVS,NVS:US,BBG000LYF3S8,[$$] Digital disrupters take big pharma 'beyond the pill',2017-04-24 16:35:34 +0000,"http://finance.yahoo.com/r/d9920a15-04af-3641-a731-87715c38b08a/d7a60642-0361-11e7-ace0-1ce02ef0def9,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev&yptr=yahoo&.tsrc=rss","After Maggie Philyaw developed Type 2 diabetes, she found solace not in the medicines of the pharmaceutical industry, but the technology of Silicon Valley. Two years ago, her then employer in North Carolina ..."
NVS,NVS:US,BBG000LYF3S8,"VEA, DDG: Big ETF Inflows",2017-04-24 16:05:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o8qFP6DRXtM/vea-ddg-big-etf-inflows-cm777841,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 14 506 435 units or a 1 2 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,Analyst Ratings and Recommendations for Novartis,2017-04-24 14:37:33 +0000,http://finance.yahoo.com/r/c9746272-3f45-33b7-8b5f-3c4bd4df32d8/analyst-ratings-and-recommendations-for-novartis?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"As of April 21, 2017, there are five analysts tracking Novartis. Of those, two have recommended a “strong buy,” and one has recommended a ""buy."""
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Rallied On French Election Results,2017-04-24 12:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cPGxni6V27A/the-swiss-stock-market-rallied-on-french-election-results-20170424-00976,The Swiss Stock Market Rallied On French Election Results
NVS,NVS:US,BBG000LYF3S8,"Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS",2017-04-24 12:04:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AixDPKrsJNM/drug-stocks-q1-earnings-releases-on-apr-25-lly-biib-nvs-cm777652,As the Q1 earnings season gets in full swing this week we believe this quarter is on track to see the highest growth in almost three years As of Apr 21 2017 95 S amp P 500 members accounting for 24 9 of the index s total market capitalization reported results according to the
NVS,NVS:US,BBG000LYF3S8,European Markets Soar On French Election Results,2017-04-24 12:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KFVcJuCsuOQ/european-markets-soar-on-french-election-results-20170424-00949,European Markets Soar On French Election Results
NVS,NVS:US,BBG000LYF3S8,Novartis’s 1Q17 Estimates for Sandoz,2017-04-24 11:38:09 +0000,http://finance.yahoo.com/r/f6c97ebc-3cc3-38a1-8ff2-1f837d537551/novartiss-1q17-estimates-for-sandoz?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Sandoz's revenues are expected to rise in 1Q17 following an increased demand for biopharmaceuticals such as biosimilars and Glatopa.
NVS,NVS:US,BBG000LYF3S8,"Drug Stocks Q1 Earnings Releases on Apr 25: LLY, BIIB, NVS",2017-04-24 09:52:09 +0000,http://finance.yahoo.com/news/drug-stocks-q1-earnings-releases-095209011.html?.tsrc=rss,"As the Q1 earnings season gets in full swing this week, we believe this quarter is on track to see the highest growth in almost three years."
NVS,NVS:US,BBG000LYF3S8,European Shares Rally After French Vote,2017-04-24 06:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zO_rUr3lUjI/european-shares-rally-after-french-vote-20170424-00223,European Shares Rally After French Vote
NVS,NVS:US,BBG000LYF3S8,Novartis Tests New Alzheimer’s Drug on People Who Don’t Have the Disease,2017-04-24 04:02:00 +0000,http://finance.yahoo.com/r/281b42a2-af8b-36cf-9017-dcbce5d5fe38/novartis-tests-new-alzheimers-drug-on-people-who-dont-have-the-disease-1492871315?ru=yahoo?mod=yahoo_itp&yptr=yahoo&.tsrc=rss,"Subjects at high risk of developing Alzheimer’s—but who don’t actually have the disease—are being recruited to help test two experimental treatments from Novartis AG, in a new focus on preventive treatment...."
NVS,NVS:US,BBG000LYF3S8,Novartis: Phase IV Real-world Data Confirms Effectiveness Of Gilenya,2017-04-24 01:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/voVDU8NOD3o/novartis-phase-iv-realworld-data-confirms-effectiveness-of-gilenya-20170424-00048,Novartis: Phase IV Real-world Data Confirms Effectiveness Of Gilenya
NVS,NVS:US,BBG000LYF3S8,Novartis Tests New Alzheimer's Drugs on People Who Don't Have the Disease,2017-04-23 22:15:41 +0000,http://finance.yahoo.com/r/281b42a2-af8b-36cf-9017-dcbce5d5fe38/novartis-tests-new-alzheimers-drug-on-people-who-dont-have-the-disease-1492871315?mod=yahoo_hs&yptr=yahoo&.tsrc=rss,"Subjects at high risk of developing Alzheimer’s—but who don’t actually have the disease—are being recruited to help test two experimental treatments from Novartis AG, in a new focus on preventive treatment...."
NVS,NVS:US,BBG000LYF3S8,Should Gilead Sciences Be Worried About Allergan?,2017-04-23 17:02:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jcp6nZILkeA/should-gilead-sciences-be-worried-about-allergan-cm777591,The next hepatitis C That s what another liver disease non alcoholic steatohepatitis NASH has been called The global market for NASH drugs could be 40 billion annually and there are no approved treatments for the disease Gilead Sciences NASDAQ GILD is sorely in need
NVS,NVS:US,BBG000LYF3S8,Should Gilead Sciences Be Worried About Allergan?,2017-04-23 15:41:00 +0000,http://finance.yahoo.com/r/f0f16d25-7a72-3578-815e-3522eec1cb2b/should-gilead-sciences-be-worried-about-allergan.aspx?yptr=yahoo&.tsrc=rss,Gilead Sciences might want to pay attention to Allergan&apos;s aggressive expansion of its NASH program.
NVS,NVS:US,BBG000LYF3S8,CHMP Recommends Approval Of Sandoz Biosimilar Rituximab And Etanercept In Europe,2017-04-22 23:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8VWzRFpohss/chmp-recommends-approval-of-sandoz-biosimilar-rituximab-and-etanercept-in-europe-20170422-00036,CHMP Recommends Approval Of Sandoz Biosimilar Rituximab And Etanercept In Europe
NVS,NVS:US,BBG000LYF3S8,Novartis’s 1Q17 Estimates: Innovative Medicines Segment,2017-04-21 20:35:43 +0000,http://finance.yahoo.com/r/4289f108-6e16-3828-a78c-ca1759ba7580/novartiss-1q17-estimates-innovative-medicines-segment?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis’s (NVS) Innovative Medicines segment includes products for therapeutic areas such as oncology, cardiometabolic, immunology, and dermatology."
NVS,NVS:US,BBG000LYF3S8,Analysts Expect Novartis’s Revenues to Remain Flat in 1Q17,2017-04-21 19:05:48 +0000,http://finance.yahoo.com/r/9bdb445f-7c07-381c-b6ea-cb42a5baaa52/analysts-expect-novartiss-revenues-to-remain-flat-in-1q17?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Analysts expect Novartis's (NVS) revenues to remain nearly flat at ~$11.7 billion in 1Q17 following the effects of its acquisitions and divestitures.
NVS,NVS:US,BBG000LYF3S8,Analyst Estimates for Novartis’s 1Q17 Earnings,2017-04-21 17:13:26 +0000,http://finance.yahoo.com/r/028d8940-3c92-3526-9ea1-50095dab59ab/analyst-estimates-for-novartiss-1q17-earnings?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis is set to release its 1Q17 earnings on April 25, 2017. Analysts estimate its 1Q17 EPS at $1.12 with revenues of ~$11.7 billion."
NVS,NVS:US,BBG000LYF3S8,What's in Store for GlaxoSmithKline (GSK) in Q1 Earnings?,2017-04-21 17:04:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LHnd6rIgHoY/whats-in-store-for-glaxosmithkline-gsk-in-q1-earnings-cm777139,GlaxoSmithKline plc GSK is scheduled to report first quarter 2017 results on Apr 26 before market opens Last quarter the company delivered a positive earnings surprise of 14 04 Glaxo s shares are up 5 7 this year so far outperforming the 4 increase witnessed by the Zacks
NVS,NVS:US,BBG000LYF3S8,Three Hot Junior Biotech Plays,2017-04-21 16:25:00 +0000,http://finance.yahoo.com/r/ceaaea51-6dd6-350c-afc2-e50fcbd538f3/three-hot-junior-biotech-plays-cnat-zyne?partner=YahooSA&yptr=yahoo&.tsrc=rss,"Major biotech funds are struggling after a series of high-profile drug pricing scandals, but that hasn't stopped the flow of junior biotech winners. (CNAT)"
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL",2017-04-21 13:05:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lhqx_1cDwZE/pharma-stock-roundup-jj-slips-on-mixed-q1-lilly-hit-by-fda-crl-cm776874,Johnson amp Johnson JNJ kicked off the first quarter earnings season for the pharma sector this week Meanwhile Lilly LLY was also in the news with the company receiving a complete response letter CRL for its experimental rheumatoid arthritis RA treatment baricitinib Recap of
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Closed Little Changed Ahead Of French Election,2017-04-21 12:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3nCSJtOeKh8/the-swiss-stock-market-closed-little-changed-ahead-of-french-election-20170421-00725,The Swiss Stock Market Closed Little Changed Ahead Of French Election
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: J&J Slips on Mixed Q1, Lilly Hit by FDA CRL",2017-04-21 11:12:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-j-j-111211147.html?.tsrc=rss,Key highlights from the pharma sector include J&J&apos;s (JNJ) first quarter results and a CRL for Lilly&apos;s RA drug.
NVS,NVS:US,BBG000LYF3S8,An Alcon Sale Will Take a Bargain Price,2017-04-20 17:40:15 +0000,http://finance.yahoo.com/r/c76e7784-2b77-3d38-84da-5a7ab2edcdcf/novartis-alcon-sale-will-take-a-bargain-price?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,There's not much of a market for a declining eye-care business.
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?,2017-04-20 16:04:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yKmXjYnEpRQ/novartis-nvs-q1-earnings-will-the-stock-disappoint-cm776412,Swiss pharmaceutical company Novartis AG NVS is scheduled to report first quarter 2017 results on Apr 25 A look at Novartis share price movement year to date shows that the stock has underperformed the Zacks classified Large Cap Pharma industry Its shares have declined 0 2 as against
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Q1 Earnings: Will the Stock Disappoint?,2017-04-20 14:19:02 +0000,http://finance.yahoo.com/news/novartis-nvs-q1-earnings-stock-141902643.html?.tsrc=rss,Swiss pharmaceutical company Novartis AG (NVS) is scheduled to report first-quarter 2017 results on Apr 25.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On Positive Corporate Earnings,2017-04-20 12:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J7Ht23ZJGnQ/the-swiss-stock-market-climbed-on-positive-corporate-earnings-20170420-01186,The Swiss Stock Market Climbed On Positive Corporate Earnings
NVS,NVS:US,BBG000LYF3S8,European Markets Climbed On Earnings Strength,2017-04-20 11:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EtAW5Exxbgo/european-markets-climbed-on-earnings-strength-20170420-01106,European Markets Climbed On Earnings Strength
NVS,NVS:US,BBG000LYF3S8,European Shares Broadly Higher Amid Earnings Cheer,2017-04-20 06:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/t32T20Gcoto/european-shares-broadly-higher-amid-earnings-cheer-20170420-00253,European Shares Broadly Higher Amid Earnings Cheer
NVS,NVS:US,BBG000LYF3S8,Novartis' (NVS) CTL109 BLA Gets Breakthrough Therapy Status,2017-04-19 16:06:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B9xUSgLjRB8/novartis-nvs-ctl109-bla-gets-breakthrough-therapy-status-cm775840,Novartis NVS announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate CTL019 The company is evaluating CTL01 an experimental chimeric antigen receptor T cell CAR T therapy for the treatment of adult patients with relapsed and refractory r r
NVS,NVS:US,BBG000LYF3S8,Allergan (AGN) Collaborates with Novartis to Treat NASH,2017-04-19 16:06:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RL6L7YsGvEA/allergan-agn-collaborates-with-novartis-to-treat-nash-cm775828,Allergan plc AGN entered into a collaboration with Novartis AG NVS to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc CVC and Novartis lead Fxr agonist to treat non alcoholic steatohepatitis NASH A look at Allergan s year to date share price movement shows
NVS,NVS:US,BBG000LYF3S8,"Novartis AG : NVS-US: Dividend Analysis : March 03rd, 2017 (record date) : By the numbers : April 19, 2017",2017-04-19 15:47:27 +0000,http://finance.yahoo.com/r/f252bfac-6fff-37d0-88d3-96fc6cc08f5f/novartis-ag-nvs-us-dividend-analysis-march-03rd-2017-record-date-by-the-numbers-april-19-2017?yptr=yahoo&.tsrc=rss,"Categories:  Yahoo FinanceGet free summary analysis Our analysis is based on comparing Novartis AG with the following peers – Pfizer Inc., Merck & Co., Inc., Johnson & Johnson, Sanofi Sponsored ADR, GlaxoSmithKline plc Sponsored ADR, Teva Pharmaceutical Industries Limited Sponsored ADR, Roche Holding Ltd Genusssch., Bristol-Myers Squibb Company, Abbott Laboratories and Astrazeneca PLC Sponsored ADR (PFE-US, MRK-US, ... Read more
<b>(Read more...)</b>"
NVS,NVS:US,BBG000LYF3S8,Allergan (AGN) Collaborates with Novartis to Treat NASH,2017-04-19 14:11:02 +0000,http://finance.yahoo.com/news/allergan-agn-collaborates-novartis-treat-141102929.html?.tsrc=rss,Allergan plc (AGN) entered into a collaboration with Novartis AG (NVS) to conduct a phase IIb study to evaluate a combination of its drug cenicriviroc (cvc) and Novartis lead Fxr agonist to treat non-alcoholic steatohepatitis
NVS,NVS:US,BBG000LYF3S8,Novartis&apos; (NVS) CTL109 BLA Gets Breakthrough Therapy Status,2017-04-19 14:01:02 +0000,http://finance.yahoo.com/news/novartis-apos-nvs-ctl109-bla-140102483.html?.tsrc=rss,"Novartis (NVS) announced that the FDA has granted Breakthrough Therapy Designation to its pipeline candidate, CTL019."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed As Nestle Weighs,2017-04-19 12:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TeHS3EBloR0/the-swiss-stock-market-finished-little-changed-as-nestle-weighs-20170419-00933,The Swiss Stock Market Finished Little Changed As Nestle Weighs
NVS,NVS:US,BBG000LYF3S8,Could Lilly Outperform These Bigger Rivals On Strong Diabetes Meds?,2017-04-18 20:36:39 +0000,http://finance.yahoo.com/r/7ba7f433-5ab4-3ca3-836f-d13d5b62232a/could-lilly-outperform-these-bigger-rivals-on-strong-diabetes-meds?src=A00220&yptr=yahoo&.tsrc=rss,Eli Lilly is set to outperform bigger drugmakers Novartis and Sanofi in terms of first-quarter diabetes sales.
NVS,NVS:US,BBG000LYF3S8,Why the Ionis Spinoff Will Be a Win for Long-Term Investors,2017-04-18 18:05:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jduLis7v5cw/why-the-ionis-spinoff-will-be-a-win-for-long-term-investors-cm775384,Last month s announcement by Ionis Pharmaceuticals NASDAQ IONS that the company was spinning off its Akcea subsidiary had some investors scratching their heads Why was the company seemingly giving up so much for so little gain It turns out that management has its focus squarely
NVS,NVS:US,BBG000LYF3S8,Why the Ionis Spinoff Will Be a Win for Long-Term Investors,2017-04-18 16:22:00 +0000,http://finance.yahoo.com/r/95201483-7c8b-3b44-b3b0-a759702b582b/why-the-ionis-spinoff-will-be-a-win-for-long-term.aspx?yptr=yahoo&.tsrc=rss,Ionis keeps doing what it&apos;s good at: developing new drugs and setting up future revenue streams
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Significant Loss,2017-04-18 12:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NfibCqF5xFY/the-swiss-stock-market-finished-with-a-significant-loss-20170418-01012,The Swiss Stock Market Finished With A Significant Loss
NVS,NVS:US,BBG000LYF3S8,European Markets Dropped After Britain Calls For Snap Elections,2017-04-18 11:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wpovWK6t_C4/european-markets-dropped-after-britain-calls-for-snap-elections-20170418-00968,European Markets Dropped After Britain Calls For Snap Elections
NVS,NVS:US,BBG000LYF3S8,Novartis Predicts Chinese Drug Market Growth Will Accelerate,2017-04-18 11:09:41 +0000,http://finance.yahoo.com/r/39b02ff4-daed-332a-9939-12bed115a4c3/novartis-predicts-growth-in-chinese-drug-market-will-accelerate?utm_source=yahoo&utm_medium=bd&utm_campaign=headline&cmpId=yhoo.headline&yptr=yahoo&.tsrc=rss,Swiss drugmaker Novartis AG expects growth in China’s pharmaceuticals market to accelerate as the nation’s health authorities expedite approvals for new medicines and increase reimbursement.
NVS,NVS:US,BBG000LYF3S8,"Novartis Snags Coveted FDA 'Breakthrough' Label for CAR-T, Trial Results Still Under Wraps",2017-04-18 11:05:00 +0000,http://finance.yahoo.com/r/fef66667-fecd-3e9b-a2d2-047ba571640b/novartis-snags-coveted-fda-breakthrough-label-for-car-t-trial-results-still-under-wraps.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,"The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite Pharma's competing ""CAR-T"" KTE-C19 in the same DLBCL patients."
NVS,NVS:US,BBG000LYF3S8,Novartis CEO Says Trump Discussed Pricing With Drug CEOs,2017-04-18 09:51:56 +0000,http://finance.yahoo.com/video/novartis-ceo-says-trump-discussed-095156105.html?.tsrc=rss,"Apr.18 -- Joseph Jimenez, chief executive officer at Novartis, discusses talks with President Trump including performance based pricing. He speaks with Francine Lacqua on &quot;Bloomberg Surveillance.&quot;"
NVS,NVS:US,BBG000LYF3S8,Novartis CEO Says Pharma Needs to Step Up Its Efforts,2017-04-18 09:37:00 +0000,http://finance.yahoo.com/video/novartis-ceo-says-pharma-needs-093700262.html?.tsrc=rss,"Apr.18 -- Joseph Jimenez, chief executive officer at Novartis, discusses the company’s efforts on neglected diseases and talks with President Trump. He speaks with Francine Lacqua on &quot;Bloomberg Surveillance.&quot;"
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Up 7.7% Since Earnings Report: Can It Continue?,2017-04-18 08:53:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8Kp5tN5BmXo/novartis-nvs-up-77-since-earnings-report-can-it-continue-cm774970,It has been about a month since the last earnings report for Novartis AG NVS Shares have added about 7 7 in that time frame outperforming the market Will the recent positive trend continue leading up to the stock s next earnings release or is it due for a pullback Before we dive into
NVS,NVS:US,BBG000LYF3S8,Novartis advances with push on cancer and liver disease,2017-04-18 08:07:07 +0000,http://finance.yahoo.com/news/novartis-advances-push-cancer-liver-080707059.html?.tsrc=rss,"Novartis's push into  oncology and liver disease, two of its treatment priorities,  advanced on Monday as the Swiss drugmaker won a second U.S.  breakthrough tag for its cancer gene therapy while striking a  separate pact with Allergan.  The Basel-based drugmaker's chimeric antigen receptor  therapy (CAR-T) treatment, called CTL019, was awarded the U.S.  Food and Drug Administration's breakthrough therapy designation  for adults with relapsed/refractory (r/r) diffuse large B-cell  lymphoma, a common blood cancer."
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Up 7.7% Since Earnings Report: Can It Continue?,2017-04-18 07:09:07 +0000,http://finance.yahoo.com/news/novartis-nvs-7-7-since-070907449.html?.tsrc=rss,Novartis (NVS) reported earnings 30 days ago. What&apos;s next for the stock? We take a look at earnings estimates for some clues.
NVS,NVS:US,BBG000LYF3S8,European Shares Retreat As Geopolitical Worries Mount,2017-04-18 06:04:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/86SnE22EqPg/european-shares-retreat-as-geopolitical-worries-mount-20170418-00206,European Shares Retreat As Geopolitical Worries Mount
NVS,NVS:US,BBG000LYF3S8,Novartis Reports Breakthrough Therapy Designation For CTL019 - Quick Facts,2017-04-18 01:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jyrUzd1Lr1c/novartis-reports-breakthrough-therapy-designation-for-ctl019--quick-facts-20170418-00038,Novartis Reports Breakthrough Therapy Designation For CTL019 - Quick Facts
NVS,NVS:US,BBG000LYF3S8,"Allergan, Novartis In Clinical Trial Deal To Treat NASH - Quick Facts",2017-04-18 01:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mz2kyXO8qcw/allergan-novartis-in-clinical-trial-deal-to-treat-nash--quick-facts-20170418-00034,"Allergan, Novartis In Clinical Trial Deal To Treat NASH - Quick Facts"
NVS,NVS:US,BBG000LYF3S8,Novartis Collaborates With Allergan On NASH - Quick Facts,2017-04-18 01:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VweJpN7-bvE/novartis-collaborates-with-allergan-on-nash--quick-facts-20170418-00032,Novartis Collaborates With Allergan On NASH - Quick Facts
NVS,NVS:US,BBG000LYF3S8,Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Could Double,2017-04-17 22:54:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9EyjUrRMIiw/why-teva-pharmaceutical-industries-ltd-adr-teva-stock-could-double-cm774920,InvestorPlace Stock Market News Stock Advice amp Trading Tips Price fixing allegations in the generic drug industry A backlash against drug price increases Costly past acquisitions that piled on debt Management turnover and fines for bribing officials for business 160 If
NVS,NVS:US,BBG000LYF3S8,10 Most Profitable Companies In Europe,2017-04-17 21:56:35 +0000,http://finance.yahoo.com/r/0c67984c-0376-3d1c-a985-d488aee5382e/10-most-profitable-companies-in-europe-574528?yptr=yahoo&.tsrc=rss,"The 10 most profitable companies in Europe are responsible for some of the top-class products and services that are being provided on just about every continent in the world. Out of the 10 companies on this list, four are from Switzerland, while three are from Germany, reflective of the favorable position of the two countries […]"
NVS,NVS:US,BBG000LYF3S8,"Jerome Dodson Buys 2 Stocks, Sells 2 in 1st Quarter",2017-04-17 17:11:44 +0000,http://finance.yahoo.com/news/jerome-dodson-buys-2-stocks-171144696.html?.tsrc=rss,Guru invests in IT and pharmaceutical companies
NVS,NVS:US,BBG000LYF3S8,Company Spotlight: Incyte,2017-04-14 21:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Al1JAVq5xSQ/company-spotlight-incyte-20170414-00197,Company Spotlight: Incyte
NVS,NVS:US,BBG000LYF3S8,"Kimberly-Clark Names Allgaier Group President, Kimberly-Clark North America",2017-04-14 08:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5mMoljmISPQ/kimberlyclark-names-allgaier-group-president-kimberlyclark-north-america-20170414-00060,"Kimberly-Clark Names Allgaier Group President, Kimberly-Clark North America"
NVS,NVS:US,BBG000LYF3S8,"Here's Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc.",2017-04-13 21:55:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A1WO6nx5XC0/heres-why-the-best-is-yet-to-come-for-ionis-pharmaceuticals-inc-cm774060,Ionis Pharmaceuticals NASDAQ IONS has had plenty of good news over the last couple of months The Food and Drug Administration approved its spinal muscular atrophy drug Spinraza in December It signed a deal with Novartis NYSE NVS to develop and
NVS,NVS:US,BBG000LYF3S8,"Here&apos;s Why the Best Is Yet to Come for Ionis Pharmaceuticals, Inc.",2017-04-13 20:21:00 +0000,http://finance.yahoo.com/r/7e9a61df-fab7-3e5f-9c63-9fcb43537175/heres-why-the-best-is-yet-to-come-for-ionis-pharma.aspx?yptr=yahoo&.tsrc=rss,A pipeline of drugs has this biotech poised for further success.
NVS,NVS:US,BBG000LYF3S8,IntelliPharmaCeutics (IPCI) Q1 Loss Narrower Than Expected,2017-04-13 16:57:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j6eCE00wBjA/intellipharmaceutics-ipci-q1-loss-narrower-than-expected-cm773882,IntelliPharmaCeutics International Inc IPCI reported loss of 7 cents per share in the first quarter of 2017 narrower than both the Zacks Consensus Estimate of a loss of 8 cents and the year ago loss of 9 cents per share The lower net loss may be primarily attributed to higher
NVS,NVS:US,BBG000LYF3S8,Why Juno Therapeutics' Stock Tumbled in the Past One Year,2017-04-13 16:57:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_WhBQ-gDtV0/why-juno-therapeutics-stock-tumbled-in-the-past-one-year-cm773876,Seattle WA based Juno Therapeutics Inc JUNO remains focused on the development of immuno oncology treatments The company is looking to revolutionize cancer treatments by engaging the body s immune system to treat the disease Juno is developing cell based cancer immunotherapies using CAR
NVS,NVS:US,BBG000LYF3S8,Company Spotlight: Incyte,2017-04-13 10:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/thqKkyD3yu8/company-spotlight-incyte-20170413-00737,Company Spotlight: Incyte
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On Strength Of Defensive Stocks,2017-04-12 12:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DfuDYt_Ud3E/the-swiss-stock-market-climbed-on-strength-of-defensive-stocks-20170412-00842,The Swiss Stock Market Climbed On Strength Of Defensive Stocks
NVS,NVS:US,BBG000LYF3S8,Endo (ENDP) Reports Preliminary Results for First Quarter,2017-04-11 23:57:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O_uaqzC9iXI/endo-endp-reports-preliminary-results-for-first-quarter-cm773013,Endo International plc ENDP recently announced preliminary results for first quarter 2017 The company projects first quarter 2017 revenues between 1 015 million and 1 035 million up from 964 million in first quarter 2016 The current Zacks Consensus Estimate is 1 05 billion The
NVS,NVS:US,BBG000LYF3S8,"Forget Novartis, Buy These Two Pharma Stocks Instead",2017-04-11 15:59:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C3Ije2DCDT4/forget-novartis-buy-these-two-pharma-stocks-instead-cm772738,Swiss pharma giant Novartis AG NVS which saw its shares decline 15 3 in 2016 will continue to face challenges in 2017 with factors like negative currency movement as well as the continued genericization of Gleevec Glivec in the U S and Europe expected to impact performance
NVS,NVS:US,BBG000LYF3S8,"Forget Novartis, Buy These Two Pharma Stocks Instead",2017-04-11 13:17:01 +0000,http://finance.yahoo.com/news/forget-novartis-buy-two-pharma-131701429.html?.tsrc=rss,"With Novartis (NVS) being a Zacks Rank #4 (Sell) stock, here is a look at two European pharma stocks that sport a strong Zacks Rank."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Slight Gain After Weak Start,2017-04-11 13:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/U_hjiiIVzuA/the-swiss-stock-market-finished-with-a-slight-gain-after-weak-start-20170411-00927,The Swiss Stock Market Finished With A Slight Gain After Weak Start
NVS,NVS:US,BBG000LYF3S8,Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint,2017-04-10 23:54:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7yjOjli5UC8/roches-lung-cancer-drug-alecensa-meets-primary-endpoint-cm772430,Roche Holdings RHHBY announced that the global randomized phase III study ALEX on lung cancer drug Alecensa met its primary endpoint as an initial first line treatment Alecensa significantly reduced the risk of disease worsening or death progression free survival PFS compared
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped As NestlÃ© Weighs,2017-04-10 12:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WnoTFxEhFpM/the-swiss-stock-market-dropped-as-nestl%C3%A3-weighs-20170410-00869,The Swiss Stock Market Dropped As NestlÃ© Weighs
NVS,NVS:US,BBG000LYF3S8,5 Pharmaceutical Stocks With the Most Reliable Dividends,2017-04-09 12:54:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cJevdJIwjnM/5-pharmaceutical-stocks-with-the-most-reliable-dividends-cm771822,What s the one thing that dividend seeking investors value the most Several answers could arguably be correct but I suspect that the best answer of all is reliability If you re looking for dividend stocks you want their dividends to be reliable Several pharmaceutical
NVS,NVS:US,BBG000LYF3S8,5 Pharmaceutical Stocks With the Most Reliable Dividends,2017-04-09 11:22:00 +0000,http://finance.yahoo.com/r/48df9374-1b78-3312-ad08-6d30133f34d5/5-pharmaceutical-stocks-with-the-most-reliable-div.aspx?yptr=yahoo&.tsrc=rss,"Johnson & Johnson, Abbott Labs, AbbVie, Novo Nordisk, and Novartis rank as the top drug stocks with the best dividend track records."
NVS,NVS:US,BBG000LYF3S8,Why Juno Therapeutics Stock Slumped in March,2017-04-08 14:54:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SGMEt93sGxU/why-juno-therapeutics-stock-slumped-in-march-cm771746,What happened Juno Therapeutics NASDAQ JUNO a clinical stage biotech shed 12 3 of its value in March according to data from S amp P Global Market Intelligence This double digit move lower was sparked by the company s decision to mothball its lead chimeric
NVS,NVS:US,BBG000LYF3S8,Why Juno Therapeutics Stock Slumped in March,2017-04-08 13:43:00 +0000,http://finance.yahoo.com/r/d210a12c-5976-3ef0-866e-8fa6e2c518de/why-juno-therapeutics-stock-slumped-in-march.aspx?yptr=yahoo&.tsrc=rss,Juno&apos;s stock slumped last month after its lead product candidate was mothballed.
NVS,NVS:US,BBG000LYF3S8,3 Big Pharma Companies With the Best Pipelines,2017-04-08 12:54:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UhSqAjHfJ48/3-big-pharma-companies-with-the-best-pipelines-cm771718,It s not the current product lineups that matter the most for big pharma companies It s their pipelines Three big pharma companies boasting the strongest pipelines are Johnson amp Johnson NYSE JNJ Novartis NYSE NVS and Roche NASDAQOTH RHHBY Here s what
NVS,NVS:US,BBG000LYF3S8,3 Big Pharma Companies With the Best Pipelines,2017-04-08 11:22:00 +0000,http://finance.yahoo.com/r/9fec55fc-0049-3112-ade1-93863c0f877d/3-big-pharma-companies-with-the-best-pipelines.aspx?yptr=yahoo&.tsrc=rss,"Why the pipelines for Johnson & Johnson, Novartis, and Roche look especially strong."
NVS,NVS:US,BBG000LYF3S8,"Dow 30 Stock Roundup: Boeing Bags Air Force Orders, DuPont to Sell Part of Crop Protection Biz",2017-04-07 22:54:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p9NHAG9Zyb0/dow-30-stock-roundup-boeing-bags-air-force-orders-dupont-to-sell-part-of-crop-protection-biz-cm771654,The Dow experienced a relatively quiet week as investors eagerly awaited the outcome of the Trump Xi meeting Markets were especially cautious ahead of crucial payrolls data to be released on Friday Dismal auto sales and manufacturing data shaved a few points off the index on Monday Gains
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC,2017-04-07 22:53:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XNabRWKDviI/novartis-nvs-in-licenses-ophthalmic-drug-from-lubris-llc-cm771639,Novartis AG NVS recently announced that it has exercised an option to in license ECF843 for ophthalmic indications worldwide outside Europe from Lubris LLC A look at Novartis share price movement over the past one year shows that the stock has underperformed the Zacks classified
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) In-Licenses Ophthalmic Drug from Lubris LLC,2017-04-07 21:03:09 +0000,http://finance.yahoo.com/news/novartis-nvs-licenses-ophthalmic-drug-210309315.html?.tsrc=rss,Novartis AG (NVS) recently announced that it has exercised an option to in-license ECF843 for ophthalmic indications worldwide from Lubris LLC.
NVS,NVS:US,BBG000LYF3S8,Analysts Release New Health Care Stock Ratings,2017-04-07 17:38:56 +0000,http://finance.yahoo.com/news/analysts-release-health-care-stock-164648433.html?.tsrc=rss,Jeffries downgrades Amgen to hold from buy
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Small Gain In Cautious Trade,2017-04-07 12:28:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BiAnoyCu2fM/the-swiss-stock-market-finished-with-a-small-gain-in-cautious-trade-20170407-00625,The Swiss Stock Market Finished With A Small Gain In Cautious Trade
NVS,NVS:US,BBG000LYF3S8,PeptiDream Reports Discovery Collaboration Agreement With Janssen,2017-04-07 08:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SrmFn_WDhzc/peptidream-reports-discovery-collaboration-agreement-with-janssen-20170407-00325,PeptiDream Reports Discovery Collaboration Agreement With Janssen
NVS,NVS:US,BBG000LYF3S8,​Tiny Mass. biotech strikes licensing deal with Novartis worth up to $1B,2017-04-07 02:20:13 +0000,http://finance.yahoo.com/r/293608eb-cae6-3439-a3c7-524424ef2485/tiny-mass-biotech-strikes-licensing-deal-with.html?ana=yahoo&yptr=yahoo&.tsrc=rss,"Lubris BioPharma, a tiny, privately-held Framingham biotech developing a treatment for dry eye, has struck a licensing deal with Swiss drug giant Novartis that could generate upwards of $1 billion in total payments and royalties.  Novartis (NVS) and Lubris announced the deal on Thursday without disclosing the financial terms.  Patients with dry eye have a deficiency of the protein, and the drug is thought to work by restoring that function."
NVS,NVS:US,BBG000LYF3S8,The First CAR-T Drugs Have Left the Gate,2017-04-06 21:55:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JxFpn9xMdn4/the-first-car-t-drugs-have-left-the-gate-cm771072,For all the talk about biotechs being nimble it s a big pharma that looks like it ll be the first company to launch a chimeric antigen receptor T cell CAR T product Novartis NYSE NVS announced last week that the Food and Drug Administration accepted its application to
NVS,NVS:US,BBG000LYF3S8,The First CAR-T Drugs Have Left the Gate,2017-04-06 20:20:00 +0000,http://finance.yahoo.com/r/6a24f973-2854-321a-9bc9-e0b20cb6eb2a/the-first-car-t-drugs-have-left-the-gate.aspx?yptr=yahoo&.tsrc=rss,Investors should keep an eye on this promising way to treat cancer.
NVS,NVS:US,BBG000LYF3S8,"VEA, NSRGY, NVS, TM: ETF Inflow Alert",2017-04-06 16:54:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h4bxPZ7c9Rw/vea-nsrgy-nvs-tm-etf-inflow-alert-cm770881,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 312 4 million dollar inflow that s a 0 7 increase week over week
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Virtually Unchanged After Recovery,2017-04-06 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v6qm4MksDwM/the-swiss-stock-market-finished-virtually-unchanged-after-recovery-20170406-00919,The Swiss Stock Market Finished Virtually Unchanged After Recovery
NVS,NVS:US,BBG000LYF3S8,Novartis Licenses ECF843 Eye Drops From Lubris,2017-04-06 12:22:00 +0000,http://finance.yahoo.com/r/b3857712-1f3d-33bc-bbfb-c37a25f890ac/novartis-licenses-ecf843-eye-drops-lubris-nvs?partner=YahooSA&yptr=yahoo&.tsrc=rss,Novartis licensed ECF843 eye drops outside Europe from Lubris LLC.
NVS,NVS:US,BBG000LYF3S8,Novartis Exercises Option To In-license ECF843 Outside Europe - Quick Facts,2017-04-06 01:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6zo8MKtYc8I/novartis-exercises-option-to-inlicense-ecf843-outside-europe--quick-facts-20170406-00033,Novartis Exercises Option To In-license ECF843 Outside Europe - Quick Facts
NVS,NVS:US,BBG000LYF3S8,Roche Announces Positive Data on Lung Cancer Drug Alecensa,2017-04-05 18:53:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lv_05UbUv18/roche-announces-positive-data-on-lung-cancer-drug-alecensa-cm770325,Roche Holdings AG RHHBY recently announced encouraging results from the phase III study ALUR on lung cancer drug Alecensa The study met its primary endpoint as data from the study demonstrated that Alecensa significantly improved progression free survival PFS in patients Those
NVS,NVS:US,BBG000LYF3S8,"Amgen Files for Xgeva Label Expansion, To Include Myeloma",2017-04-05 16:55:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gkx8_sYWCNc/amgen-files-for-xgeva-label-expansion-to-include-myeloma-cm770231,Amgen Inc AMGN recently announced that it has submitted a supplemental Biologics License Application sBLA to the FDA to expand the label of its key drug Xgeva Xgeva is currently approved for the prevention of skeletal related events SREs in solid tumors in patients with bone
NVS,NVS:US,BBG000LYF3S8,"Cowen Downgrades Novartis, Strengths 'Now Balance Its Risks'",2017-04-05 16:36:05 +0000,http://finance.yahoo.com/news/cowen-downgrades-novartis-strengths-now-163605049.html?.tsrc=rss,"Steve Scala of Cowen downgraded shares of Novartis AG (ADR) (NYSE: NVS ) from Outperform to Market Perform with a price target lowered to $77 from $87 as the company's strengths ""now balance its risks."" ..."
NVS,NVS:US,BBG000LYF3S8,Novartis Keeps 'JULIET' Study Results Close as Investors and Rival Kite Pharma Wait,2017-04-05 16:20:00 +0000,http://finance.yahoo.com/r/89d65624-8257-3479-9569-daa02c56825e/novartis-keeps-juliet-study-results-close-as-investors-and-rival-kite-pharma-wait.html?puc=yahoo&cm_ven=YAHOO&yptr=yahoo&.tsrc=rss,The data to emerge from Novartis' JULIET study is of keen interest to investors because it will be compared against Kite's competing 'CAR-T' KTE-C19 in the same DLBCL patients.
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped On Continued Caution,2017-04-05 12:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NpOOeXDoyEo/the-swiss-stock-market-dipped-on-continued-caution-20170405-00957,The Swiss Stock Market Dipped On Continued Caution
NVS,NVS:US,BBG000LYF3S8,"Novartis' Tafinlar, Mekinist Get EU Approval for NSCLC",2017-04-04 21:24:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O4lDwTmfOeY/novartis-tafinlar-mekinist-get-eu-approval-for-nsclc-cm769828,Novartis AG NVS recently announced that the European Commission has approved Tafinlar dabrafenib in combination with Mekinist trametinib for the treatment of patients with BRAF V600 positive advanced or metastatic non small cell lung cancer NSCLC A look at Novartis share
NVS,NVS:US,BBG000LYF3S8,"Novartis&apos; Tafinlar, Mekinist Get EU Approval for NSCLC",2017-04-04 19:22:07 +0000,http://finance.yahoo.com/news/novartis-apos-tafinlar-mekinist-eu-192207162.html?.tsrc=rss,Novartis AG (NVS) recently announced that the European Commission has approved Tafinlar in combination with Mekinist for the treatment of patients with BRAF V600-positive advanced or metastatic non-small cell lung cancer (NSCLC).
NVS,NVS:US,BBG000LYF3S8,Could SEG101 Revolutionize the Treatment for Sickle Cell Disease?,2017-04-04 13:06:07 +0000,http://finance.yahoo.com/r/65c1a9b6-c4b5-3f65-b819-eb2d3d5247b3/investigational-therapy-seg101-can-revolutionize-treatment-paradigm-sickle-cell-disease?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Novartis (NVS) is currently involved in developing its investigational therapy SEG101 for sickle cell disease.
NVS,NVS:US,BBG000LYF3S8,Targeted Research and Development May Boost Novartis’s Profits,2017-04-04 13:06:05 +0000,http://finance.yahoo.com/r/497bce37-63fc-35aa-bde0-f1de335d754a/targeted-research-development-strategy-may-boost-novartis-profitability-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Novartis’s research and development strategy is based on portfolio prioritization, introducing cost efficiencies, implementing breakthrough technologies, and introducing new management."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Slightly Higher In Directionless Trade,2017-04-04 12:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TvNomx69ytE/the-swiss-stock-market-finished-slightly-higher-in-directionless-trade-20170404-00991,The Swiss Stock Market Finished Slightly Higher In Directionless Trade
NVS,NVS:US,BBG000LYF3S8,Questioning Ionis Pharmaceuticals' Spinoff Announcement,2017-04-04 12:37:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JzVhvPfbBLw/questioning-ionis-pharmaceuticals-spinoff-announcement-cm769379,Ionis Pharmaceuticals NASDAQ IONS is spinning off some of its lipid disorder drugs The new company Akcea will raise 100 million from its IPO and collaboration partner Novartis NYSE NVS will acquire an additional 50 million in shares concurrently While
NVS,NVS:US,BBG000LYF3S8,Could Novartis’s CTL019 Capture Significant Market Share?,2017-04-04 11:36:20 +0000,http://finance.yahoo.com/r/a7a2f2d6-f00f-3fe6-8ff9-7201991279bc/investigational-therapy-ctl019-may-capture-significant-share-relapsedrefractory-market?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Currently, an estimated 7,000 patients suffer from pediatric ALL in the US, Europe, Japan, Canada, and Israel."
NVS,NVS:US,BBG000LYF3S8,Novartis Expects to Restore Alcon’s Profitability in the Future,2017-04-04 11:36:17 +0000,http://finance.yahoo.com/r/4c506edf-dd17-350f-82eb-dc5071cab05a/novartis-expects-restore-profitability-alcon-segment-future-years?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Novartis (NVS) has focused its efforts on improving its customer service levels and entering into lucrative partnering deals to boost profitability for its Alcon business.
NVS,NVS:US,BBG000LYF3S8,Questioning Ionis Pharmaceuticals&apos; Spinoff Announcement,2017-04-04 11:24:00 +0000,http://finance.yahoo.com/r/34c733c3-8ceb-3b21-a896-f50590ebeb04/questioning-ionis-pharmaceuticals-spinoff-announce.aspx?yptr=yahoo&.tsrc=rss,Management&apos;s taking a different route to commercializing its lipid-disorder drugs.
NVS,NVS:US,BBG000LYF3S8,Why Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Stock Is Risky,2017-04-03 18:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4def1eYGQQE/why-teva-pharmaceutical-industries-ltd-adr-teva-stock-is-risky-cm769213,InvestorPlace Stock Market News Stock Advice amp Trading Tips Teva Pharmaceutical Industries Ltd ADR NYSE TEVA stock is down 40 over the past year and down more than 50 since August 2015 Admittedly the past year and a half hasn t been great
NVS,NVS:US,BBG000LYF3S8,Pfizer Gets Regular Approval for Breast Cancer Drug Ibrance,2017-04-03 15:39:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-ChPpBsy4BY/pfizer-gets-regular-approval-for-breast-cancer-drug-ibrance-cm769020,Pfizer Inc PFE announced that its supplemental new drug application sNDA to convert accelerated approval for Ibrance to regular approval has been approved by the FDA Pfizer s shares are up 5 3 so far this year comparing unfavorably with the Zacks classified Large Cap Pharma industry
NVS,NVS:US,BBG000LYF3S8,What Have Clinical Trials of Novartis’s LEE011 Demonstrated?,2017-04-03 14:39:27 +0000,http://marketrealist.com/2017/03/investigational-drug-lee011-demonstrated-robust-safety-profile-clinical-trials/?utm_source=yahoo&utm_medium=feed,What Have Clinical Trials of Novartis’s LEE011 Demonstrated?
NVS,NVS:US,BBG000LYF3S8,What Have Clinical Trials of Novartis’s LEE011 Demonstrated?,2017-04-03 14:39:27 +0000,http://finance.yahoo.com/r/f2e1b00c-e29e-3cdb-8f78-a6482b77512e/investigational-drug-lee011-demonstrated-robust-safety-profile-clinical-trials?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"If LEE011 manages to demonstrate efficacy in difficult-to-treat cancer types, it could prove to be a major competitive advantage for Novartis."
NVS,NVS:US,BBG000LYF3S8,Novartis Aims to Turn Around Its Surgical Business in 2017,2017-04-03 14:39:12 +0000,http://marketrealist.com/2017/03/novartis-aims-turnaround-surgical-business-2017/?utm_source=yahoo&utm_medium=feed,Novartis Aims to Turn Around Its Surgical Business in 2017
NVS,NVS:US,BBG000LYF3S8,Novartis Aims to Turn Around Its Surgical Business in 2017,2017-04-03 14:39:12 +0000,http://finance.yahoo.com/r/9fbe0d32-b12b-37b1-a0cc-987e1d39092b/novartis-aims-turnaround-surgical-business-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"In 2016, the surgical business of Alcon, Novartis's (NVS) Consumables segment, witnessed a solid demand trend."
NVS,NVS:US,BBG000LYF3S8,What’s the Status of Novartis’s Investigational Breast Cancer Drug?,2017-04-03 13:07:08 +0000,http://finance.yahoo.com/r/98cfb438-04bc-3276-a850-d39cbf8c3639/investigational-drug-lee011-explored-multiple-breast-cancer-indications-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,"Besides the concluded mammary oncology assessment of LEE011's Efficacy and Safety-2 (or MONALEESA-2) trial, Novartis (NVS) is also exploring its investigational breast cancer therapy in other phase three ..."
NVS,NVS:US,BBG000LYF3S8,What’s the Status of Novartis’s Investigational Breast Cancer Drug?,2017-04-03 13:07:08 +0000,http://marketrealist.com/2017/03/investigational-drug-lee011-explored-multiple-breast-cancer-indications-2017/?utm_source=yahoo&utm_medium=feed,What’s the Status of Novartis’s Investigational Breast Cancer Drug?
NVS,NVS:US,BBG000LYF3S8,Novartis Expects to Witness Flat Revenue Growth in 2017,2017-04-03 13:06:48 +0000,http://finance.yahoo.com/r/5cb871d6-3d6b-353a-8b54-976040ba8a31/novartis-expects-witness-flat-revenue-growth-2017?utm_source=yahoo&utm_medium=feed&yptr=yahoo&.tsrc=rss,Novartis (NVS) has projected its 2017 revenue to be close to what it earned in 2016. The company also expects its core operating income to be flat or to fall in the single digits.
NVS,NVS:US,BBG000LYF3S8,Novartis Expects to Witness Flat Revenue Growth in 2017,2017-04-03 13:06:48 +0000,http://marketrealist.com/2017/03/novartis-expects-witness-flat-revenue-growth-2017/?utm_source=yahoo&utm_medium=feed,Novartis Expects to Witness Flat Revenue Growth in 2017
NVS,NVS:US,BBG000LYF3S8,Does Novartis See Much Potential for Its Surgical Business?,2017-04-03 13:05:48 +0000,http://marketrealist.com/2017/03/alcons-surgical-business-offers-significant-growth-opportunity-novartis-future-years/?utm_source=yahoo&utm_medium=feed,Does Novartis See Much Potential for Its Surgical Business?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back On Weakness Of Financial Stocks,2017-04-03 12:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VEIggHo6URM/the-swiss-stock-market-pulled-back-on-weakness-of-financial-stocks-20170403-01032,The Swiss Stock Market Pulled Back On Weakness Of Financial Stocks
NVS,NVS:US,BBG000LYF3S8,European Markets Dipped In Cautious Trade,2017-04-03 11:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5VeVZkWusXE/european-markets-dipped-in-cautious-trade-20170403-00974,European Markets Dipped In Cautious Trade
NVS,NVS:US,BBG000LYF3S8,Investigational Breast Cancer Drug Could Boost Novartis’s Position,2017-04-03 11:37:03 +0000,http://marketrealist.com/2017/03/investigational-drug-lee011-may-strengthen-novartis-position-breast-cancer-segment-2017/?utm_source=yahoo&utm_medium=feed,Investigational Breast Cancer Drug Could Boost Novartis’s Position
NVS,NVS:US,BBG000LYF3S8,Novartis Is Focused on Creating Shareholder Value in 2017,2017-04-03 11:36:41 +0000,http://marketrealist.com/2017/03/novartis-focused-creating-shareholder-value-2017/?utm_source=yahoo&utm_medium=feed,Novartis Is Focused on Creating Shareholder Value in 2017
NVS,NVS:US,BBG000LYF3S8,Will Novartis’s Alcon Business See Growth in 2017?,2017-04-03 11:35:48 +0000,http://marketrealist.com/2017/03/novartis-alcon-business-expected-witness-modest-growth-2017/?utm_source=yahoo&utm_medium=feed,Will Novartis’s Alcon Business See Growth in 2017?
NVS,NVS:US,BBG000LYF3S8,4:36 am Novartis AG receives EU approval for drug combination Tafinlar + Mekinist,2017-04-03 08:36:00 +0000,http://finance.yahoo.com/news/inplay-briefing-com-055139997.html#nvs,4:36 am Novartis AG receives EU approval for drug combination Tafinlar + Mekinist
NVS,NVS:US,BBG000LYF3S8,Novartis' Lung Cancer Drug Combo Gets EU Nod,2017-04-03 08:32:00 +0000,http://www.investopedia.com/news/novartis-lung-cancer-drug-combo-gets-eu-nod-nvs-rhhby/?partner=YahooSA,Novartis' Lung Cancer Drug Combo Gets EU Nod
NVS,NVS:US,BBG000LYF3S8,European Shares Struggle For Direction Ahead Of Trump-Xi Meeting,2017-04-03 06:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nUYGI8YWvlo/european-shares-struggle-for-direction-ahead-of-trumpxi-meeting-20170403-00256,European Shares Struggle For Direction Ahead Of Trump-Xi Meeting
NVS,NVS:US,BBG000LYF3S8,Novartis: Tafinlar + Mekinist Gets EU Approval For BRAF V600-positive NSCLC,2017-04-03 01:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vEVAm0xKF-w/novartis-tafinlar--mekinist-gets-eu-approval-for-braf-v600-positive-nsclc-20170403-00036,Novartis: Tafinlar + Mekinist Gets EU Approval For BRAF V600-positive NSCLC
NVS,NVS:US,BBG000LYF3S8,"[$$] At Glaxo, a New CEO Steps In, Must Wring More From R&D",2017-04-02 16:18:44 +0000,https://www.wsj.com/articles/glaxos-new-ceo-is-a-steady-hand-in-pharmaceuticals-rolling-seas-1490952607?mod=yahoo_hs,"[$$] At Glaxo, a New CEO Steps In, Must Wring More From R&D"
NVS,NVS:US,BBG000LYF3S8,[$$] Glaxo’s New CEO Is a Steady Hand in Pharmaceuticals’ Rolling Seas,2017-04-01 04:08:23 +0000,https://www.wsj.com/articles/glaxos-new-ceo-is-a-steady-hand-in-pharmaceuticals-rolling-seas-1490952607?ru=yahoo?mod=yahoo_itp,[$$] Glaxo’s New CEO Is a Steady Hand in Pharmaceuticals’ Rolling Seas
NVS,NVS:US,BBG000LYF3S8,How Novartis Has Improved Operational Efficiencies in R&D Program,2017-03-31 19:35:46 +0000,http://marketrealist.com/2017/03/novartis-introduced-operational-efficiencies-rd-program/?utm_source=yahoo&utm_medium=feed,How Novartis Has Improved Operational Efficiencies in R&D Program
NVS,NVS:US,BBG000LYF3S8,3 Attractive Healthy Dividend-Paying Market Gems,2017-03-31 19:32:00 +0000,http://www.forbes.com/sites/genemarcial/2017/03/31/3-attractive-healthy-dividend-paying-market-gems/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,3 Attractive Healthy Dividend-Paying Market Gems
NVS,NVS:US,BBG000LYF3S8,Consistent Performance Measurement May Improve Novartis’s R&D,2017-03-31 18:05:45 +0000,http://marketrealist.com/2017/03/consistent-performance-measurement-may-improve-novartis-research-program/?utm_source=yahoo&utm_medium=feed,Consistent Performance Measurement May Improve Novartis’s R&D
NVS,NVS:US,BBG000LYF3S8,Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?,2017-03-31 16:21:20 +0000,http://www.investors.com/news/technology/will-trumps-fda-chill-innovation-or-speed-up-to-kill-astronomical-prices/?src=A00220A,Will Trump's FDA Chill Innovation Or Kill 'Astronomical' Prices?
NVS,NVS:US,BBG000LYF3S8,Novartis Focuses on Portfolio Prioritization to Boost Profitability,2017-03-31 16:19:44 +0000,http://marketrealist.com/2017/03/novartis-focused-portfolio-prioritization-boost-profitability-future-years/?utm_source=yahoo&utm_medium=feed,Novartis Focuses on Portfolio Prioritization to Boost Profitability
NVS,NVS:US,BBG000LYF3S8,Novartis Expects to Launch 5 Key Biosimilars by 2020,2017-03-31 14:36:35 +0000,http://marketrealist.com/2017/03/novartis-expects-launch-five-key-biosimilars-2020/?utm_source=yahoo&utm_medium=feed,Novartis Expects to Launch 5 Key Biosimilars by 2020
NVS,NVS:US,BBG000LYF3S8,Entresto Could See Strong Uptake in European Markets in 2017,2017-03-31 14:35:57 +0000,http://marketrealist.com/2017/03/entresto-expected-witness-strong-uptake-european-markets-2017/?utm_source=yahoo&utm_medium=feed,Entresto Could See Strong Uptake in European Markets in 2017
NVS,NVS:US,BBG000LYF3S8,Novartis Has Revamped Its Commercial Strategy for 2017,2017-03-31 13:06:56 +0000,http://marketrealist.com/2017/03/novartis-revamped-commercial-strategy-2017/?utm_source=yahoo&utm_medium=feed,Novartis Has Revamped Its Commercial Strategy for 2017
NVS,NVS:US,BBG000LYF3S8,Entresto Could See Steep Rise in Total Prescriptions This Year,2017-03-31 13:05:59 +0000,http://marketrealist.com/2017/03/entresto-expected-witness-robust-rise-total-prescriptions-2017/?utm_source=yahoo&utm_medium=feed,Entresto Could See Steep Rise in Total Prescriptions This Year
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?",2017-03-31 13:02:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GW7LpQPRrEM/pharma-stock-roundup-fda-nod-for-sny-roche-drugs-generic-advair-relief-for-gsk-cm768132,Key highlights this week include FDA approval of two highly awaited drugs Sanofi SNY and Regeneron s Dupixent and Roche s RHHBY Ocrevus Both drugs have blockbuster potential Meanwhile Mylan MYL got a complete response letter CRL from the FDA for its generic version of Glaxo s
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped On Profit Taking,2017-03-31 12:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r2q4djOtTNM/the-swiss-stock-market-dipped-on-profit-taking-20170331-00762,The Swiss Stock Market Dipped On Profit Taking
NVS,NVS:US,BBG000LYF3S8,Novartis Has Developed a Robust Innovation Strategy,2017-03-31 11:37:10 +0000,http://marketrealist.com/2017/03/novartis-developed-robust-innovation-strategy-boost-future-profitability/?utm_source=yahoo&utm_medium=feed,Novartis Has Developed a Robust Innovation Strategy
NVS,NVS:US,BBG000LYF3S8,How Novartis Is Aiming to Increase Entresto Sales in 2017,2017-03-31 11:36:03 +0000,http://marketrealist.com/2017/03/novartis-expanding-sales-force-increase-entrestos-sales-2017/?utm_source=yahoo&utm_medium=feed,How Novartis Is Aiming to Increase Entresto Sales in 2017
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?",2017-03-31 11:21:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-fda-nod-112111194.html,"Pharma Stock Roundup: FDA Nod for SNY, Roche Drugs, Generic Advair Relief for GSK?"
NVS,NVS:US,BBG000LYF3S8,Changing Demographics Offer Novartis a Strong Growth Opportunity,2017-03-30 21:05:43 +0000,http://marketrealist.com/2017/03/changing-demographics-offers-strong-growth-opportunity-novartis-future-years/?utm_source=yahoo&utm_medium=feed,Changing Demographics Offer Novartis a Strong Growth Opportunity
NVS,NVS:US,BBG000LYF3S8,Why Have Novartis’s Valuation Multiples Fallen?,2017-03-30 19:13:07 +0000,http://marketrealist.com/2017/03/novartis-trading-lower-valuation-multiples/?utm_source=yahoo&utm_medium=feed,Why Have Novartis’s Valuation Multiples Fallen?
NVS,NVS:US,BBG000LYF3S8,Novartis' CTL109 BLA Gets Priority Review Status from FDA,2017-03-30 17:01:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fMy07Nqlb14/novartis-ctl109-bla-gets-priority-review-status-from-fda-cm767846,Novartis A G NVS announced that the FDA has accepted and granted priority review designation to its biologics license application BLA for pipeline candidate CTL019 tisagenlecleucel T The company plans to apply for market authorization with European Medicines Agency later this
NVS,NVS:US,BBG000LYF3S8,Novartis' CTL109 BLA Gets Priority Review Status from FDA,2017-03-30 14:50:02 +0000,http://finance.yahoo.com/news/novartis-ctl109-bla-gets-priority-145002874.html,Novartis' CTL109 BLA Gets Priority Review Status from FDA
NVS,NVS:US,BBG000LYF3S8,Reduced Co-pays May Boost Demand for Entresto,2017-03-30 14:36:43 +0000,http://marketrealist.com/2017/03/reduced-copays-may-boost-demand-entresto-2017/?utm_source=yahoo&utm_medium=feed,Reduced Co-pays May Boost Demand for Entresto
NVS,NVS:US,BBG000LYF3S8,Novartis' Leukemia Drug Secures Priority Review,2017-03-30 13:08:00 +0000,http://www.investopedia.com/news/novartis-leukemia-drug-secures-priority-review-nvs-kite/?partner=YahooSA,Novartis' Leukemia Drug Secures Priority Review
NVS,NVS:US,BBG000LYF3S8,What Could Boost Medicare Demand for Novartis’s Entresto?,2017-03-30 13:06:41 +0000,http://marketrealist.com/2017/03/improved-formulary-position-may-help-boost-medicare-demand-entresto-2017/?utm_source=yahoo&utm_medium=feed,What Could Boost Medicare Demand for Novartis’s Entresto?
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Rose Above 8,700 Points As Heavyweights Give Support",2017-03-30 12:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zLRCOnjWV9E/the-swiss-stock-market-rose-above-8700-points-as-heavyweights-give-support-20170330-00995,"The Swiss Stock Market Rose Above 8,700 Points As Heavyweights Give Support"
NVS,NVS:US,BBG000LYF3S8,Why Entresto Could Become Key Growth Driver for Novartis in 2017,2017-03-30 11:36:52 +0000,http://marketrealist.com/2017/03/heart-failure-drug-entresto-may-become-key-growth-driver-novartis-2017/?utm_source=yahoo&utm_medium=feed,Why Entresto Could Become Key Growth Driver for Novartis in 2017
NVS,NVS:US,BBG000LYF3S8,Performance of GlaxoSmithKline’s Vaccines Business in 2016,2017-03-30 11:36:26 +0000,http://marketrealist.com/2017/03/performance-of-glaxosmithklines-vaccines-business-in-2016/?utm_source=yahoo&utm_medium=feed,Performance of GlaxoSmithKline’s Vaccines Business in 2016
NVS,NVS:US,BBG000LYF3S8,Novartis wins speedy U.S. review of new leukaemia drug,2017-03-30 11:08:24 +0000,http://uk.finance.yahoo.com/news/novartis-wins-speedy-u-review-110824682.html,"[Reuters - UK Focus] - A new leukaemia treatment from Novartis (IOB: 0QLR.IL - news) for children and young adults will get priority review from the U.S. Food and Drug Administration (FDA), putting the Swiss drugmaker ahead of rivals working on similar cancer therapies. The FDA's announcement late Wednesday means the regulator plans to take action within six months on Novartis's so-called chimeric antigen receptor T cell therapy, or CAR (HKSE: 0699-OL.HK - news) -T, in partnership with University of Pennsylvania researchers."
NVS,NVS:US,BBG000LYF3S8,Novartis says U.S. regulator grants speedy review of CAR-T cell therapy,2017-03-30 05:36:39 +0000,http://finance.yahoo.com/news/novartis-says-u-regulator-grants-053639421.html,"[Reuters] - Novartis AG on Wednesday said the U.S. Food and Drug Administration (FDA) has agreed to accelerate its review of the Swiss drugmaker's CTL019 therapy for young patients with B-cell acute lymphoblastic leukemia. The move would keep Novartis on track with the development of its so-called chimeric antigen receptor T cell therapy, or CAR-T, in partnership with University of Pennsylvania researchers. The therapy involves a patient's own T-cells being altered in the lab to help the immune system find and kill cancer cells before being re-infused into the patient."
NVS,NVS:US,BBG000LYF3S8,Novartis Makes Plans For Its Cancer-Killing T Cells,2017-03-29 22:15:00 +0000,http://www.forbes.com/sites/matthewherper/2017/03/29/novartis-makes-plans-for-its-cancer-killing-t-cells/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Novartis Makes Plans For Its Cancer-Killing T Cells
NVS,NVS:US,BBG000LYF3S8,Novartis Says CAR-T Cell Therapy BLA Granted FDA Priority Review,2017-03-29 22:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/s2yvwrRi1HA/novartis-says-cart-cell-therapy-bla-granted-fda-priority-review-20170329-01315,Novartis Says CAR-T Cell Therapy BLA Granted FDA Priority Review
NVS,NVS:US,BBG000LYF3S8,Mylan stock sinks 2% after FDA fails to approve its generic asthma medication,2017-03-29 18:04:46 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=01BFC7CF-AB2D-4A9C-A23C-FA1297B91BE9&siteid=yhoof2,Mylan stock sinks 2% after FDA fails to approve its generic asthma medication
NVS,NVS:US,BBG000LYF3S8,"Noteworthy ETF Inflows: VEA, NSRGY, NVS, RDS.A",2017-03-29 15:59:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0l7UYQgoytM/noteworthy-etf-inflows-vea-nsrgy-nvs-rdsa-cm767214,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 394 5 million dollar inflow that s a 0 8 increase week over week
NVS,NVS:US,BBG000LYF3S8,Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe,2017-03-29 14:36:40 +0000,http://marketrealist.com/2017/03/cosentyx-continues-witness-solid-demand-psoriasis-therapy-european-markets/?utm_source=yahoo&utm_medium=feed,Cosentyx Enjoys Solid Demand as Psoriasis Therapy in Europe
NVS,NVS:US,BBG000LYF3S8,Which Segments Will Drive the Most Growth for Novartis’s Cosentyx?,2017-03-29 13:06:44 +0000,http://marketrealist.com/2017/03/psoriatic-arthritis-ankylosing-spondylitis-expected-drive-cosentyxs-revenue-growth-2017/?utm_source=yahoo&utm_medium=feed,Which Segments Will Drive the Most Growth for Novartis’s Cosentyx?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Significant Increase,2017-03-29 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ToGK5y61XAc/the-swiss-stock-market-finished-with-a-significant-increase-20170329-00875,The Swiss Stock Market Finished With A Significant Increase
NVS,NVS:US,BBG000LYF3S8,Novartis’s Cosentyx Managed to Achieve Blockbuster Status in 2016,2017-03-29 11:37:51 +0000,http://marketrealist.com/2017/03/novartis-cosentyx-managed-achieve-blockbuster-status-2016/?utm_source=yahoo&utm_medium=feed,Novartis’s Cosentyx Managed to Achieve Blockbuster Status in 2016
NVS,NVS:US,BBG000LYF3S8,"Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen",2017-03-29 00:45:00 +0000,https://www.thestreet.com/story/14062067/1/roche-wins-fda-backing-for-new-multiple-sclerosis-therapy-competition-could-crimp-biogen.html?puc=yahoo&cm_ven=YAHOO,"Roche Wins FDA Backing for New Multiple Sclerosis Therapy, Competition Could Crimp Biogen"
NVS,NVS:US,BBG000LYF3S8,Will Novartis See Rise in Net Profit Margins in 2017?,2017-03-28 22:05:43 +0000,http://marketrealist.com/2017/03/novartis-expected-witness-rise-net-profit-margins-2017/?utm_source=yahoo&utm_medium=feed,Will Novartis See Rise in Net Profit Margins in 2017?
NVS,NVS:US,BBG000LYF3S8,Ionis Pharmaceuticals Inc. Doesn't Want to Sell Drugs (Just Profit From Them),2017-03-28 21:59:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cbFJEYo1K5g/ionis-pharmaceuticals-inc-doesnt-want-to-sell-drugs-just-profit-from-them-cm766925,Most biotechs hope to grow up into the next Gilead Sciences or Celgene selling their own drugs But not Ionis Pharmaceuticals NASDAQ IONS On Monday the biotech announced that it was spinning out its subsidiary Akcea which houses its cardiovascular drugs designed
NVS,NVS:US,BBG000LYF3S8,Why Novartis Could Witness Modest Revenue Growth in 2017,2017-03-28 20:35:43 +0000,http://marketrealist.com/2017/03/novartis-expected-witness-modest-revenue-growth-2017/?utm_source=yahoo&utm_medium=feed,Why Novartis Could Witness Modest Revenue Growth in 2017
NVS,NVS:US,BBG000LYF3S8,Ionis Pharmaceuticals Inc. Doesn't Want to Sell Drugs (Just Profit From Them),2017-03-28 20:22:00 +0000,https://www.fool.com/investing/2017/03/28/ionis-pharmaceuticals-inc-doesnt-want-to-sell-drug.aspx,Ionis Pharmaceuticals Inc. Doesn't Want to Sell Drugs (Just Profit From Them)
NVS,NVS:US,BBG000LYF3S8,What Analysts Recommend for Novartis in 2017,2017-03-28 18:45:44 +0000,http://marketrealist.com/2017/03/analysts-recommendations-novartis-2017/?utm_source=yahoo&utm_medium=feed,What Analysts Recommend for Novartis in 2017
NVS,NVS:US,BBG000LYF3S8,What Do Wall Street Analysts Expect for Novartis?,2017-03-28 14:37:37 +0000,http://marketrealist.com/2017/03/what-do-wall-street-analysts-expect-for-novartis/?utm_source=yahoo&utm_medium=feed,What Do Wall Street Analysts Expect for Novartis?
NVS,NVS:US,BBG000LYF3S8,This Is Driving Merck’s Vaccines Business,2017-03-28 13:06:21 +0000,http://marketrealist.com/2017/03/this-is-driving-mercks-vaccines-business/?utm_source=yahoo&utm_medium=feed,This Is Driving Merck’s Vaccines Business
NVS,NVS:US,BBG000LYF3S8,A Look at Novartis’s Financial Guidance and Priorities for 2017,2017-03-28 13:06:15 +0000,http://marketrealist.com/2017/03/a-look-at-novartiss-financial-guidance-and-priorities-for-2017/?utm_source=yahoo&utm_medium=feed,A Look at Novartis’s Financial Guidance and Priorities for 2017
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed,2017-03-28 12:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vMooWApiF2Q/the-swiss-stock-market-finished-little-changed-20170328-00989,The Swiss Stock Market Finished Little Changed
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline’s Valuation Compared to Its Peers,2017-03-28 11:37:59 +0000,http://marketrealist.com/2017/03/glaxosmithklines-valuation-compared-to-its-peers-2/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Valuation Compared to Its Peers
NVS,NVS:US,BBG000LYF3S8,3 Big Pharma Stocks You Don't Have to Babysit,2017-03-27 16:03:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lx4Djo5-l8Y/3-big-pharma-stocks-you-dont-have-to-babysit-cm765944,Big pharma stocks don t wake up in the middle of the night and require feeding or changing like a baby does But some of them can require plenty of attention No babysitting is required however for Johnson amp Johnson NYSE JNJ Pfizer NYSE PFE and Novartis
NVS,NVS:US,BBG000LYF3S8,J&J (JNJ) Anaemia Drug Marketing Label Expanded in Europe,2017-03-27 15:58:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BikrjRbgllY/jj-jnj-anaemia-drug-marketing-label-expanded-in-europe-cm765867,Johnson amp Johnson JNJ announced that the French health authority has granted approval to expand the label of its anaemia drug Eprex to include treatment of symptomatic anaemia in patients with low or intermediate risk myelodysplastic syndromes MDS in the mutual recognition procedure
NVS,NVS:US,BBG000LYF3S8,Bristol-Myers: Maybe a Pfizer Acquisition Could Makes Sense After All?,2017-03-27 14:22:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/03/27/bristol-myers-maybe-a-pfizer-acquisition-could-makes-sense-after-all/?mod=yahoobarrons&ru=yahoo,Bristol-Myers: Maybe a Pfizer Acquisition Could Makes Sense After All?
NVS,NVS:US,BBG000LYF3S8,Cambridge-based Ionis spinout Akcea plots $100M IPO,2017-03-27 14:05:09 +0000,http://www.bizjournals.com/boston/news/2017/03/27/cambridge-based-ionis-spinout-akcea-plots-100m-ipo.html?ana=yahoo,Cambridge-based Ionis spinout Akcea plots $100M IPO
NVS,NVS:US,BBG000LYF3S8,3 Big Pharma Stocks You Don't Have to Babysit,2017-03-27 14:02:00 +0000,https://www.fool.com/investing/2017/03/27/3-big-pharma-stocks-you-dont-have-to-babysit.aspx,3 Big Pharma Stocks You Don't Have to Babysit
NVS,NVS:US,BBG000LYF3S8,Novartis’s Innovative Medicines Segment in 2016,2017-03-27 13:08:30 +0000,http://marketrealist.com/2017/03/novartiss-innovative-medicines-segment-in-2016/?utm_source=yahoo&utm_medium=feed,Novartis’s Innovative Medicines Segment in 2016
NVS,NVS:US,BBG000LYF3S8,Blog Coverage Novartis Licences its Immunosenescence Drugs to PureTech Health,2017-03-27 12:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-novartis-licences-immunosenescence-121500265.html,"[Accesswire] - Upcoming AWS Coverage on Aerie Pharmaceuticals Post-Earnings Results LONDON, UK / ACCESSWIRE / March 27, 2017 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS ). PureTech ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Kicked Off The New Trading Week With A Loss,2017-03-27 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a1aRVCosfgE/the-swiss-stock-market-kicked-off-the-new-trading-week-with-a-loss-20170327-00901,The Swiss Stock Market Kicked Off The New Trading Week With A Loss
NVS,NVS:US,BBG000LYF3S8,Novartis’s Recent Developments,2017-03-27 11:38:22 +0000,http://marketrealist.com/2017/03/novartiss-recent-developments-2/?utm_source=yahoo&utm_medium=feed,Novartis’s Recent Developments
NVS,NVS:US,BBG000LYF3S8,Exploring Novartis’s 2016 Revenue,2017-03-24 21:05:50 +0000,http://marketrealist.com/2017/03/exploring-novartiss-2016-revenue/?utm_source=yahoo&utm_medium=feed,Exploring Novartis’s 2016 Revenue
NVS,NVS:US,BBG000LYF3S8,Novartis’s Valuation Compared to Its Peers’,2017-03-24 19:07:07 +0000,http://marketrealist.com/2017/03/novartiss-valuation-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,Novartis’s Valuation Compared to Its Peers’
NVS,NVS:US,BBG000LYF3S8,Novartis Licenses 2 Drugs In Exchange for Equity,2017-03-24 15:00:00 +0000,http://www.investopedia.com/news/novartis-licenses-2-agerelated-drugs-equity-stake-nvs/?partner=YahooSA,Novartis Licenses 2 Drugs In Exchange for Equity
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved",2017-03-24 14:01:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_-mL-5KBKeU/pharma-stock-roundup-is-sanofi-buying-flexion-pfizer-merck-kgaa-drug-approved-cm765118,Shortly after the release of the Budget Blueprint for 2018 which could require companies to shell out higher fees for regulatory reviews as well as a reduction of 5 8 billion in the National Institutes of Health s NIH spending the President continued to focus on drug prices at a meeting
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Slipped Friday And Finished Negative For The Week,2017-03-24 13:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sVnX8ljdf4k/the-swiss-stock-market-slipped-friday-and-finished-negative-for-the-week-20170324-00598,The Swiss Stock Market Slipped Friday And Finished Negative For The Week
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved",2017-03-24 11:47:11 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-sanofi-buying-114711173.html,"Pharma Stock Roundup: Is Sanofi Buying Flexion? Pfizer, Merck KGaA Drug Approved"
NVS,NVS:US,BBG000LYF3S8,Valeant Pharmaceuticals is Developing its Sales Force,2017-03-24 11:35:43 +0000,http://marketrealist.com/2017/03/valeant-pharmaceuticals-actively-developing-sales-force-2017/?utm_source=yahoo&utm_medium=feed,Valeant Pharmaceuticals is Developing its Sales Force
NVS,NVS:US,BBG000LYF3S8,AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4,2017-03-23 22:59:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/44rmugTfnpM/aveo-aveo-reports-narrower-than-expected-loss-in-q4-cm764969,AVEO Pharmaceuticals Inc AVEO reported a fourth quarter 2016 loss of 7 cents per share narrower than the Zacks Consensus Estimate of a loss of 9 cents The company had reported a loss of 11 cents per share in the year ago period AVEO s share price movement shows that the stock
NVS,NVS:US,BBG000LYF3S8,"2 Leading Pharma Stocks Ready To Bounce Back (RHHBY, NVS)",2017-03-23 15:02:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ykz7dBeuroI/2-leading-pharma-stocks-ready-to-bounce-back-rhhby-nvs-cm764739,InvestorPlace Stock Market News Stock Advice amp Trading Tips Few industries have been hit as hard as pharmaceuticals over the past year From public outrage over price increases to the potential for government oversight into profits the group hasn t enjoyed the double
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Recovered Some Lost Ground,2017-03-23 13:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hI9X0JUYWxg/the-swiss-stock-market-recovered-some-lost-ground-20170323-00894,The Swiss Stock Market Recovered Some Lost Ground
NVS,NVS:US,BBG000LYF3S8,New Product Launches May Boost Valeant’s Dermatology Revenue,2017-03-23 13:06:03 +0000,http://marketrealist.com/2017/03/new-product-launches-may-boost-valeant-pharmaceuticals-dermatology-revenues-future-years/?utm_source=yahoo&utm_medium=feed,New Product Launches May Boost Valeant’s Dermatology Revenue
NVS,NVS:US,BBG000LYF3S8,Novartis' Intraocular Lens Secures FDA Approval (NVS),2017-03-23 12:26:00 +0000,http://www.investopedia.com/news/novartis-intraocular-lens-secures-fda-approval-nvs/?partner=YahooSA,Novartis' Intraocular Lens Secures FDA Approval (NVS)
NVS,NVS:US,BBG000LYF3S8,Alcon Announces FDA Approval For AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL,2017-03-23 02:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zrsEVHv-1Zw/alcon-announces-fda-approval-for-acrysof-iq-restor-25-multifocal-toric-iol-20170323-00052,Alcon Announces FDA Approval For AcrySof IQ ReSTOR +2.5 Multifocal Toric IOL
NVS,NVS:US,BBG000LYF3S8,Novartis' Acute Heart Failure Drug Fails in Late-Stage Study,2017-03-23 00:58:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B4vfKGlyqYU/novartis-acute-heart-failure-drug-fails-in-late-stage-study-cm764455,Novartis AG NVS recently suffered a setback on the announcement of disappointing data from a phase III study RELAX AHF 2 on pipeline candidate serelaxin RLX030 A look at Novartis share price movement over the past one year shows that the stock has underperformed the Zacks
NVS,NVS:US,BBG000LYF3S8,Novartis' Acute Heart Failure Drug Fails in Late-Stage Study,2017-03-22 22:12:10 +0000,http://finance.yahoo.com/news/novartis-acute-heart-failure-drug-221210135.html,Novartis' Acute Heart Failure Drug Fails in Late-Stage Study
NVS,NVS:US,BBG000LYF3S8,Novartis cancer drug combo developed partly in Cambridge shows early promise,2017-03-22 20:51:15 +0000,http://www.bizjournals.com/boston/news/2017/03/22/novartis-cancer-drug-combo-developed-in-cambridge.html?ana=yahoo,Novartis cancer drug combo developed partly in Cambridge shows early promise
NVS,NVS:US,BBG000LYF3S8,Novartis Heart Drug Flops In Second Late-Stage Trial — As Expected,2017-03-22 20:17:13 +0000,http://www.investors.com/news/technology/novartis-heart-drug-flops-in-second-late-stage-trial-as-expected/?src=A00220A,Novartis Heart Drug Flops In Second Late-Stage Trial — As Expected
NVS,NVS:US,BBG000LYF3S8,Array BioPharma's NDA for Cancer Drug Withdrawn; Shares Down,2017-03-22 16:10:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WqNeqUhC1IU/array-biopharmas-nda-for-cancer-drug-withdrawn-shares-down-cm764107,Shares of Array BioPharma Inc ARRY slipped 2 30 after the company announced that it has withdrawn its new drug application NDA for its pipeline candidate binimetinib from the FDA s Division of Oncology Products 2 The candidate was being evaluated as a monotherapy for the treatment
NVS,NVS:US,BBG000LYF3S8,Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials,2017-03-22 16:07:00 +0000,https://www.thestreet.com/story/14054413/1/novartis-shares-extend-declines-after-serelaxin-fails-global-phase-iii-trials.html?puc=yahoo&cm_ven=YAHOO,Novartis Shares Extend Declines After Serelaxin Fails Global Phase III Trials
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Recent Losses,2017-03-22 13:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r0tGVc34pG4/the-swiss-stock-market-extended-its-recent-losses-20170322-00867,The Swiss Stock Market Extended Its Recent Losses
NVS,NVS:US,BBG000LYF3S8,European Markets Slipped Further On Trump Policy Doubts,2017-03-22 13:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0_j8jQCXQeE/european-markets-slipped-further-on-trump-policy-doubts-20170322-00852,European Markets Slipped Further On Trump Policy Doubts
NVS,NVS:US,BBG000LYF3S8,"Novartis’ Heart Drug Fails Late Stage Trials (NVS, AZN)",2017-03-22 12:52:00 +0000,http://www.investopedia.com/news/novartis-heart-drug-fails-late-stage-trials-nvs-azn/?partner=YahooSA,"Novartis’ Heart Drug Fails Late Stage Trials (NVS, AZN)"
NVS,NVS:US,BBG000LYF3S8,European Shares Slump On US Policy Uncertainty,2017-03-22 07:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LSvnGVUMPQQ/european-shares-slump-on-us-policy-uncertainty-20170322-00316,European Shares Slump On US Policy Uncertainty
NVS,NVS:US,BBG000LYF3S8,Novartis: Phase III Study Fails To Confirm Efficacy Of RLX030 - Quick Facts,2017-03-22 02:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M03WLfSptco/novartis-phase-iii-study-fails-to-confirm-efficacy-of-rlx030--quick-facts-20170322-00043,Novartis: Phase III Study Fails To Confirm Efficacy Of RLX030 - Quick Facts
NVS,NVS:US,BBG000LYF3S8,"VT, NSRGY, NVS, KO: Large Inflows Detected at ETF",2017-03-21 17:08:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PZXi4AS34ns/vt-nsrgy-nvs-ko-large-inflows-detected-at-etf-cm763591,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Total World Stock ETF Symbol VT where we have detected an approximate 183 5 million dollar inflow that s a 2 6 increase week over week in
NVS,NVS:US,BBG000LYF3S8,Does Novartis (NVS) Stock Make a Good Value Pick?,2017-03-21 16:11:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8zxUAc8_9_k/does-novartis-nvs-stock-make-a-good-value-pick-cm763499,Value investing is easily one of the most popular ways to find great stocks in any market environment After all who wouldn t want to find stocks that are either flying under the radar and are compelling buys or offer up tantalizing discounts when compared to fair value One way to find
NVS,NVS:US,BBG000LYF3S8,"VEA, WDRW: Big ETF Inflows",2017-03-21 16:07:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WdO-10L4OME/vea-wdrw-big-etf-inflows-cm763448,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 30 001 099 units or a 2 6 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017,2017-03-21 15:11:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q2AQHxA2koE/6-reasons-to-invest-in-glaxosmithkline-gsk-stock-in-2017-cm763381,GlaxoSmithKline plc GSK one of the largest health care companies reshaped its business following Mar 2015 completion of the three part inter conditional transaction with Novartis AG NVS Under the deal Glaxo sold oncology assets to Novartis and acquired Novartis Vaccines
NVS,NVS:US,BBG000LYF3S8,Lilly's Breast Cancer Combo Drug Phase III Results Positive,2017-03-21 14:09:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QSMsf3fTJMs/lillys-breast-cancer-combo-drug-phase-iii-results-positive-cm763321,Eli Lilly and Company LLY recently announced that a phase III combination study evaluating its pipeline candidate abemaciclib in advanced breast cancer met the primary endpoint of progression free survival PFS The double blind MONARCH 2 phase III study evaluated abemaciclib a CDK 4
NVS,NVS:US,BBG000LYF3S8,Does Novartis (NVS) Stock Make a Good Value Pick?,2017-03-21 13:50:01 +0000,http://finance.yahoo.com/news/does-novartis-nvs-stock-good-135001469.html,Does Novartis (NVS) Stock Make a Good Value Pick?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped On Weakness In U.S. Markets,2017-03-21 13:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iIq3aJQVmXQ/the-swiss-stock-market-dropped-on-weakness-in-us-markets-20170321-00962,The Swiss Stock Market Dropped On Weakness In U.S. Markets
NVS,NVS:US,BBG000LYF3S8,6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017,2017-03-21 13:18:01 +0000,http://finance.yahoo.com/news/6-reasons-invest-glaxosmithkline-gsk-131801097.html,6 Reasons to Invest in GlaxoSmithKline (GSK) Stock in 2017
NVS,NVS:US,BBG000LYF3S8,"Novartis’ Cosentyx Shows Psoriasis Modification Potential (NVS, DERM)",2017-03-21 11:51:00 +0000,http://www.investopedia.com/news/novartis-cosentyx-shows-psoriasis-modification-potential-nvs-derm/?partner=YahooSA,"Novartis’ Cosentyx Shows Psoriasis Modification Potential (NVS, DERM)"
NVS,NVS:US,BBG000LYF3S8,Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks,2017-03-21 11:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=798740&SR=Yahoo,Our Ultimate Stock-Pickers' Top 10 Dividend-Yielding Stocks
NVS,NVS:US,BBG000LYF3S8,European Shares Seen Up As Focus Turns To French Presidential Debate,2017-03-21 03:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MAQdtTSeoyY/european-shares-seen-up-as-focus-turns-to-french-presidential-debate-20170321-00093,European Shares Seen Up As Focus Turns To French Presidential Debate
NVS,NVS:US,BBG000LYF3S8,Novartis: Cosentyx Shows Disease Modification Potential - Quick Facts,2017-03-21 02:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kK-kUumaX4w/novartis-cosentyx-shows-disease-modification-potential--quick-facts-20170321-00063,Novartis: Cosentyx Shows Disease Modification Potential - Quick Facts
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Announces Positive Data on Heart Failure Drug,2017-03-21 00:06:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rqAZrgxK2DA/novartis-nvs-announces-positive-data-on-heart-failure-drug-cm763197,Novartis AG NVS recently announced results of a new post hoc analysis from the PARADIGM HF study on Entresto in a subgroup of patients with reduced ejection fraction heart failure HFrEF and diabetes A look at Novartis share price movement over the past one year shows that the stock
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of Mar.20.: ESPR, NKTR, CTMX, CERU, GNMX...",2017-03-20 22:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cL0Np-7P7A4/gainers--losers-of-mar20-espr-nktr-ctmx-ceru-gnmx-20170320-01219,"Gainers & Losers Of Mar.20.: ESPR, NKTR, CTMX, CERU, GNMX..."
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Announces Positive Data on Heart Failure Drug,2017-03-20 22:22:10 +0000,http://finance.yahoo.com/news/novartis-nvs-announces-positive-data-222210122.html,Novartis (NVS) Announces Positive Data on Heart Failure Drug
NVS,NVS:US,BBG000LYF3S8,Here’s How You Can Invest In The World’s Most Innovative Country: Switzerland (EWL),2017-03-20 21:06:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/34gqyPheQOk/heres-how-you-can-invest-in-the-worlds-most-innovative-country-switzerland-ewl-cm763164,InvestorPlace Stock Market News Stock Advice amp Trading Tips At my premium newsletter Game Changing Stocks I have the challenging but exciting task of identifying companies that are set to change the way the world operates I m talking about companies that hold the promise
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 03/20/2017: CTMX,BMY,ESPR,CERU,NVS",2017-03-20 20:26:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xN4_-O665ng/health-care-sector-update-for-03202017-ctmxbmyesprcerunvs-cm763125,Top Health Care StocksTop Health Care Stocks JNJ 0 11 JNJ 0 11 PFE 0 25 PFE 0 25 MRK 0 44 MRK 0 44 ABT 0 30 ABT 0 30 AMGN 0 38 AMGN 0 38 Health care stocks saw their losses widen slightly this afternoon with the NYSE Health Care Index declining 0 1 while shares of health
NVS,NVS:US,BBG000LYF3S8,Why Amgen's Success Was a Big Disappointment,2017-03-20 19:07:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vmAPDGrBzhM/why-amgens-success-was-a-big-disappointment-cm763094,Amgen Inc NASDAQ AMGN recently released conclusive proof that its pricey new cholesterol lowering drug saves lives As hoped results of a long awaited outcome study showed that people taking Repatha were far less likely to suffer heart attacks and strokes Instead of lifting
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 03/20/2017: NKTR,ESPR,CERU",2017-03-20 18:46:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/STm3EU5Iid8/health-care-sector-update-for-03202017-nktresprceru-cm763100,Top Health Care StocksTop Health Care Stocks JNJ 0 00 JNJ 0 00 PFE 0 19 PFE 0 19 MRK 0 46 MRK 0 46 ABT 0 43 ABT 0 43 AMGN 0 20 AMGN 0 20 Health care stocks were drifting lower in recent trade with the NYSE Health Care Index declining about 0 1 while shares of health care companies
NVS,NVS:US,BBG000LYF3S8,Why Amgen's Success Was a Big Disappointment,2017-03-20 17:18:00 +0000,https://www.fool.com/investing/2017/03/20/why-amgens-success-was-a-big-disappointment.aspx,Why Amgen's Success Was a Big Disappointment
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped After Banks Underperform,2017-03-20 13:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XxdJdaK2PNc/the-swiss-stock-market-dipped-after-banks-underperform-20170320-00866,The Swiss Stock Market Dipped After Banks Underperform
NVS,NVS:US,BBG000LYF3S8,Novartis Heart Failure Drug Beats Enalapril (NVS),2017-03-20 13:06:00 +0000,http://www.investopedia.com/news/novartis-heart-failure-drug-beats-enalapril-nvs/?partner=YahooSA,Novartis Heart Failure Drug Beats Enalapril (NVS)
NVS,NVS:US,BBG000LYF3S8,European Shares Seen Little Changed As Dollar Slips,2017-03-20 03:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FmISKXbjxpI/european-shares-seen-little-changed-as-dollar-slips-20170320-00048,European Shares Seen Little Changed As Dollar Slips
NVS,NVS:US,BBG000LYF3S8,Novartis: Entresto Shows Metabolic Benefits For HFrEF Patients With Diabetes,2017-03-18 15:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/H1HMiSIvBU4/novartis-entresto-shows-metabolic-benefits-for-hfref-patients-with-diabetes-20170318-00010,Novartis: Entresto Shows Metabolic Benefits For HFrEF Patients With Diabetes
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Slightly Higher Ahead Of G20 Meeting,2017-03-17 13:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BQGdR9LPecE/the-swiss-stock-market-finished-slightly-higher-ahead-of-g20-meeting-20170317-00642,The Swiss Stock Market Finished Slightly Higher Ahead Of G20 Meeting
NVS,NVS:US,BBG000LYF3S8,A Look at Opdivo’s Performance in 2016,2017-03-17 11:38:01 +0000,http://marketrealist.com/2017/03/a-look-at-opdivos-performance-in-2016/?utm_source=yahoo&utm_medium=feed,A Look at Opdivo’s Performance in 2016
NVS,NVS:US,BBG000LYF3S8,Flexi-Pricing Scheme Unveiled For Novartis AG (ADR) (NVS) Kisqali In The Face Of Stiff Competition,2017-03-16 18:51:49 +0000,http://www.insidermonkey.com/blog/flexi-pricing-scheme-unveiled-for-novartis-ag-adr-nvs-kisqali-in-the-face-of-stiff-competition-566887/,Flexi-Pricing Scheme Unveiled For Novartis AG (ADR) (NVS) Kisqali In The Face Of Stiff Competition
NVS,NVS:US,BBG000LYF3S8,Conatus Pharma (CNAT) Incurs Wider-than-Expected Loss in Q4,2017-03-16 17:06:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zxjOpyPAV4U/conatus-pharma-cnat-incurs-wider-than-expected-loss-in-q4-cm761744,Conatus Pharmaceuticals Inc CNAT reported fourth quarter 2016 loss of 35 cents per share wider than both the Zacks Consensus Estimate of a loss of 32 cents and the year ago figure of 30 cents Conatus shares have traded below the Zacks classified Medical Products industry so far
NVS,NVS:US,BBG000LYF3S8,"Novartis AG :NVS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017",2017-03-16 15:15:07 +0000,http://www.capitalcube.com/blog/index.php/novartis-ag-nvs-us-earnings-analysis-q4-2016-by-the-numbers-march-16-2017/,"Novartis AG :NVS-US: Earnings Analysis: Q4, 2016 By the Numbers : March 16, 2017"
NVS,NVS:US,BBG000LYF3S8,Glaxo Files for Label Expansion of Influenza Vaccine in US,2017-03-16 15:10:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_izUCg5xDV4/glaxo-files-for-label-expansion-of-influenza-vaccine-in-us-cm761595,GlaxoSmithKline plc GSK announced that it has submitted a supplemental Biologics License Application sBLA to the FDA seeking approval to expand the label of Fluarix Quadrivalent an influenza vaccine for infants six months or older At present this vaccine is approved for
NVS,NVS:US,BBG000LYF3S8,PPH's Underlying Holdings Imply 13% Gain Potential,2017-03-16 15:07:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4d-XlMo_Kac/pphs-underlying-holdings-imply-13-gain-potential-cm761567,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped After Roche Went Ex-Dividend,2017-03-16 13:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u7rMxngrGDQ/the-swiss-stock-market-dipped-after-roche-went-exdividend-20170316-00911,The Swiss Stock Market Dipped After Roche Went Ex-Dividend
NVS,NVS:US,BBG000LYF3S8,Will Pfizer's Growth Be Threatened by Novartis' New Cancer Drug?,2017-03-15 21:06:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rERzwFgRhSU/will-pfizers-growth-be-threatened-by-novartis-new-cancer-drug-cm761348,Novartis NYSE NVS announced on Monday that the U S Food and Drug Administration FDA approved Kisqali as a first line treatment for hormone receptor positive 160 human epidermal growth factor receptor 2 negative HR HER2 160 breast cancer 160 Soon stories were
NVS,NVS:US,BBG000LYF3S8,Will Pfizer's Growth Be Threatened by Novartis' New Cancer Drug?,2017-03-15 19:41:00 +0000,https://www.fool.com/investing/2017/03/15/will-pfizers-growth-be-threatened-by-novartis-new.aspx,Will Pfizer's Growth Be Threatened by Novartis' New Cancer Drug?
NVS,NVS:US,BBG000LYF3S8,Novartis Introduces Flexible Pricing for Kisqali,2017-03-15 14:24:00 +0000,http://www.investopedia.com/news/novartis-unveils-flexipricing-kisqali-nvs-pfe/?partner=YahooSA,Novartis Introduces Flexible Pricing for Kisqali
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed Ahead Of Fed Decision,2017-03-15 13:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D4sT2RQMxLM/the-swiss-stock-market-climbed-ahead-of-fed-decision-20170315-00935,The Swiss Stock Market Climbed Ahead Of Fed Decision
NVS,NVS:US,BBG000LYF3S8,Turning Pfizer Discards Into Novartis Gold: The Story Of Ziarco,2017-03-15 12:09:00 +0000,http://www.forbes.com/sites/johnlamattina/2017/03/15/turning-pfizer-discards-into-novartis-gold-the-story-of-ziarco/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Turning Pfizer Discards Into Novartis Gold: The Story Of Ziarco
NVS,NVS:US,BBG000LYF3S8,Novartis Takes Aim at Pfizer in Breast Cancer,2017-03-14 23:06:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PkhokdKwnmg/novartis-takes-aim-at-pfizer-in-breast-cancer-cm760815,Novartis NYSE NVS has won a speedy approval for Kisqali a new breast cancer drug that pits Novartis head to head against Pfizer s NYSE PFE billion dollar blockbuster drug Ibrance It remains to be seen how Kisqali s launch will reshape the breast cancer market but
NVS,NVS:US,BBG000LYF3S8,Novartis Takes Aim at Pfizer in Breast Cancer,2017-03-14 21:41:00 +0000,http://www.fool.com/investing/2017/03/14/novartis-takes-aim-at-pfizer-in-breast-cancer.aspx,Novartis Takes Aim at Pfizer in Breast Cancer
NVS,NVS:US,BBG000LYF3S8,Novartis Breast Cancer Drug Just OK'd — And Already Losing?,2017-03-14 20:14:17 +0000,http://www.investors.com/news/technology/novartis-breast-cancer-drug-was-just-okd-and-its-already-losing/?src=A00220A,Novartis Breast Cancer Drug Just OK'd — And Already Losing?
NVS,NVS:US,BBG000LYF3S8,AstraZeneca PLC (ADR) (AZN) Rejected Drugs To Be Reconsidered,2017-03-14 17:52:19 +0000,http://www.insidermonkey.com/blog/astrazeneca-plc-adr-azn-rejected-drugs-to-be-reconsidered-566311/,AstraZeneca PLC (ADR) (AZN) Rejected Drugs To Be Reconsidered
NVS,NVS:US,BBG000LYF3S8,Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy,2017-03-14 17:07:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KA66CW70WE8/novartis-breast-cancer-drug-okd-by-fda-as-first-line-therapy-cm760615,Swiss pharma giant Novartis AG NVS announced that the FDA has approved Kisqali formerly known as ribociclib LEE011 for use in combination with an aromatase inhibitor for the first line treatment of postmenopausal women with hormone receptor positive human epidermal growth factor receptor
NVS,NVS:US,BBG000LYF3S8,"Notable ETF Inflow Detected - VXUS, NSRGY, NVS, TM",2017-03-14 17:07:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wqacS5V-l0w/notable-etf-inflow-detected-vxus-nsrgy-nvs-tm-cm760633,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard Total International Stock ETF Symbol VXUS where we have detected an approximate 122 7 million dollar inflow that s a 1 7 increase week over week
NVS,NVS:US,BBG000LYF3S8,"VEA, SMDD: Big ETF Inflows",2017-03-14 16:07:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wKkJr21BJ84/vea-smdd-big-etf-inflows-cm760534,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 14 509 807 units or a 1 3 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,Gilead Looking To Buy Incyte? It Makes Sense,2017-03-14 14:55:29 +0000,http://finance.yahoo.com/news/gilead-looking-buy-incyte-makes-145529751.html,Gilead Looking To Buy Incyte? It Makes Sense
NVS,NVS:US,BBG000LYF3S8,Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy,2017-03-14 14:41:02 +0000,http://finance.yahoo.com/news/novartis-breast-cancer-drug-okd-144102650.html,Novartis Breast Cancer Drug OK'd by FDA as First-line Therapy
NVS,NVS:US,BBG000LYF3S8,Novartis wins U.S. approval for breast cancer drug; to compete with Pfizer's Ibrance,2017-03-14 14:13:56 +0000,http://finance.yahoo.com/news/novartis-wins-u-approval-breast-141356961.html,"[Reuters] - Novartis has won U.S. Food and Drug Administration approval for Kisqali to treat postmenopausal women who have a difficult-to-treat form of breast cancer, challenging U.S. rival Pfizer's Ibrance. The Swiss company has priced Kisqali to be cheaper than Ibrance, which analysts said could help it win business, though Kisqali's approval includes additional patient monitoring requirements that could work against the new drug."
NVS,NVS:US,BBG000LYF3S8,Novartis Breast Cancer Drug Gets FDA Approval,2017-03-14 13:51:00 +0000,http://www.investopedia.com/news/novartis-breast-cancer-drug-gets-fda-ok-nvs/?partner=YahooSA,Novartis Breast Cancer Drug Gets FDA Approval
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Lower In Cautious Trade,2017-03-14 13:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1t7nCKTpI0A/the-swiss-stock-market-finished-lower-in-cautious-trade-20170314-00946,The Swiss Stock Market Finished Lower In Cautious Trade
NVS,NVS:US,BBG000LYF3S8,AstraZeneca Gives Rejected Drugs a Second Life,2017-03-14 04:03:09 +0000,https://www.wsj.com/articles/astrazeneca-gives-rejected-drugs-a-second-life-1489402801?ru=yahoo?mod=yahoo_itp,AstraZeneca Gives Rejected Drugs a Second Life
NVS,NVS:US,BBG000LYF3S8,"APRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBX",2017-03-14 02:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f4325_ZIm5A/apri-on-track-stellar-bio-shines-fda-nod-for-nvs-study-results-heat-up-htbx-20170314-00045,"APRI On Track, Stellar Bio Shines, FDA Nod For NVS, Study Results Heat Up HTBX"
NVS,NVS:US,BBG000LYF3S8,FDA OKs new Novartis drug for type of advanced breast cancer,2017-03-13 23:28:35 +0000,http://sg.finance.yahoo.com/news/fda-oks-novartis-drug-type-201347415.html,FDA OKs new Novartis drug for type of advanced breast cancer
NVS,NVS:US,BBG000LYF3S8,Novartis Kisqali Gets FDA Approval To Treat HR+/HER2- Metastatic Breast Cancer,2017-03-13 22:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AfF36w8m0YE/novartis-kisqali-gets-fda-approval-to-treat-hrher2--metastatic-breast-cancer-20170313-01310,Novartis Kisqali Gets FDA Approval To Treat HR+/HER2- Metastatic Breast Cancer
NVS,NVS:US,BBG000LYF3S8,Cambridge-based Astex Pharmaceuticals Celebrates as Cancer Drug Receives US Marketing Approval,2017-03-13 21:17:00 +0000,http://au.finance.yahoo.com/news/cambridge-based-astex-pharmaceuticals-celebrates-211700101.html,"[Business Wire] - CAMBRIDGE, England--(BUSINESSWIRE)-- Astex Pharmaceuticals (“Astex”), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics for oncology and diseases of the central nervous system, announced today that its long-standing pharmaceutical collaborator, Novartis, has received US Food and Drug Administration (FDA) marketing approval for Kisqali® (ribociclib, formerly known as LEE011) plus an aromatase inhibitor as a first-line treatment in post-menopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+/HER2-) advanced (metastatic) breast cancer. Astex is eligible to receive a milestone payment in respect of this FDA marketing approval and on approval of additional regulatory filings in Europe and Japan, as well as royalty payments on annual sales of Kisqali, under the drug discovery alliance entered into between Astex and Novartis in 2005."
NVS,NVS:US,BBG000LYF3S8,FDA approves Novartis drug as first-line treatment for breast cancer,2017-03-13 21:00:42 +0000,http://finance.yahoo.com/news/fda-approves-novartis-drug-first-210042848.html,"[Reuters] - Novartis AG said on Monday that the U.S. Food and Drug Administration had approved the company's experimental drug, kisqali, as a first-line treatment for a type of breast cancer in postmenopausal women, in combination with another breast cancer drug. Kisqali, an oral drug, helps in slowing down the progression of cancer by preventing two proteins called cyclin-dependent kinase 4 and 6 (CDK4/6). Kisqali, by targeting CDK4/6, helps in ensuring that cancer cells do not continue to replicate uncontrollably."
NVS,NVS:US,BBG000LYF3S8,FDA OKs new Novartis drug for type of advanced breast cancer,2017-03-13 20:13:58 +0000,http://finance.yahoo.com/news/fda-oks-novartis-drug-type-201347397.html,FDA OKs new Novartis drug for type of advanced breast cancer
NVS,NVS:US,BBG000LYF3S8,"Aerie Resubmits Rhopressa NDA, Roclatan Gains Traction",2017-03-13 14:07:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zDIHBZ1JcQI/aerie-resubmits-rhopressa-nda-roclatan-gains-traction-cm759899,We issued an updated research report on Aerie Pharmaceuticals Inc AERI on Mar 10 2016 Aerie Pharmaceuticals is a development stage company focused on the development and commercialization of eye disease therapies including glaucoma and other eye diseases Aerie s two lead
NVS,NVS:US,BBG000LYF3S8,[$$] AstraZeneca Gives Rejected Drugs a Second Life,2017-03-13 13:53:24 +0000,https://www.wsj.com/articles/astrazeneca-gives-rejected-drugs-a-second-life-1489402801?mod=yahoo_hs,[$$] AstraZeneca Gives Rejected Drugs a Second Life
NVS,NVS:US,BBG000LYF3S8,"Novartis AG :NVS-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017",2017-03-10 18:37:52 +0000,http://www.capitalcube.com/blog/index.php/novartis-ag-nvs-us-earnings-analysis-2016-by-the-numbers-march-10-2017/,"Novartis AG :NVS-US: Earnings Analysis: 2016 By the Numbers : March 10, 2017"
NVS,NVS:US,BBG000LYF3S8,How Incyte Stock Became a Bull Market Star for Biotech Investors,2017-03-10 15:16:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_NqMq8anG70/how-incyte-stock-became-a-bull-market-star-for-biotech-investors-cm759211,Despite many twists and turns the U S stock market has had a stupendous run since it reached a bottom in Mar 2009 The bull run has continued for eight years with the S amp P 500 gaining 198 1 during this period While several stocks performed well during this period Incyte
NVS,NVS:US,BBG000LYF3S8,How Incyte Stock Became a Bull Market Star for Biotech Investors,2017-03-10 12:51:12 +0000,http://finance.yahoo.com/news/incyte-stock-became-bull-market-125112909.html,How Incyte Stock Became a Bull Market Star for Biotech Investors
NVS,NVS:US,BBG000LYF3S8,5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade,2017-03-09 15:15:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mDwK_SzMBY8/5-reasons-celgene-will-be-a-top-biotech-stock-for-the-next-decade-cm758427,What happens to Celgene NASDAQ CELG after Revlimid runs its course The big biotech projects strong growth through 2020 but much of its revenue will still come from its wildly successful blood cancer drug However the first generic competition for Revlimid will enter the U
NVS,NVS:US,BBG000LYF3S8,5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade,2017-03-09 14:03:00 +0000,http://www.fool.com/investing/2017/03/09/5-reasons-celgene-will-be-a-top-biotech-stock-for.aspx,5 Reasons Celgene Will Be a Top Biotech Stock for the Next Decade
NVS,NVS:US,BBG000LYF3S8,Coverage initiated on Novartis AG by Liberum,2017-03-09 13:49:59 +0000,http://finance.yahoo.com/q/ud?s=NVS,Coverage initiated on Novartis AG by Liberum
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Slightly Higher After ECB Announcement,2017-03-09 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RDPMjtKzPgw/the-swiss-stock-market-finished-slightly-higher-after-ecb-announcement-20170309-00975,The Swiss Stock Market Finished Slightly Higher After ECB Announcement
NVS,NVS:US,BBG000LYF3S8,Eli Lilly's Taltz Shows Better Efficacy than J&J's Stelara,2017-03-08 17:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AFZYjxjILLk/eli-lillys-taltz-shows-better-efficacy-than-jjs-stelara-cm757980,Eli Lilly and Company LLY announced superior efficacy in a head to head study evaluating its marketed drug Taltz ixekizumab versus with Johnson amp Johnson s Stelara ustekinumab in patients with moderate to severe plaque The results from the IXORA S study were presented at the
NVS,NVS:US,BBG000LYF3S8,Trump Tweet on Drug Pricing Hits Biotech and Pharma ETFs,2017-03-08 17:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eMS5F9JVygY/trump-tweet-on-drug-pricing-hits-biotech-and-pharma-etfs-cm757946,The pharma and biotech industry has been hit badly by concerns over high drug prices in the past few years The initial panic was triggered in September 2015 when the Democratic presidential candidate Hillary Clinton tweeted about price gouging and laid out a proposal for combating
NVS,NVS:US,BBG000LYF3S8,Positive Results For AbbVie Inc (ABBV) Humira Biosimilar Reported By Novartis AG (ADR) (NVS),2017-03-08 16:00:47 +0000,http://www.insidermonkey.com/blog/positive-results-for-abbvie-inc-abbv-humira-biosimilar-reported-by-novartis-ag-adr-nvs-564605/,Positive Results For AbbVie Inc (ABBV) Humira Biosimilar Reported By Novartis AG (ADR) (NVS)
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Positive Data on Biosimilar Humira,2017-03-07 23:13:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XQQrS0hUvXM/novartis-nvs-reports-positive-data-on-biosimilar-humira-cm757583,Novartis AG NVS announced encouraging data for its proposed biosimilar verison of AbbVie s ABBV Humira adalimumab namely GP2017 from a phase III study A look at Novartis share price movement over the past one year shows that the stock has underperformed the Zacks classified Large
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Positive Data on Biosimilar Humira,2017-03-07 21:21:09 +0000,http://finance.yahoo.com/news/novartis-nvs-reports-positive-data-212109555.html,Novartis (NVS) Reports Positive Data on Biosimilar Humira
NVS,NVS:US,BBG000LYF3S8,European ADRs Edge Lower as Pharma Stocks See Mixed Fortunes,2017-03-07 16:32:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mPvIBt5Vwc0/european-adrs-edge-lower-as-pharma-stocks-see-mixed-fortunes-cm757285,American depository receipts of European stocks were 0 68 lower at 123 61 on the Bank of New York Mellon Europe ADR Index on Tuesday morning American depository receipts of European stocks were 0 68 lower at 123 61 on the Bank of New York Mellon Europe ADR Index on Tuesday morning Decliners
NVS,NVS:US,BBG000LYF3S8,"Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis",2017-03-07 13:13:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PVOuBoLZU48/better-buy-regeneron-pharmaceuticals-inc-vs-novartis-cm756996,Few companies can claim to have helped improve more individuals eyesight than Regeneron Pharmaceuticals NASDAQ REGN and Novartis NYSE NVS Regeneron s Eylea and Novartis Lucentis stand out as two of the most successful eye care drugs ever On the financial
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back On Pharma Weakness,2017-03-07 12:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u1KL9qSfZmE/the-swiss-stock-market-pulled-back-on-pharma-weakness-20170307-01095,The Swiss Stock Market Pulled Back On Pharma Weakness
NVS,NVS:US,BBG000LYF3S8,"Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis",2017-03-07 12:04:00 +0000,http://www.fool.com/investing/2017/03/07/better-buy-regeneron-pharmaceuticals-inc-vs-novart.aspx,"Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis"
NVS,NVS:US,BBG000LYF3S8,RBC Hints At Potential M&A For Kite Pharma,2017-03-06 18:10:09 +0000,http://finance.yahoo.com/news/rbc-hints-potential-m-kite-181009221.html,RBC Hints At Potential M&A For Kite Pharma
NVS,NVS:US,BBG000LYF3S8,"VEA, NSRGY, NVS, TM: Large Inflows Detected at ETF",2017-03-06 17:13:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IHPM0cMFu3w/vea-nsrgy-nvs-tm-large-inflows-detected-at-etf-cm756641,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 115 7 million dollar inflow that s a 0 3 increase week over week
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Paused At The Start Of The New Trading Week,2017-03-06 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/08-F0jwxBoc/the-swiss-stock-market-paused-at-the-start-of-the-new-trading-week-20170306-00956,The Swiss Stock Market Paused At The Start Of The New Trading Week
NVS,NVS:US,BBG000LYF3S8,"Novartis Division Sandoz Announces Proposed Biosimilar Adalimumab Shown to have Equivalent Efficacy, Similar Safety Profile as Humira",2017-03-06 09:09:17 +0000,http://finance.yahoo.com/news/novartis-division-sandoz-announces-proposed-090917041.html,"Novartis Division Sandoz Announces Proposed Biosimilar Adalimumab Shown to have Equivalent Efficacy, Similar Safety Profile as Humira"
NVS,NVS:US,BBG000LYF3S8,Novartis' Sandoz Presents Data For Proposed Biosimilar Adalimumab,2017-03-06 01:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bToLrfF5hd4/novartis-sandoz-presents-data-for-proposed-biosimilar-adalimumab-20170306-00033,Novartis' Sandoz Presents Data For Proposed Biosimilar Adalimumab
NVS,NVS:US,BBG000LYF3S8,Novartis AG (ADR) (NVS) Fined And Some Products To Be Temporarily Suspended In South Korea,2017-03-03 16:42:18 +0000,http://www.insidermonkey.com/blog/novartis-ag-adr-nvs-fined-and-some-products-to-be-temporarily-suspended-in-south-korea-563625/,Novartis AG (ADR) (NVS) Fined And Some Products To Be Temporarily Suspended In South Korea
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Managed A Slight Gain - Swiss Life In Focus,2017-03-03 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YZTpQvCOM70/the-swiss-stock-market-managed-a-slight-gain--swiss-life-in-focus-20170303-00598,The Swiss Stock Market Managed A Slight Gain - Swiss Life In Focus
NVS,NVS:US,BBG000LYF3S8,"Novartis Shares Lower on Ex Dividend Trading, Reports of Kickbacks Fine In South Korea",2017-03-02 12:58:00 +0000,https://www.thestreet.com/story/14023225/1/novartis-shares-slump-after-reports-of-fine-for-kickbacks-in-south-korea.html?puc=yahoo&cm_ven=YAHOO,"Novartis Shares Lower on Ex Dividend Trading, Reports of Kickbacks Fine In South Korea"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed After Strong Performance From Roche,2017-03-02 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j7OlC9Ha7nU/the-swiss-stock-market-climbed-after-strong-performance-from-roche-20170302-01210,The Swiss Stock Market Climbed After Strong Performance From Roche
NVS,NVS:US,BBG000LYF3S8,"South Korea fines Novartis over kickbacks, suspends sales of some drugs",2017-03-02 10:16:26 +0000,http://sg.finance.yahoo.com/news/south-korea-fines-novartis-over-064306774.html,"South Korea fines Novartis over kickbacks, suspends sales of some drugs"
NVS,NVS:US,BBG000LYF3S8,"South Korea fines Novartis over kickbacks, suspends sales of some drugs",2017-03-02 09:48:17 +0000,http://finance.yahoo.com/news/south-korea-fines-novartis-over-094817102.html,"[Reuters] - South Korea said it has fined Swiss drugmaker Novartis (NOVN.S) 200 million won ($174,937) and temporarily banned sales of some of its drugs for paying kickbacks to doctors in exchange for recommending the company's drugs. Novartis Korea said in a statement sent to Reuters that it ""acknowledges and accepts"" the government's decision. In August last year, six former and current Novartis employees in South Korea were indicted over illegal practices to boost sales of the company's drugs."
NVS,NVS:US,BBG000LYF3S8,"M&As, Pipeline Catalysts to Drive Pharma Sector",2017-03-01 23:14:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N3pJezp3vK8/mas-pipeline-catalysts-to-drive-pharma-sector-cm755151,Although pharma and biotech stocks are facing challenges in the form of increasing focus on the high prices of drugs a changing competitive scenario and mixed results the sector s fundamentals remain strong innovation mergers and acquisitions M amp As product approvals and positive
NVS,NVS:US,BBG000LYF3S8,Ionis Pharmaceuticals Inc Turns a Profit With Other Drugmakers' Money,2017-03-01 22:13:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hKIxpY9yD84/ionis-pharmaceuticals-inc-turns-a-profit-with-other-drugmakers-money-cm755063,Ionis Pharmaceuticals NASDAQ IONS reported fourth quarter earnings on Tuesday The biotech has two drugs on the market but given Kynamro s low sales and the fact that spinal muscular atrophy drug Spinraza only launched in late December most of the revenue came from partners who
NVS,NVS:US,BBG000LYF3S8,Medicines Company (MDCO) Q4 Loss Narrower than Expected,2017-03-01 17:15:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZhCq7UQ8uyc/medicines-company-mdco-q4-loss-narrower-than-expected-cm754907,The Medicines Company MDCO reported a loss of 1 29 per share including the impact of share based compensation expenses in the fourth quarter of 2016 narrower than Zacks Consensus Estimate of a loss of 1 43 The quarterly loss however widened from the year ago loss of 95 cents per
NVS,NVS:US,BBG000LYF3S8,"Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss",2017-03-01 17:15:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YXc29_Ydfxo/ophthotech-opht-q4-loss-wider-than-expected-sales-miss-cm754906,Ophthotech Corporation OPHT reported fourth quarter 2016 loss of 1 86 per share wider than both the Zacks Consensus Estimate of a loss of 1 64 and the year ago loss of 1 02 Ophthotech s shares have underperformed Zacks classified Medical Biomedical and Genetics so far this
NVS,NVS:US,BBG000LYF3S8,"Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss",2017-03-01 14:40:02 +0000,http://finance.yahoo.com/news/ophthotech-opht-q4-loss-wider-144002130.html,"Ophthotech (OPHT) Q4 Loss Wider than Expected, Sales Miss"
NVS,NVS:US,BBG000LYF3S8,A Look at Incyte’s Product Portfolio,2017-03-01 14:06:38 +0000,http://marketrealist.com/2017/02/a-look-at-incytes-product-portfolio/?utm_source=yahoo&utm_medium=feed,A Look at Incyte’s Product Portfolio
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Broke Out To A New High For The Year,2017-03-01 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ckVEdqigyGw/the-swiss-stock-market-broke-out-to-a-new-high-for-the-year-20170301-01224,The Swiss Stock Market Broke Out To A New High For The Year
NVS,NVS:US,BBG000LYF3S8,Novartis cancer division races to catch up with rivals,2017-03-01 08:58:55 +0000,http://sg.finance.yahoo.com/news/novartis-cancer-division-races-catch-085855014.html,Novartis cancer division races to catch up with rivals
NVS,NVS:US,BBG000LYF3S8,Understanding Incyte’s Revenue Stream for 2016,2017-02-28 19:35:43 +0000,http://marketrealist.com/2017/02/understanding-incytes-revenue-stream-for-2016/?utm_source=yahoo&utm_medium=feed,Understanding Incyte’s Revenue Stream for 2016
NVS,NVS:US,BBG000LYF3S8,Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?,2017-02-28 13:51:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Vghs9WOMK6U/conatus-pharmaceuticals-cnat-q4-earnings-whats-in-store-cm754032,Conatus Pharmaceuticals Inc CNAT is expected to report fourth quarter 2016 results next month Conatus performance so far has been impressive with the company surpassing expectations on three occasions while posting in line results in one Overall the company has posted an average beat
NVS,NVS:US,BBG000LYF3S8,Gene therapy to fight a blood cancer succeeds in major study,2017-02-28 13:16:12 +0000,http://finance.yahoo.com/news/gene-therapy-fight-blood-cancer-succeeds-major-study-120109345--finance.html,Gene therapy to fight a blood cancer succeeds in major study
NVS,NVS:US,BBG000LYF3S8,Gene therapy to fight a blood cancer succeeds in major study,2017-02-28 13:16:08 +0000,http://sg.finance.yahoo.com/news/gene-therapy-fight-blood-cancer-120104327.html,Gene therapy to fight a blood cancer succeeds in major study
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Slightly Higher As Traders Await Trump,2017-02-28 12:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pxkeB_MpkVo/the-swiss-stock-market-finished-slightly-higher-as-traders-await-trump-20170228-01361,The Swiss Stock Market Finished Slightly Higher As Traders Await Trump
NVS,NVS:US,BBG000LYF3S8,Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?,2017-02-28 12:24:12 +0000,http://finance.yahoo.com/news/conatus-pharmaceuticals-cnat-q4-earnings-122412501.html,Conatus Pharmaceuticals (CNAT) Q4 Earnings: What's in Store?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Slight Higher As Traders Await Trump,2017-02-28 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_ef-THMLP8c/the-swiss-stock-market-finished-slight-higher-as-traders-await-trump-20170228-01353,The Swiss Stock Market Finished Slight Higher As Traders Await Trump
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Slight Higher As Traders Await Trump,2017-02-28 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bR2pt1ykOes/the-swiss-stock-market-finished-slight-higher-as-traders-await-trump-20170228-01354,The Swiss Stock Market Finished Slight Higher As Traders Await Trump
NVS,NVS:US,BBG000LYF3S8,Novartis Shows the World a Take of 2 Charts,2017-02-27 15:14:00 +0000,http://realmoney.thestreet.com/articles/02/27/2017/novartis-shows-world-take-2-charts?puc=yahoo&cm_ven=YAHOO,Novartis Shows the World a Take of 2 Charts
NVS,NVS:US,BBG000LYF3S8,"Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM",2017-02-24 17:51:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q8lFqIuE53M/noteworthy-etf-inflows-vea-nsrgy-nvs-tm-cm752871,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 232 1 million dollar inflow that s a 0 5 increase week over week
NVS,NVS:US,BBG000LYF3S8,"Ligand (LGND) Q4 Earnings Down Y/Y, Revenues Miss Estimates",2017-02-24 16:51:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YhErBjxW2FQ/ligand-lgnd-q4-earnings-down-yy-revenues-miss-estimates-cm752780,Ligand Pharmaceuticals Incorporated LGND reported fourth quarter 2016 earnings of 50 cents per share including the impact of stock based compensation expense down 11 1 from the year ago figure The Ligand stock underperformed the Zacks classified Medical Biomed Genetics industry year
NVS,NVS:US,BBG000LYF3S8,Novartis Lung Cancer Drug Combo Gets CHMP Nod,2017-02-24 16:21:00 +0000,http://www.investopedia.com/news/novartis-lung-cancer-drug-combo-gets-chmp-nod-nvs/?partner=YahooSA,Novartis Lung Cancer Drug Combo Gets CHMP Nod
NVS,NVS:US,BBG000LYF3S8,Novartis Cancer Drug Zykadia Gets Priority Review,2017-02-24 16:05:00 +0000,http://www.investopedia.com/news/novartis-cancer-drug-zykadia-gets-priority-review-nvs/?partner=YahooSA,Novartis Cancer Drug Zykadia Gets Priority Review
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs",2017-02-24 14:54:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IzbzaW6L2ls/pharma-stock-roundup-is-bmy-the-next-acquisition-target-priority-review-for-pfe-novartis-drugs-cm752604,This week focus remained on Bristol Myers BMY with the company making additions to its Board and billionaire activist investor Carl Icahn reportedly acquiring a stake in the company Recap of the Week s Most Important Stories Is Bristol Myers the Next Takeover Target According
NVS,NVS:US,BBG000LYF3S8,Novartis wins CHMP nod for drug combo against some lung cancers,2017-02-24 13:22:23 +0000,http://sg.finance.yahoo.com/news/novartis-wins-chmp-nod-drug-132223801.html,Novartis wins CHMP nod for drug combo against some lung cancers
NVS,NVS:US,BBG000LYF3S8,Blog Coverage Novartis Gains Priority Review from the FDA for its Cancer Drug Zykadia as a Frontline Treatment for ALK-positive Non-Small Cell Lung Cancer,2017-02-24 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-novartis-gains-priority-131500861.html,"[Accesswire] - Upcoming AWS Coverage on Shire PLC Post-Earnings Results LONDON, UK / ACCESSWIRE / February 24, 2017 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS ) as the Company announced ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back On Profit Taking,2017-02-24 12:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3s3mnjEKH2U/the-swiss-stock-market-pulled-back-on-profit-taking-20170224-00853,The Swiss Stock Market Pulled Back On Profit Taking
NVS,NVS:US,BBG000LYF3S8,Ring the Register With These Upcoming Spinoffs,2017-02-24 12:35:00 +0000,https://www.thestreet.com/story/14001112/1/ring-the-register-with-these-upcoming-spinoffs.html?puc=yahoo&cm_ven=YAHOO,Ring the Register With These Upcoming Spinoffs
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs",2017-02-24 12:27:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-bmy-next-122712720.html,"Pharma Stock Roundup: Is BMY the Next Acquisition Target? Priority Review for PFE, Novartis Drugs"
NVS,NVS:US,BBG000LYF3S8,Morningstar's 5 Favorite Foreign-Stock ETFs,2017-02-24 11:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=795031&SR=Yahoo,Morningstar's 5 Favorite Foreign-Stock ETFs
NVS,NVS:US,BBG000LYF3S8,Novartis Receives Positive CHMP Opinion For Tafinlar + Mekinist - Quick Facts,2017-02-24 07:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a2bJBCzkg1E/novartis-receives-positive-chmp-opinion-for-tafinlar--mekinist---quick-facts-20170224-00372,Novartis Receives Positive CHMP Opinion For Tafinlar + Mekinist - Quick Facts
NVS,NVS:US,BBG000LYF3S8,Novartis Receives Positive CHMP Opinion For Tafinlar + Mekinist - Quick Facts,2017-02-24 07:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jjuLlopM9Ws/novartis-receives-positive-chmp-opinion-for-tafinlar--mekinist---quick-facts-20170224-00371,Novartis Receives Positive CHMP Opinion For Tafinlar + Mekinist - Quick Facts
NVS,NVS:US,BBG000LYF3S8,Teva Is Expected to See a Fall in Its Profit Margins in 2017,2017-02-23 22:06:29 +0000,http://marketrealist.com/2017/02/teva-pharmaceutical-expected-witness-drop-profit-margins-2017/?utm_source=yahoo&utm_medium=feed,Teva Is Expected to See a Fall in Its Profit Margins in 2017
NVS,NVS:US,BBG000LYF3S8,Medford's Seventh Sense wins narrow FDA approval for blood-collection device,2017-02-23 15:35:08 +0000,http://www.bizjournals.com/boston/news/2017/02/23/medfords-seventh-sense-wins-narrow-fda-approval.html?ana=yahoo,Medford's Seventh Sense wins narrow FDA approval for blood-collection device
NVS,NVS:US,BBG000LYF3S8,Here's Why Celgene's Latest Drug Is So Exciting,2017-02-23 14:52:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xwj1XiTO7bc/heres-why-celgenes-latest-drug-is-so-exciting-cm751796,Celgene NASDAQ CELG recently reported that its multiple sclerosis drug ozanimod successfully met its endpoints in reducing multiple sclerosis MS relapses and assuming a second trial pans out similarly that s got the biotech targeting a filing for FDA approval by the end of
NVS,NVS:US,BBG000LYF3S8,"Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for February 24, 2017",2017-02-23 14:20:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yAn5XZhkxJE/johnson-johnson-jnj-ex-dividend-date-scheduled-for-february-24-2017-cm751843,Johnson amp Johnson JNJ will begin trading ex dividend on February 24 2017 A cash dividend payment of 0 8 per share is scheduled to be paid on March 14 2017 Shareholders who purchased JNJ prior to the ex dividend date are eligible for the cash dividend payment This marks the
NVS,NVS:US,BBG000LYF3S8,5 reasons to invest in European stocks now,2017-02-23 13:04:58 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=C0CA04D0-F918-11E6-83E8-CFED21FD304B&siteid=yhoof2,5 reasons to invest in European stocks now
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Slightly Lower In Lackluster Trade,2017-02-23 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I-N9vXWMXYs/the-swiss-stock-market-finished-slightly-lower-in-lackluster-trade-20170223-01298,The Swiss Stock Market Finished Slightly Lower In Lackluster Trade
NVS,NVS:US,BBG000LYF3S8,Wall Street Sees Greener Territory,2017-02-23 07:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n33whKZ6BOU/wall-street-sees-greener-territory-20170223-00523,Wall Street Sees Greener Territory
NVS,NVS:US,BBG000LYF3S8,European Shares Seen A Tad Higher,2017-02-23 02:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VingsX_rnKw/european-shares-seen-a-tad-higher-20170223-00119,European Shares Seen A Tad Higher
NVS,NVS:US,BBG000LYF3S8,Novartis Says FDA Grants Priority Review For Expanded Use Zykadia,2017-02-23 01:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DwxVTfF9Odg/novartis-says-fda-grants-priority-review-for-expanded-use-zykadia-20170223-00063,Novartis Says FDA Grants Priority Review For Expanded Use Zykadia
NVS,NVS:US,BBG000LYF3S8,Swiss Re FY Profit Down; Proposes New Share Buy-back,2017-02-23 01:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/D6KM5GM241c/swiss-re-fy-profit-down-proposes-new-share-buyback-20170223-00045,Swiss Re FY Profit Down; Proposes New Share Buy-back
NVS,NVS:US,BBG000LYF3S8,"Momenta Pharmaceuticals, Inc. Earnings Take a Back Seat",2017-02-22 22:51:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/72ABv5VFcMQ/momenta-pharmaceuticals-inc-earnings-take-a-back-seat-cm751673,Momenta Pharmaceuticals NASDAQ MNTA reported fourth quarter earnings on Tuesday but analysts weren t discussing the numbers Instead most of their questions focused on the company s disclosure on Friday that the three times weekly version of Glatopa wouldn t likely be
NVS,NVS:US,BBG000LYF3S8,"In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs",2017-02-22 20:01:10 +0000,http://www.bizjournals.com/boston/news/2017/02/22/in-groundbreaking-deal-harvard-pilgrim-negotiates.html?ana=yahoo,"In 'groundbreaking' deal, Harvard Pilgrim negotiates contracts to save on two pricey drugs"
NVS,NVS:US,BBG000LYF3S8,Keytruda: Merck’s Immuno-Oncology Blockbuster Drug,2017-02-22 15:37:08 +0000,http://marketrealist.com/2017/02/keytruda-mercks-immuno-oncology-blockbuster-drug-2/?utm_source=yahoo&utm_medium=feed,Keytruda: Merck’s Immuno-Oncology Blockbuster Drug
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Gain As Nestle Provides Support,2017-02-22 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G5gdPRx5oJQ/the-swiss-stock-market-finished-with-a-gain-as-nestle-provides-support-20170222-01095,The Swiss Stock Market Finished With A Gain As Nestle Provides Support
NVS,NVS:US,BBG000LYF3S8,"ImmunoGen, Inc.: Waiting to Move FORWARD",2017-02-21 22:07:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bMyaq4EVSbM/immunogen-inc-waiting-to-move-forward-cm750911,ImmunoGen NASDAQ IMGN reported earnings on Friday for the quarter that ended in December The company is switching from a fiscal year that ends in June to one that ends in December so this report concludes the two quarter transition period Of course what the quarter s called
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of The Day: EYEG, BLPH, VSAR, MNTA, AMPH...",2017-02-21 19:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gda4OqtvtOg/gainers--losers-of-the-day-eyeg-blph-vsar-mnta-amph-20170221-01881,"Gainers & Losers Of The Day: EYEG, BLPH, VSAR, MNTA, AMPH..."
NVS,NVS:US,BBG000LYF3S8,"Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today",2017-02-21 19:09:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FIwBBq3AWBs/why-momenta-pharmaceuticals-inc-shares-got-crushed-today-cm750788,What happened Momenta Pharmaceuticals NASDAQ MNTA 160 stock is down 15 4 at 11 50 a m EST Tuesday after the company announced on Friday after the closing bell that its three times weekly version of Glatopa is unlikely to be approved this quarter due to a manufacturing
NVS,NVS:US,BBG000LYF3S8,"Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug",2017-02-21 17:37:27 +0000,http://www.investors.com/news/technology/momenta-pfizer-give-teva-pharma-breathing-room-on-generic-ms-drug/,"Momenta, Pfizer Give Teva Pharma Breathing Room On Generic MS Drug"
NVS,NVS:US,BBG000LYF3S8,"Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today",2017-02-21 17:26:26 +0000,http://www.fool.com/investing/2017/02/21/why-momenta-pharmaceuticals-inc-shares-got-crushed.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Momenta Pharmaceuticals, Inc. Shares Got Crushed Today"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On Strength Of Pharma Heavyweights,2017-02-21 12:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5MVV7iBZ71k/the-swiss-stock-market-climbed-on-strength-of-pharma-heavyweights-20170221-01298,The Swiss Stock Market Climbed On Strength Of Pharma Heavyweights
NVS,NVS:US,BBG000LYF3S8,This Keeps Driving Sanofi’s Growth,2017-02-20 12:37:20 +0000,http://marketrealist.com/2017/02/this-keeps-driving-sanofis-growth/?utm_source=yahoo&utm_medium=feed,This Keeps Driving Sanofi’s Growth
NVS,NVS:US,BBG000LYF3S8,Could Celgene Have Another Billion-Dollar Blockbuster on Its Hands?,2017-02-19 17:51:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eRsxZf19eeg/could-celgene-have-another-billion-dollar-blockbuster-on-its-hands-cm750114,A new and highly anticipated study by Celgene Corp NASDAQ CELG shows that its promising multiple sclerosis drug could soon reshape the 19 billion multiple sclerosis market On Friday management reported that ozanimod met its primary endpoint for reducing MS relapses better
NVS,NVS:US,BBG000LYF3S8,2 High-Yield Dividend Stocks That Are Ridiculously Cheap,2017-02-18 18:53:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lc05pSs3qWE/2-high-yield-dividend-stocks-that-are-ridiculously-cheap-cm750041,If you re looking for high quality dividend stocks that pay a better than average yield the pharmaceutical industry is definitely worth checking out Because of the political turmoil surrounding drug prices after all numerous pharma stocks are presently trading at
NVS,NVS:US,BBG000LYF3S8,2 High-Yield Dividend Stocks That Are Ridiculously Cheap,2017-02-18 17:09:32 +0000,http://www.fool.com/investing/2017/02/18/2-high-yield-dividend-stocks-that-are-ridiculously.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,2 High-Yield Dividend Stocks That Are Ridiculously Cheap
NVS,NVS:US,BBG000LYF3S8,Inside Sanofi’s Revenues in 4Q16,2017-02-17 21:46:44 +0000,http://marketrealist.com/2017/02/inside-sanofis-revenues-in-4q16/?utm_source=yahoo&utm_medium=feed,Inside Sanofi’s Revenues in 4Q16
NVS,NVS:US,BBG000LYF3S8,Blog Coverage Ionis Pharma Closed on its Collaboration Agreement with Novartis Following Clearance under the Hart-Scott-Rodino Antitrust Improvements Act,2017-02-17 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-ionis-pharma-closed-131500859.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / February 17, 2017 / Active Wall St. blog coverage looks at the headline from Ionis Pharmaceuticals, Inc. (NASDAQ: IONS ) and Novartis AG (NYSE: NVS ). On February 16, 2017, Ionis ..."
NVS,NVS:US,BBG000LYF3S8,Prolia Expected to Be a Significant Growth Driver for Amgen in 2017,2017-02-17 12:37:25 +0000,http://marketrealist.com/2017/02/prolia-expected-significant-growth-driver-amgen-2017/?utm_source=yahoo&utm_medium=feed,Prolia Expected to Be a Significant Growth Driver for Amgen in 2017
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed After Strong Performance From Index Heavyweights,2017-02-17 12:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PTbzCrOl7sU/the-swiss-stock-market-climbed-after-strong-performance-from-index-heavyweights-20170217-00771,The Swiss Stock Market Climbed After Strong Performance From Index Heavyweights
NVS,NVS:US,BBG000LYF3S8,NVS Crosses Above Key Moving Average Level,2017-02-16 22:54:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_ab2Bs42-EY/nvs-crosses-above-key-moving-average-level-cm749234,In trading on Thursday shares of Novartis Symbol NVS crossed above their 200 day moving average of 76 52 changing hands as high as 76 73 per share Novartis shares are currently trading up about 1 2 on the day The chart below shows the one year performance of NVS shares versus its 200
NVS,NVS:US,BBG000LYF3S8,Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback,2017-02-16 16:58:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1wX91UpN3NM/alzheimers-market-suffers-yet-another-blow-with-merck-drug-setback-cm749011,Merck amp Co Inc MRK suffered a pipeline setback with its investigational Alzheimer s disease treatment verubecestat being halted in a phase II III study The EPOCH study was stopped after an interim analysis by an external Data Monitoring Committee eDMC indicated that the study
NVS,NVS:US,BBG000LYF3S8,Ligand (LGND) Q4 Earnings: Will the Stock Pull a Surprise?,2017-02-16 14:58:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YTrr4g81MyA/ligand-lgnd-q4-earnings-will-the-stock-pull-a-surprise-cm748921,Ligand Pharmaceuticals Incorporated LGND is scheduled to report fourth quarter 2016 results on Feb 23 after the market closes Ligand s earnings history is mixed as it missed expectations in two of the last four quarters Overall the company had an average negative surprise of 5 01 in
NVS,NVS:US,BBG000LYF3S8,Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback,2017-02-16 14:27:02 +0000,http://finance.yahoo.com/news/alzheimers-market-suffers-yet-another-142702582.html,Alzheimer's Market Suffers Yet Another Blow with Merck Drug Setback
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline’s Valuation Compared to Its Peers,2017-02-16 14:05:53 +0000,http://marketrealist.com/2017/02/glaxosmithklines-valuation-compared-to-its-peers/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Valuation Compared to Its Peers
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back As Nestle Weighed,2017-02-16 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/G2dUt_9K2Rg/the-swiss-stock-market-pulled-back-as-nestle-weighed-20170216-01196,The Swiss Stock Market Pulled Back As Nestle Weighed
NVS,NVS:US,BBG000LYF3S8,"Incyte's (INCY) Beats on Q4 Earnings, Provides 2017 Outlook",2017-02-15 20:54:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r1et009E-30/incytes-incy-beats-on-q4-earnings-provides-2017-outlook-cm748510,Incyte Corporation INCY reported fourth quarter earnings of 15 cents beating the Zacks Consensus Estimate of 14 cents Incyte had reported earnings of 29 cents per share in the year ago quarter Quarterly revenues came in at 326 5 million up 33 9 year over year and beat the Zacks
NVS,NVS:US,BBG000LYF3S8,Bristol-Myers: Don't Bet on a Pfizer Acquisition,2017-02-15 17:38:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/15/bristol-myers-dont-bet-on-a-pfizer-acquisition/?mod=yahoobarrons&ru=yahoo,Bristol-Myers: Don't Bet on a Pfizer Acquisition
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Near The Highs Of The Year,2017-02-15 12:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FfjUvU_J04o/the-swiss-stock-market-finished-near-the-highs-of-the-year-20170215-01055,The Swiss Stock Market Finished Near The Highs Of The Year
NVS,NVS:US,BBG000LYF3S8,Bristol-Myers Squibb: Takeover Target?,2017-02-14 20:33:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2017/02/14/bristol-myers-squibb-takeover-target/?mod=yahoobarrons&ru=yahoo,Bristol-Myers Squibb: Takeover Target?
NVS,NVS:US,BBG000LYF3S8,4Q16 Performance of GlaxoSmithKline’s Business Segments,2017-02-14 18:35:43 +0000,http://marketrealist.com/2017/02/4q16-performance-of-glaxosmithklines-business-segments/?utm_source=yahoo&utm_medium=feed,4Q16 Performance of GlaxoSmithKline’s Business Segments
NVS,NVS:US,BBG000LYF3S8,Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education,2017-02-14 16:13:49 +0000,http://www.insidermonkey.com/blog/novartis-ag-adr-nvs-greater-use-of-technology-in-transforming-medical-education-551756/,Novartis AG (ADR) (NVS) Greater Use Of Technology In Transforming Medical Education
NVS,NVS:US,BBG000LYF3S8,"Teva (TEVA) Tops on Q4 Earnings, Maintains 2017 Guidance",2017-02-14 15:22:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZYais-jvJ_I/teva-teva-tops-on-q4-earnings-maintains-2017-guidance-cm747557,Teva Pharmaceutical Industries Ltd TEVA reported fourth quarter 2016 earnings of 1 34 per share including equity compensation expenses which beat the Zacks Consensus Estimate of 1 28 Excluding stock based compensation expenses earnings were 1 38 per share up 7 8 year over
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Snapped Its Recent Winning Streak,2017-02-14 12:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dHhxC9uK4Tk/the-swiss-stock-market-snapped-its-recent-winning-streak-20170214-01075,The Swiss Stock Market Snapped Its Recent Winning Streak
NVS,NVS:US,BBG000LYF3S8,These N.Y.C.-area doctors received the most payments from drug and device makers,2017-02-14 07:00:12 +0000,http://www.bizjournals.com/newyork/news/2017/02/14/ny-doctors-received-most-payments-from-drug-makers.html?ana=yahoo,These N.Y.C.-area doctors received the most payments from drug and device makers
NVS,NVS:US,BBG000LYF3S8,Analysts See 18% Gains Ahead For The Holdings of PPH,2017-02-13 16:20:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GYPOvYrPr44/analysts-see-18-gains-ahead-for-the-holdings-of-pph-cm746963,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed On Quiet Day,2017-02-13 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Brebji0abok/the-swiss-stock-market-finished-little-changed-on-quiet-day-20170213-00969,The Swiss Stock Market Finished Little Changed On Quiet Day
NVS,NVS:US,BBG000LYF3S8,Intercept Bounds To 3-Month High On NASH Trial Edits; Analysts Split,2017-02-10 21:10:38 +0000,http://www.investors.com/news/technology/intercept-bounds-to-3-month-high-on-nash-trial-edits-analysts-split/,Intercept Bounds To 3-Month High On NASH Trial Edits; Analysts Split
NVS,NVS:US,BBG000LYF3S8,Pharmaceutical ETF Experiences Big Inflow,2017-02-10 17:17:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5GJSjpw6n2c/pharmaceutical-etf-experiences-big-inflow-cm746340,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Pharmaceutical ETF Symbol PPH where we have detected an approximate 66 7 million dollar inflow that s a 28 8 increase week over week in outstanding units
NVS,NVS:US,BBG000LYF3S8,10 Most Diverse Companies In The US,2017-02-10 15:43:39 +0000,http://www.insidermonkey.com/blog/10-most-diverse-companies-in-the-us-536907/,10 Most Diverse Companies In The US
NVS,NVS:US,BBG000LYF3S8,Is Array BioPharma the Best Clinical-Stage Biotech Stock to Buy in 2017?,2017-02-10 15:20:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sJkRsM0MgXU/is-array-biopharma-the-best-clinical-stage-biotech-stock-to-buy-in-2017-cm746205,Increasingly complex cancer medicines are launching with six figure price tags and a larger longer living population means that global cancer drug spending is soaring Many clinical stage biotech stocks are working on new drugs that could capitalize on this growth but Array
NVS,NVS:US,BBG000LYF3S8,Is Array BioPharma the Best Clinical-Stage Biotech Stock to Buy in 2017?,2017-02-10 13:22:27 +0000,http://www.fool.com/investing/2017/02/10/is-array-biopharma-the-best-clinical-stage-biotech.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Array BioPharma the Best Clinical-Stage Biotech Stock to Buy in 2017?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Added To Its Recent Winning Streak,2017-02-10 12:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aYb4gI3i5IQ/the-swiss-stock-market-added-to-its-recent-winning-streak-20170210-00735,The Swiss Stock Market Added To Its Recent Winning Streak
NVS,NVS:US,BBG000LYF3S8,UBS Makes First Big 2017 Addition to Dividend Rulers Stocks List,2017-02-09 15:15:07 +0000,http://finance.yahoo.com/news/ubs-makes-first-big-2017-151507716.html,UBS Makes First Big 2017 Addition to Dividend Rulers Stocks List
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Winning Streak To Three,2017-02-09 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o_bQo6pknK4/the-swiss-stock-market-extended-its-winning-streak-to-three-20170209-01250,The Swiss Stock Market Extended Its Winning Streak To Three
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Slight Gain In Directionless Trade,2017-02-08 12:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B2uRcKZGp8k/the-swiss-stock-market-finished-with-a-slight-gain-in-directionless-trade-20170208-01115,The Swiss Stock Market Finished With A Slight Gain In Directionless Trade
NVS,NVS:US,BBG000LYF3S8,Propeller Health Enters into Collaboration to Connect Breezhaler™ Devices to the Propeller Platform,2017-02-08 11:00:00 +0000,http://finance.yahoo.com/news/propeller-health-enters-collaboration-connect-110000249.html,"[PR Newswire] - MADISON, Wis., Feb. 8, 2017 /PRNewswire/ -- Propeller Health, the leading digital health solution for respiratory medicine, and Novartis Pharma AG (NVS) today announced a collaboration to develop a custom add-on sensor for the Breezhaler™ inhaler, a device used for the company's portfolio of COPD treatments (Ultibro™ Breezhaler™, Onbrez™ Breezhaler™ and Seebri™ Breezhaler™), connecting these medications to Propeller's digital health platform. As patients use the Breezhaler™ inhaler, a patented capsule-based dry powder inhaler (DPI) for treatment of COPD, the new custom sensors will allow for passively recording and transmitting compliance data, better informing patients and their physicians of adherence and other treatment factors through the Propeller platform. Propeller has regulatory clearance to help patients and their physicians better understand asthma and COPD, and help to improve the symptoms and outcomes of these chronic respiratory diseases."
NVS,NVS:US,BBG000LYF3S8,"Model N (MODN) Q1 Loss Narrower than Expected, Guides Well",2017-02-07 21:17:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DY9heVqG82U/model-n-modn-q1-loss-narrower-than-expected-guides-well-cm744463,Model N Inc MODN started fiscal 2017 on a strong note reporting better than expected results for the first quarter Although the company posted adjusted loss including all one time expenses but excluding stock based compensation of 21 cents per share it was narrower than the Zacks
NVS,NVS:US,BBG000LYF3S8,"VEA, DEWJ: Big ETF Inflows",2017-02-07 17:18:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gOgO5BmXsuY/vea-dewj-big-etf-inflows-cm744274,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 10 002 446 units or a 0 9 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,"Teva: Vigodman Steps Down, Peterburg Hired as Interim CEO",2017-02-07 14:20:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mUmRy03u4nU/teva-vigodman-steps-down-peterburg-hired-as-interim-ceo-cm744119,Teva Pharmaceutical Industries Ltd TEVA recently announced that its present chief executive officer CEO Erez Vigodman is stepping down The company has named Dr Yitzhak Peterburg as the interim president and CEO effective immediately Peterburg has served as the chairman of Teva s
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Higher As Pharma Heavyweights Support,2017-02-07 12:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7c9lr7ofeTw/the-swiss-stock-market-finished-higher-as-pharma-heavyweights-support-20170207-01214,The Swiss Stock Market Finished Higher As Pharma Heavyweights Support
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Finished Lower, With Support From Novartis",2017-02-06 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wv9yundqrXY/the-swiss-stock-market-finished-lower-with-support-from-novartis-20170206-00908,"The Swiss Stock Market Finished Lower, With Support From Novartis"
NVS,NVS:US,BBG000LYF3S8,Why Biogen Inc (BIIB) Stock Is a Solid Long-Term Bet,2017-02-03 20:59:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1jkEyYT_19s/why-biogen-inc-biib-stock-is-a-solid-long-term-bet-cm743150,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Over the last five years the shares of Biogen Inc 160 NASDAQ BIIB have traded at an average price to earnings ratio of almost 28 Today BIIB stock s 160 multiple is 11 on a forward basis
NVS,NVS:US,BBG000LYF3S8,Novartis’s Valuation after the 4Q16 Results,2017-02-03 15:36:11 +0000,http://marketrealist.com/2017/02/novartiss-valuation-after-the-4q16-results/?utm_source=yahoo&utm_medium=feed,Novartis’s Valuation after the 4Q16 Results
NVS,NVS:US,BBG000LYF3S8,Why the Majority of Analysts Deem Novartis a ‘Buy’,2017-02-03 14:06:16 +0000,http://marketrealist.com/2017/02/why-the-majority-of-analysts-deem-novartis-a-buy/?utm_source=yahoo&utm_medium=feed,Why the Majority of Analysts Deem Novartis a ‘Buy’
NVS,NVS:US,BBG000LYF3S8,Amgen (AMGN) Q4 Earnings Top; Repatha Positive in CV Study,2017-02-03 13:33:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BPNDxPx6RSA/amgen-amgn-q4-earnings-top-repatha-positive-in-cv-study-cm742722,Biotech major Amgen Inc AMGN reported fourth quarter 2016 earnings of 2 89 per share beating the Zacks Consensus Estimate of 2 77 by 4 3 and increasing 11 from the year ago period Higher revenues and operating margins drove the bottom line FindTheCompany
NVS,NVS:US,BBG000LYF3S8,Novartis’s Financial Guidance and Priorities for 2017,2017-02-03 12:36:23 +0000,http://marketrealist.com/2017/02/novartiss-financial-guidance-and-priorities-for-2017/?utm_source=yahoo&utm_medium=feed,Novartis’s Financial Guidance and Priorities for 2017
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Solid Gain On Bank Strength,2017-02-03 12:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sCMoQ-z62dA/the-swiss-stock-market-finished-with-a-solid-gain-on-bank-strength-20170203-00743,The Swiss Stock Market Finished With A Solid Gain On Bank Strength
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Votubia Gets EU Approval for Label Expansion,2017-02-02 16:36:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kYyoU68Imvg/novartis-nvs-votubia-gets-eu-approval-for-label-expansion-cm742209,Novartis AG NVS announced that the European Commission has approved its oncology drug Votubia dispersible tablets as an adjunctive treatment for patients aged two years and older whose refractory partial onset seizures with or without secondary generalization are associated with
NVS,NVS:US,BBG000LYF3S8,Novartis’s Recent Developments,2017-02-02 15:37:00 +0000,http://marketrealist.com/2017/02/novartiss-recent-developments/?utm_source=yahoo&utm_medium=feed,Novartis’s Recent Developments
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Votubia Gets EU Approval for Label Expansion,2017-02-02 14:49:02 +0000,http://finance.yahoo.com/news/novartis-nvs-votubia-gets-eu-144902526.html,Novartis (NVS) Votubia Gets EU Approval for Label Expansion
NVS,NVS:US,BBG000LYF3S8,Novartis a Top Ranked SAFE Dividend Stock With 3.7% Yield (NVS),2017-02-02 14:33:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a3PsiBQOibI/novartis-a-top-ranked-safe-dividend-stock-with-37-yield-nvs-cm741999,Novartis Symbol NVS has been named to the Dividend Channel International S A F E 10 list signifying an international stock with above average DividendRank statistics including a strong 3 7 yield as well as a superb track record of at least five years of dividend growth
NVS,NVS:US,BBG000LYF3S8,Inside Novartis’s Eye Care Performance in 4Q16,2017-02-02 14:07:08 +0000,http://marketrealist.com/2017/02/inside-novartiss-eye-care-performance-in-4q16/?utm_source=yahoo&utm_medium=feed,Inside Novartis’s Eye Care Performance in 4Q16
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline (GSK) Q4 Earnings: What's in the Cards?,2017-02-02 13:34:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VuCl5k6L758/glaxosmithkline-gsk-q4-earnings-whats-in-the-cards-cm741985,GlaxoSmithKline plc GSK is scheduled to report fourth quarter 2016 and full year results on Feb 8 Last quarter the company delivered a positive earnings surprise of 7 79 Glaxo s share price was up 2 4 this year so far outperforming the 0 6 decline witnessed by the Zacks
NVS,NVS:US,BBG000LYF3S8,Inside Novartis’s Generics Performance in 4Q16,2017-02-02 12:37:51 +0000,http://marketrealist.com/2017/02/inside-novartiss-generics-performance-in-4q16/?utm_source=yahoo&utm_medium=feed,Inside Novartis’s Generics Performance in 4Q16
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell After Bank And Pharma Stocks Weakened,2017-02-02 12:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bw4-1ULkdHo/the-swiss-stock-market-fell-after-bank-and-pharma-stocks-weakened-20170202-01189,The Swiss Stock Market Fell After Bank And Pharma Stocks Weakened
NVS,NVS:US,BBG000LYF3S8,Are Teva Pharmaceutical's Best Days Behind It?,2017-02-01 23:32:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BE_s28LAP2A/are-teva-pharmaceuticals-best-days-behind-it-cm741902,After losing a patent challenge in U S District Court it s become increasingly likely that Teva Pharmaceutical Industries NYSE TEVA top selling Copaxone will face generic competition soon Since Copaxone accounts for 16 of Teva Pharmaceutical s sales and over 40 of its
NVS,NVS:US,BBG000LYF3S8,Novartis Has Bright Future,2017-02-01 22:20:46 +0000,http://finance.yahoo.com/news/novartis-bright-future-222046258.html,Novartis Has Bright Future
NVS,NVS:US,BBG000LYF3S8,Novartis’s Innovative Medicines Segment in 4Q16,2017-02-01 21:35:43 +0000,http://marketrealist.com/2017/02/novartiss-innovative-medicines-segment-in-4q16/?utm_source=yahoo&utm_medium=feed,Novartis’s Innovative Medicines Segment in 4Q16
NVS,NVS:US,BBG000LYF3S8,Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16,2017-02-01 20:05:43 +0000,http://marketrealist.com/2017/02/weighing-the-foreign-exchange-impact-on-novartiss-revenues-in-4q16/?utm_source=yahoo&utm_medium=feed,Weighing the Foreign Exchange Impact on Novartis’s Revenues in 4Q16
NVS,NVS:US,BBG000LYF3S8,Novartis’s 4Q16 Earnings Meet Analysts’ Estimates,2017-02-01 18:19:39 +0000,http://marketrealist.com/2017/02/novartiss-4q16-earnings-meet-analysts-estimates/?utm_source=yahoo&utm_medium=feed,Novartis’s 4Q16 Earnings Meet Analysts’ Estimates
NVS,NVS:US,BBG000LYF3S8,Momenta Says District of Delaware Invalidates Teva's MS Drug,2017-02-01 17:34:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ki_5fxc60Ok/momenta-says-district-of-delaware-invalidates-tevas-ms-drug-cm741652,Shares of Momenta Pharmaceuticals Inc MNTA shot up 25 2 after Mylan N V MYL announced that the U S District Court for the District of Delaware has issued a decision in favor of the latter pertaining to claims related to Teva Pharmaceutical s TEVA Copaxone 40mg mL This news is a
NVS,NVS:US,BBG000LYF3S8,"Notable ETF Inflow Detected - VEU, NSRGY, NVS, TM",2017-02-01 17:33:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZasMX82fidc/notable-etf-inflow-detected-veu-nsrgy-nvs-tm-cm741651,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 192 8 million dollar inflow that s a 1 2 increase week over week
NVS,NVS:US,BBG000LYF3S8,Roche CEO Shrugs Off Trump's Drug Stance; 2016 Sales Narrowly Miss,2017-02-01 17:24:31 +0000,http://www.investors.com/news/technology/roche-ceo-shrugs-off-trumps-drug-stance-2016-sales-narrowly-miss/,Roche CEO Shrugs Off Trump's Drug Stance; 2016 Sales Narrowly Miss
NVS,NVS:US,BBG000LYF3S8,Waltham-based cancer drug firm Cerulean Pharma may seek a buyer,2017-02-01 16:20:10 +0000,http://www.bizjournals.com/boston/news/2017/02/01/waltham-based-cancer-drug-firm-cerulean-pharma-may.html?ana=yahoo,Waltham-based cancer drug firm Cerulean Pharma may seek a buyer
NVS,NVS:US,BBG000LYF3S8,Drug Stocks Rally on Trump Meet with Pharma Bigwigs,2017-02-01 13:33:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QhqKQpny0z4/drug-stocks-rally-on-trump-meet-with-pharma-bigwigs-cm741361,Pharma and biotech shares rallied yesterday following a meeting between President Donald Trump and industry leaders including CEOs of companies like Merck amp Co Inc MRK Johnson amp Johnson JNJ Novartis AG NVS Celgene Corporation CELG Eli Lilly and Company LLY and Amgen
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Staged A Recovery As Roche Jumped,2017-02-01 12:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hIwl2i6I91s/the-swiss-stock-market-staged-a-recovery-as-roche-jumped-20170201-01107,The Swiss Stock Market Staged A Recovery As Roche Jumped
NVS,NVS:US,BBG000LYF3S8,Drug Stocks Rally on Trump Meet with Pharma Bigwigs,2017-02-01 12:14:12 +0000,http://finance.yahoo.com/news/drug-stocks-rally-trump-meet-121412868.html,Drug Stocks Rally on Trump Meet with Pharma Bigwigs
NVS,NVS:US,BBG000LYF3S8,Stock Market Roundup Jan. 31: Nasdaq Rebounds Amid Trump Biotech Meeting,2017-02-01 00:32:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8ylRTnemhSM/stock-market-roundup-jan-31-nasdaq-rebounds-amid-trump-biotech-meeting-cm741228,Following the trend set yesterday U S stocks closed mostly lower on Tuesday but still managed to record monthly gains Investors continue to weigh the latest policies from the Trump Administration as well as companies results from the current earnings season The Nasdaq however bounced
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of The Day: MNTA, BLCM, VSAR, TENX, DMTX...",2017-01-31 23:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VCATEAIBluI/gainers--losers-of-the-day-mnta-blcm-vsar-tenx-dmtx-20170131-01699,"Gainers & Losers Of The Day: MNTA, BLCM, VSAR, TENX, DMTX..."
NVS,NVS:US,BBG000LYF3S8,Biotech Stocks Gain on Latest Trump Drug Price Statements,2017-01-31 20:30:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zgx7TDxcRYs/biotech-stocks-gain-on-latest-trump-drug-price-statements-cm741065,It has been a rocky start for the Trump administration whose controversial decisions on immigration and refugees have already led to worldwide protests and clashes with leadership from both parties Nevertheless President Trump continues to double down on his campaign promises and his
NVS,NVS:US,BBG000LYF3S8,"Why Momenta Pharmaceuticals, Inc. Stock Skyrocketed Higher Today",2017-01-31 19:33:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3VdNbzq2O3E/why-momenta-pharmaceuticals-inc-stock-skyrocketed-higher-today-cm741050,Image source Getty Images What happened Shares of Momenta Pharmaceuticals NASDAQ MNTA 160 are up over 20 at 12 28 p m EST after the company announced that the U S District Court invalidated four of Teva Pharmaceutical s NYSE TEVA patents on the three times
NVS,NVS:US,BBG000LYF3S8,"Why Momenta Pharmaceuticals, Inc. Stock Skyrocketed Higher Today",2017-01-31 18:03:40 +0000,http://www.fool.com/investing/2017/01/31/why-momenta-pharmaceuticals-inc-skyrocketed-higher.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Momenta Pharmaceuticals, Inc. Stock Skyrocketed Higher Today"
NVS,NVS:US,BBG000LYF3S8,Novartis Considers Alcon Spin-Off,2017-01-31 16:47:00 +0000,http://www.forbes.com/sites/joecornell/2017/01/31/novartis-considers-alcon-spin-off/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Novartis Considers Alcon Spin-Off
NVS,NVS:US,BBG000LYF3S8,Incyte and Calithera Enter into Deal for Oncology Candidate,2017-01-31 16:34:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TY1o_SUpnAw/incyte-and-calithera-enter-into-deal-for-oncology-candidate-cm740811,Incyte Corporation INCY and Calithera Biosciences Inc CALA entered into a global collaboration and license agreement for research development and commercialization of the latter s arginase inhibitor candidate CB 1158 in the fields of hematology
NVS,NVS:US,BBG000LYF3S8,Novartis Anti-Seizure Drug Votubia Wins EU Nod,2017-01-31 16:20:00 +0000,http://www.investopedia.com/news/novartis-votubia-drug-gets-eu-approval-nvs/?partner=YahooSA,Novartis Anti-Seizure Drug Votubia Wins EU Nod
NVS,NVS:US,BBG000LYF3S8,"Trump pushes drugmakers for lower prices, more U.S. production",2017-01-31 15:33:03 +0000,http://finance.yahoo.com/news/trump-meet-novartis-ceo-other-121027538.html,"[Reuters] - U.S. President Donald Trump on Tuesday called on the pharmaceutical industry to boost U.S. production and lower prices, while also vowing to speed up approval times for new medicines and appoint a new U.S. Food and Drug Administration leader soon. Shares of five of the six drug companies at the White House meeting with Trump were up more than 1 percent on average following the president's remarks, compared with a 0.5 percent drop in the broad S&P 500. The Nasdaq Biotech Index was up 1.1 percent, reversing earlier losses, and the S&P 500 health care index gained 0.7 percent."
NVS,NVS:US,BBG000LYF3S8,Incyte and Calithera Enter into Deal for Oncology Candidate,2017-01-31 14:55:02 +0000,http://finance.yahoo.com/news/incyte-calithera-enter-deal-oncology-145502787.html,Incyte and Calithera Enter into Deal for Oncology Candidate
NVS,NVS:US,BBG000LYF3S8,"Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for February 01, 2017",2017-01-31 14:12:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3Y9VZN4wAXY/pfizer-inc-pfe-ex-dividend-date-scheduled-for-february-01-2017-cm740692,Pfizer Inc PFE will begin trading ex dividend on February 01 2017 A cash dividend payment of 0 32 per share is scheduled to be paid on March 01 2017 Shareholders who purchased PFE prior to the ex dividend date are eligible for the cash dividend payment This represents an 6 67
NVS,NVS:US,BBG000LYF3S8,15 Best Short-Term Stock Investments,2017-01-31 13:17:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J20kcOEkXyI/15-best-short-term-stock-investments-cm740619,"As any stock trader can tell you, the market can be volatile. That's why investment professionals typically recommend investors take a long-term approach to investing to reduce the risk of losing principal. If you invest at the wrong time, you could lose a significant amount of your money overnight, so keep in mind"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pared Its Early Gains And Finished With A Loss,2017-01-31 12:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QzS20DwJOd0/the-swiss-stock-market-pared-its-early-gains-and-finished-with-a-loss-20170131-01090,The Swiss Stock Market Pared Its Early Gains And Finished With A Loss
NVS,NVS:US,BBG000LYF3S8,Novartis CEO to meet Trump along other drug industry executives,2017-01-31 10:45:18 +0000,http://finance.yahoo.com/news/novartis-ceo-meet-trump-along-104518506.html,"[Reuters] - Novartis (NOVN.S) Chief Executive Joe Jimenez will meet President Donald Trump on Tuesday with other drug industry executives after the U.S. leader said pharmaceuticals companies were ""getting away with murder"" on drug prices the government pays. Jimenez, who is the president-elect of the PhRMA drug industry group, will be joined by chief executives from other member companies at the meeting at the White House, Swiss group Novartis said in an email."
NVS,NVS:US,BBG000LYF3S8,Novartis CEO to meet Trump along other drug industry execs,2017-01-31 10:41:09 +0000,http://finance.yahoo.com/news/novartis-ceo-meet-trump-along-104109399.html,"[Reuters] - Novartis Chief Executive Joe Jimenez will meet President Donald Trump on Tuesday with other drug industry executives after the U.S. leader said pharmaceuticals companies were ""getting away with murder"" on drug prices the government pays. Jimenez, who is the president-elect of the PhRMA drug industry group, will be joined by chief executives from other member companies at the meeting at the White House, Swiss group Novartis said in an email."
NVS,NVS:US,BBG000LYF3S8,"AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch",2017-01-31 03:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gUAgYE_P7wI/aezs-inches-closer-to-dday-eyeg-catches-investors-eyes-mcrb-on-watch-20170131-00111,"AEZS Inches Closer To D-Day, EYEG Catches Investors' Eyes, MCRB On Watch"
NVS,NVS:US,BBG000LYF3S8,"I-O Players Incyte, Roche Squeeze Array's Melanoma Market: Leerink",2017-01-30 21:32:30 +0000,http://www.investors.com/news/technology/i-o-players-incyte-roche-squeeze-arrays-melanoma-market-leerink/,"I-O Players Incyte, Roche Squeeze Array's Melanoma Market: Leerink"
NVS,NVS:US,BBG000LYF3S8,"Regeneron, Sanofi Could Appease LDL-Frustrated Buyers On Eczema Drug",2017-01-30 21:18:52 +0000,http://www.investors.com/news/technology/regeneron-sanofi-could-appease-ldl-frustrated-buyers-on-eczema-drug/,"Regeneron, Sanofi Could Appease LDL-Frustrated Buyers On Eczema Drug"
NVS,NVS:US,BBG000LYF3S8,Novartis Withdraws Amgen Biosimilar Application,2017-01-30 20:12:00 +0000,http://www.investopedia.com/news/novartis-pulls-application-amgen-biosimilar-nvs-amgn/?partner=YahooSA,Novartis Withdraws Amgen Biosimilar Application
NVS,NVS:US,BBG000LYF3S8,Broker Darlings of the Dow: Pfizer Ranks As a Top 15 Analyst Pick,2017-01-30 18:31:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L96T7i0jK_Y/broker-darlings-of-the-dow-pfizer-ranks-as-a-top-15-analyst-pick-cm740310,A study of analyst recommendations at the major brokerages shows that Pfizer Inc Symbol PFE is the 11 broker pick on average out of the 30 stocks making up the Dow Jones Industrial Average according to ETF Channel Pfizer Inc also comes in above the median of analyst picks among
NVS,NVS:US,BBG000LYF3S8,Amgen Wins Favorable CHMP Opinion for Humira Biosimilar,2017-01-30 14:35:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fEbG7xxDhU0/amgen-wins-favorable-chmp-opinion-for-humira-biosimilar-cm739985,Amgen Inc AMGN announced that the European Medicines Agency s EMA Committee for Medicinal Products for Human Use CHMP has rendered a positive opinion on the company s marketing authorization application MAA for ABP 501 a biosimilar version of AbbVie Inc s ABBV best selling drug
NVS,NVS:US,BBG000LYF3S8,Exploring JNJ’s 2017 Profitability and Financial Guidance,2017-01-30 14:06:06 +0000,http://marketrealist.com/2017/01/exploring-jnjs-2017-profitability-and-financial-guidance/?utm_source=yahoo&utm_medium=feed,Exploring JNJ’s 2017 Profitability and Financial Guidance
NVS,NVS:US,BBG000LYF3S8,Amgen Wins Favorable CHMP Opinion for Humira Biosimilar,2017-01-30 12:34:12 +0000,http://finance.yahoo.com/news/amgen-wins-favorable-chmp-opinion-123412462.html,Amgen Wins Favorable CHMP Opinion for Humira Biosimilar
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped On Concerns Over Trump's Travel Ban,2017-01-30 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z80ja9MykTA/the-swiss-stock-market-dropped-on-concerns-over-trumps-travel-ban-20170130-00839,The Swiss Stock Market Dropped On Concerns Over Trump's Travel Ban
NVS,NVS:US,BBG000LYF3S8,Novartis Signals Growing Ambitions for CAR-T Cancer Treatments,2017-01-30 06:00:20 +0000,http://www.bloomberg.com/news/articles/2017-01-30/novartis-signals-growing-ambitions-for-car-t-cancer-treatments?cmpid=yhoo.headline,Novartis Signals Growing Ambitions for CAR-T Cancer Treatments
NVS,NVS:US,BBG000LYF3S8,Guess Who Can't Wait for Trumpcare? (Hint: It's Not the Consumer),2017-01-29 14:31:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zdEdySDFQMU/guess-who-cant-wait-for-trumpcare-hint-its-not-the-consumer-cm739860,Image source White House Flickr It s official Donald Trump is now in the Oval Office as the 45th President of the United States and now former President Barack Obama s signature healthcare plan the Affordable Care Act ACA is living on borrowed time Obamacare never
NVS,NVS:US,BBG000LYF3S8,Guess Who Can't Wait for Trumpcare? (Hint: It's Not the Consumer),2017-01-29 13:08:05 +0000,http://www.fool.com/investing/2017/01/29/guess-who-cant-wait-for-trumpcare-hint-its-not-the.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Guess Who Can't Wait for Trumpcare? (Hint: It's Not the Consumer)
NVS,NVS:US,BBG000LYF3S8,"Amgen, Inc.: Capture Stronger Upside in AMGN Stock",2017-01-27 20:33:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VrqEJICmwzA/amgen-inc-capture-stronger-upside-in-amgn-stock-cm739618,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips No doubt Amgen Inc NASDAQ AMGN has its share of challenges both off and on the price chart But as is often the case opportunities and value may also exist Let
NVS,NVS:US,BBG000LYF3S8,"Amgen, Inc. (AMGN) Stock Is a Bet on Fatter Yields",2017-01-27 14:34:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vBBFIGTLTK8/amgen-inc-amgn-stock-is-a-bet-on-fatter-yields-cm739294,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Amgen Inc NASDAQ AMGN the largest of the so called biotech stocks is a very fat company with enormous margins and middling growth Source Richard Masoner via Flickr It is the kind of
NVS,NVS:US,BBG000LYF3S8,"Pre-Market Most Active for Jan 27, 2017 :  MSFT, NVS, AZN, PCG, AUPH, HZN, PHG, CL, SBUX, AAL, INTC, FB",2017-01-27 13:51:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IxqMfbBMfWA/pre-market-most-active-for-jan-27-2017-msft-nvs-azn-pcg-auph-hzn-phg-cl-sbux-aal-intc-fb-cm739188,The NASDAQ 100 Pre Market Indicator is up 9 to 5 157 82 The total Pre Market volume is currently 4 701 761 shares traded The following are the most active stocks for the pre market session Microsoft Corporation MSFT is 0 91 at 65 18 with 497 598 shares
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Declined After Weak Report From UBS,2017-01-27 12:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-1f0xJjAcsQ/the-swiss-stock-market-declined-after-weak-report-from-ubs-20170127-00717,The Swiss Stock Market Declined After Weak Report From UBS
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Declined After Weak Report From UBS,2017-01-27 12:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EddqWymYpdM/the-swiss-stock-market-declined-after-weak-report-from-ubs-20170127-00718,The Swiss Stock Market Declined After Weak Report From UBS
NVS,NVS:US,BBG000LYF3S8,Johnson & Johnson (JNJ) Stock Could Win BIG After Actelion Purchase,2017-01-26 19:33:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CSnEqMkSOiY/johnson-johnson-jnj-stock-could-win-big-after-actelion-purchase-cm738940,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Johnson amp Johnson NYSE JNJ shares shot down 160 down about 2 in early morning trading after it announced it will pay about 30 billion for Actelion Ltd 160 OTCMKTS ALIOF makers
NVS,NVS:US,BBG000LYF3S8,Moody's puts Novartis on notice over debt-funded buyback plan,2017-01-26 17:52:14 +0000,http://finance.yahoo.com/news/moodys-puts-novartis-notice-over-175214002.html,"[Reuters] - Moody's cut Novartis's debt rating outlook on Thursday to negative from stable, saying the Swiss drugmaker's borrowing capacity would be weakened by its debt-financed share buyback at a time of stagnating sales. While affirming Novartis' Aa3 long-term ratings, Moody's analysts wrote the proposed buyback ""puts further strain on the company's credit metrics, which were already weak for the Aa3 rating category prior to the announcement"". ""The buyback is well in excess of the company's free cash flow ... and will weaken the company's credit metrics over the next 12 months during a period where the company expects sales to be broadly in line with 2016,"" wrote analyst Knut Slatten."
NVS,NVS:US,BBG000LYF3S8,Amgen’s Enbrel Safe from Copycat Challenge for Now,2017-01-26 16:23:00 +0000,http://www.investopedia.com/news/legal-battles-delay-enbrel-biosimilar-amgn-nvs/?partner=YahooSA,Amgen’s Enbrel Safe from Copycat Challenge for Now
NVS,NVS:US,BBG000LYF3S8,Novartis AG -- Moody's changes outlook on Novartis' Aa3 rating to negative on share buy backs announcement; affirms ratings,2017-01-26 16:14:02 +0000,http://www.moodys.com/page/viewresearchdoc.aspx?docid=PR_361212&WT.mc_id=AM~WWFob29fRmluYW5jZTQyX1NCX1JhdGluZyBOZXdzX0FsbF9Fbmc=~20170126_PR_361212,Novartis AG -- Moody's changes outlook on Novartis' Aa3 rating to negative on share buy backs announcement; affirms ratings
NVS,NVS:US,BBG000LYF3S8,11 Largest Pharmaceutical Companies In The World,2017-01-26 14:28:39 +0000,http://www.insidermonkey.com/blog/11-largest-pharmaceutical-companies-in-the-world-523960/,11 Largest Pharmaceutical Companies In The World
NVS,NVS:US,BBG000LYF3S8,Blog Coverage Novartis Announced Buyback of Shares Worth $5 Billion; Considers Strategic Options for Alcon Division,2017-01-26 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-novartis-announced-buyback-131500290.html,"[Accesswire] - Upcoming AWS Coverage on Zogenix LONDON, UK / ACCESSWIRE / January 26, 2017 / Active Wall St. blog coverage looks at the headline from Swiss pharma major Novartis AG (NYSE: NVS ) as the Company announced ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Up After Long Awaited Actelion Deal Reached,2017-01-26 12:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XKNuOl-MGGw/the-swiss-stock-market-finished-up-after-long-awaited-actelion-deal-reached-20170126-01158,The Swiss Stock Market Finished Up After Long Awaited Actelion Deal Reached
NVS,NVS:US,BBG000LYF3S8,"GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000",2017-01-26 11:02:00 +0000,https://www.thestreet.com/story/13967133/1/gm-nike-microsoft-are-hot-now-that-dow-has-hit-20-000.html?puc=yahoo&cm_ven=YAHOO,"GM, Nike, Microsoft Are Hot Now That Dow Has Hit 20,000"
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis Weighs Spinoff of Alcon Eye-Care Business,2017-01-26 05:48:36 +0000,http://www.wsj.com/articles/novartis-announces-share-buyback-as-dollar-hits-earnings-1485325279?ru=yahoo?mod=yahoo_itp,[$$] Novartis Weighs Spinoff of Alcon Eye-Care Business
NVS,NVS:US,BBG000LYF3S8,"Close Update: Dow Crosses Over 20,000 Milestone As Stocks Rally Behind Trump's Infrastructure Plans",2017-01-25 21:50:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zKX7po1oXEM/close-update-dow-crosses-over-20000-milestone-as-stocks-rally-behind-trumps-infrastructure-plans-cm738338,The three benchmark averages all closed at record highs Wednesday as positive earnings and recent efforts by President Trump to advance infrastructure spending rekindled the Trump rally and drove the Dow Jones Industrial Average through the 20 000 milestone The three benchmark averages all
NVS,NVS:US,BBG000LYF3S8,Lilly's Elanco Unit & Aratana Launch Veterinary Pain Drug,2017-01-25 21:30:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Exl7mazC7A8/lillys-elanco-unit-aratana-launch-veterinary-pain-drug-cm738292,Eli Lilly and Company s LLY animal health subsidiary Elanco and partner Aratana Therapeutics Inc PETX together announced the availability of a new drug Galliprant grapiprant tablets to the veterinarians for the management of pain and inflammation associated with canine
NVS,NVS:US,BBG000LYF3S8,Incyte Gets $112 Million Boost On Novartis Jakavi Royalties: RBC,2017-01-25 21:21:25 +0000,http://www.investors.com/news/technology/incyte-gets-112-million-boost-on-novartis-jakavi-royalties-rbc/,Incyte Gets $112 Million Boost On Novartis Jakavi Royalties: RBC
NVS,NVS:US,BBG000LYF3S8,Why Eli Lilly Expects to See Revenue Growth in 4Q16,2017-01-25 17:05:53 +0000,http://marketrealist.com/2017/01/why-eli-lilly-expects-to-see-revenue-growth-in-4q16/?utm_source=yahoo&utm_medium=feed,Why Eli Lilly Expects to See Revenue Growth in 4Q16
NVS,NVS:US,BBG000LYF3S8,European markets close higher on earnings; Logitech up 15%; Deutsche Bank rises 5%,2017-01-25 16:52:56 +0000,http://www.cnbc.com/id/104238834?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104238834,[at CNBC] - European markets closed higher on Wednesday as investors took cues from overseas markets and digested fresh earnings reports.
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis: buying time,2017-01-25 16:30:44 +0000,"http://www.ft.com/cms/s/84f94c14-e2fb-11e6-9645-c9357a75844a,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - The name Novartis comes from the Latin for ""new arts"". Buying back shares, as the company pledged to do on Wednesday, is a earnings-enhancing trick that is as old as the hills. But those chiding ..."
NVS,NVS:US,BBG000LYF3S8,Novartis May Spin Off Struggling Alcon Eye Unit,2017-01-25 15:48:00 +0000,http://www.investopedia.com/news/novartis-may-spin-alcon-eye-care-unit-nvs/?partner=YahooSA,Novartis May Spin Off Struggling Alcon Eye Unit
NVS,NVS:US,BBG000LYF3S8,"Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon",2017-01-25 15:36:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6ECH7vYDmao/novartis-nvs-beats-q4-earnings-might-spin-off-alcon-cm737921,Novartis AG NVS reported fourth quarter 2016 core earnings of 1 12 per share above the Zacks Consensus Estimate of 1 09 but below than the year ago figure of 1 14 Revenues declined 2 to 12 3 billion and were marginally below the Zacks Consensus Estimate of 12 4 billion as volume
NVS,NVS:US,BBG000LYF3S8,Novartis Tries to Cure Its Eye Strain,2017-01-25 15:20:59 +0000,http://www.bloomberg.com/gadfly/articles/2017-01-25/novartis-eyes-up-a-different-future?cmpid=yhoo.headline,Novartis Tries to Cure Its Eye Strain
NVS,NVS:US,BBG000LYF3S8,Wall Street Resumes Trump-Rally Driving Dow Within Striking Distance of 20K,2017-01-25 14:32:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FY39hxBfILk/wall-street-resumes-trump-rally-driving-dow-within-striking-distance-of-20k-cm737829,Stock futures were building on Tuesday s gains setting the Dow Jones Industrial Average up to finally hit 20 000 after the open Stock futures were building on Tuesday s gains setting the Dow Jones Industrial Average up to finally hit 20 000 after the open The Trump rally was rekindled on
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis launches $5bn share buyback as it eyes Alcon spin-off,2017-01-25 14:30:31 +0000,"http://www.ft.com/cms/s/43471370-e2f4-11e6-9645-c9357a75844a,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Novartis expects a return to sales growth in 2018 after a ""difficult"" two years, its chief executive said as the Swiss drugmaker announced a $5bn share buyback and a possible spin-off of its ..."
NVS,NVS:US,BBG000LYF3S8,Behind Amgen’s Plans to Expand in Neuroscience in 2017,2017-01-25 14:07:50 +0000,http://marketrealist.com/2017/01/amgen-plans-expand-presence-neuroscience-segment-2017/?utm_source=yahoo&utm_medium=feed,Behind Amgen’s Plans to Expand in Neuroscience in 2017
NVS,NVS:US,BBG000LYF3S8,"Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon",2017-01-25 13:45:01 +0000,http://finance.yahoo.com/news/novartis-nvs-beats-q4-earnings-134501699.html,"Novartis (NVS) Beats Q4 Earnings, Might Spin-Off Alcon"
NVS,NVS:US,BBG000LYF3S8,Novartis says court battle will delay its Enbrel copy until 2018 at least,2017-01-25 12:43:40 +0000,http://sg.finance.yahoo.com/news/novartis-says-court-battle-delay-124340225.html,Novartis says court battle will delay its Enbrel copy until 2018 at least
NVS,NVS:US,BBG000LYF3S8,A Strong Performance By Novartis Provided A Boost To The Swiss Stock Market,2017-01-25 12:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pQyLv0skNlg/a-strong-performance-by-novartis-provided-a-boost-to-the-swiss-stock-market-20170125-00960,A Strong Performance By Novartis Provided A Boost To The Swiss Stock Market
NVS,NVS:US,BBG000LYF3S8,5 Things You Must Know Before the Market Opens Wednesday,2017-01-25 12:12:00 +0000,https://www.thestreet.com/story/13963107/1/5-things-you-must-know-before-the-market-opens-wednesday.html?puc=yahoo&cm_ven=YAHOO,5 Things You Must Know Before the Market Opens Wednesday
NVS,NVS:US,BBG000LYF3S8,European Markets Rallied Higher On Bank Strength,2017-01-25 12:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HkZ-ZEtoUWk/european-markets-rallied-higher-on-bank-strength-20170125-00930,European Markets Rallied Higher On Bank Strength
NVS,NVS:US,BBG000LYF3S8,"Novartis launches $5 billion share buyback, mulls Alcon spin-off",2017-01-25 11:32:53 +0000,http://sg.finance.yahoo.com/news/novartis-weighs-alcon-spinoff-launches-062857758.html,"Novartis launches $5 billion share buyback, mulls Alcon spin-off"
NVS,NVS:US,BBG000LYF3S8,"Novartis launches $5 bln share buyback, mulls Alcon spin-off",2017-01-25 11:30:57 +0000,http://finance.yahoo.com/news/novartis-considers-alcon-spin-off-074446015.html,"[Reuters] - Swiss drugmaker Novartis said on Wednesday it will buy back up to $5 billion worth of shares over the next 12 months and may spin off the Alcon eye care business as it navigates a tough year before an expected return to growth in 2018. The shares rose, as analysts said the debt-financed buyback and the prospect of action being taken over Alcon's chronic underperformance made up for the message that 2017 would be another year of stagnation for sales. The Swiss drugmaker has been trying to whip Alcon back into shape after conceding it had lost its innovative edge, but flat fourth-quarter sales and a $120 million operating loss has put the division's future under review again."
NVS,NVS:US,BBG000LYF3S8,"Alcon, Once Gem Worth Over $50 Billion, Weighs on Novartis",2017-01-25 10:59:16 +0000,http://www.bloomberg.com/news/articles/2017-01-25/alcon-goes-from-gem-worth-over-50-billion-to-drag-for-novartis?cmpid=yhoo.headline,"Alcon, Once Gem Worth Over $50 Billion, Weighs on Novartis"
NVS,NVS:US,BBG000LYF3S8,Novartis beats 4Q profit forecasts,2017-01-25 10:40:37 +0000,http://sg.finance.yahoo.com/news/novartis-beats-4q-profit-forecasts-104037470.html,Novartis beats 4Q profit forecasts
NVS,NVS:US,BBG000LYF3S8,Novartis to buy back $5 bn in shares,2017-01-25 08:58:04 +0000,http://uk.finance.yahoo.com/news/novartis-buy-back-5-bn-085804492.html,Novartis to buy back $5 bn in shares
NVS,NVS:US,BBG000LYF3S8,Drug firm Novartis mulls options for Alcon amid flat 4Q net,2017-01-25 08:24:11 +0000,http://sg.finance.yahoo.com/news/drug-firm-novartis-mulls-options-082406710.html,Drug firm Novartis mulls options for Alcon amid flat 4Q net
NVS,NVS:US,BBG000LYF3S8,Drug firm Novartis mulls options for Alcon amid flat 4Q net,2017-01-25 08:24:11 +0000,http://finance.yahoo.com/news/drug-firm-novartis-mulls-options-082406205.html,Drug firm Novartis mulls options for Alcon amid flat 4Q net
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis May Spin Off Alcon,2017-01-25 08:21:25 +0000,http://www.wsj.com/articles/novartis-announces-share-buyback-as-dollar-hits-earnings-1485325279?mod=yahoo_hs,[$$] Novartis May Spin Off Alcon
NVS,NVS:US,BBG000LYF3S8,"Novartis Misses Fourth-Quarter Earnings Estimate, Mulls Alcon Spinoff",2017-01-25 08:21:00 +0000,https://www.thestreet.com/story/13964920/1/novartis-misses-q4-earnings-estimate-mulls-alcon-spin-off.html?puc=yahoo&cm_ven=YAHOO,"Novartis Misses Fourth-Quarter Earnings Estimate, Mulls Alcon Spinoff"
NVS,NVS:US,BBG000LYF3S8,Novartis chases rivals with next wave of cancer immunotherapy,2017-01-25 08:16:01 +0000,http://finance.yahoo.com/news/novartis-chases-rivals-next-wave-081601655.html,"[Reuters] - Novartis, lagging some other big drugmakers in the first wave of immunotherapy drugs that are revolutionising cancer treatment, hopes to catch up by focusing on the next wave of immune system-boosting medicines. Setting out its research objectives in slides for a press conference on Wednesday, it said it aimed for ""a leadership position in oncology"" by focusing on second-generation immunotherapy. Merck & Co, Bristol-Myers Squibb and Roche are in the lead with cancer immunotherapies already on the market, but the field is developing fast and new treatments are expected to play an important role in drug cocktails."
NVS,NVS:US,BBG000LYF3S8,"Novartis CEO: ""The bigger the target, the higher the premium""",2017-01-25 08:11:03 +0000,http://sg.finance.yahoo.com/news/novartis-ceo-bigger-target-higher-081103788.html,"Novartis CEO: ""The bigger the target, the higher the premium"""
NVS,NVS:US,BBG000LYF3S8,"We’re looking at all options for struggling eye care business, says Novartis CEO",2017-01-25 07:42:52 +0000,http://www.cnbc.com/id/104238919?__source=yahoo%7cfinance%7cheadline%7cheadline%7cstory&par=yahoo&doc=104238919,"We’re looking at all options for struggling eye care business, says Novartis CEO"
NVS,NVS:US,BBG000LYF3S8,"Novartis Mulls Options Including Spinoff, IPO for Alcon Unit",2017-01-25 06:32:46 +0000,http://www.bloomberg.com/news/articles/2017-01-25/novartis-mulls-options-including-spinoff-ipo-for-eye-care-unit?cmpid=yhoo.headline,"Novartis Mulls Options Including Spinoff, IPO for Alcon Unit"
NVS,NVS:US,BBG000LYF3S8,"Novartis Mulls Options Including Spinoff, IPO for Eye-Care Unit",2017-01-25 06:32:46 +0000,http://finance.yahoo.com/news/novartis-mulls-options-including-spinoff-063246216.html,"Novartis Mulls Options Including Spinoff, IPO for Eye-Care Unit"
NVS,NVS:US,BBG000LYF3S8,Novartis CEO: There'll be more consolidation in sector to...,2017-01-25 06:09:00 +0000,http://finance.yahoo.com/video/novartis-ceo-therell-more-consolidation-060900516.html,Novartis CEO: There'll be more consolidation in sector to...
NVS,NVS:US,BBG000LYF3S8,Novartis: Looking at what’s best for shareholders on Alco...,2017-01-25 06:09:00 +0000,http://finance.yahoo.com/video/novartis-looking-best-shareholders-alco-060900756.html,Novartis: Looking at what’s best for shareholders on Alco...
NVS,NVS:US,BBG000LYF3S8,Novartis Profit Dips; Plans $5 Bln Buyback; Mulls Options For Alcon; Stock Up,2017-01-25 04:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jF3nexgq3os/novartis-profit-dips-plans-5-bln-buyback-mulls-options-for-alcon-stock-up-20170125-00158,Novartis Profit Dips; Plans $5 Bln Buyback; Mulls Options For Alcon; Stock Up
NVS,NVS:US,BBG000LYF3S8,European Shares Rally On Growth Optimism,2017-01-25 04:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Knt23LTXk3o/european-shares-rally-on-growth-optimism-20170125-00146,European Shares Rally On Growth Optimism
NVS,NVS:US,BBG000LYF3S8,Novartis Q4 Profit Declines; To Buy Back Up To $5 Bln In Shares  - Quick Facts,2017-01-25 01:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_DLetg55trw/novartis-q4-profit-declines-to-buy-back-up-to-5-bln-in-shares---quick-facts-20170125-00026,Novartis Q4 Profit Declines; To Buy Back Up To $5 Bln In Shares  - Quick Facts
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of The Day: GNVC, NVIV, CLRB. AQB, BIOA...",2017-01-25 00:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7IkfIqdddxg/gainers--losers-of-the-day-gnvc-nviv-clrb-aqb-bioa-20170125-00009,"Gainers & Losers Of The Day: GNVC, NVIV, CLRB. AQB, BIOA..."
NVS,NVS:US,BBG000LYF3S8,"Pre-Market Earnings Report for January 25, 2017 :  BA, UTX, ABT, ITW, NSC, STT, TEL, FCX, NVS, PGR, APH, HES",2017-01-24 21:20:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O2Q4cB6LUTI/pre-market-earnings-report-for-january-25-2017-ba-utx-abt-itw-nsc-stt-tel-fcx-nvs-pgr-aph-hes-cm737620,The following companies are expected to report earnings prior to market open on 01 25 2017 Visit our Earnings Calendar for a full list of expected earnings releases Boeing Company BA is reporting for the quarter ending December 31 2016 The aerospace
NVS,NVS:US,BBG000LYF3S8,Recent Developments at Novartis,2017-01-24 14:06:12 +0000,http://marketrealist.com/2017/01/recent-developments-at-novartis/?utm_source=yahoo&utm_medium=feed,Recent Developments at Novartis
NVS,NVS:US,BBG000LYF3S8,Bristol-Myers Squibb’s 4Q16 Estimates: Expect Growth!,2017-01-24 12:38:33 +0000,http://marketrealist.com/2017/01/bristol-myers-squibbs-4q16-estimates-expect-growth/?utm_source=yahoo&utm_medium=feed,Bristol-Myers Squibb’s 4Q16 Estimates: Expect Growth!
NVS,NVS:US,BBG000LYF3S8,Novartis’s 4Q16 Estimates: Expectations from Alcon,2017-01-24 12:36:28 +0000,http://marketrealist.com/2017/01/novartiss-4q16-estimates-expectations-from-alcon/?utm_source=yahoo&utm_medium=feed,Novartis’s 4Q16 Estimates: Expectations from Alcon
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Small Gain - Aryzta In Focus,2017-01-24 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fOHji51iRck/the-swiss-stock-market-finished-with-a-small-gain--aryzta-in-focus-20170124-01021,The Swiss Stock Market Finished With A Small Gain - Aryzta In Focus
NVS,NVS:US,BBG000LYF3S8,Incyte Has Insight Into Market With Potential Blockbuster Drugs,2017-01-23 22:31:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aNJsNL6Dqnc/incyte-has-insight-into-market-with-potential-blockbuster-drugs-cm736068,The biotech industry has a mixed outlook for 2017 with few new drugs coming to market this year but midcap Incyte INCY is one of the few companies with potential blockbusters in its pipeline Incyte closed out 2016 and started 2017 with some major developments The
NVS,NVS:US,BBG000LYF3S8,"Better Buy: Exelixis, Inc. vs. Novartis",2017-01-23 22:27:21 +0000,http://www.fool.com/investing/2017/01/23/better-buy-exelixis-inc-vs-novartis.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Exelixis, Inc. vs. Novartis"
NVS,NVS:US,BBG000LYF3S8,"Better Buy: Exelixis, Inc. vs. Novartis",2017-01-23 18:33:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tP4xP9L8oJI/better-buy-exelixis-inc-vs-novartis-cm736868,Last year Exelixis Inc NASDAQ EXEL was one of the best performing stocks in biotech notching a 164 gain With essentially one drug driving growth though it looks a bit risky Conversely shares of the diverse pharma giant Novartis NYSE NVS sank about 15 last year Yet
NVS,NVS:US,BBG000LYF3S8,Novartis’s 4Q16 Estimates: How Could Sandoz Perform?,2017-01-23 15:37:05 +0000,http://marketrealist.com/2017/01/novartiss-4q16-estimates-how-could-sandoz-perform/?utm_source=yahoo&utm_medium=feed,Novartis’s 4Q16 Estimates: How Could Sandoz Perform?
NVS,NVS:US,BBG000LYF3S8,Novartis’s 4Q16 Estimates: Innovative Medicines Segment,2017-01-23 14:07:46 +0000,http://marketrealist.com/2017/01/novartiss-4q16-estimates-innovative-medicines-segment/?utm_source=yahoo&utm_medium=feed,Novartis’s 4Q16 Estimates: Innovative Medicines Segment
NVS,NVS:US,BBG000LYF3S8,Analysts Expect Negative Growth for Novartis in 4Q16,2017-01-23 12:38:52 +0000,http://marketrealist.com/2017/01/analysts-expect-negative-growth-for-novartis-in-4q16/?utm_source=yahoo&utm_medium=feed,Analysts Expect Negative Growth for Novartis in 4Q16
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell As Bank And Pharma Stocks Struggled,2017-01-23 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7fanRw62bWs/the-swiss-stock-market-fell-as-bank-and-pharma-stocks-struggled-20170123-00903,The Swiss Stock Market Fell As Bank And Pharma Stocks Struggled
NVS,NVS:US,BBG000LYF3S8,"Burns Wealth Management, Inc. Buys Vanguard Total Bond Market, iShares Global Healthcare, ...",2017-01-21 15:36:30 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nxNwE9m--AM/burns-wealth-management-inc-buys-vanguard-total-bond-market-ishares-global-healthcare-cm736351,Burns Wealth Management Inc New Purchases BND PEY PFM SCHP AMZN IBB OGE PRFZ IYE INCY Added Positions IXJ NKE JCI PXD VBR CL PFE INTU MMM VZ Reduced Positions NVS VEA CHK UPRO T JWN AKRX ERX USB STI Sold Out FLR
NVS,NVS:US,BBG000LYF3S8,Novartis’s 4Q16 Earnings: What Is Expected?,2017-01-20 22:41:30 +0000,http://marketrealist.com/2017/01/novartiss-4q16-earnings-what-is-expected/?utm_source=yahoo&utm_medium=feed,Novartis’s 4Q16 Earnings: What Is Expected?
NVS,NVS:US,BBG000LYF3S8,Incyte Poised To Outperform Biotech Industry On Strong Pipeline,2017-01-20 22:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/y-pPosM2-7s/incyte-poised-to-outperform-biotech-industry-on-strong-pipeline-cm736068,The biotech industry has a mixed outlook for 2017 with few new drugs coming to market this year but midcap Incyte INCY is one of the few companies with potential blockbusters in its pipeline Incyte closed out 2016 and started 2017 with some major developments The
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?,2017-01-20 21:37:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/su_u7lvh8KE/novartis-nvs-q4-earnings-stock-likely-to-disappoint-cm736208,Swiss pharmaceutical company Novartis AG NVS is scheduled to report fourth quarter and full year 2016 results on Jan 25 A look at Novartis share price movement in the last 12 months shows that the stock has underperformed the Zacks classified Large Cap
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?,2017-01-20 19:52:07 +0000,http://finance.yahoo.com/news/novartis-nvs-q4-earnings-stock-195207259.html,Novartis (NVS) Q4 Earnings: Stock Likely to Disappoint?
NVS,NVS:US,BBG000LYF3S8,Are You Undervaluing These 3 Biopharmas' Pipelines?,2017-01-20 14:40:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VgOU1JyH6cI/are-you-undervaluing-these-3-biopharmas-pipelines-cm735869,Biopharma companies are continously investing in new development projects to offset the risks of competition and patent expirations but sometimes the nature of business landscape can keep investors from seeing opportunities that may be lurking in research and development pipelines
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Nearly Unchanged,2017-01-20 12:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FxtLbKkzBTI/the-swiss-stock-market-finished-nearly-unchanged-20170120-00643,The Swiss Stock Market Finished Nearly Unchanged
NVS,NVS:US,BBG000LYF3S8,Novartis CEO: Trump Understands Value of Drug Innovation,2017-01-20 07:15:04 +0000,http://www.bloomberg.com/news/videos/2017-01-20/novartis-ceo-trump-understands-value-of-drug-innovation?cmpid=yhoo.headline,Novartis CEO: Trump Understands Value of Drug Innovation
NVS,NVS:US,BBG000LYF3S8,European ADRs Edge Lower as Pharma Stocks See Mixed Fortunes,2017-01-19 16:17:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BBMEVJKiI_s/european-adrs-edge-lower-as-pharma-stocks-see-mixed-fortunes-cm735459,American depository receipts of European stocks were 0 5 lower at 121 75 on the Bank of New York Mellon Europe ADR Index on Thursday morning American depository receipts of European stocks were 0 5 lower at 121 75 on the Bank of New York Mellon Europe ADR Index on Thursday morning Decliners
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Slipped Below The 8,300 Point Level",2017-01-19 12:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_EGYyyFDpF8/the-swiss-stock-market-slipped-below-the-8300-point-level-20170119-01071,"The Swiss Stock Market Slipped Below The 8,300 Point Level"
NVS,NVS:US,BBG000LYF3S8,CSL shares jump on profit upgrade,2017-01-19 06:02:32 +0000,http://au.finance.yahoo.com/news/csl-shares-jump-profit-upgrade-060232223.html,"[AAP] - CSL shares have soared after the blood products giant unveiled a surprisingly big upgrade to its full-year profit guidance. The biotech company says it expects net profit for the 12 months to June 30 to grow between 18 per cent to 20 per cent on a constant currency basis. Pleased investors drove the company's share price up by $12.38, or 12.49 per cent, at $111.50 by the close on Thursday."
NVS,NVS:US,BBG000LYF3S8,CSL shares rally on profit guidance hike,2017-01-18 23:33:07 +0000,http://au.finance.yahoo.com/news/csl-shares-rally-profit-guidance-233307721.html,"[AAP] - CSL shares have jumped about 10 per cent after the blood products giant raised its full-year profit guidance following strong sales. After a likely first-half profit of about $US800 million ($A1.1 billion), CSL said on Thursday it expects net profit for the 12 months to June 30 to grow by between 18 and 20 per cent on a constant currency basis. At 1025 AEDT, CSL shares were up $9.66, or 9.7 per cent, to $108.78, having been as high as $109.82 against the backdrop of a higher Australian share market."
NVS,NVS:US,BBG000LYF3S8,Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug,2017-01-18 23:01:00 +0000,https://www.thestreet.com/story/13958340/1/mallinckrodt-hit-with-100m-fine-for-squelching-rival-to-infant-seizure-drug.html?puc=yahoo&cm_ven=YAHOO,Mallinckrodt Hit With $100M Fine for Squelching Rival to Infant Seizure Drug
NVS,NVS:US,BBG000LYF3S8,Mallinkrodt Shares Tank Despite $100 Million FTC Deal,2017-01-18 21:01:00 +0000,https://www.thestreet.com/story/13958250/1/mallinkrodt-reaches-100-million-settlement-with-ftc.html?puc=yahoo&cm_ven=YAHOO,Mallinkrodt Shares Tank Despite $100 Million FTC Deal
NVS,NVS:US,BBG000LYF3S8,"Mallinckrodt Dives, Rebounds, Retreats On FTC Drug Price Settlement",2017-01-18 20:49:35 +0000,http://www.investors.com/news/technology/mallinckrodt-dives-says-its-reached-ftc-drug-price-settlement/,"Mallinckrodt Dives, Rebounds, Retreats On FTC Drug Price Settlement"
NVS,NVS:US,BBG000LYF3S8,"Why the Amgen, Inc. (AMGN) Patent Case Is So Important",2017-01-18 19:38:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/huoYnl1_YEA/why-the-amgen-inc-amgn-patent-case-is-so-important-cm734969,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Good news for Amgen Inc NASDAQ AMGN shareholders or maybe it s bad news for anyone who owns AMGN stock Whatever the case the nation s judicial system is finally going to make legal sense of
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Slight Gain After Recent Weakness,2017-01-18 12:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5QArkvjG3lQ/the-swiss-stock-market-finished-with-a-slight-gain-after-recent-weakness-20170118-00939,The Swiss Stock Market Finished With A Slight Gain After Recent Weakness
NVS,NVS:US,BBG000LYF3S8,Novartis CEO Discusses Impact of Trump on Drug Industry,2017-01-18 11:56:48 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=44813E17-558E-4FD0-84CF-FA808783B1C0&siteid=yhoof2,Novartis CEO Discusses Impact of Trump on Drug Industry
NVS,NVS:US,BBG000LYF3S8,Trump tax cuts could mean more Novartis investment in U.S.,2017-01-18 09:29:31 +0000,http://sg.finance.yahoo.com/news/trump-tax-cuts-could-mean-092931589.html,Trump tax cuts could mean more Novartis investment in U.S.
NVS,NVS:US,BBG000LYF3S8,Trump tax cuts could mean more Novartis investment in U.S,2017-01-18 09:28:31 +0000,http://in.finance.yahoo.com/news/trump-tax-cuts-could-mean-092831767.html,Trump tax cuts could mean more Novartis investment in U.S
NVS,NVS:US,BBG000LYF3S8,5 Trump-Proof Pharma Dividend Stocks to Buy,2017-01-17 16:38:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/C0k6xbz5rvs/5-trump-proof-pharma-dividend-stocks-to-buy-cm734299,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Donald Trump needed just 20 minutes to knock 24 6 billion in value from the nine biggest Big Pharma companies That was the statistic bandied about recently when the president elect at
NVS,NVS:US,BBG000LYF3S8,Why Bristol-Myers Squibb May Be a Merger Target Soon,2017-01-17 14:59:00 +0000,https://www.thestreet.com/story/13955786/1/why-bristol-myers-squibb-may-be-a-merger-target-soon.html?puc=yahoo&cm_ven=YAHOO,Why Bristol-Myers Squibb May Be a Merger Target Soon
NVS,NVS:US,BBG000LYF3S8,"Pre-Market Most Active for Jan 17, 2017 :  RAI, BAC, VALE, NVS, TVIX, MS, XIV, NOK, QQQ, NFLX, FWP, ERIC",2017-01-17 13:56:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qUCClTDZWVo/pre-market-most-active-for-jan-17-2017-rai-bac-vale-nvs-tvix-ms-xiv-nok-qqq-nflx-fwp-eric-cm734084,The NASDAQ 100 Pre Market Indicator is down 5 89 to 5 053 62 The total Pre Market volume is currently 11 048 448 shares traded The following are the most active stocks for the pre market session Reynolds American Inc RAI is 2 23 at 58 20 with 4 274 358 shares
NVS,NVS:US,BBG000LYF3S8,How Did Novartis’s Innovative Medicines Segment Perform?,2017-01-17 12:37:04 +0000,http://marketrealist.com/2017/01/how-did-novartiss-innovative-medicines-segment-perform/?utm_source=yahoo&utm_medium=feed,How Did Novartis’s Innovative Medicines Segment Perform?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Losses,2017-01-17 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d9MwshVMHyg/the-swiss-stock-market-extended-its-losses-20170117-01188,The Swiss Stock Market Extended Its Losses
NVS,NVS:US,BBG000LYF3S8,How Is Novartis’s Revenue Trending?,2017-01-16 15:37:03 +0000,http://marketrealist.com/2017/01/what-are-novartiss-revenue-trends/?utm_source=yahoo&utm_medium=feed,How Is Novartis’s Revenue Trending?
NVS,NVS:US,BBG000LYF3S8,How Did Novartis Perform in 3Q16?,2017-01-16 14:07:34 +0000,http://marketrealist.com/2017/01/how-did-novartis-perform-in-3q16/?utm_source=yahoo&utm_medium=feed,How Did Novartis Perform in 3Q16?
NVS,NVS:US,BBG000LYF3S8,5 Trump-Proof Pharma Dividends Up To 5.3%,2017-01-16 13:38:00 +0000,http://www.forbes.com/sites/brettowens/2017/01/16/5-trump-proof-pharma-dividends-up-to-5-3/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,5 Trump-Proof Pharma Dividends Up To 5.3%
NVS,NVS:US,BBG000LYF3S8,How Does Novartis’s Valuation Compare to Peers?,2017-01-16 12:37:38 +0000,http://marketrealist.com/2017/01/how-does-novartiss-valuation-compare-to-peers/?utm_source=yahoo&utm_medium=feed,How Does Novartis’s Valuation Compare to Peers?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped In Light Trade,2017-01-16 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dcnqqp5xHyg/the-swiss-stock-market-dropped-in-light-trade-20170116-00465,The Swiss Stock Market Dropped In Light Trade
NVS,NVS:US,BBG000LYF3S8,"Novartis to Conduct Trial on Obese, Type II Diabetes Patients",2017-01-14 01:36:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r7LPS0vqoAQ/novartis-to-conduct-trial-on-obese-type-ii-diabetes-patients-cm733567,In a recent announcement MorphoSys AG mentioned that its partner Swiss major Novartis AG NVS will conduct a phase II clinical trial on pipeline candidate bimagrumab in obese patients with type II diabetes A look at Novartis share price movement in the last twelve months shows
NVS,NVS:US,BBG000LYF3S8,"Novartis to Conduct Trial on Obese, Type II Diabetes Patients",2017-01-13 23:11:11 +0000,http://finance.yahoo.com/news/novartis-conduct-trial-obese-type-231111312.html,"Novartis to Conduct Trial on Obese, Type II Diabetes Patients"
NVS,NVS:US,BBG000LYF3S8,[$$] Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs,2017-01-13 20:52:06 +0000,http://www.wsj.com/articles/supreme-court-to-weigh-how-soon-firms-can-sell-copycat-biotech-drugs-1484340720?mod=yahoo_hs,[$$] Supreme Court to Weigh How Soon Firms Can Sell Copycat Biotech Drugs
NVS,NVS:US,BBG000LYF3S8,"VEA, HFEZ: Big ETF Inflows",2017-01-13 17:38:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3N9YjLHeJEU/vea-hfez-big-etf-inflows-cm733353,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 14 011 978 units or a 1 3 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,4 Signs Glaxo's Turnaround Is Taking Hold,2017-01-13 16:40:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Lp6ofo5jfAQ/4-signs-glaxos-turnaround-is-taking-hold-cm733298,British healthcare giant GlaxoSmithKline plc NYSE GSK embarked on a major restructuring when it announced a multipart deal with Novartis AG NYSE NVS in 2014 The agreement involved swapping Glaxo s current portfolio of oncology drugs for most of Novartis vaccine assets
NVS,NVS:US,BBG000LYF3S8,Why Juno Therapeutics Crashed 57.1% in 2016 and What's Next,2017-01-13 16:40:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v9DdXHmQf48/why-juno-therapeutics-crashed-571-in-2016-and-whats-next-cm733296,Image source Getty Images What happened After reporting that it has halted trials of its most advanced cancer drug 160 shares in Juno Therapeutics NASDAQ JUNO lost 57 1 of their value in 2016 according to S amp P Global Market Intelligence So
NVS,NVS:US,BBG000LYF3S8,Why Juno Therapeutics Crashed 57.1% in 2016 and What's Next,2017-01-13 15:02:07 +0000,http://www.fool.com/investing/2017/01/13/why-juno-therapeutics-crashed-571-in-2016-and-what.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Juno Therapeutics Crashed 57.1% in 2016 and What's Next
NVS,NVS:US,BBG000LYF3S8,4 Signs Glaxo's Turnaround Is Taking Hold,2017-01-13 14:55:43 +0000,http://www.fool.com/investing/2017/01/13/4-signs-glaxos-turnaround-is-taking-hold.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,4 Signs Glaxo's Turnaround Is Taking Hold
NVS,NVS:US,BBG000LYF3S8,Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit,2017-01-13 14:40:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VzUn73dxtJE/lilly-wins-appeal-against-teva-in-alimta-patent-lawsuit-cm733160,Eli Lilly and Company LLY announced that it has received a favorable ruling in a lawsuit against generic drugmaker Teva Pharmaceutical Industries Limited TEVA related to the infringement of a vitamin regimen patent for its cancer drug Alimta by the U S Court of Appeals for the Federal
NVS,NVS:US,BBG000LYF3S8,"ARIAD: Acquisition by Takeda Bodes Well, Competition a Risk",2017-01-13 14:40:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bIoRW1Pndw0/ariad-acquisition-by-takeda-bodes-well-competition-a-risk-cm733158,On Jan 13 we issued an updated report on ARIAD Pharmaceuticals Inc ARIA ARIAD s one month share price movement shows that the stock has significantly outperformed the Zacks classified Medical Drugs industry Specifically the company gained 89 2 during this period while the industry
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed On The Strength Of The Bank Stocks,2017-01-13 12:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2Rq39GcsyF8/the-swiss-stock-market-climbed-on-the-strength-of-the-bank-stocks-20170113-00401,The Swiss Stock Market Climbed On The Strength Of The Bank Stocks
NVS,NVS:US,BBG000LYF3S8,Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit,2017-01-13 12:09:12 +0000,http://finance.yahoo.com/news/lilly-wins-appeal-against-teva-120912846.html,Lilly Wins Appeal Against Teva in Alimta Patent Lawsuit
NVS,NVS:US,BBG000LYF3S8,3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference,2017-01-12 21:25:50 +0000,http://www.fool.com/investing/2017/01/11/3-surprises-from-pfizer-at-the-j-p-morgan-healthca.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference
NVS,NVS:US,BBG000LYF3S8,"Drug makers, auto stocks yank European stocks lower for first time in 3 days",2017-01-12 17:20:19 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=EDD707F0-D8A4-11E6-8C94-49259E7936F9&siteid=yhoof2,"[at MarketWatch] - European stocks are down Thursday, with drug makers under pressure, but some luxury goods shares are bolstered by an update from Cartier’s parent company."
NVS,NVS:US,BBG000LYF3S8,Implied PPH Analyst Target Price: $64,2017-01-12 15:56:49 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cxHkT8afl6s/implied-pph-analyst-target-price-64-cm732651,Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel we have compared the trading price of each holding against the average analyst 12 month forward target price and computed the weighted average implied analyst target price for the ETF itself For
NVS,NVS:US,BBG000LYF3S8,Mylan’s Specialty Segment: The Effect of Falling EpiPen Sales,2017-01-12 15:37:10 +0000,http://marketrealist.com/2017/01/mylans-specialty-segment-the-effect-of-falling-epipen-sales/?utm_source=yahoo&utm_medium=feed,Mylan’s Specialty Segment: The Effect of Falling EpiPen Sales
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back As Trump Comments Weigh On Pharma Stocks,2017-01-12 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aEnBegaMOuA/the-swiss-stock-market-pulled-back-as-trump-comments-weigh-on-pharma-stocks-20170112-00664,The Swiss Stock Market Pulled Back As Trump Comments Weigh On Pharma Stocks
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of The Day: ACST, APRI, SBBP, NVDQ, NVCR",2017-01-11 23:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PEG7oGKemHs/gainers--losers-of-the-day-acst-apri-sbbp-nvdq-nvcr-20170111-00936,"Gainers & Losers Of The Day: ACST, APRI, SBBP, NVDQ, NVCR"
NVS,NVS:US,BBG000LYF3S8,3 Surprises From Pfizer at the J. P. Morgan Healthcare Conference,2017-01-11 22:58:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DSG816m4T2Y/3-surprises-from-pfizer-at-the-j-p-morgan-healthcare-conference-cm732475,It s always fun to hear what pharmaceutical company executives might say at the J P Morgan NYSE JPM Healthcare Conference This year Pfizer NYSE PFE was represented by three top members of its management team at the conference Here are three things the Pfizer
NVS,NVS:US,BBG000LYF3S8,The 1 Biotech Stock I Want to Own in 2017,2017-01-11 18:23:57 +0000,http://www.fool.com/investing/2017/01/11/the-1-biotech-stock-i-want-to-own-in.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The 1 Biotech Stock I Want to Own in 2017
NVS,NVS:US,BBG000LYF3S8,Ionis’ Stocks Surge After Novartis Deal (IONS),2017-01-11 17:19:00 +0000,http://www.investopedia.com/news/ionis-stocks-surge-after-novartis-deal-ions/?partner=YahooSA,Ionis’ Stocks Surge After Novartis Deal (IONS)
NVS,NVS:US,BBG000LYF3S8,European stocks trim gains after Trump comments send drug stocks lower,2017-01-11 17:09:45 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=682E7FCE-D7D8-11E6-8437-755BDD7CFD52&siteid=yhoof2,"[at MarketWatch] - European stocks rise for a second straight day on Wednesday, but with drugmakers capping gains after a late-session selloff following remarks by U.S. President-elect Donald Trump."
NVS,NVS:US,BBG000LYF3S8,The 1 Biotech Stock I Want to Own in 2017,2017-01-11 14:57:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lbvtJSx9Jks/the-1-biotech-stock-i-want-to-own-in-2017-cm732099,For most biotechs about to turn the profitability corner launching the first ever treatment for the most common genetic cause of infant mortality might be their biggest headline of the year But the launch of Spinraza is just the beginning of a year packed with catalysts for
NVS,NVS:US,BBG000LYF3S8,Why Novartis Dropped 15.1% in 2016,2017-01-11 14:56:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6uK1dZydhdQ/why-novartis-dropped-151-in-2016-cm732071,Image source Getty Images What happened Investors in the Swiss pharma giant Novartis NYSE NVS had a rough 2016 The company s stock swooned by more than 15 during the year according to data from S amp P Global Market Intelligence That return
NVS,NVS:US,BBG000LYF3S8,Why Novartis Dropped 15.1% in 2016,2017-01-11 14:53:55 +0000,http://www.fool.com/investing/2017/01/11/why-novartis-dropped-151-in-2016.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Novartis Dropped 15.1% in 2016
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back On Pharma Weakness,2017-01-11 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IwIvW1TCuA8/the-swiss-stock-market-pulled-back-on-pharma-weakness-20170111-00616,The Swiss Stock Market Pulled Back On Pharma Weakness
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of The Day: BIOC, CUR, ONTX, EGLT, ABAX...",2017-01-10 22:02:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rx0tCOEqBwQ/gainers--losers-of-the-day-bioc-cur-ontx-eglt-abax-20170110-01107,"Gainers & Losers Of The Day: BIOC, CUR, ONTX, EGLT, ABAX..."
NVS,NVS:US,BBG000LYF3S8,Todd Hagopian's Top Biotech Takeover Targets For 2017,2017-01-10 17:59:00 +0000,http://www.forbes.com/sites/kenkam/2017/01/10/todd-hagopians-top-biotech-takeover-targets-for-2017/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Todd Hagopian's Top Biotech Takeover Targets For 2017
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Higher In Sluggish Trade,2017-01-10 12:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4WBNGP6D3Rc/the-swiss-stock-market-finished-higher-in-sluggish-trade-20170110-00775,The Swiss Stock Market Finished Higher In Sluggish Trade
NVS,NVS:US,BBG000LYF3S8,Trumponomics Is Finally Reflating Europe And Japan,2017-01-10 00:49:00 +0000,http://www.forbes.com/sites/bryanrich/2017/01/09/trumponomics-is-finally-reflating-europe-and-japan/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Trumponomics Is Finally Reflating Europe And Japan
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of The Day: DFFN, ETRM, GNVC, EGRX, ADHD...",2017-01-09 21:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YeC3pqGuWNw/gainers--losers-of-the-day-dffn-etrm-gnvc-egrx-adhd-20170109-01108,"Gainers & Losers Of The Day: DFFN, ETRM, GNVC, EGRX, ADHD..."
NVS,NVS:US,BBG000LYF3S8,"Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation",2017-01-09 16:23:00 +0000,https://www.thestreet.com/story/13946518/1/takeda-pays-5-2b-for-leukemia-drug-maker-ariad.html?puc=yahoo&cm_ven=YAHOO,"Takeda Pays $5.2 Billion for Leukemia Drug Maker Ariad, Ending Months of Takeout Speculation"
NVS,NVS:US,BBG000LYF3S8,"Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments",2017-01-09 15:53:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ll_4LNj1PLI/ionis-novartis-ink-deal-to-focus-on-cardiovascular-treatments-cm730965,Ionis Pharmaceuticals Inc IONS along with its subsidiary Akcea Therapeutics announced that the company has entered into an exclusive worldwide collaboration agreement with Novartis AG NVS for the development and commercialization of two novel treatments AKCEA APO a L and AKCEA APOCIII
NVS,NVS:US,BBG000LYF3S8,Teva Falls on Disappointing 2017 Sales & Earnings Guidance,2017-01-09 14:53:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3B3GGPYOZl4/teva-falls-on-disappointing-2017-sales-earnings-guidance-cm730924,Teva Pharmaceutical Industries Ltd TEVA provided a weaker than expected sales and earnings guidance for 2017 seeing that its blockbuster multiple sclerosis drug Copaxone is reeling under competitive pressures Following the announcement shares of the Israeli generic pharmaceuticals
NVS,NVS:US,BBG000LYF3S8,"Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments",2017-01-09 14:01:02 +0000,http://finance.yahoo.com/news/ionis-novartis-ink-deal-focus-140102417.html,"Ionis, Novartis Ink Deal to Focus on Cardiovascular Treatments"
NVS,NVS:US,BBG000LYF3S8,"Pre-Market Most Active for Jan 9, 2017 :  ARIA, MACK, SMI, BAC, TLT, MPEL, FIT, RIO, ARWR, NVS, VALE, TVIX",2017-01-09 13:59:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HJGgm0tEcqU/pre-market-most-active-for-jan-9-2017-aria-mack-smi-bac-tlt-mpel-fit-rio-arwr-nvs-vale-tvix-cm730903,The NASDAQ 100 Pre Market Indicator is up 8 23 to 5 015 31 The total Pre Market volume is currently 5 509 890 shares traded The following are the most active stocks for the pre market session ARIAD Pharmaceuticals Inc ARIA is 10 15 at 23 89 with 5 796 629
NVS,NVS:US,BBG000LYF3S8,Blog Coverage Novartis Joins Hands with Ionis Pharma For Cardiovascular Treatment Solutions,2017-01-09 13:15:00 +0000,http://finance.yahoo.com/news/blog-coverage-novartis-joins-hands-131500134.html,"[Accesswire] - LONDON, UK / ACCESSWIRE / January 9, 2017 / Active Wall St. blog coverage looks at the headline from Novartis AG (NYSE: NVS ) and Ionis Pharmaceuticals Inc. (NASDAQ: IONS ). Novartis announced on January ..."
NVS,NVS:US,BBG000LYF3S8,What’s in Incyte’s Product Portfolio?,2017-01-09 12:36:21 +0000,http://marketrealist.com/2017/01/whats-in-incytes-product-portfolio/?utm_source=yahoo&utm_medium=feed,What’s in Incyte’s Product Portfolio?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Higher Thanks To Late Push From Heavyweights,2017-01-09 12:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ujdQu2I4am8/the-swiss-stock-market-finished-higher-thanks-to-late-push-from-heavyweights-20170109-00787,The Swiss Stock Market Finished Higher Thanks To Late Push From Heavyweights
NVS,NVS:US,BBG000LYF3S8,3 Takeover Candidates in the Drug Space,2017-01-08 19:00:00 +0000,http://realmoney.thestreet.com/articles/01/08/2017/3-takeover-candidates-drug-space?puc=yahoo&cm_ven=YAHOO,3 Takeover Candidates in the Drug Space
NVS,NVS:US,BBG000LYF3S8,Momenta (MNTA) to Receive $50M Under CSL Collaboration,2017-01-07 01:48:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Zp1bh-fPbBI/momenta-mnta-to-receive-50m-under-csl-collaboration-cm730659,Momenta Pharmaceuticals Inc MNTA announced that it has entered into an exclusive research collaboration and worldwide license agreement with CSL Limited Momenta s share price has outperformed the Zacks classified Medical Biomed Genetics in the last twelve months The stock gained 14
NVS,NVS:US,BBG000LYF3S8,Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication,2017-01-06 23:48:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UuPla4sV4Dw/roches-rhhby-lucentis-gets-fda-nod-for-fifth-indication-cm730635,Roche Holding AG RHHBY announced today that the FDA has approved a label expansion of ophthalmology drug Lucentis Notably Roche has underperformed the Zacks classified Large Cap Pharmaceuticals industry in the last twelve months In fact the stock has lost 10 9 in the last
NVS,NVS:US,BBG000LYF3S8,Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication,2017-01-06 21:42:09 +0000,http://finance.yahoo.com/news/roches-rhhby-lucentis-gets-fda-214209534.html,Roche's (RHHBY) Lucentis Gets FDA Nod for Fifth Indication
NVS,NVS:US,BBG000LYF3S8,Ionis Pharma Stock Bounds On $100 Million Novartis Investment,2017-01-06 21:24:01 +0000,http://www.investors.com/news/technology/ionis-pharma-stock-bounds-on-100-million-novartis-investment/,Ionis Pharma Stock Bounds On $100 Million Novartis Investment
NVS,NVS:US,BBG000LYF3S8,"Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties",2017-01-06 17:16:00 +0000,https://www.thestreet.com/story/13945362/1/ionis-novartis-ink-collaboration-worth-up-to-1-6b-and-royalties.html?puc=yahoo&cm_ven=YAHOO,"Ionis, Novartis Ink Collaboration Worth Up to $1.6B Plus Royalties"
NVS,NVS:US,BBG000LYF3S8,Stock Futures Turn Positive on Gains in Hourly Earnings,2017-01-06 14:37:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w5-0HeBFu6c/stock-futures-turn-positive-on-gains-in-hourly-earnings-cm730267,Stock futures turned positive in the wake of a healthy gain in average hourly earnings that compensated for a below consensus gain in December non farm payrolls Earnings rose 0 4 beating 0 3 estimates and offsetting a 0 1 decline the month prior Wages were up 2 9 from last year
NVS,NVS:US,BBG000LYF3S8,Novartis joins forces with Ionis on cardiovascular treatments,2017-01-06 07:24:58 +0000,http://in.finance.yahoo.com/news/novartis-joins-forces-ionis-cardiovascular-063330307.html,Novartis joins forces with Ionis on cardiovascular treatments
NVS,NVS:US,BBG000LYF3S8,Ionis Pharma Collaborates With Novartis On Cardiovascular Treatment,2017-01-06 01:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QLORfauJqls/ionis-pharma-collaborates-with-novartis-on-cardiovascular-treatment-20170106-00014,Ionis Pharma Collaborates With Novartis On Cardiovascular Treatment
NVS,NVS:US,BBG000LYF3S8,"Gainers & Losers Of The Day: ETRM, PIRS, GNVC, AEZS, XXII",2017-01-05 21:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b6tapGdr79I/gainers--losers-of-the-day-etrm-pirs-gnvc-aezs-xxii-20170105-01242,"Gainers & Losers Of The Day: ETRM, PIRS, GNVC, AEZS, XXII"
NVS,NVS:US,BBG000LYF3S8,"VEA, NSRGY, NVS, TM: Large Inflows Detected at ETF",2017-01-05 17:39:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yIjeuYEowH4/vea-nsrgy-nvs-tm-large-inflows-detected-at-etf-cm729910,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 390 0 million dollar inflow that s a 1 0 increase week over week
NVS,NVS:US,BBG000LYF3S8,"Eli Lilly Announces Exec Appointments, Organizational Changes",2017-01-05 16:52:00 +0000,https://www.thestreet.com/story/13943979/1/eli-lilly-announces-exec-appointments-organizational-changes.html?puc=yahoo&cm_ven=YAHOO,"Eli Lilly Announces Exec Appointments, Organizational Changes"
NVS,NVS:US,BBG000LYF3S8,Swiss Stocks Finished Higher Thanks To Gains Among Index Heavyweights,2017-01-05 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7JR2RRMsjMs/swiss-stocks-finished-higher-thanks-to-gains-among-index-heavyweights-20170105-00874,Swiss Stocks Finished Higher Thanks To Gains Among Index Heavyweights
NVS,NVS:US,BBG000LYF3S8,Eli Lilly Acquires Boehringer Ingelheim's Pet Vaccines Unit,2017-01-04 16:41:43 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d6md6qq5DIw/eli-lilly-acquires-boehringer-ingelheims-pet-vaccines-unit-cm729291,Eli Lilly and Company s LLY animal health subsidiary Elanco announced that it has closed the previously stated acquisition of German drugmaker Boehringer Ingelheim s Vetmedica U S pet vaccines unit along with a fully integrated manufacturing and R amp D site for 885 million Lilly s
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Gains From The Previous Day,2017-01-04 12:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KJlW2CZGByU/the-swiss-stock-market-extended-its-gains-from-the-previous-day-20170104-00856,The Swiss Stock Market Extended Its Gains From The Previous Day
NVS,NVS:US,BBG000LYF3S8,European Markets Finished With Mixed Results As Retailers Struggled,2017-01-04 12:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/beGnzuZYGSM/european-markets-finished-with-mixed-results-as-retailers-struggled-20170104-00826,European Markets Finished With Mixed Results As Retailers Struggled
NVS,NVS:US,BBG000LYF3S8,Greek prosecutor raids Novartis Athens offices in bribery probe,2017-01-04 11:20:05 +0000,http://finance.yahoo.com/news/greek-prosecutor-raids-novartis-athens-112005640.html,Greek prosecutor raids Novartis Athens offices in bribery probe
NVS,NVS:US,BBG000LYF3S8,Gilead poaches Novartis cancer specialist Riva,2017-01-04 11:04:48 +0000,http://finance.yahoo.com/news/gilead-poaches-novartis-cancer-specialist-110448090.html,Gilead poaches Novartis cancer specialist Riva
NVS,NVS:US,BBG000LYF3S8,"Biogen boosts price of top MS drugs, analyst says",2017-01-03 18:30:08 +0000,http://www.bizjournals.com/boston/news/2017/01/03/biogen-boosts-price-of-top-drugs-analyst-says.html?ana=yahoo,"Biogen boosts price of top MS drugs, analyst says"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Kicked Off 2017 With Gains As Banks Rise,2017-01-03 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0cOsR3M36T0/the-swiss-stock-market-kicked-off-2017-with-gains-as-banks-rise-20170103-00695,The Swiss Stock Market Kicked Off 2017 With Gains As Banks Rise
NVS,NVS:US,BBG000LYF3S8,17 Thoughts on Biotech Stocks to Kick Off 2017,2017-01-03 11:35:00 +0000,https://www.thestreet.com/story/13939672/1/17-thoughts-on-biotech-stocks-to-kick-off-2017.html?puc=yahoo&cm_ven=YAHOO,17 Thoughts on Biotech Stocks to Kick Off 2017
NVS,NVS:US,BBG000LYF3S8,Barron's Best Income Ideas For 2017,2017-01-02 22:26:22 +0000,http://finance.yahoo.com/news/barrons-best-income-ideas-2017-222622536.html,Barron's Best Income Ideas For 2017
NVS,NVS:US,BBG000LYF3S8,Incyte Treats First Patient in Phase II GVHD Study on Jakafi,2017-01-02 16:56:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uloPo7wSt-o/incyte-treats-first-patient-in-phase-ii-gvhd-study-on-jakafi-cm728377,Incyte Corporation INCY announced that the first patient has been treated in the pivotal phase II REACH 1 study assessing its marketed drug Jakafi in combination with corticosteroids for the treatment of steroid refractory acute graft versus host disease GVHD Incyte s share price has
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline’s Vaccines Business,2017-01-02 14:06:08 +0000,http://marketrealist.com/2016/12/glaxosmithklines-vaccines-business/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s Vaccines Business
NVS,NVS:US,BBG000LYF3S8,"ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong",2016-12-30 17:01:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iRoJFeP1ZcM/ariad-stock-beats-industry-in-2016-iclusig-sales-strong-cm727981,ARIAD Pharmaceuticals Inc ARIA remains focused on the discovery development and commercialization of breakthrough treatments for cancer This year was a tough one for the pharma sector which had to grapple with media and political focus on the high prices of drugs Shares of ARIAD
NVS,NVS:US,BBG000LYF3S8,"ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong",2016-12-30 14:27:02 +0000,http://finance.yahoo.com/news/ariad-stock-beats-industry-2016-142702761.html,"ARIAD Stock Beats Industry in 2016, Iclusig Sales Strong"
NVS,NVS:US,BBG000LYF3S8,How GlaxoSmithKline’s Pharmaceuticals Segment Has Performed,2016-12-30 14:07:11 +0000,http://marketrealist.com/2016/12/how-glaxosmithklines-pharmaceuticals-segment-has-performed/?utm_source=yahoo&utm_medium=feed,How GlaxoSmithKline’s Pharmaceuticals Segment Has Performed
NVS,NVS:US,BBG000LYF3S8,Exploring GlaxoSmithKline’s Business Segments,2016-12-30 12:38:05 +0000,http://marketrealist.com/2016/12/exploring-glaxosmithklines-business-segments/?utm_source=yahoo&utm_medium=feed,Exploring GlaxoSmithKline’s Business Segments
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Modest Loss,2016-12-30 12:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fLTR-XTAq0U/the-swiss-stock-market-finished-with-a-modest-loss-20161230-00189,The Swiss Stock Market Finished With A Modest Loss
NVS,NVS:US,BBG000LYF3S8,When Will the Biosimilar for Enbrel Be Available?,2016-12-29 15:36:38 +0000,http://marketrealist.com/2016/12/when-will-the-biosimilar-for-enbrel-be-available/?utm_source=yahoo&utm_medium=feed,When Will the Biosimilar for Enbrel Be Available?
NVS,NVS:US,BBG000LYF3S8,United Therapeutics’ Robust Research Pipeline,2016-12-29 12:36:09 +0000,http://marketrealist.com/2016/12/robust-research-pipeline-expected-boost-united-therapeutics-revenues-future-years/?utm_source=yahoo&utm_medium=feed,United Therapeutics’ Robust Research Pipeline
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped On Bank Weakness,2016-12-29 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bPJ2x1kcz4M/the-swiss-stock-market-dipped-on-bank-weakness-20161229-00219,The Swiss Stock Market Dipped On Bank Weakness
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 12/29/2016: SNY, NVS, GALE, ANTH, NVO",2016-12-29 09:37:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Aolinp75I54/health-care-sector-update-for-12292016-sny-nvs-gale-anth-nvo-cm727240,Corrects an item published on Dec 28 at 3 57 p m E T to remove reference to Novartis NVS American depository shares movement in the 4th paragraph The item is about a suit filed by Novo Nordisk NVO not Novartis NVS against Sanofi SNY Corrects an item published on Dec
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 12/28/2016: SNY,NVS,GALE,ANTH",2016-12-28 21:37:33 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ldnzfZwGtHc/health-care-sector-update-for-12282016-snynvsgaleanth-cm727167,Top Health Care StocksTop Health Care Stocks JNJ 0 67 JNJ 0 67 PFE 0 51 PFE 0 51 MRK 0 91 MRK 0 91 ABT 0 90 ABT 0 90 AMGN 0 45 AMGN 0 45 Health care stocks were mostly lower in late trading today with the NYSE Health Care Index falling around 0 6 while shares of health
NVS,NVS:US,BBG000LYF3S8,"VEA, RFEM: Big ETF Inflows",2016-12-28 16:59:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nk2EW--PRD8/vea-rfem-big-etf-inflows-cm726931,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 17 500 000 units or a 1 6 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,Eight Milestones Of 2016 In The War On Cancer,2016-12-28 13:35:00 +0000,http://www.forbes.com/sites/arleneweintraub/2016/12/28/eight-milestones-of-2016-in-the-war-on-cancer/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Eight Milestones Of 2016 In The War On Cancer
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped Slightly In Quiet Trade,2016-12-28 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cT7L4WHLrOM/the-swiss-stock-market-dipped-slightly-in-quiet-trade-20161228-00207,The Swiss Stock Market Dipped Slightly In Quiet Trade
NVS,NVS:US,BBG000LYF3S8,International Segment: Key Driver of VRX’s Revenue Growth in 2016,2016-12-27 23:05:35 +0000,http://marketrealist.com/2016/12/international-segment-key-driver-valeant-pharmaceuticals-revenue-growth-2016/?utm_source=yahoo&utm_medium=feed,International Segment: Key Driver of VRX’s Revenue Growth in 2016
NVS,NVS:US,BBG000LYF3S8,"VEU, NSRGY, VIS, NVS: ETF Inflow Alert",2016-12-27 17:58:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9uc-9BYNz10/veu-nsrgy-vis-nvs-etf-inflow-alert-cm726550,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 185 0 million dollar inflow that s a 1 3 increase week over week
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Small Gain As Health Stocks Rise,2016-12-27 12:32:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZNbe4n6wT2E/the-swiss-stock-market-finished-with-a-small-gain-as-health-stocks-rise-20161227-00279,The Swiss Stock Market Finished With A Small Gain As Health Stocks Rise
NVS,NVS:US,BBG000LYF3S8,Financial Metrics of Baxter’s Acquisition of Claris Injectables,2016-12-26 12:36:19 +0000,http://marketrealist.com/2016/12/financial-metrics-of-baxters-acquisition-of-claris-injectables/?utm_source=yahoo&utm_medium=feed,Financial Metrics of Baxter’s Acquisition of Claris Injectables
NVS,NVS:US,BBG000LYF3S8,The Most Likely Incyte Acquisition Deal for 2017?,2016-12-24 13:06:56 +0000,http://www.fool.com/investing/2016/12/23/is-this-the-most-likely-incyte-acquisition-deal-fo.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Most Likely Incyte Acquisition Deal for 2017?
NVS,NVS:US,BBG000LYF3S8,Ligand (LGND) Signs Licensing Deals with Ono and Novartis,2016-12-23 15:00:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ahqDxrRBxGA/ligand-lgnd-signs-licensing-deals-with-ono-and-novartis-cm725582,Ligand Pharmaceuticals Incorporated LGND announced that it has entered into a worldwide license agreement with Ono Pharmaceutical Co Ltd under which Ono will use its OmniAb platform for the discovery of fully human mono and bispecific antibodies Note that OmniAb includes
NVS,NVS:US,BBG000LYF3S8,The Most Likely Incyte Acquisition Deal for 2017?,2016-12-23 14:59:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PBqoouCoyEg/the-most-likely-incyte-acquisition-deal-for-2017-cm725574,Lots of folks want Incyte Corporation NASDAQ INCY to be part of a major acquisition Many of them would love to see Gilead Sciences NASDAQ GILD buy Incyte Could another acquisition involving Incyte be more likely though Here are some potential 2017 acquisition
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe",2016-12-23 12:58:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gu5pZXFat3c/pharma-stock-roundup-jj-back-in-talks-with-actelion-teva-settles-corruption-probe-cm725508,Several tuck in deals and licensing agreements were announced this week while healthcare giant Johnson amp Johnson JNJ is back in exclusive talks with Actelion regarding a possible deal Recap of the Week s Most Important Stories J amp J In Where Does that Leave Sanofi in
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped Ahead Of The Christmas Holiday Weekend,2016-12-23 12:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HEZF17GMyR0/the-swiss-stock-market-dipped-ahead-of-the-christmas-holiday-weekend-20161223-00323,The Swiss Stock Market Dipped Ahead Of The Christmas Holiday Weekend
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe",2016-12-23 10:48:10 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-j-j-104810335.html,"Pharma Stock Roundup: J&J Back in Talks with Actelion, Teva Settles Corruption Probe"
NVS,NVS:US,BBG000LYF3S8,Teva Settles Charges in U.S. -- WSJ,2016-12-23 02:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YQHyE8PJxiM/teva-settles-charges-in-us--wsj-20161223-00054,Teva Settles Charges in U.S. -- WSJ
NVS,NVS:US,BBG000LYF3S8,"Sensex, Nifty Extend Losses On Weak Global Cues",2016-12-22 23:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1xzsKC9apno/sensex-nifty-extend-losses-on-weak-global-cues-20161222-00877,"Sensex, Nifty Extend Losses On Weak Global Cues"
NVS,NVS:US,BBG000LYF3S8,Bad News Bashes Biotech Investors... Again,2016-12-22 15:51:44 +0000,http://www.fool.com/investing/2016/12/21/bad-news-bashes-biotech-investors-again.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Bad News Bashes Biotech Investors... Again
NVS,NVS:US,BBG000LYF3S8,Teva Settles Foreign Corruption Probe for $519 Million -- 2nd Update,2016-12-22 15:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qAtreSCEbc0/teva-settles-foreign-corruption-probe-for-519-million--2nd-update-20161222-00642,Teva Settles Foreign Corruption Probe for $519 Million -- 2nd Update
NVS,NVS:US,BBG000LYF3S8,Pfizer Ibrance sNDA Accepted by FDA under Priority Review,2016-12-22 15:00:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7OzIiB83onM/pfizer-ibrance-snda-accepted-by-fda-under-priority-review-cm725000,Pfizer Inc s PFE supplemental new drug application sNDA to convert accelerated approval for its breast cancer drug Ibrance to regular approval was accepted by the FDA under priority review Note that Ibrance is approved in the U S for the treatment of HR HER2 advanced or
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed - Actelion In Focus,2016-12-22 12:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2IAuLtf43Jo/the-swiss-stock-market-finished-little-changed--actelion-in-focus-20161222-00511,The Swiss Stock Market Finished Little Changed - Actelion In Focus
NVS,NVS:US,BBG000LYF3S8,Ligand In License And Supply Deals With Novartis For Captisol-enabled Trametinib,2016-12-22 10:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BVsBe5cZ4u0/ligand-in-license-and-supply-deals-with-novartis-for-captisolenabled-trametinib-20161222-00442,Ligand In License And Supply Deals With Novartis For Captisol-enabled Trametinib
NVS,NVS:US,BBG000LYF3S8,Ligand In License And Supply Deals With Novartis For Captisol-enabled Trametinib,2016-12-22 10:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ghrsas8nk-w/ligand-in-license-and-supply-deals-with-novartis-for-captisolenabled-trametinib-20161222-00443,Ligand In License And Supply Deals With Novartis For Captisol-enabled Trametinib
NVS,NVS:US,BBG000LYF3S8,Out-licensing of COPD products in the US,2016-12-22 00:02:11 +0000,http://www.publicnow.com/view/37A7F1D785199BB8C584B247BFF94940B0C72834,"[at noodls] - Sunovion assumes US commercialization rights for Utibron™ Neohaler®, Seebri™ Neohaler® and Arcapta® Neohaler® Novartis will continue to manufacture these important medicines for Sunovion In line with its ..."
NVS,NVS:US,BBG000LYF3S8,Bad News Bashes Biotech Investors... Again,2016-12-21 16:58:46 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m7fb_V-pvTY/bad-news-bashes-biotech-investors-again-cm724572,Push back on pricing trial failures and management misdeeds have bloodied biotech investors this year and unfortunately Alexion Pharmaceuticals NASDAQ ALXN and Ophthotech Corp NASDAQ OPHT have just delivered investors even more crushing news At Alexion
NVS,NVS:US,BBG000LYF3S8,Licensing agreement signed for the launch of Utibron/Seebri in the US,2016-12-21 14:42:06 +0000,http://www.publicnow.com/view/9833EF88006A1D29C2689EA68BCF66723E375237,"[at noodls] - December 21, 2016 at 2:00 PM Chippenham, UK - 21 December 2016: Vectura Group plc (LSE: VEC) ('Vectura', 'the Group'), an industry-leading inhaled airways disease focused business, reports that Novartis ..."
NVS,NVS:US,BBG000LYF3S8,"Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug",2016-12-21 14:25:02 +0000,http://finance.yahoo.com/news/biotech-stock-roundup-conatus-soars-142502788.html,"Biotech Stock Roundup: Conatus Soars on Novartis Deal, Early FDA Nod for Clovis Drug"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped In Light Trading Action,2016-12-21 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VLF-aq-WfgE/the-swiss-stock-market-dipped-in-light-trading-action-20161221-00579,The Swiss Stock Market Dipped In Light Trading Action
NVS,NVS:US,BBG000LYF3S8,3 Dividend Stocks to Put on Your Shopping List,2016-12-20 21:57:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3Z38Qwsd8Dw/3-dividend-stocks-to-put-on-your-shopping-list-cm724277,There s just something nice about stocks that pay you to own them Dividends make a huge difference in overall investing returns especially over long periods of time Few dividend stocks are are as attractive right now as AbbVie NYSE ABBV Pfizer NYSE PFE
NVS,NVS:US,BBG000LYF3S8,Close Update: Nasdaq Hits Record High While Dow Pulls Back From Key Level,2016-12-20 21:56:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/T5xi5acFd0g/close-update-nasdaq-hits-record-high-while-dow-pulls-back-from-key-level-cm724284,Wall Street gained for a second day on Tuesday with the Nasdaq Composite and the Dow Jones Industrial Average closing at record highs even as the latter couldn t reach a key level it s been testing in recent days Wall Street gained for a second day on Tuesday with the Nasdaq Composite and the
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 12/20/2016: AKBA,CNAT,NVS,NURO",2016-12-20 21:16:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bAuyvjFtjfk/health-care-sector-update-for-12202016-akbacnatnvsnuro-cm724268,Top Health Care StocksTop Health Care Stocks JNJ 0 43 JNJ 0 43 PFE 0 00 PFE 0 00 MRK 0 61 MRK 0 61 ABT 1 05 ABT 1 05 AMGN 0 52 AMGN 0 52 Health care stocks were slightly lower in late trading today with the NYSE Health Care Index slipping 0 2 while shares of health care companies
NVS,NVS:US,BBG000LYF3S8,3 Dividend Stocks to Put on Your Shopping List,2016-12-20 20:06:10 +0000,http://www.fool.com/investing/2016/12/20/3-dividend-stocks-to-put-on-your-shopping-list.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Dividend Stocks to Put on Your Shopping List
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 12/20/2016: SCMP,CNAT,NVS,NURO",2016-12-20 19:16:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BGbdby_y3KQ/health-care-sector-update-for-12202016-scmpcnatnvsnuro-cm724190,Top Health Care StocksTop Health Care Stocks JNJ 0 54 JNJ 0 54 PFE 0 53 PFE 0 53 MRK 0 29 MRK 0 29 ABT 1 05 ABT 1 05 AMGN 0 72 AMGN 0 72 Health care stocks were slightly lower today with the NYSE Health Care Index slipping almost 0 2 while shares of health care companies in
NVS,NVS:US,BBG000LYF3S8,Novartis reaches agreement to buy Texas-based Encore Vision,2016-12-20 17:26:04 +0000,http://finance.yahoo.com/news/novartis-says-reaches-agreement-buy-112304129.html,Novartis reaches agreement to buy Texas-based Encore Vision
NVS,NVS:US,BBG000LYF3S8,Banking Sector Leading Rally in U.S. Markets,2016-12-20 17:00:00 +0000,http://finance.yahoo.com/news/banking-sector-leading-rally-u-170000610.html,Banking Sector Leading Rally in U.S. Markets
NVS,NVS:US,BBG000LYF3S8,"VEA, AGND: Big ETF Inflows",2016-12-20 16:58:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LIZ8yPzi01o/vea-agnd-big-etf-inflows-cm723965,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 20 000 000 units or a 1 9 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,"MARKET SNAPSHOT: ''Santa Rally'' Takes Stocks To Records, But Dow 20,000 Proves Elusive",2016-12-20 16:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ECttCYA2WGE/market-snapshot-santa-rally-takes-stocks-to-records-but-dow-20000-proves-elusive-20161220-00885,"MARKET SNAPSHOT: ''Santa Rally'' Takes Stocks To Records, But Dow 20,000 Proves Elusive"
NVS,NVS:US,BBG000LYF3S8,"MARKET SNAPSHOT: 'Santa Rally' Takes Stocks To Records, But Dow 20,000 Proves Elusive",2016-12-20 16:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xtW1OmiKUjE/market-snapshot-santa-rally-takes-stocks-to-records-but-dow-20000-proves-elusive-20161220-00884,"MARKET SNAPSHOT: 'Santa Rally' Takes Stocks To Records, But Dow 20,000 Proves Elusive"
NVS,NVS:US,BBG000LYF3S8,Dow And Nasdaq Reach New Record Closing Highs - U.S. Commentary,2016-12-20 16:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/W9Vh-Soisug/dow-and-nasdaq-reach-new-record-closing-highs--us-commentary-20161220-00857,Dow And Nasdaq Reach New Record Closing Highs - U.S. Commentary
NVS,NVS:US,BBG000LYF3S8,Mid-Morning Market Update: Markets Open Higher; BlackBerry Earnings Beat Views,2016-12-20 16:07:09 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l5Id_xncf-o/mid-morning-market-update-markets-open-higher-blackberry-earnings-beat-views-cm724014,Following the market opening Tuesday the Dow traded up 0 49 percent to 19 981 09 while the NASDAQ rose 0 57 percent to 5 488 54 The S amp P also rose gaining 0 43 percent to 2 272 31 Leading and Lagging Sectors Financial shares gained around 0 54 percent in trading on
NVS,NVS:US,BBG000LYF3S8,"General Mills falls on miss, BlackBerry's profit surprise, Facebook faces EU probe over WhatsApp merger",2016-12-20 15:46:07 +0000,http://finance.yahoo.com/news/general-mills-falls-on-miss-blackberrys-profit-surprise-facebook-faces-eu-probe-over-whatsapp-merger-154607539.html,"General Mills falls on miss, BlackBerry's profit surprise, Facebook faces EU probe over WhatsApp merger"
NVS,NVS:US,BBG000LYF3S8,Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus Pharmaceuticals Inc (CNAT),2016-12-20 15:37:33 +0000,http://www.insidermonkey.com/blog/novartis-ag-adr-nvs-agrees-to-50-million-deal-with-conatus-pharmaceuticals-inc-cnat-512241/,Novartis AG (ADR) (NVS) Agrees To $50 Million Deal With Conatus Pharmaceuticals Inc (CNAT)
NVS,NVS:US,BBG000LYF3S8,Conatus Pharma Doubles On Novartis NASH Liver Drug Licensing Deal,2016-12-20 15:30:10 +0000,http://www.investors.com/news/technology/conatus-pharma-skyrockets-on-novartis-nash-liver-drug-licensing-deal/,Conatus Pharma Doubles On Novartis NASH Liver Drug Licensing Deal
NVS,NVS:US,BBG000LYF3S8,"MARKET SNAPSHOT: Dow 20,000 Tantalizingly Close As 'Santa Rally' Takes Stocks To Records",2016-12-20 15:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/A0d1mg2rsdE/market-snapshot-dow-20000-tantalizingly-close-as-santa-rally-takes-stocks-to-records-20161220-00687,"MARKET SNAPSHOT: Dow 20,000 Tantalizingly Close As 'Santa Rally' Takes Stocks To Records"
NVS,NVS:US,BBG000LYF3S8,7 Good Stocks for Your Retirement Portfolio in 2017,2016-12-20 14:20:01 +0000,http://portal.kiplinger.com/article/investing/T052-C007-S001-7-stocks-for-retirees-to-beat-the-market-in-2017.html?rid=SYN-yahoo&rpageid=15893,7 Good Stocks for Your Retirement Portfolio in 2017
NVS,NVS:US,BBG000LYF3S8,Conatus Stock Up on Liver Drug Collaboration with Novartis,2016-12-20 13:53:01 +0000,http://finance.yahoo.com/news/conatus-stock-liver-drug-collaboration-135301778.html,Conatus Stock Up on Liver Drug Collaboration with Novartis
NVS,NVS:US,BBG000LYF3S8,Conatus More Than Doubles on Key License Collaboration Agreement,2016-12-20 13:50:03 +0000,http://finance.yahoo.com/news/conatus-more-doubles-key-license-135003656.html,Conatus More Than Doubles on Key License Collaboration Agreement
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With Another Slight Gain,2016-12-20 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yGzifK31Z94/the-swiss-stock-market-finished-with-another-slight-gain-20161220-00657,The Swiss Stock Market Finished With Another Slight Gain
NVS,NVS:US,BBG000LYF3S8,EUROPE MARKETS: Stoxx Europe 600 Closes At 2016 High As Italian Banks Rise,2016-12-20 12:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/WrOFhew9w-w/europe-markets-stoxx-europe-600-closes-at-2016-high-as-italian-banks-rise-20161220-00653,EUROPE MARKETS: Stoxx Europe 600 Closes At 2016 High As Italian Banks Rise
NVS,NVS:US,BBG000LYF3S8,Stocks Give Back Ground But Remain Mostly Positive - U.S. Commentary,2016-12-20 12:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Da4RGvnGATE/stocks-give-back-ground-but-remain-mostly-positive--us-commentary-20161220-00645,Stocks Give Back Ground But Remain Mostly Positive - U.S. Commentary
NVS,NVS:US,BBG000LYF3S8,European Markets Shrugged Off Geopolitical Concerns And Finished Higher,2016-12-20 11:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lyA0W7nMgZM/european-markets-shrugged-off-geopolitical-concerns-and-finished-higher-20161220-00639,European Markets Shrugged Off Geopolitical Concerns And Finished Higher
NVS,NVS:US,BBG000LYF3S8,"MARKET SNAPSHOT: Dow 20,000 Tantalizingly Close As 'Santa Rally' Takes Stocks To New Heights",2016-12-20 11:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ed7xbQgqlcI/market-snapshot-dow-20000-tantalizingly-close-as-santa-rally-takes-stocks-to-new-heights-20161220-00619,"MARKET SNAPSHOT: Dow 20,000 Tantalizingly Close As 'Santa Rally' Takes Stocks To New Heights"
NVS,NVS:US,BBG000LYF3S8,These 5 Health Care Stocks Are Breaking Out This Christmas,2016-12-20 11:02:00 +0000,https://www.thestreet.com/story/13931953/1/these-5-health-care-stocks-are-breaking-out-this-christmas.html?puc=yahoo&cm_ven=YAHOO,These 5 Health Care Stocks Are Breaking Out This Christmas
NVS,NVS:US,BBG000LYF3S8,Dow And Nasdaq Reach New Record Intraday Highs - U.S. Commentary,2016-12-20 10:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZFyYQ1Jxga8/dow-and-nasdaq-reach-new-record-intraday-highs--us-commentary-20161220-00575,Dow And Nasdaq Reach New Record Intraday Highs - U.S. Commentary
NVS,NVS:US,BBG000LYF3S8,"MARKET SNAPSHOT: Dow Touches Intraday All-time High On Its Creep To 20,000",2016-12-20 10:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ez0LGq52jmc/market-snapshot-dow-touches-intraday-alltime-high-on-its-creep-to-20000-20161220-00564,"MARKET SNAPSHOT: Dow Touches Intraday All-time High On Its Creep To 20,000"
NVS,NVS:US,BBG000LYF3S8,Futures Pointing To Early Strength On Wall Street - U.S. Commentary,2016-12-20 08:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9rSkUAQ7tO0/futures-pointing-to-early-strength-on-wall-street--us-commentary-20161220-00394,Futures Pointing To Early Strength On Wall Street - U.S. Commentary
NVS,NVS:US,BBG000LYF3S8,"Novartis bolsters ophthalmology pipeline through acquisition of Encore Vision, Inc.",2016-12-20 07:02:05 +0000,http://www.publicnow.com/view/35D780EC8034904A3AC52120E3463193D478E859,"[at noodls] - Novartis confirms its leadership in ophthalmology by entering a new therapy area. Acquisition of Encore Vision, Inc. to add first-in-class disease modifying topical treatment for presbyopia patients to ..."
NVS,NVS:US,BBG000LYF3S8,Novartis says reaches agreement to buy Texas-based Encore Vision,2016-12-20 06:38:01 +0000,http://sg.finance.yahoo.com/news/novartis-says-reaches-agreement-buy-063801971.html,Novartis says reaches agreement to buy Texas-based Encore Vision
NVS,NVS:US,BBG000LYF3S8,"MARKET SNAPSHOT: Dow Futures Point To Slow March Higher Toward Key 20,000 Mark",2016-12-20 05:54:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sochA4dHSzk/market-snapshot-dow-futures-point-to-slow-march-higher-toward-key-20000-mark-20161220-00107,"MARKET SNAPSHOT: Dow Futures Point To Slow March Higher Toward Key 20,000 Mark"
NVS,NVS:US,BBG000LYF3S8,European Stocks Mixed After Terror Attacks,2016-12-20 05:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8oxUv6YVTcY/european-stocks-mixed-after-terror-attacks-20161220-00104,European Stocks Mixed After Terror Attacks
NVS,NVS:US,BBG000LYF3S8,EUROPE MARKETS: European Stocks Rise To 2016 High As Italian Banks Swing Higher,2016-12-20 04:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K83ub8mylxg/europe-markets-european-stocks-rise-to-2016-high-as-italian-banks-swing-higher-20161220-00087,EUROPE MARKETS: European Stocks Rise To 2016 High As Italian Banks Swing Higher
NVS,NVS:US,BBG000LYF3S8,Novartis To Acquire Encore Vision - Quick Facts,2016-12-20 01:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MOCE5zSqTOw/novartis-to-acquire-encore-vision--quick-facts-20161220-00024,Novartis To Acquire Encore Vision - Quick Facts
NVS,NVS:US,BBG000LYF3S8,Fovista Flops: What's Next?,2016-12-19 22:51:19 +0000,http://www.fool.com/investing/2016/12/19/fovista-flops-whats-next.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Fovista Flops: What's Next?
NVS,NVS:US,BBG000LYF3S8,Conatus shares skyrocket after Novartis license deal,2016-12-19 22:21:50 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=DD84390D-DCCC-4D0B-8333-A0EF460327EF&siteid=yhoof2,Conatus shares skyrocket after Novartis license deal
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Gets Positive CHMP Opinion for Key Drugs,2016-12-19 22:20:10 +0000,http://finance.yahoo.com/news/novartis-nvs-gets-positive-chmp-222010295.html,Novartis (NVS) Gets Positive CHMP Opinion for Key Drugs
NVS,NVS:US,BBG000LYF3S8,"Novartis announces exclusive option, collaboration and license agreement with Conatus to develop new oral treatments for chronic liver diseases",2016-12-19 21:52:12 +0000,http://www.publicnow.com/view/E1F608E65BFA0A3C5ACAE6229A389E21176CBDA2,"[at noodls] - Novartis to broaden liver portfolio to deliver best-in-class single and combination therapies for non-alcoholic steatohepatitis (NASH) with advanced fibrosis and cirrhosis through an option, collaboration ..."
NVS,NVS:US,BBG000LYF3S8,Novartis Inks Deal With Conatus Pharma For Chronic Liver Diseases,2016-12-19 21:50:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fu7uxJJOOUQ/novartis-inks-deal-with-conatus-pharma-for-chronic-liver-diseases-20161219-01011,Novartis Inks Deal With Conatus Pharma For Chronic Liver Diseases
NVS,NVS:US,BBG000LYF3S8,Incyte Could Step Onto Auction Block With Strong Jakafi Sales: RBC,2016-12-19 21:14:27 +0000,http://www.investors.com/news/technology/incyte-could-step-onto-auction-block-with-strong-jakafi-sales-rbc/,Incyte Could Step Onto Auction Block With Strong Jakafi Sales: RBC
NVS,NVS:US,BBG000LYF3S8,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch",2016-12-19 20:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9I2-LeJFKKM/clvs-gets-fda-nod-pbyi-leaves-big-board-loxo-hits-alltime-high-cnat-on-watch-20161219-01000,"CLVS Gets FDA Nod, PBYI Leaves Big Board, LOXO Hits All-time High, CNAT On Watch"
NVS,NVS:US,BBG000LYF3S8,Fovista Flops: What's Next?,2016-12-19 17:59:38 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/l9JPSLZbYfo/fovista-flops-whats-next-cm723400,After delivering solid results in mid stage studies Ophthotech s NASDAQ OPHT Fovista has flunked its phase 3 trials Fovista s inability to improve vision in wet age related macular degeneration patients derails a multibillion dollar opportunity for Ophthotech and casts doubt on
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case",2016-12-19 13:58:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kl0cHeX8hw8/pharma-stock-roundup-lilly-up-on-guidance-merck-awarded-254b-in-hcv-case-cm723128,Lilly LLY provided better than expected guidance for 2017 leaving investors happy with the numbers Merck MRK also had some good news with a jury awarding the company 2 54 billion in its patent infringement case against Gilead Meanwhile drug pricing remains in the news with 20 states
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case",2016-12-19 12:33:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-lilly-guidance-123312897.html,"Pharma Stock Roundup: Lilly Up on Guidance, Merck Awarded $2.54B in HCV Case"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Small Gain,2016-12-19 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZYvT5qXQJcw/the-swiss-stock-market-finished-with-a-small-gain-20161219-00653,The Swiss Stock Market Finished With A Small Gain
NVS,NVS:US,BBG000LYF3S8,Novartis' Big News at ASH? It's Still in the CAR-T Race,2016-12-17 14:05:25 +0000,http://www.fool.com/investing/2016/12/16/novartis-big-news-at-ash-its-still-in-the-car-t-ra.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Novartis' Big News at ASH? It's Still in the CAR-T Race
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis Buys Dermatology Company Ziarco,2016-12-16 23:51:06 +0000,http://www.wsj.com/articles/novartis-buys-dermatology-company-ziarco-1481932261?mod=yahoo_hs,[$$] Novartis Buys Dermatology Company Ziarco
NVS,NVS:US,BBG000LYF3S8,"ETFs with exposure to Novartis AG : December 16, 2016",2016-12-16 17:01:14 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-novartis-ag-december-16-2016/,"ETFs with exposure to Novartis AG : December 16, 2016"
NVS,NVS:US,BBG000LYF3S8,Novartis' Big News at ASH? It's Still in the CAR-T Race,2016-12-16 15:59:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nDtWYqA-X6o/novartis-big-news-at-ash-its-still-in-the-car-t-race-cm722485,Novartis NYSE NVS may not get the splashy coverage bestowed on CAR T competitors Juno Therapeutics NASDAQ JUNO and Kite Pharma NASDAQ KITE but that doesn t mean that Novartis isn t still among the leaders in developing this revolutionary new way of fighting cancer
NVS,NVS:US,BBG000LYF3S8,Health Care Sector Update for 12/16/2016: NVS,2016-12-16 15:16:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QbN-6M1pLqs/health-care-sector-update-for-12162016-nvs-cm722418,Top Health care stocks Top Health care stocks JNJ 0 4 JNJ 0 4 PFE 0 2 PFE 0 2 ABT 0 2 ABT 0 2 MRK 0 3 MRK 0 3 AMGN 0 1 AMGN 0 1 Health care shares were mainly higher in early trade on Friday Health care shares were mainly higher in early trade on Friday In health
NVS,NVS:US,BBG000LYF3S8,Novartis receives positive CHMP recommendation for Ilaris® to treat rare diseases in adults and children called Periodic Fever Syndromes,2016-12-16 12:38:11 +0000,http://www.publicnow.com/view/FE56646714FFC7E8C1B9F54BDA1C6D476621D5F0,[at noodls] - Periodic Fever Syndromes are rare diseases mostly affecting children and cause recurrent and disabling fevers with potentially life-threatening complications Ilaris® (canakinumab) is recommended ...
NVS,NVS:US,BBG000LYF3S8,Novartis drug Votubia® recommended by CHMP for EU approval to treat refractory partial-onset seizures in patients with TSC,2016-12-16 12:38:11 +0000,http://www.publicnow.com/view/41847D1DB4E9C62002D27CA4ABB1C55B77B6827E,"[at noodls] - If approved, Votubia would be the first adjunctive treatment specifically for refractory seizures in children and adults with tuberous sclerosis complex (TSC) Seizures are the most common TSC-related ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Managed A Slight Gain In Quiet Trade,2016-12-16 12:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/UAYD3jkMDjI/the-swiss-stock-market-managed-a-slight-gain-in-quiet-trade-20161216-00493,The Swiss Stock Market Managed A Slight Gain In Quiet Trade
NVS,NVS:US,BBG000LYF3S8,Novartis: CHMP Recommends Approval Of Ilaris In Europe - Quick Facts,2016-12-16 07:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-YZeSx8tO2k/novartis-chmp-recommends-approval-of-ilaris-in-europe--quick-facts-20161216-00185,Novartis: CHMP Recommends Approval Of Ilaris In Europe - Quick Facts
NVS,NVS:US,BBG000LYF3S8,Novartis says buys Ziarco Group to expand skin care portfolio,2016-12-16 06:32:23 +0000,http://sg.finance.yahoo.com/news/novartis-says-buys-ziarco-group-063223472.html,Novartis says buys Ziarco Group to expand skin care portfolio
NVS,NVS:US,BBG000LYF3S8,Novartis bolsters innovative dermatology portfolio through acquisition of Ziarco Group Limited,2016-12-16 06:28:09 +0000,http://www.publicnow.com/view/B8A464C762BD2E4B8274F220BEB936E150BD4CB1,"[at noodls] - Acquisition to add a once-daily oral H receptor antagonist, ZPL389, to treat atopic dermatitis, commonly known as eczema, to the Novartis industry-leading pipeline Investigational ZPL389 showed a clinically ..."
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Acquisition Of Ziarco Group - Quick Facts,2016-12-16 01:37:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/epyzih9T2vk/novartis-announces-acquisition-of-ziarco-group--quick-facts-20161216-00017,Novartis Announces Acquisition Of Ziarco Group - Quick Facts
NVS,NVS:US,BBG000LYF3S8,"VEU, NSRGY, NVS, TM: Large Inflows Detected at ETF",2016-12-15 16:58:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w_P5EAAgBV8/veu-nsrgy-nvs-tm-large-inflows-detected-at-etf-cm721967,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 159 9 million dollar inflow that s a 1 1 increase week over week
NVS,NVS:US,BBG000LYF3S8,Pfizer: FDA Approves Eczema Ointment; Xtandi Fails Study,2016-12-15 12:58:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dLr7fK1IuNo/pfizer-fda-approves-eczema-ointment-xtandi-fails-study-cm721732,Pfizer Inc PFE announced that it received FDA approval for crisaborole topical ointment to treat mild to moderate eczema or atopic dermatitis in patients two years and older The ointment will be sold under the brand name Eucrisa Pfizer shares have risen 2 1 this month so far lower
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Broke Out Past The 8,200 Point Level",2016-12-15 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1bFULoIpGrs/the-swiss-stock-market-broke-out-past-the-8200-point-level-20161215-00791,"The Swiss Stock Market Broke Out Past The 8,200 Point Level"
NVS,NVS:US,BBG000LYF3S8,Grifols To Buy Hologic's NAT Donor Screening Unit For $1.85 Bln,2016-12-14 17:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kb8KmTR2IwQ/grifols-to-buy-hologics-nat-donor-screening-unit-for-185-bln-20161214-01005,Grifols To Buy Hologic's NAT Donor Screening Unit For $1.85 Bln
NVS,NVS:US,BBG000LYF3S8,Washington Cuts a Check to Spark Healthcare Innovation,2016-12-14 14:58:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fm5wcQe7Ui8/washington-cuts-a-check-to-spark-healthcare-innovation-cm721178,The 21st Century Cures Act aims to 160 ignite 160 innovation with 160 perks to biopharma and medical device makers that could increase drug and device development shrink regulation and accelerate how quickly new treatments make it to market Will the 21st Century Cure Act be a boon
NVS,NVS:US,BBG000LYF3S8,Washington Cuts a Check to Spark Healthcare Innovation,2016-12-14 13:04:05 +0000,http://www.fool.com/investing/2016/12/14/washington-cuts-a-check-to-spark-healthcare-innova.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Washington Cuts a Check to Spark Healthcare Innovation
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Slipped In Cautious Trade Ahead Of Fed Decision,2016-12-14 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/djZDpR76Y9w/the-swiss-stock-market-slipped-in-cautious-trade-ahead-of-fed-decision-20161214-00687,The Swiss Stock Market Slipped In Cautious Trade Ahead Of Fed Decision
NVS,NVS:US,BBG000LYF3S8,How You Can Profit as the Market for COPD Drugs Grows,2016-12-13 19:12:00 +0000,https://www.thestreet.com/story/13924244/1/how-you-can-profit-as-the-market-for-copd-drugs-grows.html?puc=yahoo&cm_ven=YAHOO,How You Can Profit as the Market for COPD Drugs Grows
NVS,NVS:US,BBG000LYF3S8,European ADRs Rally as Telecommunications Stocks Advance,2016-12-13 16:16:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1S-pyqLlYEQ/european-adrs-rally-as-telecommunications-stocks-advance-cm720726,American depository receipts of European stocks were 1 2 higher at 120 75 on the Bank of New York Mellon Europe ADR Index on Tuesday morning American depository receipts of European stocks were 1 2 higher at 120 75 on the Bank of New York Mellon Europe ADR Index on Tuesday morning Gainers
NVS,NVS:US,BBG000LYF3S8,Ophthotech Hits 52-Week Low on Unfavorable Fovista Data,2016-12-13 16:00:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/n-GHZjv1X-o/ophthotech-hits-52-week-low-on-unfavorable-fovista-data-cm720664,Ophthotech Corporation s OPHT shares tumbled 86 4 after the company along with partner Novartis AG NVS announced disappointing results from two pivotal phase III studies OPH1002 and OPH1003 evaluating Fovista an anti PDGF therapy in combination with Novartis Roche Holding AG s
NVS,NVS:US,BBG000LYF3S8,Ophthotech Hits 52-Week Low on Unfavorable Fovista Data,2016-12-13 14:03:02 +0000,http://finance.yahoo.com/news/ophthotech-hits-52-week-low-140302223.html,Ophthotech Hits 52-Week Low on Unfavorable Fovista Data
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Surged As Heavyweights Charge Higher,2016-12-13 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qA60Byu_X2E/the-swiss-stock-market-surged-as-heavyweights-charge-higher-20161213-00683,The Swiss Stock Market Surged As Heavyweights Charge Higher
NVS,NVS:US,BBG000LYF3S8,Regeneron Spikes On Blurry-Eye Win Vs. Failed Ophthotech Drug,2016-12-12 21:18:39 +0000,http://www.investors.com/news/technology/regeneron-spikes-on-blurry-eye-win-vs-failed-ophthotech-drug/,Regeneron Spikes On Blurry-Eye Win Vs. Failed Ophthotech Drug
NVS,NVS:US,BBG000LYF3S8,Ophthotech Plunges After Eye Drug Fails Phase 3,2016-12-12 19:20:00 +0000,http://www.investopedia.com/news/ophthotech-novartis-eye-drug-fails-opht-nvs/?partner=YahooSA,Ophthotech Plunges After Eye Drug Fails Phase 3
NVS,NVS:US,BBG000LYF3S8,Keep An Eye On Regeneron,2016-12-12 19:17:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/12/12/keep-an-eye-on-regeneron/?mod=yahoobarrons&ru=yahoo,Keep An Eye On Regeneron
NVS,NVS:US,BBG000LYF3S8,Here's Why Ophthotech Corporation Is Being Obliterated Today,2016-12-12 18:58:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M2lE4X-7vPo/heres-why-ophthotech-corporation-is-being-obliterated-today-cm720260,Image source Getty Images What happened Investors in Ophthotech NASDAQ OPHT 160 a clinical stage biotech primarily focused on diseases of the eye are having a brutal start to the trading week Shares have utterly collapsed falling by 84 as of 11 15 a m EST
NVS,NVS:US,BBG000LYF3S8,"VEA, PWC: Big ETF Inflows",2016-12-12 16:57:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bhcq3GZ1JDc/vea-pwc-big-etf-inflows-cm720103,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE Developed Markets ETF VEA which added 13 000 000 units or a 1 2 increase week over week Among the largest underlying components of VEA
NVS,NVS:US,BBG000LYF3S8,Novartis Offers Positive Data on Breast Cancer Drug LEE011,2016-12-12 16:00:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DqB4t1x20g8/novartis-offers-positive-data-on-breast-cancer-drug-lee011-cm720002,Shares of Novartis AG NVS gained 3 2 after the company announced encouraging data from a phase III study MONALEESA 2 on its breast cancer candidate LEE011 ribociclib A look at Novartis year to date share price movement shows that the stock has underperformed the Zacks classified
NVS,NVS:US,BBG000LYF3S8,Ophthotech Plunges on Eye-Drug-Study Failure,2016-12-12 15:23:00 +0000,https://www.thestreet.com/story/13921785/1/ophthotech-plunges-on-eye-drug-study-failure.html?puc=yahoo&cm_ven=YAHOO,Ophthotech Plunges on Eye-Drug-Study Failure
NVS,NVS:US,BBG000LYF3S8,Novartis Offers Positive Data on Breast Cancer Drug LEE011,2016-12-12 14:18:02 +0000,http://finance.yahoo.com/news/novartis-offers-positive-data-breast-141802012.html,Novartis Offers Positive Data on Breast Cancer Drug LEE011
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Started The Week With A Loss - Lonza Under Pressure,2016-12-12 12:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4R_HjPUJ4fg/the-swiss-stock-market-started-the-week-with-a-loss--lonza-under-pressure-20161212-00667,The Swiss Stock Market Started The Week With A Loss - Lonza Under Pressure
NVS,NVS:US,BBG000LYF3S8,Novartis eye drug franchise hit by failed Fovista studies,2016-12-12 08:57:54 +0000,http://finance.yahoo.com/news/novartis-eye-drug-franchise-hit-085754435.html,Novartis eye drug franchise hit by failed Fovista studies
NVS,NVS:US,BBG000LYF3S8,3 reasons to buy GlaxoSmithKline plc’s 5.5% yield before the market catches on,2016-12-12 08:56:41 +0000,http://uk.finance.yahoo.com/news/3-reasons-buy-glaxosmithkline-plc-085641805.html,3 reasons to buy GlaxoSmithKline plc’s 5.5% yield before the market catches on
NVS,NVS:US,BBG000LYF3S8,Novartis eye drug franchise takes hit with failed Fovista studies,2016-12-12 07:52:51 +0000,http://finance.yahoo.com/news/novartis-eye-drug-franchise-takes-075251111.html,Novartis eye drug franchise takes hit with failed Fovista studies
NVS,NVS:US,BBG000LYF3S8,Novartis: Pegpleranib Trial In Wet AMD Patients Fails To Meet Primary Endpoint,2016-12-12 01:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KnZN_6otwS8/novartis-pegpleranib-trial-in-wet-amd-patients-fails-to-meet-primary-endpoint-20161212-00017,Novartis: Pegpleranib Trial In Wet AMD Patients Fails To Meet Primary Endpoint
NVS,NVS:US,BBG000LYF3S8,Do Hedge Funds Love Toyota Motor Corporation (ADR) (TM)?,2016-12-10 20:22:16 +0000,http://www.insidermonkey.com/blog/do-hedge-funds-love-toyota-motor-corporation-adr-tm-504325/,Do Hedge Funds Love Toyota Motor Corporation (ADR) (TM)?
NVS,NVS:US,BBG000LYF3S8,Cohen's Point72 Bets Big Ahead of Ophthotech Corp. Trial Results,2016-12-09 21:56:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-XIxeiyblk0/cohens-point72-bets-big-ahead-of-ophthotech-corp-trial-results-cm719594,Ophthotech Corp NASDAQ OPHT is poised to report registration ready late stage trial results for its vision restoring drug Fovista and it appears at least one iconic hedge fund manager thinks that those results will be good On Thursday Point72 Asset Management the family
NVS,NVS:US,BBG000LYF3S8,3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats,2016-12-09 17:08:00 +0000,https://www.thestreet.com/story/13919344/1/3-hot-and-undervalued-biotechs-that-are-immune-to-trump-s-threats.html?puc=yahoo&cm_ven=YAHOO,3 Hot and Undervalued Biotechs That Are Immune to Trump's Threats
NVS,NVS:US,BBG000LYF3S8,European ADRs Advance as Biopharmaceutical Stocks Rally,2016-12-09 16:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pt9xgokOD6g/european-adrs-advance-as-biopharmaceutical-stocks-rally-cm719362,American depository receipts of European stocks were 0 16 higher at 119 09 on the Bank of New York Mellon Europe ADR Index on Friday morning American depository receipts of European stocks were 0 16 higher at 119 09 on the Bank of New York Mellon Europe ADR Index on Friday morning Gainers
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Surged Back Above 8,000 Points On Pharma Strength",2016-12-09 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VHo5X7w9mec/the-swiss-stock-market-surged-back-above-8000-points-on-pharma-strength-20161209-00448,"The Swiss Stock Market Surged Back Above 8,000 Points On Pharma Strength"
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Addl Analyses From Phase III MONALEESA-2 Study,2016-12-09 09:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_RE7Q9RNNdc/novartis-announces-addl-analyses-from-phase-iii-monaleesa2-study-20161209-00289,Novartis Announces Addl Analyses From Phase III MONALEESA-2 Study
NVS,NVS:US,BBG000LYF3S8,"FitBit, Gilead Sciences in Thursday’s 52-Week Low Club",2016-12-08 21:04:36 +0000,http://247wallst.com/investing/2016/12/08/fitbit-gilead-sciences-in-thursdays-52-week-low-club/,"FitBit, Gilead Sciences in Thursday’s 52-Week Low Club"
NVS,NVS:US,BBG000LYF3S8,Novartis Lung Cancer Drug Beats Chemo in Study,2016-12-08 18:50:00 +0000,http://www.investopedia.com/news/novartis-lung-cancer-drug-succeeds-trial-nvs/?partner=YahooSA,Novartis Lung Cancer Drug Beats Chemo in Study
NVS,NVS:US,BBG000LYF3S8,European ADRs Edge Lower as Manufacturers Post Mixed Fortunes,2016-12-08 16:35:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/L3Uzfto19FM/european-adrs-edge-lower-as-manufacturers-post-mixed-fortunes-cm718712,American depository receipts of European stocks were 0 52 lower at 118 50 on the Bank of New York Mellon Europe ADR Index on Thursday morning American depository receipts of European stocks were 0 52 lower at 118 50 on the Bank of New York Mellon Europe ADR Index on Thursday morning Decliners
NVS,NVS:US,BBG000LYF3S8,7 Stocks for Retirees to Beat the Market in 2017,2016-12-08 13:55:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/MULiXOZlXUE/7-stocks-for-retirees-to-beat-the-market-in-2017-cm718483,When I look for good stocks I often turn to Morningstar Although it s much better known for its mutual fund research the Chicago based firm boasts a superb record with its stock selections What s more few institutional investors seem to pay attention to Morningstar s stock picks That
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Modestly Higher After ECB Decision,2016-12-08 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Oiu4JdF8928/the-swiss-stock-market-finished-modestly-higher-after-ecb-decision-20161208-00746,The Swiss Stock Market Finished Modestly Higher After ECB Decision
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Modestly Higher After ECB Decision,2016-12-08 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2WjdI6xgT1E/the-swiss-stock-market-finished-modestly-higher-after-ecb-decision-20161208-00745,The Swiss Stock Market Finished Modestly Higher After ECB Decision
NVS,NVS:US,BBG000LYF3S8,Novartis Says Ultibro Breezhaler Improved Lung Function,2016-12-08 02:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kY54PYJ9Wi4/novartis-says-ultibro-breezhaler-improved-lung-function-20161208-00047,Novartis Says Ultibro Breezhaler Improved Lung Function
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study,2016-12-07 16:00:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GpJtBczOatE/novartis-nvs-zykadia-positive-in-phase-iii-ascend-4-study-cm717962,Novartis AG NVS announced results from the phase III ASCEND 4 study on its oncology drug Zykadia for the treatment of patients with advanced anaplastic lymphoma kinase positive ALK non small cell lung cancer NSCLC A look at Novartis year to date share price movement shows that
NVS,NVS:US,BBG000LYF3S8,Teva Copaxone EU Label to Omit Pregnancy Contraindication,2016-12-07 16:00:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qH8ieVntLC4/teva-copaxone-eu-label-to-omit-pregnancy-contraindication-cm717944,Teva Pharmaceutical Industries Ltd TEVA announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU The latest label update will improve the safety and tolerability profile of the multiple sclerosis drug
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study,2016-12-07 14:00:02 +0000,http://finance.yahoo.com/news/novartis-nvs-zykadia-positive-phase-140002227.html,Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
NVS,NVS:US,BBG000LYF3S8,Sanofi and Johnson & Johnson May Battle for the Right to Overpay for Actelion,2016-12-07 13:56:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h6uJ_TbYeJ8/sanofi-and-johnson-johnson-may-battle-for-the-right-to-overpay-for-actelion-cm717825,Image source Getty Images Who said mergers and acquisitions M amp A were slowing down in the drug industry Certainly not healthcare conglomerate Johnson amp Johnson NYSE JNJ which has made two bids now to acquire Swiss drugmaker Actelion NASDAQOTH ALIOF
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Small Gain - Credit Suisse In Focus,2016-12-07 12:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xCQJT9uy1Os/the-swiss-stock-market-finished-with-a-small-gain--credit-suisse-in-focus-20161207-00773,The Swiss Stock Market Finished With A Small Gain - Credit Suisse In Focus
NVS,NVS:US,BBG000LYF3S8,Sanofi May Battle Johnson & Johnson For European Biotech Actelion,2016-12-06 21:49:03 +0000,http://www.investors.com/news/technology/sanofi-pressures-johnsons-27-billion-on-european-biotech-actelion/,Sanofi May Battle Johnson & Johnson For European Biotech Actelion
NVS,NVS:US,BBG000LYF3S8,3 Beaten-Down Generic Drugmakers to Buy,2016-12-06 21:27:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Eme2rex36mo/3-beaten-down-generic-drugmakers-to-buy-cm717611,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Earlier in November some of the largest firms in the generic drugs firm space received subpoenas from the U S Justice Department The Justice Department is alleging that certain generic drugmakers may
NVS,NVS:US,BBG000LYF3S8,Novartis' drug tops chemotherapy in untreated lung cancer patients,2016-12-06 13:47:10 +0000,http://finance.yahoo.com/news/novartis-drug-tops-chemotherapy-untreated-134710417.html,"[Reuters] - Novartis AG said its cancer drug, Zykadia, was twice as effective as chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study. Patients with anaplastic lymphoma kinase-positive (ALK+)advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to 8.1 months for those on chemotherapy. Novartis' drug also has conditional approval as a second-line treatment in Europe."
NVS,NVS:US,BBG000LYF3S8,Exclusive: Novartis in talks to sell some central nervous system drugs - sources,2016-12-06 13:27:17 +0000,http://finance.yahoo.com/news/exclusive-novartis-talks-sell-central-132717954.html,Exclusive: Novartis in talks to sell some central nervous system drugs - sources
NVS,NVS:US,BBG000LYF3S8,Novartis' drug tops standard therapy in untreated lung cancer patients,2016-12-06 13:08:01 +0000,http://finance.yahoo.com/news/novartis-drug-tops-standard-therapy-130801080.html,"[Reuters] - Novartis AG said its cancer drug, Zykadia, was twice as effective as standard chemotherapy in slowing the progression of a rare form of lung cancer in a late-stage study. Patients with anaplastic lymphoma kinase-positive (ALK+)advanced non-small cell lung cancer treated with Zykadia had a median progression-free survival of 16.6 months, compared to 8.1 months for those on standard chemotherapy."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed Again As Banks Rally,2016-12-06 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0sCfgCJHSJU/the-swiss-stock-market-climbed-again-as-banks-rally-20161206-00850,The Swiss Stock Market Climbed Again As Banks Rally
NVS,NVS:US,BBG000LYF3S8,Has GlaxoSmithKline Finally Turned the Corner?,2016-12-06 12:02:06 +0000,http://www.fool.com/investing/2016/12/06/has-glaxosmithkline-finally-turned-the-corner.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Has GlaxoSmithKline Finally Turned the Corner?
NVS,NVS:US,BBG000LYF3S8,Novartis: Zykadia More Than Doubles Progression-free Survival In ASCEND-4 Study,2016-12-06 04:08:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0xns9YxNVfs/novartis-zykadia-more-than-doubles-progressionfree-survival-in-ascend4-study-20161206-00094,Novartis: Zykadia More Than Doubles Progression-free Survival In ASCEND-4 Study
NVS,NVS:US,BBG000LYF3S8,Here is What Hedge Funds Think About Chevron Corporation (CVX),2016-12-05 22:54:23 +0000,http://www.insidermonkey.com/blog/here-is-what-hedge-funds-think-about-chevron-corporation-cvx-3-499237/,Here is What Hedge Funds Think About Chevron Corporation (CVX)
NVS,NVS:US,BBG000LYF3S8,Novartis Announces New Data From Tasigna ENESTop TFR,2016-12-05 22:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qs5pdfFZLqI/novartis-announces-new-data-from-tasigna-enestop-tfr-20161205-01184,Novartis Announces New Data From Tasigna ENESTop TFR
NVS,NVS:US,BBG000LYF3S8,What Smart Money Has To Say About Novartis AG (ADR) (NVS),2016-12-05 21:11:38 +0000,http://www.insidermonkey.com/blog/what-smart-money-has-to-say-about-novartis-ag-adr-nvs-492902/,What Smart Money Has To Say About Novartis AG (ADR) (NVS)
NVS,NVS:US,BBG000LYF3S8,Bloomberg : Sanofi To Explore Counterbid For Actelion Amid J&J Talks,2016-12-05 20:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1Y7NzYi8umA/bloomberg--sanofi-to-explore-counterbid-for-actelion-amid-jj-talks-20161205-01153,Bloomberg : Sanofi To Explore Counterbid For Actelion Amid J&J Talks
NVS,NVS:US,BBG000LYF3S8,"Novartis, Kite Race for Next-Gen Cancer Drug (NVS, KITE)",2016-12-05 18:07:00 +0000,http://www.investopedia.com/news/novartis-kite-cart-cancer-drug-race-nvs-kite/?partner=YahooSA,"Novartis, Kite Race for Next-Gen Cancer Drug (NVS, KITE)"
NVS,NVS:US,BBG000LYF3S8,Here are 4 Mass. biotechs making noise at the ASH conference so far,2016-12-05 18:00:08 +0000,http://www.bizjournals.com/boston/news/2016/12/05/here-are-4-mass-biotechs-making-noise-at-the-ash.html?ana=yahoo,Here are 4 Mass. biotechs making noise at the ASH conference so far
NVS,NVS:US,BBG000LYF3S8,"Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out",2016-12-05 12:15:00 +0000,https://www.thestreet.com/story/13913270/1/patient-deaths-safety-concerns-cause-juno-s-car-t-pipeline-to-skid-out.html?puc=yahoo&cm_ven=YAHOO,"Patient Deaths, Safety Concerns Cause Juno's CAR-T Pipeline to Skid Out"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Up As Investors Shrug Off Italian Referendum,2016-12-05 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AB_EFzgD3Uo/the-swiss-stock-market-finished-up-as-investors-shrug-off-italian-referendum-20161205-00773,The Swiss Stock Market Finished Up As Investors Shrug Off Italian Referendum
NVS,NVS:US,BBG000LYF3S8,European Markets Finished Higher Despite Italian Referendum Result,2016-12-05 11:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jZNMcfB6rWY/european-markets-finished-higher-despite-italian-referendum-result-20161205-00759,European Markets Finished Higher Despite Italian Referendum Result
NVS,NVS:US,BBG000LYF3S8,European Shares Recover From Early Losses,2016-12-05 04:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Kmxj-06424s/european-shares-recover-from-early-losses-20161205-00083,European Shares Recover From Early Losses
NVS,NVS:US,BBG000LYF3S8,Novartis: Interim Data Shows Potential Of GP2013 As Alternative Rituximab,2016-12-05 01:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Pt0xAA_hzzI/novartis-interim-data-shows-potential-of-gp2013-as-alternative-rituximab-20161205-00020,Novartis: Interim Data Shows Potential Of GP2013 As Alternative Rituximab
NVS,NVS:US,BBG000LYF3S8,Novartis CEO plays down prospects for Actelion bid: Blick,2016-12-04 12:52:36 +0000,http://finance.yahoo.com/news/novartis-ceo-plays-down-prospects-125236099.html,"[Reuters] - Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction. Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight, he said: ""We have always said that we will concentrate on complementary acquisitions in the range of $2 billion to $5 billion."" He did not elaborate. Actelion is worth nearly $20 billion at Friday's closing price."
NVS,NVS:US,BBG000LYF3S8,Novartis CEO plays down prospects for Actelion bid - Blick,2016-12-04 12:44:03 +0000,http://finance.yahoo.com/news/novartis-ceo-plays-down-prospects-124403010.html,"[Reuters] - Novartis Chief Executive Joe Jimenez has played down suggestions the Swiss drugmaker could bid for Swiss biotech group Actelion, which is in talks with U.S. healthcare group Johnson & Johnson about a transaction. Asked by Swiss Sunday newspaper SonntagsBlick whether Novartis could emerge as a white knight, he said: ""We have always said that we will concentrate on complementary acquisitions in the range of $2 billion to $5 billion."" He did not elaborate. Actelion is worth nearly $20 billion at Friday's closing price."
NVS,NVS:US,BBG000LYF3S8,Novartis Presents CTL019 Trial Results In Patients With R/r B-ALL,2016-12-04 06:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IitdCqdp964/novartis-presents-ctl019-trial-results-in-patients-with-rr-ball-20161204-00004,Novartis Presents CTL019 Trial Results In Patients With R/r B-ALL
NVS,NVS:US,BBG000LYF3S8,Novartis says 82 pct of leukemia patients in remission after CAR-T,2016-12-04 01:39:52 +0000,http://finance.yahoo.com/news/novartis-says-82-pct-leukemia-000001632.html,Novartis says 82 pct of leukemia patients in remission after CAR-T
NVS,NVS:US,BBG000LYF3S8,[$$] Our Favorite 10 Stock Picks for 2017,2016-12-03 05:01:00 +0000,http://www.barrons.com/articles/top-10-stock-picks-for-2017-1480748688?mod=yahoobarrons&ru=yahoo,[$$] Our Favorite 10 Stock Picks for 2017
NVS,NVS:US,BBG000LYF3S8,"How China Makes Money (BABA, PFE)",2016-12-02 16:23:00 +0000,http://www.investopedia.com/articles/investing/042815/fundamentals-how-china-makes-its-money.asp?partner=YahooSA,"How China Makes Money (BABA, PFE)"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Turned Positive Just Before The Close,2016-12-02 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nv-3bHD2VSQ/the-swiss-stock-market-turned-positive-just-before-the-close-20161202-00495,The Swiss Stock Market Turned Positive Just Before The Close
NVS,NVS:US,BBG000LYF3S8,"Noteworthy ETF Inflows: VEA, NSRGY, NVS, TM",2016-12-01 17:16:42 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B_6_ApNJpX4/noteworthy-etf-inflows-vea-nsrgy-nvs-tm-cm716372,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE Developed Markets ETF Symbol VEA where we have detected an approximate 180 4 million dollar inflow that s a 0 5 increase week over week
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Was Dragged Lower By Weak Performance Of Heavyweight,2016-12-01 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xu7qIjfPZFE/the-swiss-stock-market-was-dragged-lower-by-weak-performance-of-heavyweight-20161201-00884,The Swiss Stock Market Was Dragged Lower By Weak Performance Of Heavyweight
NVS,NVS:US,BBG000LYF3S8,"Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects",2016-11-30 22:20:00 +0000,https://www.thestreet.com/story/13909407/1/bluebird-celgene-t-cell-therapy-eliminates-multiple-myeloma-with-minimal-side-effects.html?puc=yahoo&cm_ven=YAHOO,"Bluebird, Celgene T-Cell Therapy Eliminates Multiple Myeloma With Minimal Side Effects"
NVS,NVS:US,BBG000LYF3S8,ARIAD's Leukemia Drug Iclusig Gets Full Approval in U.S.,2016-11-30 16:58:15 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z8cY7ZeXyuQ/ariads-leukemia-drug-iclusig-gets-full-approval-in-us-cm715746,ARIAD Pharmaceuticals Inc ARIA announced that the FDA has granted a full approval to its leukemia drug Iclusig ponatinib following its successful completion of the commitments made on the receipt of accelerated approval in Dec 2012 Iclusig is approved for the treatment of
NVS,NVS:US,BBG000LYF3S8,Royal Dutch Shell plc (ADR) (RDS): Are Hedge Funds Right About This Stock?,2016-11-30 16:36:24 +0000,http://www.insidermonkey.com/blog/royal-dutch-shell-plc-adr-rds-are-hedge-funds-right-about-this-stock-491730/,Royal Dutch Shell plc (ADR) (RDS): Are Hedge Funds Right About This Stock?
NVS,NVS:US,BBG000LYF3S8,10 Undervalued High-Yield Dividend Stocks Worth Buying Today,2016-11-30 15:27:00 +0000,https://www.thestreet.com/story/13905366/1/10-undervalued-high-yield-dividend-stocks-worth-buying-today.html?puc=yahoo&cm_ven=YAHOO,10 Undervalued High-Yield Dividend Stocks Worth Buying Today
NVS,NVS:US,BBG000LYF3S8,Johnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion,2016-11-30 14:55:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pw9VK8YRax8/johnson-johnson-throws-caution-to-the-wind-with-a-large-bid-for-actelion-cm715553,CEO Alex Gorsky Image source Johnson amp Johnson Healthcare conglomerate Johnson amp Johnson NYSE JNJ is a trend setter in the sector Anytime it makes a move its drug and device peers and Wall Street monitor closely Though Johnson amp Johnson has a cadre of
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Higher With Continued Focus On Actelion,2016-11-30 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/u-7HL8phtys/the-swiss-stock-market-finished-higher-with-continued-focus-on-actelion-20161130-00786,The Swiss Stock Market Finished Higher With Continued Focus On Actelion
NVS,NVS:US,BBG000LYF3S8,Johnson & Johnson Reportedly Hikes Bid For Swiss Drugmaker Actelion,2016-11-29 21:07:37 +0000,http://www.investors.com/news/technology/johnson-johnson-reportedly-hikes-bid-for-swiss-drugmaker-actelion/,Johnson & Johnson Reportedly Hikes Bid For Swiss Drugmaker Actelion
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Bounced Back From Early Weakness To Finish Higher,2016-11-29 12:19:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B94bFmKo5S8/the-swiss-stock-market-bounced-back-from-early-weakness-to-finish-higher-20161129-00817,The Swiss Stock Market Bounced Back From Early Weakness To Finish Higher
NVS,NVS:US,BBG000LYF3S8,Sleepy Johnson & Johnson (JNJ) Stock Could Finally Wake Up,2016-11-28 15:32:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TTu-Kh2F_vU/sleepy-johnson-johnson-jnj-stock-could-finally-wake-up-cm714469,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips While most of the drug industry went through merger mania this decade Johnson amp Johnson NYSE JNJ kept quiet The company did a number of acquisitions but they were all on the small side 160
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell Due To Weakness In Financials & Cyclicals,2016-11-28 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HMdNZ8vPYpg/the-swiss-stock-market-fell-due-to-weakness-in-financials--cyclicals-20161128-00618,The Swiss Stock Market Fell Due To Weakness In Financials & Cyclicals
NVS,NVS:US,BBG000LYF3S8,Johnson & Johnson Confirms Takeover Talks With Actelion Pharmaceuticals,2016-11-25 21:46:26 +0000,http://www.investors.com/news/technology/johnson-johnson-confirms-takeover-talks-with-actelion-pharmaceuticals/,Johnson & Johnson Confirms Takeover Talks With Actelion Pharmaceuticals
NVS,NVS:US,BBG000LYF3S8,Novartis Launches Heart Failure Network (NVS),2016-11-25 18:16:00 +0000,http://www.investopedia.com/news/novartis-unveils-heart-failure-social-network-nvs/?partner=YahooSA,Novartis Launches Heart Failure Network (NVS)
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Jumped On Strength Of Index Heavyweights,2016-11-25 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/b5c4R9rl4I8/the-swiss-stock-market-jumped-on-strength-of-index-heavyweights-20161125-00202,The Swiss Stock Market Jumped On Strength Of Index Heavyweights
NVS,NVS:US,BBG000LYF3S8,Here is What Hedge Funds Think About Chevron Corporation (CVX),2016-11-25 02:42:31 +0000,http://www.insidermonkey.com/blog/here-is-what-hedge-funds-think-about-chevron-corporation-cvx-2-491393/,Here is What Hedge Funds Think About Chevron Corporation (CVX)
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Closed Slightly Higher With Support From Novartis,2016-11-23 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RyphxKdmhI0/the-swiss-stock-market-closed-slightly-higher-with-support-from-novartis-20161123-00520,The Swiss Stock Market Closed Slightly Higher With Support From Novartis
NVS,NVS:US,BBG000LYF3S8,"AstraZeneca, Novartis Drop into Tuesday’s 52-Week Low Club",2016-11-22 21:04:46 +0000,http://finance.yahoo.com/news/astrazeneca-novartis-drop-tuesday-52-210446625.html,"AstraZeneca, Novartis Drop into Tuesday’s 52-Week Low Club"
NVS,NVS:US,BBG000LYF3S8,Novartis Buys Sickle Cell Drug Maker for $665M (NVS),2016-11-22 18:45:00 +0000,http://www.investopedia.com/news/novartis-buys-selexys-665-million-deal-nvs/?partner=YahooSA,Novartis Buys Sickle Cell Drug Maker for $665M (NVS)
NVS,NVS:US,BBG000LYF3S8,Stocks Slightly Higher; Amazon.com Among Hot Retail Stocks,2016-11-22 18:31:43 +0000,http://www.investors.com/market-trend/stock-market-today/stocks-slightly-higher-amazon-com-among-hot-retail-stocks/,Stocks Slightly Higher; Amazon.com Among Hot Retail Stocks
NVS,NVS:US,BBG000LYF3S8,"Company News for November 22, 2016",2016-11-22 17:20:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sDUPTc53B5w/company-news-for-november-22-2016-cm712734,Tyson Foods Inc s TSN shares slumped 14 5 after reporting fiscal fourth quarter earnings of 0 96 per share missing the Zacks Consensus Estimate of 1 24 Shares of Facebook Inc FB increased 4 1 after announcing a share repurchase program of nearly 6 billion starting
NVS,NVS:US,BBG000LYF3S8,Novartis Buys Selexys on Favorable Phase II Data on SelG1,2016-11-22 16:21:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/foGvRZBHge8/novartis-buys-selexys-on-favorable-phase-ii-data-on-selg1-cm712677,Swiss drug maker Novartis AG NVS announced that it has acquired Selexys Pharmaceuticals Corporation a privately held company specializing in the development of therapeutics for certain hematologic and inflammatory disorders following the receipt of results from the phase II SUSTAIN study
NVS,NVS:US,BBG000LYF3S8,European ADRs Fractionally Lower as Commodities Stocks See Mixed Fortunes,2016-11-22 15:58:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xxug7sni888/european-adrs-fractionally-lower-as-commodities-stocks-see-mixed-fortunes-cm712693,American depository receipts of European stocks were 0 1 lower at 114 96 on the Bank of New York Mellon Europe ADR Index on Tuesday morning American depository receipts of European stocks were 0 1 lower at 114 96 on the Bank of New York Mellon Europe ADR Index on Tuesday morning Decliners
NVS,NVS:US,BBG000LYF3S8,Novartis AG (ADR) (NVS) Acquires Selexys Pharmaceuticals Corp.,2016-11-22 15:28:34 +0000,http://www.insidermonkey.com/blog/novartis-ag-adr-nvs-acquires-selexys-pharmaceuticals-corp-489542/,Novartis AG (ADR) (NVS) Acquires Selexys Pharmaceuticals Corp.
NVS,NVS:US,BBG000LYF3S8,Teva's Leukemia Drug Gets EU Approval in First-Line Setting,2016-11-22 15:22:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fa9RVWjLN1g/tevas-leukemia-drug-gets-eu-approval-in-first-line-setting-cm712595,Teva Pharmaceutical Industries Ltd TEVA announced that the European Commission EC has approved a label expansion of Trisenox Now Trisenox in combination with retinoic acid can be used for the first line treatment of low to intermediate risk Acute Promyelocytic Leukemia APL Trisenox
NVS,NVS:US,BBG000LYF3S8,"Google, Novartis Delay Smart Lens (NVS, GOOGL)",2016-11-22 15:15:00 +0000,http://www.investopedia.com/news/novartis-delays-smart-contact-lens-nvs-googl/?partner=YahooSA,"[at Investopedia] - Novartis has delayed human trials of the ""smart"" contact lenses it's developing with Google."
NVS,NVS:US,BBG000LYF3S8,"Company News for November 22, 2016",2016-11-22 15:10:03 +0000,http://finance.yahoo.com/news/company-news-november-22-2016-151003037.html,"Company News for November 22, 2016"
NVS,NVS:US,BBG000LYF3S8,Novartis Buys Selexys on Favorable Phase II Data on SelG1,2016-11-22 13:59:01 +0000,http://finance.yahoo.com/news/novartis-buys-selexys-favorable-phase-135901345.html,Novartis Buys Selexys on Favorable Phase II Data on SelG1
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Losing Streak,2016-11-22 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/IzuXfHm3HQ4/the-swiss-stock-market-extended-its-losing-streak-20161122-00832,The Swiss Stock Market Extended Its Losing Streak
NVS,NVS:US,BBG000LYF3S8,"[$$] Novartis Picks Up Option to Buy Selexys Pharma, Could Pay $665M",2016-11-21 22:28:12 +0000,http://www.wsj.com/articles/novartis-picks-up-option-to-buy-selexys-pharma-could-pay-665m-1479767289?mod=yahoo_hs,"[$$] Novartis Picks Up Option to Buy Selexys Pharma, Could Pay $665M"
NVS,NVS:US,BBG000LYF3S8,Novartis Stock Dips On Selexys Pharma Acquisition,2016-11-21 21:43:43 +0000,http://www.investors.com/news/technology/novartis-stock-topples-on-665-million-selexys-pharma-buy/,Novartis Stock Dips On Selexys Pharma Acquisition
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis acquires Selexys in deal worth up to $665m,2016-11-21 17:18:19 +0000,"http://www.ft.com/cms/s/e3380f3e-aff4-11e6-a37c-f4a01f1b0fa1,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Swiss drugmaker Novartis is expanding its portfolio of blood disease medicines with the acquisition of Selexys Pharmaceuticals, the developer of a treatment for sickle cell disease, worth up to $665m. ..."
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar,2016-11-21 16:53:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dYq39BZg1Zo/novartis-nvs-reports-favorable-data-on-enbrel-biosimilar-cm711969,Novartis AG s NVS generic arm Sandoz announced the publication of results from EGALITY study in the British Journal of Dermatology The study showed that its biosimilar version of Amgen Inc s AMGN blockbuster drug Enbrel Erelzi is equivalent to the originator product in more than 500
NVS,NVS:US,BBG000LYF3S8,Nasdaq Back to New Highs; Energy Stocks Power Up,2016-11-21 15:15:42 +0000,http://www.investors.com/market-trend/stock-market-today/nasdaq-back-to-new-highs-energy-stocks-power-up/,Nasdaq Back to New Highs; Energy Stocks Power Up
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar,2016-11-21 14:59:02 +0000,http://finance.yahoo.com/news/novartis-nvs-reports-favorable-data-145902448.html,Novartis (NVS) Reports Favorable Data on Enbrel Biosimilar
NVS,NVS:US,BBG000LYF3S8,"Stocks Open Higher; LifeLock, Headwaters Spike On Merger News",2016-11-21 14:43:53 +0000,http://www.investors.com/market-trend/stock-market-today/stock-futures-oil-rise-lifelock-headwaters-spike/,"Stocks Open Higher; LifeLock, Headwaters Spike On Merger News"
NVS,NVS:US,BBG000LYF3S8,Stocks Rise With Advancing Metals,2016-11-21 13:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OhOCLXGHTpE/stocks-rise-with-advancing-metals-20161121-00219,Stocks Rise With Advancing Metals
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back After Weak Performance Of Novartis,2016-11-21 12:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vp8skiTPOoI/the-swiss-stock-market-pulled-back-after-weak-performance-of-novartis-20161121-00759,The Swiss Stock Market Pulled Back After Weak Performance Of Novartis
NVS,NVS:US,BBG000LYF3S8,European Markets Finished Mostly Higher After Rally In Commodities,2016-11-21 11:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vITWWwncWYI/european-markets-finished-mostly-higher-after-rally-in-commodities-20161121-00744,European Markets Finished Mostly Higher After Rally In Commodities
NVS,NVS:US,BBG000LYF3S8,Novartis buys U.S.-based sickle cell drugmaker Selexys,2016-11-21 10:03:37 +0000,http://www.marketwatch.com/News/Story/Story.aspx?guid=14C3EA48-8A56-4181-86DB-9EB564ABE8EC&siteid=yhoof2,Novartis buys U.S.-based sickle cell drugmaker Selexys
NVS,NVS:US,BBG000LYF3S8,Novartis buys US blood disease drugmaker in $665 mln deal,2016-11-21 08:58:31 +0000,http://finance.yahoo.com/news/novartis-buys-us-blood-disease-085831836.html,Novartis buys US blood disease drugmaker in $665 mln deal
NVS,NVS:US,BBG000LYF3S8,Novartis acquires Selexys Pharmaceuticals Corporation and SelG1 antibody for reduction of pain crises in sickle cell disease (SCD),2016-11-21 07:40:16 +0000,http://www.publicnow.com/view/DD8967505DA754B04561B2F47083499CE0F55021,"[at noodls] - Deal followed results of Phase II SUSTAIN study of SelG1 in reduction of vaso-occlusive pain crises, a major complication of SCD with limited treatment options Results of SUSTAIN will be presented in the ..."
NVS,NVS:US,BBG000LYF3S8,Novartis acquires US pharma research firm Selexys Pharmaceuticals,2016-11-21 07:13:07 +0000,http://uk.finance.yahoo.com/news/novartis-acquires-us-pharma-research-070945461.html,Novartis acquires US pharma research firm Selexys Pharmaceuticals
NVS,NVS:US,BBG000LYF3S8,Novartis commends publication of major report which recommends broad use of dual bronchodilators to treat COPD,2016-11-21 06:40:05 +0000,http://www.publicnow.com/view/1050D8FDBBF08191E179C94BEE31408A979AC665,"[at noodls] - 2017 GOLD report recommends the first-line use of dual bronchodilators, such as Ultibro Breezhaler, in the treatment of the majority of symptomatic COPD patients Bronchodilation regarded as the foundation ..."
NVS,NVS:US,BBG000LYF3S8,European Shares Edge Lower Ahead Of Draghi Speech,2016-11-21 05:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5U0LYJFnTqY/european-shares-edge-lower-ahead-of-draghi-speech-20161121-00094,European Shares Edge Lower Ahead Of Draghi Speech
NVS,NVS:US,BBG000LYF3S8,"European Stocks Edge Lower, Asia Gains -- Update",2016-11-21 04:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VL_f7AxAjsQ/european-stocks-edge-lower-asia-gains--update-20161121-00085,"European Stocks Edge Lower, Asia Gains -- Update"
NVS,NVS:US,BBG000LYF3S8,FTSE 100 Drifts Lower As Essentra Warns On Profits,2016-11-21 04:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tKQ9siWx-lU/ftse-100-drifts-lower-as-essentra-warns-on-profits-20161121-00084,FTSE 100 Drifts Lower As Essentra Warns On Profits
NVS,NVS:US,BBG000LYF3S8,European Stocks Edge Lower,2016-11-21 04:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9elS9qGj3Nk/european-stocks-edge-lower-20161121-00091,European Stocks Edge Lower
NVS,NVS:US,BBG000LYF3S8,Stocks Head for Trifecta of Closing Records,2016-11-21 04:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/abn8J38qcQc/stocks-head-for-trifecta-of-closing-records-20161121-00838,Stocks Head for Trifecta of Closing Records
NVS,NVS:US,BBG000LYF3S8,U.S. Stocks Close at Record Highs,2016-11-21 04:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FvyPbm_1vHg/us-stocks-close-at-record-highs-20161121-01030,U.S. Stocks Close at Record Highs
NVS,NVS:US,BBG000LYF3S8,S&P 500 Sets Intraday Record,2016-11-21 04:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nopHOS7rK4Y/sp-500-sets-intraday-record-20161121-00817,S&P 500 Sets Intraday Record
NVS,NVS:US,BBG000LYF3S8,Novartis Buys Selexys Following Receipt Of Results Of SelG1 Study,2016-11-21 01:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ldglN87IGrE/novartis-buys-selexys-following-receipt-of-results-of-selg1-study-20161121-00020,Novartis Buys Selexys Following Receipt Of Results Of SelG1 Study
NVS,NVS:US,BBG000LYF3S8,"Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis",2016-11-18 21:50:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v4deIMjQNUM/better-buy-regeneron-pharmaceuticals-inc-vs-novartis-cm711440,Both Regeneron Pharmaceuticals NASDAQ REGN and Novartis NYSE NVS have had better years However both drugmakers also have reasons to remain optimistic about the future Which of these two beaten down healthcare stocks is the better pick for long term investors Here s
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 11/18/2016: NVS,GOOG,GOOGL,EYEG,APRI",2016-11-18 21:29:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VBMecCIXHSY/health-care-sector-update-for-11182016-nvsgooggoogleyegapri-cm711472,Top Health Care StocksTop Health Care Stocks JNJ 0 27 JNJ 0 27 PFE 0 58 PFE 0 58 MRK 1 10 MRK 1 10 ABT 1 02 ABT 1 02 AMGN 1 18 AMGN 1 18 Health care stocks were sharply lower today with the NYSE Health Care Index falling over 1 2 while shares of health care companies in the S amp
NVS,NVS:US,BBG000LYF3S8,"Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis",2016-11-18 20:52:59 +0000,http://www.fool.com/investing/2016/11/18/better-buy-regeneron-pharmaceuticals-inc-vs-novart.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Better Buy: Regeneron Pharmaceuticals, Inc. vs. Novartis"
NVS,NVS:US,BBG000LYF3S8,Novartis backs off from 2016 date for testing Google autofocus lens,2016-11-18 18:03:41 +0000,http://sg.finance.yahoo.com/news/novartis-backs-off-2016-date-180341943.html,"[Reuters] - ""It is too early to say when exactly human clinical trials for these lenses will begin,"" a spokeswoman for the Basel-based drugmaker said in an email on Friday. Novartis Chief Executive Joe Jimenez said last year his company's Alcon eye care unit was on track to begin testing in 2016. In 2014, Jimenez said he hoped the lens would be on the market in about five years."
NVS,NVS:US,BBG000LYF3S8,Novartis backs off from 2016 date for testing Google autofocus lens,2016-11-18 16:59:04 +0000,http://sg.finance.yahoo.com/news/novartis-backs-off-2016-date-165904071.html,Novartis backs off from 2016 date for testing Google autofocus lens
NVS,NVS:US,BBG000LYF3S8,Novartis/Amgen Migraine Drug Positive in Phase III Study,2016-11-18 15:50:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Nl33DJdNgqY/novartisamgen-migraine-drug-positive-in-phase-iii-study-cm711157,Novartis AG NVS and partner Amgen Inc AMGN announced positive top line data from the second pivotal phase III study STRIVE on their calcitonin gene related peptide CGRP receptor AMG 334 erenumab for the prevention of episodic migraine The multicenter randomized 24 week double
NVS,NVS:US,BBG000LYF3S8,Novartis/Amgen Migraine Drug Positive in Phase III Study,2016-11-18 13:54:01 +0000,http://finance.yahoo.com/news/novartis-amgen-migraine-drug-positive-135401165.html,Novartis/Amgen Migraine Drug Positive in Phase III Study
NVS,NVS:US,BBG000LYF3S8,Seventh Sense gets $10 million funding injection,2016-11-18 12:10:08 +0000,http://www.bizjournals.com/boston/news/2016/11/18/medford-based-seventh-sense-gets-10-million.html?ana=yahoo,Seventh Sense gets $10 million funding injection
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Declined Due To Weakness Of The Defensive Heavyweights,2016-11-18 12:10:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X0mazJMp6j0/the-swiss-stock-market-declined-due-to-weakness-of-the-defensive-heavyweights-20161118-00550,The Swiss Stock Market Declined Due To Weakness Of The Defensive Heavyweights
NVS,NVS:US,BBG000LYF3S8,Pfizer (PFE) Ibrance Positive in Phase III Breast Cancer Study,2016-11-18 05:51:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FX5TAO-dTIE/pfizer-pfe-ibrance-positive-in-phase-iii-breast-cancer-study-cm710964,Pfizer Inc PFE announced that detailed results of phase III PALOMA 2 study evaluating the combination of its breast cancer drug Ibrance palbociclib and Novartis AG s NVS Femara letrozole for the treatment of first line ER HER2 metastatic breast cancer were published in The New
NVS,NVS:US,BBG000LYF3S8,Cramer Remix: Why the bank stocks are here to stay,2016-11-18 00:00:00 +0000,http://finance.yahoo.com/video/cramer-remix-why-bank-stocks-000000967.html,Cramer Remix: Why the bank stocks are here to stay
NVS,NVS:US,BBG000LYF3S8,"Amgen On Track For 2018 Migraine-Drug Launch, Beating 'Crowded Field'",2016-11-17 21:18:05 +0000,http://www.investors.com/news/technology/amgen-on-track-for-2018-migraine-drug-launch-beating-crowded-field/,"Amgen On Track For 2018 Migraine-Drug Launch, Beating 'Crowded Field'"
NVS,NVS:US,BBG000LYF3S8,Amgen's Migraine Drug Hits Primary Endpoint in STRIVE Study,2016-11-17 17:50:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SDkDXfPWt00/amgens-migraine-drug-hits-primary-endpoint-in-strive-study-cm710685,Amgen Inc AMGN announced top line data from a phase III study STRIVE which showed that its calcitonin gene related peptide CGRP receptor erenumab significantly reduced monthly migraine days in patients with episodic migraine Erenumab is being evaluated in two phase III studies for
NVS,NVS:US,BBG000LYF3S8,3 Compelling Reasons to Buy Celgene Corporation Stock Right Now,2016-11-17 16:04:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P27Nz3RBrVw/3-compelling-reasons-to-buy-celgene-corporation-stock-right-now-cm710581,If I didn t already own shares of Celgene NASDAQ CELG it would probably be the top stock on my list to buy There are plenty of reasons why buying this biotech stock makes sense including sustained growth of its blockbuster blood cancer drug But Celgene isn t just
NVS,NVS:US,BBG000LYF3S8,NYPD Union Goes After Drug Prices Amid DOJ Pharma Probe,2016-11-17 16:00:00 +0000,http://www.bloomberg.com/news/articles/2016-11-17/nypd-union-goes-after-drug-prices-amid-doj-pharma-investigation?cmpid=yhoo.headline,NYPD Union Goes After Drug Prices Amid DOJ Pharma Probe
NVS,NVS:US,BBG000LYF3S8,Amgen's Migraine Drug Hits Primary Endpoint in STRIVE Study,2016-11-17 15:14:03 +0000,http://finance.yahoo.com/news/amgens-migraine-drug-hits-primary-151403648.html,Amgen's Migraine Drug Hits Primary Endpoint in STRIVE Study
NVS,NVS:US,BBG000LYF3S8,Performance of Novartis’s Innovative Medicines Segment in 3Q16,2016-11-17 15:04:35 +0000,http://marketrealist.com/2016/11/performance-of-novartiss-innovative-medicines-segment-in-3q16/?utm_source=yahoo&utm_medium=feed,Performance of Novartis’s Innovative Medicines Segment in 3Q16
NVS,NVS:US,BBG000LYF3S8,Novartis’s Revenue Trend in 3Q16,2016-11-17 13:04:58 +0000,http://marketrealist.com/2016/11/novartiss-revenue-trend-in-3q16/?utm_source=yahoo&utm_medium=feed,Novartis’s Revenue Trend in 3Q16
NVS,NVS:US,BBG000LYF3S8,"Amgen, Novartis aim for big, crowded migraine market after new drug data",2016-11-17 09:47:15 +0000,http://finance.yahoo.com/news/amgen-novartis-aim-big-crowded-094715360.html,"Amgen, Novartis aim for big, crowded migraine market after new drug data"
NVS,NVS:US,BBG000LYF3S8,Novartis’s 3Q16 Earnings Surpass Analyst Estimates,2016-11-16 22:04:08 +0000,http://marketrealist.com/2016/11/novartiss-3q16-earnings-surpass-analyst-estimates/?utm_source=yahoo&utm_medium=feed,Novartis’s 3Q16 Earnings Surpass Analyst Estimates
NVS,NVS:US,BBG000LYF3S8,Changes in Novartis’s Valuation for 3Q16,2016-11-16 21:04:08 +0000,http://marketrealist.com/2016/11/changes-in-novartiss-valuation-for-3q16/?utm_source=yahoo&utm_medium=feed,Changes in Novartis’s Valuation for 3Q16
NVS,NVS:US,BBG000LYF3S8,Novartis AMG334 Reduces Monthly Migraine Days In PhaseIII Episodicmigraine Study,2016-11-16 19:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h2UefOVD-JY/novartis-amg334-reduces-monthly-migraine-days-in-phaseiii-episodicmigraine-study-20161116-01272,Novartis AMG334 Reduces Monthly Migraine Days In PhaseIII Episodicmigraine Study
NVS,NVS:US,BBG000LYF3S8,Most Analysts Rate Novartis a ‘Buy’,2016-11-16 18:51:45 +0000,http://marketrealist.com/2016/11/most-analysts-rate-novartis-a-buy/?utm_source=yahoo&utm_medium=feed,Most Analysts Rate Novartis a ‘Buy’
NVS,NVS:US,BBG000LYF3S8,Novartis Leukemia Drug Expedited by FDA (NVS),2016-11-16 17:31:00 +0000,http://www.investopedia.com/news/novartis-leukemia-drug-gets-fda-priority-nvs/?partner=YahooSA,Novartis Leukemia Drug Expedited by FDA (NVS)
NVS,NVS:US,BBG000LYF3S8,Novartis Offers Positive Data on Cardiovascular Drug Entresto,2016-11-16 14:53:07 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VLlNIYs-GC4/novartis-offers-positive-data-on-cardiovascular-drug-entresto-cm709875,Novartis AG NVS announced new analysis of the PARADIGM HF study on its cardiovascular drug Entresto at a scientific session of the American Heart Association AHA Findings from the study demonstrated that Entresto reduced the risk of first and repeated heart failure hospitalizations
NVS,NVS:US,BBG000LYF3S8,"Teva Pharmaceutical (TEVA) Beats on Q3 Earnings, Cuts View",2016-11-16 13:51:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/z1bL4GeFYyI/teva-pharmaceutical-teva-beats-on-q3-earnings-cuts-view-cm709844,Teva Pharmaceutical Industries Ltd TEVA reported third quarter earnings of 1 28 per share including equity compensation expenses which beat the Zacks Consensus Estimate of 1 27 However revenues of 5 6 billion missed the Zacks Consensus Estimate of 5 90 billion On a year over
NVS,NVS:US,BBG000LYF3S8,Novartis Offers Positive Data on Cardiovascular Drug Entresto,2016-11-16 12:59:12 +0000,http://finance.yahoo.com/news/novartis-offers-positive-data-cardiovascular-125912102.html,Novartis Offers Positive Data on Cardiovascular Drug Entresto
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Turned Positive In Late Trade,2016-11-16 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PgfA8B47DyY/the-swiss-stock-market-turned-positive-in-late-trade-20161116-00870,The Swiss Stock Market Turned Positive In Late Trade
NVS,NVS:US,BBG000LYF3S8,Novartis data at ASH and SABCS showcase latest innovations in development for patients with blood disorders and breast cancer,2016-11-16 06:38:04 +0000,http://www.publicnow.com/view/7823897F0B8BD7916BB82CBF23EAE52790578B9B,"[at noodls] - First results from global registrational trial of CAR T therapy, CTL019, in pediatric relapsed/refractory acute lymphoblastic leukemia Sub-group analyses from pivotal MONALEESA-2 trial of LEE011 (ribociclib) ..."
NVS,NVS:US,BBG000LYF3S8,"Amgen, Biogen, Eli Lilly Poised To Rocket On 'Most Important Event'",2016-11-15 21:28:18 +0000,http://www.investors.com/news/technology/amgen-biogen-eli-lilly-poised-to-rocket-on-the-most-important-event/,"Amgen, Biogen, Eli Lilly Poised To Rocket On 'Most Important Event'"
NVS,NVS:US,BBG000LYF3S8,New analysis of Novartis' Entresto® data shows long-term benefits on heart failure readmissions and total cardiovascular deaths,2016-11-15 18:28:09 +0000,http://www.publicnow.com/view/F5A8FADF0EF3F8C20B98542E6A1BF9300F4723EA,[at noodls] - Entresto reduced the risk of first and subsequent events of heart failure hospitalizations and cardiovascular deaths following heart failure hospitalization by 20%-24% compared to enalapril These findings ...
NVS,NVS:US,BBG000LYF3S8,Novartis Eyes $8B Buy of Generic Drug Firm (NVS),2016-11-15 16:45:00 +0000,http://www.investopedia.com/news/novartis-may-buy-generics-maker-amneal-8b-nvs/?partner=YahooSA,Novartis Eyes $8B Buy of Generic Drug Firm (NVS)
NVS,NVS:US,BBG000LYF3S8,Sanofi Opts into Alnylam's Fitusiran Hemophilia Program in U.S.,2016-11-15 16:31:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BsDv5OCn-Uo/sanofi-opts-into-alnylams-fitusiran-hemophilia-program-in-us-cm709457,Alnylam Pharmaceuticals Inc ALNY announced that Genzyme the specialty care global business unit of Sanofi SNY has elected to opt in to co develop and co commercialize fitusiran in the United States Canada and Western Europe Notably Fitusiran is an investigational RNA
NVS,NVS:US,BBG000LYF3S8,Novartis In Talks to Buy Generic Drug Maker,2016-11-14 22:23:00 +0000,http://www.thestreet.com/video/13892399/novartis-in-talks-to-buy-generic-drug-maker.html?puc=yahoov&cm_ven=YAHOOV,Novartis In Talks to Buy Generic Drug Maker
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 11/14/2016: NVS,CRBP,DVAX",2016-11-14 21:27:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oYgzmelGoiE/health-care-sector-update-for-11142016-nvscrbpdvax-cm708979,Top Health Care StocksTop Health Care Stocks JNJ 1 56 JNJ 1 56 PFE 0 61 PFE 0 61 MRK 0 66 MRK 0 66 ABT 2 37 ABT 2 37 AMGN 1 09 AMGN 1 09 Health care stocks were ending moderately lower during Monday trade with the NYSE Health Care Index falling about 0 5 while shares of health
NVS,NVS:US,BBG000LYF3S8,Stocks Close Mixed Following Lackluster Session - U.S. Commentary,2016-11-14 16:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xPWMrUJLOj8/stocks-close-mixed-following-lackluster-session--us-commentary-20161114-01198,Stocks Close Mixed Following Lackluster Session - U.S. Commentary
NVS,NVS:US,BBG000LYF3S8,Rummaging in the Medicine Cabinet,2016-11-14 15:11:20 +0000,http://www.bloomberg.com/gadfly/articles/2016-11-14/novartis-amneal-deal-would-do-little-for-drugmaker-s-pipeline?cmpid=yhoo.headline,Rummaging in the Medicine Cabinet
NVS,NVS:US,BBG000LYF3S8,The Novartis house that Vasella built gets extreme makeover,2016-11-14 14:31:12 +0000,http://sg.finance.yahoo.com/news/novartis-house-vasella-built-gets-143112392.html,The Novartis house that Vasella built gets extreme makeover
NVS,NVS:US,BBG000LYF3S8,Bank Strength Helps Swiss Stock Market Post A Small Gain,2016-11-14 12:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XmSxsVL2JSU/bank-strength-helps-swiss-stock-market-post-a-small-gain-20161114-00958,Bank Strength Helps Swiss Stock Market Post A Small Gain
NVS,NVS:US,BBG000LYF3S8,European Markets Pared Early Gains After Crude Oil Prices Turned Lower,2016-11-14 11:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/v8c3rk3aVs8/european-markets-pared-early-gains-after-crude-oil-prices-turned-lower-20161114-00913,European Markets Pared Early Gains After Crude Oil Prices Turned Lower
NVS,NVS:US,BBG000LYF3S8,Novartis drug PKC412 (midostaurin) granted FDA Priority Review for newly-diagnosed FLT3-mutated AML and advanced systemic mastocytosis,2016-11-14 06:57:06 +0000,http://www.publicnow.com/view/6F43052DF92BA58DBE2BD40465E632B4D9960555,"[at noodls] - Priority Review based on data from the largest clinical trials conducted to date in each indication, Designation will shorten FDA expected review time to within six months; EMA also accepted the ..."
NVS,NVS:US,BBG000LYF3S8,Novartis presents new Cosentyx data showing long-lasting efficacy in psoriatic arthritis over 3 years including patient-reported pain,2016-11-14 06:37:07 +0000,http://www.publicnow.com/view/F17AC450570E3C239BC000262F3022912421F9CF,[at noodls] - Cosentyx data show sustained improvements in the signs and symptoms of psoriatic arthritis (PsA) in approximately 80% of patients over 3 years* New data show that with Cosentyx the high ACR response ...
NVS,NVS:US,BBG000LYF3S8,European Shares Rally As Investors Ponder Trump''s Policies,2016-11-14 06:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8CJIBgK-c4I/european-shares-rally-as-investors-ponder-trumps-policies-20161114-00175,European Shares Rally As Investors Ponder Trump''s Policies
NVS,NVS:US,BBG000LYF3S8,Novartis: New Cosentyx Data Shows Long-lasting Efficacy In Psoriatic Arthritis,2016-11-14 01:51:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jj1V7dBN1cE/novartis-new-cosentyx-data-shows-longlasting-efficacy-in-psoriatic-arthritis-20161114-00029,Novartis: New Cosentyx Data Shows Long-lasting Efficacy In Psoriatic Arthritis
NVS,NVS:US,BBG000LYF3S8,Novartis'' PKC412 Granted FDA Priority Review For FLT3-mutated AML & Advanced SM,2016-11-14 01:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f2GXu8I5Gbo/novartis-pkc412-granted-fda-priority-review-for-flt3mutated-aml--advanced-sm-20161114-00025,Novartis'' PKC412 Granted FDA Priority Review For FLT3-mutated AML & Advanced SM
NVS,NVS:US,BBG000LYF3S8,Novartis improves ranking in 2016 Access to Medicine Index,2016-11-14 00:07:05 +0000,http://www.publicnow.com/view/55A7EED64B124D0CB46C51FA85A77811F01A96F2,[at noodls] - Novartis ranks third in 2016 ranking Company tops the industry in access-to-medicine management and capacity building Novartis integrated access strategy addressing all income segments stands out as best ...
NVS,NVS:US,BBG000LYF3S8,Novartis Reportedly Considering Sale Of Alcon Eye Care Division,2016-11-13 22:43:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HWZK5PCPzhU/novartis-reportedly-considering-sale-of-alcon-eye-care-division-20161113-00087,Novartis Reportedly Considering Sale Of Alcon Eye Care Division
NVS,NVS:US,BBG000LYF3S8,Novartis Said to Hold Talks to Buy Generics Maker Amneal,2016-11-13 21:39:48 +0000,http://www.bloomberg.com/news/articles/2016-11-13/novartis-said-to-hold-talks-to-buy-u-s-generics-maker-amneal?cmpid=yhoo.headline,Novartis Said to Hold Talks to Buy Generics Maker Amneal
NVS,NVS:US,BBG000LYF3S8,Inside AstraZeneca’s Revenue Fall in 3Q16,2016-11-11 23:04:10 +0000,http://marketrealist.com/2016/11/inside-astrazenecas-revenue-fall-in-3q16/?utm_source=yahoo&utm_medium=feed,Inside AstraZeneca’s Revenue Fall in 3Q16
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 11/11/2016: AZN,NVS,PTCT,CRMD",2016-11-11 21:27:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3zSiIDR87o4/health-care-sector-update-for-11112016-aznnvsptctcrmd-cm708115,Top Health Care StocksTop Health Care Stocks JNJ 0 91 JNJ 0 91 PFE 2 85 PFE 2 85 MRK 1 10 MRK 1 10 ABT 1 83 ABT 1 83 AMGN 1 90 AMGN 1 90 Health care stocks were closing considerably lower Friday with the NYSE Health Care Index sinking nearly 1 3 while shares of health
NVS,NVS:US,BBG000LYF3S8,Juno Therapeutics (JUNO) Q3 Loss Narrower than Expected,2016-11-11 15:16:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Z-EY87SM77g/juno-therapeutics-juno-q3-loss-narrower-than-expected-cm707707,Juno Therapeutics Inc JUNO reported a loss of 58 cents per share including stock based compensation expense in the third quarter of 2016 narrower than the Zacks Consensus Estimate loss of 64 cents However quarterly loss widened from the year ago figure of 53 cents The company
NVS,NVS:US,BBG000LYF3S8,Juno Therapeutics (JUNO) Q3 Loss Narrower than Expected,2016-11-11 13:13:01 +0000,http://finance.yahoo.com/news/juno-therapeutics-juno-q3-loss-131301370.html,Juno Therapeutics (JUNO) Q3 Loss Narrower than Expected
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Fell Friday, But Finished The Week Higher",2016-11-11 12:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/osVgHtBDGlU/the-swiss-stock-market-fell-friday-but-finished-the-week-higher-20161111-00460,"The Swiss Stock Market Fell Friday, But Finished The Week Higher"
NVS,NVS:US,BBG000LYF3S8,Looking Abroad for Dividend Growth,2016-11-11 11:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=779662&SR=Yahoo,Looking Abroad for Dividend Growth
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Slightly Higher On Bank Strength,2016-11-10 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/igeXFqUWAA0/the-swiss-stock-market-finished-slightly-higher-on-bank-strength-20161110-01010,The Swiss Stock Market Finished Slightly Higher On Bank Strength
NVS,NVS:US,BBG000LYF3S8,Pfizer wins EU's approval for Ibrance as Novartis readies rival drug,2016-11-10 08:05:47 +0000,http://finance.yahoo.com/news/pfizer-wins-eus-approval-ibrance-080547701.html,"[Reuters] - U.S. drugmaker Pfizer said on Wednesday it had won approval from the European Union for its best-selling breast cancer drug Ibrance, making it the first medicine of its kind to reach the European market. The decision, which had been expected following a positive recommendation from the European Medicines Agency in September, comes as Novartis readies a rival treatment called ribociclib. Novartis plans to file its rival medicine for approval worldwide this year, following promising clinical trial results."
NVS,NVS:US,BBG000LYF3S8,"Novartis, Pfizer cut prices to win UK approval for cancer drugs",2016-11-10 00:06:28 +0000,http://sg.finance.yahoo.com/news/novartis-pfizer-cut-prices-win-000628489.html,"Novartis, Pfizer cut prices to win UK approval for cancer drugs"
NVS,NVS:US,BBG000LYF3S8,This Unlucky Biotech Stock Has Entered The Value-Buy Zone (OPHT),2016-11-09 19:54:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3ySmC3IGV34/this-unlucky-biotech-stock-has-entered-the-value-buy-zone-opht-cm706666,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips The inherent volatility of biotech shares makes biotech investing among the most lucrative ways to invest in the stock market At the same time that volatility also makes it one of the
NVS,NVS:US,BBG000LYF3S8,"VEU, VTHR: Big ETF Inflows",2016-11-09 16:54:37 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LzA9f1fjFro/veu-vthr-big-etf-inflows-cm706461,Comparing units outstanding versus one week ago at the coverage universe of ETFs at ETF Channel the biggest inflow was seen in the Vanguard FTSE All World ex US ETF VEU which added 7 200 006 units or a 2 3 increase week over week Among the largest underlying components of VEU in
NVS,NVS:US,BBG000LYF3S8,"Ophthotech (OPHT) Q3 Loss Wider than Expected, Sales Fall",2016-11-09 14:57:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cHryhnPh_kQ/ophthotech-opht-q3-loss-wider-than-expected-sales-fall-cm706275,Ophthotech Corporation OPHT reported third quarter 2016 loss of 1 71 per share wider than both the Zacks Consensus Estimate of a loss of 1 60 and the year ago loss of 1 14 Since Ophthotech does not have any approved product in its portfolio yet the company s top line solely
NVS,NVS:US,BBG000LYF3S8,"Ophthotech (OPHT) Q3 Loss Wider than Expected, Sales Fall",2016-11-09 13:05:01 +0000,http://finance.yahoo.com/news/ophthotech-opht-q3-loss-wider-130501517.html,"Ophthotech (OPHT) Q3 Loss Wider than Expected, Sales Fall"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Jumped Despite Early Weakness,2016-11-09 12:44:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TKZSmOtwV9E/the-swiss-stock-market-jumped-despite-early-weakness-20161109-00918,The Swiss Stock Market Jumped Despite Early Weakness
NVS,NVS:US,BBG000LYF3S8,Is Juno Therapeutics a Bargain or a Value Trap?,2016-11-08 18:59:00 +0000,http://www.fool.com/investing/2016/11/07/is-juno-therapeutics-a-bargain-or-a-value-trap.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is Juno Therapeutics a Bargain or a Value Trap?
NVS,NVS:US,BBG000LYF3S8,Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance,2016-11-08 18:47:00 +0000,https://www.thestreet.com/story/13885447/1/gilead-sciences-next-challenge-to-incyte-s-myelofibrosis-drug-dominance.html?puc=yahoo&cm_ven=YAHOO,Gilead Sciences' Next Challenge to Incyte's Myelofibrosis Drug Dominance
NVS,NVS:US,BBG000LYF3S8,5 Healthcare Stocks Kahn Brothers Is Bullish On,2016-11-08 13:44:21 +0000,http://www.insidermonkey.com/blog/5-healthcare-stocks-kahn-brothers-is-bullish-on-485758/,5 Healthcare Stocks Kahn Brothers Is Bullish On
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Closed With A Slight Gain Ahead Of US Election,2016-11-08 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FgA2z1FrHVg/the-swiss-stock-market-closed-with-a-slight-gain-ahead-of-us-election-20161108-00904,The Swiss Stock Market Closed With A Slight Gain Ahead Of US Election
NVS,NVS:US,BBG000LYF3S8,AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected,2016-11-07 22:53:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cx8FZ9ZaKK0/aveo-pharmaceuticals-aveo-q3-loss-lower-than-expected-cm705275,AVEO Pharmaceuticals Inc AVEO reported a third quarter 2016 loss of 7 cents per share narrower than the Zacks Consensus Estimate of a loss of 12 cents The company had reported earnings of 14 cents per share in the year ago period FindTheCompany Graphiq AVEO does
NVS,NVS:US,BBG000LYF3S8,AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected,2016-11-07 20:59:08 +0000,http://finance.yahoo.com/news/aveo-pharmaceuticals-aveo-q3-loss-205908357.html,AVEO Pharmaceuticals' (AVEO) Q3 Loss Lower than Expected
NVS,NVS:US,BBG000LYF3S8,Is Juno Therapeutics a Bargain or a Value Trap?,2016-11-07 19:53:50 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/27Yn1uKBC5U/is-juno-therapeutics-a-bargain-or-a-value-trap-cm705173,Image source Getty Images What happened Shares of the clinical stage biotech Juno Therapeutics NASDAQ JUNO tumbled by more than 18 in October 160 according to data from S amp P Global Market Intelligence JUNO data by
NVS,NVS:US,BBG000LYF3S8,"Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for November 08, 2016",2016-11-07 15:22:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/N2pY8OMkrMA/pfizer-inc-pfe-ex-dividend-date-scheduled-for-november-08-2016-cm704812,Pfizer Inc PFE will begin trading ex dividend on November 08 2016 A cash dividend payment of 0 3 per share is scheduled to be paid on December 01 2016 Shareholders who purchased PFE prior to the ex dividend date are eligible for the cash dividend payment This marks the 4th quarter
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing Pressure",2016-11-07 13:39:01 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-pfizer-allergan-133901017.html,"Pharma Stock Roundup: Pfizer, Allergan Q3 Results Fall Short, Insulin Drugmakers under Pricing Pressure"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Jumped On Hopes For Clinton Victory,2016-11-07 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Xb-bbqJpKs8/the-swiss-stock-market-jumped-on-hopes-for-clinton-victory-20161107-00974,The Swiss Stock Market Jumped On Hopes For Clinton Victory
NVS,NVS:US,BBG000LYF3S8,"Roche says flexible pricing ready for cancer, not MS drugs",2016-11-07 10:28:53 +0000,http://finance.yahoo.com/news/roche-says-flexible-pricing-ready-102853713.html,"[Reuters] - The spotlight on finding a cancer cure has spurred improvements in systems to collect and analyze oncology data, but efforts to track patients with other diseases lag behind, Roche pricing head Jens Grueger said. Consequently, new data-driven flexible pricing schemes the Swiss drugmaker and others in the industry are pushing to replace today's ""pay-per-pill"" approach are well advanced in cancer treatment but will take longer for conditions like multiple sclerosis (MS), Grueger said. Such schemes foresee drug pricing based on measurable benefits for a patient or health care systems, an approach seen as becoming more important as aging populations and chronic disease put the squeeze on health care systems."
NVS,NVS:US,BBG000LYF3S8,"Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales",2016-11-04 21:48:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8aVPQLr9OTM/momenta-pharmaceuticals-inc-continues-its-wait-for-higher-sales-cm704411,Image source Getty Images Momenta Pharmaceuticals NASDAQ MNTA released third quarter earnings on Wednesday The drug company is producing solid sales for what it has to work with but next year and beyond offer larger opportunities for investors to look forward to
NVS,NVS:US,BBG000LYF3S8,Incyte Recoups Losses After Price-Fixing Fracas On Strong Chemo Results,2016-11-04 21:18:59 +0000,http://www.investors.com/news/technology/incyte-recoups-losses-after-price-fixing-fracas-on-strong-chemo-results/,Incyte Recoups Losses After Price-Fixing Fracas On Strong Chemo Results
NVS,NVS:US,BBG000LYF3S8,Regeneron Bounds On EPS Beat; Stock Muzzled On Amgen Drug Brouhaha,2016-11-04 20:11:12 +0000,http://www.investors.com/news/technology/regeneron-bounds-on-eps-beat-stock-muzzled-on-amgen-drug-brouhaha/,Regeneron Bounds On EPS Beat; Stock Muzzled On Amgen Drug Brouhaha
NVS,NVS:US,BBG000LYF3S8,"Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales",2016-11-04 20:09:26 +0000,http://www.fool.com/investing/2016/11/04/momenta-pharmaceuticals-inc-continues-its-wait-for.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Momenta Pharmaceuticals, Inc. Continues Its Wait for Higher Sales"
NVS,NVS:US,BBG000LYF3S8,"Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen",2016-11-04 15:12:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h2S-ZpUH7RI/zacks-industry-outlook-highlights-mylan-lilly-pfizer-novartis-and-amgen-cm703967,For Immediate Release Chicago IL November 01 2016 Today Zacks Equity Research discusses the Pharmaceuticals part 1 including Mylan NASDAQ MYL Free Report Lilly NYSE LLY Free Report Pfizer NYSE PFE Free Report Novartis NYSE NVS Free
NVS,NVS:US,BBG000LYF3S8,"Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen",2016-11-04 13:30:01 +0000,http://finance.yahoo.com/news/zacks-industry-outlook-highlights-mylan-133001635.html,"Zacks Industry Outlook Highlights: Mylan, Lilly, Pfizer, Novartis and Amgen"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Losing Streak To 6 Sessions,2016-11-04 13:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CJa6PO6f-p8/the-swiss-stock-market-extended-its-losing-streak-to-6-sessions-20161104-00349,The Swiss Stock Market Extended Its Losing Streak To 6 Sessions
NVS,NVS:US,BBG000LYF3S8,Pharma Industry Outlook - November 2016,2016-11-04 08:18:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-E90rqxFwkw/pharma-industry-outlook-november-2016-cm703807,It s been a rough year for pharma and biotech stocks with several factors weighing on the sector including media and political focus on the high price of drugs mixed performance results slower than expected new product launches and increasing competition The impact of these issues is
NVS,NVS:US,BBG000LYF3S8,"Momenta (MNTA) Q3 Loss Narrower than Expected, Sales Up",2016-11-03 15:10:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CeNe-bZBRfI/momenta-mnta-q3-loss-narrower-than-expected-sales-up-cm703215,Momenta Pharmaceuticals Inc MNTA reported a loss of 26 cents per share in the third quarter of 2016 narrower than both the Zacks Consensus Estimate of a loss of 29 cents and the year ago loss of 44 cents FindTheCompany Graphiq Moreover revenues in the quarter
NVS,NVS:US,BBG000LYF3S8,Novartis Takes Aim at Pfizer,2016-11-03 15:09:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/6dYoolo24qU/novartis-takes-aim-at-pfizer-cm703249,Novartis NYSE NVS application for FDA approval of ribociclib for first line use alongside letrozole in patients who have advanced breast cancer with an amenable genetic makeup has been accepted by regulators under priority review The priority review timeline accelerates a
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Losing Streak As Credit Suisse Dropped,2016-11-03 13:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RWoVaz2jCGo/the-swiss-stock-market-extended-its-losing-streak-as-credit-suisse-dropped-20161103-00647,The Swiss Stock Market Extended Its Losing Streak As Credit Suisse Dropped
NVS,NVS:US,BBG000LYF3S8,"Momenta (MNTA) Q3 Loss Narrower than Expected, Sales Up",2016-11-03 13:16:01 +0000,http://finance.yahoo.com/news/momenta-mnta-q3-loss-narrower-131601282.html,"Momenta (MNTA) Q3 Loss Narrower than Expected, Sales Up"
NVS,NVS:US,BBG000LYF3S8,Novartis Takes Aim at Pfizer,2016-11-03 13:10:03 +0000,http://www.fool.com/investing/2016/11/03/novartis-takes-aim-at-pfizer.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Novartis Takes Aim at Pfizer
NVS,NVS:US,BBG000LYF3S8,"Gilead Cuts Losses On NASH Drug, But Liver Is 'Area Of Opportunity'",2016-11-02 20:28:04 +0000,http://www.investors.com/news/technology/gilead-cuts-losses-on-nash-drug-but-liver-area-of-opportunity/,"Gilead Cuts Losses On NASH Drug, But Liver Is 'Area Of Opportunity'"
NVS,NVS:US,BBG000LYF3S8,Novartis AG (ADR) (NVS) And Pfizer Inc. (PFE) Are In A Race To Gain Favor In Breast Cancer,2016-11-02 17:37:03 +0000,http://www.insidermonkey.com/blog/novartis-ag-adr-nvs-and-pfizer-inc-pfe-are-in-a-race-to-gain-favor-in-breast-cancer-484619/,Novartis AG (ADR) (NVS) And Pfizer Inc. (PFE) Are In A Race To Gain Favor In Breast Cancer
NVS,NVS:US,BBG000LYF3S8,Incyte (INCY) Stock Up as Q3 Earnings & Revenues Rise Y/Y,2016-11-02 15:10:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/beyAAjTnkUw/incyte-incy-stock-up-as-q3-earnings-revenues-rise-yy-cm702365,Incyte Corporation INCY reported third quarter earnings of 11 cents including the impact of a change in fair value of acquisition related contingent consideration and unrealized gain on long term investment The Zacks Consensus Estimate was of breakeven results Incyte had reported a loss of
NVS,NVS:US,BBG000LYF3S8,Incyte (INCY) Stock Up as Q3 Earnings & Revenues Rise Y/Y,2016-11-02 13:17:01 +0000,http://finance.yahoo.com/news/incyte-incy-stock-q3-earnings-131701972.html,Incyte (INCY) Stock Up as Q3 Earnings & Revenues Rise Y/Y
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Losses Amidst US Election Uncertainty,2016-11-02 13:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7hF0kbAN110/the-swiss-stock-market-extended-its-losses-amidst-us-election-uncertainty-20161102-01852,The Swiss Stock Market Extended Its Losses Amidst US Election Uncertainty
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Dropped Below 7,800 Points",2016-11-01 13:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/95ca5SPGyL8/the-swiss-stock-market-dropped-below-7800-points-20161101-00516,"The Swiss Stock Market Dropped Below 7,800 Points"
NVS,NVS:US,BBG000LYF3S8,European Markets Dropped After Early Gains Eroded,2016-11-01 13:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YHV_P2ybWBM/european-markets-dropped-after-early-gains-eroded-20161101-00493,European Markets Dropped After Early Gains Eroded
NVS,NVS:US,BBG000LYF3S8,"Novartis breast cancer drug gets FDA fast track, takes on Pfizer",2016-11-01 08:19:35 +0000,http://finance.yahoo.com/news/novartis-breast-cancer-drug-gets-081935967.html,"[Reuters] - The U.S. Food and Drug Administration gave fast-track review status to Novartis's medication ribociclib in first-line treatment of postmenopausal women with advanced breast cancer as the Swiss company seeks to challenge Pfizer's Ibrance drug. Ribociclib, or LEE011, was also accepted by the European Medicines Agency (EMA) for review in use with letrozole in the same patient population, the company said in a statement on Tuesday. The U.S. priority review of LEE011 is based on data presented last month at a cancer conference."
NVS,NVS:US,BBG000LYF3S8,Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (Ribociclib) Plus Letrozole as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer,2016-11-01 06:30:00 +0000,http://uk.finance.yahoo.com/news/astex-achieves-milestone-us-fda-063000756.html,Astex Achieves Milestone on US FDA Filing of New Drug Application (NDA) for LEE011 (Ribociclib) Plus Letrozole as a First-Line Treatment for HR+/HER2- Advanced Breast Cancer
NVS,NVS:US,BBG000LYF3S8,Novartis LEE011 (ribociclib) granted FDA Priority Review for first-line treatment of HR+/HER2- advanced breast cancer,2016-11-01 06:23:06 +0000,http://www.publicnow.com/view/F729CE72BE6925A8C7A28C511BEE1FB2E386C509,"[at noodls] - Priority Review based on Phase III MONALEESA-2 trial, which showed LEE011 plus letrozole, as initial treatment for advanced breast cancer, significantly extended progression-free survival compared to letrozole ..."
NVS,NVS:US,BBG000LYF3S8,European Shares Rise After Strong China Data,2016-11-01 04:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r6e4_RH2QAI/european-shares-rise-after-strong-china-data-20161101-01291,European Shares Rise After Strong China Data
NVS,NVS:US,BBG000LYF3S8,"Pfizer Q3 Sales Challenged By Eli Lilly, Novartis Amid Breakup Bust",2016-10-31 20:19:51 +0000,http://www.investors.com/news/technology/pfizer-q3-sales-challenged-by-eli-lilly-novartis-amid-breakup-bust/,"Pfizer Q3 Sales Challenged By Eli Lilly, Novartis Amid Breakup Bust"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Kicked Off The New Trading Week With A Loss,2016-10-31 13:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hElXdPPiXq8/the-swiss-stock-market-kicked-off-the-new-trading-week-with-a-loss-20161031-01005,The Swiss Stock Market Kicked Off The New Trading Week With A Loss
NVS,NVS:US,BBG000LYF3S8,Biogen Quietly Abandons a Key Next-Gen Multiple Sclerosis Drug,2016-10-29 13:38:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CTI7Vic5EMk/biogen-quietly-abandons-a-key-next-gen-multiple-sclerosis-drug-cm700675,Biogen Inc NASDAQ BIIB 160 controls over 30 of market share in the 19 billion and growing multiple sclerosis drug market but a recent decision to abandon development of MT 1303 calls into question whether or not Biogen can maintain its dominance in the indication over
NVS,NVS:US,BBG000LYF3S8,Biogen Quietly Abandons a Key Next-Gen Multiple Sclerosis Drug,2016-10-29 10:41:08 +0000,http://www.fool.com/investing/2016/10/29/biogen-quietly-abandons-a-key-next-gen-multiple-sc.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Biogen Quietly Abandons a Key Next-Gen Multiple Sclerosis Drug
NVS,NVS:US,BBG000LYF3S8,"ETF’s with exposure to Novartis AG : October 28, 2016",2016-10-28 19:12:19 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-novartis-ag-october-28-2016/,"ETF’s with exposure to Novartis AG : October 28, 2016"
NVS,NVS:US,BBG000LYF3S8,Amgen (AMGN) Q3 Earnings & Sales Top; Enbrel Hurts Stock,2016-10-28 14:35:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/X0IylNAM4ao/amgen-amgn-q3-earnings-sales-top-enbrel-hurts-stock-cm700070,Biotech major Amgen Inc AMGN reported third quarter 2016 earnings of 3 02 per share beating the Zacks Consensus Estimate of 2 79 by 8 24 and increasing 11 from the year ago period FindTheCompany Graphiq Total revenues increased 2 to 5 81 billion in the
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Slightly Lower & Down For The Week,2016-10-28 12:40:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B0AubB6zn9E/the-swiss-stock-market-finished-slightly-lower--down-for-the-week-20161028-00610,The Swiss Stock Market Finished Slightly Lower & Down For The Week
NVS,NVS:US,BBG000LYF3S8,"Amgen Sees Profit Increase, Raises Guidance -- Update",2016-10-27 18:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Al3fzEjs_H8/amgen-sees-profit-increase-raises-guidance--update-20161027-01750,"Amgen Sees Profit Increase, Raises Guidance -- Update"
NVS,NVS:US,BBG000LYF3S8,The Medicines Co. (MDCO) Q3 Loss Narrower than Expected,2016-10-27 16:46:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hoa1kLrNVSw/the-medicines-co-mdco-q3-loss-narrower-than-expected-cm699494,The Medicines Company MDCO reported a loss of 75 cents per share including the impact of share based compensation expenses in the third quarter of 2016 significantly narrower than both the Zacks Consensus Estimate of a loss of 1 38 and the year ago loss of 94 cents Meanwhile
NVS,NVS:US,BBG000LYF3S8,"Amgen Sees Profit Increase, Raises Guidance",2016-10-27 16:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vY5T1Go7zm4/amgen-sees-profit-increase-raises-guidance-20161027-01487,"Amgen Sees Profit Increase, Raises Guidance"
NVS,NVS:US,BBG000LYF3S8,Inlyta Expected to Witness Competitive Pressures in 2016,2016-10-27 15:04:51 +0000,http://marketrealist.com/2016/10/inlyta-expected-witness-competitive-pressures-2016/?utm_source=yahoo&utm_medium=feed,Inlyta Expected to Witness Competitive Pressures in 2016
NVS,NVS:US,BBG000LYF3S8,"Novartis AG :NVS-US: Earnings Analysis: Q3, 2016 By the Numbers : October 27, 2016",2016-10-27 12:58:34 +0000,http://www.capitalcube.com/blog/index.php/novartis-ag-nvs-us-earnings-analysis-q3-2016-by-the-numbers-october-27-2016/,"Novartis AG :NVS-US: Earnings Analysis: Q3, 2016 By the Numbers : October 27, 2016"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Snapped Its Recent Losing Streak,2016-10-27 12:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Bm4Eg9XRLbQ/the-swiss-stock-market-snapped-its-recent-losing-streak-20161027-01129,The Swiss Stock Market Snapped Its Recent Losing Streak
NVS,NVS:US,BBG000LYF3S8,Novartis' Is Challenging Biogen on Biogen's Own Turf,2016-10-26 22:51:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Jjqu7yamiUA/novartis-is-challenging-biogen-on-biogens-own-turf-cm698999,Biogen Inc NASDAQ BIIB may be the Goliath in the 17 billion and growing market for multiple sclerosis MS treatment but it s Novartis NYSE NVS Gilenya not Biogen s Tecfidera that s growing more quickly this year Image source Novartis Some
NVS,NVS:US,BBG000LYF3S8,Novartis' Is Challenging Biogen on Biogen's Own Turf,2016-10-26 21:02:07 +0000,http://www.fool.com/investing/2016/10/26/novartis-is-challenging-biogen-on-biogens-own-turf.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Novartis' Is Challenging Biogen on Biogen's Own Turf
NVS,NVS:US,BBG000LYF3S8,European ADRs Edge Lower as Miners Head South,2016-10-26 15:09:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qGeU8FTWDJE/european-adrs-edge-lower-as-miners-head-south-cm698517,American depository receipts of European stocks were 0 7 lower at 117 65 on the Bank of New York Mellon Europe ADR Index on Wednesday morning American depository receipts of European stocks were 0 7 lower at 117 65 on the Bank of New York Mellon Europe ADR Index on Wednesday morning Decliners
NVS,NVS:US,BBG000LYF3S8,"Inside Opdivo, Bristol-Myers Squibb’s Oncology Drug",2016-10-26 14:04:32 +0000,http://marketrealist.com/2016/10/inside-opdivo-bristol-myers-squibbs-oncology-drug/?utm_source=yahoo&utm_medium=feed,"Inside Opdivo, Bristol-Myers Squibb’s Oncology Drug"
NVS,NVS:US,BBG000LYF3S8,"Drug Stock Q3 Earnings Roster for Oct 27: AMGN, BMY & More",2016-10-26 13:50:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oh1yETFMaVw/drug-stock-q3-earnings-roster-for-oct-27-amgn-bmy-more-cm698462,The Q3 earnings season has so far seen encouraging reports with 116 S amp P 500 companies having already released results as of Oct 21 Of the total 80 2 surpassed earnings estimates while 62 9 trumped revenue expectations The Q3 earnings cycle is on track to be the first quarter to
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell Again With Novartis Shares Under Pressure,2016-10-26 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d3xYI9DsDcg/the-swiss-stock-market-fell-again-with-novartis-shares-under-pressure-20161026-01213,The Swiss Stock Market Fell Again With Novartis Shares Under Pressure
NVS,NVS:US,BBG000LYF3S8,Merck Crushes Q3 Expectations Following Lung Cancer Drug Win,2016-10-25 20:35:00 +0000,http://www.investors.com/news/technology/merck-crushes-q3-expectations-following-lung-cancer-drug-win/,Merck Crushes Q3 Expectations Following Lung Cancer Drug Win
NVS,NVS:US,BBG000LYF3S8,Novartis Tumbles On Q3 Sales Miss; Chemo Sales May Boost Incyte,2016-10-25 20:12:53 +0000,http://www.investors.com/news/technology/novartis-tumbles-on-q3-sales-miss-chemo-sales-may-boost-incyte/,Novartis Tumbles On Q3 Sales Miss; Chemo Sales May Boost Incyte
NVS,NVS:US,BBG000LYF3S8,"Eli Lilly Q3 Revenue, EPS Miss; CEO Praises Drug Pipeline",2016-10-25 20:05:22 +0000,http://www.investors.com/news/technology/eli-lilly-plummets-on-q3-sales-eps-miss-announces-ceo-swap/,"Eli Lilly Q3 Revenue, EPS Miss; CEO Praises Drug Pipeline"
NVS,NVS:US,BBG000LYF3S8,Drug price pressure,2016-10-25 17:38:00 +0000,http://finance.yahoo.com/video/drug-price-pressure-173800510.html,Drug price pressure
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline’s 3Q16 Revenues Are Expected to Rise,2016-10-25 17:04:08 +0000,http://marketrealist.com/2016/10/glaxosmithklines-3q16-revenues-are-expected-to-rise/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline’s 3Q16 Revenues Are Expected to Rise
NVS,NVS:US,BBG000LYF3S8,Stocks Fall on Mixed Earnings Reports,2016-10-25 16:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xmFvIxLdKRE/stocks-fall-on-mixed-earnings-reports-20161025-00749,Stocks Fall on Mixed Earnings Reports
NVS,NVS:US,BBG000LYF3S8,"European ADRs Fractionally Lower as Pharma, Telecom Stocks See Mixed Fortunes",2016-10-25 15:24:36 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1VB4LHnnmek/european-adrs-fractionally-lower-as-pharma-telecom-stocks-see-mixed-fortunes-cm697831,American depository receipts of European stocks were 0 3 lower at 118 61 on the Bank of New York Mellon Europe ADR Index on Tuesday morning American depository receipts of European stocks were 0 3 lower at 118 61 on the Bank of New York Mellon Europe ADR Index on Tuesday morning Decliners
NVS,NVS:US,BBG000LYF3S8,Novartis Shouldn't Play Its Ace Too Soon,2016-10-25 15:16:52 +0000,http://www.bloomberg.com/gadfly/articles/2016-10-25/novartis-earnings-no-rush-to-sell-roche-stake?cmpid=yhoo.headline,Novartis Shouldn't Play Its Ace Too Soon
NVS,NVS:US,BBG000LYF3S8,"Novartis (NVS) Tops Q3 Earnings, Misses Sales Estimates",2016-10-25 14:25:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EdFxmxEHzp8/novartis-nvs-tops-q3-earnings-misses-sales-estimates-cm697809,Novartis AG NVS reported third quarter 2016 core earnings of 1 23 per share above the Zacks Consensus Estimate of 1 18 but below than the year ago figure of 1 27 Moreover revenues declined 1 1 to 12 1 billion and missed below the Zacks Consensus Estimate of 12 3
NVS,NVS:US,BBG000LYF3S8,Update on Roche’s Analyst Recommendations,2016-10-25 14:04:59 +0000,http://marketrealist.com/2016/10/update-on-roches-analyst-recommendations/?utm_source=yahoo&utm_medium=feed,Update on Roche’s Analyst Recommendations
NVS,NVS:US,BBG000LYF3S8,Novartis CEO sees tougher U.S. drug pricing over next 3-5 years,2016-10-25 13:41:41 +0000,http://finance.yahoo.com/news/novartis-ceo-sees-tougher-u-134141016.html,Novartis CEO sees tougher U.S. drug pricing over next 3-5 years
NVS,NVS:US,BBG000LYF3S8,"Novartis (NVS) Tops Q3 Earnings, Misses Sales Estimates",2016-10-25 12:59:12 +0000,http://finance.yahoo.com/news/novartis-nvs-tops-q3-earnings-125912900.html,"Novartis (NVS) Tops Q3 Earnings, Misses Sales Estimates"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Losing Streak To Four Sessions,2016-10-25 12:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YcuD4U-r9HU/the-swiss-stock-market-extended-its-losing-streak-to-four-sessions-20161025-01553,The Swiss Stock Market Extended Its Losing Streak To Four Sessions
NVS,NVS:US,BBG000LYF3S8,European Markets Finished Mostly Lower After Early Gains Eroded,2016-10-25 12:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nKGVGMgN2Wc/european-markets-finished-mostly-lower-after-early-gains-eroded-20161025-00796,European Markets Finished Mostly Lower After Early Gains Eroded
NVS,NVS:US,BBG000LYF3S8,"Stocks Lifted by Upbeat Data, Earnings",2016-10-25 09:24:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QzEpr9bRh6I/stocks-lifted-by-upbeat-data-earnings-20161025-00697,"Stocks Lifted by Upbeat Data, Earnings"
NVS,NVS:US,BBG000LYF3S8,Novartis beats 3Q profit forecasts,2016-10-25 09:02:09 +0000,http://sg.finance.yahoo.com/news/novartis-beats-3q-profit-forecasts-090209992.html,Novartis beats 3Q profit forecasts
NVS,NVS:US,BBG000LYF3S8,Novartis focus on still-ailing Alcon shifts to 2017,2016-10-25 08:38:57 +0000,http://finance.yahoo.com/news/novartis-focus-still-ailing-alcon-083857712.html,Novartis focus on still-ailing Alcon shifts to 2017
NVS,NVS:US,BBG000LYF3S8,"Stocks Lifted by Upbeat Data, Earnings -- 2nd Update",2016-10-25 08:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZPkKcq33cQM/stocks-lifted-by-upbeat-data-earnings--2nd-update-20161025-01204,"Stocks Lifted by Upbeat Data, Earnings -- 2nd Update"
NVS,NVS:US,BBG000LYF3S8,Novartis profit slips as key drug goes generic,2016-10-25 08:02:09 +0000,http://sg.finance.yahoo.com/news/novartis-profit-slips-key-drug-080209591.html,Novartis profit slips as key drug goes generic
NVS,NVS:US,BBG000LYF3S8,Eli Lilly''s Profit Dented by Higher Costs,2016-10-25 07:45:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O5A4kCQD12s/eli-lillys-profit-dented-by-higher-costs-20161025-01179,Eli Lilly''s Profit Dented by Higher Costs
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis Profit Helped by GlaxoSmithKline Joint Venture,2016-10-25 07:23:40 +0000,http://www.wsj.com/articles/novartis-profit-helped-by-glaxosmithkline-joint-venture-1477374676?mod=yahoo_hs,[$$] Novartis Profit Helped by GlaxoSmithKline Joint Venture
NVS,NVS:US,BBG000LYF3S8,"Novartis Beats Third-Quarter Earnings Forecasts on Growth Products, Cost Cuts",2016-10-25 07:13:00 +0000,https://www.thestreet.com/story/13864958/1/novartis-beats-third-quarter-earnings-on-growth-products-cost-cuts.html?puc=yahoo&cm_ven=YAHOO,"Novartis Beats Third-Quarter Earnings Forecasts on Growth Products, Cost Cuts"
NVS,NVS:US,BBG000LYF3S8,Stocks Higher Ahead of Key Data -- 2nd Update,2016-10-25 06:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nXZdfrr416I/stocks-higher-ahead-of-key-data--2nd-update-20161025-00245,Stocks Higher Ahead of Key Data -- 2nd Update
NVS,NVS:US,BBG000LYF3S8,European Stocks Higher Ahead of Key Data -- Update,2016-10-25 06:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vRGKXbHfKOA/european-stocks-higher-ahead-of-key-data--update-20161025-00190,European Stocks Higher Ahead of Key Data -- Update
NVS,NVS:US,BBG000LYF3S8,Novartis delivered solid third quarter with Growth Products offsetting Gleevec patent expiration; several positive readouts for potential blockbusters,2016-10-25 05:31:05 +0000,http://www.publicnow.com/view/1F3510C6167C81ED5839AC34AAEBF10BFF22F3BB,"[at noodls] - Q3 net sales (-1% cc and USD) broadly in line with prior year due to strong performance of Growth Products Gilenya (USD 790 million, +15% cc) continued double-digit growth Cosentyx (USD 301 million) ..."
NVS,NVS:US,BBG000LYF3S8,European Shares Rise As Miners Rally,2016-10-25 05:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ffUhhWoJMb8/european-shares-rise-as-miners-rally-20161025-00142,European Shares Rise As Miners Rally
NVS,NVS:US,BBG000LYF3S8,Novartis Profit Falls as Generics Hurt Sales of Gleevec Drug,2016-10-25 05:05:43 +0000,http://www.bloomberg.com/news/articles/2016-10-25/novartis-profit-declines-as-competition-hits-cancer-drug-sales?cmpid=yhoo.headline,Novartis Profit Falls as Generics Hurt Sales of Gleevec Drug
NVS,NVS:US,BBG000LYF3S8,European Stocks Up Ahead of Key Data,2016-10-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kKRzSMKlQSw/european-stocks-up-ahead-of-key-data-20161025-00127,European Stocks Up Ahead of Key Data
NVS,NVS:US,BBG000LYF3S8,Stocks Up Ahead of Key Data,2016-10-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cDqMvfj6oKM/stocks-up-ahead-of-key-data-20161025-00251,Stocks Up Ahead of Key Data
NVS,NVS:US,BBG000LYF3S8,Novartis Q3 Profit Tops View; Maintains FY16 Outlook,2016-10-25 03:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bUlCl3Ooa8U/novartis-q3-profit-tops-view-maintains-fy16-outlook-20161025-00112,Novartis Q3 Profit Tops View; Maintains FY16 Outlook
NVS,NVS:US,BBG000LYF3S8,Novartis Q3 Profit From Cont. Ops. Rises; Confirms 2016 Outlook,2016-10-25 01:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nDqi9lyTrq8/novartis-q3-profit-from-cont-ops-rises-confirms-2016-outlook-20161025-00032,Novartis Q3 Profit From Cont. Ops. Rises; Confirms 2016 Outlook
NVS,NVS:US,BBG000LYF3S8,Can AbbVie (ABBV) Sustain Earnings Beat Trend in Q3?,2016-10-24 22:25:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M7lh_Sx0b_U/can-abbvie-abbv-sustain-earnings-beat-trend-in-q3-cm697501,We expect pharma company AbbVie Inc ABBV to beat expectations when it reports third quarter earnings results on Oct 28 before market open AbbVie had delivered a positive earnings surprise of 5 00 in the second quarter AbbVie s performance has been pretty impressive with consistent
NVS,NVS:US,BBG000LYF3S8,Novartis’s 3Q16 Estimates: Will Alcon Recover Its Growth?,2016-10-24 15:04:42 +0000,http://marketrealist.com/2016/10/novartiss-3q16-estimates-will-alcon-recover-its-growth/?utm_source=yahoo&utm_medium=feed,Novartis’s 3Q16 Estimates: Will Alcon Recover Its Growth?
NVS,NVS:US,BBG000LYF3S8,"Drug Stocks Q3 Earnings Roster for Oct 25: MRK, LLY & More",2016-10-24 14:27:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Cqpf-7ymC40/drug-stocks-q3-earnings-roster-for-oct-25-mrk-lly-more-cm697035,The third quarter earnings season has picked up pace with 116 S amp P 500 members as of Oct 21 accounting for 23 2 of the index s total market capitalization having reported results according to the Earnings Preview report While total earnings for these 116 index members were up 3 3
NVS,NVS:US,BBG000LYF3S8,Novartis’s 3Q16 Estimates: How Has Sandoz Performed?,2016-10-24 14:05:06 +0000,http://marketrealist.com/2016/10/novartiss-3q16-estimates-how-has-sandoz-performed/?utm_source=yahoo&utm_medium=feed,Novartis’s 3Q16 Estimates: How Has Sandoz Performed?
NVS,NVS:US,BBG000LYF3S8,"Drug Stocks Q3 Earnings Roster for Oct 25: MRK, LLY & More",2016-10-24 12:28:12 +0000,http://finance.yahoo.com/news/drug-stocks-q3-earnings-roster-122812341.html,"Drug Stocks Q3 Earnings Roster for Oct 25: MRK, LLY & More"
NVS,NVS:US,BBG000LYF3S8,Analyst Recommendations for Pfizer and Its Peers in 2016,2016-10-24 12:06:20 +0000,http://marketrealist.com/2016/10/analyst-recommendations-pfizer-peers-2016/?utm_source=yahoo&utm_medium=feed,Analyst Recommendations for Pfizer and Its Peers in 2016
NVS,NVS:US,BBG000LYF3S8,Novartis’s 3Q16 Estimates: Innovative Medicines Segment,2016-10-24 12:05:34 +0000,http://marketrealist.com/2016/10/novartiss-3q16-estimates-innovative-medicines-segment/?utm_source=yahoo&utm_medium=feed,Novartis’s 3Q16 Estimates: Innovative Medicines Segment
NVS,NVS:US,BBG000LYF3S8,Do Analysts Expect Negative Growth for Novartis in 3Q16?,2016-10-21 22:04:10 +0000,http://marketrealist.com/2016/10/do-analysts-expect-negative-growth-for-novartis-in-3q16/?utm_source=yahoo&utm_medium=feed,Do Analysts Expect Negative Growth for Novartis in 3Q16?
NVS,NVS:US,BBG000LYF3S8,What’s to Be Expected from Novartis’s 3Q16 Earnings?,2016-10-21 19:47:21 +0000,http://marketrealist.com/2016/10/whats-to-be-expected-from-novartiss-3q16-earnings/?utm_source=yahoo&utm_medium=feed,What’s to Be Expected from Novartis’s 3Q16 Earnings?
NVS,NVS:US,BBG000LYF3S8,Will Amgen (AMGN) Sustain its Earnings Beat Trend in Q3?,2016-10-21 16:24:19 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2_WmokWLPXI/will-amgen-amgn-sustain-its-earnings-beat-trend-in-q3-cm696608,We expect biotech major Amgen Inc AMGN to beat expectations when it reports third quarter earnings results on Oct 27 after market close Amgen had delivered a positive earnings surprise of 3 65 in the second quarter Amgen s performance has been pretty impressive with consistent
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline (GSK) Q3 Earnings: What's in the Cards?,2016-10-21 15:27:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/5-rUMmrAk_g/glaxosmithkline-gsk-q3-earnings-whats-in-the-cards-cm696591,GlaxoSmithKline plc GSK is scheduled to report third quarter 2016 results on Oct 26 Last quarter the company delivered a positive earnings surprise of 27 27 Let s see how things are shaping up for this quarter Factors at Play Glaxo focuses on its three core
NVS,NVS:US,BBG000LYF3S8,"The Zacks Analyst Blog Highlights: Pfizer, Novartis AG, Amgen, Merck and Momenta Pharmaceuticals",2016-10-21 15:27:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aanaJa6VeUU/the-zacks-analyst-blog-highlights-pfizer-novartis-ag-amgen-merck-and-momenta-pharmaceuticals-cm696583,For Immediate Release Chicago IL October 21 2016 Zacks com announces the list of stocks featured in the Analyst Blog Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets Stocks recently featured in the blog
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Another Strong Quarter from J&J, Lilly Cancer Drug Approved",2016-10-21 14:04:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iHEfrrCHCpA/pharma-stock-roundup-another-strong-quarter-from-jj-lilly-cancer-drug-approved-cm696502,Earnings started on a positive note for the pharma sector with industry bellwether Johnson amp Johnson JNJ reporting better than expected results Swiss company Roche RHHBY also reported nine month sales figures this week Recap of the Week s Most Important Stories J amp J
NVS,NVS:US,BBG000LYF3S8,Should You Buy Novartis (NVS) Ahead of Earnings?,2016-10-21 14:03:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LgFwl27Vk20/should-you-buy-novartis-nvs-ahead-of-earnings-cm696477,Investors are always looking for stocks that are poised to beat at earnings season and Novartis AG NVS may be one such company The firm has earnings coming up pretty soon and events are shaping up quite nicely for their report That is because Novartis is seeing favorable earnings
NVS,NVS:US,BBG000LYF3S8,Novartis May Be Too Generic,2016-10-21 13:43:00 +0000,https://www.thestreet.com/story/13861950/1/novartis-may-be-too-generic.html?puc=yahoo&cm_ven=YAHOO,Novartis May Be Too Generic
NVS,NVS:US,BBG000LYF3S8,"The Zacks Analyst Blog Highlights: Pfizer, Novartis AG, Amgen, Merck and Momenta Pharmaceuticals",2016-10-21 13:30:01 +0000,http://finance.yahoo.com/news/zacks-analyst-blog-highlights-pfizer-133001778.html,"The Zacks Analyst Blog Highlights: Pfizer, Novartis AG, Amgen, Merck and Momenta Pharmaceuticals"
NVS,NVS:US,BBG000LYF3S8,Should You Buy Novartis (NVS) Ahead of Earnings?,2016-10-21 12:42:12 +0000,http://finance.yahoo.com/news/buy-novartis-nvs-ahead-earnings-124212942.html,Should You Buy Novartis (NVS) Ahead of Earnings?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Lower After Early Gains Eroded,2016-10-21 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fWSIbbDHeaw/the-swiss-stock-market-finished-lower-after-early-gains-eroded-20161021-00538,The Swiss Stock Market Finished Lower After Early Gains Eroded
NVS,NVS:US,BBG000LYF3S8,Eli Lilly and Co.’s 3Q16: Expectations for Elanco,2016-10-21 12:04:08 +0000,http://marketrealist.com/2016/10/eli-lilly-and-co-s-3q16-expectations-for-elanco/?utm_source=yahoo&utm_medium=feed,Eli Lilly and Co.’s 3Q16: Expectations for Elanco
NVS,NVS:US,BBG000LYF3S8,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?,2016-10-20 16:28:56 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZpbkDdnx5VQ/can-biogen-biib-keep-the-earnings-streak-alive-in-q3-cm696043,Biogen Inc BIIB a well known name in the multiple sclerosis MS market will be reporting third quarter 2016 earnings on Oct 26 before market open Last quarter the company delivered a positive earnings surprise of 11 09 Biogen s performance has been pretty impressive with
NVS,NVS:US,BBG000LYF3S8,7 Drug Stocks to Consider as Biosimilars Pick Up Pace,2016-10-20 16:28:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fPImImuLMiY/7-drug-stocks-to-consider-as-biosimilars-pick-up-pace-cm696033,Interest in biosimilars has picked up considerably with Pfizer Inc s PFE announcement this week regarding its plans to launch a biosimilar version of Johnson amp Johnson s blockbuster drug Remicade in late November What are Biosimilars A biosimilar is a biologic product
NVS,NVS:US,BBG000LYF3S8,Celgene (CELG) Q3 Earnings: What's in Store for the Stock?,2016-10-20 15:29:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aSbcsZF3ltU/celgene-celg-q3-earnings-whats-in-store-for-the-stock-cm695954,Celgene Corporation CELG is scheduled to report third quarter 2016 results on Oct 27 before the opening bell Celgene s track record has been decent with the company beating earnings estimates on three occasions over the trailing four quarters Overall the company has delivered an
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Q3 Earnings: Stock to Beat Estimates Again?,2016-10-20 15:29:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GqlEdEiHZy8/novartis-nvs-q3-earnings-stock-to-beat-estimates-again-cm695944,Novartis AG NVS is scheduled to report third quarter 2016 results on Oct 25 In the last reported quarter it recorded a positive earnings surprise of 3 39 Overall Novartis has posted an average negative earnings surprise of 2 38 in the four trailing quarters Let s see how things
NVS,NVS:US,BBG000LYF3S8,Alexion (ALXN) Q3 Earnings: Can the Stock Pull a Surprise?,2016-10-20 15:29:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vElM-CBd3Pg/alexion-alxn-q3-earnings-can-the-stock-pull-a-surprise-cm695938,Alexion Pharmaceuticals Inc ALXN is scheduled to report third quarter 2016 results on Oct 27 before the opening bell The company s track record has been mixed Over the last four quarters the company has beaten estimates on two occasions Overall Alexion has posted an average
NVS,NVS:US,BBG000LYF3S8,What's in Store for BioMarin (BMRN) This Earnings Season?,2016-10-20 15:28:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/holgreg2CpE/whats-in-store-for-biomarin-bmrn-this-earnings-season-cm695926,BioMarin Pharmaceutical Inc BMRN is scheduled to report third quarter 2016 results on Oct 27 after the market closes In the last reported quarter the company had posted a positive surprise of 78 00 Let s see how things are shaping up for this announcement Factors Influencing
NVS,NVS:US,BBG000LYF3S8,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?,2016-10-20 14:21:02 +0000,http://finance.yahoo.com/news/biogen-biib-keep-earnings-streak-142102268.html,Can Biogen (BIIB) Keep the Earnings Streak Alive in Q3?
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Q3 Earnings: Stock to Beat Estimates Again?,2016-10-20 13:52:01 +0000,http://finance.yahoo.com/news/novartis-nvs-q3-earnings-stock-135201568.html,Novartis (NVS) Q3 Earnings: Stock to Beat Estimates Again?
NVS,NVS:US,BBG000LYF3S8,"CERU Gains Big On Nanoparticle Deal, LLY Gets FDA Nod, BABY Makes Big Strides",2016-10-20 01:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yBWOilte3bA/ceru-gains-big-on-nanoparticle-deal-lly-gets-fda-nod-baby-makes-big-strides-20161020-00031,"CERU Gains Big On Nanoparticle Deal, LLY Gets FDA Nod, BABY Makes Big Strides"
NVS,NVS:US,BBG000LYF3S8,"Close Update: Stocks Stay Positive as Oil Reaches 15-Month High, Bank Earnings Beat Expectations",2016-10-19 21:07:14 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jKIKYePjRuc/close-update-stocks-stay-positive-as-oil-reaches-15-month-high-bank-earnings-beat-expectations-cm695626,Stocks closed modestly higher for a second consecutive day buoyed by a 15 month high in brent crude oil and positive quarterly earnings from the financial sector Stocks closed modestly higher for a second consecutive day buoyed by a 15 month high in brent crude oil and positive quarterly
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 10/19/2016: MRNS,CERU,PBYI",2016-10-19 20:27:13 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kav3qBghUns/health-care-sector-update-for-10192016-mrnscerupbyi-cm695598,Top Health Care StocksTop Health Care Stocks JNJ 0 62 JNJ 0 62 PFE 0 17 PFE 0 17 MRK 0 MRK 0 ABT 2 79 ABT 2 79 AMGN 1 03 AMGN 1 03 Health care stocks were moderately lower Wednesday with the NYSE Health Care Index slipping about 0 3 while shares of health care companies in
NVS,NVS:US,BBG000LYF3S8,Mid-Afternoon Market Update: Imperva Tumbles Amid Sale Concerns; Banc of California Shares Surge,2016-10-19 20:12:02 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FMRY2tV3hZk/mid-afternoon-market-update-imperva-tumbles-amid-sale-concerns-banc-of-california-shares-surge-cm695597,Toward the end of trading Wednesday the Dow traded up 0 38 percent to 18 230 12 while the NASDAQ gained 0 08 percent to 5 247 96 The S amp P also rose gaining 0 29 percent to 2 145 69 Leading and Lagging Sectors Wednesday afternoon energy shares gained by 1 33 percent
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 10/19/2016: XOMA, CERU, PBYI, NVS",2016-10-19 18:48:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rf52UrouFkg/health-care-sector-update-for-10192016-xoma-ceru-pbyi-nvs-cm695546,Top Health Care StocksTop Health Care Stocks JNJ 0 62 JNJ 0 62 PFE 0 11 PFE 0 11 MRK 0 05 MRK 0 05 ABT 2 43 ABT 2 43 AMGN 0 67 AMGN 0 67 Health care stocks were cutting earlier losses with the NYSE Health Care Index slipping about 0 1 while shares of health care companies in
NVS,NVS:US,BBG000LYF3S8,Midday Update: Wall Street Stays Positive on Gains in Oil and Banking Sector,2016-10-19 17:27:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q8DeNSm9P6I/midday-update-wall-street-stays-positive-on-gains-in-oil-and-banking-sector-cm695516,Led by gains in the financial and energy sectors the Dow Jones Industrial Average and S amp P 500 were maintaining solid gains at midday on Wednesday while the Nasdaq was struggling to stay positive on steep losses in Intel INTC and technical resistance at the 50 day moving average Led
NVS,NVS:US,BBG000LYF3S8,Can Eli Lilly (LLY) Pull a Surprise this Earnings Season?,2016-10-19 15:51:04 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/maogj0NV0yo/can-eli-lilly-lly-pull-a-surprise-this-earnings-season-cm695370,Eli Lilly and Company LLY is set to report third quarter 2016 results on Oct 25 before the market opens Last quarter the company posted a positive earnings surprise of 1 18 The company s performance has been pretty strong so far with earnings surpassing expectations in three of the
NVS,NVS:US,BBG000LYF3S8,Can Merck (MRK) Keep the Earnings Streak Alive in Q3?,2016-10-19 14:49:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bDBwkEvGgR8/can-merck-mrk-keep-the-earnings-streak-alive-in-q3-cm695237,Merck amp Co Inc MRK is set to report third quarter 2016 results on Oct 25 before the market opens Last quarter the company delivered a positive earnings surprise of 1 09 Merck s performance has been pretty impressive with the company beating earnings expectations consistently
NVS,NVS:US,BBG000LYF3S8,Stock Futures Trade Higher on Housing Starts Miss,2016-10-19 13:47:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/O7cB1fmFnKM/stock-futures-trade-higher-on-housing-starts-miss-cm695223,U S stock futures are trading marginally higher in the wake of an unexpected decline in housing starts that further clouded the outcome to the next Federal Reserve meeting Amplified by upbeat earnings from Morgan Stanley MS and higher oil prices Dow futures are grinding higher with
NVS,NVS:US,BBG000LYF3S8,Cerulean In Deal With Novartis To Develop NDCs; Gets $20 Mln Firm Commitment,2016-10-19 08:59:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zf4yILKxWHY/cerulean-in-deal-with-novartis-to-develop-ndcs-gets-20-mln-firm-commitment-20161019-01094,Cerulean In Deal With Novartis To Develop NDCs; Gets $20 Mln Firm Commitment
NVS,NVS:US,BBG000LYF3S8,Pfizer to Launch Remicade Biosimilar in U.S. in November,2016-10-18 15:50:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZxFOpmTNv_M/pfizer-to-launch-remicade-biosimilar-in-us-in-november-cm694736,Pfizer Inc PFE announced that its Inflectra injection a biosimilar version of Johnson amp Johnson s JNJ blockbuster drug Remicade will be available in the U S in late November Inflectra is the first and only biosimilar monoclonal antibody mAb therapy and only the second biosimilar
NVS,NVS:US,BBG000LYF3S8,Pfizer to launch cheaper version of J&J immune drug Remicade,2016-10-17 22:16:06 +0000,http://sg.finance.yahoo.com/news/pfizer-launch-cheaper-version-j-202221529.html,Pfizer to launch cheaper version of J&J immune drug Remicade
NVS,NVS:US,BBG000LYF3S8,Pfizer Plans to Launch Remicade Biosimilar in November -- Update,2016-10-17 19:01:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/56M57p3FOvI/pfizer-plans-to-launch-remicade-biosimilar-in-november--update-20161017-00947,Pfizer Plans to Launch Remicade Biosimilar in November -- Update
NVS,NVS:US,BBG000LYF3S8,Roche's Lucentis Prefilled Syringe Approved in the U.S.,2016-10-17 15:43:06 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zp-qAY5au-M/roches-lucentis-prefilled-syringe-approved-in-the-us-cm694119,Roche Holding AG RHHBY announced that its ophthalmology drug Lucentis 0 5 mg prefilled syringe PFS was approved in the U S as a new method of administering the drug for the treatment of patients with wet age related macular degeneration AMD and macular edema after retinal vein
NVS,NVS:US,BBG000LYF3S8,What to Expect from J&J's (JNJ) Pharmaceutical Segment in Q3?,2016-10-17 13:42:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/4nK4vBdrQpY/what-to-expect-from-jjs-jnj-pharmaceutical-segment-in-q3-cm694060,Healthcare giant Johnson amp Johnson JNJ will be reporting third quarter results tomorrow before the market opens The company has a pretty good earnings track record having surpassed expectations in each of the last four quarters While J amp J has three segments
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped Amidst Global Uncertainty,2016-10-17 12:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d7ZICHj_w1U/the-swiss-stock-market-dropped-amidst-global-uncertainty-20161017-00762,The Swiss Stock Market Dropped Amidst Global Uncertainty
NVS,NVS:US,BBG000LYF3S8,How Much Is Pfizer’s Return Potential?,2016-10-14 15:04:38 +0000,http://marketrealist.com/2016/10/much-pfizers-return-potential/?utm_source=yahoo&utm_medium=feed,How Much Is Pfizer’s Return Potential?
NVS,NVS:US,BBG000LYF3S8,"Pre-Market Most Active for Oct 14, 2016 :  ERIC, BAC, RSPP, EBAY, MWA, XIV, HAWK, JPM, NVS, SNY, MELI, TVIX",2016-10-14 13:00:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dpea2rsrPV4/pre-market-most-active-for-oct-14-2016-eric-bac-rspp-ebay-mwa-xiv-hawk-jpm-nvs-sny-meli-tvix-cm693308,The NASDAQ 100 Pre Market Indicator is up 14 6 to 4 817 7 The total Pre Market volume is currently 9 529 487 shares traded The following are the most active stocks for the pre market session Ericsson ERIC is 0 01 at 5 45 with 1 815 546 shares traded ERIC is
NVS,NVS:US,BBG000LYF3S8,Can These Top 5 Biotechs Climb Q3 'Wall Of Worry'? RBC Calls For Rally,2016-10-13 20:37:53 +0000,http://www.investors.com/news/technology/can-these-top-5-biotechs-climb-q3-wall-of-worry-rbc-calls-for-rally/,Can These Top 5 Biotechs Climb Q3 'Wall Of Worry'? RBC Calls For Rally
NVS,NVS:US,BBG000LYF3S8,Amazon Partners With VMware to Extend Its Computing Cloud,2016-10-13 20:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/0WCF20QTFVM/amazon-partners-with-vmware-to-extend-its-computing-cloud-20161013-01019,Amazon Partners With VMware to Extend Its Computing Cloud
NVS,NVS:US,BBG000LYF3S8,Prothena Slammed On Politics; Could Win Eli Lilly Or Pfizer Partnership,2016-10-13 20:09:21 +0000,http://www.investors.com/news/technology/prothena-slammed-on-politics-could-win-eli-lilly-or-pfizer-partnership/,Prothena Slammed On Politics; Could Win Eli Lilly Or Pfizer Partnership
NVS,NVS:US,BBG000LYF3S8,Top 5 Jefferies Big Pharma Stock Picks for Q4,2016-10-13 14:40:03 +0000,http://247wallst.com/healthcare-business/2016/10/13/top-5-jefferies-big-pharma-stock-picks-for-q4/,Top 5 Jefferies Big Pharma Stock Picks for Q4
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Slipped Beneath The 8,000 Point Level",2016-10-13 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PtlbtR1i8ZE/the-swiss-stock-market-slipped-beneath-the-8000-point-level-20161013-00815,"The Swiss Stock Market Slipped Beneath The 8,000 Point Level"
NVS,NVS:US,BBG000LYF3S8,Which Healthcare Company Is the Best Dividend Stock?,2016-10-13 12:06:48 +0000,http://www.fool.com/investing/2016/10/12/which-healthcare-company-is-best-dividend-stock.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Which Healthcare Company Is the Best Dividend Stock?
NVS,NVS:US,BBG000LYF3S8,Which Healthcare Company Is the Best Dividend Stock?,2016-10-12 13:18:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ztg9HHeTJ1U/which-healthcare-company-is-the-best-dividend-stock-cm692206,Image source Getty Images With the S amp P 500 near its all time high and interest rates still hovering near their all time lows it s getting harder than ever to generate safe income from your nest egg Thankfully it s still possible for investors to earn decent yields
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped As Pharmaceutical Heavyweights Weakened,2016-10-12 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/aCQZhkvHoZM/the-swiss-stock-market-dropped-as-pharmaceutical-heavyweights-weakened-20161012-00700,The Swiss Stock Market Dropped As Pharmaceutical Heavyweights Weakened
NVS,NVS:US,BBG000LYF3S8,"Why Momenta Pharmaceuticals, Inc. Jumped Higher Today",2016-10-11 20:29:38 +0000,http://www.fool.com/investing/2016/10/11/why-momenta-pharmaceuticals-inc-jumped-higher-toda.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"Why Momenta Pharmaceuticals, Inc. Jumped Higher Today"
NVS,NVS:US,BBG000LYF3S8,Teva Acquires Rights to Oncology Biosimilar Candidates,2016-10-11 15:22:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BOkBUoVdxco/teva-acquires-rights-to-oncology-biosimilar-candidates-cm691786,Generic drug maker Teva Pharmaceutical Industries Ltd TEVA has entered into an exclusive biosimilar commercial partnership with Korean biopharmaceutical company Celltrion Inc and its distribution partner Celltrion Healthcare Per the deal Teva gets exclusive rights to commercialize two
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Lower Due To Weakness On Wall Street,2016-10-11 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/fITyNvYg_to/the-swiss-stock-market-finished-lower-due-to-weakness-on-wall-street-20161011-00668,The Swiss Stock Market Finished Lower Due To Weakness On Wall Street
NVS,NVS:US,BBG000LYF3S8,Merck Topples Bristol-Myers On Lung Cancer Drug Win,2016-10-10 20:20:21 +0000,http://www.investors.com/research/ibd-industry-themes/esmo-2016-merck-topples-bristol-myers-on-lung-cancer-drug-win/,Merck Topples Bristol-Myers On Lung Cancer Drug Win
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Rose On Strength From Financials & Cyclicals,2016-10-10 12:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dbLc2pUPteo/the-swiss-stock-market-rose-on-strength-from-financials--cyclicals-20161010-00495,The Swiss Stock Market Rose On Strength From Financials & Cyclicals
NVS,NVS:US,BBG000LYF3S8,Encouraging Results For Ribociclib In Advanced Breast Cancer,2016-10-09 20:15:00 +0000,http://www.forbes.com/sites/elaineschattner/2016/10/09/encouraging-results-for-ribociclib-in-advanced-breast-cancer/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Encouraging Results For Ribociclib In Advanced Breast Cancer
NVS,NVS:US,BBG000LYF3S8,Novartis ALK+ Metastatic NSCLC Therapy Zykadia Extends PFS Beyond 18 Months,2016-10-09 07:39:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QtNmk65LkNE/novartis-alk-metastatic-nsclc-therapy-zykadia-extends-pfs-beyond-18-months-20161009-00019,Novartis ALK+ Metastatic NSCLC Therapy Zykadia Extends PFS Beyond 18 Months
NVS,NVS:US,BBG000LYF3S8,Novartis ALK+ metastatic NSCLC therapy Zykadia® extends progression-free survival beyond 18 months in Phase II study,2016-10-09 06:53:05 +0000,http://www.publicnow.com/view/C6333731986C40D2D8CF52E20A0703DC54279B99,[at noodls] - Progression-free survival (PFS) in ALKi-naïve patients is consistent with results previously reported from Phase I ASCEND-1 study Phase II study also showed overall response rate of 63.3% in ALKi-naïve ...
NVS,NVS:US,BBG000LYF3S8,Novartis' Tafinlar® (dabrafenib) + Mekinist® (trametinib) demonstrate superior overall survival benefit in advanced melanoma patients at three-year follow up,2016-10-08 06:53:10 +0000,http://www.publicnow.com/view/01C08A1C1D013A809848D05B56944415E639BBB1,[at noodls] - Latest data confirm an estimated 45% of patients who received Tafinlar + Mekinist combination therapy are alive versus 31% of patients on BRAF monotherapy Second trial to confirm three-year landmark ...
NVS,NVS:US,BBG000LYF3S8,Novartis: Tafinlar + Mekinist Demonstrate Superior Overall Survival Benefit,2016-10-08 06:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uJY9uO5CZcg/novartis-tafinlar--mekinist-demonstrate-superior-overall-survival-benefit-20161008-00018,Novartis: Tafinlar + Mekinist Demonstrate Superior Overall Survival Benefit
NVS,NVS:US,BBG000LYF3S8,Novartis breakthrough therapy LEE011 plus letrozole demonstrates superior progression-free survival as first-line treatment for HR+/HER2- advanced breast cancer compared to a standard of care,2016-10-08 06:43:09 +0000,http://www.publicnow.com/view/651D5C8BC3652D705D5D4505A0C7FC0355BF2251,"[at noodls] - LEE011 (ribociclib) plus letrozole reduced the risk of progression or death by 44% over letrozole alone, significantly extending progression-free survival (PFS) across all patient subgroups Results showed ..."
NVS,NVS:US,BBG000LYF3S8,Novartis challenges Pfizer with strong breast cancer drug data,2016-10-08 06:15:01 +0000,http://finance.yahoo.com/news/novartis-challenges-pfizer-strong-breast-061501508.html,"[Reuters] - An experimental Novartis pill given with an older drug kept advanced breast cancer in check far longer than standard treatment alone, putting it on track to challenge Pfizer's blockbuster Ibrance, data showed on Saturday. Novartis' ribociclib works in a similar way to Ibrance and is set to be second to market in the category, since it could go on sale next year, ahead of rivals like Eli Lilly's abemaciclib. The 44 percent reduction in progression-free survival seen with ribociclib, which is also known as LEE011, compared with a 42 percent fall reported in a comparable late-stage trial involving Ibrance."
NVS,NVS:US,BBG000LYF3S8,Novartis Targets Breast Cancer Drug Approval to Take on Pfizer,2016-10-08 06:15:00 +0000,http://www.bloomberg.com/news/articles/2016-10-08/novartis-targets-breast-cancer-drug-approval-to-take-on-pfizer?cmpid=yhoo.headline,Novartis Targets Breast Cancer Drug Approval to Take on Pfizer
NVS,NVS:US,BBG000LYF3S8,3 Beaten-Up Big Pharma Stocks: Are They Bargains Now?,2016-10-07 23:26:42 +0000,http://www.fool.com/investing/2016/10/07/3-beaten-up-big-pharma-stocks-are-they-bargains.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Beaten-Up Big Pharma Stocks: Are They Bargains Now?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell After Lackluster U.S. Jobs Report,2016-10-07 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sO1ez-huNTA/the-swiss-stock-market-fell-after-lackluster-us-jobs-report-20161007-00304,The Swiss Stock Market Fell After Lackluster U.S. Jobs Report
NVS,NVS:US,BBG000LYF3S8,"Coherus' Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz",2016-10-07 01:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2aUwCvo9mAU/coherus-neulasta-biosimilar-at-fda-altar-cytodyn-on-fast-track-vive-abuzz-20161007-00003,"Coherus' Neulasta Biosimilar At FDA Altar, CytoDyn On Fast Track, VIVE Abuzz"
NVS,NVS:US,BBG000LYF3S8,"New CAR-T Cell Therapy May Cure Tumors (JUNO, KITE)",2016-10-07 00:15:00 +0000,http://www.investopedia.com/news/new-cart-cell-therapy-may-cure-tumors-juno-kite/?partner=YahooSA,"New CAR-T Cell Therapy May Cure Tumors (JUNO, KITE)"
NVS,NVS:US,BBG000LYF3S8,Novartis AG (NVS) Relocates NITD To California,2016-10-06 18:37:48 +0000,http://www.insidermonkey.com/blog/novartis-ag-nvs-relocates-nitd-to-california-479112/,Novartis AG (NVS) Relocates NITD To California
NVS,NVS:US,BBG000LYF3S8,Merck & Co. Inc. (MRK) Shuts Down Florida Facility,2016-10-06 17:15:56 +0000,http://www.insidermonkey.com/blog/merck-co-inc-mrk-shuts-down-florida-facility-479108/,Merck & Co. Inc. (MRK) Shuts Down Florida Facility
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good",2016-10-06 14:47:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k9ivxzZZw6s/pharma-stock-roundup-lilly-inks-animal-health-deal-jjs-psoriasis-data-looks-good-cm689700,Once again acquisitions and deals were in focus in the pharma sector with Lilly LLY announcing a deal to boost its animal health segment and Allergan AGN and AstraZeneca AZN announcing licensing agreements Meanwhile companies like Johnson amp Johnson JNJ and Novartis NVS presented data
NVS,NVS:US,BBG000LYF3S8,Eli Lilly to Buy Boehringer's Vetmedica Pet Vaccines Unit,2016-10-06 12:46:23 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ge1xYaP_0Ow/eli-lilly-to-buy-boehringers-vetmedica-pet-vaccines-unit-cm689581,Eli Lilly and Company LLY announced that its Elanco animal health business has agreed to acquire the U S pet vaccines unit Vetmedica and a Fort Dodge IA based manufacturing site from German drugmaker Boehringer Ingelheim for 885 million The acquisition of the Vetmedica portfolio
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell After Early Gains Eroded,2016-10-06 12:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CaQ08vOfivg/the-swiss-stock-market-fell-after-early-gains-eroded-20161006-00731,The Swiss Stock Market Fell After Early Gains Eroded
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good",2016-10-06 12:12:12 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-lilly-inks-121212940.html,"Pharma Stock Roundup: Lilly Inks Animal Health Deal, J&J's Psoriasis Data Looks Good"
NVS,NVS:US,BBG000LYF3S8,Eli Lilly Looks To Corral More Animal-Health Business Vs. Zoetis,2016-10-05 20:04:55 +0000,http://www.investors.com/news/technology/eli-lilly-looks-to-corral-more-animal-health-business-vs-zoetis/,Eli Lilly Looks To Corral More Animal-Health Business Vs. Zoetis
NVS,NVS:US,BBG000LYF3S8,"Novartis reshapes research, closes some Swiss, Chinese units",2016-10-05 13:36:01 +0000,http://finance.yahoo.com/news/novartis-reshapes-research-closes-swiss-133601146.html,"Novartis reshapes research, closes some Swiss, Chinese units"
NVS,NVS:US,BBG000LYF3S8,"Novartis closes Swiss, Chinese centres in research revamp",2016-10-05 11:42:30 +0000,http://finance.yahoo.com/news/novartis-closes-swiss-chinese-centres-114230852.html,"Novartis closes Swiss, Chinese centres in research revamp"
NVS,NVS:US,BBG000LYF3S8,Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio,2016-10-05 08:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j303XdD6gGk/eli-lilly-to-buy-boehringer-ingelheim-pet-vaccines-portfolio-20161005-00367,Eli Lilly to Buy Boehringer Ingelheim Pet Vaccines Portfolio
NVS,NVS:US,BBG000LYF3S8,Eli Lilly To Buy Boehringer Ingelheim Pet Vaccines Portolio for $885 Million,2016-10-05 07:53:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Dnymujw47fg/eli-lilly-to-buy-boehringer-ingelheim-pet-vaccines-portolio-for-885-million-20161005-00288,Eli Lilly To Buy Boehringer Ingelheim Pet Vaccines Portolio for $885 Million
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis to shift Singapore research facility,2016-10-05 07:20:27 +0000,"http://www.ft.com/cms/s/e756bd0c-8abc-11e6-8cb7-e7ada1d123b1,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Novartis is moving a key research facility from Singapore to the US, in a blow to the city-state's efforts to foster job creation in the pharmaceutical sector. On Wednesday, the Swiss said that its Singapore-based ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed Again As Banks & Cyclicals Continue Recovery,2016-10-04 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pBH4its-Yug/the-swiss-stock-market-climbed-again-as-banks--cyclicals-continue-recovery-20161004-00513,The Swiss Stock Market Climbed Again As Banks & Cyclicals Continue Recovery
NVS,NVS:US,BBG000LYF3S8,Novartis Is Surviving,2016-10-03 16:44:24 +0000,http://finance.yahoo.com/news/novartis-surviving-164424371.html,Novartis Is Surviving
NVS,NVS:US,BBG000LYF3S8,"Friends or Foes: Amgen and Novartis (AMGN, NVS)",2016-10-03 13:48:00 +0000,http://www.investopedia.com/news/friends-or-foes-amgen-and-novartis-amgn-nvs/?partner=YahooSA,"Friends or Foes: Amgen and Novartis (AMGN, NVS)"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Higher As Banks Recover,2016-10-03 12:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w4dbKTAz83Y/the-swiss-stock-market-finished-higher-as-banks-recover-20161003-00889,The Swiss Stock Market Finished Higher As Banks Recover
NVS,NVS:US,BBG000LYF3S8,European Markets Finished Mixed Despite Easing Deutsche Bank Concerns,2016-10-03 11:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DxDM7ivNrgo/european-markets-finished-mixed-despite-easing-deutsche-bank-concerns-20161003-00865,European Markets Finished Mixed Despite Easing Deutsche Bank Concerns
NVS,NVS:US,BBG000LYF3S8,Big Pharma vs Big Pharma in court battles over biosimilar drugs,2016-10-03 09:00:01 +0000,http://uk.finance.yahoo.com/news/big-pharma-vs-big-pharma-090001886.html,Big Pharma vs Big Pharma in court battles over biosimilar drugs
NVS,NVS:US,BBG000LYF3S8,European Shares Steady In Cautious Trade; FTSE 100 Outperforms,2016-10-03 06:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CVy-T1TQTkU/european-shares-steady-in-cautious-trade-ftse-100-outperforms-20161003-00202,European Shares Steady In Cautious Trade; FTSE 100 Outperforms
NVS,NVS:US,BBG000LYF3S8,Novartis reports over half of psoriasis patients do not reach the achievable treatment goal of clear skin in largest global survey,2016-10-03 05:46:06 +0000,http://www.publicnow.com/view/0EBB6635C94CF0FDC0D395C9AB7DF08419552A54,"[at noodls] - Global survey of over 8,300 patients shows over half have not achieved clear skin (57%), with the majority taking the historical standard of care treatment Majority (84%) face discrimination and humiliation ..."
NVS,NVS:US,BBG000LYF3S8,Novo Nordisk Bets on Riskier Insulin Research,2016-10-02 23:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/FG75k0yXfyc/novo-nordisk-bets-on-riskier-insulin-research-20161002-00060,Novo Nordisk Bets on Riskier Insulin Research
NVS,NVS:US,BBG000LYF3S8,Big Pharma vs Big Pharma in court battles over biosimilar drugs,2016-10-02 09:00:01 +0000,http://uk.finance.yahoo.com/news/big-pharma-vs-big-pharma-090001659.html,"[Reuters - UK Focus] - ZURICH, Oct (Shenzhen: 000069.SZ - news) 2 (Reuters) - The line dividing makers of brand-name drugs and copycat medicines is blurring as companies known for innovative treatments queue up to peddle copies of rivals' complex biological medicines. Biologics, manufactured in living cells, then extracted and purified, are more complex than traditional medicines and cannot be copied with precision, and so their knock-off versions are called biosimilars instead of generics. The allure of biosimilars is clear, with insurers and other payers counting on the steep discounts."
NVS,NVS:US,BBG000LYF3S8,"Novartis' Cosentyx Shows High, Long-lasting Skin Clearance In Plaque Psoriasis",2016-10-01 15:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-9rjd2IDhpU/novartis-cosentyx-shows-high-longlasting-skin-clearance-in-plaque-psoriasis-20161001-00029,"Novartis' Cosentyx Shows High, Long-lasting Skin Clearance In Plaque Psoriasis"
NVS,NVS:US,BBG000LYF3S8,Novartis late-breaking data show Cosentyx delivers high and long-lasting skin clearance over 4 years for psoriasis patients,2016-10-01 05:51:07 +0000,http://www.publicnow.com/view/776781F48DE2E3852AC1F8C6E0A5996A05D87993,[at noodls] - Cosentyxdelivers long-lasting clear or almost clear skin (PASI 90 to PASI 100) in the vast majority of patients and continues to show a favorable safety profile over 4 years New data show that with ...
NVS,NVS:US,BBG000LYF3S8,Novartis psoriasis drug maintains efficacy after 4 years - study,2016-10-01 05:15:01 +0000,http://finance.yahoo.com/news/novartis-psoriasis-drug-maintains-efficacy-051501170.html,"[Reuters] - Novartis's psoriasis drug Cosentyx showed long-term efficacy in keeping patients' skin clear, the Swiss drugmaker said on Saturday, citing a study it hopes will ultimately help the company to win business from rival medicines made by Amgen and Johnson & Johnson . More than 66 percent of Cosentyx patients achieved ""clear or almost clear"" skin after four years, Novartis said, comparable with the 68.5 percent who hit that milestone after one year. A durable response is important, since older biotech drugs for plaque psoriasis, known as anti-TNFs, can lose their effectiveness over time."
NVS,NVS:US,BBG000LYF3S8,Prothena Builds On Psoriasis Science For Arthritis Treatment,2016-09-30 20:54:31 +0000,http://www.investors.com/news/technology/prothena-builds-on-psoriasis-science-for-arthritis-treatment/,Prothena Builds On Psoriasis Science For Arthritis Treatment
NVS,NVS:US,BBG000LYF3S8,Here's Why Ophthotech Corporation Is Dropping Today,2016-09-30 18:23:27 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SIub0_cKoNI/heres-why-ophthotech-corporation-is-dropping-today-cm687258,Image source Getty Images What happened Shares of Ophthotech NASDAQ OPHT a clinical stage biotech primarily focused on diseases of the eye are down by 13 as of 12 00 p m EDT on Friday So what The sell off can be traced to less than stellar
NVS,NVS:US,BBG000LYF3S8,Amgen (AMGN) Migraine Drug Hits Phase III Primary Endpoint,2016-09-30 16:24:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rKvo6B6iSSE/amgen-amgn-migraine-drug-hits-phase-iii-primary-endpoint-cm687174,Amgen Inc AMGN announced positive top line data from a phase III study ARISE on calcitonin gene related peptide CGRP receptor erenumab AMG 334 for the prevention of episodic migraine The multi center randomized 12 week double blind placebo controlled study evaluated the safety
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Shares Cross Below 200 DMA,2016-09-30 16:22:05 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VFBM72ThXws/novartis-nvs-shares-cross-below-200-dma-cm687147,In trading on Friday shares of Novartis Symbol NVS crossed below their 200 day moving average of 78 66 changing hands as low as 78 28 per share Novartis shares are currently trading off about 1 on the day The chart below shows the one year performance of NVS shares versus its 200
NVS,NVS:US,BBG000LYF3S8,Is It Too Late to Get In on This Millionaire-Maker Stock?,2016-09-30 15:23:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nfr9EG4KMUw/is-it-too-late-to-get-in-on-this-millionaire-maker-stock-cm687085,Image source Getty Images If you d invested in Ligand Pharmaceuticals NASDAQ LGND on the first trading day of 2011 then you would have lucked into an 11 bagger Not bad LGND data by YCharts While I m cherry picking the data to make
NVS,NVS:US,BBG000LYF3S8,Which Pfizer Products Reported Declining Sales?,2016-09-30 15:05:21 +0000,http://marketrealist.com/2016/09/which-pfizer-products-reported-declining-sales/?utm_source=yahoo&utm_medium=feed,Which Pfizer Products Reported Declining Sales?
NVS,NVS:US,BBG000LYF3S8,"SQZ Biotech nabs $16M funding, hires former Novartis exec",2016-09-30 11:10:11 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/09/sqz-biotech-nabs-16m-funding-hires-former-novartis.html?ana=yahoo,"SQZ Biotech nabs $16M funding, hires former Novartis exec"
NVS,NVS:US,BBG000LYF3S8,The Pfizer-Anacor Deal: A Review,2016-09-29 22:04:12 +0000,http://marketrealist.com/2016/09/the-pfizer-anacor-deal-a-review/?utm_source=yahoo&utm_medium=feed,The Pfizer-Anacor Deal: A Review
NVS,NVS:US,BBG000LYF3S8,"Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market",2016-09-29 20:09:25 +0000,http://www.investors.com/news/technology/amgen-migraine-drug-likely-to-beat-eli-lilly-alder-teva-to-market/,"Amgen Migraine Drug Likely To Beat Eli Lilly, Alder, Teva To Market"
NVS,NVS:US,BBG000LYF3S8,7 Healthcare Stocks in Focus on World Heart Day,2016-09-29 16:24:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/a05pILds2Pk/7-healthcare-stocks-in-focus-on-world-heart-day-cm686605,Every year on Sep 29 World Heart Day is observed to raise awareness about cardiovascular CV diseases including heart disease and stroke The focus is on creating heart healthy environments that will help reduce cardiovascular risk be it at work or at home According to the World
NVS,NVS:US,BBG000LYF3S8,"Noteworthy ETF Inflows: VEU, NSRGY, NVS, TM",2016-09-29 16:22:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3qjERdoK_8A/noteworthy-etf-inflows-veu-nsrgy-nvs-tm-cm686576,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 68 6 million dollar inflow that s a 0 5 increase week over week
NVS,NVS:US,BBG000LYF3S8,7 Healthcare Stocks in Focus on World Heart Day,2016-09-29 14:03:02 +0000,http://finance.yahoo.com/news/7-healthcare-stocks-focus-world-140302072.html,7 Healthcare Stocks in Focus on World Heart Day
NVS,NVS:US,BBG000LYF3S8,Swiss Stocks Finished Lower After OPEC Rally Fizzles,2016-09-29 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ZN04H8meeBo/swiss-stocks-finished-lower-after-opec-rally-fizzles-20160929-00746,Swiss Stocks Finished Lower After OPEC Rally Fizzles
NVS,NVS:US,BBG000LYF3S8,5 Big Breakout Trades You Should Have in Your Portfolio This Fall,2016-09-29 11:49:00 +0000,https://www.thestreet.com/story/13835389/1/5-big-breakouts-trades-you-should-have-in-your-portfolio-this-fall.html?puc=yahoo&cm_ven=YAHOO,5 Big Breakout Trades You Should Have in Your Portfolio This Fall
NVS,NVS:US,BBG000LYF3S8,"ADHD Doesn''t MEASURE Up, AMGN ARISEs To The Occasion, ITCI Misses Study Goal",2016-09-29 01:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OfY1JuLkPtY/adhd-doesnt-measure-up-amgn-arises-to-the-occasion-itci-misses-study-goal-20160929-00034,"ADHD Doesn''t MEASURE Up, AMGN ARISEs To The Occasion, ITCI Misses Study Goal"
NVS,NVS:US,BBG000LYF3S8,Amgen Reports Positive Results For Erenumab From A Phase 3 Study,2016-09-28 22:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pmuK10KkZZI/amgen-reports-positive-results-for-erenumab-from-a-phase-3-study-20160928-01103,Amgen Reports Positive Results For Erenumab From A Phase 3 Study
NVS,NVS:US,BBG000LYF3S8,Novartis announces Phase III study shows AMG 334 significantly reduces monthly migraine days in people with episodic migraine,2016-09-28 20:59:05 +0000,http://www.publicnow.com/view/34AED1B7BE7AB7AEA71E3D57BA2378B4E727E7F1,"[at noodls] - ARISE, first pivotal Phase III study of AMG 334 (erenumab) in episodic migraine prevention, met primary endpoint, showing a statistically significant reduction in monthly migraine days vs placebo People ..."
NVS,NVS:US,BBG000LYF3S8,–… Stocks John Rogers Keeps Buying,2016-09-28 20:20:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/k7dTz90Ibsg/-stocks-john-rogers-keeps-buying-cm686173,John Rogers Trades Portfolio is the founder of Ariel Investment LLC which he started in 98 He is also a long term Forbes columnist writing a column called Patient Investor In both the first and second quarters the guru bought shares in the following stocks Cullen
NVS,NVS:US,BBG000LYF3S8,"3 Reasons Not to Lose Faith in Amgen, Inc. (AMGN)",2016-09-28 18:21:40 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EkrAmdPVPkM/3-reasons-not-to-lose-faith-in-amgen-inc-amgn-cm686100,InvestorPlace InvestorPlace Stock Market News Stock Advice amp Trading Tips Ugh Just when it looks like Amgen Inc NASDAQ AMGN shares are going to find the catalyst they need to break out of a two year rut news comes along to upend the effort
NVS,NVS:US,BBG000LYF3S8,Teva’s Commercial Strategy May Be Successful across Europe,2016-09-28 15:05:25 +0000,http://marketrealist.com/2016/09/teva-pharmaceuticals-commercial-strategy-may-prove-successful-across-market-structures-europe/?utm_source=yahoo&utm_medium=feed,Teva’s Commercial Strategy May Be Successful across Europe
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Added To Yesterday's Gains,2016-09-28 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eDUJj6fi4lQ/the-swiss-stock-market-added-to-yesterdays-gains-20160928-00716,The Swiss Stock Market Added To Yesterday's Gains
NVS,NVS:US,BBG000LYF3S8,Kite Pharma Soars As Cancer Drug Trial Supportive Of FDA Approval,2016-09-27 20:20:24 +0000,http://www.investors.com/news/technology/kite-pharma-soars-as-cancer-drug-trial-supportive-of-fda-approval/,Kite Pharma Soars As Cancer Drug Trial Supportive Of FDA Approval
NVS,NVS:US,BBG000LYF3S8,Kite Pharma Reports Favorable Data from Lymphoma Study,2016-09-27 16:24:47 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rdGfddAUwhU/kite-pharma-reports-favorable-data-from-lymphoma-study-cm685355,Kite Pharma Inc KITE announced encouraging top line data from a pre planned interim analysis of a pivotal phase II portion of the ZUMA 1 study on its lead pipeline candidate KTE C19 an anti CD19 CAR based therapy The candidate is being evaluated for the treatment of patients
NVS,NVS:US,BBG000LYF3S8,Why Kite Pharma's Stock Is Soaring Today,2016-09-27 15:23:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GAm2JvTaXJI/why-kite-pharmas-stock-is-soaring-today-cm685297,What happened Shares of Kite Pharma NASDAQ KITE a clinical stage biotech developing cell based cancer therapies rose by more than 13 in premarket trading today The biotech s surge higher was sparked by a positive interim data readout for the 160 chimeric
NVS,NVS:US,BBG000LYF3S8,Kite Pharma Reports Favorable Data from Lymphoma Study,2016-09-27 14:28:02 +0000,http://finance.yahoo.com/news/kite-pharma-reports-favorable-data-142802085.html,Kite Pharma Reports Favorable Data from Lymphoma Study
NVS,NVS:US,BBG000LYF3S8,Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19,2016-09-27 13:42:47 +0000,http://finance.yahoo.com/news/juno-therapeutics-viewed-sympathy-play-134247295.html,Juno Therapeutics Viewed As A Sympathy Play On Kite Pharma's KTE-C19
NVS,NVS:US,BBG000LYF3S8,Why Kite Pharma's Stock Is Soaring Today,2016-09-27 13:24:00 +0000,http://www.fool.com/investing/2016/09/27/why-kite-pharmas-stock-is-flying-high-today.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Kite Pharma's Stock Is Soaring Today
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Higher Thanks To Support From Heavyweights,2016-09-27 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j5tmLP-hU2Y/the-swiss-stock-market-finished-higher-thanks-to-support-from-heavyweights-20160927-00413,The Swiss Stock Market Finished Higher Thanks To Support From Heavyweights
NVS,NVS:US,BBG000LYF3S8,Novartis Ilaris Approved for Extended Use in Periodic Fever,2016-09-26 15:25:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Q7SPQXyy2YM/novartis-ilaris-approved-for-extended-use-in-periodic-fever-cm684463,Switzerland based Novartis AG NVS announced that its arthritis drug Ilaris was approved in the U S for expanded use in the treatment of three distinct types of periodic fever syndromes tumor necrosis factor receptor associated periodic syndrome TRAPS hyperimmunoglobulin
NVS,NVS:US,BBG000LYF3S8,The Internet of Medical Things: 6 Stocks in Focus,2016-09-26 15:24:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lzQhfP0_jp4/the-internet-of-medical-things-6-stocks-in-focus-cm684443,The Internet of Medical Things IoMT is fast gaining pace as pharma companies look to innovate and keep up with technology to help patients and physicians better monitor and track diseases With a couple of deals being announced this month IoMT seems like the future of healthcare IoMT
NVS,NVS:US,BBG000LYF3S8,"ETF’s with exposure to Novartis AG : September 26, 2016",2016-09-26 15:11:17 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-novartis-ag-september-26-2016/,"ETF’s with exposure to Novartis AG : September 26, 2016"
NVS,NVS:US,BBG000LYF3S8,The Internet of Medical Things: 6 Stocks in Focus,2016-09-26 13:33:01 +0000,http://finance.yahoo.com/news/internet-medical-things-6-stocks-133301649.html,The Internet of Medical Things: 6 Stocks in Focus
NVS,NVS:US,BBG000LYF3S8,Novartis Ilaris Approved for Extended Use in Periodic Fever,2016-09-26 13:18:01 +0000,http://finance.yahoo.com/news/novartis-ilaris-approved-extended-periodic-131801541.html,Novartis Ilaris Approved for Extended Use in Periodic Fever
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped On Bank Weakness,2016-09-26 12:11:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LLws411tkPc/the-swiss-stock-market-dropped-on-bank-weakness-20160926-00793,The Swiss Stock Market Dropped On Bank Weakness
NVS,NVS:US,BBG000LYF3S8,European Markets Tumbled As Bank Shares Weakened Further,2016-09-26 11:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qezHff7mbrY/european-markets-tumbled-as-bank-shares-weakened-further-20160926-00773,European Markets Tumbled As Bank Shares Weakened Further
NVS,NVS:US,BBG000LYF3S8,European Shares Retreat As Banks And Resource Stocks Tumble,2016-09-26 06:55:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j2cZVYno41o/european-shares-retreat-as-banks-and-resource-stocks-tumble-20160926-00195,European Shares Retreat As Banks And Resource Stocks Tumble
NVS,NVS:US,BBG000LYF3S8,"FDA Approves AMGN's 1st Biosimilar, MRNS On Track, All Ears For DRRX, PTIE",2016-09-26 01:09:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xmAd31XN2xM/fda-approves-amgns-1st-biosimilar-mrns-on-track-all-ears-for-drrx-ptie-20160926-00017,"FDA Approves AMGN's 1st Biosimilar, MRNS On Track, All Ears For DRRX, PTIE"
NVS,NVS:US,BBG000LYF3S8,Teva’s Valuation Multiples Compared to Other Generic Drug Players,2016-09-23 21:25:53 +0000,http://marketrealist.com/2016/09/teva-pharmaceuticals-valuation-multiples-compare-generic-pharmaceutical-players/?utm_source=yahoo&utm_medium=feed,Teva’s Valuation Multiples Compared to Other Generic Drug Players
NVS,NVS:US,BBG000LYF3S8,"Health Care Sector Update for 09/23/2016: ACHN,BLRX,APRI",2016-09-23 20:40:52 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m555Ryka1SY/health-care-sector-update-for-09232016-achnblrxapri-cm684054,Top Health Care StocksTop Health Care Stocks JNJ 0 40 JNJ 0 40 PFE 0 47 PFE 0 47 MRK 0 07 MRK 0 07 ABT 0 07 ABT 0 07 AMGN 0 40 AMGN 0 40 Health care stocks were slightly lower Friday afternoon with the NYSE Health Care Index declining about 0 2 while shares of health care
NVS,NVS:US,BBG000LYF3S8,Novartis receives three new FDA approvals for the expanded use of Ilaris for patients with rare Periodic Fever Syndrome conditions,2016-09-23 17:09:00 +0000,http://finance.yahoo.com/news/novartis-receives-three-fda-approvals-170900286.html,"[PR Newswire] - EAST HANOVER, N.J., Sept. 23, 2016 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has granted three simultaneous approvals for the expanded use of Ilaris ® (canakinumab) ..."
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study,2016-09-23 16:25:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/xvaHY886C0Y/novartis-nvs-zykadia-positive-in-phase-iii-ascend-4-study-cm683849,Novartis AG NVS announced positive top line data from a phase III study ASCEND 4 on its oncology drug Zykadia for the treatment of patients with advanced anaplastic lymphoma kinase positive ALK non small cell lung cancer NSCLC We expect investors to react positively to the news
NVS,NVS:US,BBG000LYF3S8,Novartis receives three new FDA approvals for the expanded use of Ilaris treating rare Periodic Fever Syndrome conditions,2016-09-23 16:12:12 +0000,http://www.publicnow.com/view/3D4A287784607486E4A681567F56728AE7139E5C,"[at noodls] - Ilaris (canakinumab) is the first and only US FDA-approved biologic treatment for patients with TRAPS, HIDS/MKD and FMF disease These three simultaneous approvals conducted under FDA Priority Review follow ..."
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study,2016-09-23 14:01:02 +0000,http://finance.yahoo.com/news/novartis-nvs-zykadia-positive-phase-140102801.html,Novartis (NVS) Zykadia Positive in Phase III ASCEND-4 Study
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell As Investors Took Profits,2016-09-23 12:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pZ_xRKrQWoE/the-swiss-stock-market-fell-as-investors-took-profits-20160923-00217,The Swiss Stock Market Fell As Investors Took Profits
NVS,NVS:US,BBG000LYF3S8,European Markets Hit By Profit Taking After Yesterday's Rally,2016-09-23 11:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XPDmq9v-hhY/european-markets-hit-by-profit-taking-after-yesterdays-rally-20160923-00205,European Markets Hit By Profit Taking After Yesterday's Rally
NVS,NVS:US,BBG000LYF3S8,"UPDATE 1-Novartis's Zykadia gets positive results, faces Roche pressure",2016-09-23 11:29:56 +0000,http://finance.yahoo.com/news/novartiss-zykadia-gets-positive-results-111251277.html,"[Reuters] - Novartis's Zykadia drug performed well against a rare form of lung cancer, the Swiss company said on Friday, citing a study it hopes will help it win expanded regulatory approval for the use of the drug. Novartis released results of a phase III clinical trial of Zykadia, or ceritinib, on previously untreated patients with advanced anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer. Patients treated with Zykadia showed a significant improvement in their chances of surviving without the cancer spreading compared with standard chemotherapy, the firm said."
NVS,NVS:US,BBG000LYF3S8,"Novartis announces positive top-line results from ASCEND-4, a Phase III trial of Zykadia® in untreated adult ALK+ NSCLC patients",2016-09-23 05:52:05 +0000,http://www.publicnow.com/view/129E94C30AF161365A54482F40F43FBA71933BBF,"[at noodls] - In a Phase III clinical study, Zykadia extended progression-free survival (PFS) when compared with standard chemotherapy, including maintenance Novartis is moving forward with global regulatory submissions ..."
NVS,NVS:US,BBG000LYF3S8,Novartis: Zykadia Phase III Trial Meets Primary Endpoint - Quick Facts,2016-09-23 01:33:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lJ90Nqu7Lm8/novartis-zykadia-phase-iii-trial-meets-primary-endpoint--quick-facts-20160923-00354,Novartis: Zykadia Phase III Trial Meets Primary Endpoint - Quick Facts
NVS,NVS:US,BBG000LYF3S8,"Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle",2016-09-22 20:35:02 +0000,http://www.investors.com/news/technology/gilead-allergan-seen-trailing-intercept-in-ongoing-nash-battle/,"Gilead, Allergan Seen Trailing Intercept In Ongoing NASH Battle"
NVS,NVS:US,BBG000LYF3S8,A Double Dose of Trouble at Novartis,2016-09-22 18:00:39 +0000,http://finance.yahoo.com/news/double-dose-trouble-novartis-180039888.html,A Double Dose of Trouble at Novartis
NVS,NVS:US,BBG000LYF3S8,Does Novartis AG (NVS) Have The Solution For Malaria?,2016-09-22 17:05:43 +0000,http://www.insidermonkey.com/blog/does-novartis-ag-nvs-have-the-solution-for-malaria-476348/,Does Novartis AG (NVS) Have The Solution For Malaria?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Jumped After Fed Maintains Rates,2016-09-22 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ob7cat_JVEo/the-swiss-stock-market-jumped-after-fed-maintains-rates-20160922-00720,The Swiss Stock Market Jumped After Fed Maintains Rates
NVS,NVS:US,BBG000LYF3S8,"Novartis' Antimalarial Compound Shows Activity Against Vivax, Falciparum Malaria",2016-09-21 21:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PQLMJ-U3LrI/novartis-antimalarial-compound-shows-activity-against-vivax-falciparum-malaria-20160921-01060,"Novartis' Antimalarial Compound Shows Activity Against Vivax, Falciparum Malaria"
NVS,NVS:US,BBG000LYF3S8,Novel Novartis malaria compound shows potential to be effective against infections resistant to all currently available antimalarial drugs,2016-09-21 21:21:05 +0000,http://www.publicnow.com/view/A3922A9AAA4E4C10790D104920D45EF6E3A5DBF4,"[at noodls] - Results published in the New England Journal of Medicine demonstrate that KAF156 shows activity against blood and liver stages of malaria parasites, including artemisinin-resistant parasites KAF156, currently ..."
NVS,NVS:US,BBG000LYF3S8,Reckitt Benckiser Struggles to Move Past Disinfectant Deaths,2016-09-21 14:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/81q_eIEJH_U/reckitt-benckiser-struggles-to-move-past-disinfectant-deaths-20160921-00756,Reckitt Benckiser Struggles to Move Past Disinfectant Deaths
NVS,NVS:US,BBG000LYF3S8,Reckitt Benckiser Apologizes for Disinfectant Deaths,2016-09-21 14:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/iMFB7mO7PLI/reckitt-benckiser-apologizes-for-disinfectant-deaths-20160921-01065,Reckitt Benckiser Apologizes for Disinfectant Deaths
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Turned Lower Ahead Of Fed Announcement,2016-09-21 12:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/26E0HF_SMkQ/the-swiss-stock-market-turned-lower-ahead-of-fed-announcement-20160921-00675,The Swiss Stock Market Turned Lower Ahead Of Fed Announcement
NVS,NVS:US,BBG000LYF3S8,"VEU, NSRGY, NVS, TM: ETF Inflow Alert",2016-09-20 16:22:58 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yNnwkyXAAwo/veu-nsrgy-nvs-tm-etf-inflow-alert-cm682029,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 93 5 million dollar inflow that s a 0 7 increase week over week
NVS,NVS:US,BBG000LYF3S8,Breaking the mould: GSK picks Big Pharma's first female CEO,2016-09-20 15:17:58 +0000,http://in.finance.yahoo.com/news/breaking-mould-gsk-picks-big-151758799.html,Breaking the mould: GSK picks Big Pharma's first female CEO
NVS,NVS:US,BBG000LYF3S8,Novartis A Buy At Chardan,2016-09-20 14:15:50 +0000,http://finance.yahoo.com/news/novartis-buy-chardan-141550715.html,Novartis A Buy At Chardan
NVS,NVS:US,BBG000LYF3S8,Pfizer (PFE) Breast Cancer Drug Ibrance Wins CHMP Backing,2016-09-20 13:24:01 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/mSpbTun2iss/pfizer-pfe-breast-cancer-drug-ibrance-wins-chmp-backing-cm681729,Pfizer Inc PFE came up with a couple of announcements related to its breast cancer drug Ibrance and PF 06438179 a biosimilar version of Johnson amp Johnson s JNJ blockbuster drug Remicade infliximab Ibrance a Step Closer to EU Approval Pfizer announced that the European
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Gains To A Second Session,2016-09-20 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Gb_W7mCS1fM/the-swiss-stock-market-extended-its-gains-to-a-second-session-20160920-01138,The Swiss Stock Market Extended Its Gains To A Second Session
NVS,NVS:US,BBG000LYF3S8,"Entering Migraine Market Won’t Be Easy for Novartis, Amgen",2016-09-20 12:05:40 +0000,http://marketrealist.com/2016/09/novartis-amgen-may-grab-slice-migraine-market-cgrp-inhibitor-amg-334/?utm_source=yahoo&utm_medium=feed,"Entering Migraine Market Won’t Be Easy for Novartis, Amgen"
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Presents Positive Data on Cardiovascular Drug,2016-09-19 16:24:24 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EC6p-TEQjh4/novartis-nvs-presents-positive-data-on-cardiovascular-drug-cm681339,Novartis AG NVS announces new analysis from the PARADIGM HF study on its cardiovascular drug Entresto at a scientific meeting of the Heart Failure Society of America Results from the study demonstrated the benefits of Entresto in heart failure patients with reduced ejection
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Presents Positive Data on Cardiovascular Drug,2016-09-19 14:16:02 +0000,http://finance.yahoo.com/news/novartis-nvs-presents-positive-data-141602423.html,Novartis (NVS) Presents Positive Data on Cardiovascular Drug
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Rebounded At The Start Of The New Trading Week,2016-09-19 12:38:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/BEKb7TUtPws/the-swiss-stock-market-rebounded-at-the-start-of-the-new-trading-week-20160919-00742,The Swiss Stock Market Rebounded At The Start Of The New Trading Week
NVS,NVS:US,BBG000LYF3S8,"European Markets Finished Higher, But Investors Remain Cautious",2016-09-19 12:03:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hMrz4ZgT_j8/european-markets-finished-higher-but-investors-remain-cautious-20160919-00707,"European Markets Finished Higher, But Investors Remain Cautious"
NVS,NVS:US,BBG000LYF3S8,European Shares Rally Ahead Of Central Bank Meetings,2016-09-19 06:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/7SSNONRS-hU/european-shares-rally-ahead-of-central-bank-meetings-20160919-00132,European Shares Rally Ahead Of Central Bank Meetings
NVS,NVS:US,BBG000LYF3S8,Important new analysis shows that Novartis' Entresto® is associated with higher relative health-related quality of life scores among HFrEF patients,2016-09-19 05:38:11 +0000,http://www.publicnow.com/view/523A7E93B53E2E4D409F53A257104EE0AD1E319A,"[at noodls] - New analysis of PARADIGM-HF data shows that among patients who had been hospitalized for heart failure, those on Entresto reported higher relative health-related quality of life (HRQL) scores compared ..."
NVS,NVS:US,BBG000LYF3S8,Is This New Market the Biggest Investment Idea of the Decade?,2016-09-17 17:20:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/o9nhQMEtSno/is-this-new-market-the-biggest-investment-idea-of-the-decade-cm680951,Image source Stockmonkeys com via Flickr Over 100 billion in annual sales for top selling biologic medicines will soon be up for grabs and that s leading to a gold rush to develop biosimilars With the biosimilar market poised to eclipse 20 billion as early as 2020 you might
NVS,NVS:US,BBG000LYF3S8,Is This New Market the Biggest Investment Idea of the Decade?,2016-09-17 15:41:06 +0000,http://www.fool.com/investing/2016/09/17/is-this-new-market-the-biggest-investment-idea-of.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Is This New Market the Biggest Investment Idea of the Decade?
NVS,NVS:US,BBG000LYF3S8,Novartis says MS drug cut risk of disability advance in study,2016-09-17 15:00:01 +0000,http://finance.yahoo.com/news/novartis-says-ms-drug-cut-150001408.html,"[Reuters] - Novartis's investigational multiple sclerosis drug cut the risk of disability progression in patients with a tough-to-treat form of the disease versus a placebo, the Swiss company said on Saturday, citing a new analysis of a late-stage trial. Novartis is testing BAF312 against secondary progressive multiple sclerosis (SPMS), which includes patients whose relapsing-remitting MS moves to a new phase characterised by a progressive worsening of neurologic function. Some analysts contend Novartis's BAF312 is an underappreciated part of its drug pipeline that promises to help the company shake off recent challenges including the sluggish launch of its Entresto heart failure drug and a sales slump at its Alcon eye care and surgical instruments division."
NVS,NVS:US,BBG000LYF3S8,Novartis Reports Positive Results From Phase III EXPAND Study,2016-09-17 12:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dns8ATIBha4/novartis-reports-positive-results-from-phase-iii-expand-study-20160917-00030,Novartis Reports Positive Results From Phase III EXPAND Study
NVS,NVS:US,BBG000LYF3S8,Novartis BAF312 reduces the risk of disability progression in pivotal phase III study in secondary progressive MS patients,2016-09-17 09:08:03 +0000,http://www.publicnow.com/view/3303D97227A5C3D50CF5DF09AD94996CFC8871D9,[at noodls] - EXPAND study data presented at ECTRIMS show that treatment with BAF312 (siponimod) reduced the risk of three-month confirmed disability progression by 21% vs placeboin people with secondary progressive ...
NVS,NVS:US,BBG000LYF3S8,Novartis Drug for Multiple Sclerosis Shows Reduction in Risks,2016-09-17 09:00:00 +0000,http://www.bloomberg.com/news/articles/2016-09-17/novartis-drug-for-multiple-sclerosis-shows-reduction-in-risks?cmpid=yhoo.headline,Novartis Drug for Multiple Sclerosis Shows Reduction in Risks
NVS,NVS:US,BBG000LYF3S8,Novartis Reports Positive Phase II Data on Migraine Drug,2016-09-16 17:21:22 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Rf14IKck64I/novartis-reports-positive-phase-ii-data-on-migraine-drug-cm680501,Novartis AG NVS announced results from a phase II study on migraine candidate AMG334 Data from the study were presented at the fifth European Headache and Migraine Trust International Congress EHMTIC in Glasgow Scotland The study enrolled 667 patients who had a mean baseline
NVS,NVS:US,BBG000LYF3S8,Novartis says experimental drug helps chronic migraine sufferers,2016-09-16 16:09:50 +0000,http://finance.yahoo.com/news/novartis-says-experimental-drug-helps-160950402.html,Novartis says experimental drug helps chronic migraine sufferers
NVS,NVS:US,BBG000LYF3S8,Novartis Reports Positive Phase II Data on Migraine Drug,2016-09-16 13:21:01 +0000,http://finance.yahoo.com/news/novartis-reports-positive-phase-ii-132101454.html,Novartis Reports Positive Phase II Data on Migraine Drug
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped Due To Weakness In Bank Stocks,2016-09-16 12:29:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oL7DIu0CFj0/the-swiss-stock-market-dropped-due-to-weakness-in-bank-stocks-20160916-00435,The Swiss Stock Market Dropped Due To Weakness In Bank Stocks
NVS,NVS:US,BBG000LYF3S8,An Attractive European Stock ETF,2016-09-16 10:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=769676&SR=Yahoo,An Attractive European Stock ETF
NVS,NVS:US,BBG000LYF3S8,New Novartis data presented at ECTRIMS show benefit of Gilenya® on patient disability progression at 10 years,2016-09-16 05:38:11 +0000,http://www.publicnow.com/view/BDC886E77B3CFC92BF2F73A9136EB2AA335C8436,[at noodls] - ACROSS study shows that patients with relapsing remitting multiple sclerosis (RRMS) continuously treated with Gilenya (fingolimod) had significantly lower disability progression compared to those whose ...
NVS,NVS:US,BBG000LYF3S8,"ARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX",2016-09-16 02:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/_-b5Ef8NgOE/arlz-gets-fda-nod-acrx-scores-hat-trick-otic-on-watch-no-relief-for-nvax-20160916-00036,"ARLZ Gets FDA Nod, ACRX Scores Hat Trick, OTIC On Watch, No Relief For NVAX"
NVS,NVS:US,BBG000LYF3S8,Novartis Says AMG 334 Reduces Monthly Migraine Days In Chronic Migraine,2016-09-15 22:05:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RPxbplB_HNE/novartis-says-amg-334-reduces-monthly-migraine-days-in-chronic-migraine-20160915-01217,Novartis Says AMG 334 Reduces Monthly Migraine Days In Chronic Migraine
NVS,NVS:US,BBG000LYF3S8,Novartis presents new positive data at EHMTIC showing AMG 334 significantly reduces monthly migraine days in chronic migraine,2016-09-15 20:58:07 +0000,http://www.publicnow.com/view/1FCF9C138F6A7C0F586D62FC67B7DAD2CAAD37E1,[at noodls] - Detailed results from Phase II study in chronic migraine prevention showed patients on AMG 334 (erenumab) were significantly more likely to experience a 50% or more reduction in monthly migraine days compared ...
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Snapped Losing Streak Thanks To Late Day Surge,2016-09-15 12:23:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gnW-Wb8y6WI/the-swiss-stock-market-snapped-losing-streak-thanks-to-late-day-surge-20160915-00812,The Swiss Stock Market Snapped Losing Streak Thanks To Late Day Surge
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Extended Its Losing Streak To 5 Sessions,2016-09-14 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TNHCPx9pAwc/the-swiss-stock-market-extended-its-losing-streak-to-5-sessions-20160914-00774,The Swiss Stock Market Extended Its Losing Streak To 5 Sessions
NVS,NVS:US,BBG000LYF3S8,Our Ultimate Stock-Pickers Top 10 Dividend-Yielding Stocks,2016-09-14 11:00:00 +0000,http://news.morningstar.com/articlenet/article.aspx?id=768937&SR=Yahoo,Our Ultimate Stock-Pickers Top 10 Dividend-Yielding Stocks
NVS,NVS:US,BBG000LYF3S8,Xencor (XNCR) Doses First Patient in Myeloid Leukemia Trial,2016-09-13 19:47:34 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/km-U6R_g6W0/xencor-xncr-doses-first-patient-in-myeloid-leukemia-trial-cm678986,Xencor Inc XNCR announced that the first patient has been dosed in a phase I trial on lead candidate XmAb14045 for the treatment of acute myeloid leukemia AML and other CD123 expressing hematologic malignancies The trial will evaluate the safety and tolerability of weekly
NVS,NVS:US,BBG000LYF3S8,Xencor (XNCR) Doses First Patient in Myeloid Leukemia Trial,2016-09-13 17:36:05 +0000,http://finance.yahoo.com/news/xencor-xncr-doses-first-patient-173605034.html,Xencor (XNCR) Doses First Patient in Myeloid Leukemia Trial
NVS,NVS:US,BBG000LYF3S8,Biotech Stocks Bounce Back in Monday Trading: 3 Picks,2016-09-13 15:49:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/kjcnaOB1Djo/biotech-stocks-bounce-back-in-monday-trading-3-picks-cm678799,The healthcare sector has been choppy since the beginning of 2016 continuing the volatile trend from the second half of 2015 Media and political focus on the high prices of drugs have made things difficult for the pharma biotech sector since the past one year Democratic presidential
NVS,NVS:US,BBG000LYF3S8,GSK Optimistic about Future of Its Consumer Healthcare Segment,2016-09-13 15:04:30 +0000,http://marketrealist.com/2016/09/gsk-optimistic-about-future-of-its-consumer-healthcare-segment/?utm_source=yahoo&utm_medium=feed,GSK Optimistic about Future of Its Consumer Healthcare Segment
NVS,NVS:US,BBG000LYF3S8,Jefferies Issues Top Pharma and Biohealth Stocks to Buy,2016-09-13 14:25:04 +0000,http://247wallst.com/healthcare-business/2016/09/13/jefferies-issues-top-pharma-and-biohealth-stocks-to-buy/,Jefferies Issues Top Pharma and Biohealth Stocks to Buy
NVS,NVS:US,BBG000LYF3S8,GlaxoSmithKline Giving a Shot to Its Vaccines Business,2016-09-13 14:04:27 +0000,http://marketrealist.com/2016/09/glaxosmithkline-giving-a-shot-to-its-vaccines-business/?utm_source=yahoo&utm_medium=feed,GlaxoSmithKline Giving a Shot to Its Vaccines Business
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Slipped Into The Red After Late Day Sell-Off,2016-09-13 12:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ChFMXxINsSI/the-swiss-stock-market-slipped-into-the-red-after-late-day-selloff-20160913-00853,The Swiss Stock Market Slipped Into The Red After Late Day Sell-Off
NVS,NVS:US,BBG000LYF3S8,Companies Join To Fight Diabetes -- WSJ,2016-09-13 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NS64i4G0XnY/companies-join-to-fight-diabetes--wsj-20160913-00075,Companies Join To Fight Diabetes -- WSJ
NVS,NVS:US,BBG000LYF3S8,This Firm Wins Battle Against Glaucoma By Putting A Stick In Your Eye,2016-09-12 21:46:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m6J63v5l1DM/this-firm-wins-battle-against-glaucoma-by-putting-a-stick-in-your-eye-cm676780,Given the choice between undergoing 160 eye surgery or 160 simply squeezing a few drops of solution into your eye 160 every day picking the latter 160 might seem 160 like a no brainer for people suffering from 160 mild to moderate glaucoma why let someone cut into your eyeball
NVS,NVS:US,BBG000LYF3S8,This Firm Wins Battle Against Glaucoma By Putting A Stick In Your Eye,2016-09-12 20:36:21 +0000,http://www.investors.com/research/the-new-america/glaukos-new-america/,This Firm Wins Battle Against Glaucoma By Putting A Stick In Your Eye
NVS,NVS:US,BBG000LYF3S8,"Noteworthy ETF Inflows: VEU, NSRGY, NVS, TM",2016-09-12 16:30:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qw7VGtSOwiE/noteworthy-etf-inflows-veu-nsrgy-nvs-tm-cm677978,Looking today at week over week shares outstanding changes among the universe of ETFs covered at ETF Channel one standout is the Vanguard FTSE All World ex US ETF Symbol VEU where we have detected an approximate 81 5 million dollar inflow that s a 0 6 increase week over week
NVS,NVS:US,BBG000LYF3S8,The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working,2016-09-12 15:34:25 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/01l6Ki16PSM/the-only-thing-more-extraordinary-than-glaxosmithklines-growth-strategy-is-that-its-working-cm677964,Image source Getty Images Big pharma GlaxoSmithKline NYSE GSK is doubling down on cheaper meds Unlike its pharma peers many of which appear blind to the growing public outrage over sky high priced meds Glaxo is blazing a different trail The U K based pharma
NVS,NVS:US,BBG000LYF3S8,The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working,2016-09-12 13:54:47 +0000,http://www.fool.com/investing/2016/09/12/the-only-thing-more-extraordinary-than-glaxosmithk.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,The Only Thing More Extraordinary Than GlaxoSmithKline's Growth Strategy Is That It's Working
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Kicked Off The New Trading Week Wit A Loss,2016-09-12 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GZRtjA1zFPg/the-swiss-stock-market-kicked-off-the-new-trading-week-wit-a-loss-20160912-00816,The Swiss Stock Market Kicked Off The New Trading Week Wit A Loss
NVS,NVS:US,BBG000LYF3S8,"Of GSK’s Business Segments, This One Is the Sales Laggard",2016-09-12 12:05:08 +0000,http://marketrealist.com/2016/09/of-gsks-business-segments-this-one-is-the-sales-laggard/?utm_source=yahoo&utm_medium=feed,"Of GSK’s Business Segments, This One Is the Sales Laggard"
NVS,NVS:US,BBG000LYF3S8,Google Parent and Sanofi Name Diabetes Joint Venture Onduo--2nd Update,2016-09-12 08:52:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/bWHK-ck9zbY/google-parent-and-sanofi-name-diabetes-joint-venture-onduo2nd-update-20160912-00502,Google Parent and Sanofi Name Diabetes Joint Venture Onduo--2nd Update
NVS,NVS:US,BBG000LYF3S8,Google Parent and Sanofi Name Diabetes Joint Venture Onduo--Update,2016-09-12 07:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NUhnfLkfUbU/google-parent-and-sanofi-name-diabetes-joint-venture-onduoupdate-20160912-00242,Google Parent and Sanofi Name Diabetes Joint Venture Onduo--Update
NVS,NVS:US,BBG000LYF3S8,Google Parent and Sanofi Name Diabetes Joint Venture Onduo,2016-09-12 02:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/x2kBnDAmZ9U/google-parent-and-sanofi-name-diabetes-joint-venture-onduo-20160912-00040,Google Parent and Sanofi Name Diabetes Joint Venture Onduo
NVS,NVS:US,BBG000LYF3S8,"Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression",2016-09-11 21:09:48 +0000,http://finance.yahoo.com/news/reads-weed-kend-marijuana-roadside-210948912.html,"Reads For The Weed-Kend: Marijuana Roadside Testing, Pregnancy And Depression"
NVS,NVS:US,BBG000LYF3S8,"This Could Save Medicare at Least $16 Billion a Year, but the Agency Is Barred From Doing It",2016-09-11 17:30:45 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cYEczH8qDeg/this-could-save-medicare-at-least-16-billion-a-year-but-the-agency-is-barred-from-doing-it-cm677468,Image source Getty Images Somebody get the gurney because Medicare is sick Ask seniors about their most immediate concern and you ll likely hear about the Social Security program s impending cash shortfall which is forecasted to happen by the year 2034 But this same forecast
NVS,NVS:US,BBG000LYF3S8,"This Could Save Medicare at Least $16 Billion a Year, but the Agency Is Barred From Doing It",2016-09-11 15:53:59 +0000,http://www.fool.com/retirement/2016/09/11/this-could-save-medicare-at-least-16-billion-a-yea.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"This Could Save Medicare at Least $16 Billion a Year, but the Agency Is Barred From Doing It"
NVS,NVS:US,BBG000LYF3S8,"To Beat Glaucoma, This Company Thrives By Putting A Stick In Your Eye",2016-09-09 20:32:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pMguGFPnBDM/to-beat-glaucoma-this-company-thrives-by-putting-a-stick-in-your-eye-cm676780,Given the choice between undergoing 160 eye surgery or 160 simply squeezing a few drops of solution into your eye 160 every day picking the latter 160 might seem 160 like a no brainer for people suffering from 160 mild to moderate glaucoma why let someone cut into your eyeball
NVS,NVS:US,BBG000LYF3S8,"Will These Cancer Therapies Pay Off? (KITE, JUNO)",2016-09-09 17:11:00 +0000,http://www.investopedia.com/news/will-these-cancer-therapies-pay-kite-juno/?partner=YahooSA,"Will These Cancer Therapies Pay Off? (KITE, JUNO)"
NVS,NVS:US,BBG000LYF3S8,"3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August",2016-09-09 16:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/GS4sTUgfaFs/3-reasons-bluebird-bio-inc-stock-dipped-137-in-august-cm676996,Image source Getty Images What Shares of bluebird bio Inc NASDAQ BLUE 160 a clinical stage biotech developing cellular therapies fell 13 7 in August according to data from S amp P Global Market Intelligence A larger than expected loss in the second
NVS,NVS:US,BBG000LYF3S8,"3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August",2016-09-09 14:24:51 +0000,http://www.fool.com/investing/2016/09/09/3-reasons-bluebird-bio-inc-stock-dipped-137-in-aug.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,"3 Reasons bluebird bio, Inc. Stock Dipped 13.7% in August"
NVS,NVS:US,BBG000LYF3S8,The Biotech ETF With The Unusual Investment Strategy,2016-09-09 13:48:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/LzdJHyilsgk/the-biotech-etf-with-the-unusual-investment-strategy-cm676816,"With most of the investable universe covered by an ETF in some form or another, fund providers are targeting increasingly narrow spaces for new product launches.     Management style tactics are also veering from the norm, as evidenced by the boom in smart beta products. While many of the ETFs are perfectly"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped On Fed Rate Hike Concerns,2016-09-09 12:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-DaVMhUk7Xk/the-swiss-stock-market-dropped-on-fed-rate-hike-concerns-20160909-00489,The Swiss Stock Market Dropped On Fed Rate Hike Concerns
NVS,NVS:US,BBG000LYF3S8,New Novartis point of care Niji(TM) System may provide earlier diagnosis of severe allergic asthma and faster treatment decisions,2016-09-09 06:00:28 +0000,http://www.publicnow.com/view/B43C9083BF054B22A703D49D8925D4FFCFFE3AE8,"[at noodls] - NijiTM System, Total IgE Test delivers results rapidly, allowing for quick in-office diagnosis of IgE-mediated allergic disorders and faster treatment decisions Point of care in office diagnostics may ..."
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dipped After ECB Disappoints,2016-09-08 12:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/CeoC4BgMeRQ/the-swiss-stock-market-dipped-after-ecb-disappoints-20160908-00869,The Swiss Stock Market Dipped After ECB Disappoints
NVS,NVS:US,BBG000LYF3S8,European Markets Finished Mixed After ECB Holds Firm,2016-09-08 11:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Fvs18gGetQo/european-markets-finished-mixed-after-ecb-holds-firm-20160908-00845,European Markets Finished Mixed After ECB Holds Firm
NVS,NVS:US,BBG000LYF3S8,European Shares Mixed As Investors Look To ECB,2016-09-08 05:56:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/uUer0b2BV48/european-shares-mixed-as-investors-look-to-ecb-20160908-00142,European Shares Mixed As Investors Look To ECB
NVS,NVS:US,BBG000LYF3S8,"Novartis: Alcon, TrueVision 3D Launch NGENUITY 3D Visualization System",2016-09-08 01:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VR36Jo1B2nM/novartis-alcon-truevision-3d-launch-ngenuity-3d-visualization-system-20160908-00034,"Novartis: Alcon, TrueVision 3D Launch NGENUITY 3D Visualization System"
NVS,NVS:US,BBG000LYF3S8,"Novartis: Alcon, TrueVision 3D Launch NGENUITY 3D Visualization System",2016-09-08 01:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/OO8rr0C3tbo/novartis-alcon-truevision-3d-launch-ngenuity-3d-visualization-system-20160908-00035,"Novartis: Alcon, TrueVision 3D Launch NGENUITY 3D Visualization System"
NVS,NVS:US,BBG000LYF3S8,Forget Gilead Sciences Inc.: These 3 Stocks Are Better Buys,2016-09-07 22:18:08 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DcUaGPB4Zvc/forget-gilead-sciences-inc-these-3-stocks-are-better-buys-cm675929,If you re a growth oriented investor Gilead Sciences NASDAQ GILD may no longer be a particularly good fit for your portfolio This blue chip biotech after all has seen the sales of its top selling hepatitis C drug Harvoni fall dramatically in the last quarter and its top line
NVS,NVS:US,BBG000LYF3S8,Europe: New safe haven?,2016-09-07 21:44:00 +0000,http://finance.yahoo.com/video/europe-safe-haven-214400696.html,Europe: New safe haven?
NVS,NVS:US,BBG000LYF3S8,GW Pharmaceuticals Stock Pops On Report Of Buyout Interest,2016-09-07 21:24:42 +0000,http://www.investors.com/news/technology/gw-pharmaceuticals-stock-pops-on-report-of-buyout-interest/,GW Pharmaceuticals Stock Pops On Report Of Buyout Interest
NVS,NVS:US,BBG000LYF3S8,Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent,2016-09-07 13:17:51 +0000,http://news.investornetwork.com/2016/09/07/post-earnings-coverage-as-cooper-cos-earnings-grows-97-percent/?1=1&1473254271,Post Earnings Coverage as Cooper Cos Earnings Grows 97 Percent
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Gain After Late Jump,2016-09-07 12:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QTz659hs444/the-swiss-stock-market-finished-with-a-gain-after-late-jump-20160907-00958,The Swiss Stock Market Finished With A Gain After Late Jump
NVS,NVS:US,BBG000LYF3S8,Gretchen Carlson's $20 Million And Some Of The Biggest Sexual Harassment Payouts Ever,2016-09-06 16:23:28 +0000,http://finance.yahoo.com/news/gretchen-carlsons-20-million-biggest-162328447.html,Gretchen Carlson's $20 Million And Some Of The Biggest Sexual Harassment Payouts Ever
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Positive Data on Ultibro Breezhaler,2016-09-06 16:20:16 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-8k__pqJovU/novartis-nvs-reports-positive-data-on-ultibro-breezhaler-cm675059,Novartis Pharma AG NVS announced positive results from a head to head study FLAME on Ultibro Breezhaler at the 2016 European Respiratory Society ERS International Congress The randomized double blinded double dummy parallel group non inferiority active controlled 52 week
NVS,NVS:US,BBG000LYF3S8,"Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids",2016-09-06 14:26:59 +0000,http://finance.yahoo.com/news/old-state-agencies-seem-prefer-142659881.html,"Out With The Old, In With The New: State Agencies Seem To Prefer Marijuana Over Opioids"
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Positive Data on Ultibro Breezhaler,2016-09-06 13:38:01 +0000,http://finance.yahoo.com/news/novartis-nvs-reports-positive-data-133801012.html,Novartis (NVS) Reports Positive Data on Ultibro Breezhaler
NVS,NVS:US,BBG000LYF3S8,Incyte’s Product Portfolio Includes Potentially Lucrative Drugs,2016-09-05 12:04:36 +0000,http://marketrealist.com/2016/09/incytes-product-portfolio-includes-potentially-lucrative-drugs/?utm_source=yahoo&utm_medium=feed,Incyte’s Product Portfolio Includes Potentially Lucrative Drugs
NVS,NVS:US,BBG000LYF3S8,Vectura: Study Confirms Ultibro Breezhaler More Effective Than Seretide,2016-09-05 02:34:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NGZeK_qv_WU/vectura-study-confirms-ultibro-breezhaler-more-effective-than-seretide-20160905-00023,Vectura: Study Confirms Ultibro Breezhaler More Effective Than Seretide
NVS,NVS:US,BBG000LYF3S8,How Google Plans to Reinvent Healthcare,2016-09-04 18:05:59 +0000,http://www.fool.com/investing/2016/09/03/how-google-plans-to-reinvent-healthcare.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,How Google Plans to Reinvent Healthcare
NVS,NVS:US,BBG000LYF3S8,Novartis' Ultibro® Breezhaler® consistently more effective than Seretide®* in reducing COPD flare-ups across different patient groups,2016-09-03 05:26:04 +0000,http://www.publicnow.com/view/74FEA5EFAF4F35BA8F06153B78D1A03B6BD8D3AD,[at noodls] - Ultibro Breezhaler reduced rate of all COPD exacerbations across different patient sub-groups vs Seretide in new analyses from FLAME study Analyses show that Ultibro Breezhaler lowered patients' need for ...
NVS,NVS:US,BBG000LYF3S8,3 Biotech Stocks That Could Make Big Moves In September,2016-09-02 20:12:40 +0000,http://www.investors.com/news/technology/3-biotech-stocks-that-could-make-big-moves-in-september/,3 Biotech Stocks That Could Make Big Moves In September
NVS,NVS:US,BBG000LYF3S8,Understanding Incyte’s Revenue Stream in 2Q16,2016-09-02 20:04:05 +0000,http://marketrealist.com/2016/09/understanding-incytes-revenue-stream-2q16/?utm_source=yahoo&utm_medium=feed,Understanding Incyte’s Revenue Stream in 2Q16
NVS,NVS:US,BBG000LYF3S8,Is Incyte Hurt by Having Only One FDA-Approved Drug?,2016-09-02 18:04:05 +0000,http://marketrealist.com/2016/09/incyte-hurt-one-fda-approved-drug/?utm_source=yahoo&utm_medium=feed,Is Incyte Hurt by Having Only One FDA-Approved Drug?
NVS,NVS:US,BBG000LYF3S8,Array (ARRY) Oncology Drug Accepted for Review in the U.S.,2016-09-02 15:22:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/sQUdwgmSqHM/array-arry-oncology-drug-accepted-for-review-in-the-us-cm674007,Array BioPharma ARRY announced that the FDA has accepted a New Drug Application NDA for its pipeline candidate binimetinib The NDA was submitted in Jun 2016 based on positive results from the phase III trial NEMO which compared binimetinib with dacarbazine in unresectable or
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar",2016-09-02 14:18:59 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/pLG-q-y9fZ4/pharma-stock-roundup-mylan-epipen-pricing-in-focus-fda-nod-for-novartis-biosimilar-cm674021,It was a rough week for drug stocks with focus once again shifting to the pricing policies of pharma and biotech companies Mylan s MYL pricing policy for EpiPen raised a storm with lawmakers questioning the company s pricing actions Meanwhile companies like Novartis NVS and Roche RHHBY
NVS,NVS:US,BBG000LYF3S8,PFE to Enjoy Being Sole Provider of Key Breast Cancer Treatment,2016-09-02 14:04:10 +0000,http://marketrealist.com/2016/08/pfe-to-enjoy-being-sole-provider-of-key-breast-cancer-treatment/?utm_source=yahoo&utm_medium=feed,PFE to Enjoy Being Sole Provider of Key Breast Cancer Treatment
NVS,NVS:US,BBG000LYF3S8,"Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar",2016-09-02 13:17:01 +0000,http://finance.yahoo.com/news/pharma-stock-roundup-mylan-epipen-131701905.html,"Pharma Stock Roundup: Mylan EpiPen Pricing in Focus, FDA Nod For Novartis Biosimilar"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Jumped After U.S. Jobs Report Disappoints,2016-09-02 12:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/lvAc2DujqTI/the-swiss-stock-market-jumped-after-us-jobs-report-disappoints-20160902-00468,The Swiss Stock Market Jumped After U.S. Jobs Report Disappoints
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Jumped After U.S. Jobs Report Disappoints,2016-09-02 12:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/j-h0nAxkF8U/the-swiss-stock-market-jumped-after-us-jobs-report-disappoints-20160902-00469,The Swiss Stock Market Jumped After U.S. Jobs Report Disappoints
NVS,NVS:US,BBG000LYF3S8,Novartis Enters Oversold Territory,2016-09-01 18:09:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/29pKrryqLUY/novartis-enters-oversold-territory-cm673590,Legendary investor Warren Buffett advises to be fearful when others are greedy and be greedy when others are fearful One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index or RSI which measures momentum on
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis Carts Itself Off,2016-09-01 15:10:00 +0000,http://www.barrons.com/articles/novartis-carts-itself-off-1472742605?mod=yahoobarrons&ru=yahoo,[$$] Novartis Carts Itself Off
NVS,NVS:US,BBG000LYF3S8,Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgens Enbrel,2016-09-01 13:17:34 +0000,http://news.investornetwork.com/2016/09/01/blog-coverage-fda-approves-novartis-erelzi-as-biosimilar-to-amgens-enbrel/?1=1&1472735854,Blog Coverage FDA Approves Novartis Erelzi as Biosimilar to Amgens Enbrel
NVS,NVS:US,BBG000LYF3S8,Novartis Rings Another Cell-Therapy Alarm Bell,2016-09-01 13:02:18 +0000,http://www.bloomberg.com/gadfly/articles/2016-09-01/novartis-cell-therapy-pullback-a-warning?cmpid=yhoo.headline,Novartis Rings Another Cell-Therapy Alarm Bell
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell After Disappointing U.S. Manufacturing Report,2016-09-01 12:26:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9ifqGP4GTzQ/the-swiss-stock-market-fell-after-disappointing-us-manufacturing-report-20160901-00824,The Swiss Stock Market Fell After Disappointing U.S. Manufacturing Report
NVS,NVS:US,BBG000LYF3S8,How Analysts See United Therapeutics’ Continued Performance,2016-09-01 12:04:29 +0000,http://marketrealist.com/2016/08/analyst-recommendations-united-therapeutics-2016/?utm_source=yahoo&utm_medium=feed,How Analysts See United Therapeutics’ Continued Performance
NVS,NVS:US,BBG000LYF3S8,"CYNA Snapped Up For $624 Mln, AMRN On Track, Genmab Gets FDA Nod",2016-08-31 23:00:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/r3ontxmEK5k/cyna-snapped-up-for-624-mln-amrn-on-track-genmab-gets-fda-nod-20160831-01178,"CYNA Snapped Up For $624 Mln, AMRN On Track, Genmab Gets FDA Nod"
NVS,NVS:US,BBG000LYF3S8,Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth,2016-08-31 22:14:30 +0000,http://finance.yahoo.com/news/merck-hold-steady-div-increase-221430916.html,Merck Will Hold Steady on Div Increase Despite Flat Revenue Growth
NVS,NVS:US,BBG000LYF3S8,Novartis Closing Cell Therapy Unit; CAR-T Stocks Tumble,2016-08-31 20:43:44 +0000,http://www.investors.com/news/technology/novartis-closing-cell-therapy-unit-car-t-stocks-tumble/,Novartis Closing Cell Therapy Unit; CAR-T Stocks Tumble
NVS,NVS:US,BBG000LYF3S8,Juno and Kite hit today,2016-08-31 18:39:00 +0000,http://finance.yahoo.com/video/juno-kite-hit-today-183900358.html,Juno and Kite hit today
NVS,NVS:US,BBG000LYF3S8,Future of immunotherapy,2016-08-31 18:34:00 +0000,http://finance.yahoo.com/video/future-immunotherapy-183400939.html,Future of immunotherapy
NVS,NVS:US,BBG000LYF3S8,"Novartis Disbands Cell Therapy Unit; What's Ahead For Kite, Juno?",2016-08-31 17:32:00 +0000,http://blogs.barrons.com/stockstowatchtoday/2016/08/31/novartis-disbands-cell-therapy-unit-whats-ahead-for-kite-juno/?mod=yahoobarrons&ru=yahoo,"Novartis Disbands Cell Therapy Unit; What's Ahead For Kite, Juno?"
NVS,NVS:US,BBG000LYF3S8,"Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions",2016-08-31 16:00:08 +0000,http://www.bloomberg.com/news/articles/2016-08-31/novartis-dissolves-its-cell-therapy-unit-cutting-120-positions?cmpid=yhoo.headline,"Novartis Dissolves Its Cell Therapy Unit, Cutting 120 Positions"
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel,2016-08-31 15:16:44 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Sw4WvC6NwMg/novartis-nvs-gets-fda-nod-for-biosimilar-version-of-enbrel-cm672792,"Novartis AGNVS received a major boost when its generic arm, Sandoz obtained FDA approval for Erelzi, the biosimilar version of Amgen's AMGN blockbuster drug Enbrel (etanercept).  The FDA has approved Erelzi for all indications stated in"
NVS,NVS:US,BBG000LYF3S8,Why Pfizer Is Trading at a Discount on an Earnings Basis,2016-08-31 14:05:13 +0000,http://marketrealist.com/2016/08/why-pfizer-is-trading-at-a-discount-on-an-earnings-basis/?utm_source=yahoo&utm_medium=feed,Why Pfizer Is Trading at a Discount on an Earnings Basis
NVS,NVS:US,BBG000LYF3S8,BTIG Is 'Generally Skeptical' On Kite Pharma Expectations,2016-08-31 13:17:00 +0000,http://finance.yahoo.com/news/btig-generally-skeptical-kite-pharma-131700761.html,BTIG Is 'Generally Skeptical' On Kite Pharma Expectations
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel,2016-08-31 12:59:12 +0000,http://finance.yahoo.com/news/novartis-nvs-gets-fda-nod-125912035.html,Novartis (NVS) Gets FDA Nod for Biosimilar Version of Enbrel
NVS,NVS:US,BBG000LYF3S8,"Novartis Dissolves CAR-T Unit, Cutting 120 Positions",2016-08-31 12:32:00 +0000,http://www.forbes.com/sites/matthewherper/2016/08/31/novartis-dissolves-car-t-unit-cutting-120-positions/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,"Novartis Dissolves CAR-T Unit, Cutting 120 Positions"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back On Pharma Weakness,2016-08-31 12:17:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/2ak_aHrpOTg/the-swiss-stock-market-pulled-back-on-pharma-weakness-20160831-00705,The Swiss Stock Market Pulled Back On Pharma Weakness
NVS,NVS:US,BBG000LYF3S8,Novartis bid to sell new biosimilar crimped by U.S. court battles,2016-08-31 11:01:07 +0000,http://sg.finance.yahoo.com/news/novartis-bid-sell-biosimilar-crimped-110107928.html,Novartis bid to sell new biosimilar crimped by U.S. court battles
NVS,NVS:US,BBG000LYF3S8,Struggling Vaccines From Novartis Turn Into Sales Boon for Glaxo,2016-08-31 04:00:00 +0000,http://www.bloomberg.com/news/articles/2016-08-31/struggling-vaccines-from-novartis-turn-into-sales-boon-for-glaxo?cmpid=yhoo.headline,Struggling Vaccines From Novartis Turn Into Sales Boon for Glaxo
NVS,NVS:US,BBG000LYF3S8,"CEMP To Face FDA Panel, RIGL On A High, FDA Nod For Erelzi, KPTI Awaits STORM",2016-08-31 01:49:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/NgXcbz2q8oo/cemp-to-face-fda-panel-rigl-on-a-high-fda-nod-for-erelzi-kpti-awaits-storm-20160831-00024,"CEMP To Face FDA Panel, RIGL On A High, FDA Nod For Erelzi, KPTI Awaits STORM"
NVS,NVS:US,BBG000LYF3S8,Novartis wins US OK for biosimilar version of Amgen's Enbrel,2016-08-30 22:29:47 +0000,http://finance.yahoo.com/news/novartis-wins-us-ok-biosimilar-version-amgens-enbrel-212144648.html,Novartis wins US OK for biosimilar version of Amgen's Enbrel
NVS,NVS:US,BBG000LYF3S8,Novartis wins US OK for biosimilar version of Amgen's Enbrel,2016-08-30 22:29:44 +0000,http://sg.finance.yahoo.com/news/novartis-wins-us-ok-biosimilar-212136216.html,Novartis wins US OK for biosimilar version of Amgen's Enbrel
NVS,NVS:US,BBG000LYF3S8,FDA Okays Sandoz Erelzi To Treat Multiple Inflammatory Diseases,2016-08-30 21:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dkeVJLGOWWY/fda-okays-sandoz-erelzi-to-treat-multiple-inflammatory-diseases-20160830-01022,FDA Okays Sandoz Erelzi To Treat Multiple Inflammatory Diseases
NVS,NVS:US,BBG000LYF3S8,U.S. FDA approves Novartis biosimilar to Amgen's Enbrel,2016-08-30 20:40:12 +0000,http://finance.yahoo.com/news/u-fda-approves-novartis-biosimilar-204012449.html,"[Reuters] - The U.S. Food and Drug Administration on Tuesday approved Novartis AG's biosimilar version of Amgen Inc's arthritis drug Enbrel. The FDA approved the drug, Erelzi, known also as etanercept-szzs, for multiple inflammatory conditions including rheumatoid arthritis and plaque psoriasis, a skin condition. The agency approved the drug as a biosimilar, meaning there is no clinically meaningful differences between Erelzi and Enbrel."
NVS,NVS:US,BBG000LYF3S8,FDA approves Sandoz Erelzi(TM) to treat multiple inflammatory diseases,2016-08-30 20:23:01 +0000,http://www.publicnow.com/view/4EF0180F593F851777ACE77E2057B051FE6EE703,"[at noodls] - Erelzi is the first biosimilar etanercept approved by the FDA, offering expanded access to this important medicine Erelzi is approved for all indications included in the reference product's label Erelzi ..."
NVS,NVS:US,BBG000LYF3S8,Generic Competition Not a Threat to UTHR’s Remodulin,2016-08-30 20:04:21 +0000,http://marketrealist.com/2016/08/united-therapeutics-expects-safeguard-remodulin-sales-generic-competition-2016/?utm_source=yahoo&utm_medium=feed,Generic Competition Not a Threat to UTHR’s Remodulin
NVS,NVS:US,BBG000LYF3S8,FDA Approves Novartis''s Biosimilar to Amgen''s Enbrel,2016-08-30 18:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I7v2ie5hIXg/fda-approves-novartiss-biosimilar-to-amgens-enbrel-20160830-00968,FDA Approves Novartis''s Biosimilar to Amgen''s Enbrel
NVS,NVS:US,BBG000LYF3S8,FDA Approves Novartis's Biosimilar to Amgen's Enbrel,2016-08-30 18:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/1nO2erjNphw/fda-approves-novartiss-biosimilar-to-amgens-enbrel-20160830-00969,FDA Approves Novartis's Biosimilar to Amgen's Enbrel
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Higher On Strength Of Financial Stocks,2016-08-30 12:30:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cvXTNARWfzI/the-swiss-stock-market-finished-higher-on-strength-of-financial-stocks-20160830-00687,The Swiss Stock Market Finished Higher On Strength Of Financial Stocks
NVS,NVS:US,BBG000LYF3S8,Biotech Stocks Facing FDA Decision In September,2016-08-30 03:06:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/JLuJRoV-b_w/biotech-stocks-facing-fda-decision-in-september-20160830-00044,Biotech Stocks Facing FDA Decision In September
NVS,NVS:US,BBG000LYF3S8,Your Complete Guide to the Generic Drug Industry,2016-08-29 23:11:28 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/PYxkSVeu3VI/your-complete-guide-to-the-generic-drug-industry-cm671899,"On Monday, embattled drugmaker Mylan NV MYL announced that it will launch a generic version of the EpiPen at a 50% discount to the branded version as the company continues to respond to widespread criticism surrounding the"
NVS,NVS:US,BBG000LYF3S8,Here’s What’s Important With The Novartis AG (ADR) (NVS) MS Data,2016-08-29 17:41:57 +0000,http://www.insidermonkey.com/blog/heres-whats-important-with-the-novartis-ag-adr-nvs-ms-data-471204/,Here’s What’s Important With The Novartis AG (ADR) (NVS) MS Data
NVS,NVS:US,BBG000LYF3S8,Almost The Whole World In This ETF's Hands,2016-08-29 17:30:32 +0000,http://finance.yahoo.com/news/almost-whole-world-etfs-hands-173032587.html,Almost The Whole World In This ETF's Hands
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished With A Modest Increase,2016-08-29 12:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HSLASmZELX4/the-swiss-stock-market-finished-with-a-modest-increase-20160829-00547,The Swiss Stock Market Finished With A Modest Increase
NVS,NVS:US,BBG000LYF3S8,Novartis convenes experts to discuss new technologies in healthcare at Novartis International BioCamp,2016-08-29 05:23:03 +0000,http://www.publicnow.com/view/14E9DB518BE389AA958654BA6AB6B76A50C86BE1,[at noodls] - 13th International Biotechnology Leadership Camp focuses on potential of new technologies to fundamentally transform biomedical research and the pharmaceutical business Interactive program brings 60 top ...
NVS,NVS:US,BBG000LYF3S8,Can Novartis Tide Over the Alcon Crisis?,2016-08-26 22:18:44 +0000,http://finance.yahoo.com/news/novartis-tide-over-alcon-crisis-221844366.html,Can Novartis Tide Over the Alcon Crisis?
NVS,NVS:US,BBG000LYF3S8,Novartis AG (NVS) Announces Positive Phase III Results For MS Drug,2016-08-26 20:03:49 +0000,http://www.insidermonkey.com/blog/novartis-ag-nvs-announces-positive-phase-iii-results-for-ms-drug-470787/,Novartis AG (NVS) Announces Positive Phase III Results For MS Drug
NVS,NVS:US,BBG000LYF3S8,6 More Pharma Companies Selling Overpriced Drugs,2016-08-26 17:30:10 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/p4yb8i3lp6k/6-more-pharma-companies-selling-overpriced-drugs-cm670871,Kudos to Mylan NV (NASDAQ  MYL ) for offering discounts on the exorbitant price on EpiPen for patients with a high out of pocket
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Positive Phase III Results on MS Drug,2016-08-26 16:31:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ubgubmalurg/novartis-nvs-reports-positive-phase-iii-results-on-ms-drug-cm670807,"Novartis AGNVS announced positive results from the phase III EXPAND study on its pipeline candidate, BAF312 (siponimod).  The randomized, double blinded, placebo controlled study was evaluating the efficacy and safety of once daily oral BAF312 in"
NVS,NVS:US,BBG000LYF3S8,Vanda Stock Up on Favorable U.S. Court Ruling for Fanapt,2016-08-26 14:48:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/XmP5ZkJuhZ0/vanda-stock-up-on-favorable-us-court-ruling-for-fanapt-cm670602,"Shares of Vanda PharmaceuticalsVNDA surged 20.6% after the U.S. District of Delaware ruled in favor of the company in a patent infringement lawsuit against Roxane Laboratories Inc., a part of West Ward Pharmaceuticals now.  The court"
NVS,NVS:US,BBG000LYF3S8,Burden of Health-Care Costs Moves to the Middle Class -- Update,2016-08-26 14:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/B2gp7BFmvm0/burden-of-healthcare-costs-moves-to-the-middle-class--update-20160826-00450,Burden of Health-Care Costs Moves to the Middle Class -- Update
NVS,NVS:US,BBG000LYF3S8,Novartis (NVS) Reports Positive Phase III Results on MS Drug,2016-08-26 14:20:02 +0000,http://finance.yahoo.com/news/novartis-nvs-reports-positive-phase-142002362.html,Novartis (NVS) Reports Positive Phase III Results on MS Drug
NVS,NVS:US,BBG000LYF3S8,Yellen''s Speech Propelled The Swiss Market Into Positive Territory,2016-08-26 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/S7wz-lShYY0/yellens-speech-propelled-the-swiss-market-into-positive-territory-20160826-00379,Yellen''s Speech Propelled The Swiss Market Into Positive Territory
NVS,NVS:US,BBG000LYF3S8,Yellen's Speech Propelled The Swiss Market Into Positive Territory,2016-08-26 12:15:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zYykAwZQfM0/yellens-speech-propelled-the-swiss-market-into-positive-territory-20160826-00380,Yellen's Speech Propelled The Swiss Market Into Positive Territory
NVS,NVS:US,BBG000LYF3S8,Notable Two Hundred Day Moving Average Cross - NVS,2016-08-25 21:45:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AFkIwNOTTh0/notable-two-hundred-day-moving-average-cross-nvs-cm670315,"In trading on Thursday, shares of Novartis (Symbol NVS) crossed below their 200 day moving average of $79.51, changing hands as low as $77.66 per share. Novartis shares are currently trading off about 0.8% on the day. The chart"
NVS,NVS:US,BBG000LYF3S8,AbbVie Expects to Launch Zinbryta in the US in August,2016-08-25 15:04:05 +0000,http://marketrealist.com/2016/08/abbvie-expects-launch-multiple-sclerosis-drug-zinbryta-u-s-august-2016/?utm_source=yahoo&utm_medium=feed,AbbVie Expects to Launch Zinbryta in the US in August
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Pulled Back On Pharma Weakness,2016-08-25 12:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/K2VQ_4uJ0Q4/the-swiss-stock-market-pulled-back-on-pharma-weakness-20160825-00659,The Swiss Stock Market Pulled Back On Pharma Weakness
NVS,NVS:US,BBG000LYF3S8,Stocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 2nd Update,2016-08-25 08:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/05wO9Obz3Ps/stocks-fall-as-investors-look-to-feds-jackson-hole-meeting--2nd-update-20160825-00340,Stocks Fall as Investors Look to Fed's Jackson Hole Meeting -- 2nd Update
NVS,NVS:US,BBG000LYF3S8,Novartis announces positive phase III results showing efficacy of BAF312 in patients with secondary progressive MS,2016-08-25 05:38:09 +0000,http://www.publicnow.com/view/191F80FFD998C95D552FD30002F82915E6207258,[at noodls] - The Phase III EXPAND study of BAF312 (siponimod) in secondary progressive multiple sclerosis (SPMS) met its primary endpoint of reducing the risk of three-month confirmed disability progression versus ...
NVS,NVS:US,BBG000LYF3S8,Shares Fall as Health-Care Sector Loses Ground -- Update,2016-08-25 05:36:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/14spsZmvCl0/shares-fall-as-healthcare-sector-loses-ground--update-20160825-00096,Shares Fall as Health-Care Sector Loses Ground -- Update
NVS,NVS:US,BBG000LYF3S8,Shares Fall as Health-Care Sector Loses Ground,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VKowsBKn6yg/shares-fall-as-healthcare-sector-loses-ground-20160825-00086,Shares Fall as Health-Care Sector Loses Ground
NVS,NVS:US,BBG000LYF3S8,Stocks Slip as Fed's Jackson Hole Meeting Eyed,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/M4RllTRrKeE/stocks-slip-as-feds-jackson-hole-meeting-eyed-20160825-00720,Stocks Slip as Fed's Jackson Hole Meeting Eyed
NVS,NVS:US,BBG000LYF3S8,Stocks Sag Ahead of Fed Summit,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/QOHkeERAlHg/stocks-sag-ahead-of-fed-summit-20160825-00985,Stocks Sag Ahead of Fed Summit
NVS,NVS:US,BBG000LYF3S8,Stocks Fall as Investors Look to Fed's Jackson Hole Meeting,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y1kxpGsADXU/stocks-fall-as-investors-look-to-feds-jackson-hole-meeting-20160825-00332,Stocks Fall as Investors Look to Fed's Jackson Hole Meeting
NVS,NVS:US,BBG000LYF3S8,Stocks Fall as Investors Look to Fed''s Jackson Hole Meeting,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/w3Ou5cpVHkg/stocks-fall-as-investors-look-to-feds-jackson-hole-meeting-20160825-00155,Stocks Fall as Investors Look to Fed''s Jackson Hole Meeting
NVS,NVS:US,BBG000LYF3S8,Stocks Sag Ahead of Fed Summit,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/ubDYT8aEQ_Q/stocks-sag-ahead-of-fed-summit-20160825-00984,Stocks Sag Ahead of Fed Summit
NVS,NVS:US,BBG000LYF3S8,Shares Fall as Investors Look to Fed's Jackson Hole Meeting,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AZwPXBwJWTw/shares-fall-as-investors-look-to-feds-jackson-hole-meeting-20160825-00102,Shares Fall as Investors Look to Fed's Jackson Hole Meeting
NVS,NVS:US,BBG000LYF3S8,Shares Fall as Investors Look to Fed''s Jackson Hole Meeting,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/wZi4cT-dscI/shares-fall-as-investors-look-to-feds-jackson-hole-meeting-20160825-00101,Shares Fall as Investors Look to Fed''s Jackson Hole Meeting
NVS,NVS:US,BBG000LYF3S8,Stocks Slip as Fed''s Jackson Hole Meeting Eyed,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yZbw_NPELFM/stocks-slip-as-feds-jackson-hole-meeting-eyed-20160825-00719,Stocks Slip as Fed''s Jackson Hole Meeting Eyed
NVS,NVS:US,BBG000LYF3S8,Stocks Higher as Fed's Jackson Hole Meeting Eyed,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V2lx5CxO0V8/stocks-higher-as-feds-jackson-hole-meeting-eyed-20160825-00646,Stocks Higher as Fed's Jackson Hole Meeting Eyed
NVS,NVS:US,BBG000LYF3S8,Stocks Flat as Fed's Jackson Hole Meeting Eyed,2016-08-25 04:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/gUeX04Uzotc/stocks-flat-as-feds-jackson-hole-meeting-eyed-20160825-00661,Stocks Flat as Fed's Jackson Hole Meeting Eyed
NVS,NVS:US,BBG000LYF3S8,Novartis Announces Positive Phase III Results Showing Efficacy Of BAF312 In SPMS,2016-08-25 01:47:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f-gDQgIRONc/novartis-announces-positive-phase-iii-results-showing-efficacy-of-baf312-in-spms-20160825-00027,Novartis Announces Positive Phase III Results Showing Efficacy Of BAF312 In SPMS
NVS,NVS:US,BBG000LYF3S8,Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher,2016-08-24 22:46:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/hRlmPDPNc78/why-momenta-pharmaceuticals-shares-made-a-late-day-jump-higher-cm669815,Image source  Getty Images.  What  Momenta Pharmaceuticals (NASDAQ  MNTA) ended the day up 11% after spending most of the afternoon in negative territory. The come from behind victory for the day
NVS,NVS:US,BBG000LYF3S8,"Merck & Co., Inc. Features Slow and Steady Dividend Growth (MRK)",2016-08-24 22:45:51 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/f8_bd9vlJi8/merck-co-inc-features-slow-and-steady-dividend-growth-mrk-cm669813,"Merck & Co., Inc. ( MRK ) is a blue chip dividend stock that has paid a consistent dividend since 1970 and has grown its"
NVS,NVS:US,BBG000LYF3S8,Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher,2016-08-24 20:49:49 +0000,http://www.fool.com/investing/2016/08/24/why-momenta-pharmaceuticals-shares-made-a-late-day.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Why Momenta Pharmaceuticals Shares Made a Late-Day Jump Higher
NVS,NVS:US,BBG000LYF3S8,"Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares",2016-08-24 19:30:36 +0000,http://finance.yahoo.com/news/waiting-growth-better-valuation-argus-193036539.html,"Waiting For Growth, Or A Better Valuation, Argus Stays Sidelined On Novartis Shares"
NVS,NVS:US,BBG000LYF3S8,Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics,2016-08-24 17:48:54 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Y2PmVdnGABc/novartis-licenses-anti-pcsk9-antibody-to-cyon-therapeutics-cm669456,"Novartis AGNVS entered into a license agreement with privately held Cyon Therapeutics Inc. for its anti PCSK9 antibody, LGT 209, as per a press release issued by the latter.  Although financial details of the agreement were"
NVS,NVS:US,BBG000LYF3S8,Imbruvica Continues to Report Better-than-Expected Sales in 2016,2016-08-24 15:04:05 +0000,http://marketrealist.com/2016/08/imbruvica-continues-report-better-expected-sales-2016/?utm_source=yahoo&utm_medium=feed,Imbruvica Continues to Report Better-than-Expected Sales in 2016
NVS,NVS:US,BBG000LYF3S8,Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics,2016-08-24 12:50:12 +0000,http://finance.yahoo.com/news/novartis-licenses-anti-pcsk9-antibody-125012107.html,Novartis Licenses Anti-PCSK9 Antibody to Cyon Therapeutics
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Little Changed,2016-08-24 12:14:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RbRTD8JNPC8/the-swiss-stock-market-finished-little-changed-20160824-00524,The Swiss Stock Market Finished Little Changed
NVS,NVS:US,BBG000LYF3S8,Performance of AstraZeneca’s Growth Platforms in 2Q16,2016-08-23 23:04:05 +0000,http://marketrealist.com/2016/08/performance-astrazenecas-growth-platforms-2q16/?utm_source=yahoo&utm_medium=feed,Performance of AstraZeneca’s Growth Platforms in 2Q16
NVS,NVS:US,BBG000LYF3S8,Why AstraZeneca Reported Negative Growth in 2Q16,2016-08-23 21:04:05 +0000,http://marketrealist.com/2016/08/astrazeneca-reported-negative-growth-2q16/?utm_source=yahoo&utm_medium=feed,Why AstraZeneca Reported Negative Growth in 2Q16
NVS,NVS:US,BBG000LYF3S8,Top 6 Pharmaceutical Companies Globally,2016-08-23 15:11:00 +0000,http://www.investopedia.com/articles/investing/082316/top-6-pharmaceutical-companies-globally-jnj-nvs.asp?partner=YahooSA,Top 6 Pharmaceutical Companies Globally
NVS,NVS:US,BBG000LYF3S8,Cyon Therapeutics Inc. acquires world-wide rights to an anti-PCSK9 antibody for use in Severe Infection and Sepsis,2016-08-23 15:00:00 +0000,http://finance.yahoo.com/news/cyon-therapeutics-inc-acquires-world-150000361.html,[CNW Group] - Cyon Therapeutics Inc. acquires world-wide rights to an anti-PCSK9 antibody for use in Severe Infection and Sepsis
NVS,NVS:US,BBG000LYF3S8,"The Swiss Stock Market Finished Slightly Higher, Extending Recent Gains",2016-08-23 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/33ZQIsh1J7Y/the-swiss-stock-market-finished-slightly-higher-extending-recent-gains-20160823-00613,"The Swiss Stock Market Finished Slightly Higher, Extending Recent Gains"
NVS,NVS:US,BBG000LYF3S8,Business Watch -- WSJ,2016-08-23 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V6EMGlcbyBE/business-watch--wsj-20160823-00044,Business Watch -- WSJ
NVS,NVS:US,BBG000LYF3S8,How Merial Contributes to Sanofi’s Growth,2016-08-22 15:04:20 +0000,http://marketrealist.com/2016/08/how-merial-contributes-to-sanofis-growth/?utm_source=yahoo&utm_medium=feed,How Merial Contributes to Sanofi’s Growth
NVS,NVS:US,BBG000LYF3S8,"Eli Lilly, AstraZeneca Progress With Alzheimer's Drug",2016-08-22 08:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/tuUaQMihg6U/eli-lilly-astrazeneca-progress-with-alzheimers-drug-20160822-00296,"Eli Lilly, AstraZeneca Progress With Alzheimer's Drug"
NVS,NVS:US,BBG000LYF3S8,"Eli Lilly, AstraZeneca Progress With Alzheimer''s Drug",2016-08-22 08:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/erEC0FN_2e0/eli-lilly-astrazeneca-progress-with-alzheimers-drug-20160822-00295,"Eli Lilly, AstraZeneca Progress With Alzheimer''s Drug"
NVS,NVS:US,BBG000LYF3S8,"Eli Lilly, AstraZeneca Get Fast-Track Designation for Alzheimer''s Drug--Update",2016-08-22 07:57:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/zWSuDbO0zUc/eli-lilly-astrazeneca-get-fasttrack-designation-for-alzheimers-drugupdate-20160822-00167,"Eli Lilly, AstraZeneca Get Fast-Track Designation for Alzheimer''s Drug--Update"
NVS,NVS:US,BBG000LYF3S8,3 Reasons Medivation Is the Juiciest Target in Biotech,2016-08-21 15:41:00 +0000,http://www.fool.com/investing/2016/08/21/3-reasons-medivation-is-the-juiciest-target-in-bio.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,3 Reasons Medivation Is the Juiciest Target in Biotech
NVS,NVS:US,BBG000LYF3S8,"5 Stocks That Beat The Market In A Crash (KO, SO, PG)",2016-08-19 21:48:03 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/V8rAoVU-PHo/5-stocks-that-beat-the-market-in-a-crash-ko-so-pg-cm667990,"The current bull run in stocks has lasted longer than any other, save the tech bubble of the 90s.  That in itself shouldn't be"
NVS,NVS:US,BBG000LYF3S8,Novartis: First-Class Pharmaceuticals,2016-08-19 17:19:15 +0000,http://finance.yahoo.com/news/novartis-first-class-pharmaceuticals-171915018.html,Novartis: First-Class Pharmaceuticals
NVS,NVS:US,BBG000LYF3S8,What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16?,2016-08-19 15:04:35 +0000,http://marketrealist.com/2016/08/what-happened-to-sanofis-consumer-healthcare-and-generics-franchise-in-2q16/?utm_source=yahoo&utm_medium=feed,What Happened to Sanofi’s Consumer Healthcare and Generics Franchise in 2Q16?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Ended The Trading Week With A Loss,2016-08-19 12:31:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/SQZ1f655Wt8/the-swiss-stock-market-ended-the-trading-week-with-a-loss-20160819-00317,The Swiss Stock Market Ended The Trading Week With A Loss
NVS,NVS:US,BBG000LYF3S8,5 Stocks That Beat The Market In A Crash,2016-08-18 17:30:00 +0000,http://finance.yahoo.com/news/5-stocks-beat-market-crash-173000423.html,5 Stocks That Beat The Market In A Crash
NVS,NVS:US,BBG000LYF3S8,"Johnson & Johnson (JNJ) Ex-Dividend Date Scheduled for August 19, 2016",2016-08-18 13:19:20 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DAKWJGpK3Wc/johnson-johnson-jnj-ex-dividend-date-scheduled-for-august-19-2016-cm666992,"Johnson & Johnson ( JNJ ) will begin trading ex dividend on August 19, 2016. A cash dividend payment of $0.8 per share is scheduled to be paid on September 06, 2016. Shareholders who purchased JNJ prior to the"
NVS,NVS:US,BBG000LYF3S8,Genzyme Continued to Boost Growth for Sanofi in 2Q16,2016-08-18 13:06:08 +0000,http://marketrealist.com/2016/08/genzyme-continued-to-boost-growth-for-sanofi-in-2q16/?utm_source=yahoo&utm_medium=feed,Genzyme Continued to Boost Growth for Sanofi in 2Q16
NVS,NVS:US,BBG000LYF3S8,Ozanimod May Prove to Be a Strong Growth Driver for Celgene,2016-08-18 13:04:26 +0000,http://marketrealist.com/2016/08/ozanimod-may-prove-strong-growth-driver-celgene-future-years/?utm_source=yahoo&utm_medium=feed,Ozanimod May Prove to Be a Strong Growth Driver for Celgene
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed After Strong Performance From Nestle,2016-08-18 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/EbCHvKqJSZU/the-swiss-stock-market-climbed-after-strong-performance-from-nestle-20160818-00610,The Swiss Stock Market Climbed After Strong Performance From Nestle
NVS,NVS:US,BBG000LYF3S8,Turkey's investigation into drugmaker Novartis 'ongoing' -official,2016-08-17 18:22:51 +0000,http://in.finance.yahoo.com/news/turkeys-investigation-drugmaker-novartis-ongoing-142430427.html,Turkey's investigation into drugmaker Novartis 'ongoing' -official
NVS,NVS:US,BBG000LYF3S8,Turkey's investigation into drugmaker Novartis 'ongoing' - official,2016-08-17 15:35:44 +0000,http://sg.finance.yahoo.com/news/turkeys-investigation-drugmaker-novartis-ongoing-140858788.html,Turkey's investigation into drugmaker Novartis 'ongoing' - official
NVS,NVS:US,BBG000LYF3S8,CELG’s Otezla Continues Dominating US Inflammation and Immunology,2016-08-17 15:04:21 +0000,http://marketrealist.com/2016/08/celgenes-otezla-continues-dominate-inflammation-immunology-segment-u-s/?utm_source=yahoo&utm_medium=feed,CELG’s Otezla Continues Dominating US Inflammation and Immunology
NVS,NVS:US,BBG000LYF3S8,Better Buy: Amgen Inc. vs. Biogen,2016-08-17 13:33:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/9v6kqVRo4so/better-buy-amgen-inc-vs-biogen-cm666379,"Image source  Getty Images.  Blue chip biotech stocks Amgen (NASDAQ  AMGN) and Biogen (NASDAQ  BIIB) are two of the oldest and largest in their industry. Both are highly profitable, but they"
NVS,NVS:US,BBG000LYF3S8,Better Buy: Amgen Inc. vs. Biogen,2016-08-17 12:21:00 +0000,http://www.fool.com/investing/2016/08/17/better-buy-amgen-inc-vs-biogen.aspx?source=yahoo-2&utm_campaign=article&utm_medium=feed&utm_source=yahoo-2,Better Buy: Amgen Inc. vs. Biogen
NVS,NVS:US,BBG000LYF3S8,"With new president and focus on big investors, Cellceutix aims for the Nasdaq",2016-08-17 11:00:11 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/08/with-new-president-and-focus-on-big-investors.html?ana=yahoo,"With new president and focus on big investors, Cellceutix aims for the Nasdaq"
NVS,NVS:US,BBG000LYF3S8,CSL to hike spending after profit fall,2016-08-17 06:54:11 +0000,http://au.finance.yahoo.com/news/csl-hike-spending-profit-fall-065411000.html,"[AAP] - Blood products giant CSL has committed to boosting spending to grow its global operations after suffering a 10 per cent slide in profits due to continuing losses on its recently acquired Novartis flu vaccines business. CSL - which has major facilities in Australia, Germany, Switzerland, UK and the US - on Wednesday posted a 10 per cent fall in annual net profit to $US1.24 billion, hurt by a $US205.5 million loss from Novartis and a $US115 million hit from currency swings. Chief executive Paul Perreault said Novartis sales were lower than expected due to a mild flu season."
NVS,NVS:US,BBG000LYF3S8,Asian Shares Mixed Ahead Of Fed Minutes,2016-08-17 04:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/d8cx5OcLERg/asian-shares-mixed-ahead-of-fed-minutes-20160817-00065,Asian Shares Mixed Ahead Of Fed Minutes
NVS,NVS:US,BBG000LYF3S8,Asian Shares Mixed Ahead Of Fed Minutes,2016-08-17 04:16:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/RmsnbvtJx_0/asian-shares-mixed-ahead-of-fed-minutes-20160817-00064,Asian Shares Mixed Ahead Of Fed Minutes
NVS,NVS:US,BBG000LYF3S8,CSL to raise $US500m after mixed results,2016-08-17 01:23:37 +0000,http://au.finance.yahoo.com/news/csl-raise-us500m-mixed-results-012337554.html,"[AAP] - CSL plans to raise $US500 million ($A649 million) to plough into the biotechnology giant's extensive operations and has flagged another share buyback of up to $500 million after delivering mixed annual earnings results. Chief executive Paul Perreault says the additional funds will be invested into the business, including its recently enlarged vaccine unit Seqirus, and can be used for dividend payments and share buybacks. The group says it will consider a further on market share buyback program of $A500 million following the completion of its current $A1 billion buyback, which was unveiled in October 2015."
NVS,NVS:US,BBG000LYF3S8,CSL Stock Down On Weak Profit; Sees Earnings Growth; To Buy Back A$500 Mln Stock,2016-08-17 00:27:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/qoa57p7YkrQ/csl-stock-down-on-weak-profit-sees-earnings-growth-to-buy-back-a500-mln-stock-20160817-00006,CSL Stock Down On Weak Profit; Sees Earnings Growth; To Buy Back A$500 Mln Stock
NVS,NVS:US,BBG000LYF3S8,Novartis Needs to Stem the Bleeding From Gleevec Decline,2016-08-16 22:48:24 +0000,http://finance.yahoo.com/news/novartis-needs-stem-bleeding-gleevec-224824879.html,Novartis Needs to Stem the Bleeding From Gleevec Decline
NVS,NVS:US,BBG000LYF3S8,Valeant: Are the Salix and Dermatology Portfolios Recovering?,2016-08-16 13:05:44 +0000,http://marketrealist.com/2016/08/valeant-are-the-salix-and-dermatology-portfolios-recovering/?utm_source=yahoo&utm_medium=feed,Valeant: Are the Salix and Dermatology Portfolios Recovering?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Dropped As Investors Take Profits,2016-08-16 12:13:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Yu9UsAl5XyI/the-swiss-stock-market-dropped-as-investors-take-profits-20160816-00682,The Swiss Stock Market Dropped As Investors Take Profits
NVS,NVS:US,BBG000LYF3S8,"Allergan to Buy ForSight VISION5, Boost Glaucoma Pipeline",2016-08-15 14:39:17 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J7m9W9nNbww/allergan-to-buy-forsight-vision5-boost-glaucoma-pipeline-cm665348,"Late last week, Allergan plcAGN announced that it will be acquiring a privately held, clinical stage biotechnology company focused on eye care. ForSight VISION5 will be acquired by Allergan for an upfront payment of $95 million as well as"
NVS,NVS:US,BBG000LYF3S8,Apricus Biosciences Transfers UK Marketing Authorization For Vitaros To Ferring,2016-08-15 07:21:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/q5aiG1xG9LM/apricus-biosciences-transfers-uk-marketing-authorization-for-vitaros-to-ferring-20160815-00167,Apricus Biosciences Transfers UK Marketing Authorization For Vitaros To Ferring
NVS,NVS:US,BBG000LYF3S8,Novartis Korea executives charged with bribing doctors,2016-08-13 11:33:47 +0000,http://sg.finance.yahoo.com/news/novartis-korea-executives-charged-bribing-102255344.html,Novartis Korea executives charged with bribing doctors
NVS,NVS:US,BBG000LYF3S8,[$$] 5 Safe European Stocks With Yields Up to 5%,2016-08-13 04:01:00 +0000,http://www.barrons.com/articles/5-safe-european-stocks-with-yields-up-to-5-1471060913?mod=yahoobarrons&ru=yahoo,[$$] 5 Safe European Stocks With Yields Up to 5%
NVS,NVS:US,BBG000LYF3S8,"Who Is Driving Novarti's Management Team? (NVS, BAYRY)",2016-08-12 14:00:00 +0000,http://www.investopedia.com/articles/insights/081216/who-driving-novartis-management-team-nvs-bayry.asp?partner=YahooSA,"Who Is Driving Novarti's Management Team? (NVS, BAYRY)"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Hardly Changed,2016-08-12 12:41:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/YcF-XlV99Ao/the-swiss-stock-market-finished-hardly-changed-20160812-00471,The Swiss Stock Market Finished Hardly Changed
NVS,NVS:US,BBG000LYF3S8,"Novartis says bribe allegations in Turkey groundless, matter closed",2016-08-12 07:46:35 +0000,http://sg.finance.yahoo.com/news/novartis-says-bribe-allegations-turkey-074635818.html,"Novartis says bribe allegations in Turkey groundless, matter closed"
NVS,NVS:US,BBG000LYF3S8,Novartis could face S.Korea sales ban amid corruption allegations: media,2016-08-11 16:48:36 +0000,http://uk.finance.yahoo.com/news/novartis-could-face-korea-sales-164836880.html,Novartis could face S.Korea sales ban amid corruption allegations: media
NVS,NVS:US,BBG000LYF3S8,Novartis Upends Early-Stage Drug Research,2016-08-11 14:00:00 +0000,http://www.forbes.com/sites/jonathansalembaskin/2016/08/11/novartis-upends-early-stage-drug-research/?utm_source=yahoo&utm_medium=partner&utm_campaign=yahootix&partner=yahootix,Novartis Upends Early-Stage Drug Research
NVS,NVS:US,BBG000LYF3S8,Jacobs Awarded Contract for Novartis Biotechnology Center Expansion in France,2016-08-11 12:01:04 +0000,http://www.publicnow.com/view/6CAC2450D6DF75FCB19AD14A0ABF79CD65ABDB49,"[at noodls] - PASADENA, Calif.--(BUSINESS WIRE)-- Jacobs Engineering Group Inc. (NYSE:JEC) announced today it was awarded a contract to expand the Novartis Pharma S.A.S. Biotechnology Center in Huningue, France. ... ..."
NVS,NVS:US,BBG000LYF3S8,[$$] Novartis faces potential South Korea sales ban,2016-08-11 10:19:06 +0000,"http://www.ft.com/cms/s/8e451760-5f9a-11e6-ae3f-77baadeb1c93,s01=1.html?ftcamp=traffic/partner/feed_headline/us_yahoo/auddev","[at Financial Times] - Novartis has come under fresh pressure in South Korea, facing the potential suspension of some of its popular medicines, after several executives were charged with offering illegal rebates. South Korean ..."
NVS,NVS:US,BBG000LYF3S8,Jacobs Wins Contract For Novartis Biotechnology Center Expansion - Quick Facts,2016-08-11 07:58:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/3yEmOCYhfV8/jacobs-wins-contract-for-novartis-biotechnology-center-expansion--quick-facts-20160811-00279,Jacobs Wins Contract For Novartis Biotechnology Center Expansion - Quick Facts
NVS,NVS:US,BBG000LYF3S8,"Lilly Breast Cancer Drug Study Rolls On, Pushing Back Launch Date",2016-08-10 20:41:49 +0000,http://www.investors.com/news/technology/lilly-breast-cancer-drug-study-goes-on-pushing-back-launch-date/,"Lilly Breast Cancer Drug Study Rolls On, Pushing Back Launch Date"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Ends Choppy Session In Negative Territory,2016-08-10 12:22:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Ivx9l4p3lhg/the-swiss-stock-market-ends-choppy-session-in-negative-territory-20160810-00722,The Swiss Stock Market Ends Choppy Session In Negative Territory
NVS,NVS:US,BBG000LYF3S8,"Momenta Pharmaceuticals, Inc.: Good News from Courts and the FDA Ahead?",2016-08-09 19:56:41 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/jaF57oIO9PM/momenta-pharmaceuticals-inc-good-news-from-courts-and-the-fda-ahead-cm662801,"Image source  Getty Images.  Momenta Pharmaceuticals (NASDAQ  MNTA) released second quarter earnings last week. While the report included sales of Momenta's and partner Novartis AG 's(NYSE  NVS) Glatopa, the generic version"
NVS,NVS:US,BBG000LYF3S8,"ETF’s with exposure to Novartis AG : August 9, 2016",2016-08-09 17:55:59 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-novartis-ag-august-9-2016/,"ETF’s with exposure to Novartis AG : August 9, 2016"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Finished Solidly In The Green,2016-08-09 12:25:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/-zTUv6BwbDA/the-swiss-stock-market-finished-solidly-in-the-green-20160809-00840,The Swiss Stock Market Finished Solidly In The Green
NVS,NVS:US,BBG000LYF3S8,New Novartis Asthma Pill Shows Promise,2016-08-09 03:17:12 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/TKn1oj6h7Dc/new-novartis-asthma-pill-shows-promise-cm662190,A new asthma pill developed by  Novartis AG (ADR) (NYSE NVS ) could revolutionize the treatment of the respiratory illness. Source WikipediaThe trial  of the drug fevipiprant lasted 12 weeks
NVS,NVS:US,BBG000LYF3S8,Canada's Plan To Fight Opioid Addiction Might Hurt Its Weakest Patients,2016-08-08 20:59:34 +0000,http://finance.yahoo.com/news/canadas-plan-fight-opioid-addiction-205934163.html,Canada's Plan To Fight Opioid Addiction Might Hurt Its Weakest Patients
NVS,NVS:US,BBG000LYF3S8,"Drug Stocks to Watch for Earnings on Aug 9: MYL, INCY & More",2016-08-08 16:18:35 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/eseeB-oZiz8/drug-stocks-to-watch-for-earnings-on-aug-9-myl-incy-more-cm661877,The Q2 earnings season is almost approaching its end with 87.7% (as of Aug 5) of the S&P 500 members having already reported results. The Retail sector is the only one at this point that has a substantial number
NVS,NVS:US,BBG000LYF3S8,How Will Novartis (NVS) Stock React to Asthma Pill Trial Success?,2016-08-08 15:53:00 +0000,https://www.thestreet.com/story/13668067/1/how-will-novartis-nvs-stock-react-to-asthma-pill-trial-success.html?puc=yahoo&cm_ven=YAHOO,How Will Novartis (NVS) Stock React to Asthma Pill Trial Success?
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Fell Due To Weakness In The Index Heavyweights,2016-08-08 12:20:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KstX0dRchbo/the-swiss-stock-market-fell-due-to-weakness-in-the-index-heavyweights-20160808-00670,The Swiss Stock Market Fell Due To Weakness In The Index Heavyweights
NVS,NVS:US,BBG000LYF3S8,"Despite trial setback, Momenta shares surge on generics news and buyout rumors",2016-08-08 11:15:11 +0000,http://www.bizjournals.com/boston/blog/bioflash/2016/08/despite-trial-setback-momenta-shares-surge-on.html?ana=yahoo,"Despite trial setback, Momenta shares surge on generics news and buyout rumors"
NVS,NVS:US,BBG000LYF3S8,AbbVie Sues Amgen Over Humira -- WSJ,2016-08-06 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m2dtsTk0qqI/abbvie-sues-amgen-over-humira--wsj-20160806-00006,AbbVie Sues Amgen Over Humira -- WSJ
NVS,NVS:US,BBG000LYF3S8,AbbVie Files Patent Suit Over Amgen''s Copy of Humira -- Update,2016-08-05 16:42:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/J-3f2cejctQ/abbvie-files-patent-suit-over-amgens-copy-of-humira--update-20160805-00661,AbbVie Files Patent Suit Over Amgen''s Copy of Humira -- Update
NVS,NVS:US,BBG000LYF3S8,5 Drug Stocks Reporting Q2 Earnings on Aug 8: AGN & More,2016-08-05 15:38:48 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/dDUWfkCkQ88/5-drug-stocks-reporting-q2-earnings-on-aug-8-agn-more-cm661157,"As the Q2 earnings cycle draws to a close, the overall picture that has emerged does not appear as grim as we feared. As per our Earnings Trend report, approximately 414 S&P 500 members (accounting for 85.2% of the"
NVS,NVS:US,BBG000LYF3S8,AbbVie Sues Amgen Over Humira,2016-08-05 14:35:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/nQtDnxlb3hU/abbvie-sues-amgen-over-humira-20160805-00579,AbbVie Sues Amgen Over Humira
NVS,NVS:US,BBG000LYF3S8,Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick,2016-08-05 14:20:28 +0000,http://247wallst.com/healthcare-business/2016/08/05/jefferies-keeps-red-hot-dividend-pharmaceutical-stock-as-top-sector-pick/,Jefferies Keeps Red-Hot Dividend Pharmaceutical Stock as Top Sector Pick
NVS,NVS:US,BBG000LYF3S8,AbbVie Files Patent Suit Over Amgen''s Copy of Humira,2016-08-05 14:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/yEXW-PkZYcQ/abbvie-files-patent-suit-over-amgens-copy-of-humira-20160805-00574,AbbVie Files Patent Suit Over Amgen''s Copy of Humira
NVS,NVS:US,BBG000LYF3S8,AbbVie Files Patent Suit Over Amgen's Copy of Humira,2016-08-05 14:18:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/I-JW6eepFr8/abbvie-files-patent-suit-over-amgens-copy-of-humira-20160805-00660,AbbVie Files Patent Suit Over Amgen's Copy of Humira
NVS,NVS:US,BBG000LYF3S8,"Juno (JUNO) Q2 Loss Wider-than-Expected, Focus on Pipeline",2016-08-05 12:56:26 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/8uLnKdhU2go/juno-juno-q2-loss-wider-than-expected-focus-on-pipeline-cm660954,"Juno Therapeutics Inc.JUNO reported a loss of 67 cents per share (including stock based compensation expense) in the second quarter of 2016, wider than the Zacks Consensus Estimate of a loss of 51 cents per share and the year"
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Climbed After Better Than Expected U.S. Jobs Report,2016-08-05 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/DWFYLWKfDag/the-swiss-stock-market-climbed-after-better-than-expected-us-jobs-report-20160805-00513,The Swiss Stock Market Climbed After Better Than Expected U.S. Jobs Report
NVS,NVS:US,BBG000LYF3S8,The Race To Cure Spinal Muscular Atrophy,2016-08-05 06:07:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/oFrvWa6kz24/the-race-to-cure-spinal-muscular-atrophy-20160805-00108,The Race To Cure Spinal Muscular Atrophy
NVS,NVS:US,BBG000LYF3S8,The Swiss Stock Market Bounced Back After BoE Stimulus Announcement,2016-08-04 12:12:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/HuCjBrEy6UI/the-swiss-stock-market-bounced-back-after-boe-stimulus-announcement-20160804-01008,The Swiss Stock Market Bounced Back After BoE Stimulus Announcement
NVS,NVS:US,BBG000LYF3S8,Generics Keeping The Pressure On Big Pharma,2016-08-03 21:13:42 +0000,http://finance.yahoo.com/news/generics-keeping-pressure-big-pharma-211342182.html,Generics Keeping The Pressure On Big Pharma
NVS,NVS:US,BBG000LYF3S8,Can Novartis Win the Entresto Bet?,2016-08-03 19:05:38 +0000,http://finance.yahoo.com/news/novartis-win-entresto-bet-190538050.html,Can Novartis Win the Entresto Bet?
NVS,NVS:US,BBG000LYF3S8,Health Care Sector Update for 08/03/2016: NVS,2016-08-03 13:51:57 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/VgH3h2H0wfA/health-care-sector-update-for-08032016-nvs-cm659533,"Top Health care stocks JNJ +0.4% PFE +0.2% ABT flat MRK flat AMGN 0.4% Health care shares were mixed in pre market trade on Wednesday. In health care stocks news, Novartis AG ( NVS ) said the U.S. Food"
NVS,NVS:US,BBG000LYF3S8,Novartis pill gets U.S. breakthrough designation in breast cancer,2016-08-03 05:30:10 +0000,http://finance.yahoo.com/news/novartis-pill-gets-u-breakthrough-053010408.html,"[Reuters] - Novartis AG breast cancer pill LEE011 has won breakthrough therapy designation from U.S. regulators as a first-line treatment for a form of advanced breast cancer, the Swiss drugmaker said on Wednesday. The Food and Drug Administration granted the designation to LEE011 in combination with letrozole for treating hormone receptor positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced or metastatic breast cancer. The designation aims to expedite the development and review of potential new medicines that treat serious or life-threatening conditions."
NVS,NVS:US,BBG000LYF3S8,"A First Look at Exelixis, Inc.'s Rocket-Ship Drug",2016-08-02 22:59:18 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/AYl2sJVN5QM/a-first-look-at-exelixis-incs-rocket-ship-drug-cm659063,"Image source  Getty Images.  Exelixis (NASDAQ  EXEL) is scheduled to release earnings after the closing bell on Wednesday, when investors will get a first look at how quickly sales of its kidney"
NVS,NVS:US,BBG000LYF3S8,This Under-the-Radar Stock Powers the Pharma Industry -- and It Just Raised 2016 Guidance,2016-08-02 22:52:21 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/cIqut_RBvR4/this-under-the-radar-stock-powers-the-pharma-industry-and-it-just-raised-2016-guidance-cm659199,Image source  Chris Potter  Flickr .  Investors eyeing the pharmaceutical and biotech industries usually have to take the potential for amazing growth with the potential for spectacular failures when drug candidates stall in the clinic
NVS,NVS:US,BBG000LYF3S8,What Awaits Radius Health (RDUS) this Earnings Season?,2016-08-02 15:59:31 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/Yx_b07gVtA0/what-awaits-radius-health-rdus-this-earnings-season-cm658822,"Radius Health, Inc.RDUS is scheduled to report second quarter 2016 results on Aug 4. Last quarter, the company recorded a negative earnings surprise of 13.25%. Let's see how things are shaping up for the company this quarter.Factors Influencing This"
NVS,NVS:US,BBG000LYF3S8,CVS Cuts Coverage of Dozens of Drugs in Exclusion Expansion,2016-08-02 13:36:50 +0000,http://www.bloomberg.com/news/articles/2016-08-02/cvs-plans-to-bar-novartis-cancer-drug-from-2017-covered-drugs?cmpid=yhoo.headline,CVS Cuts Coverage of Dozens of Drugs in Exclusion Expansion
NVS,NVS:US,BBG000LYF3S8,"Pfizer, Inc. (PFE) Ex-Dividend Date Scheduled for August 03, 2016",2016-08-02 13:18:11 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/m1vdbRRrfIg/pfizer-inc-pfe-ex-dividend-date-scheduled-for-august-03-2016-cm658636,"Pfizer, Inc. ( PFE ) will begin trading ex dividend on August 03, 2016. A cash dividend payment of $0.3 per share is scheduled to be paid on September 01, 2016. Shareholders who purchased PFE prior to the ex"
NVS,NVS:US,BBG000LYF3S8,"Alphabet, Glaxo Team Up On 'Bioelectronic' Medicines -- WSJ",2016-08-02 02:48:00 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/P8KArQteUKM/alphabet-glaxo-team-up-on-bioelectronic-medicines--wsj-20160802-00052,"Alphabet, Glaxo Team Up On 'Bioelectronic' Medicines -- WSJ"
NVS,NVS:US,BBG000LYF3S8,What Awaits MNK & Other Drug Stocks this Earnings Season?,2016-08-01 15:58:29 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/vkfnB-JWuvA/what-awaits-mnk-other-drug-stocks-this-earnings-season-cm658055,"The Q2 earnings season is picking up pace and so far, we have seen better than expected results from the majority of the companies. Going into specifics, approximately 317 companies (accounting for 73.5% of the S&P 500 index's total"
NVS,NVS:US,BBG000LYF3S8,Rapidly Rising Prescription Drug Costs Could Put Medicare on Life Support,2016-07-31 16:51:55 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/h7rhY0qbV94/rapidly-rising-prescription-drug-costs-could-put-medicare-on-life-support-cm657782,"Image source  Getty Images.  The importance of Medicare can't be overstated for the 56 million people currently enrolled in the program, a majority of whom are seniors aged 65 and up.  According"
NVS,NVS:US,BBG000LYF3S8,"ETF’s with exposure to Novartis AG : July 29, 2016",2016-07-29 17:44:37 +0000,http://www.capitalcube.com/blog/index.php/etfs-with-exposure-to-novartis-ag-july-29-2016/,"ETF’s with exposure to Novartis AG : July 29, 2016"
NVS,NVS:US,BBG000LYF3S8,What Awaits ACUR & Other Drug Stocks this Earnings Season?,2016-07-29 15:28:32 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/KNAt_jFQxH4/what-awaits-acur-other-drug-stocks-this-earnings-season-cm657210,"Getting into the thick of the Q2 earnings season, we have seen releases from 208 S&P 500 members, accounting for 50.5% of the index's total market capitalization, as of Jul 27. As per our Earnings Trend report, earnings for"
NVS,NVS:US,BBG000LYF3S8,"AstraZeneca (AZN) Stock Up After Q2 Earnings, Revenue Beat",2016-07-28 18:13:00 +0000,https://www.thestreet.com/story/13656572/1/astrazeneca-azn-stock-up-after-q2-earnings-revenue-beat.html?puc=yahoo&cm_ven=YAHOO,"AstraZeneca (AZN) Stock Up After Q2 Earnings, Revenue Beat"
NVS,NVS:US,BBG000LYF3S8,"Glaxo (GSK) Beats Q2 Earnings Estimates, Revenues Up Y/Y",2016-07-28 17:28:53 +0000,http://articlefeeds.nasdaq.com/~r/nasdaq/symbols/~3/rL6ULw1hNDA/glaxo-gsk-beats-q2-earnings-estimates-revenues-up-yy-cm656671,"GlaxoSmithKline plcGSK reported second quarter 2016 core earnings of 70 cents per American Depositary Share (ADS), beating the Zacks Consensus Estimate of 55 cents. Core earnings were also up 16% year over year at a constant exchange rate (CER)."
NVS,NVS:US,BBG000LYF3S8,AstraZeneca a bid target again? CEO says someone may spot value,2016-07-28 16:20:32 +0000,http://sg.finance.yahoo.com/news/astrazeneca-takeover-target-again-ceo-094936506.html,AstraZeneca a bid target again? CEO says someone may spot value
NVS,NVS:US,BBG000LYF3S8,AstraZeneca a bid target again? CEO says someone may spot value,2016-07-28 15:00:18 +0000,http://uk.finance.yahoo.com/news/astrazeneca-bid-target-again-ceo-123422676.html,AstraZeneca a bid target again? CEO says someone may spot value
NVS,NVS:US,BBG000LYF3S8,AstraZeneca a takeover target again? CEO not commenting,2016-07-28 09:43:43 +0000,http://uk.finance.yahoo.com/news/astrazeneca-takeover-target-again-ceo-094343937.html,AstraZeneca a takeover target again? CEO not commenting
NVS,NVS:US,BBG000LYF3S8,"Analyst Recommendations for Roche: Buy, Hold, or Sell?",2016-07-27 15:04:21 +0000,http://marketrealist.com/2016/07/analyst-recommendations-for-roche-buy-hold-or-sell/?utm_source=yahoo&utm_medium=feed,"Analyst Recommendations for Roche: Buy, Hold, or Sell?"
NVS,NVS:US,BBG000LYF3S8,"Novartis AG :NVS-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016",2016-07-26 14:15:45 +0000,http://www.capitalcube.com/blog/index.php/novartis-ag-nvs-us-earnings-analysis-q2-2016-by-the-numbers-july-26-2016/,"Novartis AG :NVS-US: Earnings Analysis: Q2, 2016 By the Numbers : July 26, 2016"
NVS,NVS:US,BBG000LYF3S8,What Do the Recent Changes in Novartis’s 2Q16 Valuation Tell Us?,2016-07-26 13:04:26 +0000,http://marketrealist.com/2016/07/recent-changes-novartiss-2q16-valuation-tell-us/?utm_source=yahoo&utm_medium=feed,What Do the Recent Changes in Novartis’s 2Q16 Valuation Tell Us?
NVS,NVS:US,BBG000LYF3S8,Novartis profit slips as generic drug competition hits sales,2016-07-19 13:59:14 +0000,http://sg.finance.yahoo.com/news/novartis-2q-net-slips-generic-062859229.html,Novartis profit slips as generic drug competition hits sales
NVS,NVS:US,BBG000LYF3S8,Novartis in no rush to sell down stake on GSK consumer venture,2016-07-19 13:25:37 +0000,http://sg.finance.yahoo.com/news/novartis-no-rush-sell-down-132537303.html,Novartis in no rush to sell down stake on GSK consumer venture
NVS,NVS:US,BBG000LYF3S8,Novartis in no rush to sell down stake on GSK consumer venture,2016-07-19 13:20:40 +0000,http://uk.finance.yahoo.com/news/novartis-no-rush-sell-down-132040851.html,Novartis in no rush to sell down stake on GSK consumer venture
NVS,NVS:US,BBG000LYF3S8,Novartis beats 2Q profit forecasts,2016-07-19 10:05:59 +0000,http://sg.finance.yahoo.com/news/novartis-beats-2q-profit-forecasts-100559294.html,Novartis beats 2Q profit forecasts
NVS,NVS:US,BBG000LYF3S8,"Novartis, world's top drugmaker, plays down Brexit threat",2016-07-19 07:44:38 +0000,http://sg.finance.yahoo.com/news/novartis-worlds-top-drugmaker-plays-074438170.html,"Novartis, world's top drugmaker, plays down Brexit threat"
NVS,NVS:US,BBG000LYF3S8,"Novartis, world's top drugmaker, plays down Brexit threat",2016-07-19 07:43:16 +0000,http://uk.finance.yahoo.com/news/novartis-worlds-top-drugmaker-plays-074316071.html,"Novartis, world's top drugmaker, plays down Brexit threat"
NVS,NVS:US,BBG000LYF3S8,AstraZeneca resolves Faslodex patent litigation in U.S.,2016-07-13 07:22:27 +0000,http://sg.finance.yahoo.com/news/astrazeneca-resolves-faslodex-patent-litigation-072227953.html,AstraZeneca resolves Faslodex patent litigation in U.S.
NVS,NVS:US,BBG000LYF3S8,Novartis adds bispecific antibodies to its growing immuno-oncology portfolio through collaboration and licensing agreement with Xencor,2016-06-28 05:41:09 +0000,http://www.publicnow.com/view/00A6A00EFCC9F2C44432D42D7E29E6BA58FB46AF,[at noodls] - Agreement is the latest in a series of acquisitions and strategic collaborations that have bolstered Novartis' deep and diverse immuno-oncology pipeline Collaboration will co-develop Xencor's two T-cell ...
NVS,NVS:US,BBG000LYF3S8,"Timely use of Novartis' Entresto could prevent or postpone over 28,000 US deaths per year among HFrEF patients, according to an expert analysis in JAMA Cardiology",2016-06-22 15:39:08 +0000,http://www.publicnow.com/view/924F4786ED78C32ACAD3BB05C5170B775AFB4271,[at noodls] - Findings are first to quantify magnitude of potential survival benefits if Entresto were prescribed to all eligible US HFrEF patients (as defined by authors) Cardiology experts highlight risk of delaying ...
NVS,NVS:US,BBG000LYF3S8,"Roche skin cancer drugs ""too expensive"", says UK cost agency",2016-06-16 13:38:21 +0000,http://uk.finance.yahoo.com/news/roche-skin-cancer-drugs-too-133821011.html,"Roche skin cancer drugs ""too expensive"", says UK cost agency"
NVS,NVS:US,BBG000LYF3S8,Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalarial treatment,2016-06-15 05:29:11 +0000,http://www.publicnow.com/view/6F2AE092EAD6318E9598ADE94DBA4753903E6C21,[at noodls] - Novartis will lead the development of antimalarial compound KAF156 with scientific and financial support from Medicines for Malaria Venture in collaboration with the Bill & Melinda Gates Foundation KAF156 ...
NVS,NVS:US,BBG000LYF3S8,"Novartis highlights long-term safety data of Revolade® in adults with chronic immune thrombocytopenia, a rare blood disorder",2016-06-10 06:59:03 +0000,http://www.publicnow.com/view/E286335FA8A1475270DAE71BB4A7A3C99C1B4B4E,[at noodls] - EXTEND study provides long-term safety data for Revolade that are consistent with the findings from the pivotal Phase III RAISE study Immune thrombocytopenia (ITP) is a rare and potentially serious ...
NVS,NVS:US,BBG000LYF3S8,Novartis presents data showing Jakavi® is superior to best available therapy in patients with less advanced polycythemia vera (PV),2016-06-10 06:59:03 +0000,http://www.publicnow.com/view/470B14E47BD4937A5AC8986062C761FF831C33F1,[at noodls] - Three times as many patients with inadequately controlled PV without enlarged spleen had hematocrit control without phlebotomy on Jakavi (ruxolitinib) vs BAT RESPONSE-2 complements data from pivotal ...
NVS,NVS:US,BBG000LYF3S8,Novartis announces AMG 334 significantly reduces patients' monthly migraine days in phase II study of chronic migraine prevention,2016-06-08 20:58:04 +0000,http://www.publicnow.com/view/CA284DB6F77343DE93172B0BEB4CF2260E97F6AB,"[at noodls] - Phase II 20120295 study of AMG 334 met primary endpoint, confirming efficacy and safety in patients with chronic migraine over 12 weeks of treatment Migraine is a leading cause of disability, affecting ..."
NVS,NVS:US,BBG000LYF3S8,Novartis presents new scientific evidence for Cosentyx in ankylosing spondylitis and psoriatic arthritis patients at EULAR 2016,2016-06-08 05:38:10 +0000,http://www.publicnow.com/view/B93FC5D5C75E1FC0251692EF0BC58306D9D7C15B,"[at noodls] - Up to 80% of ankylosing spondylitis and 84% of psoriatic arthritis patients treated with Cosentyxat two years had no radiographic progression in the spine or joints, respectively, Cosentyx may improve ..."
NVS,NVS:US,BBG000LYF3S8,Novartis combination therapy Tafinlar® + Mekinist® demonstrates overall survival benefit at three-year follow-up in patients with advanced melanoma,2016-06-06 19:08:05 +0000,http://www.publicnow.com/view/A2E668748EA65A9EB0F212A2845240D27037B2AD,[at noodls] - Study is longest Ph III survival follow-up to date of BRAF V600E/K mutation-positive melanoma patients who received a targeted combination therapy Latest data show an estimated 44% of patients alive after ...
NVS,NVS:US,BBG000LYF3S8,Novartis study shows skin cancer combo also works on lungs,2016-06-06 17:20:31 +0000,http://uk.finance.yahoo.com/news/novartis-study-shows-skin-cancer-144501783.html,Novartis study shows skin cancer combo also works on lungs
NVS,NVS:US,BBG000LYF3S8,Novartis pivotal data for Tafinlar® + Mekinist® demonstrated a 63 percent overall response rate in treating rare form of lung cancer,2016-06-06 15:28:03 +0000,http://www.publicnow.com/view/162CB688B589B5B88B3423F5895BA31685B7EA17,[at noodls] - The median Duration of Response for BRAF V600E-mutant NSCLC patients treated with Tafinlar + Mekinist combination therapy was 9 months Efficacy analyses also presented for INC280 (capmatinib) in cMET+ ...
NVS,NVS:US,BBG000LYF3S8,British biopharma start-up Mereo to list in London,2016-06-05 23:25:15 +0000,http://sg.finance.yahoo.com/news/british-biopharma-start-mereo-list-232515682.html,British biopharma start-up Mereo to list in London
NVS,NVS:US,BBG000LYF3S8,British biopharma start-up Mereo to list in London,2016-06-05 23:01:01 +0000,http://uk.finance.yahoo.com/news/british-biopharma-start-mereo-list-230101242.html,British biopharma start-up Mereo to list in London
NVS,NVS:US,BBG000LYF3S8,Novartis data show more than 50 percent of eligible Ph+ CML patients maintain Treatment-free Remission (TFR) after stopping Tasigna®,2016-06-04 20:08:01 +0000,http://www.publicnow.com/view/27FBE448456CDD9FB3564570E6FFF61792233368,"[at noodls] - In ENESTfreedom, 51.6% of eligible first-line Tasigna patients maintained TFR for 48 weeks after stopping treatment; study did not meet its statistical primary endpoint, specifically the > 50% lower ..."
NVS,NVS:US,BBG000LYF3S8,Eisai Inc. Enters Into Collaboration Agreement to Co-Promote Eisai's Anticancer Agent Lenvima in Combination with Evorolimus as Treatment for Advanced Renal Cell Carcinoma in the United States,2016-06-03 02:42:00 +0000,http://au.finance.yahoo.com/news/eisai-inc-enters-collaboration-agreement-024200217.html,"[ACN Newswire] - TOKYO, June 3, 2016 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, ""Eisai"") announced today that its U.S. subsidiary Eisai Inc. has entered into an agreement with ..."
NVS,NVS:US,BBG000LYF3S8,Novartis drug Afinitor® receives EU approval to treat certain types of advanced gastrointestinal (GI) and lung neuroendocrine tumors (NET),2016-06-02 05:25:11 +0000,http://www.publicnow.com/view/3312DEFB68479C011E969FA003C2AAD319E55586,"[at noodls] - Afinitor fills critical need in EU as first approved therapy for advanced, progressive, nonfunctional lung NET and first oral therapy for this type of GI NET Nonfunctional GI and lung NET are rare cancers ..."
NVS,NVS:US,BBG000LYF3S8,Novartis willing to sell Roche stake without demanding premium - CEO,2016-05-25 09:43:42 +0000,http://sg.finance.yahoo.com/news/novartis-willing-sell-roche-stake-094342392.html,Novartis willing to sell Roche stake without demanding premium - CEO
NVS,NVS:US,BBG000LYF3S8,Novartis willing to sell Roche stake without demanding premium - CEO,2016-05-25 09:32:48 +0000,http://uk.finance.yahoo.com/news/novartis-willing-sell-roche-stake-093248001.html,Novartis willing to sell Roche stake without demanding premium - CEO
NVS,NVS:US,BBG000LYF3S8,"Novartis highlights its strong foundation for long-term, sustainable growth at the third Meet Novartis Management event",2016-05-25 05:16:06 +0000,http://www.publicnow.com/view/EE2C8D01012CB2EE013C5885DE01AE3FE4B1B9B1,"[at noodls] - Outlines actions underway to accelerate launch of Entresto, including further expansion of US primary care field force, and reinforce strong uptake of Cosentyx Highlights leading pipeline of second generation ..."
NVS,NVS:US,BBG000LYF3S8,Indian shares snap 4 days of losses on better corporate earnings,2016-05-24 13:00:57 +0000,http://in.finance.yahoo.com/news/sensex-track-snap-4-days-083940683.html,Indian shares snap 4 days of losses on better corporate earnings
NVS,NVS:US,BBG000LYF3S8,Novartis executive exodus complicates drugmaker's rebuilding job,2016-05-23 19:01:20 +0000,http://sg.finance.yahoo.com/news/novartis-executive-exodus-complicates-drugmakers-190120181.html,Novartis executive exodus complicates drugmaker's rebuilding job
NVS,NVS:US,BBG000LYF3S8,Novartis sticks to $200 million FY Entresto forecast after recommendation,2016-05-23 17:17:02 +0000,http://sg.finance.yahoo.com/news/novartis-sticks-200-million-fy-171702170.html,Novartis sticks to $200 million FY Entresto forecast after recommendation
NVS,NVS:US,BBG000LYF3S8,"Novartis' Entresto® given strong Class I recommendation in both US and EU heart failure guidelines, less than a year after regulatory approvals",2016-05-21 00:13:05 +0000,http://www.publicnow.com/view/C7C60159A00FBADD0C549D83D4A4FA5F8F26B43D,[at noodls] - US guidelines now recommend Entresto as standard of care for HFrEF as an alternative to ACEs or ARBs; call for doctors to switch patients with mild to moderate symptoms to Entresto Updated guidelines ...
NVS,NVS:US,BBG000LYF3S8,Novartis launches new Entresto trials in bid to boost sales,2016-05-19 14:22:17 +0000,http://sg.finance.yahoo.com/news/novartis-launches-entresto-trials-bid-142217351.html,Novartis launches new Entresto trials in bid to boost sales
NVS,NVS:US,BBG000LYF3S8,Novartis announces investment in FortiHFy clinical program of Entresto® and heart failure,2016-05-19 06:32:22 +0000,http://www.publicnow.com/view/B42B7BA74AA634479B96C5757057158F32EF928F,[at noodls] - Fortifying Heart Failure clinical evidence and patient quality of life (FortiHFy) is an umbrella clinical program comprising over 40 active or planned trials The global clinical program will generate additional ...
NVS,NVS:US,BBG000LYF3S8,Novartis to present pivotal data in hematologic and solid tumor cancers at 2016 ASCO Annual Meeting,2016-05-18 23:12:09 +0000,http://www.publicnow.com/view/0B46762DD67029248DC57493D1EA6F5E72A8F8BF,[at noodls] - First data from two treatment-free remission (TFR) studies of Ph+ CML patients treated with Tasigna both in front-line and second-line following Glivec* First genomic analysis and 3-year efficacy/safety ...
NVS,NVS:US,BBG000LYF3S8,Colombia battles world's biggest drugmaker over cancer drug,2016-05-18 21:47:18 +0000,http://sg.finance.yahoo.com/news/colombia-battles-worlds-biggest-drugmaker-040103471.html,Colombia battles world's biggest drugmaker over cancer drug
NVS,NVS:US,BBG000LYF3S8,NT Pharma's Acquisition of Novartis's Well-known International Orthopedic Brand Miacalcic Helps to Enrich Product Portfolio and Enhance Profitability,2016-05-18 16:18:00 +0000,http://au.finance.yahoo.com/news/nt-pharmas-acquisition-novartiss-well-161800916.html,"[ACN Newswire] - HONG KONG, May 18, 2016 - (ACN Newswire) - China NT Pharma Group Company Limited (""NT Pharma"" or the ""Company"") (stock code: 01011.HK) is pleased to announce the major transaction in ..."
NVS,NVS:US,BBG000LYF3S8,"Novartis splits drugs business into two, pharma chief to leave",2016-05-17 19:38:48 +0000,http://sg.finance.yahoo.com/news/novartis-splits-drugs-business-two-160325088.html,"Novartis splits drugs business into two, pharma chief to leave"
NVS,NVS:US,BBG000LYF3S8,"Novartis splits drugs business into two, pharma chief to leave",2016-05-17 19:18:53 +0000,http://uk.finance.yahoo.com/news/novartis-splits-drugs-business-two-165708806.html,"Novartis splits drugs business into two, pharma chief to leave"
NVS,NVS:US,BBG000LYF3S8,Pfizer buying skin drug maker Anacor for $5.2 billion,2016-05-16 18:54:14 +0000,http://sg.finance.yahoo.com/news/pfizer-buying-anacor-pharmaceuticals-5-112120058.html,Pfizer buying skin drug maker Anacor for $5.2 billion
NVS,NVS:US,BBG000LYF3S8,Drugs giant GSK reports slump in profits,2016-04-27 12:39:16 +0000,http://uk.finance.yahoo.com/news/drugs-giant-gsk-reports-slump-123916343.html,Drugs giant GSK reports slump in profits
NVS,NVS:US,BBG000LYF3S8,Novartis could refuel M&A machine with $14 billion Roche stake sale,2016-04-25 09:44:39 +0000,http://sg.finance.yahoo.com/news/novartis-discussing-roche-stake-sale-085310449.html,Novartis could refuel M&A machine with $14 billion Roche stake sale
NVS,NVS:US,BBG000LYF3S8,"Novartis to prepare the sale of its Roche stake, paper says",2016-04-25 07:44:08 +0000,http://in.finance.yahoo.com/news/novartis-prepare-sale-roche-stake-074408472.html,"Novartis to prepare the sale of its Roche stake, paper says"
NVS,NVS:US,BBG000LYF3S8,"Novartis CEO says ""legacy"" bribery allegations provisioned for",2016-04-21 14:41:59 +0000,http://uk.finance.yahoo.com/news/novartis-ceo-says-legacy-bribery-125850282.html,"Novartis CEO says ""legacy"" bribery allegations provisioned for"
NVS,NVS:US,BBG000LYF3S8,Exclusive - Novartis investigating $85 million bribery allegations in Turkey,2016-03-29 20:22:39 +0000,http://in.finance.yahoo.com/news/exclusive-novartis-investigating-85-million-202239679.html,Exclusive - Novartis investigating $85 million bribery allegations in Turkey
NVS,NVS:US,BBG000LYF3S8,Drugmaker Novartis settles with US over China bribe claims,2016-03-24 13:16:38 +0000,http://uk.finance.yahoo.com/news/drugmaker-novartis-settles-us-over-131638069.html,Drugmaker Novartis settles with US over China bribe claims
NVS,NVS:US,BBG000LYF3S8,GSK refuses to be bounced into early consumer unit spin-off,2016-02-03 14:33:34 +0000,http://uk.finance.yahoo.com/news/gsk-refuses-bounced-early-consumer-143334883.html,GSK refuses to be bounced into early consumer unit spin-off
NVS,NVS:US,BBG000LYF3S8,Drugs giant GSK says annual net profits triple,2016-02-03 13:41:15 +0000,http://uk.finance.yahoo.com/news/drugs-giant-gsk-says-annual-134115346.html,Drugs giant GSK says annual net profits triple
NVS,NVS:US,BBG000LYF3S8,Sun hopes cut-price generic Gleevec will win third of U.S. market,2016-02-02 02:55:49 +0000,http://in.finance.yahoo.com/news/sun-hopes-cut-price-generic-025549928.html,Sun hopes cut-price generic Gleevec will win third of U.S. market
NVS,NVS:US,BBG000LYF3S8,European shares recover after late rally in oil,2016-01-27 18:00:40 +0000,http://uk.finance.yahoo.com/news/european-shares-recover-rally-oil-180040863.html,European shares recover after late rally in oil
NVS,NVS:US,BBG000LYF3S8,Novartis profits jump 73% on asset sales,2016-01-27 17:02:56 +0000,http://uk.finance.yahoo.com/news/novartis-profits-jump-73-asset-170256872.html,Novartis profits jump 73% on asset sales
NVS,NVS:US,BBG000LYF3S8,Novartis hires Hospira's $90 mln man to save Alcon,2016-01-27 13:53:25 +0000,http://uk.finance.yahoo.com/news/novartis-replaces-head-eye-care-091710860.html,"[Reuters - UK Focus] - Fresh from engineering Hospira (NYSE: HSP - news) 's $15 billion sale to Pfizer (NYSE: PFE - news) , drug company executive Michael Ball has a new mission -- rescuing Novartis's Alcon eye care division, whose continuing slump led the Swiss drugmaker to fall short of earnings forecasts once again at the end of 2015. The Canadian-born Ball was appointed to replace Alcon chief Jeff George, Novartis said on Wednesday as it reported financial results for the last three months of 2015."
NVS,NVS:US,BBG000LYF3S8,Big Pharma's bet on Big Data creates opportunities and risks,2016-01-26 13:14:57 +0000,http://in.finance.yahoo.com/news/big-pharmas-bet-big-data-131457361.html,Big Pharma's bet on Big Data creates opportunities and risks
NVS,NVS:US,BBG000LYF3S8,Elanco finalises Novartis Animal Health India acquisition,2016-01-04 13:58:03 +0000,http://in.finance.yahoo.com/news/elanco-finalises-novartis-animal-health-135803576.html,Elanco finalises Novartis Animal Health India acquisition
NVS,NVS:US,BBG000LYF3S8,Novartis opens new office complex in Hyderabad,2015-12-17 15:32:04 +0000,http://in.finance.yahoo.com/news/novartis-opens-office-complex-hyderabad-153204955.html,Novartis opens new office complex in Hyderabad
NVS,NVS:US,BBG000LYF3S8,U.S. FDA warns Novartis on manufacturing violations at 2 India plants,2015-10-28 10:21:37 +0000,http://in.finance.yahoo.com/news/u-fda-warns-novartis-manufacturing-102137219.html,U.S. FDA warns Novartis on manufacturing violations at 2 India plants
NVS,NVS:US,BBG000LYF3S8,Novartis profit hit by $390 mln settlement in U.S. kickbacks case,2015-10-27 10:28:12 +0000,http://in.finance.yahoo.com/news/novartis-q3-income-lags-estimates-064356758.html,Novartis profit hit by $390 mln settlement in U.S. kickbacks case
NVS,NVS:US,BBG000LYF3S8,Roche shows its intent with Switzerland's tallest skyscraper,2015-09-18 17:47:01 +0000,http://in.finance.yahoo.com/news/roche-shows-intent-switzerlands-tallest-174701461.html,Roche shows its intent with Switzerland's tallest skyscraper
NVS,NVS:US,BBG000LYF3S8,"Novartis flags margin increase, higher dividends, bolt-on deals",2015-06-18 11:24:31 +0000,http://in.finance.yahoo.com/news/novartis-flags-margin-increase-higher-112431520.html,"Novartis flags margin increase, higher dividends, bolt-on deals"
NVS,NVS:US,BBG000LYF3S8,Novartis India arm says unaware of any delisting plan,2015-06-11 13:13:42 +0000,http://in.finance.yahoo.com/news/novartis-india-arm-says-unaware-131342059.html,Novartis India arm says unaware of any delisting plan
NVS,NVS:US,BBG000LYF3S8,GSK scraps plan to list HIV drugs business and shields dividend,2015-05-06 14:17:09 +0000,http://in.finance.yahoo.com/news/glaxosmithkline-targets-growth-across-units-114609534.html,GSK scraps plan to list HIV drugs business and shields dividend
NVS,NVS:US,BBG000LYF3S8,Interview - New-look GSK bets on consumer health spending,2015-05-06 11:22:55 +0000,http://in.finance.yahoo.com/news/interview-look-gsk-bets-consumer-112255844.html,Interview - New-look GSK bets on consumer health spending
NVS,NVS:US,BBG000LYF3S8,Doubts grow over GlaxoSmithKline's $6 bln capital return plan,2015-05-01 11:36:49 +0000,http://in.finance.yahoo.com/news/doubts-grow-over-glaxosmithklines-6-113649231.html,Doubts grow over GlaxoSmithKline's $6 bln capital return plan
NVS,NVS:US,BBG000LYF3S8,Novartis posts Q1 profit beat despite dollar drag,2015-04-23 07:55:20 +0000,http://in.finance.yahoo.com/news/novartis-warns-currency-drag-2015-072959397.html,Novartis posts Q1 profit beat despite dollar drag
NVS,NVS:US,BBG000LYF3S8,Novartis sues Cipla over respiratory drug Onbrez,2014-12-17 13:29:22 +0000,http://in.finance.yahoo.com/news/novartis-sues-indias-cipla-over-132844065.html,Novartis sues Cipla over respiratory drug Onbrez
